

ECMCC Board of Director's Meeting

March 25, 2025

Zizzi Conference Center Erie County Medical Center 462 Grider Street Buffalo, NY 14215

AGENDA Regular Meeting of the Board of Directors of Erie County Medical Center Corporation March 25, 2025

- I. CALL TO ORDER: EUGENIO RUSSI, CHAIR
- II. APPROVAL OF MINUTES:
- III. RESOLUTIONS MAY BE DISTRIBUTED TO THE BOARD OF DIRECTORS DURING THE MEETING ON MARCH 25, 2025
- IV. REPORTS FROM THE CORPORATION'S LEADERSHIP TEAM
 - A) Chief Executive Officer & President
 - B) Chief Financial Officer
 - C) All other reports from leadership are received and filed
- V. REPORTS FROM STANDING COMMITTEE CHAIRS
 - A) **Executive Committee** (by Eugenio Russi)
 - B) Finance Committee (by Michael Seaman)
 - C) **Buildings and Grounds** (by Ronald Bennett)
 - D) Human Resources Committee (by Michael Seaman)
 - E) Quality Improvement and Patient Safety Committee (by Benjamin Swanekamp)
- VI. EXECUTIVE SESSION
- VII. Adjourn

ERIE COUNTY MEDICAL CENTER CORPORATION FEBRUARY 25, 2025 MINUTES OF THE BOARD OF DIRECTORS MEETING HYBRID MEETING HELD

| Present: | Ronald Bennett, Reverend Mark Blue, Jonathan Dandes*, Darby Fishkin*, Sharon Hanson*, Christian Johnson*, James Lawicki*, Christopher O'Brien*, Hon. John O'Donnell, Reverend Kinzer Pointer, Thomas J. Quatroche*, Eugenio Russi, Michael Seaman, Philip Stegemann, Benjamin Swanekamp* |
|------------------|---|
| Excused: Also | Michael Hoffert, Jennifer Persico |
| Present: | Donna Brown*, Samuel Cloud, MD, Anthony J. Colucci, III*, Peter Cutler*, Andrew Davis, Cassandra Davis, Joseph Giglia, Pamela Lee, Charlene Ludlow, Michael Manka, MD, Phyllis Murawski, Stacy Roeder, Jonathan Swiatkowski |
| | *virtual |

I. <u>Call to Order</u>

The meeting was called to order at 4:50 pm by Chair, Eugenio Russi.

II. <u>Minutes</u>

Upon a motion made by Reverend Kinzer Pointer and seconded by Reverend Mark Blue, the minutes of the January 28, 2025 regular meeting of the Board of Directors were unanimously approved.

III. <u>Action Items</u>

<u>Resolution Approving the Amended 2025 Capital Budget of the Corporation</u> Moved by Michael Seaman and seconded by Reverend Kinzer Pointer **Motion approved unanimously**

<u>Resolution of the Board of Director's Approving Items for Annual Review</u> Moved by Reverend Pointer Kinzer and seconded by Reverend Mark Blue **Motion approved unanimously**

Resolution Receiving and Filing Medical-Dental Staff Meeting Minutes for February Moved by Reverend Mark Blue and seconded by Michael Seaman

Motion approved unanimously

IV. <u>Reports from the Corporation's Leadership Team</u>

Chief Executive Officer and President

Dr. Thomas Quatroche reported that there were zero (0) patient safety indicator occurrences during the month of January. Hospital acquired infections were higher than the CMS goal for 2025. Human Experience scores reflected the hospital meeting

statewide standards. Dr. Quatroche reviewed several events held for and in honor of the employees. The hospital will be hosting several employee events to celebrate Black History Month. ECMC Foundation announced this year's Springfest honorees: Phydician Honoree, Jennifer Pugh, MD; Nursing Honoree, Thameena Z. Hunter, MS, RN; and Community Honoree, Susan M. Gonzalez. The Foundation held it's annual Springfest luncheon and will hold the Springfest Auction and Basket Raffle on April 8, 2025. There have been 101 new hires year-to-date. The SNUG program received a \$2.8 million grant.

Chief Financial Officer

Jonathan Swiatkowski reviewed the January 2025 Key Statistics. January saw throughput and length of stay being higher than budget. A downturn in inpatient surgeries had a significant impact on the budget. However, discharges, outpatient surgeries and acute case mix index were higher than both budget and last year. Mr. Swiatkowski reported an operating loss of \$4.5M. Mr. Swiatkowski updated the board on DHS/IGT payment status, VAPAP, NYS Budget and Federal Policy. A summary of the preliminary financial results through January 31, 2025 was reviewed and the full set of these materials are received and filed.

V. **Standing Committees**

- a. Executive Committee: Eugenio Russi reported on the most recent Executive Committee meeting.
- b. Finance Committee: Mr. Seaman had nothing more to report from the Finance Committee.
- c. MWBE Committee: Reverend Mark Blue reported that the hospital continues to offer community businesses opportunities to work.
- d. Quality Improvement and Patient Safety Committee: Reverend Kinzer Pointer updated the group on the February committee meeting.

All reports except that of the Performance Improvement Committee are received and filed.

VI.

<u>Recess to Executive Session – Matters Made Confidential by Law</u> Moved by Reverend Kinzer Pointer and seconded by Michael Seaman to enter into Executive Session at 4:53 p.m. to consider matters made confidential by law, including strategic planning.

Motion approved unanimously

VII. **Reconvene in Open Session**

Moved by Michael Seaman and seconded Reverend Kinzer Pointer to reconvene in Open Session at 5:26 p.m. No action was taken by the Board of Directors in Executive Session

Motion approved unanimously

VII. <u>Adjournment</u>

Moved by Reverend Kinzer Pointer to adjourn the Board of Directors meeting at 5:27 p.m.

1. Hanson

Sharon L. Hanson Corporation Secretary

Resolution Approving the Amended 2025 Capital Budget of the Corporation

Approved February 25, 2025

WHEREAS, the Corporation has previously submitted its 2025 Operating and Capital Budget as required by New York Public Authorities Law. It was previously submitted and approved not later than ninety (90) days before the commencement of the Corporation's fiscal year, on January 1; and

WHEREAS, consistent with New York law and regulations, an approved budget was publicly filed not later than September 30, 2024; and

WHEREAS, the Corporation's management team has prepared an Amended Capital Budget for the year 2025 and has presented this amended budget, and the assumptions upon which it is based, to the Finance Committee of the Board of Directors on February 17, 2025 and the Finance Committee is recommending approval of the Amended Capital Budget as presented;

Now, THEREFORE, the Board of Directors resolves as follows:

1. The 2025 Amended Capital Budget of the Corporation as presented to the Board of Directors on February 25, 2025 is approved.

2. The Corporation is directed to timely file this amended budget in accordance with applicable law and regulation.

3. This resolution shall take effect immediately.

haven A. Hanson

Sharon L. Hanson Corporation Secretary

A Resolution of the Board of Directors Approving Items for Annual Review

Approved February 25, 2025

WHEREAS, pursuant to New York Public Authorities Law, Erie County Medical Center Corporation (the "Corporation") is required to annually review and approve its procurement guidelines, property disposal guidelines, investment policy, and mission statement (collectively, the "Items for Annual Review"); and

WHEREAS, the Governance Committee of the Board has reviewed the Items for Annual Review and wishes to recommend their approval to the Board; and

WHEREAS, the Board wishes to approve the Items for Annual Review in the form presented;

Now, THEREFORE, the Board of Directors resolves as follows:

1. The Board of Directors of the Corporation approve the Items for Annual Review in the form presented.

2. The Corporation is authorized to do all things necessary and appropriate to effectuate this resolution.

3. This resolution shall take effect immediately.

Hanson

Sharon Ĺ. Hanson Corporation Secretary

MEMORANDUM

| To: | ECMCC Board of Directors |
|----------|---------------------------------|
| From: | Joseph T. Giglia, II |
| Subject: | Policies requiring Board review |
| DATE: | February 13, 2025 |

Under New York Public Authorities Law, the ECMCC Board of Directors is required to annually review and approve a number of items on an annual basis. Additionally, ECMCC is required to present any proposed changes to its By-Laws to the Board prior to their approval.

A summary of these items, attached to this correspondence and already reviewed and approved by various Board Committees, is as follows:

- 1. **By-Laws (pp. 2-22).** Changes to ECMCC's By-Laws, reflected in redline, were approved by the Governance Committee in November 2024 and are presented here for further Board review.
- 2. **Disposal of Property Guidelines (pp. 23-29).** The current policy, governing the process and procedures under which ECMCC may dispose of property, was revised in March 2017, and remains compliant with current law. The Guidelines were reviewed by the Governance Committee in November 2024 and no further changes have been made.
- 3. **Investment Policy (pp. 30-52).** The policy, governing ECMCC's investment guidelines, objectives, and processes, was last revised and approved by the Investment Committee in October 2024. Changes have been made to Appendix B, Fund Allocations and Benchmarks.
- 4. **Mission Statement (pp. 53-54).** Adopted in 2015, no changes have been made to ECMCC's mission statement.
- 5. **Procurement Guidelines (pp. 55-83).** Numerous changes to these guidelines, which set forth the processes under which ECMCC purchases goods and services, are reflected in redline, and were reviewed and approved by the Governance Committee in November 2024.

Please review the documents included with this correspondence in preparation for discussion at the February 25 Board Meeting.

ERIE COUNTY MEDICAL CENTER CORPORATION

DISPOSAL OF PROPERTY GUIDELINES

Revised MARCH 28, 2017

TABLE OF CONTENTS

| I. | Statement of Purpose | 1 |
|------|--|---|
| II. | Definition of Terms | 1 |
| III. | Annual Review, Approval and Distribution | 2 |
| IV. | Contracting Officer's Responsibilities | 2 |
| | Section 1 - Administration | 2 |
| | Section 2 - Publication | 2 |
| | Section 2 - Reporting | 2 |
| V. | Disposal of Property | 2 |
| | Section 1 - Supervision and Direction | 2 |
| | Section 2 - Custody and Control | 3 |
| | Section 3 - Method of Disposition | 3 |
| | Section 4 - Sales by the Commissioner of General Services | 3 |
| | Section 5 - Validity of Instruments | 3 |
| | Section 6 - Bids for Disposal | 3 |
| | Section 7 - Disposal by Negotiation; Explanatory Statement | 4 |

ERIE COUNTY MEDICAL CENTER CORPORATION

DISPOSAL OF PROPERTY GUIDELINES

I. <u>STATEMENT OF PURPOSE</u>

These Guidelines are adopted pursuant to the provisions Article 9, Title 5-A "Disposal of Property by Public Authorities" of the Public Authorities Law of the State of New York. These Guidelines set forth Erie County Medical Center Corporation's ["ECMCC's"] operative policy and instructions regarding the use, awarding, monitoring and reporting of contracts for the disposal of property, and the designation of a Contracting Officer (hereinafter defined) who shall be responsible for ECMCC's compliance with, and enforcement of, the Guidelines.

These Guidelines shall be consistent with ECMCC's procurement contract guidelines, Article 10-C of the Public Authorities Law of the State of New York [the "ECMCC Act"], Article 5-A of the General Municipal Law, New York Public Authorities Law Article 9, Title 5-A and other applicable law for the disposition of property.

II. <u>DEFINITION OF TERMS</u>

For purposes of these Guidelines, the following terms shall have the following meanings:

- a. "Contracting Officer" means the ECMCC employee as appointed by resolution of the ECMCC Board of Directors to be responsible for the disposition of property.
- b. "Dispose" or "disposal" means transfer of title or any other beneficial interest in personal or real property in accordance with these Guidelines.
- c. "ECMCC" shall mean Erie County Medical Center Corporation.
- d. "ECMCC Act" means Article 10-C of the New York Public Authorities Law.
- e. "Property" shall mean personal property in excess of five thousand dollars in value, real property, and any inchoate or other interest in such property, to the extent that such interest may be conveyed to another person for any purpose, excluding an interest securing a loan or other financial obligation of another party.

III. ANNUAL REVIEW, APPROVAL AND DISTRIBUTION

The Board of Directors shall annually review and approve these Guidelines, and any amendments thereto, by no later than March 31st each year. On or before March 31st each year, the Contracting Officer shall 1) file with the New York Office of the State Comptroller a copy of these Guidelines, as most recently approved by the Board of Directors, and 2) post on the ECMCC website a copy of these Guidelines, as most recently approved by the Board of Directors. A copy of the then-current Disposal of Property Guidelines shall be continuously maintained on the ECMCC website.

IV. CONTRACTING OFFICER'S RESPONSIBILITIES

<u>Section 1.</u> <u>Administration.</u> The ECMCC Contracting Officer shall be responsible for implementing these Guidelines and enforcing ECMCC's compliance therewith. In addition to the foregoing, the Contracting Officer shall be the person responsible for performing the following duties on behalf of ECMCC:

- a. maintain adequate inventory controls and accountability systems for all property under ECMCC's control;
- b. periodically inventory such property to determine which property shall be disposed of;
- c. produce a written report of such property in accordance with the requirements set forth below; and
- d. transfer or dispose of such property as promptly as possible in accordance with the procedures set forth below.

<u>Section 2.</u> <u>Publication.</u> In addition to his/her responsibilities under Article II above, the Contracting Officer shall publish, not less frequently than annually, a report listing all ECMCC property. Such report shall consist of a list and full description of all real and personal property disposed of during such period. The report shall contain the price received by ECMCC and the name of the purchaser for all such property sold by ECMCC during such period. The Contracting Officer shall deliver copies of such report to the State Comptroller, the Director of the Budget, the Commissioner of General Services, and the New York State Legislature.

<u>Section 3.</u> <u>Reporting.</u> The Contracting Officer shall report to the ECMCC Chief Financial Officer and shall provide such reports at such times and in such manner as may be requested by the Chief Financial Officer or the finance committee of the Board of Directors.

V. <u>DISPOSAL OF PROPERTY</u>

<u>Section 1.</u> <u>Supervision and Direction</u>. Except as otherwise provided herein, the Contracting Officer shall have supervision and direction over the disposition of ECMCC property.

<u>Section 2.</u> <u>Custody and Control</u>. The custody and control of the property of ECMCC, pending its disposition, and the disposal of such property, shall be performed by ECMCC or by the Commissioner of General Services when so authorized under New York Public Authorities Law Article 9, Title 5-A and these Guidelines.

<u>Section 3.</u> <u>Method of Disposition</u>. Except as otherwise provided herein, ECMCC may dispose of property for not less than the fair market value of such property by sale, exchange, or transfer, for cash, credit, or other property, with or without warranty, and upon such other terms and conditions as the Contracting Officer deems proper, and it may execute such documents for the transfer of title or other interest in property and take such other action as it deems necessary or proper to dispose of such property under the provisions of these Guidelines. Any property, including any interest therein, which because of its unique nature is not subject to fair market pricing, shall be disposed of only after an appraisal of the value of such property has been made by an independent appraiser and such appraisal is included in the record of the transaction. In engaging an appraiser, the Contracting Officer shall comply with ECMCC's procurement contract guidelines.

<u>Section 4.</u> <u>Sales by the Commissioner of General Services</u>. When it shall be deemed advantageous to the State of New York, ECMCC may enter into an agreement with the Commissioner of General Services where he/she may dispose of ECMCC property under terms and conditions agreed to by ECMCC and the Commissioner of General Services. In disposing of any such property, the Commissioner of General Services shall be bound by the terms of New York Public Authorities Law Article 9, Title 5-A and in such instances, references therein to the contracting officer shall be deemed to refer to such commissioner.

<u>Section 5.</u> <u>Validity of Instruments</u>. A deed, bill of sale, lease, or other instrument executed by or on behalf of ECMCC, purporting to transfer title or any other interest in property of ECMCC under these Guidelines shall be conclusive evidence of compliance with the provisions of New York Public Authorities Law Article 9, Title 5-A concerning title or other interest of any bona fide grantee or transferee.

Section 6. Bids for Disposal.

Except as provided in Section 7 below, all disposals, or contracts for disposal, of property shall be made after publicly advertising for bids as follows:

- a. the Contracting Officer shall advertise for bids prior to disposal or contract for disposal of property by publishing notice thereof in at least one newspaper of general circulation, and the Contracting Officer shall have the discretion to advertise for bids through such additional methods, and on such terms and conditions as shall permit full and free competition consistent with the value and nature of the property;
- b. all bids shall be publicly disclosed at the time and place stated in the advertisement; and

c. the award shall be made with reasonable promptness by written notice from the Contracting Officer to the responsible bidder whose bid, conforming to the invitation for bids, will be most advantageous to the state and ECMCC, price and other factors considered; provided, that all bids may be rejected when it is in the public interest to do so.

Section 7. Disposal by Negotiation; Explanatory Statement.

a. Disposals and contracts for disposal of property may be negotiated or made by public auction without regard to Section 6 above, but subject to obtaining such competition as is feasible under the circumstances, if, in the opinion of the Contracting Officer:

- 1) the personal property involved is of a nature and quantity which, if disposed of under Section 6 above, would aversely affect the state or local market for such property, and the estimated fair market value of such property and other satisfactory terms of disposal can be obtained by negotiation;
- 2) the fair market value of the property does not exceed fifteen thousand dollars;
- 3) bid prices after advertising therefor are not reasonable, either as to all or some part of the property, or have not been independently arrived at in open competition;
- 4) the disposal will be to the state or any political subdivision, and the estimated fair market value of the property and other satisfactory terms of disposal are obtained by negotiation;
- 5) the disposal is for an amount less than the estimated fair market value of the property, the terms of such disposal are obtained by public auction or negotiation, the disposal of the property is intended to further the public health, safety or welfare or an economic development interest of the state or a political subdivision (to include but not limited to, the prevention or remediation of a substantial threat to public health or safety, the creation or retention of a substantial number of job opportunities, or the creation or retention of a substantial source of revenues, or where the ECMMC Act permits), the purpose and the terms of such disposal are documented in writing by the Contracting Officer and approved by resolution of the ECMCC Board of Directors; or
- 6) such action is otherwise authorized by applicable law.
- b. The Contracting Officer shall prepare an explanatory statement describing the

circumstances of each disposal by negotiation of any of the following:

- 1) any personal property which has an estimated fair market value in excess of fifteen thousand dollars;
- 2) any real property that has an estimated fair market value in excess of one hundred thousand dollars, except that any real property disposed of by lease or exchange shall only be subject to paragraphs 3 and 4 of this subparagraph;
- 3) any real property disposed of by lease for a term of five years or less, if the estimated fair annual rent is in excess of one hundred thousand dollars for any of such years;
- 4) any real property disposed of by lease for a term of more than five years, if the total estimated rent over the term of the lease is in excess of one hundred thousand dollars; or
- 5) any real property or real and related personal property disposed of by exchange, regardless of value, or any property, any part of the consideration for which is real property.

Each such statement shall be transmitted to the State Comptroller, the Director of the Budget, the Commissioner of General Services, and the New York State Legislature not less than ninety days in advance of such disposal, and a copy thereof shall be preserved in the files of ECMCC.

Erie County Medical Center Corporation

Statement of Investment Policy and Guidelines

Drafted: December 12, 2006 Revised: April 15, 2014 December 2014 September 2015 October 2016 December 2019 March 2020 March 2021 October 2022 November 2023 October 2024

TABLE OF CONTENTS

| I. | INTRODUCTION1 |
|------|---|
| II. | GENERAL INVESTMENT GUIDELINES AND OBJECTIVES 1 |
| III. | DELEGATION OF AUTHORITY AND RESPONSIBILITIES |
| IV. | ADMINISTRATION AND REPORTING |
| V. | INVESTMENT MANAGER SELECTION AND GUIDELINES |
| VI. | INVESTMENT MANAGER PERFORMANCE MEASUREMENT |
| VII. | ALLOWABLE AND PROHIBITED INVESTMENTS |
| | |
| | APPENDIX A: FUND OBJECTIVES AND CONSTRAINTS |
| | NYS RETIREMENT RESERVE FUND 13 |
| | CAPITAL RESERVE FUND14 |
| | RETIREE HEALTH RESERVE FUND 15 |
| | W/C PROFESSIONAL LIABILITY RESERVE FUND |
| | GENERAL DEPOSITORY & GENERAL OPERATING RESERVE 17 |
| | DEBT SERVICE AND DEBT SERVICE RESERVE FUNDS |
| | GNMA BOND RESERVE FUND19 |
| | APPENDIX B: FUND ALLOCATIONS AND BENCHMARKS |
| | APPENDIX C: DESIGNATED PARTIES AND PRIMARY CONTACTS |

I. INTRODUCTION

In accordance with Public Authorities Law §2925 and its associated regulations, Public Authorities Law § 3636, and the Investment Guidelines for Public Authorities issued by the New York State Comptroller, an investment program involving public funds must include four basic ingredients – legality, safety, liquidity and reasonable return.

It is the responsibility of each public authority to determine and evaluate its own risk in all its investment transactions with due regard to prudent business principles and practices and diligence under the circumstances then prevailing that a knowledgeable and prudent investor would act. The financial resources of the public authority should be properly managed to achieve investment income consistent with sound investment practice.

This document defines the investment policies, objectives, and guidelines applicable to the Erie County Medical Center Corporation's ("Corporation") Investment Funds. It was developed by the Corporation's Investment Committee ("Committee") in conjunction with its Investment Management Consultant.

The purpose of this document is threefold. First, it will constitute the investment plan for these assets. Second, it will serve as a communication tool between the Committee and its investment manager(s). Third, these guidelines will provide a framework to measure the ongoing progress of the recommended structure, and as such should be reviewed annually and revised as necessary to reflect changes in available investment opportunities and market conditions or as a result of any recommendations from the periodic evaluation of the performance of the investment program or any audits of the investment program.

II. GENERAL INVESTMENT GUIDELINES AND OBJECTIVES

General Investment Return Objective

The long-term objective of the Corporation's Investment Funds is to generate returns which are sufficient to meet current and expected future financial requirements. To accomplish this, the Corporation seeks to earn the greatest total return possible, consistent within its general risk tolerance, eligible asset classes, and asset allocation strategies outlined in this document.

General Investment Risk Objective

Permanent loss of capital is the most significant risk to achievement of the Funds' objectives. The Committee will seek to avoid such losses through a robust approach to risk assessment. Risk considerations will be viewed from a total portfolio perspective rather than at the individual investment level.

Risk tolerance can be defined by the *ability* and *willingness* to take risk. Several factors influence the ability to take risk, including the Investment Funds' purpose, time horizon, liquidity needs, and any other unique factors such as their effect on organizational debt covenants, where applicable. Variables that affect the Corporation's willingness to take risk include market or economic conditions, valuation and interest rate levels, and the Corporation's strategic plans or operating environment.

It is recognized that volatility is a widely-used measure of risk in the short term and that market fluctuations may result in varying levels of interim performance. It is expected that volatility will be managed through specific asset allocation strategies and diversification based upon the appropriate investment time horizon. Diversification shall exist at multiple levels of the investment program, including asset class, sub-asset class, risk factor, investment manager type, and underlying exposures of each investment manager (e.g. prudent levels of sector and company/issuer diversification).

Asset Allocation Process

It is recognized that asset allocation is a key determinant of investment return variability. The Committee expects the asset allocation policies to reflect and be consistent with the investment objectives and risk tolerances expressed throughout this document. These policies are designed to increase the likelihood of achieving return objectives over a full market cycle and within acceptable risk parameters.

The Investment Committee and Management, with assistance from the Investment Management Consultant, shall engage in a thorough process to determine appropriate policy asset allocations for the Funds. The Investment Management Consultant shall recommend a policy asset allocation for each Fund and formulate forward-looking return and volatility projections based on its capital markets expectations.

Individual Fund objectives and constraints that serve as key inputs to determining policy asset allocation can be found in Appendix A of this document.

Performance Evaluation

Total Fund performance against objectives shall be viewed from a long-term perspective, generally a full market cycle (approximately 7+ years). This can be augmented with comparisons over rolling periods such as 3 or 5 years. The investment performance of the Funds, as well as their asset class components, shall be measured against commonly accepted performance benchmarks as shown in the Appendix B.

Permissible Investments

The asset allocation of the Funds is expected to include a wide range of asset classes. The addition or removal of asset classes will necessitate deliberation by the Investment Committee, Management, and Investment Consultant regarding the merits of an asset class from an organizational and total portfolio context. A list of asset classes currently included in the Corporation's Fund allocations can be found in Appendix B.

III. DELEGATION OF AUTHORITY AND RESPONSIBILITIES

Board of Directors and Investment Committee

The Board of Directors is charged by law with the responsibility for the management of the assets of the Corporation. The Board of Directors shall discharge its duties solely in the interest of the Corporation, with the care, skill, prudence and diligence under the circumstances then prevailing. In this regard, the Board of Directors, the Investment Committee, and Corporation management shall invest and manage Corporation funds as a prudent investor would, by considering the purposes, terms and other circumstances of the funds in the Corporation's care and by pursuing an overall investment strategy reasonably suited to the Corporation, and they shall require the same standard of prudence from investment managers and consultants they engage to assist them.

Within the broad framework of policy set by the Board of Directors, the Investment Committee shall have direct responsibility for the oversight and management of the invested assets of the Corporation and for the establishment of investment policies and procedures. Such oversight shall include:

- A. Establishing reasonable and consistent investment objectives, policies and guidelines which will direct the investment of the Corporation's assets.
- B. Determining the Corporation's risk tolerance and investment horizon and communicating these to the appropriate parties.

- C. Designating an appropriate Corporation individual as "Investment Officer" whose responsibility it will be to proscribe and maintain a control structure to protect investment assets from loss, theft, and misuse.
- D. Developing and enacting proper control procedures (for example, replacing Investment Manager(s) due to fundamental change in investment management process, or failure to comply with established guidelines).
- E. Advising and communicating with the Board of Directors as necessary with respect to investment matters.
- F. Recommending to the Board of Directors proposed changes and revisions to this Investment Policy.
- G. Reviewing any independent audits of the investment program if requested to do so by the Corporation's Audit Committee.
- H. Prudently and diligently selecting qualified investment professionals in compliance with the Corporation's procurement requirements, including Investment Management Consultants, Investment Managers, and Custodians. Additional specialists such as attorneys, auditors, and others may be employed by the Board of Directors, acting on its own or through its Investment Committee, to assist in meeting its responsibilities and obligations to administer Corporation assets prudently.
- I. Regularly evaluating the performance of the Investment Manager(s) to assure adherence to policy guidelines and monitoring investment objective progress.

Responsibilities of the Investment Managers

Investment Manager

The Corporation enters into agreements with selected investment managers who provide day-to-day investment management services to the Corporation. Each investment manager will have discretion to purchase, sell or hold the specific securities that will be used to meet the Corporation's investment objectives. Such appointments do not relieve the Committee from the responsibilities of overseeing the investment program.

Adherence to Investment guidelines

The investments are to be managed in accordance with the guidelines expressed herein, or expressed by separate written instructions, when deviation is deemed prudent and desirable by the Investment Committee. Written instructions amending this document must be authorized by the Investment Committee of the Board (Committee) and should be communicated through the Chief Investment Officer.

Discretionary Authority

The Investment Managers are expected to exercise complete investment discretion within the boundaries of the restrictions outlined in this Statement of Investment Policy and Guidelines.

Such discretion includes decisions to buy, hold, or sell equity or fixed-income securities (including cash equivalents) in amounts and proportions reflective of each manager's current investment strategy. However, the Committee is aware that its decision to invest in a commingled account and/or mutual fund may relieve the manager from strict adherence to all elements of the policy. In such case, the manager's strategy shall be dictated by its fund prospectus or other relevant governing documents.

Realized Gains/Losses

In addition to investment income, fiscal year net realized gains/losses are an important element of the Corporation's budgeting process. Specifically, the Corporation requires that its investment managers communicate, in advance, any intentions to realize fiscal year losses in excess of \$250,000.

Reporting

The Investment Managers shall provide, on a timely basis, quarterly reports containing portfolio activity, valuations at market, and quarterly strategy updates.

Compliance with Prudency and Diversification Measures

As a fiduciary, each investment manager is expected to diversify the portfolio to minimize the risk of large losses. The manager is expected to invest the assets with care, skill, prudence, and diligence under the circumstances then prevailing. In this regard, the manager shall invest and manage Corporation funds as a prudent investor would, by considering the purposes, terms and other circumstances of the funds in the Corporation's care and by pursuing an overall investment strategy reasonably suited to the Corporation. Furthermore, the investment manager is expected to acknowledge its intention to comply with the Statement of Investment Policy and Guidelines as it currently exists or as modified by the Committee in the future.

Responsibilities of the Trustee / Custodian

The Trustee/Custodian will be selected by the Investment Committee and will provide full custodian services. It will maintain possession of securities owned by the Corporation, collect dividend and interest payments, and redeem maturing securities, and effect receipt and delivery following purchases and sales. The Trustee/Custodian may also perform regular accounting of assets owned, purchased, or sold, as well as movement of assets into and out of the Corporation accounts. In addition, the custodian will provide monthly documentation of portfolio activity and portfolio value.

The Trustee/Custodian is responsible for the safekeeping of Corporation assets, assuring protection from loss, theft or misuse, and timely/reliable auditing of earnings and transactions. Specific responsibilities of the Trustee/Custodian include:

- 1. Maintaining possession of securities owned by the Corporation, collecting dividend and interest payments, redeeming maturing securities, and effecting receipt and delivery following purchases and sales.
- 2. Performing regular accounting of assets owned, purchased, or sold, as well as movement of assets into and out of the Corporation accounts.
- 3. Providing monthly documentation of portfolio activity and portfolio value.
- 4. Furnishing to the Corporation's Investment Officer a copy of its "SSAE 16 Report" from its independent auditors on an annual basis.

Safekeeping Accounts

Securities purchased should be delivered against payment and held in a custodian safekeeping account in investment accounts segregated from the custodian's own assets.

Collateralization

As it pertains to demand deposits, time deposits, or certificates of deposit, the Corporation will seek to ensure New York State Public Authorities collateralization guidelines are followed for such assets through its relationship with custodial banking institutions. Given the nature of vehicles utilized in the Corporation's investment portfolios (i.e. pooled funds), it is not anticipated that collateralization guidelines shall apply to such funds. However, in the event it is deemed necessary that any of the Corporation's investment assets shall be collateralized, the Corporation shall ensure compliance.

Responsibilities of the Investment Management Consultant

Generally

The Investment Management Consultant may assist the Investment Committee in: establishing investment policy, objectives, and guidelines, including investment time horizon risk tolerance and total return objectives; selecting one or more investment managers; reviewing and evaluating such manager's performance over time; measuring and evaluating investment performance; and other tasks as deemed appropriate.

The Investment Management Consultant's role is to provide investment advice to the Investment Committee concerning the investment management of Corporation assets. Such advice will be consistent with the investment objectives, policies, guidelines and constraints as established in this statement. Specific responsibilities of the Investment Consultant include:

- 1. Assisting in the development and periodic review of investment policy, objectives, risk tolerance, and guidelines and making recommendations to the Committee.
- 2. Conducting investment manager searches where appropriate and making recommendations as required.
- 3. Monitoring the performance of the Investment Manager(s) and providing the Committee periodic reports so that it may determine the Corporation's progress toward its investment objectives and adherence to its investment program compliance.
- Monitoring the total fees, commissions, and other charges paid in rendering investment services to the Corporation, at least annually.
- 5. Communicating matters of policy, manager research, and manager performance to the Committee and making recommendations where appropriate.
- 6. Reviewing Corporation investment history, historical capital markets performance and the contents of this investment policy statement with any newly appointed members of the Committee.
- 7. Providing "due diligence" on investment managers such as any qualitative change to investment management organizations: Examples include changes in portfolio management personnel, ownership structure, investment philosophy, etc.
- Providing current Statement of Investment Policy and Guidelines to existing, replacement and additional Investment Managers when changes occur. This applies to any strategy with a separately-managed account (SMA) format and excludes commingled formats such as mutual funds.
- 9. Maintaining timely and appropriate communications with the Chief Financial Officer, Chief Investment Officer and Chairman of the Committee relative to matters of substance regarding:
 - A. Changes in investment forecast, investment strategies, or changes in portfolio structure;
 - B. Changes in ownership, organization, financial conditions, and key personnel within the investment management organization.

Communication

The Committee encourages, and the Investment Management Consultant is responsible for, frequent and open communication with the Committee on all significant matters pertaining to the

investment of the Corporation's assets. These communications would generally be addressed to the Chief Investment Officer. In this manner, the Consultant will advise the Committee of any major changes in investment outlook, investment strategy, asset allocation, portfolio structure, market value of the investments, managers and other substantive matters affecting the assets under their advisement. The Consultant will advise the Committee promptly of any significant changes in the ownership, organization structure, financial condition, or senior personnel of their organization.

All documents, exhibits, and other written material, etc., which will be used during review meetings between the Committee and the Consultant, should be submitted to the Committee, at least one week in advance of these meetings. It is expected that these meetings will take place periodically at the Committee's direction.

The Committee recognizes that the Statement of Investment Policy and Guidelines requires periodic re-examination and perhaps revision if it is to continue to serve as a working document to encourage effective investment management. Whenever the Consultant believes that the Statement should be altered, it is the responsibility of the Consultant to initiate written communication with the Committee through the Chief Investment Officer.

IV. ADMINISTRATION AND REPORTING

Policy Review

This document shall be reviewed by the Investment Committee annually and the results of the review reported to the Board of Directors.

Portfolio Rebalancing

Since asset allocation is the most critical component of portfolio returns, it is desirable to rebalance when necessary to minimize deviations from policy allocations.

The Funds shall be rebalanced in the event any individual asset class allocation differs from its policy by more than 20% of the target weight, but with a minimum deviation threshold of 2% of the total portfolio value. For example, if the policy asset allocation for an asset class is 20% of the total portfolio, then the portfolio's actual asset allocation must be below 16% or above 24% before rebalancing is required (20% rule). If, however, the policy asset allocation for an asset class is 3% of the total portfolio, then the portfolio's actual allocation must be either below 1% or above 5% before rebalancing is required (2% rule). This approach is designed to keep the portfolios reasonably in line with their target policies while avoiding excessive rebalancing.

This rebalancing policy may be suspended or altered based on assessment of market, operational, or other relevant considerations subject to Investment Committee approval.

The Investment Management Consultant shall be responsible for making rebalancing recommendations to Management who, in turn, shall be responsible for providing the necessary instructions to the Custodian. Investment Committee approval is not required. From time-to-time, it may be deemed appropriate to forego portfolio rebalancing.

Compliance with the Law

All actions undertaken or contemplated by this document shall follow appropriate law and applicable state statutes.

Annual Investment Reporting

The Corporation shall submit an annual investment report to the Division of the Budget with copies to the Office of the State Comptroller, the Senate Finance Committee, and the Assembly Ways and Means Committee. Such report shall include:

- 1. Investment guidelines and any amendments to such guidelines since the last investment report;
- 2. An explanation of the investment guidelines and amendments;
- 3. The results of the annual independent audit;
- 4. The investment income record of the Corporation; and
- A list of total fees, commissions or other charges paid to each investment banker, broker, agent, dealer and advisor rendering investment associated services to the Corporation since the last investment report.

Conflicts of Interest

All persons responsible for investment decisions or who are involved in the management of the portfolios or who are consulting to, or providing any advice or service whatsoever to Corporation's Investment Funds shall disclose in writing at the beginning of any discussion or consideration by the Investment Committee, any relationships, material beneficial ownership, or other material interest(s) which the person has or may reasonably be expected to have, with respect to any investment issue under consideration. The Investment Committee may require such persons to remove themselves from the decision-making process.

Operating Procedures

Investments should be made in accordance with the following Operating Procedures:

- The investment selection process should utilize competitive quotations or negotiated prices, except in the purchase of government securities at their initial value.
- 2. Each disbursement of funds (and corresponding receipt and securities) or delivery of securities (and corresponding receipt of funds) should be based upon proper written authorization. If the authorization is initially given verbally, there should be written or telegraphic confirmation from the Investment Officer to the Custodian.
- 3. Payment of funds should only be made upon delivery of securities. Written confirmation of delivery should be obtained from the Custodian.
- 4. The process of initiating, reviewing and approving requests to buy and sell investments should be documented and retained for audit purpose. Dealer limits should be established and reviewed regularly.
- 5. Custodians must have prior authorization from ECMCC to deliver obligations and collateral. All transactions must be confirmed in writing to the authority. Delivery of obligations sold should only be made upon receipt of funds.
- 6. Custodial banks should be required to report whenever activity has occurred in ECMCC's custodial account.
- 7. There should be at least monthly verifications of both the principal amount and the market values of all investments and collateral. Appropriate listings should be obtained from the Custodian and compared against ECMCC's records.

A record of investments shall be maintained by the Investment officer. The records should identify the security, the fund for which held, the place where kept, date of disposition and amount realized and the market value and custodian of collateral.

Annual Independent Audits

ECMCC shall require an annual independent audit of all investments. The annual investment audit:

- shall determine whether: ECMCC complies with its own investment policies; investment assets are adequately safeguarded; adequate accounts and records are maintained which accurately reflect all transactions and report on the disposition of authority investment assets; and a system of adequate internal controls is maintained;
- 2. shall determine whether ECMCC complied with the applicable laws, regulations and State Comptroller's Investment Guidelines; and
- 3. should be designed to the extent practical to satisfy both the common interests of ECMCC and the public officials accountable to others.

A written audit report should be prepared presenting the results of the annual independent audit of all investments and should include:

- 1. a description of the scope and objectives of the audit;
- a statement that the audit was made in accordance with generally accepted government auditing standards;
- 3. a description of any material weaknesses found in the internal controls;
- 4. a description of all non-compliance with the authority's own investment policies as well as applicable laws, regulations and the State Comptroller's Investment Guidelines;
- 5. a statement of positive assurance of compliance on the items tested and negative assurance on those items not tested; and
- 6. a statement on any other material deficiency or finding identified during the audit not covered in (5) above.

The audit report shall be filed within 90 days after the close of the authority's fiscal year with the Coordinator of Public Authority Programs, Office of the State Comptroller, A.E. Smith Office Building, Albany, New York, 12236.

V. INVESTMENT MANAGER SELECTION AND GUIDELINES

Investment Manager Selection

The selection of Investment Managers must be based on prudent due diligence procedures and, when applicable, the Corporation's procurement requirements. Each Investment Manager must be registered with the Securities and Exchange Commission under the Investment Advisors Act of 1940 as Registered Investment Advisors or documented as exempt by the same laws.

The Investment Management Consultant shall assist in establishing criteria and identifying suitable candidates, which shall be periodically presented for the Investment Committee's consideration. At a minimum, selection criteria will include historical risk and return, correlation to asset class and investment style, experience of investment professionals, depth of research capability, strength of investment process, diversification of portfolios, assets under management, and consideration of the investment manager as a going concern. Applying these criteria, the Investment Committee shall establish an approved list of Investment Managers on a periodic basis.

Investment Manager Contracts and Guidelines

The Corporation intends to use the investment manager guidelines set forth in this document as a framework to help the Investment Managers achieve their investment objectives at a level of risk deemed acceptable. The policies and restrictions are designed to minimize interfering with Investment Managers' efforts to attain overall objectives and to minimize excluding them from appropriate investment objectives. This document allows the Investment Managers discretion over the diversification of assets for the purposes of increasing investment returns and/or reducing risk exposure. When appropriate, Investment Managers are given responsibility to shift the allocation of assets among industry sectors and individual securities to pursue opportunities presented by changes within the capital markets.

For mutual fund, commingled trust, partnership, or any other non-separately-managed account structure, it is recognized that such vehicles will invest according to the strategy outlined in their prospectus or any other relevant fund documentation. Thus, it is incumbent upon the Corporation, with assistance from the Investment Management Consultant, to ensure comfort with underlying investments in those vehicle types. For these types of pooled investment vehicles, it may not be practical to have a written contract between the Corporation and Investment Manager. Rather, it is expected that execution of subscription documents, limited partnership agreements, or any other relevant documentation will serve to secure the Corporation's financial interest in an Investment Manager's strategy. In addition, for purchase of mutual fund shares it is expected that the Trustee / Custodian will document the Corporation's financial interest in an Investment Manager's strategy.

For separately-managed account structures (SMAs), specific restrictions for an Investment Manager shall be identified in the Investment Management Agreement or other governing document for the account. In addition, the Investment Manager shall maintain procedures sufficient to secure the Corporation's financial interest in an investment, including, where applicable, appropriate collateral requirements. SMA Investment Managers shall also acknowledge receipt of this IPS in writing.

VI. INVESTMENT MANAGER PERFORMANCE MEASUREMENT

The performance for each Investment Manager shall be reported and measured against commonly accepted performance benchmarks as shown in Appendix B. It is expected that Investment Managers with actively-managed strategies shall outperform their benchmarks on an absolute and/or risk-adjusted basis over meaningful time frames, preferably full market cycles. For functional purposes, full market cycles are defined as seven years or longer. In addition, it is preferred that such Investment Managers rank favorably within an applicable peer universe over meaningful time frames such as rolling 3- to 5-year periods. While not the sole determinant, if an active manager exhibits underperformance over a full market cycle, its inclusion in the portfolio(s) shall be revisited along with the merits of active management within the manager's asset class, in general.

As mentioned above, when considering removal of an Investment Manager, performance shall not be the sole determinant. Rather, it shall be based upon a more comprehensive review including an understanding of the reasons for underperformance, continued suitability within the portfolio, and whether or not better options exist.

VII. ALLOWABLE AND PROHIBITED INVESTMENTS

For mutual fund, commingled trust, partnership, or any other non-separately-managed account structure, it is recognized that such vehicles will invest according to the strategy outlined in their prospectus or any other relevant fund documentation. Thus, it is incumbent upon the Investment Committee, with assistance from the Investment Management Consultant, to ensure comfort with underlying investments in those vehicle types.

For separately-managed account structures (SMAs), specific guidelines for investment managers are outlined below.

Allowable Investments

A. Fixed Income and Cash Equivalents

- 1. Instruments and Credit Quality
 - a. Instruments issued and fully guaranteed by the U.S. Government or any of its agencies and instrumentalities.
 - b. Instruments issued by domestic corporations, including corporate notes and floating rate notes, must be rated "Baa"/"BBB" or better at time of purchase by Moody's Investor Service or Standard and Poor's. Asset-backed securities and collateralized mortgage obligations must be rated "Aaa"/"AAA" by the rating agencies. If the domestic corporation has a senior debt rating of "Baa" or better, the issuer's commercial paper rating and/or CD rating must be one of "A1", "P1", or "F1". If the issuer does not have a senior debt rating, the issuer's commercial paper rating and/or CD rating must be any two of "A1", "P1", "F1" or have a letter of credit drawn on the issuer, meeting the above guidelines.
 - Obligations of domestic banks, including banker's acceptances, certificates of deposit, time deposits, notes, and other debt instruments.
 - d. Instruments of countries or foreign corporations rated at least "Aa"/"AA" by appropriate rating organization. Instruments issued by the U.S. agency of a foreign corporation are also permitted, subject to the same quality constraints. Instruments referred to in this section cannot comprise more than 20% of the total combined portfolio, at market.
 - e. The following types of Euro issues: banker's acceptances, time deposits, bonds, and floating rate notes of any issue rated "Aa"/"AA" or better by Standard and Poor's or Moody's.
 - f. Yankee securities are subject to the quality constraints outlined in section "d" above.
 - g. Securities resold under SEC Rule 144A subject to the quality constraints outlined in section "b" above.
 - h. Repurchase Agreements are permitted with such government dealers who have and maintain a minimum equity value of \$50 million, as the investment manager shall, in its discretion, determine from time to time. Repurchase Agreements shall be subject to: 102% initial market value collateralization of the loaned amount, collateral market value is priced daily and always maintained above 100% of the loaned amount, and physical custody must be taken by the custodial bank in the form of direct obligations of the United States Government.
 - i. This guideline is intended to give the investment manager sufficient latitude to periodically take advantage of bond-quality yield spreads. The average cost- weighted quality shall be no less than 3.0 based on the following scale:

| U.S. Government and Agencies | 5.0 |
|------------------------------|-----|
| Aaa Bonds | 4.0 |
| Aa Bonds | 3.0 |
| A Bonds | 2.0 |
| Baa Bonds | 1.0 |
| | |

2. Maturity

a. Cash Equivalent Manager

The weighted average maturity of the fund is at the discretion of the investment manager, however, no instrument may have a maturity greater than eighteen months. Issues with maturities greater than six months may not exceed 25% of the value of the portfolio:

- (1) Floating rate issues may have a longer maturity if the interest adjustment is based on an instrument with an effective maturity of less than six months.
- (2) A putable bond may be utilized if the put can be exercised within six months.
- (3) An asset-backed security, collateralized-mortgage obligation, or similar instrument, is permitted if the average life is projected to be less than six months. Issues of this type should be limited to an amount consistent with normal liquidity requirements, but should not exceed 25% of the value of the portfolio.
- b. Short-Term Fixed Income Manager

The portfolio's maximum duration should be less than 120% of the Merrill 1-3 Treasury Index, and no instrument with a maturity greater than 5 years is permissible, except that:

- (1) Floating rate issues may have a longer maturity if the interest adjustment is based on an instrument with a maturity of less than 5 years.
- (2) A putable bond may be utilized if the put can be exercised within 5 years.
- (3) An asset-backed security, collateralized-mortgage obligation, or similar instrument, is permitted if the average life is projected to be less than three years at the date of purchase and subsequently less than five years. Issues of this type should be limited to an amount consistent with normal liquidity requirements, but should not exceed 15% of the value of the portfolio.
- c. Long-Term Fixed-Income Manager

The portfolio's maximum duration should be less than 135% of the ML (7-10 yrs.) Gov't./Corp. Index.

- 3. Diversification
 - a. The manager will maintain prudent diversification across instruments, market sectors, industries, and specific issuers.
 - b. Except for issues guaranteed directly or indirectly by the U.S. Government, the combined holdings of securities from one issuer shall not constitute more than 5% of the fund. All letters of credit shall be part of the invested amount of the guarantor for purposes of the 5% rule.

B. Equities

- 1. Instruments and Credit Quality
 - a. The managers will be invested in high-quality common stocks. Convertible bonds, convertible preferred stocks, preferred stocks and non-voting stocks are permitted if

the risk/return characteristics are favorable versus the underlying common equity. American Depository Receipts are permitted. Specific constraints include the avoidance of restricted issues, which have limited marketability, excluding SEC Rule 144A securities.

- b. There are no qualitative guidelines suggested with regard to domestic equity ratings, rankings, etc., except that prudent standards should be utilized by the investment managers. Convertible bonds will be considered as equity investments and must be rated "Baa"/"BBB" or better by both Moody's and Standard & Poor's.
- 2. Diversification

The investment managers should diversify the equity portfolio in an attempt to minimize the impact of substantial loss in any specific industry or issue. Therefore, no more than the greater of 20% of the total portfolio or two times the appropriate equity market weighting may be invested in any one economic sector as defined by Standard & Poor's for domestic equities or as defined by MSCI for international equities, valued at market. In addition, no more than 5% of the total portfolio may be invested in any one company, valued at cost, and no more than 10% valued at market.

Prohibited Investments

The following categories of securities are not considered appropriate:

- A. Interest only and principal only portions of collateralized mortgage obligations, or similar securities,
- B. Private placements,
- C. Margin trading,
- D. Options and futures, except for hedging purposes

APPENDIX A: FUND OBJECTIVES AND CONSTRAINTS

NYS RETIREMENT RESERVE FUND

Fund Purpose

The NYS Retirement Reserve Fund provides for short-term NYS pension obligations of the Corporation. This Fund is also sometimes referred to as "General Operating – ECMC" in Fund reporting.

Investment Objectives

The investment objectives of the Fund are to:

- provide for the funding of the NYS retirement system obligations when excess cash allows for short term investing;
- assure that safety of principal is paramount;
- consistently invest assets in a prudent, diversified, risk-averse manner;
- achieve the acceptable return possible within the specified risk parameters;
- adhere to the established guidelines.

Time Horizon

The assets are viewed as having a short-term time horizon.

Liquidity Needs

The Fund's cash flow is generally positive but it needs to maintain a high degree of liquidity to meet annual obligations.

Overall Risk Tolerance

The Fund can assume a low risk profile.

Asset Allocation

Given the nature of the Funds' objectives, there can be no volatility of results. Consequently, the Committee has decided to control volatility by setting up long-term asset allocation targets. The Committee's goal is to minimize risk which favors cash equivalent investments.

CAPITAL RESERVE FUND

Fund Purpose

The Capital Reserve Fund provides for spending needs of the Corporation.

Investment Objectives

The investment objectives of the Fund are to:

- provide for the capital spending needs of the Corporation in excess of operations;
- consistently invest assets in a prudent, high-quality, diversified, manner;
- achieve the optimal return possible within the specified risk parameters;
- adhere to the established guidelines.

Time Horizon

The assets are viewed as having a short-term time horizon.

Liquidity Needs

The Fund needs to maintain a high degree of liquidity to meet unexpected needs.

Overall Risk Tolerance

The Fund can assume low risk profile.

Asset Allocation

Given the nature of the Fund's objectives, there can be no volatility of results. Consequently, the Committee has decided to control volatility by setting up long-term asset allocation targets. The Committee's goal is to minimize risk which favors cash equivalent investments.

RETIREE HEALTH RESERVE FUND

Fund Purpose

The Retiree Health Reserve Fund provides for intermediate- to long-term spending needs consistent with retiree health expenses.

Investment Objectives

The investment objectives of the Fund are to:

- provide for the funding and payment of retiree health obligations;
- consistently invest assets in a prudent, high-quality, diversified, manner;
- achieve the optimal return possible within the specified risk parameters;
- adhere to the established guidelines.

Time Horizon

The assets are viewed as having a long-term time horizon.

Liquidity Needs

The Fund's cash flow is generally positive, but it needs to maintain a moderate degree of liquidity to meet unexpected needs.

Overall Risk Tolerance

The Fund can assume a low-to-moderate risk profile.

Asset Allocation

Historical performance results and future expectations suggest that common stocks will provide higher total investment returns than fixed-income securities over a long-term investment horizon. However, one can expect an increase in portfolio volatility as the stock percentage is increased, particularly over the short term.

It is believed that the most significant decision to affect the overall volatility of results is that which controls the split among various asset classes, particularly the equity versus fixed-income ratio. Consequently, the Committee has decided to control this ratio by setting up long-term asset allocation targets. The Committee's goal is to maximize returns over the long term and has, therefore, taken a conservative investment posture that includes equity holdings, but favors fixed-income holdings.

W/C PROFESSIONAL LIABILITY RESERVE FUND

Fund Purpose

The WC/Professional Liability Reserve Fund provides for intermediate- to long-term spending needs consistent with actuarial determined estimates of workers' compensation and medical malpractice claims.

Investment Objectives

The investment objectives of the Fund are to:

- provide for the payment of workers' compensation and professional liability claims;
- consistently invest assets in a prudent, high-quality, diversified, manner;
- achieve the optimal return possible within the specified risk parameters;
- adhere to the established guidelines.

Time Horizon

The assets are viewed as having a long-term time horizon.

Liquidity Needs

The Fund's cash flow is generally positive, but it needs to maintain a moderate degree of liquidity to meet unexpected needs.

Overall Risk Tolerance

The Fund can assume a low-to-moderate risk profile.

Asset Allocation

Historical performance results and future expectations suggest that common stocks will provide higher total investment returns than fixed-income securities over a long-term investment horizon. However, one can expect an increase in portfolio volatility as the stock percentage is increased, particularly over the short term.

It is believed that the most significant decision to affect the overall volatility of results is that which controls the split among various asset classes, particularly the equity versus fixed-income ratio. Consequently, the Committee has decided to control this ratio by setting up long-term asset allocation targets. The Committee's goal is to maximize returns over the long term and has, therefore, taken a conservative investment posture that includes equity holdings, but favors fixed-income holdings.

GENERAL DEPOSITORY & GENERAL OPERATING RESERVE

Fund Purpose

The General Depository Reserve provides funding and a source of liquidity for operating expenses of the Corporation. The General Operating Reserve provides Delivery System Reform Incentive Payments (DSRIP) to other district members of the Millennium Collaborative Care Performance Provider System (PPS).

Investment Objectives

The investment objectives of the Fund are to:

- provide the necessary funds and liquidity for operating expenses of the Corporation;
- assure that safety of principal is paramount;
- consistently invest assets in a prudent, diversified, risk-averse manner;
- achieve the acceptable return possible within the specified risk parameters;
- transfer excess liquidity assets as determined by management to the General Operating Reserve Fund;
- adhere to the established guidelines.

Time Horizon

The assets are viewed as having a short time horizon.

Liquidity Needs

The assets are viewed as having high liquidity needs.

Overall Risk Tolerance

The Fund will assume a very conservative risk profile.

Asset Allocation

Given the nature of the Funds' objectives, there can be no volatility of results. Consequently, the Committee has decided to control volatility by setting up long-term asset allocation targets. The Committee's goal is to minimize risk which favors cash equivalent investments.

DEBT SERVICE and DEBT SERVICE RESERVE FUNDS – 2004 SERIES and 2011 SERIES

Fund Purpose

The Debt Service Reserve Fund is used to satisfy necessary interest payments. The Debt Service Reserve Fund is held in contingency by the Trustee to offset principal and/or interest payments, if needed. Note, in 2017, Series 2011 was refunded and had a zero balance.

Investment Objectives

The investment objectives of the Fund are to:

- provide for the funding for debt service coverage;
- consistently invest assets in a prudent, high-quality, diversified manner;
- achieve the optimal return possible within the specified risk parameters;
- adhere to the established guidelines.

Time Horizon

The assets are viewed as having a short-to-intermediate time horizon.

Liquidity Needs

The assets are viewed as having moderate liquidity needs. The required funds must be available for disbursement on the May 1 and November 1 payment dates for the 2004 Series Funds; and on the First of Each Month for the 2011 Series Funds. Any shortfall would need to come from operations.

Overall Risk Tolerance

The Fund can assume a low-to-moderate risk profile.

Asset Allocation

Historical performance results and future expectations suggest that common stocks will provide higher total investment returns than fixed-income securities over a long-term investment horizon. However, one can expect an increase in portfolio volatility as the stock percentage is increased, particularly over the short term.

It is believed that the most significant decision to affect the overall volatility of results is that which controls the split among various asset classes, particularly the equity versus fixed-income ratio.

Consequently, the Committee has decided to control this ratio by setting up long-term asset allocation targets. The Committee's goal is to maximize returns over the long term and has, therefore, taken a low-to-moderate investment posture which holds a modicum of equity holdings.

GNMA BOND RESERVE FUND

Fund Purpose

The GNMA Bond Reserve Fund originally held bonds used for construction of the Gates Vascular Institute with earnings from the fund paid to the The Grider Initiative, Inc. on an annual basis. The bonds issued for construction of the Gates Vascular Institute have since been redeemed and remaining funds are considered unrestricted. The Fund currently serves as a pledged collateral account in relation to the Corporation's line of credit.

Investment Objectives

The investment objectives of the Fund are to:

- consistently invest assets in a prudent, high-quality, diversified manner;
- achieve the optimal return possible within the specified risk parameters;
- adhere to the established guidelines.

Time Horizon

The assets are viewed as having an intermediate-term time horizon.

Liquidity Needs

The assets are viewed as having high liquidity needs.

Overall Risk Tolerance

The Fund can assume a very conservative risk profile.

Asset Allocation

Given the nature of the Fund's objectives, there can be no volatility of results. Consequently, the Committee has decided to control volatility by setting up long-term asset allocation targets. The Committee's goal is to minimize risk which favors cash equivalent investments.

APPENDIX B: FUND ALLOCATIONS AND BENCHMARKS

| | NYS Retirement Reserve (Gen Op-ECMC) | Capital Reserve | Retiree Health Reserve | WC / PL Reserve | General Operating DSRIP | GNMA Bond Reserve | Policy Benchmark |
|--------------------------------|--|--------------------|------------------------------|--------------------|-------------------------------|-------------------------|---|
| Growth Assets | | | | | | | |
| US Large Stocks | | | 11% | 11% | | | S&P 500 |
| US Large Quality Stocks | | | 4% | 4% | | | Vanguard Spliced Dividend Growth Index, S&P 500 |
| US Small / Mid Stocks | | | 4% | 4% | | | Vanguard Spliced Extended Market Index |
| US Small Value Stocks | | | 2% | 2% | | | Vanguard Spliced Small Cap Value Index |
| US Stocks | 0% | 0% | 21% | 21% | 0% | 0% | |
| Intl Large Stocks | | | 9% | 9% | | | FTSE Developed All Cap ex-US |
| Emerging Market Stocks | | | 5% | 5% | | | Vanguard Spliced Emerging Markets Index |
| International Stocks | 0% | 0% | 14% | 14% | 0% | 0% | |
| Total Public Stocks | 0% | 0% | 35% | 35% | 0% | 0% | |
| Total Growth Assets | 0% | 0% | 35% | 35% | 0% | 0% | |
| Risk Reduction Assets | | | | | | | |
| Cash | 100% | 100% | 5% | 5% | 100% | 100% | 90-Day T-Bills |
| US Short Duration Fixed Income | | | 20% | 20% | | | Bloomberg US Gov't/Credit: 1-5 Year |
| US Broad Fixed Income | | | 35% | 35% | | | Bloomberg US Aggregate; Bloomberg US MBS |
| US Inflation Protected Fixed | | | 5% | 5% | | | Bloomberg Barclays US TIPS |
| Total Risk Reduction Assets | 100% | 100% | 65% | 65% | 100% | 100% | |
| Total | 100% | 100% | 100% | 100% | 100% | 100% | |

| | NYS Retirement Reserve (Gen Op-ECMC) | Capital Reserve | Retiree Health Reserve | WC / PL Reserve | General Operating DSRIP | GNMA Bond Reserve | Policy Benchmark |
|--|--|--------------------|------------------------------|------------------------|-------------------------------|-------------------------|---|
| Growth Assets US Large Stocks | | | 12% 5% | 12% 5% | | | S&P 500 |
| US Large Quality Stocks US Small / Mid Stocks US Stocks | 0% | 0% | 5% 5% 22% | 5% 5% 22% | 0% | 0% | Vanguard Spliced Dividend Growth Index, S&P 500 Vanguard Spliced Extended Market Index |
| Intl Large Stocks Emerging Market Stocks | | | 9% 4% | 9% 4% | | | FTSE Developed All Cap ex-US Vanguard Spliced Emerging Markets Index |
| International Stocks Total Public Stocks | | 0% 0% | 13% 35% | 13% 35% | 0% 0% | 0% 0% | |
| Total Growth Assets | 0% | 0% | 35% | 35% | 0% | 0% | |
| Risk Reduction Assets Cash US Short Duration Fixed Income US Broad Fixed Income US Inflation Protected Fixed | 100% | 100% | 5% 10% 45% 5% | 5% 10% 45% 5% | 100% | 100% | 90-Day T-Bills Bloomberg US Gov't/Credit: 1-5 Year Bloomberg US Aggregate: Bloomberg US MBS Bloomberg Barclays US TIPS |
| Total Risk Reduction Assets | | 100% | 65% | | 100% | 100% | |
| Total | 100% | 100% | 100% | 100% | 100% | 100% | |

Note: Policy asset allocation was excluded for the General Depository Fund since it is a bank deposit account.

Commented [KZ1]: Note, this table includes the recommended allocations for the Retiree Health Reserve and WC/PL portfolios.

APPENDIX C: DESIGNATED PARTIES AND PRIMARY CONTACTS

Erie County Medical Center Corporation

Chief Financial Officer Jonathan Swiatkowski – (716) 898-6291 Director of Finance and Authorized Investment Decision Maker Vanessa S. Hinderliter – (716) 898-3730

Mercer (Investment Consultant)

Dan Holmes, Partner – (314) 446-5307 Kyle Zotta, CFA, CAIA, Principal – (314) 982-5726

<u>M&T Bank</u>

Joshua P. Heim, VP Government Banking – (716) 848-7318

Wilmington Trust (Custodian)

Kevin J. McCarthy, Assistant Vice President, Relationship Manager II – (716) 842-5592

U.S. Bank National Association, Debt Service Accounts Trustee

Christopher Grell, Vice President - (212) 951-6990

Mission Vision Core Values

Mission

To provide every patient the highest quality of care delivered with compassion.

Vision

ECMC WILL BE A LEADER IN AND RECOGNIZED FOR:

- High quality family centered care resulting in exceptional patient experiences.
- Superior clinical outcomes.
- The hospital of choice for physicians, nurses, and staff.
- Strong collaboration with community partners to improve access to healthcare and the quality of life and vitality of the region.
- Academic affiliations that provide the best education for physicians, dentists, nurses, and other clinical staff.

The difference between healthcare and true care[™]



Mission | Vision | Core Values

Core Values

ACCESS

All patients get equal care regardless of their ability to pay or source of payment. We address the healthcare needs of each patient that we can appropriately serve, without bias or pre-judgment.

EXCELLENCE

Excellence is a standard that will never be lowered; there is an expectation of excellence in all areas.

DIVERSITY

We recognize the importance and value of diversity and the enrichment that diversity can bring to ECMCC.

FULFILLING POTENTIAL

We respect the value and potential of each individual as offering a significant contribution to the good of the whole organization. Personal growth and development is important for organizational success.

DIGNITY

Each individual, no matter his or her limitations, background or situation, has intrinsic dignity and unique capabilities.

PRIVACY

We honor each person's right to privacy and confidentiality.

The difference between healthcare and true care™



FAIRNESS and INTEGRITY

Equity and fairness are guidelines for all decision-making. We demand personal and institutional integrity.

COMMUNITY

In accomplishing our mission we remain mindful of the public's trust and are always responsive to the immediate surrounding community and our natural environment. This commitment represents both our organization and us as individuals. A successful future for ECMCC depends on a vibrant community and a healthy environment.

COLLABORATION

Collaboration with other organizations is beneficial within the context of our mission and is fundamental to achieving our goals.

COMPASSION

All involved with ECMCC's service delivery demonstrate caring, compassion, and understanding for patients, employees, volunteers, and families.

STEWARDSHIP

We can only be successful in carrying out our mission through solid financial performance and by assuring that resources provided to us are used effectively, in the way they were intended, and for the benefit of our patients and community.

Erie County Medical Center Corporation

Procurement Guidelines

Effective March 1, 20212024

CONTENTS

| I. | STATEMENT OF PURPOSE AND SCOPE4 | | | | | | | | |
|------|---------------------------------|-----|---|--|--|--|--|--|--|
| | A. | | Authority | | | | | | |
| | B. | | Purpose | | | | | | |
| | C. | | Interpretation | | | | | | |
| | D. | | Application of These Guidelines | | | | | | |
| | E. | | Referenced Policies | | | | | | |
| II. | DE | FIN | ITION OF TERMS | | | | | | |
| III. | SO | UR | CE SELECTION | | | | | | |
| | A. | | Methods of Source Selection | | | | | | |
| | В. | | Preferred Source | | | | | | |
| | C. | | Invitation for Bid9 | | | | | | |
| | D. | | Request for Proposal | | | | | | |
| | E. | | Discretionary Procurements | | | | | | |
| | F. | | Medical Projects | | | | | | |
| | G. | | Exemptions from Formal Competition | | | | | | |
| | | 1. | Professional Services | | | | | | |
| | | 2. | Additional Items under Existing Contract | | | | | | |
| | | 3. | Standardization | | | | | | |
| | | 4. | Sole Source | | | | | | |
| | | 5. | Emergency Procurement | | | | | | |
| | | 6. | Joint Hospital Purchases | | | | | | |
| | | 7. | Group Purchasing Organizations15 | | | | | | |
| | | 8. | Surplus and Second-Hand15 | | | | | | |
| | | 9. | Recycled Products15 | | | | | | |
| | | 10. | Government Sources | | | | | | |
| | | 11. | Board Waiver of Competitive Requirements15 | | | | | | |
| | | 12. | Professional Health Care Services15 | | | | | | |
| | H. | | Pre-qualification/Request for Qualifications | | | | | | |
| | I. | | New York State Business Enterprises | | | | | | |
| IV. | PR | OCI | EDURES and STANDARD PROVISIONS16 | | | | | | |
| | A. | | New York State Contract Reporter | | | | | | |
| | В. | | Cancellation of IFB or RFP | | | | | | |
| | C. | | Responsibility of Bidders and Respondents17 | | | | | | |
| | D. | | Compliance with Procurement Lobbying Law | | | | | | |
| | E. | | Vendor Preparation of Technology Specifications | | | | | | |

| | F. | Contract Provisions | 18 |
|------|-------|---|----|
| | G. | Contract Review and Approval | 19 |
| | H. | ECMCC Reserved Rights | 19 |
| V. | BOND | REQUIREMENT | 20 |
| | A. | Bid Security. | 20 |
| | B. | Other Forms of Security on Construction Contracts | 21 |
| VI. | ETHIC | 'S | 21 |
| | A. | Definitions | 21 |
| | B. | Conflict of Interest | 21 |
| | C. | Kickbacks | 21 |
| | D. | Procurement Disclosure Policy | 21 |
| VII. | MINO | RITY AND WOMEN BUSINESS ENTERPRISE ("M/WBE") REQUIREMENTS | 22 |
| | A. | Scope | 22 |
| | B. | M/WBE Goal Plan | 22 |
| | C. | ECMCC's Good Faith Efforts | 23 |
| | D. | Documentation of Good Faith Efforts | 23 |
| | E. | Contractor's Good Faith Efforts | 23 |
| | F. | Joint Ventures and Teaming Agreements | 24 |
| | G. | M/WBE Utilization | 24 |
| | H. | Self-Performance | 25 |
| | I. | Commercially Useful Function | 25 |
| | J. | Contractor Reporting | 25 |
| | K. | Non-Compliance | 25 |
| | L. | Waivers | 25 |
| | M. | M/WBE Discretionary Purchases | 26 |
| | N. | Consideration of Diversity Practices | 27 |

I. STATEMENT OF PURPOSE AND SCOPE

A. Authority.

- 1. Public Authorities Law ("PAL"), Article 9, Title 4, New York Statutes, as amended.
- 2. Public Authorities Law, Article 10-C, New York Statutes, as amended (the "ECMCC Act").
- 3. General Municipal Law ("GML"), Article 5-A, New York Statutes, as amended.
- 4. Public Health Law ("PHL"), Article 28, New York Statutes, as amended.
- 5. Executive Law ("EL") Article 15A, New York Statutes, as amended.
- 6. State Finance Law ("SFL"), Article 9, New York Statutes, as amended.
- 7. Economic Development Law ("EDL"), Article 4-C, as amended.

B. Purpose.

The purpose of these Procurement Guidelines ("Guidelines") is to set forth the procedures for purchasing supplies, equipment, materials, construction and services, (including professional services), and Public Works, for Erie County Medical Center Corporation ("ECMCC"). These Guidelines are applicable to ECMCC and may be applied by ECMCC in other contexts, in its discretion.

C. Interpretation.

These Guidelines shall be construed and applied to promote compliance with all applicable laws. In the event of a conflict between these Guidelines and the requirements of any applicable law, the applicable law will prevail.

D. Application of These Guidelines.

- 1. <u>Effective Date</u>. These Guidelines are effective March 1, <u>2022</u>2024.
- 2. <u>Scope</u>. These Guidelines shall apply to all contracts for construction and the purchase of all supplies, equipment, materials and services, <u>(including professional services)</u>, <u>as well as Public Works</u>, made by ECMCC irrespective of the source of funds, except as otherwise provided by law.
- 3. <u>Severability</u>. If any provision of these Guidelines or application thereof to any person or circumstance is held invalid, such invalidity shall not affect other provisions or application of these Guidelines which can be given effect without the invalid provision or application, and to this end the provisions of these Guidelines are declared to be severable.
- 4. <u>Annual Review</u>. These Guidelines, as adopted pursuant to Section 2879 of the Public Authorities Law and Section 104-b of the General Municipal

Law, shall be subject to annual review and may otherwise be changed without notice by the Board of Directors of ECMCC. The Guidelines are for the use of ECMCC and should not be relied upon as establishing any right by any person or entity other than ECMCC.

II. **DEFINITION OF TERMS**

T

The following terms shall, for purposes of these Guidelines, have the meanings set forth below unless the context clearly indicates a different meaning:

- 1. <u>Best Value</u>. The basis for awarding Contracts for services to a Contractor that optimizes quality, cost and efficiency, among responsive and responsible respondents. Such basis shall reflect, wherever possible, objective and quantifiable analysis. Such basis may also identify a quantitative factor for respondents that are Small Businesses or Minority- or Women-owned Business Enterprises ("M/WBE") to be used in evaluation of Bids or Proposals for awarding of Contracts for services. In any case where a respondents' gross price is reducible by an allowance for the value of used machinery, equipment, apparatus or tools to be traded in by a political subdivision, the gross price shall be reduced by the amount of such allowance, for the purpose of determining the Best Value. (SFL § 163(1)(j) and GML § 103).
- 2. <u>Bid.</u> An offer or proposal submitted in response to an Invitation for Bids.
- 3. <u>Contract</u>. A written agreement, memorandum of understanding, letter agreement, letter of intent, or purchase order that formalizes the obligations of all parties involved.
- 4. <u>Contractor</u>. Any individual, business or other legal entity awarded a Contract to furnish goods or services to ECMCC.
- 5. <u>Contract Value</u>. The total value of a Contract, including all renewal options. If the value of the Contract is not known or cannot be determined at the time the Contract is awarded (i.e., a service Contract that states an hourly fee but does not state the total hours of service to be provided; a commodities Contract that states the price of the commodities but does not state the total volume of commodities to be purchased), the Contract Value shall be the total amount that ECMCC reasonably anticipates spending under the Contract during the term and any renewal options. With respect to joint Procurements, the amount to be expended by entities other than ECMCC shall be excluded from the Contract Value.
- 6. <u>County</u>. The County of Erie, New York.
- 7. <u>Group Purchasing Organization (GPO)</u>. An entity that aggregates the purchasing volume of members, such as hospitals and health-care providers, to leverage discounts with manufacturers, distributors and other vendors intending to realize administrative savings and efficiencies.
- 8. <u>Invitation for Bids (IFB)</u>. A formal competitive solicitation seeking sealed Bids for <u>Construction workPublic Works</u> or specified goods or services, pursuant to which award is made to the responsive and responsible bidder(s) submitting the lowest

price, provided that Contracts for goods and services (excluding Contracts for services necessary for the completion of a Construction project) may be awarded on the basis of Best Value to a responsive and responsible bidder. Generally, IFBs are used for the Procurement of ConstructionPublic Works, equipment, materials and supplies.

- 9. <u>Medical Building</u>. The component of a Medical Project constituting appurtenant structures or facilities necessary to house or render the remaining components of the Medical Project operational. Medical Building does not include apparatus, equipment, devices, systems, supplies, or any combination thereof. (PAL § 3628(11)(g)(iii)).
- 10. <u>Medical Project</u>. Any substantial durable apparatus, equipment, devise, or system, or any combination of the foregoing, including services necessary to install, erect, or assemble the foregoing, and any Medical Building, to be used for the purpose of care, treatment or diagnosis of disease or injury or the relief of pain and suffering of sick or injured persons. Medical Projects do not include ordinary supplies and equipment expended or used in the customary care and treatment of patients. (PAL § 3628(11)(g)(iv)).
- 11. <u>Minority or Women-Owned Business Enterprise ("M/WBE")</u>. A business certified under Article 15-A of the Executive Law that is independently owned, operated and authorized to do business in New York State; and is owned and controlled by at least 51% women or minority group members, respectively, who are citizens of the U.S. or permanent resident aliens. Such ownership must be real, substantial and continuing, and the minorities or women must have and exercise the authority to control independently the day-to-day business decisions of the enterprise. <u>The</u> <u>determination of M/WBE certification is made by New York State, not ECMCC</u>.
- 12. <u>New York State Business Enterprise</u>. A business enterprise, including a sole proprietorship, partnership, limited liability company or business corporation, which offers for sale or lease or other form of exchange, goods which are sought by <u>ECMCC and which are substantially manufactured</u>, produced or assembled in New York State, or services which are sought by ECMCC and which are substantially performed within New York State. (PAL § 2879(5)(b)(ii)).
- 13.12. New York State Contract Reporter ("NYSCR"). A publication listing of procurement opportunities printed made electronically available for by the New York State Economic Development Bureau pursuant to the New York State Economic Development Law. (EDL §§ 141 - 143).
- 14.13. Personal Services. Any services performed for a fee, commission or other compensation by persons or organizations that are not providing such services as employees of ECMCC. Personal Services include, but are not limited to, professional services or any other services of a consulting, technical or professional nature.
- 15.14. Preferred Source. Contractors selected in accordance with ECMCC's Preferred Source Policy and State Finance Law Section 162, offering specific commodities or services that meet the form, function and utility requirements of ECMCC.
- 16.15. Project Developer. Any individual or entity that has submitted a Proposal in

response to a Request for Proposals for a Medical Project. (PAL § 3628(11)(g)(i)).

- 17.16. Procurement. The acquisition of goods and/or services.
- 18.17. Procurement Contract. Any written agreement to which ECMCC is a party for the acquisition of goods or services of any kind in the actual or estimated amount of five thousand dollars (\$5,000) or more. (EDL § 141).
- 19.18. Procurement Record. Documentation of the decisions made and the approach taken with respect to a Procurement.
- 20.19. Professional Services. Services involving the provision of advice, instruction or specialized work from an individual, firm or corporation specifically qualified or licensed to provide such services including, but not limited to, accounting, legal, health care, consulting and management services.
- <u>21.20. Proposal</u>. An offer or response submitted in response to a Request for Proposals.
- 22.21. Public Works. The building, renovation, retrofitting, rehabilitation, restoration, painting, alteration, maintainencemaintenance, or repair of any real property or improvements thereon, exclusive of the installation and assembly of any medical equipment, apparatus or device.
- 23.22. Recycled Product. A product that is manufactured from secondary materials as defined in the EDL § 261(1)(d).
- 24.23. Request for Proposal ("RFP"). A competitive solicitation seeking Proposals for a specified service or technology, pursuant to which an award is made to the responsive and responsible respondent offering the <u>best_Best_valueValue</u>. Generally, (examples: RFPs are generally used for the Procurement of services, information technology systems, and consultants).
- 25.24. Responsible. The status afforded an individual or company based on factors such as: financial ability and organization capacity; legal authority to conduct business in New York state; integrity as it relates to business related conduct; and past performance. ECMCC may establish a list of vendors deemed Responsible via a Request for Qualifications process that may be awarded Discretionary Contracts without further competitive bidding.
- 26.25. <u>Responsive</u>. Meeting the minimum Specifications or Requirements as prescribed in a solicitation for goods or services.
- 27.26. —<u>Small Business</u>. A business which is resident in New York State, independently owned and operated, not dominant in its field and employs one hundred or less persons. (SFL § 163(1)(e)).
- 28.27. Specifications (Requirements). Description of the physical or functional characteristics or the nature of a good, the work to be performed, the service or products to be provided, the necessary qualifications of the offeror, the capacity and capability of the offeror to successfully carry out the proposed Contract, the process for achieving specific results and/or anticipated outcomes, or any other requirement necessary to perform the work.

III. SOURCE SELECTION

A. Methods of Source Selection.

Unless otherwise authorized by law, all ECMCC Contracts will be awarded in accordance with one of the following Sections of these Guidelines.

B. Preferred Source.

Prior to engaging in any other method of source selection for the purchase of goods or services, ECMCC shall assess, in accordance with the ECMCC Preferred Source Policy and Section 162 of the State Finance Law, whether the desired goods or services are available from an offeror that has been afforded Preferred Source status by New York State. If a Preferred Source has goods or services available in the form, function and utility consistent with the needs of ECMCC, such goods or services shall be procured in accordance with the requirements of State Finance Law sectionSFL § 162 and ECMCC's Preferred Source Policy. If a good or service is not available in form, function and utility consistent with the needs of ECMCC from a Preferred Source, ECMCC may then exercise its authority to utilize any of the other applicable procurement methods set forth in these Guidelines.

C. Invitation for Bid.

- 1. <u>Invitation for Bid</u>. When the estimated amount of Procurement exceeds \$20,000 for supplies and services, or \$35,000 for Public Works projects, and alternate means of procurement <u>(including Requests for Proposals)</u> described herein are otherwise not available, ECMCC will issue an Invitation for Bid which shall include Specifications and the contractual terms and conditions applicable to the Procurement. (GML § 103(1)).
- 2. <u>Public Notice</u>. ECMCC must publish notice of the IFB in a daily newspaper, having general circulation in the County, at least five (5) days prior to the date set forth therein for the opening of Bids. Such notice shall state the time and place for opening of the Bids. Where applicable, ECMCC must also publish notice of the IFB in the Contract Reporter in accordance with Section IV.A. (GML § 103(2), PAL § 3628(10)(b)).
- 3. <u>Bid Acceptance and Evaluation</u>. Timely bids will be unconditionally accepted and evaluated for Responsiveness based on the requirements set forth in the IFB, which may include criteria to determine acceptability such as inspection, quality, workmanship, delivery and suitability for a particular purpose.
- 4. <u>Correction or Withdrawal of Bids; Cancellation of Awards</u>. ECMCC may permit, where appropriate, the withdrawal of inadvertently erroneous Bids before or after award, or cancellation of awards or Contracts based on such Bid mistakes. After Bid opening, no changes to Bid prices or other provisions of Bids prejudicial to the interest of ECMCC or fair competition shall be permitted.

- 5. Descoping. ECMCC may engage in a formal descoping with Bidders to ensure that they properly understand the scope of the IFB and are able to perform the work or provide the goods or services at the prices set forth in their Bids. A Bid may be disqualified if ECMCC determines that it did not appropriately account for all Specifications and does not accurately reflect the cost.
- 5.6. <u>Award</u>. A Contract will be awarded after all necessary approvals have been obtained by written notice to the lowest Responsible and Responsive bidder (or bidders, in the case of multiple awards) whose Bid meets the Specifications set forth in the IFB.
- 6.7. <u>Bid Retention</u>. All Bids received, including all related documentation and communications received from bidders during the bidding process, will be maintained in a Procurement Record by ECMCC for at least twelve three (123) monthsyears.

D. Request for Proposal.

- 1. <u>Request for Proposals</u>. A Contract may be solicited through an RFP rather than an IFB if the estimated amount of Procurement exceeds \$20,000 for supplies and services and factors other than price are critical to the Procurement (such as specialized skills or equipment) and alternate means of procurement described herein are otherwise not available. For example, an RFP might be used for the Procurement of Personal Services or the Procurement of biotechnology, electronic, software and system applications. (GML § 103(1)). ECMCC will issue an RFP, which shall include a statement of work and/or Specifications, and the contractual terms and conditions applicable to the Procurement. Notwithstanding the foregoing, a minimum of thirty five percent (35%) of the points allocated to the RFP evaluation shall be appliedawarded based on to cost of the Procurement.
- 2. <u>Public Notice</u>. ECMCC shall, if applicable, publish notice of the RFP in the <u>NYS</u> Contract Reporter in accordance with Section IV.A. ECMCC may also publish notice of the RFP in a newspaper or other publication for purposes of soliciting participation as determined by the Director of Procurement Compliance.
- 3. <u>Evaluation</u>. Where the basis for award is the Best Value offer, the Procurement Record shall include a determination of the evaluation criteria in advance of the initial receipt of proposals, which whenever possible, shall be quantifiable, and shall describe the process to be used in the determination of Best Value and the manner in which the evaluation process and selection shall be conducted. The RFP shall set forth criteria stating the relative importance of each evaluation factor to the Procurement, including price, to be used by ECMCC during the evaluation period. <u>A minimum of thirty-five percent (35%) of the points allocated to the RFP evaluation shall be awarded based on price.</u> Each Procurement based on Best Value shall be evaluated by a selection committee of no fewer than two (2) impartial employees or contractors of ECMCC with subject matter expertise. The Procurement Record shall include a full record of all evaluations performed by selection committee, including scorecards of the criteria.

- 4. Negotiations with Responsible Offeror and Revisions to Proposals. As provided in the RFP, ECMCC may conduct negotiations with Responsible offerors who timely submit Proposals determined to be reasonably qualified to be selected for award. The purpose of negotiations will be to seek the Best Value for ECMCC and to clarify for and advise offerors of the deficiencies in both the technical and price aspects of their Proposals so as to assure ensure the conformance to full understanding of and the solicitation requirements<u>Requirements</u>, and to ensure all proposals may be evaluated on a true like-for-like comparison. No offeror will be provided information about any other offeror's Proposal, and no offeror will be assisted in bringing its Proposal up to the level of any other Proposal. Offerors will not be directed to reduce their Proposal prices to a specified amount in order to be considered for award. A common deadline will be established for receipt of Proposal revisions and communicated to Responsible offerors.
- 5. <u>Award</u>. After evaluation of Proposal revisions, if any, award will be made to the responsible offeror (or offerors, in the case of multiple awards) whose Proposal is determined to <u>present Best Value be the most advantageous</u> to ECMCC, taking into consideration price and the evaluation factors set forth in the RFP.
- 6. <u>Proposal Retention</u>. All Proposals received, including all related documentation and communications received from offerors during the selection process, will be maintained by ECMCC for at least twelve-three (123) monthsyears.

6.

E. Discretionary Procurements.

For purchases up to the discretionary Discretionary Procurement thresholds set forth below, ECMCC shall not be required to conduct formal competitive bidding processes either IFBs or RFPs. With respect to any discretionary Discretionary Procurement, ECMCC must (i) ensure that the goods, services or technology acquired meet ECMCC's form, function and utility needs; (ii) document and justify the selection of the vendor; (iii) document and justify the reasonableness of the price; and (iv) ensure that the vendor is a Responsible vendor. Reasonableness of price may be determined by obtaining two (2) alternate quotes or comparing the proposed price to prices paid for similar goods or services within the previous twelve (12) months.

- 1. <u>Supplies and Services under \$20,000</u>. Any Procurement of goods and services, including Professional Services, with a Contract Value that does not exceed \$20,000 including all renewal options may be made without a competitive bidding process; provided, however, that reasonable efforts shall be made to ensure that the price to be paid is reasonable. A Procurement shall not be artificially divided so as to constitute a <u>discretionary</u> <u>Discretionary</u> Procurement under this Section. (GML § 103(1)).
- 2. <u>Public Works under \$35,000</u>. Any Public Works project with a total Contract Value that does not exceed \$35,000 may be awarded without a competitive bidding process; provided, however, that reasonable efforts shall be made to

ensure that the price paid is reasonable. A Public Works project may not be divided into more than one project so as to constitute a discretionary Discretionary Procurement under this Section. The Director of Procurement Compliance shall determine whether the Public Works contract is for regular work (such as ongoing maintenance) or for an individual and distinct project in determining whether the \$35,000 threshold is exceeded. For example, a Contract for ongoing elevator inspection and maintenance may be determined to exceed the \$35,000 threshold in the aggregate due to its recurring nature, while separate and distinct repairs to drywall damage that occur at differing times may need not be aggregated. –(GML § 103(1)).

- 3. M/WBE and SDVOB Goods and Services under \$500,000. Any Procurement Contract for goods or services with a Contract Value that does not exceed \$500,000 may be awarded to an M/WBE or Service-Disabled Veteran-Owned Business ("SDVOB") without a competitive bidding process, provided that the price for the goods or services is determined to be reasonable in accordance with these guidelines. The reasonably expected aggregate amount of all purchases of the same commodities or services from the same provider within the twelve-month period commencing on the date of the first purchase cannot exceed the \$500,000 limit. Therefore, even though the value of an individual Procurement Contract may be below the discretionary Discretionary <u>Procurement</u> threshold, expected purchases during the following twelve (12) month period should be evaluated to determine whether the discretionary Discretionary procurement Procurement exception is available. Where the Contract Value exceeds \$50,000, the Contract award, and if applicable, the mini-bid directed to M/WBE or SDVOB firms (as applicable), must be advertised in the New York State Contract Reporter in accordance with Section IV.A. (PAL § 2879).
- 4. Small Business Goods and Services under \$500,000. Any Procurement Contract for goods or services with a Contract Value that does not exceed \$500,000, including all renewal options, may be awarded to a Small Business without competitive bidding process, provided that the price for the goods or services is determined to be reasonable. For purposes of determining reasonableness of price, the same process set forth relating to M/WBE discretionary Discretionary Procurements awards shall apply to Small Business discretionary Discretionary awards Procurements. The Discretionary Procurement requirements shall not be artificially divided so as to constitute a discretionary Discretionary Procurement under this Section III.G. Where the Contract Value exceeds \$50,000, the Contract award and, if applicable, the solicitation directed to Small Businesses, must be advertised in the New York State Contract Reporter in accordance with Section IV.A. Small Business status may be established by a regional, statewide, or national certification. (PAL § 2879).

F. Medical Projects.

1. <u>Source Selection</u>. ECMCC may award Contracts for Medical Projects to Project Developers on the basis of factors other than cost alone, including but not limited to, facility design, system reliability, efficiency, safety and compatibility with other elements of patient care. Notwithstanding any contrary provisions of law, a Contract for a Medical Project with a Project

Developer may be awarded pursuant to the competitive bidding process outlined in Section III.C (Invitation for Bid) or pursuant to the Proposal evaluation process outlined in Section III.D (Request for Proposal). (PAL § 3628(10)).

- 2. <u>Public Notice</u>. When an RFP is issued for a Medical Project, ECMCC shall publish notice of such issuance in at least one (1) newspaper of general circulation in the County. Concurrent with the publication of such notice, a draft RFP shall be filed with the County Commissioner of Health. (PAL § 3628(10)(b)).
- 3. <u>Board Resolution</u>. If after issuance of an RFP for a Medical Project, a Contract is awarded to a Project Developer who is not the lowest bidder, ECMCC shall adopt a resolution containing particularized findings indicating that the requirements of ECMCC are met by the award and that such award is in the public's best interest. (PAL § 3628(10)(b)).
- 4. <u>Project Cost over \$500,000</u>. Where a Medical Project expected to cost more than \$500,000 involves the construction of a Medical Building, ECMCC's Contract with the Project Developer shall provide that the Medical Building shall be constructed through Contracts awarded through a competitive bidding process outlined in within Public Authorities Law Section 3628, and shall require separate and independent competitive bidding in each of the following subdivisions:
 - (a) plumbing and gas fitting;
 - (b) steam heating, hot water heating, ventilating and air conditioning apparatus; and
 - (c) electric wiring and standard illuminating fixtures.

(PAL §§ 3628(11)(b)(i)-(iii)).

5. <u>Bid Security</u>. Where a Medical Project expected to cost more than \$500,000 involves the construction of a Medical Building, the Project Developer or the Project Developer's construction subcontractors shall furnish bid security as provided in Section V.A(1). (PAL § 3628(11)).

G. Exemptions from Formal Competition.

The following types of Procurements are exempt from the competitive procurement processes outlined in Section III.C and III.D, provided however that unless otherwise noted herein, exemption from such competitive procurement processes shall not exempt the Procurement from applicable M/WBE participation requirements set forth herein or Contract Reporter publication requirements set forth in Section IV.A:

1. <u>Sole and Single Sources</u>. When ECMCC determines that there is only one source for required goods or services, and no other vendor offers functionally equivalent goods or services in the marketplace, a Procurement Contract for such goods or services may be awarded without competitive procedures, provided that a Sole Source Justification Form is completed by the

Department initiating the Procurement and approved by the Vice President of Materials Management, Office of General Counsel, and CEO or CFO. Sole source Procurements with Contract Values exceeding \$50,000 shall be advertised in the Contract Reporter in accordance with Section IV.A. The definition of "Sole Source" under these Guidelines shall include those instances where goods or services are available from two or more vendors. but a particular vendor is preferable because of specific factors described in this section. Factors supporting an award in such a "single source" situation include: (i) legislation or appropriation mandates use of particular vendor; (ii) warranty voided if service or parts are provided by a different vendor; (iii) software license renewals, additions, or upgrades available from only one source, or (iv) other circumstances as may be identified in the Sole Source Justification Form, as may be amended. Advertisements with local media sources and endorsement agreements with celebrities shall automatically be categorized as "Sole Source" agreements by ECMCC due to the unique, exclusive characteristics of such relationships. (1983 Op. St. Compt. No. 83-67; 1986 Op. St. Compt. No. 86-41; 1988 Op. St. Compt. No. 88-35; and related case law).

- 2. <u>Emergency Procurement</u>. Notwithstanding any other provision of these Guidelines, ECMCC may make or authorize others to make an emergency Procurement in the event of an accident or unforeseen occurrence or condition that affects its buildings or property, or the life, health, safety, or property of its staff or patients, or to prevent or minimize serious disruption of ECMCC services jeopardizing patient health, welfare or safety; subject to the following provisions:
 - (a) The emergency Procurement shall be limited to those supplies, services or construction items necessary to meet the immediate emergency;
 - (b) Emergency Procurements shall be made with such competition as is practicable under the circumstances;
 - (c) When practicable, approval of the CEO shall be obtained prior to the Procurement;
 - (d) For emergency Procurements that equal or exceed two hundred fifty thousand dollars (\$250,000), the Board of Directors must ratify the Emergency Procurement at the next Board meeting. (GML § 103(4)).
- 3. <u>Joint Hospital Purchases</u>. ECMCC may participate in a joint purchasing agreement for the Procurement of goods, supplies and services with one or more other municipal, state, federal or privately-owned hospital or other health related facility or medical school that receives public funding without a competitive procurement process. Such cooperative or joint purchasing may include, but is not limited to, multi-party contracts between public Procurement units and open-ended public Procurement unit contracts that are made available to other entities. Such joint purchases are exempt from traditional M/WBE goals but must comply with other applicable M/WBE policies ECMCC has in place governing joint purchases. (GML § 103(8); PHL § 2803-a).

- 4. <u>Group Purchasing Organizations</u>. ECMCC recognizes purchases made through Group Purchasing Organizations as a best practice in hospital purchasing nationwide with associated efficiencies, savings and speed. ECMCC may participate in one or more group purchasing organizations ("GPO"). Procurements made pursuant to a GPO arrangement shall not be subject to competitive procurement processes or traditional M/WBE goals. ECMCC is permitted to execute a final Contract with a GPO vendor that has terms more favorable than those available on GPO. (PHL § 2803-a; 1989 Op. St. Compt. No. 89-2).
- 5. <u>Professional Health Care Services</u>. Contracts for professional health care services including but not limited to services performed by health care agencies or entities, physicians, dentists, physician's assistants, home health and personal care aides, occupational, speech, respiratory and physical therapists, nurses, <u>nurse practitioners, licensed practical nurses, nurses</u>; assistants, medical and laboratory technicians, diagnosticians, social workers, psychiatric workers, <u>veterinarians, pharmacists, dieticians,</u> and persons who provide care, treatment, counseling, case management, rehabilitative or preventative services to the mentally ill, developmentally disabled and those suffering from the disease of alcoholism or substance abuse are exempt from competitive procurement processes. (case law and various State Comptroller opinions)
- Government Sources. ECMCC may purchase utilizing a contract let by the New York State Office of General Services ("OGS") when the purchase exceeds \$500 pursuant to the procedures set forth in NY State Finance Law § 163. Additionally, ECMCC may utilize the terms of a federal government general services contract where the terms are to the advantage of ECMCC and have been offered to ECMCC by the contractor. Finally, ECMCC may further make purchases of apparatus, materials, equipment or supplies, or contract for services related to the installation, maintenance or repair of apparatus, materials, equipment, and supplies, through the use of a eContract let by the federal government, any federal agency, and or any other State or political subdivision or district, if the eContract was let to the lowest responsible bidder or on the basis of Best Value, made available for use by other governmental entities, and where "Best Value" is permitted for such use by the governmental entity. Purchases from such any of these federal or state sources -may be made without regard to the competitive Bid process or M/WBE goals, but in the case of the Office of General ServicesOGS, must follow any specific requirements issued by the Office OGS pertaining to that Procurement. However, when When ECMCC elects to use a federal source for the purchase of goods or services, no purchase may be made where a Bid for such good or service has been received, unless the purchase may be entered into upon the same terms, conditions, and Specifications and represent a cost savings to ECMCC. ECMCC is permitted to execute a final Contract with a government source vendor that has terms more favorable than those available on GPO from the government source. (GML § 103(16); GML § 104; SFL § 163(3)(iv); PAL § 3628(9)).
- 6. ECMCC may further make purchases of apparatus, materials, equipment or supplies, or contract for services related to the installation, maintenance or repair of apparatus, materials, equipment, and supplies, through the use of a contract let by the federal government, any federal agency, and any other State

or political subdivision or district if the contract was let to the lowest responsible bidder or on the basis of Best Value and made available for use by other governmental entities. (GML § 103(16)).

- 7. County Contracts. ECMCC may purchase goods or services, other than services subject to article nine of the labor law, through Erie County or through any County within New York subject to the rules established pursuant to NY County Law § 408-a(2); provided that (1) ECMCC accept sole responsibility for any payment due the vendor, (2) prior to making such purchases or contracts ECMCC consider whether such contracts will result in cost savings after all factors, including charges for service, material, and delivery, have been considered, and (3) ECMCC actively audit expenditures under such agreement. No Procurement may be made under this section where Bids or Proposals for such goods or services have been received, unless the Procurement may be entered into upon the same terms, conditions, and Specifications and represent a cost savings to ECMCC. (GML § 103(3)).
- Additional Items under Existing Contract. Where the need for additional items 7.8. or services arises under an existing Contract awarded pursuant to an IFB or RFP, such Procurement may be made without issuing a new IFB or RFP, provided that the additional items or services were are within the scope of contemplated under the original IFB or RFP, are provided within eighteen (18) months of the original RFP or IFB and the quantity of additional items or services does not exceed thirty (30%) percent of the quantity of items or services procured under the original Contract (for examples: a new surgical implant device is made available under a Contract for other surgical implant devices; an add-on or upgrade is made available to an electronic medical record platform already in use at ECMCC). This requirement shall not extend to contract extensions for the same services or products awarded pursuant to a compliant IFB or RFP. All communications and documentation related to the Procurement of additional items or services will be maintained in the Procurement Record. For avoidance of doubt, this Section shall not apply to any discretionary Discretionary Procurements to the extent that the additional items or services would cause the Contract Value to exceed the discretionary Discretionary Procurement threshold. To the extent that the additional items or services impact the Contract Value, and the Contract is subject to M/WBE goals, ECMCC shall require the Contractor to submit an updated M/WBE Utilization Plan in accordance with these guidelines.
- **8.9.** Professional Services. Where the issuance of an RFP is impractical due to the professional nature or scope of the services to be provided, such Professional Services may be procured through the solicitation of price quotations from no less than three (3) offerors. Such quotations must be obtained in writing. Award will be made to the offeror providing the Best Value to ECMCC based on an evaluation of the price and other specified factors. If factors other than price are utilized in the evaluation of the quotes, such factors shall be disclosed to all offerors at the time the price quotation is solicited. The names, addresses and/or telephone numbers of the offerors and persons contacted, along with the date and amount of each quotation shall be recorded and maintained in the Procurement Record. Any award of a Contract under this Section shall comply with ECMCC's M/WBE policies and procedures and the Contractor Reporter publication requirements set forth in Section IV.A.

- 9.10. Standardization. For reasons of efficiency or economy, purchase Contracts for equipment, material, supplies or services may be standardized to a particular make, model or brand upon the approval by at least three-fifths of the members of the Board of Directors of ECMCC. The resolution adopted by the Board shall specify the reasons that standardization is appropriate. A common reason for standardization is to ensure that equipment purchased is compatible with existing equipment or spare parts. For such purchases to be justified, the original equipment should be suitable for the required purpose, the price should be reasonable when compared to the overall cost, and the advantages of another make or source of equipment shall have been considered and rejected on grounds acceptable to ECMCC. After a resolution is adopted, ECMCC may specify the standardized make, model or brand in specification document, however all competitive processes set forth in these Guidelines must still be followed. (GML § 103(5)).
- 10.11. Surplus and Second-Hand. Surplus and second-hand supplies, equipment and materials purchased from the federal government, New York State, or any other political subdivision, district or public benefit corporation are not subject to the competitive bidding process. (GML § 103(6)).
- 11.12. Recycled Products. Recycled products may be purchased without regard to the competitive Bid process so long as they meet the specified requirements and are reasonably competitive. Reasonably competitive shall mean that the cost of the recycled product does not exceed a cost premium of ten (10%) percent above a comparable non- recycled product. (GML § 104-a).
- 12.13. Board Waiver of Requirements for Competitive Selection of Contractors. The ECMCC Board may, <u>upon careful deliberation and a vote of 2/3 of the Directors present at a meeting of the Board at which such Contract is presented</u>, by resolution, waive requirements for the competitive selection of contractors for a specific procurement that otherwise would be awarded on a competitive basis when such waiver is in the best interest of ECMCC. Accordingly, the Board of Directors may, upon careful deliberation and a vote of 2/3 of the Directors present at a meeting of the Board at which such Contract is presented, waive the selection of contractors on a competitive basis when doing so is in the best interest of ECMCC. (PAL § 2879(3)(b)(i)).
- 13.14. Subsidiaries of the Corporation. ECMCC may own, in whole or in part, one or more subsidiary corporations formed to exercise and perform portions of its purposes, powers, duties, functions, or activities. Delegation of such activities to these corporations shall not be subject to competitive procurement processes or traditional M/WBE goals. (PAL § 3631(9)).
- 15. Affiliated Entities. Upon compliantly procuring goods or services (including via lease), ECMCC may, without need for a separate IFB or RFP, enter into one or more separate agreements with an affiliated entity of the contracted vendor for purposes of securing financing for the goods or services.-without need for a separate Procurement.
- <u>16.</u> Lease Agreements. ECMCC may lease or purchase real property from private

entities without engaging in a competitive procurement process. (GML § 103 and related case law).

- 17. Contract Assignments. If ECMCC has awarded a Procurement Contract through a valid Procurement process to a vendor, the vendor validly assigns the Contract to a secondary vendor as permitted by the Contract and by New York law, and the secondary vendor agrees to assume all rights, responsibilities, and liabilities under the assignment contract, ECMCC may Contract with such secondary vendor without the need for a further RFP or IFB.
- 18. Lack of Response. If, after two (2) attempts at good faith advertisement of a Procurement opportunity through an IFB or RFP, ECMCC receives no proposals or Bids in response to such advertisement, ECMCC may purchase the goods or services that are subject of the IFB or RFP in the open market without having to further re-issue the IFB or RFP. (1978 Op. St. Compt. No. 78-523).

H. Pre-qualification.

Prospective suppliers may be pre-qualified for particular types of supplies, services or construction<u>Public Works</u>. Such pre-qualification, however, is subject to subsequent review and does not necessarily constitute a finding of Responsibility for any particular contract award nor does it guarantee an amount to be awarded. Notice of the Pre-Qualification solicitation shall be published at least annually in a newspaper of general circulation, and shall be published in the New York State Contract Reporter, similar to an IFB/RFP. The pre-qualified vendor list generated by the Pre-Qualification solicitation shall not contain less than five (5) bidders and must remain open for additional qualified bidders. Prequalification of bidders does not constitute competitive bidding. An IFB or RFP must still be used to determine how a particular Procurement will be awarded. (GML § 103(15)(b)).

I. Request for Qualifications.

In instances where ECMCC wishes to award contracts in accordance with the discretionary procedures forth in Sections III.E.1 and III.E.2, it may, but shall not be required to, award such contracts after first issuing a public Request for Qualifications ("RFQ"). Such RFQs shall not be subject to any formal notice requirements or MWBE goals, but shall be used to establish lists within ECMCC of vendors permitted to perform work (or provide supplies) on projects up to but not exceeding the discretionary thresholds. Such qualified vendors should meet the Responsible requirements set within these Guidelines and, whenever possible, should enter into a Contract with ECMCC prior to providing goods or services. An RFQ shall not be required in order to make a Discretionary Procurement, but rather is a tool to be used by ECMCC for creating established lists for these Discretionary Procurements. If a list is established through an RFQ process for a specific good, service, or Public Works, ECMCC should endeavor to only enter into Discretionary Procurements with the vendors on such list absent extraordinary circumstances.

J. New York State Business Enterprises.

It is the goal of ECMCC to shall promote the participation of New York State Business Enterprises and New York State Residents whenever possible within Procurement Contracts. (PAL §§ 2879(3)(n)-(p)).

IV. PROCEDURES and STANDARD PROVISIONS

- A. New York State Contract Reporter. Except as otherwise set forth below, All all Procurements (other than joint purchases and contracts for health care services) of goods, services or public works having a Contract Value of fifty thousand dollars (\$50,000) or more shall be published in the New York State Contract Reporter (except as provided below).<u>CertainECMCC shall advertise certain Procurement</u> opportunities <u>are required to be published</u> in the New York State Contract Reporter as set forth below.:
 - 1. Notice of Procurement. For all Procurement Contracts IFBs, RFPs, and RFQs regardless of value, and all Sole Source Procurements and M/WBE Discretionary Procurements with a Contract value equal to or greater than \$50,000, ECMCC will, prior to issuing an IFB or RFP, submit the following information to the New York State Contract Reporter-website: (1) ECMCC's name and address; (2) the IFB or RFP number; (3) a brief description of the goods and/or services sought, the location where goods are to be delivered and/or services provided and the contract term; (4) the address where bids or proposals are to be submitted; (5) the due date for Bids or Proposals; (6) a description of any eligibility or qualification requirements or preferences; (7) a statement as to whether the contract requirements may be fulfilled by a subcontracting, joint venture or coproduction arrangement; (8) any other information deemed useful to potential contractors; (9) the name, address, and phone number of the person to be contacted for additional information, and (10) a statement as to whether the goods and/or services sought have, in the immediately preceding three-year period, been supplied by a Foreign Business Enterprise (as defined in EDL § 141(2)), and (11) the name of any individual or business enterprise that has been awarded an identical or substantially similar Procurement Contract within the past five years. In the case of IFBs, RFPs, and RFQs, The the notice of Procurement opportunity information shall appear in the NYSCR at least fifteen (15) business days prior to the a Bid or Proposal due date. (EDL § 142(2)(c)).
 - 2. <u>Notice of Contract Award</u>. At the time a determination of intent to award a Procurement Contract <u>through an IFB or RFQ</u> is made, the following information shall be submitted for publication in NYSCR:
 - (a) For Procurement Contracts obtained through IFB, the result of the Bid opening including the names of bidding firms and the amounts bid by each;
 - (b) For Procurement Contracts obtained through <u>an RFP</u> or <u>quote <u>RFQ</u> solicitation</u>, the names of vendors submitting Proposals or quotes and the vendor submitting the selected Best Value Proposal or quote.

(c) For all Sole Source Procurements and M/WBE Discretionary Procurements with a Contract value equal to or greater than \$50,000, all other Procurement Contracts (including Procurement Contracts with a value of \$50,000 or more awarded on a sole source or single source basis, including such Contracts not exceeding \$500,000 awarded to Small Businesses or M/WBE firms, or for the purchase of goods and/or technology that are recycled or remanufactured, and certain other Procurement Contracts exempt from the general advertising requirement for procurement contract bidding opportunities), the name of the proposed awardee. (EDL §§ 143(2)-(3)).

(d)(c)

3. <u>Exemptions</u>. This Section IV.A shall not apply (a) in the event of an Emergency Procurement, (b) if the Procurement is being resolicited within forty five (45) business days after the date Bids or Proposals were originally due, or (c) to Procurement Contracts awarded to not for profit human services providers. (EDL § 144).

B. Cancellation of Invitation for Bid or Request for Proposal.

An IFB, RFP or other solicitation may be canceled, or any or all Bids or Proposals may be rejected in whole or in part as may be specified in the solicitation or otherwise, when it is in the best interest of ECMCC. Such cancellation and reissuance may include such instances in which ECMCC determines that a re-issuance may result in more favorable bids or responses. The reasons for the cancellation or rejection shall be made part of the Procurement Record. (GML § 103(1)).

C. Responsibility of Bidders and Respondents.

- 1. <u>Standards</u>. Factors to be considered in determining whether the standard of "Responsibility" has been met include whether a prospective contractor has:
 - (a) Available the appropriate financial, material, equipment, facility and/or personnel resources and expertise, or the ability to obtain them, necessary to indicate its ability to meet all contractual requirements;
 - (b) A satisfactory record of performance with projects of a similar size and nature;
 - (c) A satisfactory record of integrity;
 - (d) Qualified legally to contract with ECMCC; and
 - (e) Promptly supplied all necessary information in connection with the inquiry concerning responsibility.
- 2. Written Determination of Non-Responsibility or Non-responsiveness <u>Required</u>. If a bidder or offeror who otherwise would have been awarded a contract is found non-responsible or nonresponsive, ECMCC shall issue a written determination of non-responsibility or non-responsiveness setting forth the basis of the finding.

- D. Compliance with Procurement Lobbying Laws. In accordance with State Finance Law Section 139-j, potential Contractors are prohibited from contacting ECMCC in an effort to influence a decision on a pending Procurement during the "Restricted Period" set forth within such law. Further, in accordance with State Finance Law Section 139-k, bidders and offerors are required to disclose findings of non-responsibility made within the previous four years by any governmental entity where such prior finding of non-responsibility was due to: (a) a violation of Section 139-j, or (b) the intentional provision of false or incomplete information to a governmental entity. ECMCC shall investigate any report of violation of these laws. Failure to comply with these laws may result in the disqualification of a Contractor from future Procurement opportunities.
- E. Contractor Preparation of Technology Specifications. If a Contractor prepares and furnishes specifications for a technology Procurement proposal, to be used in a competitive Procurement, such Contractor shall not be permitted to bid or propose on such Procurement, either as a prime contractor or as a subcontractor. Contracts for evaluation of offers for products or services shall not be awarded to a Contractor that would then evaluate its own offers for products or services. Such restrictions shall not apply where:
 - 1. The Contractor is the sole source or single source of the product or service;
 - 2. More than one Contractor has been involved in preparing the specifications for a Procurement proposal; or
 - 3. A Contractor has furnished at ECMCC's request specifications or information regarding a product or service they provide, but such Contractor has not been directly requested to write specifications for such product or service or an ECMCC technology procurement proposal.

F. Contract Provisions.Non-collusive bidding.

1. All Contracts for Personal Services shall detail the scope of services to be performed and the time frame for performance, the monitoring or reviewing of that performance by ECMCC personnel and, where appropriate, any permitted use of supplies, facilities or personnel. Such contracts also shall state the compensation for the services, the timing of payment, the preconditions for receiving payment from ECMCC, procedures for termination of the contract and any other provisions counsel deems necessary or appropriate for each particular contract. If the performance of any contract permits or requires the use of subcontractors, the Contract shall require the Contractor to act affirmatively to secure such participation by M/WBEs and to report the nature and extent of such efforts to ECMCC in accordance with predetermined ECMCC participation goals.

All Bid documents must include the following non-collusive bidding certification language:

By submission of this bid, each bidder and each person signing on behalf of any bidder certifies, and in the case of a joint bid each party thereto certifies as to its own organization, under penalty of perjury, that to the best of knowledge and belief:

- The prices in this bid have been arrived at independently without collusion, consultation, communication, or agreement, for the purpose of restricting competition, as to any matter relating to such prices with any other bidder or with any competitor;
- Unless otherwise required by law, the prices which have been quoted in this bid have not been knowingly disclosed by the bidder and will not knowingly be disclosed by the bidder prior to opening, directly or indirectly, to any other bidder or to any competitor; and
- No attempt has been made or will be made by the bidder to induce any other person, partnership or corporation to submit or not to submit a bid for the purpose of restricting competition.

G. Trial Agreements.

From time to time, ECMCC may have need to trial a new product on a short-term basis prior to purchasing. Such trial should be limited in duration to the extent of time necessary to make a decision on the product, but in no event more than ninety days, and should only be permitted if there is an existing compliant procurement method in keeping with these Guidelines that would permit the purchase of the product following conclusion of the trial.

G.H. Contract Review and Approval.

- 1. <u>General Counsel</u>. All contracts and amendments to contracts must be reviewed and approved by ECMCC's General Counsel, with the exception of renewals or extensions to existing contracts upon the same terms and conditions previously reviewed and approved by the General Counsel. General Counsel may designate an <u>attorney</u> member of the Office of General Counsel to perform review in any particular instance.
- 2. <u>Board Approval of Non-Budgeted Contracts</u>. Any Contract with a Contract Value in excess of \$500,000 that does not appear in the budget must be approved by the Board of Directors.
- 3. <u>Board Approval and Annual Review of Certain Contracts for Services</u>. Any Procurement Contract for services with an actual or anticipated term of more than one (1) year must be approved by and annually reviewed by the Board of Directors. (PAL § 2879).
- 4. <u>Signing Authority</u>. The Chief Executive Officer, and Chief Financial Officer and President are the only persons authorized to sign Contracts on behalf of ECMCC._
- **H.I. ECMCC Reserved Rights.** The following statement of reserved rights may be incorporated in all RFPs and IFBs.

ECMCC reserves the right to:

1. Reject any and all proposals submitted in response to this Request for Proposals or Invitation for Bids;

- 2. Disqualify any respondent whose conduct or proposal fails to conform to the requirements of this RFP/IFB;
- 3. Withdraw this RFP/IFB at any time at its sole discretion;
- 4. Prior to submission of proposals to amend the RFP/IFB specifications to correct errors or oversights, or to supply additional information as it becomes available;
- 5. Change any of the scheduled dates;
- 6. Waive any requirements that are not material;
- 7. Waive any non-conformity with the requirements of this RFP/IFB;
- 8. Terminate this RFP/IFB process at any time;
- 9. Seek clarification from a respondent at any time throughout the RFP/IFB process for the purpose of resolving ambiguities or questioning information presented in proposals;
- 10. Award the contract in whole or in part and/or apportion the award among one or more respondents;
- 11. Negotiate final terms with the successful respondent(s);
- 12. Conduct contract negotiations with the next responsible bidder, should ECMCC be unsuccessful in negotiating with the selected bidder;
- 13. Prepare a list of finalists based on initial proposal evaluations and request that finalists present in-person or telecommunicated presentations to ECMCC;
- 14. Extend the term of any resulting contract for the items or services described herein for additional lengths of time at ECMCC's discretion;
- 15. Add additional similar products to any resulting agreement as they become available and meet ECMCC's needs; and
- 16. In the event that the selected bidder is unable to fulfill ECMCC's request for the products/services, choose another bidder through any compliant procurement means available to ECMCC.

V. <u>BOND REQUIREMENT</u>

A. Bid Security.

1. <u>Requirement for Bid Security on Certain Construction–Public Works</u> <u>Contracts</u>. Bid security shall be required for Contracts involving the construction of a Medical Building when the cost is estimated to exceed \$500,000. Bid security shall be in the form of a bond from the Project Developer or the Project Developer's construction subcontractor guaranteeing prompt payment when due to all persons furnishing labor and materials. Such bond shall be provided by a surety company authorized to do business in New York, or the equivalent in cash or otherwise supplied in a form satisfactory to ECMCC. Nothing herein prevents the requirement of such bonds on other construction Contracts or Contracts valued under \$500,000 when the circumstances warrant. (PAL § 3628(11))

- 2. <u>Bid Security on Supply or Services Contracts</u>. Bid security may be required for supply or service contracts, as ECMCC deems necessary to protect ECMCC's interests. Any security requirements shall be set forth in the solicitation. Bid security shall be a bond provided by a surety company authorized to do business in New York or the equivalent in cash or otherwise supplied in a form satisfactory to ECMCC. Bid security shall not be used as a substitute for a determination of a bidder or offeror's responsibility.
- 3. <u>Rejection of Solicitations for Noncompliance with Bid Security</u> <u>Requirements</u>. When the solicitation requires security, noncompliance requires that the Bid or Proposal be rejected unless otherwise waived by ECMCC pursuant to these Guidelines. (PAL § 3628(11)).

B. Other Forms of Security on Construction Public Works Contracts.

ECMCC may require other forms of security to assure timely, faithful and uninterrupted performance, including, but not limited to, operations period surety bonds, letters of credit, and appropriate written guarantees from the Contractor.

VI. <u>ETHICS</u>

A. Definitions.

- 1. <u>Direct and Indirect Participation</u>. Involvement through decision, approval, disapproval, recommendation, preparation of any part of a purchase request, influencing the content of any specification or Procurement standard, rendering of advice, investigation, auditing, or in any other advisory capacity.
- 2. <u>Employee</u>. Any individual drawing a salary from ECMCC or any noncompensated individual performing services for ECMCC.
- 3. <u>Relative</u>. An individual residing in the same household as the ECMCC employee and any individual who is a direct descendent of the employee's grandparents or the spouse of such descendent.

B. Conflict of Interest.

1. <u>Conflict of Interest</u>. It shall be a breach of ethical standards for any Employee to participate directly or indirectly in a Procurement when the Employee knows that:

- (a) The Employee or a Relative of the Employee has a financial interest pertaining to the Procurement;
- (b) A business or organization in which the Employee or Relative is involved has a financial interest pertaining to the Procurement;
- (c) Any other person, business, or organization with whom the Employee or Relative is negotiating or has an arrangement concerning prospective employment is involved in the Procurement.

C. Kickbacks.

It shall be a breach of ethical standards for any payment, gratuity, or offer of employment to be made by or on behalf of a subcontractor under a contract to the prime contractor, higher tier subcontractor or any person associated therewith, or a relative of such contractors or subcontractors, as an inducement for the award of a subcontract or order.

VII. <u>MINORITY AND WOMEN BUSINESS ENTERPRISE ("M/WBE")</u> <u>REQUIREMENTS.</u>

A. Scope. All Procurement Contracts entered into by ECMCC exceeding \$25,000 for labor, services, supplies, equipment, or materials or exceeding \$100,000 for the acquisition, construction, demolition, replacement, major repair or renovation of real property and improvements, must comply with the M/WBE requirements set forth in New York State Executive Law Article 15-A, as well as 5 NYCRR Parts 142-144 ("M/WBE Regulations") ("State Contracts"). With respect to procurement of services and commodities, ECMCC shall consider the reasonably expected aggregate amount of all purchases of the same commodities or services to be made within a twelve (12) month period commencing on the date of purchase when determining whether these requirements apply. Aggregate purchases of the same commodities or services within a twelve (12) month period are deemed a single transaction.

B. M/WBE Goal Plan.

- 1. <u>Generally</u>. Annually, ECMCC shall submit to the director of the NYS Department of Economic Development, Division of Minority and Women's Business Development (the "Division"), an M/WBE Goal Plan setting forth the percentage of ECMCC expenditures targeted for the participation of M/WBEs in the following State Contract categories:
 - Construction;
 - Commodities;
 - Construction related professional services; and
 - Non-construction related professional and non-professional services.
- 2. <u>Establishment of Goals</u>. ECMCC shall review all State Contracts and establish overall goals for each contract as well as goals for specific MBE and WBE participation, as required by 5 NYCRR 142.2. Generally, ECMCC is committed to achieving an overall M/WBE utilization percentage of thirty percent (30%) of ECMCC's agency budget, which 24

percentage goal may be amended from time to time as set forth in the M/WBE Goal Plan (the "M/WBE Goal"). This goal is generally subdivided into twenty percent (20%) MBE and ten percent (10%) WBE participation, but may be reduced or increased on an individual basis upon analysis and review of potential subcontracting opportunities by ECMCC.

- 3. <u>Exempt and Excluded Expenditures</u>. The M/WBE Goal Plan includes a list of "Exempt" and "Excluded" expenditures, which expenditures are not included in ECMCC's agency budget. Such exemptions and exclusions shall include those otherwise described within these Guidelines, but may also include other areas that ECMCC determines insufficient M/WBE utilization is available, subject to approval by NYS.
- 4. <u>State Contract Goals</u>. Each IFB, RFP, and proposed contract that is expected to result in a State Contract (other than an exempt or excluded State Contract) shall set forth the M/WBE Goal for the State Contract. Individual goals may be set for each State Contract, taking into consideration the factors set forth in 5 NYCRR 141.2(e). Each IFB and RFP shall include detailed instructions on M/WBE compliance and requirements to be met in responding the IFB or RFP.
- **C. ECMCC's Good Faith Efforts.** For all procurements anticipated to result in a State Contract (other than an exempt or excluded State Contract), ECMCC shall employ good faith efforts to achieve M/WBE participation in accordance with 5 NYCRR 141.6, including, but not limited to, the following notice of solicitation strategies:
 - 1. <u>NYS Contract Reporter</u>. With respect to all procurements expected to result in a State Contract exceeding \$50,000, such procurements shall be advertised in the New York State Contract Reporter.
 - 2. <u>Direct Solicitation of M/WBEs</u>. Notice of the solicitation (by email or letter) shall be sent by ECMCC's Department of Purchasing directly to certified M/WBEs that have been identified by ECMCC as M/WBE vendors qualified to provide the service or commodity.
 - 3. <u>Other Media</u>. Advertisements for RFPs, IFBs and other solicitations anticipated to result in a State Contract will also be placed in minority and women-focused media as appropriate.
- **D. Documentation of Good Faith Efforts.** ECMCC shall document its Good Faith Efforts by including in the procurement record: (1) documentation showing M/WBE vendors, organizations and associations that were solicited and/or copies of advertisements placed in general circulation media, trade association, publications and/or minority-focused media, and (2) all bids, quotes, proposals or other responses received from M/WBE vendors.
- E. Contractor's Good Faith Efforts. When an opportunity for subcontracting or indirect expenditure with an M/WBE firm exists on a State Contract, ECMCC shall ensure that prime vendors employ a good faith effort to utilize M/WBE subcontractors as required under 5 NYCRR 142.8. In determining whether a Contractor has made good faith efforts to utilize M/WBE subcontractors, ECMCC

shall consider whether the Contractor has undertaken efforts including but not limited to:

- 1. Solicit certified M/WBEs and provide copies of solicitations and responses thereto upon ECMCC's request;
- 2. Advertise for participation of M/WBEs in in appropriate general circulation, trade and minority- or women-oriented publications, and provide copies of the listing(s) and date(s) of the publication to ECMCC upon request; and
- 3. Undertake steps to reasonably structure the contract scope of work for the purpose of subcontracting with, or obtaining supplies from, certified M/WBEs.

F. Joint Ventures and Teaming Agreements.

Where a State Contract does not afford opportunities for subcontracting or subconsulting, potential contractors shall be encouraged to enter into joint ventures and teaming agreements with M/WBEs.

- 1. <u>Joint Venture</u>. A contractual agreement joining together two or more business enterprises, one of which is a certified M/WBE, for the purpose of performing on a State Contract. The M/WBE must provide a percentage of value added services representing an equitable interest in the joint venture. All parties to the joint venture must agree to share in the profits and losses of the business endeavor according to their percentage of equitable interest.
- 2. <u>Teaming Agreement</u>. A utilization plan arrangement between two or more business enterprises, one of which is a certified M/WBE, to perform on a specific State Contract if awarded to the team. The team itself may be a joint venture, or one of the team members may be designated to act as the prime contractor, and the other member(s) designated to act as subcontractors.
- 3. <u>Information Required</u>. In the event that a contractor responding to a solicitation is a joint venture, teaming agreement, or other similar arrangement that includes a certified M/WBE, such a contractor must submit the M/WBEs identifying information, including federal identification number and copy of certification, as well as a copy of the joint venture or teaming agreement.

G. M/WBE Utilization.

- 1. <u>M/WBE Utilization Plan</u>. With respect to procurements that are anticipated to result in the execution of a State Contract, ECMCC shall include a blank M/WBE Utilization Plan with any IFB, RFP, or proposed contract (where the contract is exempt from competition requirements set forth in GML § 103).
- 2. <u>Review of Utilization Plan</u>. ECMCC shall review and approve all M/WBE documentation (Utilization Plan, etc.), or otherwise notify the potential contractor of disapproval or deficiency of the documentation within twenty (20) business days of submission, as required by 5 NYCRR §142.4. If the

Utilization Plan is not approved, the M/WBE Analyst will provide the contractor with a written notice of deficiency of the Utilization Plan within twenty (20) business days of its receipt, as required under 5 NYCRR Part 142.6(c). The potential contractor must respond to the notice of deficiency by submitting to the M/WBE Analyst a written remedy within the period of time set forth in the Bid or RFP documents, as permitted by 5 NYCRR Part 142.6(e). If the written remedy submitted is found to be inadequate, the M/WBE Analyst will notify the contractor and may request the contractor to submit a request for a waiver. If a contractor is deemed non-responsive or non-responsible by ECMCC any request for waiver shall be deemed to be moot (5 NYCRR Part 142.7(a)(1)(b)).

- 3. <u>Determination of Non-Responsiveness</u>. ECMCC may disqualify a potential contractor as non-responsive (5 NYCRR §142.6(f)) to the requirements of NYS Executive Law Article 15-A upon the occurrence of any of the following:
 - (i) Contractor fails to submit a M/WBE Utilization Plan in accordance with the requirements of this Policy or apply for a waiver;
 - (ii) Contractor fails to submit a written remedy in response to a notice of Utilization Plan deficiency in accordance with this Policy;
 - (iii) Contractor fails to submit a request for waiver upon request by ECMCC;
 - (iv) Denial of a request for waiver by the M/WBE Analyst or the Division; or
 - (v) M/WBE Analyst determines that the contractor has failed to perform good faith efforts.
- H. Self-Performance. Contractors that are NYS certified M/WBEs and will self-perform all or a portion of a State Contract may count the value of the self-performed work as either MBE or WBE involvement up to the dollar value of such involvement. Contractor must also engage participation from another MBE or WBE firm of the opposite designation in order to meet the requirements of ECMCC's M/WBE Program. Example: On a contract for services with a 30% M/WBE goal (15% MBE and 15% WBE), ABC Company is a WBE and intends to self-perform 20% of the contract work. Company ABC may count 20% of the contract value as WBE utilization performed by Company ABC. Company ABC must still engage at least one NYS certified MBE as a subcontractor or supplier to perform at least 15% of the contract work in order to meet the M/WBE requirements of the contract unless otherwise approved by the Division.
- I. Commercially Useful Function. In accordance with 5 NYCRR 140.1(f), only sums paid to M/WBEs for the performance of a commercially useful function may be applied towards the achievement of the applicable M/WBE participation goal. An M/WBE performs a commercially useful function when it is responsible for execution of the work of the contract and is carrying out its responsibilities by actually performing, managing, and supervising the work involved and is consistent with the commodity classifications assigned to the M/WBE by the Division. An M/WBE does not perform a commercially useful function if its role adds no substantive value and is limited to that of an extra participant in a transaction, contract, or project through which funds are passed in order to obtain the appearance of participation.

- **J. Contractor Reporting.** The State Contract shall require contractor to report on their M/WBE utilization throughout the term of the Contract in the format and timeline indicated by ECMCC.
- **K. Non-Compliance.** Contractors who fail to comply with the utilization percentages set forth in their approved Utilization Plan shall be subject to disqualification, liquidated damages, termination of the State Contract, or other enforcement as set forth in the Contract.
- L. Waivers. If a contractor or potential contractor, after engaging in good faith efforts as described within the M/WBE Regulations, is unable to achieve the M/WBE goals applicable to the RFP, IFB, or State Contract, ECMCC may permit the contractor to request a total or partial waiver of the M/WBE goals by submitting a request for waiver accompanied by documentation of good faith efforts. Within the timeframe set forth in the Bid or RFP documents, ECMCC will determine in its discretion whether the request should be approved, denied, or whether additional action should be taken by the contractor to reach the applicable goal. As required by New York State, Such determinations by ECMCC shall be reviewed and approved by Empire State Development prior to ECMCC issuing final determination. Contractors are responsible for preparation of all Requests for Waiver and supporting documentation, and waiver requests that do not contain sufficient documentation of Good Faith Efforts should not be approved.
- M. M/WBE Discretionary PurchasesProcurements. Consistent with New York Public Authorities Law Section 2879, where goods or services are available from certified M/WBEs, procurements may be made by ECMCC in amounts not exceeding \$500,000 without competitive procurement process, in accordance with the November 26, 2019 resolution of the ECMCC Board of Directors (each a "Discretionary M/WBE Procurement"). ECMCC must document in the procurement record support for both the reasonableness of the price and the selection of the M/WBE vendor.
 - 1. <u>Solicitation of discretionary quotes</u>. When making a Discretionary Procurement, ECMCC may solicit quotes from multiple M/WBE vendors ("M/WBE Mini-Bid"). Generally, the Discretionary M/WBE Procurement should be awarded to the responsible M/WBE vendor submitting the lowest price.
 - 2. Advertisement of Discretionary M/WBE Procurements.

Advertising requirements under NYS Economic Development Law stillapply to Discretionary M/WBE Procurements in excess of \$50,000 shall be advertised in the New York State Contract Reporter. The language that should be used for advertisement of a Discretionary M/WBE Procurement is as follows for M/WBE Mini-Bids (as described below):

"ECMCC intends to procure [insert project description, i.e. 1,000 widgets] pursuant to its discretionary purchasing authority under New York Public Authorities Law section 2879. This procurement opportunity is limited to New York State businesses certified pursuant to Article 15-A of the New York State Executive Law." If this is <u>not</u> intended as an M/WBE Mini-Bid, the following language shall be used:

"ECMCC intends to procure [insert project description, e.g. 1,000 widgets] as a discretionary spend pursuant to its purchasing authority under New York Public Authorities Law section 2879. ECMCC will procure these services or goods from a New York State businesses certified pursuant to Article 15-A of the New York State Executive Law. This is not a bid opportunity. Please do not contact ECMCC requesting bid information."

- 3. <u>Negotiation of Procurement Price</u>. When an M/WBE submits a quote for a commodity or service in a Discretionary M/WBE Procurement (not exceeding \$500,000) and the quote is deemed high, ECMCC should engage in direct negotiation with the M/WBE vendor in an attempt to reach reasonableness of price. This step is not permitted for a competitive procurement.
- 4. <u>Reasonableness of Price</u>. ECMCC must document in the procurement record the "reasonableness of price" for any Discretionary M/WBE Procurement. Generally, reasonableness of price can be determined by: (1) Comparing the quoted price with the price for the same or similar services purchased by <u>ECMCC</u>, the County, OGS, or federal contract within the last six-twelve (12) months; (2) comparing the price with other quoted prices; (3) comparing the quoted price with prices in various procurement publications; (4) reviewing the type of work that was previously accepted by ECMCC at a similar price; or (5) comparing the price of the product or service with the current market value of the same product or service.
- 5. <u>Justification for the Selection of M/WBE Vendor</u>. ECMCC must document justification for the selection of the M/WBE vendor in the procurement record. Selection may be supported by: (1) demonstrating reasonableness of cost; (2) showing enhanced or best value provided by the vendor; (3) (if applicable) noting the vendor is a NYS small business; and (4) identifying the vendor as an M/WBE (this cannot be the sole justification).
- N. Quantitative Factors. When developing an RFP awarding a procurement contract on the basis of Best Value, M/WBE regulations allow ECMCC to designate up to 5% of the total technical evaluation scale to be awarded to a Respondent who meets one of the following criteria:
 - (1) a New York State certified M/WBE;
 - (2) a New York State certified Service-Disabled Veteran-Owned Business (SDVOB) as defined in Veterans' Services Law Article 3.

The above-referenced 5% designation included in the RFP technical evaluation is called a "Quantitative Factor." Note although a Respondent may meet more than one of the criteria, credit is to be awarded for only one category, not multiple categories.

Erie County Medical Center Corporation

MINUTES

Credentials Committee Meeting February 6, 2025

Executive Conference Room/Teams Meeting

Present: Dr. Yogesh Bakhai, Christopher Resetartis, CRNA, Dr. Victor Vacanti, Dr. Samuel Cloud, Dr. Ashvin Tadakamalla (via teleconference), Dr. Richard Hall (via teleconference)

Excused: Dr. Lakshpaul Chauhan, Dr. Mandip Panesar, Dr. Thamer Qaqish, Dr. Siva Yedlapati

| Agenda Item | Discussion | Action | Follow-up |
|--|---|--|--|
| I. CALL TO ORDER | Dr. Bakhai called the meeting to order at 3:02 pm. | | |
| II. ADMINISTRATIVE | | | |
| A. Minutes | Minutes from the January 2, 2025 meeting were reviewed and approved | A motion was made by Dr. Vacanti, and unanimously carried to approve the minutes of the January 2, 2025 meeting. | Via these minutes, the Credentials Committee recommends same to the Medical Staff Executive Committee. |
| B. Deceased | None | None | None |
| C. Applications Withdrawn/Processing Cessation | None | None | None |
| D. Automatic Conclusion (Init Appointment) | ial None | None | None |
| E. Name Changes | Orthopedic Surgery: Halley Kreminski, PA-C changed her name to Halley Biersbach, PA-C. All required documentation was submitted and verified. | Noted | Informational purposes only |

| F. Leave of Absence (2) G. Resignations (5) | | Internal Medicine • Leigh-Anne DiOrio, FNP-maternity; RTW 05/01/25 Plastic & Reconstructive Surgery • Bridget Fitzgerald, PA-C-maternity; RTW 03/01/25 Files are updated and resignation protocol followed. The Committee discussed retention rates and Wellness Committee initiatives to investigate and manage. | | Reviewed Informational purp only Notification via the minutes to MEC, B Directors, Revenue Management, Dec Support | | via these IEC, Board of venue | | |
|--|---|---|--|--|---|-------------------------------------|------------|------------|
| NAME | DEPARTMENT | | PRACTICE PLAN/REASON | COVERING/COLLABORATING/ SUPERVISING | RESIGN DATE | INITIAL DATE | | |
| Gregory DiFrancesco, MD Michael Maloney, PA-C | Emergency Medicine Internal Medicine | | Great Lakes Physician Services Des not come to ECMC Confirmed in email Apogee Per Apogee, he has never worked a shift at | N/A N/A | 01/01/2025 01/24/2025 | 06/28/2022 04/28/2015 | | |
| Dominic Stutz, PA-C | Orthopedic Surgery | | ECMC Confirmed in email UBMD Leaving practice plan Confirmed in email | N/A | <mark>12/31/2024</mark> | 09/27/2022 | | |
| Katherine Boyle, MD | Orthopedic Surgery | | Orthopedic Surgery | | UBMD Moving out of state Confirmed in email | N/A | 01/02/2025 | 11/24/2020 |
| Supra Khare, MD | Psychiatry | | UPP "life circumstances prevented her from joining ECMC" Confirmed in email | N/A | <mark>01/28/2025</mark> | 01/28/2025 | | |

Highlight: Initiate FPPE

| III. CHANGE IN STAFF CATEGORY | | | |
|---|--|---|---|
| | None | | |
| IV. CHANGE/ADDITION Collaborating/Supervising (2) | | | |
| A. Azadeh Hassan-Tehrani, FNP | Family Medicine Changing from Dr. Ryan Mikac to Dr. Maira Ilahi All required documentation was submitted. | Noted | No follow-up necessary. For informational purposes |
| B. Casey Krug, PA-C | Family Medicine Changing from Dr. Ryan Mikac to Dr. Romain Calini All required documentation was submitted. | Noted | No follow-up necessary. For informational purposes |
| V. CHANGE DEPARTMENT/ PRIVILEGE ADDITION/ REVISION (2) | | | |
| A. Joseph Quackenbush, PA-C | Family Medicine Joining GPPC for Terrace View Adding privilege of "Management of care in long term care setting" Supervising MD: Mikac Remaining per diem with UBMD Addition Medicine, Supevising MD: Wilber | The Committee voted, all in favor, to approve the changes as requested. | Via these minutes, the Credentials Committee recommends approval to the Medical Executive Committee. Notification to Revenue Cycle and Decision Support upon approval of the Board. |
| B. Joseph Rasnick, ANP | Internal Medicine – S&K Adding privilege in <i>"Plastic & Reconstructive Surgery with First Assist"</i> Collaborating MD: Burke Temps granted for 01-24-2025 | The Committee voted, all in favor, to approve the changes as requested. | Via these minutes, the Credentials Committee recommends approval to the Medical Executive Committee. |

Highlight: Initiate FPPE

| | | | | Notification to Revenue Cycle and Decision Support upon approval of the Board. |
|------------|--------------------------|---|--|---|
| <u>VI.</u> | A. William Belles, MD | Dr. Belles is withdrawing his request for Robotic TORS privileges. It is noted that Dr. Belles has already reached out to schedule the required training. Once this is completed, his request will be reconsidered. Discussion ensued regarding the fact that ECMC does not have a Robotics Committee who could be vetting new technologies and who can be authorized to use them. It was recommended that the Surgical Executive Committee could serve in this capacity, as the ability to vet new technology is noted in their charter. | The Committee voted, all in favor, to recommend that the Surgical Executive Committee be authorized to vet new technology and its appropriate uses as it is brought into the organization. | Via these minutes, the Credentials Committee recommends approval to the Medical Executive Committee. Notification to Revenue Cycle and Decision Support upon approval of the Board. EXTRACT -MEC EXEC SESSION |
| VII. | UNACCREDITED FELLOWSHIPS | | | |
| | | Surgery-Bariatric An application was emailed on 12/11/24 for Dr. Xavier Jean. The practice plan has pushed back the start date to March 1, 2025. | Noted | Informational purposes only |

| VIII. INITIAL APPOINTMENTS (6) | | | |
|--|--|--|---|
| Cynthia Chen, MD Emergency Medicine | Wayne State University MD June 2015 Wayne State University School of Medicine Henry Ford Hospital Emergency Medicine Residency June 2015 to June 2018 and Staff Physician July 2018 to July 2019 University of Michigan Hospice and Palliative Medicine Fellowship July 2018 to June 2019 Academic appointment – University of Michigan Clinical Instructor July 2019 to August 2022 and Clinical Assistant Professor September 2022 to present of Emergency and Internal Medicine Attending Physician – Department of Emergency Medicine Ann Arbor Veterans Affairs Hospital and Adult Palliative Care Consultation Service and Adult Emergency Services at University of Michigan July 2019 to present Joining UEMS March 1, 2025 American Board of Emergency Medicine and Palliative Medicine certified | The Committee voted, all in favor, to approve the appointment with privileges granted as requested. | Via these minutes, the Credentials Committee recommends approval to the Medical Executive Committee. Notification to Revenue Cycle and Decision Support upon approval of the Board. |
| Shella Dargout, PA-C Emergency Medicine | D'Youville College Bachelor and Master of Science Physician Assistant December 2011 Time gap - pending license, board, and credentialing January 2012 to March 2012 | The Committee voted, all in favor, to approve the appointment with privileges granted as requested. | Via these minutes, the Credentials Committee recommends approval to the Medical Executive Committee. |

| | Physician Assistant – Mash Care Network April 2012 to October 2016, Advantis Occupational Health July 2013 to July 2019, UEMS November 2016 to present, and UBMD Internal Medicine April 2016 to present Joining UEMS at ECMC March 15, 2025 Supervising Physician – Dr. Jessica Strauss (1) NCCPA certified | | Notification to Revenue Cycle and Decision Support upon approval of the Board. |
|---|---|--|---|
| Andrew Rogers, PhD internal Medicine | University of Houston Doctor of Philosophy Clinical Psychology May 2023 University of Washington School of Medicine Clinical Internship June 2022 to June 2023 and Research Scientist Suicide Care Research Center July 2023 to July 2024 Assistant Professor Division of Behavioral Medicine, Department of Medicine, University at Buffalo August 2024 to present Joining UBMD IM Behavioral Medicine Clinic in the DK Miller Building. Clinical work will be onsite; however, he will not be treating ECMC patients | The Committee voted, all in favor, to approve the appointment with privileges granted as requested. | Via these minutes, the Credentials Committee recommends approval to the Medical Executive Committee. Notification to Revenue Cycle and Decision Support upon approval of the Board. |

| Assaf Berger, MD | • Tel Aviv University MD June 2010 | Flags were reviewed and | Via these minutes, the |
|------------------|--|------------------------------|--------------------------|
| Neurosurgery | • Time gap – Vacation July 2010 | application was endorsed by | Credentials Committee |
| | Medical Doctor Officer at the | the Chief of Service. Dr. | recommends approval to |
| | Israeli Defense Medical Corps | Richard Spiro to address the | the Medical Executive |
| | August 2010 to December 2014 | international pathway to | Committee. |
| | ECFMG certificate issued October | Board Certification at MEC. | |
| | 2011 | | Notification to Revenue |
| | • Time gap – Vacation December | The Committee voted, all in | Cycle and Decision |
| | 2014 to April 2015 | favor, to approve the | Support upon approval of |
| | Tel Aviv Sourasky Medical Center | appointment with privileges | the Board. EXTRACT FOR |
| | Neurosurgery Residency April | granted as requested. | MEC – EXECUTIVE |
| | 2015 to April 2021 | | SESSION |
| | • Time gap – Vacation April 2021 to | | |
| | June 2021 | | |
| | NYU Grossman School of Medicine | | |
| | Neurological Surgery – | | |
| | Stereotactic Radiosurgery (non- | | |
| | ACGME) Fellowship July 2021 to | | |
| | June 2022 and Neurological | | |
| | Surgery – Functional | | |
| | Neurosurgery (non-ACGME) | | |
| | Residency July 2022 to June 2023 | | |
| | Time gap – Vacation July 2023 to | | |
| | September 2023 | | |
| | Attending Neurosurgeon with | | |
| | University at Buffalo Neurosurgery | | |
| | at Buffalo General September | | |
| | 2023 to present | | |
| | Assistant Professor, Department | | |
| | of Neurosurgery Jacobs School of | | |
| | Medicine and Biomedical Sciences | | |
| | University at Buffalo | | |
| | Board status – not eligible until | | |
| | minimum of 6 years of | | |
| | employment as full time, core | | |
| | faculty at the primary teaching | | |
| | site of an ACGME Neurological | | |

| | Surgery Residency program as an Associate Professor or higher | | |
|------------------------------------|--|--|---|
| Jonathan Riley, MD Neurosurgery | Case Western Reserve University MD May 2009 Time gap – moving May 2009 to June 2009 Emory University School of Medicine Neurological Surgery Residency July 2009 to June 2016 Thomas Jefferson University Hospital Neurological Surgery Fellowship July 2016 to July 2017 Time gap – moving July 2017 to September 2017 Medical Director, Functional Neurosurgery Kaleida Health September 2017 to present Assistant Professor, Department of Neurosurgery Jacobs School of Medicine and Biomedical Sciences University at Buffalo September 2017 to present American Board of Neurosurgery certified | The Committee voted, all in favor, to approve the appointment with privileges granted as requested. | Via these minutes, the Credentials Committee recommends approval to the Medical Executive Committee. Notification to Revenue Cycle and Decision Support upon approval of the Board. |
| Joshua Dudziak, NP Radiology | St. John Fisher University Master of Science PCFNP MSN Program December 2024 Registered nurse Buffalo General Hospital Neurology/Telemetry December 2016 to April 2018 and Diagnostic and Interventional Radiology April 2018 to present Joining Great Lakes Medical Imaging February 2025 | The Committee voted, all in favor, to approve the appointment with privileges granted as requested. | Via these minutes, the Credentials Committee recommends approval to the Medical Executive Committee. Notification to Revenue Cycle and Decision Support upon approval of the Board. |

| | | Collaborating Physicia McGrath (8) ANCC eligible – sitting | | | |
|---|--------|---|------------|--|---|
| X. Temporary Privileges | | Joseph Rasnick, ANP: Reconstructive Surger 01/24/2025 | | Noted | For informational purposes only |
| IX. REAPPOINTMENTS (40) | | See reappointment summary (Attachment B) | | The Committee voted, all in favor, to recommend approval of the re- appointments listed with privileges granted as requested. | Via these minutes, the Credentials Committee recommends approval to the Medical Executive Committee. Notification to Revenue Cycle and Decision Support upon approval of the Board. |
| NAME | | DEPARTMENT | CATEGORY | / PRIVILEGES | |
| Greenaway, Wanda AGNP-C Collaborating MD: DePlato | Anesth | esia | AHP | | |
| Nowak, Kevin MD | Anesth | | | | |
| Cirulli-Linde, Francesca FNP | | esia | Active | | |
| Collaborating MD: Igoe | Emerge | esia ency Medicine | AHP | | |
| Collaborating MD: Igoe Jurek, Jeffrey PA-C Collaborating MD: Cloud/Anillo | - | | | | |
| Jurek, Jeffrey PA-C Collaborating MD: Cloud/Anillo Kaczor, Eric MD | Emerge | ency Medicine | АНР | | |
| Jurek, Jeffrey PA-C Collaborating MD: Cloud/Anillo | Emerge | ency Medicine ency Med/Internal Med | AHP AHP | | |

Highlight: Initiate FPPE

| Boyd, Nicole AHP NEW Collaborating MD: Barkowski | Family Medicine | АНР | |
|---|-------------------|--------|--|
| Evans, Stephen MD | Family Medicine | Active | |
| Aquilina, Alan MD | Internal Medicine | CR&F | |
| Bais, Anshu MD | Internal Medicine | Active | |
| Beall, Katherine ANP Collaborating MD: Rochester | Internal Medicine | AHP | |
| Calandra, Salvatore MD | Internal Medicine | CR&F | |
| Carlson, Richard MD | Internal Medicine | CR&F | |
| Cline, Mercedes ACNP Collaborating MD: Ilyas/Cheng | Internal Medicine | AHP | |
| Czarny, Dawid MD | Internal Medicine | Active | |
| Fenire, Mahmoud MD | Internal Medicine | Active | |
| Kalinin, Alexy MD | Internal Medicine | Active | Withdraw Privileges: (2) -Central Venous Catheter Insertion, percutaneous: internal jugular, subclavian, femoral, etc. Internal Jugular Puncture (with/without catheter) -Paracentesis |
| Matthews, George MD | Internal Medicine | CR&F | |
| Murray, Brian MD | Internal Medicine | Active | |
| Sandhu, Annumeet DO | Internal Medicine | Active | |
| Wolfe, Gil MD | Neurology | Active | |
| Jones, Joshua MD | Ortho Surgery | Active | Adding new privileges: (3) -Level II Core Elbow Privileges -Level II Core Shoulder Privileges -Level II Core Orthopaedic Oncology Privileges Privilege form was updated and the criteria changed to ACGME accredited training. Provider held above privileges since 2011. Chief of service approved due to experience. |
| Rachko, Morgan PA-C Collaborating MD: Bernas | Ortho Surgery | АНР | Adding new privilege: (1) -First Assist with Bone graft harvesting Privilege form does not have any special criteria |

| Young, Paul MD | Otolaryngology | Active | |
|---|------------------------------|-----------|--|
| Liu, Lin MD | Pathology | Active | |
| Yusuf, Yasmin MD | Pathology | Active | Withdraw privilege: (1) -History & physical exam privileges limited to suitability determination for blood donation/apheresis procedures |
| Bortel, Jessica MD | Psych & Behavioral Med | Active | |
| Brooks, Victoria MD | Psych & Behavioral Med | Active | |
| Bevilacqua, Thomas MD | Radiology | Active | |
| Bloss, Michael MD | Radiology | Active | |
| Brown, Harry MD | Radiology | Active | |
| Novick, Michael MD | Radiology | Active | Withdraw privileges: (2) Nuclear Medicine -In vivo diagnostic interpretation -In vitro diagnostic interpretation |
| Rai, Surinder DO | Radiology | Active | |
| Regenbogen, Victor MD | Radiology | Active | |
| Rinaldi, James MD | Radiology | Active | |
| Shatkin, Samuel MD | Plastic Surgery | Associate | |
| Roland, Todd PA-C Collaborating MD: Aldridge | Thoracic/Cardiovascular Surg | АНР | |
| Gonka-Griffo, Jacquelyn MD | Urology | Active | |
| Greco, Joseph MD | Urology | Active | |
| Bold highlighted names are reappointment dates that will be changed to align with | | | |
| Kaleida | | | |

| X. AUTOMATIC CONCLUSION | Reappointment Expiration | | |
|-------------------------|--------------------------|-----------------------------|-----------------|
| 1 st Notice | None | For informational purposes. | None necessary. |
| | | purposes. | |

| 2 nd Notice | None | For informational purposes. | None necessary. |
|--|---|---|--|
| 3 rd Notice | None | For informational purposes. | None necessary. |
| XI. PROFESSIONAL PRACTICE EVALUATIONS | | | |
| OPPE | Completed January 2025: Departments of OB/GYN, Otolaryngology, Thoracic Surgery, and Oral Maxillofacial Surgery. No opportunities identified. | Noted | Follow up at March 2025 Credentials Committee |
| FPPE | 22 FPPE's were distributed, no triggers identified. | Noted | Follow up at March 2025 Credentials Committee |
| Tracking/Trending: | VIP: One (1) Department of Internal Medicine Physician VIP: One (1) Plastic Surgery Physician | Monitoring continues for both physicians. | Follow up at March 2025 Credentials Committee |
| XII. OLD BUSINESS | | | |
| A. Expirables | Expirables were reviewed and discussed with the Credentials Committee. | None | For informational purposes |
| B. DEA, License, Boards | January 2025 • DEA- 8 • License- 25 • Boards-0 February 2025 • DEA- 26 • License- 35 Boards- 2 AHP/ 62 Psych MDs | No action necessary at this time. | For informational purposes |

| C. MDStaff Updates | The MDStaff project is moving along well. ECMC is looking to go live in March 2026. It may come sooner than that since the data required for MDStaff will be feeding EPIC. Kaleida is expected to go live in May 2025, we will need to be testing before that date. Several questions have arisen: do we want to go from 3 peer references to 2 upon initial appointment? We can do that in accordance with NYS regulations. Do we want to change the vendor for background checks – if we switch to Pre-Check, it will automatically put the data into the files since that is the program MDStaff uses. We need to create a DocuSign account. We opted for individual signing to allow physicians to look at each piece if they wish. We are trying to align with Kaleida whenever possible to streamline the process. | Noted | An Update will be provided to the Credentials Committee as we continue to move through the implementation process. |
|----------------------------------|--|---|---|
| D. Pain Management Procedures | Tabled. The Committee awaits feedback from Dr. Suchy. | Noted. | None at this time |
| E. Psychiatric Boards | Dr. Vinayak Gokhale still owes the Board one last piece of information – the quality section. It is noted that his extension to obtain his Boards ends in May 2025. Dr. Gokhale has not been responsive to emails or phone calls. Dr. Balwant Nagra has been taking Board prep courses and studying for the exam. He is scheduled to sit for his Board examination in 2026. | Dr. Yogesh Bakhai will begin telephoning Dr. Gokhale each week to obtain an update and remind him of his extension end date. | An Update will be provided to the Credentials Committee monthly until completed. |
| XIII. NEW BUSINESS | | | |
| A. Annual Dues | Dues will be sent out in mid-February 2025. | Noted | None at this time |
| B. Timely Report Completion | Dr. Cloud noted that a process needs to be created for when physicians do not complete their charting in a timely fashion. The Op Notes as well as the Discharge Summary should be done within 24 hours. Cases cannot be billed without this documentation. This creates a large financial impact to the facility. It was suggested that when these issues arrive, they should be forwarded to the Leadership Council and the Medical Staff Executive Committee. The Bylaws allow the Credentials Committee to hold up reappointment of a staff member who has not completed their required medical records. It was recommended that a process be formalized. | A policy will be created and provided to the MEC for their review and recommendations. | EXTRACT FOR MEC – Credentials Report |

| C. AHP Privilege Update | The ECMC AHP (NP/PA) privilege form leads to confusion due to the scope of practice services listed. When someone applies to Kaleida as a NP/PA, they are only granted core privileges. They can apply for sub-specialties, but then Kaleida has the ability to ask for experience levels, case logs, etc. The physician also needs to sign off attesting to the training program. Kaleida AHP privileges are very close to best practice, and we would like to adopt what they do. We would like to give the Chiefs of Service copies of our forms, Kaleida forms and explain what we would like to do. We would be able to get these out to them quickly since our forms will need to be finalized before the end of March. | The Committee agreed with sending the privilege forms and explanations to the Chiefs of Service as soon as possible in order to have them ready by the end of March 2025. | Privilege forms will be distributed requested a short turnaround time from Chiefs of Service. |
|----------------------------------|--|---|---|
| D. Oral & Maxillofacial Surgery | Dr. Tara Halliwell-Kemp has decided to not let her medical license lapse. Originally, she was going to only maintain her DDS and Board certification in Oral & Maxillofacial Surgery. Dr. Richard Hall clarified this information with the Committee. | Noted. | None required. |
| E. ACLS for Moderate Sedation | Letters have been sent to all Medical Staff with Moderate Sedation Privileges regarding their need to become ACLS certified. Medical Staff members have been returning proof of their certifications. The deadline for all of these documents to be provided to the Medical Staff Office is April 29, 2025. | Noted. | An update will be provided to the Credentials Committee monthly until completed. |
| XIV. ADJOURNMENT | The meeting was adjourned at 4:00 pm | | |

Respectfully submitted,

yatatha

Yogesh Bakhai, MD Chair, Credentials Committee

ERIE COUNTY MEDICAL CENTER CORPORATION FEBRUARY 18, 2025 MEETING MINUTES EXECUTIVE COMMITTEE OF THE BOARD OF DIRECTORS HYBRID MEETING

PRESENT: JONATHAN DANDES, SHARON HANSON, THOMAS QUATROCHE, EUGENIO RUSSI

Absent: Darby Fishkin

Also

PRESENT: SAMUEL CLOUD, ANDREW DAVIS, JOSEPH GIGLIA, JONATHAN SWIATKOWSKI

I. <u>Call to Order</u>

The meeting was called to order at 4:01 p.m. by Board Chair Eugenio Russi.

II. <u>Minutes</u>

Motion was made by Sharon Hanson, seconded by Jon Dandes and unanimously passed to approve the minutes of the Executive Committee meeting of January 21, 2025.

III. <u>Hospital Update</u>

General Overview

Dr. Thomas Quatroche reported that the hospital received its IGT payment from the County. He thanked Jon Swiatkowski and Benjamin Swanekamp for their hard work and effort. Twice during the month of February, length of stay dropped under 7. Megan Riley and Joanne Wolf have been instrumental in reducing the LOS. The honorees for Springfest have been announced: Distinguished Physician honoree, Jennifer Pugh, MD; Distinguished Nurse honoree, Thameena Hunter, RN; Community Honoree, Susan Gonzalez. Discussion followed regarding Federal funding and what effect the new Administration might have on the hospital.

Finances Report

Jonathan Swiatkowski presented key statistics and performance drivers for January. Discharges were slightly higher than budget and the previous year by 2.2% and 4.1% respectively. Total average length of has declined by 5.5% from last year but less so compared to the budget, only 1.2%. The CMI was 2.0, higher than budget and last year. FTEs were higher thank budget this month. January reflected a net loss of \$4.5M; January 2024 showed a net loss of \$5.4M. Discussion followed.

IV. Budget Amendment

The Committee discussed the budget amendment needed for the Epic contract.

V. <u>State Medicaid Update</u>

Dr. Quatroche reported on the next steps available o ECMC with the State for Safety Net funding and VAPAP. Additionally, the hospital is working with the State to look at ways to get more Medicaid funding. Dr. Quatroche and Mr. Swiatkowski will continue their efforts.

VI. <u>Physician Practice</u>

Dr. Quatroche and Andy Davis spoke about the need for the current physician practice to be separated from Kaleida.

- VII. <u>Other</u> There was no other business.
- VIII. Adjourn

There being no other business, the meeting was adjourned at 4:43 p.m.

ERIE COUNTY MEDICAL CENTER CORPORATION

BOARD OF DIRECTORS MINUTES OF THE FINANCE COMMITTEE MEETING

TUESDAY, FEBRUARY 18, 2025 – 8:30 AM

| Board Members Present or Attending by Video Conference or Telephone: | Michael Seaman Rev. Mark Blue * Benjamin Swanekamp * | * Attending by Video Conference or Phone |
|--|---|---|
| BOARD MEMBERS EXCUSED: | Darby Fishkin Philip Stegemann, MD | |
| Also Present: | Thomas Quatroche * Jonathan Swiatkowski Andrew Davis * Vanessa Hinderliter John Cumbo | |

I. CALL TO ORDER

The meeting was called to order at 8:30 AM by Chair Michael Seaman.

II. REVIEW AND APPROVAL OF MINUTES

Motion was made by Reverend Mark Blue, seconded by Benjamin Swanekamp and unanimously passed to approve the minutes of the Finance Committee meeting of January 21, 2025.

III. JANUARY 2025 OPERATING PERFORMANCE

Mr. Swiatkowski reviewed key statistics for the month of January and reported that inpatient discharges, outpatient surgeries and acute case mix index exceeded budget projections for the month. Inpatient surgeries were fewer than projected in the operating plan, offsetting some of the favorable revenue related to volume and higher medical and surgical case severity. Mr. Swiatkowski noted that the 2025 operating plan includes projected increases in surgical volume based on prior year results and future growth in certain service lines and expanded operating room service hours. The organization expects the expansion of service hours in the operating room to be fully implemented by May of this year.

Mr. Swiatkowski reported that favorable inpatient discharge volume resulted in lower acute average length of stay at 7.9 days for the month of January, down from 8.2 days during the

prior month. Mr. Swiatkowski credited the ongoing efforts of the case management and utilization review teams led by Dr. Ashvin Tadakamalla, Ms. Charlene Ludlow, and Dr. Samuel Cloud.

Mr. Swiatkowski briefly reviewed the finance dashboard, noting that operating performance was slightly behind plan. Mr. Swiatkowski discussed operating expenses including salary expense and purchased services costs related to temporary agency staffing. Mr. Swiatkowski also reviewed FTE's and cash flow for the month of January.

Mr. Swiatkowski reviewed financial performance for the month. The Corporation incurred an operating loss for the month of January which slightly exceeded budget projections. However, after the recognition of positive non-operating income due to strong investment market performance, the overall operating loss was lower than projected in the operating plan.

Mr. Swiatkowski reviewed January operating revenue and expenses. Net patient service revenue was greater than budget due to overall volume and case mix but was offset by fewer inpatient surgeries during the month. Mr. Swiatkowski noted that Management is closely monitoring inpatient surgical volume. Other revenue was positive for the month due to continued growth in ECMCC's specialty pharmacy.

Mr. Swiatkowski reviewed salary expense, other expenses, and physician fees. Mr. Swiatkowski advised the Committee of one-time costs incurred during the month of January related to physician fees and also reported that a new agreement was finalized with the University at Buffalo partner group related to graduate medical resident salaries. General medical surgical supply expense was slightly lower than budget projections while pharmaceutical supply expense was greater than budget due to continuing growth in ECMCC's specialty pharmacy and oncology services.

IV. OTHER UPDATES

Mr. Swiatkowski discussed the status of the upcoming IGT payment and NYS advocacy efforts by the Corporation and the County of Erie. Mr. Swiatkowski thanked representatives from the County of Erie for their advocacy efforts.

Mr. Swiatkowski also provided updates to the Committee regarding the annual NYS pension payment and the IGT reconciliation payment due in March.

Mr. Swiatkowski advised the Committee that the Corporation has filed an application for the 2025 - 2026 NYS VAPAP program and reported that the next monthly meeting with representatives from NYS is scheduled for next week.

Mr. Swiatkowski also presented updates regarding the upcoming NYS Budget process and advised that Management is closely monitoring Federal policy updates.

Mr. Swiatkowski invited questions from the Committee. In response to a question from Chair Seaman relating to CPEP patient volume over the last several years, Mr. Davis offered brief comments regarding an increase in treatment options within the community for patients with lower case acuity and offered general observations regarding how the additional treatment options are impacting CPEP.

V. CAPITAL BUDGET AMENDMENT

Mr. Swiatkowski presented a proposed amendment to the 2025 Capital budget for the Committee's review and consideration. During 2024, Management began planning for a capital project to upgrade the Electronic Health Record (EHR) system and ERP system, encompassing the Corporation's general ledger and purchasing operations. As this planning occurred after the 2025 Operating and Capital budgets were approved, they excluded capital costs for these projects as the organization worked to finalize these costs and the implementation and timeline for the project.

The Corporation is now submitting a request for Finance Committee's review and recommendation of approval of an amendment to the approved 2025 Capital budget for implementation costs related to the approved Epic EHR capital project and a conversion from the MediTech accounting system to the Infor system. Mr. Swiatkowski led a detailed discussion outlining the total project implementation costs for 2025 and 2026 (project years 1 and 2) and planned funding sources for each year.

Mr. Swiatkowski advised that it is important to note that Management considered two potential system upgrade options, and the capital investments required for each option. Mr. Swiatkowski reviewed the costs to upgrade the EHR system to Epic and the ERP system to Infor on a community-wide shared option as compared to a stand-alone option for ECMCC to upgrade the current MediTech system. After thorough review and consideration, Management elected to move forward with the community shared EHR option of Epic and the Infor system upgrades. It is anticipated that the projected go live dates will be in late 2026.

Mr. Swiatkowski invited questions from the Committee. In response to a question from Chair Seaman, Mr. Swiatkowski reviewed the actions required by ECMCC's Finance Committee to recommend approval of the proposed amendment to the 2025 Capital budget to the Corporation's Board of Directors for formal review and approval. Mr. Swiatkowski also discussed the actions required upon final approval of an amendment to the 2025 Capital budget by the ECMCC Board in compliance with New York State public reporting obligations.

The Committee held further discussion regarding the proposed Capital budget amendment. In response to questions raised by Mr. Swanekamp relating to outstanding FEMA payments due to ECMCC and reserve funding for the capital projects, Mr. Swiatkowski provided additional information to the satisfaction of the Committee. Upon final review, Chair Michael Seaman called for a motion to recommend approval of the proposed amendment to the 2025 Capital budget as presented to the ECMCC Board of Directors. Upon motion by Reverend Mark Blue and seconded by Benjamin Swanekamp, the Committee voted unanimously to recommend approval to the ECMCC Board.

VI. ADJOURNMENT

There being no further business, the meeting was adjourned at 8:58 AM by Chair Michael Seaman.

ERIE COUNTY MEDICAL CENTER CORPORATION

BOARD OF DIRECTORS MINUTES OF THE AUDIT COMMITTEE MEETING

TUESDAY, NOVEMBER 12, 2024 – 2:00 PM

| BOARD MEMBERS PRESENT OR Attending by Video Conference or Telephone: | Darby Fishkin * James Lawicki * Christopher O'Brien * Rev. Kinzer Pointer * | * ATTENDING VIA VIDEO Conference or Phone |
|--|---|--|
| BOARD MEMBERS EXCUSED: | | |
| Also Present: | Thomas J. Quatroche Andrew Davis Joseph Giglia, ex-officio Jonathan Swiatkowski | |
| GUESTS | MATTHEW GARVEY, CPA * - RSM US, LLP DAVID L. NESBITT NADINE MUND REGINA DEL VECCHIO AMY FLAHERTY | |

I. CALL TO ORDER

Chair Darby Fishkin called the Audit Committee meeting to order at 2:01 PM.

II. REVIEW AND APPROVAL OF MINUTES

Motion was made by Reverend Pointer, seconded by James Lawicki and unanimously passed to approve the minutes of the Audit Committee meeting of September 18, 2024.

III. INDEPENDENT AUDITOR REPORT OF RSM, LLP (2024 AUDIT PLAN)

Mr. Matthew Garvey, CPA, Audit Partner of RSM, US, LLP presented a brief introduction to RSM's report to the Audit Committee, noting that pre-audit communication requirements per RSM's professional standards are consistent with prior years. Mr. Garvey noted that one new GASB accounting pronouncement was required to be implemented in the current calendar year to align differences in reporting practices related to accrued compensated absences. Mr. Garvey advised that the new accounting pronouncement will not have a significant impact to ECMCC's financial reporting as the organization's current reporting practices are similar to the new accounting policy. Mr. Garvey presented required pre-audit communications and reviewed RSM's scope of services and auditor responsibilities, noting that the audit will be conducted in accordance with government auditing standards and Uniform Guidance. Mr. Garvey reviewed the audit timeline and discussed preliminary field work to be conducted during the month of December for the purpose of setting the scope of the audit and refining the audit plan.

Mr. Garvey led a detailed discussion regarding several topics, including shared responsibility for independence, RSM's audit strategy and development of the audit plan, and performance of risk assessment procedures. Mr. Garvey welcomed communication from Committee members throughout the course of the audit should they have any questions or matters of note for RSM.

Mr. Garvey advised the Committee of enhancements to RSM's existing internal processes and formal documentation of RSM's independence procedures which have been reviewed and discussed with ECMCC's Finance leaders. At the conclusion of the annual audit, RSM will issue an opinion on the corporation's financial statement and a report on internal controls and compliance. RSM is also required to perform a single audit of Federal program awards and expenditures, pursuant to Uniform Guidance audit requirements.

Mr. Garvey led further discussion regarding several topics including internal control and compliance, materiality, significant risks and areas of audit focus. Consistent with prior years, RSM has engaged subject area specialists to assist with specific areas of the audit.

Mr. Garvey reviewed and discussed a new auditing standard No. 145 that is applicable to the upcoming audit. The main purpose of the new standard is to clarify and enhance audit quality. Mr. Garvey noted that RSM may be required to do some additional work during the planning stage of the upcoming audit that will result in additional work effort by ECMC staff to further document certain internal controls in place in order to comply with requirements of the new auditing standard.

Mr. Garvey also advised the Committee that RSM does not rely on internal audit work but may review internal audit work to refine the scope of the annual external audit.

Mr. Garvey invited questions from Committee members and Management. In response to a question from Mr. Swiatkowski, Mr. Garvey advised the Committee of several changes to the RSM team that will be engaged on the ECMCC audit.

With no further questions from Committee members, Mr. Garvey of RSM was excused at 2:23 PM.

IV. COMPLIANCE UPDATE

Mr. David L. Nesbitt, Esq., presented updates regarding several compliance topics which were discussed at the September 2024 meeting. Mr. Nesbitt reported that as part of the 2025 Compliance Plan, the Compliance department is starting their risk assessment process. Updates from regulatory agencies will be forthcoming by year-end and will be included in the 2025 Compliance Plan.

Mr. Nesbitt also presented updates regarding required compliance education and training for ECMCC vendors and volunteers. Ms. Nadine Mund discussed past efforts by ECMCC's Compliance Department to provide in person ethics training for all personnel as required by NYS COELIG and the challenges associated with it. Ms. Mund noted that ECMCC is attempting to obtain a waiver for the in-person requirement of the training due to the burden on the organization.

V. INTERNAL AUDIT UPDATE

Mr. Nesbitt reported that a draft Internal Audit Charter was prepared by the Compliance department and reviewed with ECMCC's Audit Committee Chair, Ms. Darby Fishkin. A copy of the draft Internal Audit Charter was provided to Committee members in advance of today's meeting. The draft charter is based on a standard charter document from the Institute of Internal Auditor's ("IIA") with adaptations applicable to ECMCC and it's reporting structure.

Mr. Nesbitt and Ms. Fishkin reviewed key areas outlined in the draft Charter. Ms. Fishkin invited comments or questions from the Committee.

Upon final review, Chair Darby Fishkin called for a motion to adopt the Internal Audit Charter. Upon motion by Reverend Kinzer Pointer and seconded by Mr. Christopher O'Brien, the Committee voted unanimously to adopt the Internal Audit Charter as presented.

At this time, Mr. Nesbitt also presented a brief update regarding recruitment for the position of Director of Internal Audit.

VI. DRAFT LITIGATION REPORT

Ms. Regina DelVecchio, Esq., Associate General Counsel, presented the Office of General Counsel (OGC) annual report for 2024. Ms. DelVecchio noted that the OGC manages and supervises all litigation for the Corporation. ECMCC retains outside counsel via the RFP procurement process to assist the Corporation with all matters in litigation.

Ms. DelVecchio presented a summary of health professional liability and general liability lawsuits and claims for 2024 and advised the Committee that lawsuit and claim activity is on par with prior year. Ms. DelVecchio also reviewed general information relating to open matters and case resolutions for the calendar year to date.

Ms. DelVecchio reviewed the Corporation's management of case reserves and reported that measurable results were achieved in 2024 allowing the Corporation to achieve a net savings in reserves. Mr. Joseph Giglia, Esq. offered additional comments and discussed actions taken by the Corporation relating to management of indemnity reserves.

VII. DRAFT RISK MANAGEMENT AND CORPORATE INSURANCE REPORT

Ms. Amy Flaherty, Esq., Director of Risk Management and Corporate Insurance, reported that ECMCC is in the first year of a contract extension of the brokerage services agreement

3

with Lawley Insurance. ECMCC and Lawley Insurance are currently finalizing annual renewals of insurance coverages for the Corporation. Coverage limits are anticipated to remain the same as prior year with minor changes in insurance carriers. In response to a question from Chair Darby Fishkin, Ms. Flaherty reported that as part of the annual underwriting process, all coverage limits are evaluated.

Ms. Flaherty presented updated information to the Committee regarding current insurance related matters.

VIII. ADJOURN

There being no further business, the meeting was adjourned at 2:52 PM by Chair Darby Fishkin.

| Item/topic | Details | Priority (H,M,L) | Action Steps | Collaborating Parties |
|---|--|---------------------|--|--|
| | New 2025-Specific E | | | |
| Background Checks (Terrace View) | New York employers should always conduct thorough pre-employment background checks in order to hire qualified and trustworthy staff, avoid legal liabilities, and ensure compliance with FCRA and state laws. | Н | ECMCC/Terrace View will need to access all relevant records to conduct comprehensive, accurate, and FCRA-compliant employment background checks, includig for vendors who may have contact with TV residents. | HR, Terrace View |
| Board Training | Training to be provided as part of the CMS and Medicaid mandate for annual compliance training. | М | Board Members to be provided training in 2025 on Compliance and their fidiciuary responsibilities. | Admin, Compliance |
| Epic Transition | The Epic transition creates potential risks for the organization surrounding the use, storage, and access to ECMCC's patient data. ECMCC must ensure Epic has appropriate processes in place for handling ECMCC's "Part 2" data and safeguards in place firewalling our data from other providers. | H | Participation in numerous decision-making workgroups by the Compliance department, including research, privacy, and consent. | Kaleida |
| Expiring Agreements | Expiring contracts create exposure for ECMCC from liability standpoints and from regulatory compliance standpoints. | М | Updating existing data in contract management database; setting reminder triggers when contracts expire; working with department heads and Legal to revise and/or extend contracts. | |
| Patient billing issues | Various staff members receive complaints from patients regarding potential billing issues. | М | Compliance has established a regular committee consisting of billing/coding and patient advocacy to address and resolve issues as they arise. This committee will meet weekly in 2025. | Revenue Cycle; HIM; patient advocacy |
| Physician compensation review | Physician compensation is an area that must be carefully monitored for Stark and Antikickback Statute compliance. Key areas to be reviewed are: Whether the compensation paid to physicians is fair market value, commercially reasonable, set in advance, and does not take into account the value or volume of referrals. | Н | In 2024, ECMCC revised its physician compensation policy. In 2025, Compliance will provide written fair market value/commercial reasonableness documentation for 100% of incoming physician contract requests and develop an internal database of comp scenarios and how we handle them. Additionally, Compliance is recommending a physician admin timesheet process Internal Audit review. | Medical Staff, Legal |
| Professional Corporation Structure | ECMCC is in the process of establishing a "captive PC" relationship to be owned by its Chief Medical Officer. Compliance is ensuring ongoing compliance in structure and setup with applicable laws and regulations. | М | Compliance to work with Legal in ensuring PC is set up in compliance with NY corporate practice of medicine doctrines, captive PC requirements, and Stark and Antikickback. | Operations |
| Subsidiary Compliance | Establish compliance programs for ECMCC subsidiaries and professional corporation. | Н | Set up compliance programs and regular/ongoing compliance training for ECMCC subsidiaries and professional corporation. | Operations |
| | Ongoing Eleme | ents | | |
| Inpatient | | | | |
| Inpatient claims billed with Comprehensive Error Rate Testing (CERT) high-error rate DRG codes | Certain DRG codes have higher risk for billing errors and must be monitored on a regular basis: 149, 312, 313, 518, 519, 520, 742, 743, 947, and 948. | М | ECMCC will perform annually auditing by developing a HIM Code audit list. DRGs are rarely billed at ECMCC. | НІМ |
| Coding audits | Focus on audits for specific codes identified by previous DOJ audit and guidance and known high risk areas: sepsis DRG 871, severe malnutrition, respiratory failure, respiratory infections and inflammationss, mechanical ventilation, infectious and parasitic diseases, tendonitis, shock with CHF, osteomyelitis, hypertension with MCC and w/o MCC 5. | | ECMCC has engaged a third party auditing firm to review these on an ongoing basis. | HIM, RCM |
| One Day Stays / Two Midnight Rule Compliance (Medicare) | Inpatient admissions are generally payable under Medicare if the admitting practitioner expects the patient to require a hospital stay that crossed two midnights and the medical record supported that reasonable expectation. Otherwise, outpatient / observation should be used. CMS has identified high rates of error for hospital services rendered in medically-unnecessary settings. | М | Utilization Review identifies one day stays and assesses the medical necessity of these admissions. Review is then completed by UR & UR Physician and a repayment determination is made. One day stays are monitored concurrently every day. If documentation is missing, they are to have the physician document prior to patient discharge. | Utilization Review, Revenue Cycle |

| ltem/topic | Details | Priority (H,M,L) | Action Steps | Collaborating Parties |
|---|--|---------------------|---|--------------------------------|
| Copy and Paste Monitoring | Common documentation risks that can result from using a copy-and-paste or cloning feature include: Information "copied and pasted" from a different patient's record Vital signs that never change from visit to visit Documentation from another provider including their attestation statement Identical verbiage used repeatedly for all patients seen by a provider for a specific timeframe with little or no modification regardless of the nature of the presenting problem or intensity of the service | Η | ECMCC has developed policies designed to address inappropriate use of these tools to minimize non-compliance, which include information governance, patient identification, authorship validation, amendments and record corrections as well as auditing the record for documentation validity when submitting reimbursement claims. Letters are being sent to providers who have been identified as utilizing copy/paste by Medical Staff. | Medical Staff, HIM, Nursing |
| Outpatient | | | | |
| Outpatient coding audits | Certain codes have been identified as high risk for noncompliance: lesion removal, ED level, and modifier 59. | | ECMCC has engaged a third party auditing firm to perform sample audits on an ongoing basis. | HIM, RCM |
| ED E/M Coding | ED E/M coding monitoring to define and clarify what interventions are included in resource use, the number of points assigned and frequency limits. | Н | To manage E/M levels in the ED, we track and trend the data quarterly. The E/M distribution of ED levels of service is monitored with hospital-specific dashboards, which identify spikes in levels four or five. | НІМ |
| Psychotherapy | Outpatient Group Psychotherapy needs to have the number of attendees and time spent documented. | | Ensure templates facilitate obtaining required documentation. Additional Documentation Requests (ADRs) are being received from CMS. Conducted previous CMS Targeted Probe and Educate audit of psychotherapy services conducted late 2023. Findings were mostly missing documentation. BH has educated regarding audits and documentation required. Ensure compliance with documentation and billing regulations. | Behavioral Health |
| Dental reviews | OMIG will review providers of dental services to verify that billed services were performed, documentation supports the billed services, and that the claims are submitted in accordance with Medicaid program rules, regulations, manuals and policy. | | Ongoing reviews to ensure dental services are performed, billed, documented and submitted in accordance to Medicaid regulations. | Dental |
| Terrace View | | | | |
| Psychotic Medications | Monitoring of drug diversion and anti-psychotic monitoring. | | Ongoing monitoring for drug diversion and facilty usage of anti- psychotic medications. QAPI | Terrace View |
| Rate Audits | DOH to ensure facilities conform to the Bureau of Long Term Care Reimbursement policy and reimbursement regulations. | Н | NAMI work group developed to work and monitor payments. | Terrace View, Revenue Cycle |
| Minimum Data Set | OMIG will continue to coordinate with BLTCR to review the accuracy of nursing home MDS submissions. | Η | Compliance utilizes triple check audit process to ensure billing accuracy and compliance with regulatory guidelines prior to submission of claims to Medicare and Managed Care payers. Terrace View provides monthly submissions to Compliance Department of the triple check to ensure compliance. OIG SNF 3- Day Rule added as part of triple check process. QAPI | Terrace View |
| Nursing Facility Staffing: Reported Levels and CMS Oversight | Staffing levels in nursing facilities can impact resident's quality of care. Must provide sufficient licensed nursing services 24 hours a day. | Μ | Monitor staffing schedules and payroll reporting to ensure regulatory compliance. QAPI | Terrace View, Finance |
| Appropriate Use of Place-of-Service Codes | Office of the Inspector General found that providers didn't always comply with federal requirements when reporting the place-of-service code on a claim line. | L | Audit billing for accurate place of service for residents. | Terrace View, Revenue Cycle |
| Unreported Incidents of Potential Abuse and Neglect Pharmacy | Ongoing OIG reviews indicate the potential for unreported instances of abuse and neglect. OIG assesses the incidence of abuse and neglect of Medicare beneficiaries receiving treatment at SNFs and determine whether these incidences were properly reported and investigated. | М | Monitor reporting within in 2 hours of reported allegations and/or incidents. QAPI | Terrace View |

| ltem/topic | Details | Priority (H,M,L) | Action Steps | Collaborating Parties |
|---|---|---------------------|---|--|
| 340B | 340B Compliance Assessment to identify potential issues or gaps in the adherence to the 340B program regulations. | М | Regular self-audits of the program, including reviews of facility-administered and contract pharmacy 340B drug utilization. Ensure that reviews are looking at all aspects of patient definition (location, provider, Medicaid billing, etc.). Engaged SpendMend as our 2025 outside auditor, as required by HRSA, to review our 340B program. | Pharmacy, Compliance |
| Drug Diversion | OMIG will review the proper authorization of written prescriptions, the complicit and non-complicit overprescribing of drugs, and the resale of drugs. OMIG will continue its efforts to identify and investigate forged prescriptions and seek prosecutions and administrative actions against recipients involved in these activities. | М | Ongoing efforts to identify, mitigate and confront drug diversions. Diversion Committee in place. Fair Warning program being utilized to identify aberrant patterns and monitoring. Audits being conducted by Pharmacy and Nursing Department heads. Diversion Prevention Meetings held quarterly. | Pharmacy, Diversion team |
| Stark, Antikickback | Statute, & Other Regulatory Issues | | | |
| Physician leasing compliance | ECMCC leases space to a number of physicians who are also referral sources to ECMCC. In compliance with Stark and Antikickback, ECMCC must ensure that it is paid fair market value for space provided and that physicians do not obtain space for which they are not paying rent. | H | ECMCC will require annual walkthrough and reconciliation of space occupied by physicians. Compliance working with Legal and administration to ensure execution of leases when not in place. | Facilities, medical staff, Legal |
| Vendor interaction with employees / physicians | There have been instances of vendors contacting physicians and employees directly to attempt to influence purchasing decisions. This violates New York's Project Sunlight (requiring reporting of individuals who appear before ECMCC in attempts to influence procurement decisions) and risks ECMCC utilization of products that are not under contract, raising both liability risks and risks of nonpayment for services ECMCC renders. | М | Recommended audit of vendor access policy and process to Internal Audit. Added compliance training to credentialing process. Education of appropriate departmental heads. Collaboration with Purchasing to identify purchases not on contract and roll out penalty program for vendors who fail to adhere to policies. | OR, Purchasing |
| HIPAA | | | | |
| HIPAA violations | Ensuring regulatory compliance laws for healthcare organizations and professionals were developed to protect the private information of patients when it comes to personal, medical history, and payment information. It also outlines the requirements to ensure quality patient care and to combat fraud within healthcare organizations. The HIPAA law passed in 1996 was implemented in 2003. It defines the steps that every healthcare organization and professional must follow when collecting, storing, handling, and sharing patient information. As stiff penalties await those who violate the se regulations to ensure strict compliance. We strive to ensure and communicate the value and requirements of HIPAA regulations-information security and privacy compliance. | н | Proactive monitoring by Privacy Officer for actual or potential HIPAA violations. Ongoing weekly meetings with privacy, IT security and compliance. Ongoing monitoring with FairWarning. Policies and procedures for guidance for all staff to ensure compliance. Disciplinary actions taken against employees who violate PHI access rules. Compliance, Legal and Privacy review of any large exchanges of data with other entities. Legal review of all business associate agreements. | |
| Business Associate Agreements with Physician Groups | Often, physician groups provide a range of services that overlap between "covered entity" services (clinical) and "business associate" services (administrative) under HIPAA. In instances where business associate services are being provided, business associate agreements must be executed between ECMCC and the physician group. | М | Identification of affected physician groups. Negotiation and execution of business associate agreements ongoing. | Outside physician groups |
| Regular Ongoing C | ompliance education | I | <u> </u> | |
| Annual Training | Training provided as part of the CMS and Medicaid mandate for annual compliance training. | М | All new employees are required to go through orientation and established employees are required to complete mandatory yearly compliance education. Tracted through LMS system. | HR, Compliance |
| Vendor and Volunteer Training | Training provided as part of the CMS and Medicaid mandate for annual compliance training. | М | Training provided to vendors and volunteers during their annual mandatory training, including general compliance; Code of Conduct, Conflict of Interest, False Claims Act, Stark/Antikickback Statute and Fraud, Waste and Abuse; and HIPAA. Letters to be sent to vendors. | Purchasing, Volunteer Office |

| Item/topic | Details | Priority (H,M,L) | Action Steps | Collaborating Parties |
|---------------|--|---------------------|--|---|
| | Required physician Medical Staff compliance annual training; additional compliance training will be provided as needed or requested. | М | Training provided to physicians during their annual mandatory training, including general compliance; Code of Conduct, Conflict of Interest, False Claims Act, Stark/Antikickback Statute and Fraud, Waste and Abuse; human trafficking; sexual harassment; opioids; and EMTALA. | Medical Staff, HIM |
| Billing | Training and monitoring of billing staff to enhance the accuracy and consistency of coding and billing. | H | Revenue Integrity monitors charge entry/billing daily. They provide feedback, education and training. Revenue Cycle has also implemented bi-monthly meeting instituted to communication across revenue cycle of ongoing or recent issues or challenges. As an identified high risk department, separate compliance training is also performed. | Revenue Cycle, Compliance |
| Registration | Training and monitoring of billing staff to enhance the accuracy and consistency of registration. | М | As an identified high risk department, separate compliance training is also performed. | Registration, Compliance |
| Coding | Training and monitoring provided to coding staff to enhance the accuracy and consistency of coding and billing. | Н | HIM Department has an outside consulting firm conduct random audits for coding accuracy. They provide feedback, education and training. HIM Department has also implemented monthly coders roundtable instituted for better communication. Internal coding audits have also been implemented to further ensure coding accuracy and feedback to staff. (included in Revenue Cycle meeting mentioned above). As an identified high risk department, a separate compliance training session was completed on 9/16/2024. | HIM, compliance |
| | As of 7/8/2022 according to Executive Law §94 (8), all NYS Public Benefit employees must complete ethics training and report to the State. | L | ECMCC continuing to train all new employees during orientation and has held dozens of additional trainings for existing employees. OnDemand COELIG Ethics training has been incorporate into our LMS system for reorientation in 10/2024. | HR, compliance |
| Miscellaneous | | | | |
| | ECMCC is required to verify all medical/dental staff, employees and vendors have not been excluded from participation in Medicare, Medicaid and other Federal/State health care programs. Includes review of CMS reclusion and OIG exclusion lists. | М | Sanction/exclusion checking is conducted on a monthly basis after hire with Kchecks for employees, providers, vendors, consultants. To ensure our vendors are complying with ECMCC policy, they are required to sign into Symplr every time they come to ECMCC. Symplr reports are being sent from Purchasing to Compliance for review. | Medical/Dental Staff, HR, Purchasing, AP, IT |
| | OMIG has developed an Abbreviated Self-Disclosure Process that Medicaid entities may utilize to report and explain overpayments that are considered routine or transactional errors in nature or meet other defined characteristics and have already been voided or adjusted. | М | Developed biller comments to identify overpayments considered routine or transactional errors. Submitting monthly to OMIG. | Revenue Cycle |

| ltem/topic | Details | Priority (H,M,L) | Action Steps | Collaborating Parties |
|---------------|---|---------------------|--|---|
| | ECMCC is a teaching facility and must comply with the PATH regulations. Also, PHE flexibilities will need to be transitioned. | L | Revenue cycle professional coders review physician documentation and ensuring the teaching physician statement is present prior to billing. Policy for Teaching Physicians was approved by Medical Executive Committee and now in place. EHR systems (Meditech and Allscripts) enable the teaching physician to place their supervision attestation. In addition, limitation of EHR access to Medical Students to ensure compliance. Quarterly meetings held with Revenue Cycle to discuss professional billing/coding concerns. | Medical Staff, HIM, Revenue Cycle |
| Facility Fees | NYS Public Health Law 2830, effective June 21, 2023, now requires hospitals and healthcare professionals to provide written notice to patients prior to charging them for facility fees explaining the amount of the fee, the purpose of the fee and whether the patient's insurance plan will pay the fee. | М | Good Faith Estimate notification to the patient was updated to include facility fee notification. Need to have translated in top 6 languages in 12 pt font. | Registration |

BOARD OF DIRECTORS MINUTES OF THE HUMAN RESOURCES COMMITTEE MEETING TUESDAY, DECEMBER 3, 2024 10:00 - 11:00 A.M. THIS MEETING WAS HELD VIRTUALLY VIA TEAMS

| VOTING BOARD | MICHAEL SEAMAN | MICHAEL HOFFERT |
|------------------|----------------|-----------------|
| MEMBERS PRESENT: | MICHAEL SEAMAN | WICHAEL HOFFERT |

EXCUSED:

| ALSO | |
|----------|--|
| PRESENT: | |

ANDREW DAVIS ERIN CONLEY CYNTHIA BASS LISA HIGHWAY HEATHER GALLAGHER SEAN BEITER

I. CALL TO ORDER

Chair, Michael Seaman called the meeting to order at 9:59 a.m.

II. <u>APPROVAL OF MINUTES</u>

Moved by Michael Hoffert and seconded by Michael Seaman to receive and file the minutes from the September 10, 2024 Human Resources Committee Meeting of the Board of Directors.

III. HOSPITAL UPDATE

Andrew Davis, Chief Operating Officer, reported the hospital finished November with favorable volumes. Admissions and discharges were over budget and ALC cases decreased thanks to continuous team efforts. Interviews are in the final stages for two leadership positions, Vice President of Behavioral Health/CPEP and Executive Director for the Foundation. Mr. Davis mentioned we will be celebrating our annual Holiday Luncheon on December 4th.

IV. <u>EMPLOYEE RECOGNITION – ECMC AND TERRACE VIEW</u>

Erin Conley, Training Coordinator, reported there were several employee recognition efforts for the months of October and November. ECMC was delighted to honor the award recipients for their accomplishments and dedication. Ms. Conley presented the following employee recognition events.

ECMC Employee of the Month

- October 2024 Mike Kotch, Sr. Technical Assistant Information Technology Systems
- November 2024 Jacob Frankhauser, Lead Pharmacy Technician Inpatient Pharmacy

Terrace View Employee of the Month

- October 2024 Jim Alvarez, Certified Nursing Assistant MLK
- November 2024 Marie Gister, Social Work Assistant Terrace View

Employee Recognition

- Daisy Award
 - Q2 2024 John Baston, RN, GDN MICU North
- Tulip Award
 - September/October 2024 Breon Myree, Med/Surg Technician 12z2
- Nurse Hero of the Month
 - o October 2024 Kellie Najmulski, Team Leader 4z3
 - November 2024 Katie Pistorio, GDN 8z1

In addition, Ms. Conley mentioned the Employee Recognition Committee assisted the Foundation with some of their holiday initiatives, which included the Thanksgiving gift card distribution for staff and volunteering at the Holiday Luncheon. We are looking forward to the new year and the Employee Years of Service Dinner in early spring.

V. <u>DIVERSITY, EQUITY, AND INCLUSION</u>

Cynthia Bass, Chief Diversity Officer, reported the key department events and initiatives for September through November which included the following:

- <u>National Hispanic Heritage Month</u>
 - Celebrated September 15-October 15, 2024 in collaboration with Metz Culinary. Lunch specials and musical entertainment were featured on Wednesdays.
- <u>Global Diversity Awareness Month</u>
 - Several events were offered during the month of October, including:
 - Lunch & Learn session on "Implicit Bias: Developing Awareness of Our Unconscious Biases in the Workplace."
 - World Bazaar Pop Up Shops at ECMC Several small local businesses were onsite at ECMC and Terrace View. A donation of over \$2,500 was made to the Foundation.
 - Taste of Diversity Celebrated tasting events at ECMC (4th Annual) and Terrace View (1st Annual) in collaboration with Metz Culinary featuring food and desserts from various countries.
- Veterans' Day
 - The celebration on November 7th included several members of the executive team honoring our employee veterans. This was the first year we hosted local veteran-owned small business vendors to attend.
- <u>Career Development</u>
 - Public Speaking Workshop November 13, 2024
 - Career Development Panel Discussion November 15, 2024
 - o Career Development Day at Health Sciences Charter School November 21, 2024
 - o Development & Donuts Workshop November 22, 2024
- Learning & Organizational Development Center (L&OD) Updates
 - Dr. Kiera Duckworth continues to provide various training opportunities. Some of the highlights include:
 - DEI trainings: Implicit Bias, Microaggressions, Inclusive Language and LGBTQ+, Communication, Team Building and Conflict Resolution Skills.
 - Leadership Academy: Manager Enhancement Program had five graduates.
 - HealthStream Update: Library Administrators (Matt Bailen, Sarah Maggio and Dr. Duckworth) have been system-trained and are working to roll out the libraries to staff incrementally.

VI. <u>RECRUITMENT AND RETENTION</u>

Lisa Highway, Director of Recruitment and Retention, reported the Career Development event at Health Sciences Charter School was a success. The recruitment team provided presentations on interviewing, job applications, and civil service. The team is exploring opportunities to host similar events at area schools.

Several new employees were hired for the hospital and Terrace View during a job fair at Weinberg Campus. The recruitment team has been attending end of semester job fairs and hosting weekly tabling events at NCCC and area nursing schools. In addition, a nurse-intern program for final semester nursing students starts on December 17th.

Recruitment efforts continue for all areas. The selection process is down to two candidates for the VP of Behavioral Health/CPEP position.

VII. <u>COMPENSATION, BENEFITS, AND HRIS</u>

Heather Gallagher, Sr. Director of Compensation, Benefits, and HRIS, summarized the key highlights and initiatives.

- <u>Benefits Update</u>
 - Benefits Open Enrollment was a success with only a few minor issues.
 - The employee health insurance transition from Highmark to Univera is set for January 1, 2025. The team is working on the final details.
- <u>Compliance</u>
 - Joint Commission Mock Survey: the Human Resources department did very well with only one minor finding.
 - Annual employee performance reviews and re-orientation are underway. Completion rates will be reported at the next meeting.
- <u>Compensation</u>
 - Currently in progress with union merit increments and general increases effective January 1, 2025. Notices will be mailed to employees.
- <u>HRIS Timekeeping and Scheduling System</u>
 - Finalizing the workforce management timekeeping/scheduling agreement, starting project on January 1, 2025.

VIII. <u>EMPLOYEE AND LABOR RELATIONS</u>

Sean Beiter, Director of Labor and Employee Relations, reported the labor team continues to implement the philosophy of cooperative labor relations with the three bargaining units. Key highlights include:

- The Employee and Labor Relations team is currently in the midst of negotiations with our Certified Registered Nurse Anesthetists (CRNAs), members of the NYSNA bargaining unit. We are hopeful to finalize by the end of the end of the month.
- Continue to participate actively and proactively with labor management meetings to review nursing protest of assignment, grievance negotiations/settlements and other administration.

- Monthly and quarterly labor management meetings with AFSCME, CSEA and NYSNA to discuss staffing ratios, state regulations, measure progress and address concerns.
- Continue to engage with NYS agencies, such as, the Public Employee Relations Board (PERB), Division of Human Rights (DHR), and the Department of Labor Unemployment Office regarding employee matters.
- Continue to investigate employee grievances/harassment complaints and seek to restore cooperative working relationships. The majority of our investigation activity is derived from the RiskConnect reporting system. Grievances are received and then routed to the appropriate HR Business Partner for review/investigation. We respond to a large volume of issues concerning our employees and work with managers and department leaders to improve performance and avoid future situations.

IX. <u>CLOSING REMARKS</u>

Mr. Hoffert and Mr. Seaman commended the Human Resources team for their leadership and contributions to the community and organization. They emphasized the importance of being engaged with community schools and encouraging students to consider careers in healthcare, as well as, providing education and training resources tailored to enhance the workplace culture.

The next meeting is scheduled for March 11, 2025.

X. <u>ADJOURNMENT</u>

Moved by Michael Hoffert and seconded by Michael Seaman to adjourn the meeting at 10:39 a.m.

ERIE COUNTY MEDICAL CENTER CORPORATION

BOARD OF DIRECTORS MINUTES OF THE QUALITY IMPROVEMENT/ PATIENT SAFETY COMMITTEE MEETING

Tuesday, February 11, 2025 Microsoft Teams Platform

BOARD MEMBERS PRESENT: REV KINZER POINTER, JOHN O'DONNELL, CHRISTIAN JOHNSON

PRESENTERS: SAURIN POPAT, MD AND CHARLENE LUDLOW, RN, CIC

ATTENDANCE:

SERGIO ANILLO, MD WILLIAM BELLES, MD Donna Brown CHARLES CAVARETTA SAM CLOUD, DO PETER CUTLER ANDY DAVIS CASSIE DAVIS BECKY DELPRINCE, RN KEITH KRABILL, MD MARC LABELLE, RN Pam Lee CHARLENE LUDLOW, RN, CIC PHYLLIS MURAWSKI YARON PERRY, MD TOM QUATROCHE, CEO MEG RILEY, RN CHRISTOPHER RITTER, MD JOANNE WOLF, RN **KIZZIE HUNLEY** DAN MCCARTAN

CALL TO ORDER

Chair Michael Hoffert was not in attendance, Rev. Kinzer Pointer called the meeting to order at 8:01 am.

1 | Page

I. MINUTES

The November 12, 2024, and the January 14, 2025 meeting minutes were distributed for review. A motion was made and seconded to approve the minutes. They will be forwarded to the Board of Directors for filing.

II. COMMISSION ON CANCER – SAURIN POPAT, MD, MBA, FRCSC, FACS, FSSO

Dr. Popat shared an update on the Commission on Cancer Services. He had a full agenda beginning with CoC Cancer Services Background. Permission for formal accreditation was received in the fall of 2019. In November of 2022 ECMC obtained accreditation from the American College of Surgeons Commission on Cancer for 3 years.

Some developments and achievements include the recruitment of two Palliative Care physicians for outpatient care, advancing robotic surgery for surgical oncology, oncologic research and plastic and reconstructive surgery training programs. The department anticipates an increase in assessment standards from the ACS in 2025 (currently 36 to increase to 38).

Quality improvement goals consist of improved chemotherapy wait times, establish outpatient palliative care services, and low dose lung cancer screening CT smokers. Quality improvement goals for 2025 include improve cancer patient tumor molecular/ genetic testing, continue with 2024 palliative care initiative, formalize chemotherapy nursing education, and access to outpatient mammography.

Critical objective for the department for this year is to successfully complete the 2025 Commission on Cancer Re-Accreditation.

III. ENVIRONMENT OF CARE ANNUAL MANAGEMENT PLAN - CHARLENE LUDLOW, RN, CIC

Charlene Ludlow shared the EOC Annual Report. The plan contained the 2024 goals and performances along with goals for 2025. For the year 2024, Ms. Ludlow reviewed EOC life safety goals, utilities management goals, security management goals, medical equipment goals, emergency management goals, and hazardous waste goals.

Ms. Ludlow also reviewed the 2025 EOC management plan goals. Some life safety goals include label door frames for areas that have regulated pressure differential along with implementing accessibility to dampers, requiring extensive remedial work. Several utilities management goals will include a modification to the electrical system for the elevator operation, medical gas regulatory corrections, water management program changes, and working on the emergency generator replacement project. Security management goals include a new access control protocol for the Snyder Ambulatory Center, review access control to the Med Srug units, and have increased camera coverage focused on the dietary department and food preparation areas of the main hospital. Medical equipment goals include using our inventory management system to be able to track supplies and parts that are used during repairs or preventative maintenance, proactive program to identify life span of equipment so we can prepare departments for the replacement of equipment prior to it reaching end-of-life, and to reduce cost for repair and downtime of the equipment, we will educate in-house technicians on outsourced equipment. Some of the management goals will include two drills or live events each year, at a minimum at least one with our community partners to comply with Joint Commission EM Standards and continue re-certification process by select staff for compliance for NIMS. Hazardous waste goals include update hazardous material management plan to include comprehensive system to close gap between all departments and to provide recertification of DOT hazardous materials training for 100% of front-line housekeeping staff.

IV. REGULATORY/QUALITY REPORT – PHYLLIS MURAWSKI, RN, MS

Phyllis Murawski gave an update on Regulatory and Quality reporting. Phyllis reviewed adverse events from 2024 and reviewed the Patient Safety Committee (RCA) driven improvements for 2024.

The Regulatory report reflected a survey in Diagnostic Imaging which went well with zero findings. There were no other surveys during the month of January.

VII. ADJOURN

There being no further business, the motion was made and seconded to adjourn the meeting. The next meeting will be held on March 11, 2025.

Dear ECMC Board Members,

The positive operations and patient volume trends we experienced in January continued in February. Year-to-date increases versus February 2024 occurred in Outpatient Surgeries, ED visits and Outpatient visits. However, the ability to discharge patients continues to be a challenge for both ECMC, our community, and our State.

Also of note, *Business First* on March 18th published a story highlighting ECMC's #1 position in our market for ED visits in 2024, moving up from #3 in 2023. This is further confirmation of the vital role ECMC plays in trauma and emergency care in Western New York and that ECMC continues to be the hospital of choice.

As the Board is aware, we recently had our American College of Surgeons Level 1 Trauma recertification survey. The virtual visit went very well with only one process of non-compliance with their standards, which has already been corrected. The surveyors were extremely complimentary of the program and repeatedly talked about the level of collaboration and collegiality within disciplines and the strong support of the program from all levels of the organization. We also had a virtual tour of areas related to the trauma program, which they said was the best they have ever seen. During this time, we also had an unannounced visit from the Joint Commission for our Chemical Dependency reaccreditation. This one-day survey resulted in four "low" risk findings and no "moderate" or "high" risk findings. Again, the surveyors were very complimentary of the team and program and the impact we are making on the patients in our community. We look forward to soon receiving the official Level 1 Trauma recertification and Chemical Dependency reaccreditation from each entity.

ECMC's Center for Rehabilitation Services' Rehab Symposium 2025, held on March 8th on our health campus was a tremendous success. With the theme, *Interdisciplinary Approaches to Neuro Trauma: From Injury to Independence*, the full-day symposium attracted over 100 area rehabilitation professionals who participated in a variety of presentations, break-out sessions and an exhibit hall program featuring rehab industry vendors sharing information on their services and expertise, particularly on issues focusing on individuals experiencing neuro trauma. This annual event is another way in which our caregivers demonstrate their leadership in a variety of healthcare services, sharing their clinical experiences and industry knowledge with their colleagues from around Western New York.

In further recognition of our ECMC Family's clinical achievements, particularly on a national level, Katie Fik, MSN, RN, CWON and Martha Metz, MS, RN, CPHQ were selected to present in Dallas, TX at the national convention for NPIAP (National Pressure Injury Advisory Panel) in late February. Their selected poster highlighted developing an algorithm for identification of hypoperfusion injuries in critically patients through an interdisciplinary team. And an abstract developed by Amanda Farrell, BSN,RN,CMSRN,AMB-BC, Population Health Clinical Data Analyst – *Optimizing Diabetes Management in Primary Care*, was selected earlier this month by the Program Planning Committee to present as a poster presentation at the American Academy of Ambulatory Care Nursing's (AAACN) 2025 Annual Conference in San Diego.

As we have done since January, our ECMC team continues to work with our lobbyists and advocacy organization like HANYS regarding the state budget, which, as mandated in the State

Constitution, must be enacted on April 1st. While the Governor's budget was supportive of healthcare, both houses of the State Legislature earlier this month introduced their one house budget bills. Once that action takes place, the negotiations between the Governor and Legislature will get underway. We were encouraged that both the Assembly and the Senate each restored funding for the Vital Access Provider Assurance program, which is a significantly important funding source for us and other safety net hospitals across the state. And, importantly, both houses accepted the Governor's proposal to invest an additional \$1.3 billion to expand the existing Safety Net Hospital Transformation Program. Neither the Governor nor the Legislature include substantial offsets for any anticipated Federal actions that might impact the state's budget in their health care budget proposals, with leaders noting that they are approaching issues such as Medicaid without addressing potential federal cuts. We also continue to monitor very closely any actions at the federal level and will keep the Board fully apprised of any actions that could affect ECMC.

We remain very appreciative of the Board's continuing support and confidence in Executive Leadership. Together, we have faced and contend with many significant challenges to our institution and other safety net institutions across the nation and in every instance, we have maintained the high-quality care of our patients.

Best,

Tom

Erie County Medical Center Board Report President & Chief Operating Officer March 25, 2025

Submitted by Andrew Davis

OPERATIONS

Ambulatory Medical Practices

Population Health

On 2/7/2025, in honor of the American Heart Association's Go Red for Women's Heart Health Day, Population Health set up a table in the lobby to provide educational materials on various heart health topics. These materials covered hypertension, stroke, cardiac arrest, cholesterol management, heart failure, smoking cessation, primary care referrals, and specialty resources, and they offered blood pressure screenings to raise awareness and promote heart health among women.



Center of Cancer Care Research

<u>February 2025</u> Monthly Oncology Research Report – Dr. Jennifer Frustino Research Updates:

- The fifth subject was dosed with study drug for our Lipella sponsored trial: A Multicenter, Dose-Ranging Trial Evaluating the Safety, Tolerability, and Efficacy of LP-10 in Subjects with Symptomatic Oral Lichen Planus. The 6th and 7th subjects were enrolled.
- A compassionate use application was approved by the FDA and the UB IRB to continue the Lipella LP-10 rinse on a subject who had excellent results. This is a huge accomplishment considering the early phase trial and rare disease.
- We underwent a monitoring visit with Alira of our Lipella trial with no significant findings.
- ECMC was selected as a site for a new clinical trial sponsored by Merck (MK2140-011) for patients with B Cell Lymphoma. Dr. Naheed Alam will be the PI with other ECMC Medical Oncology, Pathology and Radiology co-investigators.

- WNY HPV Coalition met for its quarterly meeting and continues to grow in attendance of multidisciplinary stakeholders, including the Population Health team.
- Monthly Oncology Multidisciplinary Research Meeting was held on 2/11/25.
- The research team had introductory meetings with the UB Population Health team working out of ECMC in the DK Miller Building.
- The research team is participating in the Epic transition on the Research Advisory Council and two different workgroups and have been attending all of the Epic meetings.
- CRCs attended UB CTSI Open Research Office webinar titled: "Recruiting Older Adults for Research".

Center of Cancer Care

CLARENCE RED DEVILS HOCKEY FIGHTS CANCER!

 On January 17, 2025, Clarence High School Hockey Boosters held a "Hockey Fights Cancer" event where all funds from ticket sales, raffle and puck toss were donated to the ECMC Foundation. This event honored a student and hockey player who is currently in treatment at the ECMC Center for Cancer Care. This event raised \$2,500 and a check was presented at the Clarence Hockey Senior Night on February 8th.

Outpatient Behavioral Health

Program Updates/Initiatives

- Help Center Adolescent Service Expansion
 - Continued efforts related to the Mental Health Outpatient Treatment & Rehabilitative Services (MHOTRS) grant issued by NYSOMH. Currently targeting to fill psychiatric coverage and implement a three stage expansion of services for adolescent mental health needs within the community.

<u>MRU</u>

•

- For 2025, CARF goals have been established for the Medical Rehabilitation Unit (MRU) pertaining to the required domains of Business Function and Service Delivery. The Service Delivery domain is further divided into effectiveness, efficiency, service access, patient satisfaction, and stakeholder satisfaction. New goals for 2025:
 - **Business Function:** Increase revenue capture of cases identified in triple check meeting with an increase from 20 to 25 charts to >=75%.
 - **Service Access:** Average Daily Census goal >=11.5 days, based on 2024 avg = 11.5 days.
 - **Effectiveness Outcomes:** *Self-Care* Improve bathing score by 5% from 2024 baseline of 4.0. *Mobility* Improve car transfer scores by 7% from 2024 baseline of 3.7.
 - **Efficiency Goal**: Improved via efficiency as evidenced by decreased onset days to MRU admission from baseline of 2024 of 16.3 days, as identified in UDSMR Comprehensive Report to <=16.3 days.
 - **Patient Satisfaction**: Upon 90 day follow up phone call>=90% of patients surveyed will report they will recommend ECMC's MRU.

Biomedical Services

Department Initiatives/Projects/Updates:

• The 30 dialysis chairs arrived and were taken to OP dialysis for distribution.

- Worked with Baxter and the Value Analysis team to distribute the 840 pumps throughout the facility and pick up old pumps.
- The focus department for March is 12z4 beds and IV pumps.
- The focus departments for February are the 7th, 8th and 9th floors.

<u>Dialysis</u>

- The new B. Braun Hemodialysis machines are expected in early 2025 for deployment in the final pod.
- Thirty (30) new dialysis chairs were deployed the second week of February.

Food & Nutrition Services

- A new retail menu and new retail pricing was implemented on February 10, 2025.
- New retail pricing for all items was implemented on February 10, 2025.
- New *Bleni Smoothie* vending machine was installed on February 26, 2025. There have been some technical challenges, and we are awaiting delivery of a new machine on March 16, 2025.
- *Overnight Variety*: We are working to establish a more consistent overnight and weekend menu rotation for our customers. The overnight grill menu will reflect the lunch menu for the entrée station.

Laboratory Services

Equipment Upgrades/Replacements/Contracts:

- <u>Chemistry/IA Specimen Processing Technology upgrade</u>: Department leadership recommendation is to pursue Abbott technology which will standardize with the KH system. Current Roche agreement terminates in June 2025. Contract has been executed and final stages of facility and IT planning underway. Targeted delivery of equipment April 2025. Discussion with Roche has been initiated for required contract extension beyond June 2025 termination date in alignment with Abbott installation process.
- <u>ECMC/ KH Joint VAT Initiative</u>: Vendor evaluation of RFP for coagulation technology across the network is under review. Vendor selection awarded to Werfen for upgrade of two coagulation devices. The eight-year lease proposal has an estimated sevenyear savings opportunity of \$185K over the term of the contract. Equipment was installed February 2025 and instrument validation is ongoing.
- <u>Pathology AB&T</u>: Project in partnership with Kaleida Pathology to implement advanced barcode and tracking of Pathology specimens, blocks, and slides. AB&T will improve specimen tracking and traceability of Pathology material. System went live on January 7, 2025.

Plant Operations / Capital Projects

Plant Operations/Facility project updates include the following: Mammography Suite – In Progress (In-House Crew / Contractor)

- **Work completed:** Construction contract executed; contractors' mobilization late February into early March; work area demo and filed verification by trades.
- Work anticipated: Completion of framing and rough-in of all trades.

Dental Clinic – 1st Floor – In Progress (concurrent with Mammography Suite project)

- Work completed: The majority of work in Triage room and Room #18.
- Work anticipated: Completion of above, substantial completion of Room #13.

General Construction – Maintenance Projects with DMyles, Inc. – In Progress (Contractor)

- Work completed: Loading Dock project
- Work in progress: Obtained several quotes for various projects/tasks identified, all varying status.
- Pending projects:
 - o Grounds Garage Floor Repairs/Trench Train Replacement
 - Trash Compactor Concrete Pad
 - Main Hospital 4th and 5th Floors Behavioral Health Ceiling Access Panels
 - 1st Floor Internal Medicine Millwork

Medical Gas Equipment Replacement – Complete (Contractor)

• Work completed: Final completion and project closeout.

Campus Grounds - In Progress (In-House Crew)

- Winter operations mode. (65) tons of rock salt on site and (17) pallets (49 bags/pallet)of ice melter delivered. Ordered 20 tons of sand to have on hand in the event of salt shortage.
- Trucks, plows and salters are operational. Winter equipment rentals (skid-steer and small wheel loader) will be returned at the end of March.

Supportive Care & Palliative Medicine

Meeting participation includes the following:

- Caregiver Support/Assessment: Forty-one (41) identified caregivers were screened, with fourteen (14) full assessments completed and transferred to ECDSS.
- Monthly Advancing Palliative Synergy meetings.

Surgical Services

Robotic Volume – February 2025

| Bariatrics | 10 |
|--|----|
| Cardiovascular/Thoracic | 4 |
| Head, Neck, Plastic & Reconstructive Surgery | 5 |
| Orthopedics | 33 |
| Transplant | 0 |
| Urology | 2 |

- Surgical volume was below budget, however above 2024 volume.
- ION robotic cases continue to grow.
- Increased daily volume with the expansion of OR hours past 3:00pm Monday-Friday.
- Mammography/Pain Management Expansion project: construction began, completion slated for June 2025.
- VIZ-AI: Radiology software to improve imaging. This is the same system as Kaleida and GLMI. Go-live Q1 2025.
- Radiology Fuji-PACS shared platform to view radiology images between ECMC, Kaleida and GLMI, successful implementation.
- Globus Navigation/Robotics: Meeting with vendor to discuss pricing options.

Terrace View

Operations

- <u>Census</u>: The average monthly census for February was 374.
- <u>Pharmacy Services RFP</u>: The award selection is being evaluated. The current contract is extended to June 30, 2025, to provide adequate response time during the vetting process.
- Renovations:
 - Servery renovations on the Albright neighborhood were completed in February 2025. Eventually, all serveries will be replaced. The MLK neighborhood is next on the schedule. There will be temporary repairs to the Roosevelt server in early April.
 - Replaced four (4) bathroom floors on the neighborhoods with an additional five (5) to be completed in March.
 - Resident room window replacement on the Kensington neighborhood.

PATIENT EXPERIENCE

February 2025

| Patient Experience | YTD Feb. 1 st , 2025- | YTD Feb. 1 st , 2024- | NYS 2025 |
|--------------------|----------------------------------|-------------------------------------|-----------|
| | Feb. 28 th , 2025 | Feb. 28 th , 2024 | Benchmark |
| | N= 37 (est) | N= 93 (final) | |
| HCAHPS - Nurses | 86 (est) | 76 | 76 |
| HCAHPS – Doctors | 82 (est) | 75 | 76 |
| Discharge Info | 92 (est) | 86 | 84 |
| Overall Rate | 76 (est) | 60 | 65 |

Ambulatory Medical Practices

Population Health

In preparation for launching a retinal imaging system (Retinavue) designed for in-office diabetic eye exams, Population Health conducted an outreach campaign using Twistle. This initiative focused on engaging patients, assisting with scheduling, and ensuring providers had access to complete ophthalmology records. By proactively addressing gaps in care, we aimed to enhance patient access, improve documentation, and support the early detection of diabetic eye disease.


| Outreach Initiative | Outcome |
|---|---------|
| Patients Outreached | 1,434 |
| Assisted with Scheduling Diabetic Eye Exams | 38 |
| Referrals Mailed per Patient Request | 42 |
| Ophthalmology Offices Contacted for Missing Records | 56 |

Food & Nutrition Services


Press Ganey - Patient Satisfaction Top Box Scores (Goal - 50%)


- The graphs include Press Ganey patient satisfaction scores for the past 12 months. Initiatives are showing improvement since August 2024, although we are experiencing a dip in December and January. The "n" for February is still low for the month, as we have not received all surveys at the time of the report.
- We feel the temperature and quality issues are related to our speed of tray delivery and not our trayline equipment. We have been conducting time studies and found that we have training opportunities with our Hospitality Associates. We continue to recommend the purchase of the Aladdin Boost System to resolve the temperature issue related to the time it takes to deliver a cart from the trayline to the patient units.


Meals Overall












<u>Courtesy of Server</u>



Patient Service Initiatives

- Increased supervisor rounds with designated priority areas (ED, CPEP, Med-Surg, Obs).
- Enhanced galley area communication tool using QR code to request floor stock.
- Escalation tree reworked to include the phone number of our Patient Advocate which has improved our responsiveness to concerns.
- Focus on meal timeliness, tray accuracy and galley cleanliness.
- We added two additional Patient Services Managers to help with weekend accountability, operational coverage and patient rounding.

Quality Improvement Initiatives

- The Food and Nutrition Services (FNS) department is committed to continuous improvement in service quality. During February, we implemented a Metz Tray Accuracy tool. We are gathering data that shows the specific error types.
- Patient Advocacy and Nursing Relations: Our Food and Nutrition Patient Advocate, Kathryn Lynk, has focused her efforts on rounding with nursing staff and patients and taking the lead on employee engagement activities within the Food and Nutrition department. She fosters collaboration with the nursing team and identifies opportunities to improve the patient dining experience. Katie toured the floors in February with special Valentine treats for hospital employees. We created a calendar of events for 2025 with a goal to tour the floors at least once a month in 2025. She also collaborates closely with the General Manager to address and investigate staff and patient risk connect issues.
- Kathryn discusses all case calls with the Food and Nutrition team during tour daily Food and Nutrition manager huddle. She also shares all Press Ganey feedback with the entire management team at our weekly manager meeting.

Laboratory Services

The following initiatives are underway or completed for improvement of testing turnaround time and patient experience.

- <u>HbA1c POCT</u>: Capital request approved for expansion of the Siemens UniPoc middleware for electronic transfer of HbA1c orders and results to mitigate the redundant manual transcription process of results into Altera and Meditech. Contract executed; project kick-off expected by the end of Q1 2025.
- <u>Community HCV Screening</u>: Working with Immunodeficiency team to implement community screening for HCV in high-risk populations. Q1 2025 target implementation.

<u>Transplant</u>

 Lobby days continued at Davita to increase transplantation awareness and continue to grow partnerships with community dialysis centers.

PEOPLE


Ambulatory Medical Practices

<u>Hepatology</u>

On February 27, 2025, Dr. Celine Gounder, chief medical correspondent for CBS national news, interviewed Dr. Anthony Martinez and filmed a segment at his clinic "La Bodega" at ECMC. Dr. Martinez, our medical director of Hepatology, has been involved with the White House regarding a bipartisan-supported national Hepatitis C elimination plan. The segment featured La Bodega's globally recognized rapid start test and treat model of care for hepatitis and also highlighted the outpatient specialty pharmacy. The segment will air on the CBS national news and CBS mornings, potentially as a three-minute segment. This culminates a year in which the Bodega model was presented in Europe, Canada, Mexico, and Australia. Dr. Martinez was also recognized with a global hepatitis champion award from the Coalition for Global Hepatitis Elimination as the sole representative from the United States.

Population Health

Population Health participated in four (4) community outreach events in February 2025, engaging with nearly 305 individuals. The events strongly emphasized cancer screening education, mental health resources, and preventive care. Additionally, linkages to dental care, smoking cessation support (with a newly developed brochure), and resources for women's health and chronic disease management, particularly for hypertension and diabetes, were provided to ensure a comprehensive approach to community health.



Center of Occupational Environmental Medicine (COEM)

In February 2025, COEM continued its community outreach efforts through a series of impactful events. On February 3, staff attended the Erie County Overdose Prevention Task Force Meeting, where they participated as community members seeking to improve workplace-ready organizations by gaining knowledge of the ongoing crisis. This event is pending additional information on Erie County Black Balloon Day. On February 5, staff took part in a CSEA meeting focused on COEM services, and while the event was tabled, continued involvement with the union remains ongoing. On February 6, a presentation on CMV was made to staff and board members at Ripen with Us Day Care. Then, on February 12, staff introduced themselves and provided mental health resources to employees at the Terrace View Safety Fair, fostering conversations about how social work, EAP, and ECMC outpatient clinics can support employees. Presented COEM services at the CSEA meeting, generating interest from members and organizations such as the Sewer Authority and Erie County Sheriff's Department.

Wellness Initiatives

 Family Day at Kissing Bridge, held on February 22, 2025, was a great opportunity for ECMC employees to engage in wellness activities with their families. The event allowed staff to enjoy skiing and other outdoor activities, promoting family bonding and physical well-being. It was a perfect chance to participate in an active, fun day outdoors, supporting both personal and family health while enjoying the beautiful winter setting.

System Health and Safety

In 2024, we made significant strides in reducing the workplace violence (WPV) incidents. Through our continuous efforts and strategic initiatives, we have seen a steady decline in WPV events throughout the year, with the most notable reduction in August. As we move into 2025, early data is even more promising. In just the first two months of 2025, our WPV numbers show a remarkable **decrease** compared to the same period last year. This progress highlights the effectiveness of our commitment to creating a safer and more supportive work environment for all.



Falls Prevention

• There has been ongoing interdisciplinary collaboration to relaunch the Mobility Program in conjunction with the Falls Prevention Program. This includes the

development of a PT Mentorship Program for Nurses, research and trial of gait belts, and the initiation of chair alarms in each room. Additionally, par levels for chair alarm pads are being established for each unit.

The Terrace View Gait Belt Initiative aims to consistently use gait belts for transfers and ambulation with appropriate residents. Gait belt competencies were initiated during the Safety Fair and are currently being conducted on the units. A UKG Pro module on the proper use of gait belts has been assigned to Terrace View staff. Gait belts, which were purchased previously, are now ready for distribution to the neighborhoods. Peter Buckley, the Team Leader and a member of the TV Employee Safety Committee, is conducting in-person competencies with staff.

Center of Cancer Care Research

- Dr. Frustino, Juli Chikaraishi and Vanessa McDonough represented ECMC the "Operation Clean Sweep's Medical Model Interventions" planning session on February 12th. There were many community stakeholders present at the event hosted by the Invest Health Team and Rita Hubbard Robinson, which was held at The Loud House on Hertel Ave. The 2024 events were re-capped and break-out sessions were held for brainstorming 2025 ideas.
- Dr. Frustino and ECMC PGY-2 dental resident Dr. Iesha DeLesline attended a Friday evening outreach on February 7th called "Elim Girls to Women". The event was aimed to inspire young women about careers in the health professions. It was held at the Elim Christian Fellowship on Chalmers Ave. Also present were UB Dental and medical students, sisters from the local chapter of The Links, Inc and medical students from the local chapter of Black Men in White Coats. The young girls learned about robotic surgery, dentistry, and suturing (bananas) as well as heard about the many aspects of being a doctor. (Photos below)



Food & Nutrition Services

Staffing/Recruitment:

- We welcomed several new staff members to our department during February.
- We are planning a second off-site job fair during March at the Delevan/Grider Community Center. We hired 15 new employees form the job fair in January.
- We are currently focusing on sourcing strong Hospitality Associates, Floor Stock and dish room personnel.

Staff Development:

• Our HR Manager, Robin Martinelli, has worked with the GM to provide a better and more consistent HR experience for all of our employees. Robin has improved the organization in our office and has set up systems that are helping us to better track our vacancies. Robin has organized all the employee files and ensured that everything is up to date and on record, coinciding with NY State law. She has also worked with our AGM on all the new policies we have put in place and those we have revised/reissued and set up a monthly HR calendar to help cover training and events we plan on hosting. Robin's efforts have already helped us to hold our employees more accountable.

Employee Engagement:

 We have a Committee organizing Employee Engagements, Nurse Rounds, and special events we plan on hosting. This committee is meeting on a regular basis to review what is needed for the next month to ensure that we have everything needed and the vital time needed to leave an impression. We also celebrated Valentine's Day and Black History Month with special treats.

Laboratory Services

- Shawndre Horne has assumed the Chief Clinical Laboratory Technologist position for the Chemistry department un advance of the retirement of Robert Walter effective February 28, 2025.
- Extension of the current MOA for Shift Differential: Request extension for 6/30/25, pending final approval.
- Cross-Training: Cross-training activities continue with full cross-training of new staff and expanded cross-training of Sr. CLTs and evening/night shift staff.
- Schedules: Alternate schedule models continue to be evaluated for feasibility. Implementation of 10-hr or 8-hr shift across all sections/units as of April 2025 for the Clinical Laboratory Technology titles.

Outpatient Behavioral Health

<u>Staff Updates</u>

- New team members
 - 1285 Main Street OTPT BH Laura Vogel, LCSW Psychiatric Case Manager
 - 1285 Main Street SUTS Mackenzie Gullo, CASAC Substance Use Counselor
 - Northern Erie Clinical Services SUTS Charles Wilber, MD
- Congratulations/Achievements
 - Danielle DeLong Completion and achievement of LCSW
 - o Samantha Galloway Completion and achievement of LMHC-D
 - o Alyssa Gallagher Completion and achievement of LMHC-D

Community Outreach Event

- Events/Outreach
 - Attendance and participation in the Erie County Mental Health Crisis Response Initiative meeting at Buffalo State University.

Rehabilitation Services

- An ECMC Rehab patient was honored at the Springfest Gift Gathering Luncheon at Kleinhans on February 5, 2025. The presentation included his entire rehab continuum at ECMC.
- Five Cancer Care subcommittee members attended course offered by UB Department of Rehabilitation Sciences, "Taking the Fear Out of Treating the Oncology Patient in the Community". The course included presenters from Roswell's Therapy Department and offered evidence-based treatment options for oncology patients in the inpatient and outpatient settings and heavily supported the benefit of therapy services for cancer patients at all levels of treatment.
- Rehab leadership participated in a meeting with PRISM Recovery Team (PRI) who is currently managing all transitional stroke care at BGH. PRISM is a new communitybased patient navigation company dedicated to stroke patients which currently being utilized by UB Neurosurgery. ECMC Outpatient Rehabilitation is one of the identified primary sites for the outpatient stroke care. This relationship is part of the larger community post-stroke care program in WNY that ECMC participates in along with Dr. Kandel from GVI, Kaleida, and Catholic Health.
- As part of the WNY Stroke collaborative group in WNY with Kaleida, Catholic Health and other community stakeholders, OP Occupational Therapy conducted a course of Constraint Induced Movement Therapy for patients with hemiplegia speech therapy first 4-week trials intensive aphasia program. Results of this programming will be reviewed and assessed for efficacy, patient outcome and sustainability.
- The Director of Outpatient Rehab and Senior OTR for Driver Program completed a presentation at the Center of Elder Law on the topic of Driver Evaluations, especially in the context of patients that require guardianship.

Acute Care Therapy

- Acute Therapy will be participating in a new mobility training initiative for nursing that will include PT shadowing nursing staff, who are identified by the unit managers as needing mobility training. This will include EMR documentation, chart review, use of SPH equipment/DME, as well as setting daily mobility goals and determining if the patient needs a PT or OT order.
- Starting February 1st Acute Care PT began a trial of additional weekend PT staffing to treat/mobilize high-functioning patients requiring Subacute Rehabilitation (SAR) to evaluate if increased mobility support over the weekend can accelerate progress and facilitate discharge to home. Greater than 50% of this group of patients with increased mobility over the weekend were cleared for home when medically ready and avoided going to SAR.

Surgical Services

- Hired new AVP of Surgical Services, David Brown, start date February 24, 2025.
- Hired new Surgical Services Data Reviewer, Naseera Edwards in February 2025. She will report directly to Phyllis Murawski, Chief Quality Officer.

• Additional positions approved to expand Main OR hours past 3:00pm, employees hired and in orientation.

QUALITY

Ambulatory Medical Practices

On February 18, 2025, ECMC Primary Care departments submitted for their annual PCMH renewal for ECMC Internal Medicine and ECMC Family Health. The team is proud to announce both Primary Care medical practices were accepted for recertification for March 3, 2025 to April 15, 2026!



<u>Dialysis</u>

- There are no surveys, however a full NYSDOH onsite survey is expected in early 2025.
- Quarterly preview report for The Dialysis Compare (DFC) star rating maintains the program at a 2-star rating.

Laboratory Services

The Laboratory Medicine department continues to focus on 2025 QIPS Plan Initiatives. The 2025 QIPS initiatives are the following:

- Outcomes and Alignment: Evaluate the effectiveness of the implementation of the Whole Blood MTP pathway for improved timeliness of release of product compared to Component MTP, with targeted reduction in release time of 2 minutes when compared to Component MTP. Evaluate the stability of the Whole Blood inventory with the ability to maintain WB inventory monitored monthly greater than 5 units 95% of the time. YTD, the Whole Blood inventory has been maintained greater than the 5-unit threshold. Turnaround time for release will be monitored on a quarterly basis for improvement trends.
- Safety and Resiliency: Improve the Glucometer cleaning documentation rate across all POCT locations to >=90% monthly. For January, the Med/Surg, Ambulatory Care and Inpatient Dialysis areas achieved the >90% rate. Outpatient Dialysis and Critical Care are within the 5% benchmark. The OR, Behavioral Health and Terrace View locations all have compliance rates less than 75% and will be the targeted areas of focus.

Outpatient Behavioral Health

<u>QA/QI</u>

- Help Center Semi-annual and Annual Reporting developed and in process for 2024 data
- IOP template and initiation of Monthly Trending reporting occurred for 2025
- PHP template and initiation of Monthly Trending reporting occurred for 2025
- Productivity Dashboard within the data repository is in development

Surgical Services

- GI Lab training for Provation documentation scheduled for end of March.
- Working with Trauma Program preparing for upcoming ACR survey in March.
- Hired new Surgical Services Data Reviewer, Naseera Edwards in February 2025. She will report directly to Phyllis Murawski, Chief Quality Officer.
- Collaboration between PAT and Quality to create standardized protocols for elective spine surgeries and decrease SSIs. Reviewing protocols with Ortho Spine team.

Terrace View

- Continue to adhere Environmental Round process/written feedback for neighborhoods to ensure adherence to Life Safety Code and Safety and environmental general safety.
- <u>Nursing Administration</u>: ADON's continue to monitor the neighborhoods that they maintain administrative responsibility for, to ensure units are in a state of regulatory compliance.
- <u>Life Safety POC</u>: The facility requested a time-limited waiver, secondary to procurement and to contract with a third party to complete the installation of the exterior light fixtures required by the Life Safety Code Plan of Correction, with a completion date of March 31, 2025. On October 24, 2025, the facility received the approval for the time-limited waiver, which will expire on March 31, 2025.
- The facility has submitted the architectural plans for the installation of the aforementioned exterior lights and anticipates completion of this project by early February 2025. The facility continues to communicate with the Buffalo Region NYSDOH Field Office regarding same. <u>UPDATE</u>: The wiring has been installed for all of the exterior lights. Light fixtures are expected to be delivered within the deadline of March 31, 2025 and the local DOH sanitarian will be notified.

<u>Transplant</u>

• MPSC continues to monitor our outcomes; our next submission is due April 14, 2025.

FINANCIAL

Ambulatory Medical Practices

 In February 2025, the Ambulatory Department saw 12,117 patients, while being budgeted for 12,699 visits (-4.6% budget). Departments that exceeded budget include: Bariatrics, ECMC Family Medicine, EEG, Infusion Center, Neurology, Oral Oncology, Orthopedics and Rheumatology. Additionally, there were 25 visits for Covid testing and/or Covid vaccinations. Despite being under budget for the year, the ambulatory department is 1,969 (8.4%) over volume from the same time period (Jan-Feb) in 2024.

<u>Dialysis</u>

Budget and Variance:

- Outpatient (in-center treatments): 2025 Budget **3,857**, Variance **(-15)**
- Home Program: (Home Peritoneal & Home Hemodialysis): YTD Budget 240 treatments, favorable to the budget, Variance (45)
- Total: **30** treatments for the year

Census Volume:

- Outpatient (in-center treatments): February = 1,742 treatments, YTD 2025 total = 3,615
- Home Program: (Home Peritoneal & Home Hemodialysis): February = 129 treatments, 2025 total = 285, favorable to budget.

| Dialys | Dialysis | | | 2024 | | | 2025 | | | |
|--------|-------------|---------------------------|--------|--------|----------|-------|-------|-------|--------|----------|
| | _ | | YTD | Budget | Variance | Jan | Feb | YTD | Budget | Variance |
| 4555 | AKI | Hemodialysis - AKI | 413 | - | - | 14 | 8 | 22 | - | - |
| | DIALNON | Hemodialysis - Non-ESRD | 0 | - | - | 0 | 0 | 0 | - | - |
| | DIALTRAN | Hemodialysis - Transient | 1,085 | - | - | 106 | 114 | 220 | - | - |
| | HD | Hemodialysis - Chronic | 22,745 | - | - | 1,873 | 1,742 | 3,615 | - | - |
| | 4555 Totals | · | 24,243 | 24,293 | -50 — | 1,993 | 1,864 | 3,857 | 3,872 | -15 💳 |
| 5660 | HOMEHD | Hemodialysis - Home | 0 | - | - | 0 | 0 | 0 | - | - |
| | PD | Hemodialysis - Peritoneal | 1,574 | - | - | 156 | 129 | 285 | - | - |
| | 5660 Totals | · | 1,574 | 1,976 | -402 🦊 | 156 | 129 | 285 | 240 | 45 👚 |
| Totals | | | 25,817 | 26,269 | -452 ⋟ | 2,149 | 1,993 | 4,142 | 4,112 | 30 |

Environmental Services

- Overall expenses for January/February was 6% over budget. Employee benefits and vacation accrual account fo the overage.
- Overall supply and labor budget was in line with budget. Additional Head Janitor salary will be moved to TV budget line.

Food & Nutritional Services

| Retail Sales (after 20% discount) | | | | | | | | |
|-----------------------------------|--------------------|----------------------|-----------------------|------------------|--|--|--|--|
| February | 2025 Actual | \$156,451 | January 2025 Actual | \$170,593 | | | | |
| February | 2025 Budget | \$183,291 | January 2025 Budget | \$181,566 | | | | |
| Variance be | low target (\$27,4 | 471) = 85% to target | Variance below target | (\$10,973) = 94% | | | | |

For comparison, February 2024 sales were \$157,997.

Laboratory Services


The department budget volumes for February YTD were positive 3.7% to budget target and level to FY24. The FY25 January YTD operating expense has a negative variance of 10% to budget target and a negative variance of 13.6% to FY24. The personnel expense January YTD had a negative variance of 7.6% to budget target and a negative variance of 7.6% to FY24 actual. The non-personnel expense demonstrated a negative variance of 13.2% to budget target and a negative variance of 15.3% to FY24. The negative non-personnel variance is impacted by the overall

positive 3.7% to budget volume YTD. Expenses are in alignment with laboratory volumes and utilization.

• The Chemistry and Hematology cost centers had procedure volumes positive to budget target by 5.0% and 14.2% respectively, which attributed to the negative nonpersonnel expense to budget target for FY25. The seasonal increase in Repsiratory testing has impacted volume and expenses in alignment with test utilization. Department will continue to monitor expenses in alignment with volume and test utilization.

Rehabilitation Services

- <u>Acute Care Therapy (see graphs below)</u>
 - PT productivity overall was 3,743 against a budget of 3,095 units for a positive variance of 17%.
 - OT productivity overall was 2,619 against a budget of 2,357 units, for a positive variance of 10%



<u>MRU</u>

• 19 admissions and 14 discharges with 230 patient days and a LOS of 16.4 days, **ADC = 8.2 days**.

- <u>PEDS</u>
 - o Early intervention program increased by 47% visits in February.
- Outpatient Rehab
 - Occupational Therapy, Physical Therapy, Speech Therapy, Rehab Psychology and Physiatry all exceeded budget by 9.3% in February.

Supportive Care & Palliative Medicine

- Total Inpatient Consults for February: 112
- Transitions of Care: 18
- Discharge with Home Hospice: 2
- Terrace View: 6


Surgical Services

- Unexpected need for a new microscope, ongoing dicsussions with vendors and surgeons, trialing several scopes.
- Monthly meetings with Purchasing to review contracts and savings opportunities.
- Weekly meetings to capital needs with new ENT provider for skull base and sinus procedures, ordering will begin next month.


- Exploring opportuntiies to combine VAC and IR department cost codes.
- Monthly meetings reviewing high implant costs and reimbursement.

Transplant

- As of March 3, 2025, we have performed (19) transplants, which is (+4) transplants than this time last year (2024). Based on current volume, we have projected (141) transplants for 2025.
- Pre-Transplant Clinic is below budget by (-30). We are still limited with our shortage of providers; however, a new nephrologist started in January.
- Post-Transplant is below budget by (-63) visits.
- Total clinic variance is below budget (-93).



| | DD-K | LD-K | KP | Pancreas | Total |
|------|------|------|----|----------|-------|
| 2009 | 15 | 5 | 0 | 0 | 20 |
| 2010 | 5 | 11 | 0 | 0 | 16 |
| 2011 | 10 | 2 | 0 | 0 | 12 |
| 2012 | 7 | 3 | 0 | 1 | 11 |
| 2013 | 15 | 4 | 0 | 0 | 19 |
| 2014 | 10 | 5 | 0 | 0 | 15 |
| 2015 | 3 | 1 | 0 | 0 | 4 |
| 2016 | 23 | 2 | 3 | 1 | 29 |
| 2017 | 19 | 5 | 0 | 0 | 24 |
| 2018 | 27 | 2 | 0 | 0 | 29 |
| 2019 | 19 | 1 | 2 | 0 | 22 |
| 2020 | 27 | 0 | 2 | 0 | 29 |
| 2021 | 31 | 0 | 0 | 0 | 31 |
| 2022 | 18 | 5 | 0 | 0 | 23 |
| 2023 | 15 | 1 | 2 | 0 | 18 |
| 2024 | 15 | 0 | 0 | 0 | 15 |
| 2025 | 18 | 0 | 1 | 0 | 19 |



| | DD-K | LD-K | KP | Pancreas | Total |
|------------|------|------|----|----------|-------|
| 2009 | 55 | 37 | 2 | 0 | 94 |
| 2010 | 60 | 33 | 2 | 0 | 95 |
| 2011 | 52 | 14 | 5 | 2 | 73 |
| 2012 | 48 | 20 | 1 | 3 | 72 |
| 2013 | 48 | 18 | 1 | 2 | 69 |
| 2014 | 68 | 9 | 1 | 1 | 79 |
| 2015 | 82 | 11 | 5 | 4 | 102 |
| 2016 | 104 | 11 | 10 | 3 | 128 |
| 2017 | 119 | 15 | 4 | 0 | 138 |
| 2018 | 124 | 12 | 8 | 0 | 144 |
| 2019 | 107 | 15 | 5 | 0 | 127 |
| 2020 | 122 | 8 | 4 | 0 | 134 |
| 2021 | 132 | 7 | 7 | 1 | 147 |
| 2022 | 125 | 16 | 7 | 0 | 148 |
| 2023 | 129 | 12 | 10 | 0 | 151 |
| 2024 | 127 | 10 | 6 | 0 | 143 |
| 2025 | 18 | 0 | 1 | 0 | 19 |
| 2025 Proje | 126 | 8 | | | 141 |

| Trans | Fransplant / Vascular | | | 2024 | | | 2025 | | | |
|--------|-----------------------|-------------------|-------|--------|----------|-----|------|-----|--------|----------|
| | | _ | YTD | Budget | Variance | Jan | Feb | YTD | Budget | Variance |
| 6430 | TRANPRE | Transplant Clinic | 562 | - | - | 36 | 38 | 74 | - | - |
| | TRANPREPRC | Transplant Clinic | 2 | - | - | 0 | 0 | 0 | - | - |
| | 6430 Totals | | 564 | 997 | -433 🦊 | 36 | 38 | 74 | 104 | -30 🦊 |
| 6431 | TRANPOSPRC | Transplant Clinic | 0 | - | - | 0 | 0 | 0 | - | - |
| | TRANPOST | Transplant Clinic | 4,166 | - | - | 322 | 315 | 637 | - | - |
| | 6431 Totals | | 4,166 | 4,000 | 166 🖉 | 322 | 315 | 637 | 700 | -63 🦊 |
| Totals | | | 4,730 | 4,997 | -267 🦊 | 358 | 353 | 711 | 804 | -93 🦊 |

The difference between healthcare and true care™



Internal Financial Reports For the month ended February 28, 2025

Erie County Medical Center Corporation Financial Dashboard February 28, 2025

| Statement of Operations: | Mo | onth | <u>Year-t</u> | <u>o-Date (YTD)</u> | L | YTD Budget |
|--|----|---------|---------------|---------------------|----|------------|
| Net patient revenue | \$ | 53,567 | \$ | 113,961 | \$ | 112,871 |
| Other | | 17,749 | | 35,978 | | 34,930 |
| Total revenue | | 71,316 | | 149,939 | | 147,801 |
| Salary & benefits | | 39,751 | | 83,120 | | 80,827 |
| Physician fees | | 10,007 | | 20,695 | | 20,499 |
| Purchased services | | 6,201 | | 13,347 | | 13,541 |
| Supplies & other | | 16,346 | | 33,445 | | 31,667 |
| Depreciation and amortization | | 3,851 | | 7,702 | | 7,699 |
| Interest | | 917 | | 1,862 | | 1,933 |
| Total expenses | | 77,073 | | 160,171 | | 156,166 |
| Operating Income/(Loss) Before Other Items | | (5,757) | | (10,232) | | (8,365) |
| Grant revenue | | - | | - | | |
| Income/(Loss) from Operations With Other Items | | (5,757) | | (10,232) | | (8,365) |
| Other Non-operating gain/(loss) | | 1,321 | | 2,813 | | 622 |
| Change in net assets | \$ | (4,436) | \$ | (7,419) | \$ | (7,743) |
| Operating margin | | -8.1% | | -6.8% | | -5.7% |

| Cash Flow Summary: | <u>Month</u> | | | <u>YTD</u> |
|--|--------------|---------|--|--------------|
| Net cash provided by (used in): | | | | |
| - Operating activities | \$ | 25,682 | | \$ 7,249 |
| - Investing activities | | (2,321) | | (4,970) |
| - Financing activities | | (1,019) | | (3,105) |
| Increase/(decrease) in cash and cash equivalents | | 22,342 | | (826) |
| Cash and cash equivalents - beginning | | 10,348 | | 33,516 |
| Cash and cash equivalents - ending | \$ | 32,690 | | \$ 32,690 |

| Balance Sheet: | |
|---|---------------|
| Assets: | |
| Cash & short-term investments | \$ 78,248 |
| Patient receivables | 93,393 |
| Assets whose use is limited | 191,826 |
| Other assets | 479,766 |
| | \$ 843,233 |
| Liabilities & Net Assets: | |
| Accounts payable & accrued expenses | \$ 352,103 |
| Estimate self-insurance reserves | 51,862 |
| Other liabilities | 485,865 |
| Long-term debt, including current portion | 190,833 |
| Lease liability, including current portion | 20,447 |
| Subscription liability, including current portion | 20,695 |
| Line of credit | 10,000 |
| Net assets | (288,572) |
| | \$ 843,233 |

| Key Statistics: | | <u>Month</u> | YTD | YTD Budget |
|--------------------------|---------------------------|----------------|-----------------|-----------------|
| Discharges: | - Acute - Exempt units | 972 366 | 2,086 785 | 2,052 829 |
| Observation Cases: | | 308 | 638 | 392 |
| Patient days: | - Acute - Exempt units | 7,760 4,206 | 16,594 8,812 | 15,597 9,516 |
| Average length of stay, | acute | 8.0 | 8.0 | 7.6 |
| Case mix index | Blended | 1.90 | 1.95 | 1.89 |
| Average daily census: | Medical Center | 427 | 431 | 426 |
| | Terrace View LTC | 374 | 372 | 377 |
| Emergency room visits | , including admissions | 5,002 | 10,441 | 9,907 |
| Outpatient Visits | | 22,875 | 47,575 | 49,666 |
| Days in patient receival | bles | | 48.4 | |

The difference between healthcare and true care™



Erie County Medical Center Corporation Management Discussion and Analysis For the month ended February 28, 2025 (Amounts in Thousands)

February 2025 Operating Performance

During February 2025, ECMCC was faced with some continued operational challenges specifically related to throughput during the month leading to operating performance which fell below the operating target for the month. ECMCC's length of stay and alternative level of care patients exceeded targets significantly for the month leading to shortfalls to the budget in inpatient cases and total inpatient surgeries. The case severity in medical and surgical cases this month was slightly above plan led to an overall increase in acute case mix index helping to partially offset the shortfalls. The revenue variances derived from these trends during February resulted in overall revenue in line with budgeted expectations but were accompanied by additional expenses to accommodate the in-house volume reflected within the higher acute average length of stay, increased staffing related costs, temporary agency costs and increased utility costs. The overall result drove an operating loss for the month of (\$5,757). This operating loss is unfavorable due to the above drivers when compared to the month's budgeted loss of (\$4,486) and an improvement when compared to the (\$5,428) loss in January 2024.

Inpatient discharges during the month of 1,338 were less than the planned discharges of 1,381 (3.1%). Within the total, all service areas including acute, behavioral health, chemical dependency and medical rehab fell below plan. This decrease in discharges drove an increase in the acute average length of stay to 8.0 days during February, an increase from 7.9 days during January and variance of 5.1% to the budget of 7.6 days. This movement has continued into March with significant efforts underway related to throughput initiatives.

ECMCC continues to see growth within the specialty pharmacy service line which provides a convenient onsite option for ECMCC clinic patients to have their specialty drug prescriptions filled. This growth is reflected within the other operating revenue and corresponding additional supply costs.

Total FTEs during February were higher than budgeted targets for the month by 38 FTEs but only slightly higher if compared to the FTE levels 3,806 FTE budgeted for the full 2025 year. With the acute average length of stay higher than plan and ongoing volume fluctuations, additional FTEs in addition to plan continue to be necessary in order to meet the New York State minimum staffing standards. To continue to meet those standards, the use of incentives is utilized fill vacancies and off-shifts, such as the authorization of overtime, shift differential, and additional bonus rates per hour.

Although at a reduced level, ECMCC continues to incur costs for temporary nursing staff in both the hospital and Terrace View to assist in meeting minimum standards during the month and to accommodate some staff vacancies during specific shifts. Management expects to have the need for a certain number of temporary agency clinical personnel through much of 2025 to continue to meet the New York State minimum standards given the volume increases. The majority of these FTEs are working with the Terrace View skilled nursing facility.

Total benefit costs for the month were above the operating plan as a result of unfavorable health insurance claim costs. Given the change in our employee healthcare insurance provider as of January 1st, management is monitoring the costs and activity closely. Also noteworthy is that the year-to-date increase in total benefit costs as compared to 2024 levels is the result of anticipated significant increases in actuarial book expenses related to both the pension plan and the retiree health benefit plan.

Supply costs exceeded the operating plan during the month by \$622. The additional cost during the month was related primarily to pharmaceutical costs related to specialty pharmacy and growth in oncology services.



Erie County Medical Center Corporation Management Discussion and Analysis For the month ended February 28, 2025 (Amounts in Thousands)

Balance Sheet

ECMCC saw an increase in cash from January 31, 2025 due to the receipt of the annual DSH/IGT initial payment on February 20, 2025, and reflects a slight decrease in cash from December 2024. The net changes resulted in 30 days operating cash at February 28, 2025 as compared to 33 days operating cash at the end of 2024. At this day's operating cash level, ECMCC saw an increase from 21 days operating cash when compared to January 2025.

Patient receivables increased approximately \$2.7 million from December 31, 2024. The increase in accounts receivable is due to the expected increases due to higher reimbursement rates placed into effect January 1st as well as typical ramp up time in collections during the beginning of the year. This is an expected increase given the fluctuation of receipts around the calendar year end. Although the patient net receivables increased from year end, the Days in Accounts Receivable (average number of days a bill is outstanding) decreased from 52.3 days to 48.4 days at February 28, 2025. Management is continuing to monitor this especially given the recent billings of all of the backlogged professional billing from 2024 delayed due to the Change Healthcare cyber-attack.

The change in other accrued expenses reflects the recognition of the deferred revenue related to the amounts received for DSH/IGT during February. This revenue for this payment will be recognized ratably over the course of the year in the income statement. A significant portion of these payments resulted in an amount which are expected to be recouped by March 31st by New York State and CMS.



Balance Sheet February 28, 2025 and December 31, 2024

(Dollars in Thousands)

| | Febr | uary 28, 2025 | Dece | mber 31, 2024 | nge from mber 31st |
|---|------|---------------|------|------------------|-----------------------|
| Assets | | | | <u> </u> | |
| Current Assets: | | | | | |
| Cash and cash equivalents | \$ | 32,690 | \$ | 33,516 | \$ (826) |
| Investments | | 45,558 | | 42,826 | 2,732 |
| Patient receivables, net | | 93,393 | | 93,708 | (315) |
| Prepaid expenses, inventories and other receivables | | 45,365 | | 38,753 | 6,612 |
| Total Current Assets | | 217,006 | | 208,803 | 8,203 |
| Assets Whose Use is Limited | | 191,826 | | 191,600 | 226 |
| Property and equipment, net | | 273,053 | | 277,043 | (3,990) |
| Other assets | | 161,348 | | 161,656 | (308) |
| Total Assets | \$ | 843,233 | \$ | 839,102 | \$ 4,131 |
| Liabilities & Net Position | | | | | |
| Current Liabilities: | | | | | |
| Current portion of long-term debt | \$ | 12,755 | \$ | 13,520 | \$ (765) |
| Current portion of lease liability | | 7,281 | | 6,264 | 1,017 |
| Current portion of subscription liability | | 8,576 | | 8,118 | 458 |
| Line of credit | | 10,000 | | 10,000 | - |
| Accounts payable | | 67,069 | | 64,553 | 2,516 |
| Accrued salaries and benefits | | 76,050 | | 85,393 | (9,343) |
| Other accrued expenses | | 203,517 | | 146,172 5,643 | 57,345 |
| Estimated third party payer settlements | | 5,467 | | | (176) |
| Total Current Liabilities | | 390,715 | | 339,663 | 51,052 |
| Long-term debt | | 178,078 | | 179,574 | (1,496) |
| Long-term lease liability | | 13,166 | | 14,394 | (1,228) |
| Long-term subscription liability | | 12,119 | | 13,210 | (1,091) |
| Estimated self-insurance reserves | | 51,862 | | 50,424 | 1,438 |
| Other liabilities | | 485,865 | | 522,990 | (37,125) |
| Total Liabilities | | 1,131,805 | | 1,120,255 | 11,550 |
| Total Net Position | | (288,572) | | (281,153) | (7,419) |
| Total Liabilities and Net Position | \$ | 843,233 | \$ | 839,102 | \$ 4,131 |

The difference between healthcare and true care™



Statement of Operations

For the month ended February 28, 2025

(Dollars in Thousands)

| | Actual | Budget | Favorable/ (Unfavorable) | Prior Year |
|--|------------|------------|-----------------------------|------------|
| Operating Revenue: | | | | |
| Net patient revenue | 54,991 | 55,253 | (262) | 53,688 |
| Less: Provision for uncollectable accounts | (1,424) | (1,170) | (254) | (850) |
| Adjusted Net Patient Revenue | 53,567 | 54,083 | (516) | 52,838 |
| Disproportionate share / IGT revenue | 11,018 | 11,018 | - | 10,273 |
| Other revenue | 6,731 | 6,211 | 520 | 4,434 |
| Total Operating Revenue | 71,316 | 71,312 | 4 | 67,545 |
| Operating Expenses: | | | | |
| Salaries & wages | 28,973 | 28,201 | (772) | 27,673 |
| Employee benefits | 10,778 | 10,363 | (415) | 8,729 |
| Physician fees | 10,007 | 10,249 | 242 | 9,806 |
| Purchased services | 6,201 | 6,625 | 424 | 6,058 |
| Supplies | 13,382 | 12,760 | (622) | 11,078 |
| Other expenses | 2,061 | 2,213 | 152 | 1,880 |
| Utilities | 903 | 575 | (328) | 631 |
| Depreciation & amortization | 3,851 | 3,850 | (1) | 4,133 |
| Interest | 917 | 962 | 45 | 977 |
| Total Operating Expenses | 77,073 | 75,798 | (1,275) | 70,965 |
| Operating Income/(Loss) Before Other Items | (5,757) | (4,486) | (1,271) | (3,420) |
| Other Gains/(Losses) | | | | |
| Grant revenue | | | | 609 |
| Income/(Loss) from Operations | (5,757) | (4,486) | (1,271) | (2,811) |
| Other Non-operating Gain/(Loss): | | | | |
| Interest and dividends | 704 | 292 | 412 | 485 |
| Unrealized gain/(loss) on investments | 617 | 19 | 598 | 787 |
| Non-operating Gain/(Loss) | 1,321 | 311 | 1,010 | 1,272 |
| Excess of Revenue/(Deficiency) Over Expenses | \$ (4,436) | \$ (4,175) | \$ (261) | \$ (1,539) |

Statement of Operations

For the two months ended February 28, 2025

(Dollars in Thousands)

| | Actual | Budget | Favorable/ (Unfavorable) | Prior Year |
|--|------------|------------|-----------------------------|------------|
| Operating Revenue: | | | | |
| Net patient revenue | 117,151 | 115,289 | 1,862 | 109,442 |
| Less: Provision for uncollectable accounts | (3,190) | (2,418) | (772) | (1,890) |
| Adjusted Net Patient Revenue | 113,961 | 112,871 | 1,090 | 107,552 |
| Disproportionate share / IGT revenue | 22,036 | 22,036 | - | 20,547 |
| Other revenue | 13,942 | 12,894 | 1,048 | 9,010 |
| Total Operating Revenue | 149,939 | 147,801 | 2,138 | 137,109 |
| Operating Expenses: | | | | |
| Salaries & wages | 61,507 | 59,411 | (2,096) | 58,415 |
| Employee benefits | 21,613 | 21,416 | (197) | 17,393 |
| Physician fees | 20,695 | 20,499 | (196) | 19,692 |
| Purchased services | 13,347 | 13,541 | 194 | 12,910 |
| Supplies | 27,501 | 26,290 | (1,211) | 22,481 |
| Other expenses | 4,430 | 4,346 | (84) | 3,837 |
| Utilities | 1,514 | 1,031 | (483) | 1,000 |
| Depreciation & amortization | 7,702 | 7,699 | (3) | 8,257 |
| Interest | 1,862 | 1,933 | 71 | 1,972 |
| Total Operating Expenses | 160,171 | 156,166 | (4,005) | 145,957 |
| Income/(Loss) from Operations | (10,232) | (8,365) | (1,867) | (8,848) |
| Other Gains/(Losses) Grant revenue | | | | 609 |
| Income/(Loss) from Operations | (10,232) | (8,365) | (1,867) | (8,239) |
| Other Non-operating Gain/(Loss): | | | | |
| Interest and dividends | 1,421 | 583 | 838 | 793 |
| Unrealized gain/(loss) on investments | 1,392 | 39 | 1,353 | 281 |
| Non-operating Gain/(Loss) | 2,813 | 622 | 2,191 | 1,074 |
| Excess of Revenue/(Deficiency) Over Expenses | \$ (7,419) | \$ (7,743) | \$ 324 | \$ (7,165) |

Statement of Changes in Net Position

For the month and two months ended February 28, 2025

(Dollars in Thousands)

| | _ | Month | Yea | ar-to-Date |
|---|----|-----------|-----|------------|
| Unrestricted Net Assets: | | | | |
| Excess/(Deficiency) of revenue over expenses | \$ | (4,436) | \$ | (7,419) |
| Other transfers, net | | - | | |
| Contributions for capital acquisitions | | - | | - |
| Change in accounting principle | | - | | - |
| Net assets released from restrictions for capital acquisition | | - | | - |
| Change in Unrestricted Net Assets | | (4,436) | | (7,419) |
| Temporarily Restricted Net Assets: | | | | |
| Contributions, bequests, and grants | | - | | - |
| Other transfers, net | | - | | - |
| Net assets released from restrictions for operations | | - | | - |
| Net assets released from restrictions for capital acquisition | | - | | - |
| Change in Temporarily Restricted Net Assets | | | | - |
| Change in Net Position | | (4,436) | | (7,419) |
| Net Position, beginning of period | | (284,136) | | (281,153) |
| | | (207,100) | | (201,100) |
| Net Position, end of period | \$ | (288,572) | \$ | (288,572) |

The difference between healthcare and true care™



Statement of Cash Flows

For the month and two months ended February 28, 2025

(Dollars in Thousands)

| | Month | | Year-to-Date | |
|---|-------|----------|--------------|----------|
| Cash Flows from Operating Activities: | | | | |
| Change in net assets | \$ | (4,436) | \$ | (7,419) |
| Adjustments to Reconcile Changes in Net Assets to Net Cash Provided by/(Used in) Operating Activities: | | | | |
| Depreciation and amortization | | 3,851 | | 7,702 |
| Provision for bad debt expense | | 1,424 | | 3,190 |
| Net change in unrealized (gain)/loss on Investments | | (617) | | (1,392) |
| Changes in Operating Assets and Liabilities: | | | | |
| Patient receivables | | 1,598 | | (2,875) |
| Prepaid expenses, inventories and other receivables | | (3,102) | | (6,612) |
| Accounts payable | | 1,061 | | 2,516 |
| Accrued salaries and benefits | | (3,132) | | (9,343) |
| Estimated third party payer settlements | | (176) | | (176) |
| Other accrued expenses | | 67,579 | | 57,345 |
| Self Insurance reserves | | 876 | | 1,438 |
| Other liabilities | | (39,244) | | (37,125) |
| Net Cash Provided by/(Used in) Operating Activities | | 25,682 | | 7,249 |
| Cash Flows from Investing Activities: | | | | |
| Additions to Property and Equipment, net | | (3,106) | | (3,712) |
| Decrease/(increase) in assets whose use is limited | | 1,144 | | (226) |
| Sale/(Purchase) of investments, net | | (472) | | (1,340) |
| Change in other assets | | 113 | | 308 |
| Net Cash Provided by/(Used in) Investing Activities | | (2,321) | | (4,970) |
| Cash Flows from Financing Activities: | | | | |
| Principal payments on / proceeds from long-term debt, net | | (630) | | (2,261) |
| Principal payments on / additions to long-term lease liability, net | | (586) | | (211) |
| Principal payments on / additions to long-term subscription, net | | 197 | | (633) |
| Increase/(Decrease) in Cash and Cash Equivalents | | 22,342 | | (826) |
| Cash and Cash Equivalents, beginning of period | | 10,348 | | 33,516 |
| Cash and Cash Equivalents, end of period | \$ | 32,690 | \$ | 32,690 |



Statistical and Ratio Summary

| | Febr | uary 28, 2025 | Dece | mber 31, 2024 | 3 | ECMCC Year Avg.)22 - 2024 |
|--|------|--|------|--|----|--|
| Liquidity Ratios: Current Ratio Days in Operating Cash & Investments Days in Patient Receivables Days Expenses in Accounts Payable Days Expenses in Current Liabilities Cash to Debt Working Capital Deficit | \$ | 0.6 30 48.4 56.4 139.5 69.1% (173,709) | \$ | 0.6 33 52.3 53.7 145.7 67.3% (130,860) | \$ | 0.7 24.7 56.4 59.1 140.5 53.1% (105,982) |
| <u>Capital Ratios:</u> Long-Term Debt to Fixed Assets Assets Financed by Liabilities Debt Service Coverage (Covenant > 1.1) Capital Expense Average Age of Plant Debt Service as % of NPSR Capital as a % of Depreciation | | 65.2% 134.2% 1.6 8.7% 7.1 3.4% 48.2% | | 64.8% 133.5% 1.7 3.0% 8.0 3.9% 35.5% | | 67.3% 131.7% 1.8 2.9% 8.6 4.0% 21.9% |
| <u>Profitability Ratios:</u> Operating Margin Net Profit Margin Return on Total Assets Return on Equity | | -6.8% -6.3% -5.3% 15.4% | | 0.7% -0.7% -0.6% 1.8% | | -11.5% -2.5% -1.6% 5.4% |
| <u>Productivity and Cost Ratios:</u> Total Asset Turnover Total Operating Revenue per FTE Personnel Costs as % of Total Revenue | \$ | 1.1 270,546 54.3% | \$ | 1.1 266,577 50.0% | \$ | 0.9 230,021 56.0% |

The difference between healthcare and true care™



Key Statistics Period Ended February 28, 2025

| | Currer | nt Period | | | | | Year | to Date | |
|-------------|-----------|-------------|------------|------------------------------------|--------|------|-----------|-------------|------------|
| Actual | Budget | % to Budget | Prior Year | | Actu | al | Budget | % to Budget | Prior Year |
| | v | Ŭ | | Discharges: | | | v | | |
| 972 | 978 | -0.6% | 1,039 | Med/Surg (M/S) - Acute | 2, | 086 | 2,052 | 1.7% | 2,105 |
| 210 | 217 | -3.1% | 228 | Behavioral Health | | 438 | 450 | -2.6% | 440 |
| 142 | 170 | -16.2% | 153 | Chemical Dependency (CD) - Detox | | 307 | 344 | | 328 |
| 14 | 17 | -18.7% | 18 | Medical Rehab | | 40 | 36 | 11.7% | 37 |
| 1,338 | 1,381 | -3.1% | 1,438 | Total Discharges | 2, | 871 | 2,881 | -0.3% | 2,910 |
| | | | | Patient Days: | | | | | |
| 7,760 | 7,427 | 4.5% | 8,213 | M/S - Acute | 16, | 594 | 15,597 | 6.4% | 17,041 |
| 3,453 | 3,682 | | 3,693 | Behavioral Health | 7, | 032 | 7,475 | | 7,441 |
| 523 | 642 | | 613 | CD - Detox | | 181 | 1,297 | -8.9% | 1,304 |
| 230 | 367 | -37.3% | 411 | Medical Rehab | | 599 | 744 | -19.5% | 807 |
| 11,966 | 12,118 | -1.3% | 12,930 | Total Patient Days | 25, | 406 | 25,113 | 1.2% | 26,593 |
| | | | | Average Daily Census (ADC): | | | | | |
| 277 | 265 | 4.5% | 283 | M/S - Acute | | 281 | 264 | 6.4% | 284 |
| 123 | 132 | | 127 | Behavioral Health | | 119 | 127 | | 124 |
| 19 | 23 | -18.5% | 21 | CD - Detox | | 20 | 22 | | 22 |
| 8 | 13 | -37.3% | 14 | Medical Rehab | | 10 | 13 | -19.5% | 13 |
| 427 | 433 | -1.3% | 446 | Total ADC | | 431 | 426 | 1.2% | 443 |
| | | | | Average Length of Stay: | | | | | |
| 8.0 | 7.6 | 5.1% | 7.9 | M/S - Acute | | 8.0 | 7.6 | 4.7% | 8.1 |
| 16.4 | 17.0 | -3.2% | 16.2 | Behavioral Health | 1 | 6.1 | 16.6 | | 16.9 |
| 3.7 | 3.8 | -2.7% | 4.0 | CD - Detox | | 3.8 | 3.8 | | 4.0 |
| 16.4 | 21.3 | -22.9% | 22.8 | Medical Rehab | 1 | 5.0 | 20.8 | -27.9% | 21.8 |
| 8.9 | 8.8 | 1.9% | 9.0 | Average Length of Stay | | 8.8 | 8.7 | 1.5% | 9.1 |
| | | | | Occupancy: | | | | | |
| 79.0% | 84.2% | -6.2% | 82.4% | % of M/S Acute staffed beds | 79 | 0.0% | 84.2% | -6.2% | 82.4% |
| | | | | Case Mix Index: | | | | | |
| 1.90 | 1.86 | 1.8% | 1.76 | Blended (Acute) | 1 | .95 | 1.89 | 3.4% | 1.82 |
| 308 | 200 | 54.0% | 262 | Observation Status | | 638 | 392 | 62.8% | 566 |
| 400 | 435 | -8.0% | 399 | Inpatient General Surgeries | | 804 | 907 | -11.3% | 819 |
| 620 | 636 | -2.5% | 616 | Outpatient General Surgeries | 1, | 342 | 1,304 | 2.9% | 1,272 |
| 21 | 19 | 10.5% | 30 | Inpatient Ancillary Surgeries | | 41 | 40 | 2.5% | 50 |
| 23 | 36 | -36.1% | 29 | Outpatient Ancillary Surgeries | | 60 | 74 | -18.9% | 71 |
| 22,875 | 24,048 | -4.9% | 22,687 | Outpatient Visits | 47, | 575 | 49,666 | -4.2% | 46,003 |
| 5,002 | 4,859 | 2.9% | 5,039 | Emergency Visits Including Admits | 10, | 441 | 9,907 | 5.4% | 10,121 |
| 48.4 | 44.2 | 9.3% | 55.4 | Days in A/R | 2 | 8.4 | 44.2 | 9.3% | 55.4 |
| 2.4% | 2.1% | | 1.4% | Bad Debt as a % of Net Revenue | 2 | 2.6% | 2.1% | | 1.6% |
| 3,343 | 3,262 | 2.5% | 3,232 | FTE's | 3. | 342 | 3,261 | 2.5% | 3,243 |
| 4.34 | 4.22 | | 4.12 | FTE's per Adjusted Occupied Bed | | .29 | 4.30 | | 4.10 |
| 20,544 | \$ 20,303 | 1.2% | \$ 20,053 | Net Revenue per Adjusted Discharge | \$ 20, | 330 | \$ 20,338 | 0.0% | \$ 19,563 |
| 29,389 | | | | Cost per Adjusted Discharge | | | \$ 27,878 | | |
| <i>.</i> | . , | | ψ 27,030 | Cost per Adjusted Discharge | ψ 20, | 000 | ψ 21,010 | 1.770 | ψ 20,474 |
| errace Viev | • | | | | - | | | | . |
| 10,483 | 10,527 | -0.4% | 10,780 | Patient Days | 21, | 921 | 22,214 | -1.3% | 22,113 |
| 374 | 376 | -0.4% | 372 | Average Daily Census | | 372 | 377 | -1.3% | 369 |
| 96.0% | 96.4% | -0.4% | 95.3% | Occupancy - % of Staffed beds | 95 | 5.3% | 96.5% | -1.3% | 94.5% |
| | | | | | | | | | |
| 467 | 510 | | 457 | FTE's | | 463 | 510 | | 464 |
| 7.1 | 7.8 | -8.2% | 6.8 | Hours Paid per Patient Day | | 6.8 | 7.4 | -8.1% | 6.7 |

Medical Executive Committee

CMO Report to the ECMC Board of Directors

March 2025

<u>University at Buffalo Update</u>

- Congratulations to Dr. Beth Smith, new Chair for the Department of Psychiatry.
- There is an ongoing search for Division Chief of Nephrology and a new search for Chair of ENT.

Current hospital operations

| • | Admissions YTD: | 2,394 |
|---|-----------------------|--------|
| • | ED visits YTD: | 10,084 |
| • | CPEP visits: | 1,844 |
| • | Observation: | 732 |
| • | Inpatient Surgeries: | 920 |
| • | Outpatient Surgeries: | 1,507 |
| • | ALČ days YTD: | 2,305 |

The average length of stay MTD 8.1 CMI 1.9407

CMO Update

- Congratulations to Dr. Flynn and the Trauma Team for their recent ACS survey.
- Doctor's Day Celebration Wednesday, March 26th in the Overflow Café'. Breakfast will be served form 7 9:00 am with a physician award ceremony beginning at 8:00 am.

ERIE COUNTY MEDICAL CENTER CORPORATION Charlene Ludlow MS-MHA, RN, CIC Sr. Vice President of Nursing

Department of Nursing Report March 2025

The Nursing team continues to focus on staff growth and professional development. Our team has continued to be successful in precepting our newly hired Nurses as well as focus on providing a great clinical environment for student nurse school rotations. ECMC is a desired site for Nursing school clinical rotations. Our focus on developing new students in the community by facilitating a positive clinical experience has been recognized by an increase in students reaching out for Inter or other part-time work experiences while they are completing their education.

We recently celebrated several outstanding Nursing team members:

Nurse Hero - David Krupatwinski RN in Behavioral Health TICU 1st Quarter Outstanding Employees Quiona Thomas RN Isabela Sirica, Nurse Intern

At the recent Nurse Management meeting we recognized Nurses that achieved advanced certifications:

Lisa Marie Hauss - Certified Case Manager Jinchao "Chris" Zhang" - Trauma Certified Registered Nurse Karly Klosterman - Psychiatric Mental Health - Board Certified Alicia Keeney - Ambulatory Nursing Certification

There were 12 staff members that achieved Critical Incident Stress Management (CISM) Certification, which will be part of our CISM response team to help our staff with event management concerns. This is a team that will focus on patient safety and staff wellness. Congratulations to:

John Rizzo Hannah Elling Kiera Duckworth Melissa Perry Katie Sullivan Loretta Miller Benjamin Hunt Leah Brittain

Melinda Brennan Brooke Eck Karly Klostermann Carrie Wieder

Nurse Recognition committee hosted a "Meat Raffle" fund raiser on 2/28/2025 . Funds raised are utilized to celebrate our Nursing staff and promote wellness as well as professional development . It was a fun night to share with our staff and their families and friends. Congratulations to Marc LaBelle and Tara Gregorio for their leadership of the Nurse Recognition Committee that planned this successful fun event.

The new Baxter IV pumps have been successfully rolled out to all areas with 800 pieces of equipment deployed over 10 hours. The team effort was very successful to change out the equipment in one day.

Communications and External Affairs Report Submitted by Peter K. Cutler Senior Vice President of Communications and External Affairs March 25, 2025

Marketing

- Preparing new advertising/marketing efforts in 2025 that will focus on key service lines that generate high patient volume and revenue for ECMC. Notably, the effort will highlight service lines like Orthopedics, as well as other opportunities with Head and Neck Oncology. Continue to maintain ECMC's long secured billboard just east of Grider Street on the outbound side of NYS Route 33 with graphics highlighting ECMC's nationally ranked Orthopedic services.
- Final preparations are underway for launching ECMC's new website, which should take place by mid-April.

Media Report

- Continue coordination of media interviews related to ECMC service lines including coverage of transplantation, orthopedics, behavioral health, surgical services, physical therapy and emergency services.
- ECMC's Medical Minute partnership with WGRZ-TV included the featured following topics in February/March: Colon & Rectal Cancer (Dr. Mills), Breast Reconstruction (Dr. Frey) and Hip & Knee Arthritis (Dr. Mutty).

Community and Government Relations

- On March 10th, the Senate and Assembly released their respective "one-house" budget proposals in response to the Governor's proposed FY 2026 Executive Budget. Neither the Governor nor the Legislature include substantial offsets for any anticipated Federal actions that might impact the state's budget in their health care budget proposals, with leaders noting that they are approaching issues such as Medicaid without addressing potential federal cuts. The Governor and legislature have three weeks to negotiate a final budget agreement to meet the April 1 deadline for an on-time budget.
- Below is an analysis of the position of the Senate and Assembly on key health and health-related proposals in the Executive Budget, as well as new proposals and funding advanced by the houses. We highlight several that may be of greatest interest:
 - Both houses modify the Executive's MCO Tax revenue expenditure plan. The Assembly reduces the use of funds to support Global Cap deficits and the Senate eliminates the use of revenue to offset Global Cap spending. The houses increase funding allocated to providers above to the Executive's proposal and include funding for Certified Home Health Agencies (CHHAs), Early Intervention (EI) rates, and dental providers.
 - Both houses accept the Executive's proposal to invest an additional \$1.3 billion to expand the existing Safety Net Hospital Transformation Program.
 - Both houses provide funding to restore the Vital Access Provider Assurance Program (VAPAP) for financially distressed hospitals and nursing homes.
 - Both houses increase capital support for SUNY hospitals above the Executive's proposal and propose to shift the cost of debt service from the hospitals to the State.
 - The Senate accepts the Executive's Hospital at Home proposal, but limits the authorization to 2 years, while the Assembly rejects the proposal.
 - Both accept the proposal to align MMC policy for individuals with a long-term nursing home placement with the Managed Long-Term Care (MLTC) program.
 - Both houses reject the Executive's administrative proposal modifying the Applied Behavioral Analysis (ABA) benefit.

- The Senate modifies the Executive's proposal to authorize the Department of Health (DOH) to levy penalties on Medicaid managed care (MMC) plans for issues of noncompliance to include due process protections, while the Assembly rejects the proposal.
- Both houses have accepted the Executive's proposal to discontinue the MLTC Quality Incentive Pool.
- Both houses reject the Executive's proposal to expand the use of involuntary confinement for individuals with serious mental illness. Both houses include new proposals to enhance discharge planning for patients with complex needs and increase community outreach.
- Both houses increase the targeted inflationary increase for eligible mental hygiene and other human services programs to 7.8%, compared to 2.1%

MEDICAL EXECUTIVE COMMITTEE MEETING Monday, January 27, 2025 MEETING HELD VIA MICROSOFT TEAMS PLATFORM/HYBRID DR. ZIZZI CONFERENCE ROOM SECOND FLOOR

Attendance (Voting Members):

| Dr. Bakhai | Dr. Belles | Dr. Brewer | Dr. DePlato | |
|-----------------|----------------|--------------|--------------|--|
| Dr. Cheng | Dr. Griffith | Dr. Hall | Dr. Kapral | |
| Dr. Manka | Parveen Minhas | Dr. Murray | Dr. Nagai | |
| Dr. Perry | Dr. Pugh | Dr. Rossitto | Dr. Ruggieri | |
| Dr. Stegemann | Dr. Welch | Dr. Wilkins | Dr. Williams | |
| Dr. Tadakamalla | Dr. Yedlapati | | | |
| | | | | |

Non-Voting Members and Guests:

| Sam Cloud, DO | Tom Quatroche, CEO | Jon Swiatkowski | Peter Cutler |
|--------------------|--------------------|------------------|-------------------|
| Mandip Panesar, MD | Becky DelPrince | Cheryl Carpenter | Charles Cavaretta |
| John Cumbo | Pam Lee | Michael Ott | Andy Davis |
| Kaori Tanaka | Charlene Ludlow | Dr. Frustino | Phyllis Murawski |

CALL TO ORDER

A. Dr. Michael Manka, President, called the meeting to order at 11:30 pm.

B. PRESIDENT'S REPORT:

- 1. Dr. Manka asked physicians to review the delinquent report that was included in their packet previously emailed. Please remind your staff to address any outstanding records.
- 2. Dr. Manka shared the passing of a former pathologist from ECMC. Dr. Sigmund Sinwohn Yoon worked here more than 40 years and refired in 2014.

II. ADMINISTRATIVE REPORTS

- A. CEO/COO/CFO REPORT –Tom Quatroche, CEO, Andrew Davis, COO, Jon Swiatkowski, CFO
 - 1. <u>CEO Dr. Tom Quatroche, PhD.</u>
 - a. Dr. Quatroche spoke on the notice that was sent out last week addressing Andy Davis as COO and President. Dr. Quatroche also explained that he will be involved with duties at the state level.
 - b. Dr. Quatroche will be involved with state meetings regarding Medicaid funding.
 - c. Dr. Quatroche thanked everyone for the work being completed on length of stay and other operational areas making an impact on the bottom line.

Erie County Medical Center - Medical Executive Committee January 27, 2025 Minutes of Record 1 | P a g e

- 2. <u>COO Report Andy Davis</u>
 - a. Mr. Davis discussed the work around Epic. There will be several work group sessions taking place. Watch your calendars for invites and updates. Things will be moving rapidly with this project.
- 3. CFO REPORT Jon Swiatkowski
 - a. Mr. Swiatkowski spoke on the December 2024 Key Statistics.
 - b. A review of observation cases, case mix discharges, acute average length of stay, case mix adjusted length of stay, acute case mix index numbers along with admissions via the ED and outpatient visits took place.
 - c. The hospital continues to look for grant opportunities.

III. UNIVERSITY REPORT – Dean Allison Brashear, MD, MBA

a. No Report

IV. CHIEF NURSING OFFICER REPORT – Charlene Ludlow, RN, CIC

- a. Ms. Ludlow spoke on the throughput initiative which includes bed huddles, fall prevention and early mobility with patients.
- b. Recruitment and retention continue. There is a large orientation which started today.
- c. The nursing department continues with hourly rounding.
- d. Pathways survey is underway and closes out February 2, 2025.
- e. The hospital is seeing an increased number of influenzas, COVID and RSV cases.

V. CHIEF MEDICAL OFFICER REPORT – Samuel D. Cloud, DO

- a. Dr. Cloud shared an operation update 2024 a year in review. His report included ED volumes, CPEP volumes, admissions, observation, average length of stay, ALC days, along with inpatient and outpatient surgeries comparing the last two years with 2019.
- b. A review of the length of stay challenges took place.
- c. An update on the Baxter IV Fluid shortage took place.
- d. Dr. Cloud reviewed and reminded physicians of the Child Abuse Training Requirements. This is a mandatory requirement for state certification.
- e. A University update reflected an ongoing search for the Chief of Nephrology, Chief of GI, and the Chair of Psychiatry. Dr. Schwaitzberg will be Interim Chair of ENT.
- f. Dr. Cloud reminded physicians of the 2024 Physician Time Study. This is due back to Pain Thanki by Friday, January 31, 2025.

VI. ASSOCIATE MEDICAL DIRECTORS REPORT – Michael Cummings, MD Ashvin Tadakamalla, MD and William Flynn, MD

a. Dr. Tadakamalla noted the positive financial impact that has taken place based on changes and a new query process that is being utilized.

VII. CHIEF MEDICAL INFORMATION OFFICER REPORT – Mandip Panesar, MD

a. Dr. Panesar along with John Cumbo updated on the Epic ECMC Project Leadership. Workgroups are starting to meet this week. Dr. Panesar is working with the Physician Advisory Council, please reach out if you have any

> Erle County Medical Center - Medical Executive Committee January 27, 2025 Minutes of Record 2 | P a g e

questions. Tuesday, January 27, 2025, kicks off a 3-day session which begins in-person at Jacobs School of Medicine. Day 1 will be a high-level overview with Wednesday and Thursday working with individual work groups.

Important Points

- Project is just exiting the Pre-Work phase you aren't missing anything
- ECMC is a very large Connect customer; unusual but not unprecedented for Epic
- Kaleida Health and Epic are being very intentional with early-ECMC involvement. Double-edged sword, but expect "good intentions"
- No way around the work this is a huge endeavor
- It's up to all of us to ensure ECMC is represented properly in this project




Epic Orientation & Next Steps

Epic Orientation Week (EOW)

- Serves as operational kick-off to the project
- January 28, 29, and 30 at UB (Jacobs School of Medicine)
- Three days of sessions/demos
 - Day 1: Kick-off and integrated sessions (advisory council members)
 - Day 2-3: Workgroup breakouts for service -line specific content
- Next Steps:
 - · Look for invites if you are in a council or workgroup.
 - · Continued communication on logistics if you are attending in person.
 - Show up ready to learn and participate!

Erie County Medical Center - Medical Executive Committee January 27, 2025 Minutes of Record **3** | P a g e



VIII. CREDENTIALS COMMITTEE REPORT – Yogesh Bakhai, MD

 Please refer to your packet and review/implement the new Medical Staff Policy- Expiring Documents Policy. There will be one extraction reviewed in Executive Session.

IX. CONSENT CALENDAR

| MEETING MINUTES/MOTIONS | PAGE # | |
|--|-----------|--------------------|
| MINUTES of the Previous MEC Meeting: November 25, 2024 | 7-11 | Receive and File |
| 2. CREDENTIALS COMMITTEE: December 5, 2024 and January 2, 2025 | 13-37 | Receive and File |
| Appointments/ Reappointments/ Resignations | | Review and Approve |
| Dual Reappointment Applications | | Review and Approve |
| New Business | | Review and Approve |
| Expiring Documents Policy | 38-40 | Review and Approve |
| Psychiatry NP Privilege Delineation Form | 41-44 | Review and Approve |
| Privilege Delineation Form Request for Privileges Internal Medicine Form AHP | 45-50 | Review and Approve |
| Department of Internal Medicine General Internal Medicine Privilege Delineation Form | 51-57 | Review and Approve |
| Privilege Delineation Form AHP Dept of Radiology | 58-61 | Review and Approve |
| Template Delinquent Dues | 62 | Review and Approve |
| Extraction for Executive Session | | |
| B. HIM – Minutes of November 2024 | 67 | Receive and File |
| Living Donor Initial Consent | 68-76 | Review and Approve |

Erie County Medical Center - Medical Executive Committee January 27, 2025 Minutes of Record 4 | P a g e

| | MEETING MINUTES/MOTIONS | PAGE # | |
|--------------------|--|------------------|---------------------------------|
| | Authorization for Performance of Operations & Other Procedures & Surgeries | 77-78 | Review and Approve |
| | Procedural Progress note | 79 | Review and Approve |
| | Patient Selection Criteria and Approval for Listing Kidney Simultaneous Pancreas | 80 | Review and Approve |
| | Attestation Regarding Requested Use or Disclosure of Protected Health/ Reproductive Health | 81-83 | Review and Approve |
| | ECMC MRI In-patient /ER History and Screening Form | 84-86 | Review and Approve |
| | ECMC MRI In-Patient /ER History and Screening Form for Unconscious Patients | 87-89 | Review and Approve |
| | ECMC MRI Outpatient History and Screening Form | 90-92 | Review and Approve |
| 4. | OR Committee – No Report | A STATE OF STATE | the second second second second |
| 5. | University GME Committee – Minutes of November and December 2024 | 94- 103 | Receive and File |
| 6. | P & T Committee – Minutes of December 3, 2024 | 105 | Receive and File |
| | Additions to formulary | | |
| | Cholestyramine Addition | 117 | Review and Approve |
| 1 | Phosphate Binder Formulary | 126 | Review and Approve |
| | P & T Committee – Minutes of January 7, 2025 | 149 | Receive and File |
| | Additions to Formulary | | |
| | Symbicort, Acyclovir 400 mg tablet | 156 | Review and Approve |
| Constanting of the | Removal From Formulary | | |
| | Seven Fact and Advair | 157 | Review and Approve |
| | Guideline Approval | | |
| | High Risk/High Alert Medication List | 162 | Review and Approve |
| 22.2 | Angiotensin II Guidance and Calculator | 160 | Review and Approve |
| 1 | Antimicrobial CCVHD Dosing Guide | 168 | Review and Approve |
| | CCB and BB Overdose Management and Guideline | 166 | Review and Approve |
| | Guideline for Titration of Continuous IV Infusion in Critical Care | 160 | Review and Approve |
| 7. | Professional Dev. & Wellness Committee – Minutes of December 19, 2024 | 171 | Receive and File |
| 8. | Resource Management Committee – Minutes of Nov and Dec 2024 | 176 | Receive and File |
| 9. | Ethics Committee – Minutes of November 15, 2024 | 174 | Receive and File |

MOTION to APPROVE all items in the CONSENT CALENDAR was made and seconded. Motion to approve all items in the Consent Calendar is carried. UNANIMOUSLY APPROVED.

X. NEW BUSINESS – Michael Manka, MD

Appointment approvals include:

1. Appointment of Jennifer Frustino, DDS as Associate Chief of Service for the Department of Dentistry

> Erie County Medical Center - Medical Executive Committee January 27, 2025 Minutes of Record 5 | P a g e

- 2. Appointment of Brian Murray, MD as a member of the Resource Utilization Committee
- 3. Appointment of David Holmes, MD as a member of the Professional Development and Wellness Committee
- 4. Renewal of term for Suzanne Griffith, MD 3-year term for Chief of Service
- 5. Renewal of term for Mary Welch, MD 3-year term for Chief of Service

MOTION TO APPROVE all appointments was made and seconded. Motion to approve all items is carried.

UNANIMOUSLY APPROVED.

XI. EXECUTIVE SESSION

A motion was made and carried at 12:05 pm to move to Executive Session. The following items were discussed and motion(s) made:

Motion made and carried, all-in favor to receive and file:

- a. Board Quality P/I meeting minutes of November 12 and December 10, 2024
- b. Chiefs of Service meeting minutes of November 14 and December 12, 2024
- c. Leadership Council Report for December 2024

XII. ADJOURNMENT

There was no further business conducted. Motion to adjourn the meeting was made and seconded. The next meeting will be Monday, February 24, 2025, at 11:30 am. via Teams/Hybrid in the Dr. Zizzi conference room at ECMC. Meeting was adjourned at 12:23 pm.

Respectfully submitted,

MD, FACS Michael Nagai, MD

Secretary Medical Executive Committee

> Erie County Medical Center - Medical Executive Committee January 27, 2025 Minutes of Record 6 | P a g e

Resolution Receiving and Filing the Report of Annual Audit Performed by RSM US LLP

Approved March 25, 2025

WHEREAS, under section 3642 of the Public Authorities Law, Erie County Medical Center Corporation (the "Corporation") is obligated to have an annual audit performed by an independent certified public accountant; and

WHEREAS, the Corporation has engaged RSM US LLP to perform an annual audit of the Corporation's books, records, and accounts, among other things, for the period ending December 31, 2024; and

WHEREAS, the audit report has been reviewed by the Audit Committee of the Corporation's Board of Directors and said committee has recommended that the Corporation's annual audit report be received and filed.

Now, THEREFORE, the Board of Directors resolves as follows:

1. The 2024 Annual Audit performed by RSM US LLP is hereby received and filed and the Corporation's management is directed to distribute the report in accordance with law.

2. This resolution shall take effect immediately.

Sharon L. Hanson Corporation Secretary

Erie County Medical Center Corporation

(A Component Unit of the County of Erie)

Financial Report December 31, 2024

PRELIMINARY DRAFT poses Only PRELIMINARY DRAFT poses Only PRELIMINARY DRAFT poses Only PRELIMINARY DRAFT Post to be purposed subject to performed Not to be produced Not to be produced

Contents

| Independent auditor's report | 1-3 |
|---|-------|
| Management's discussion and analysis Basic financial statements | 4-15 |
| Statements of net position | 16 |
| Statements of revenues, expenses and changes in net position | 17 |
| Statements of cash flows | 18-19 |
| Statements of net position—discretely presented component units | 20 |
| Statements of revenues, expenses and changes in net position—discretely presented component units | 21 |
| Notes to the financial statements | 22-56 |
| Required supplementary information | |
| Schedule of corporation's contributions NYSLRS pension plan | 57 |
| Schedule of corporation's proportionate share of net pension liability NYSLRS pension plan | 58 |
| Schedule of corporation's changes in total OPEB liability and related ratios | 59 |
| Uniform guidance audit requirements | |
| Schedule of expenditures of federal awards | 60 |
| Notes to schedule of expenditures of federal awards | 61 |
| Report on internal control over financial reporting and on compliance and other matters based on an audit of financial statements performed in accordance with <i>Government Auditing Standards</i> | 62-63 |
| Report on compliance for each major federal program; report on internal control over compliance; and report on schedule of expenditures of federal awards required by the Uniform Guidance | 64-66 |
| Schedule of findings and questioned costs | 67-68 |
| Summary schedule of prior year findings and questioned costs | 69 |

Independent Auditor's Report

Board of Directors Erie County Medical Center Corporation

Report on the Audit of the Financial Statements

Opinions

We have audited the financial statements of the business-type activities and the aggregate discretely presented component units of Erie County Medical Center Corporation (the Corporation), a component unit of the County of Erie, as of and for the years ended December 31, 2024 and 2023, and the related notes to the financial statements, which collectively comprise the Corporation's basic financial statements as listed in the table of contents.

In our opinion, the accompanying financial statements referred to above present fairly, in all material respects, the respective financial position of the business-type activities and the aggregate discretely presented component units of Erie County Medical Center Corporation, as of December 31, 2024 and 2023, and the respective changes in financial position, and, where applicable, cash flows thereof for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinions

We conducted our audits in accordance with auditing standards generally accepted in the United States of America (GAAS) and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States (*Government Auditing Standards*). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of the Corporation and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinions. The financial statements of ECMC Foundation, Inc., the Grider Initiative, Inc., and Research for Health in Erie County, Inc. were not audited in accordance with *Government Auditing Standards*.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Corporation's ability to continue as a going concern for twelve months beyond the financial statement date, including any currently known information that may raise substantial doubt shortly thereafter.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinions. Reasonable assurance is a high level of assurance but is not absolute assurance and, therefore, is not a guarantee that an audit conducted in accordance with GAAS and *Government Auditing Standards* will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with GAAS and Government Auditing Standards, we

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to
 fraud or error, and design and perform audit procedures responsive to those risks. Such procedures
 include examining, on a test basis, evidence regarding the amounts and disclosures in the financial
 statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Corporation's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that
 raise substantial doubt about the Corporation's ability to continue as a going concern for a reasonable
 period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

Required Supplementary Information

Accounting principles generally accepted in the United States of America require that management's discussion and analysis as well as the required supplementary information for certain pension and other postemployment benefits (OPEB) related data, as listed in the table of contents, be presented to supplement the basic financial statements. Such information is the responsibility of management and, although not a part of the basic financial statements, is required by the Governmental Accounting Standards Board (GASB) who considers it to be an essential part of financial reporting for placing the basic financial statements in an appropriate operational, economic or historical context. We have applied certain limited procedures to the required supplementary information in accordance with auditing standards generally accepted in the United States of America, which consisted of inquiries of management about the methods of preparing the information and comparing the information for consistency with management's responses to our inquiries, the basic financial statements, and other knowledge we obtained during our audits of the basic financial statements. We do not express an opinion or provide any assurance.

Other Reporting Required by Government Auditing Standards

In accordance with *Government Auditing Standards*, we have also issued our report dated [DATE] on our consideration of the Corporation's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements and other matters. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the Corporation's internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the Corporation's internal control over financial reporting and compliance.

Cleveland, Ohio [DATE]

For Review and be Reproduced Not to be Reproduced

Management's Discussion and Analysis December 31, 2024 (Dollars in Thousands)

Management's Discussion and Analysis

Erie County Medical Center Corporation (the Corporation or ECMCC) is a state public benefit corporation dedicated to providing every patient the highest quality of care delivered with compassion. The Corporation fully embraces its position as a safety net provider for the eight-county region of Western New York State (encompassing over 1.5 million residents), supporting persons in need who lack the ability to pay.

To assist the reader in understanding the operations of the Corporation, this annual report has been organized into three parts that should be read together:

- Management's discussion and analysis
- Financial statements and notes to the financial statements and
- Supplemental schedules

The purpose of the discussion and analysis is to provide the reader with objective data to evaluate the financial position and the activities of the Corporation for the year ended December 31, 2024. This narrative and the financial statements and footnotes are the responsibility of the Corporation's management.

The financial statements (the statements of net position, the statements of revenues, expenses and changes in net position and the statements of cash flows) present financial information in a form similar to that used by other government hospitals and have been prepared in accordance with accounting principles generally accepted in the United States of America.

The accompanying financial statements of the Corporation include financial data of the Corporation's discretely presented component units: (i) ECMC Foundation, Inc., and (ii) The Grider Initiative, Inc. however, Management's Discussion and Analysis focuses on the Corporation.

Introduction

During 2024, the Corporation improved in both quality outcome metrics and operational growth while facing another year of financial challenges. During this period, despite these challenges, ECMCC continued to provide high quality, compassionate care to the tens of thousands of Western New Yorkers who depend on it, serve as the region's community hospital and trauma center, and help patients from the most influential to the most vulnerable. ECMCC's dedicated caregivers, support staff, executive leadership, as well as an involved and supportive Board of Directors, continue to advance the mission of the Corporation and its service to the greater Western New York area. The Corporation continues to be a provider of choice in our community as a result of its continual focus on high quality healthcare services, the patient experience and physician engagement.

Management's Discussion and Analysis December 31, 2024 (Dollars in Thousands)

Operations Analysis

The Corporation continued its recovery across inpatient and outpatient care, serving not only Western New York residents but also many individuals from beyond the region, bringing patient volume closer to pre-pandemic levels. The following outlines the patient volume encounters (not expressed in thousands):

| | | | | | | % Growth |
|-------------|---------|---------|---------|---------|---------|-----------|
| | 2020 | 2021 | 2022 | 2023 | 2024 | 2023-2024 |
| | | | | | | |
| Inpatients | 19,110 | 18,903 | 17,412 | 17,643 | 18,105 | 2.6% |
| Surgeries | 12,481 | 13,803 | 12,478 | 13,321 | 13,672 | 2.6% |
| Emergency | 65,261 | 68,384 | 59,064 | 63,715 | 63,917 | 0.3% |
| Outpatients | 299,297 | 280,611 | 274,402 | 297,168 | 299,098 | 0.6% |
| Dialysis | 27,973 | 26,116 | 24,961 | 25,159 | 25,771 | 2.4% |
| Transplants | 134 | 146 | 148 | 151 | 143 | -5.3% |

During 2024, the healthcare industry both nationally and locally faced several challenges, including rising costs and workforce shortages. Despite these obstacles, the Corporation successfully increased patient volumes through a dedicated focus on improving patient throughput. ECMCC's inpatient volumes ended the year 2.6% higher in patient discharges and 6.2% higher in inpatient surgeries, while the average length of stay improved by 3.7%. Outpatient surgeries saw a slight increase of 0.4% compared to the previous year, and emergency department visits rose by 0.3%, contributing to a 0.6% overall growth in total outpatient visits. As the Regional Center of Excellence for Transplantation and Kidney Care, the Corporation completed 143 transplant surgeries (kidney and pancreas) in 2024, following a record year in 2023.

The COVID-19 pandemic officially ended on May 11, 2023. While the public emergency concluded, the Corporation continues to await reimbursement for certain incremental eligible expenses incurred during the pandemic from the Federal Emergency Management Agency (FEMA), which provided financial relief through its Disaster Relief Fund. As of December 31, 2024, the Corporation has received \$23.9 million from FEMA to cover eligible COVID-19-related expenses.

Rising costs due to inflation and workforce shortages continue to affect both the healthcare industry and the Corporation. To sustain mission-critical services, ECMCC continues to work closely with the New York State Department of Health's various grant and operational assistance programs to address cash flow funding gaps. ECMCC has implemented a series of operational improvements aimed at mitigating cost escalations and increasing payor reimbursement. These efforts have led to financial improvements, and when coupled with certain supplemental funding receipts from FEMA, the Corporation did not require supplemental funding from the New York State Department of Health in 2024 after having received \$76.3 million of supplemental funding during 2023.

Management's Discussion and Analysis December 31, 2024 (Dollars in Thousands)

Operations Analysis (Continued)

The continued volume and visit trends reflect the trust that the Western New York community has placed in ECMCC. Notable achievements in 2024 include:

- **Global Healthcare Exchange** (GHX) announced that ECMCC is among the inaugural class of its "Supply Chains of Distinction Award for 2024," which recognized 75 top performing hospitals and health systems in North America. The Supply Chains of Distinction Award honors GHX Exchangeconnected provider organizations that excelled in driving best-in-class supply chain operations.
- ECMCC was honored by the **Buffalo Purchasing Initiative** for achieving Highest Outreach and Engagement for local Minority Business Enterprise vendors.
- ECMC is one of 462 national healthcare institutions to earn an "LGBTQ+ Healthcare Equality High Performer" designation from the Human Rights Campaign; 1,065 healthcare facilities nationwide were evaluated for their dedication and commitment to LGBTQ+ inclusion.
- Dr. Anthony Martinez, ECMC's Medical Director of Hepatology who was honored with the Coalition for Global Hepatitis Elimination's 2024 Hepatitis Elimination Champion award. Dr. Martinez was one of eight Champions selected worldwide from seven countries. His clinic at ECMC, "La Bodega," has been recognized nationally and globally as a novel co-localized model for managing viral hepatitis and addiction disorders.
- In Orthopedics, ECMCC was honored by **US News and Annual Report** in their annual High Performance Hospitals report as a High Performing Institution for Hip Replacement.
- ECMCC again recognized by the Lown Institute among the best nationally and in New York State, receiving 'A' grades on the 2024-2025 Lown Institute Hospitals Index across five metrics, including: health equity, community benefit, inclusivity, value of care, and avoiding overuse.
- Terrace View Long-Term Care Facility recognized on **Newsweek's Best Nursing Homes** 2024 list. Only four percent of nursing homes nationwide received this distinction. This is the fifth consecutive year Terrace View has received this recognition.
- Terrace View Long-Term Care Facility received an overall 4-star rating from a recent survey conducted by The Centers for Medicare and Medicaid Services (CMS).
- Terrace View Long-Term Care Facility received its **formal recertification from the NYS Department of Health** following a multi-day survey in August.
- ECMCC's Medical Intensive Care Units (MICU) North and South were each recognized by the American Association of Critical-Care Nurses (AACN) with a gold-level Beacon Award for Excellence.
- In another indication of national affirmation of ECMCC's clinical excellence, we earned status in 2024 as an **American College of Surgeons (ACS) Surgical Quality Partner** due to ECMC's participation in multiple ACS quality programs.
- The American College of Emergency Physicians (ACEP) informed ECMCC that our Emergency Department in 2024 achieved the bronze standard — Level 3 Geriatric Emergency Department Accreditation (GEDA) accreditation.
- ECMCC celebrated the opening of our new satellite **Trauma Recovery Center**, that is affiliated with the institution's BRAVE (Buffalo Rising Against Violence) initiative, which is our hospital-based violence intervention trauma recovery effort that serves individuals who have experienced acute victimization and violence.

Management's Discussion and Analysis December 31, 2024 (Dollars in Thousands)

Operations Analysis (Continued)

Financial Metric Analysis

The Corporation's total net position decreased in 2024 primarily due to significant non-cash expenses related to the actuarial liability adjustments for the New York State Pension Plan and Post-Retirement Health Benefit obligations. Additional drivers of performance are discussed in further detail below.

Comparative financial ratios for the Corporation to the 2023 (most recent publicly available audited data) averages of other comparable New York State (NYS) Public Benefit Corporation (PBC) hospitals are presented in the following table. The financial statements used for the calculation of the following ratios, where appropriate, have been reclassified to conform to the presentation used in the development of the benchmarks, consistent with generally accepted accounting principles (U.S. GAAP) for entities not subject to the Governmental Accounting Standards Board (GASB) standards.

| | | ECMCC | S | NYS PBC Average |
|--------------------------------|-----------|--------|--------|--------------------|
| | 2024 | 2023 | 2022 | 2023 |
| | MALAN -RO | M | | |
| Operating margin | -2.0% | -14.2% | -10.8% | -14.3% |
| Operating cash flow margin | 4.6% | -6.0% | 4.6% | -8.2% |
| Debt service coverage | 1.70 | 2.7 | 1.5 | -0.5 |
| Unrestricted days cash on hand | 32.8 | 14.1 | 29.2 | 25.6 |
| Days cash on hand | 114.0 | 90.5 | 118.7 | 56.6 |
| Days in accounts receivable | 52.3 | 66.0 | 53.9 | 40.9 |
| Average age of plant | 17.3 | 15.4 | 13.0 | 19.1 |

The operational performance ratios for 2024 generally represent improvements from the Corporation's 2023 performance ratios and favorable comparisons to the NYS Healthcare Public Benefit Corporations' ratios. Notably, the operating margin for 2024 improved to -2.0%, compared to -14.2% in 2023, reflecting a positive shift but remaining negative. This improvement is largely driven by operational growth, despite the continued unfavorable impact of amortization components of the pension and postemployment benefit liabilities. Although these changes have no cash flows associated with them, the changes to the liabilities associated with them are included within the operating margin. Excluding the impact of the amortization components of pension and postemployment benefits, the operating margin for 2024 and 2023 stands at 2.1% and -11.6%, respectively. This shift indicates favorable operational performance and growth during 2024. Grants received from the New York State Department of Health (NYSDOH) and FEMA have been recognized as non-operating revenue and are excluded from the operating margin ratio calculations as required under GASB accounting standards. Unrestricted days cash on hand increased 18.7 days (132.6%) due to receipt of FEMA grant awards, accumulation of unrestricted investment income and an increase in annual Disproportionate Share Hospital (DSH) Revenue, a portion of which is subject to future reconciliation and repayment. Days in accounts receivable decreased by 13.7 days (20.1%) due to the improved collection efforts, improved staffing levels, and successful payment settlements with various insurance plans. Average age of plant increased by 1.9 years (12.3%) as a result of reduced capital investment aimed at managing cash flow needs to maintain essential community services amid operating challenges.

Management's Discussion and Analysis December 31, 2024 (Dollars in Thousands)

Summary Financial Statements with Analysis

Management is providing the following summary financial statements and variance analysis for certain financial statement lines where it believes the readers understanding of the financial statements is enhanced.

Statements of Net Position

Net position is categorized as follows:

Net investment in capital assets: Consists of capital assets, net of accumulated depreciation and reduced by outstanding debt and deferred inflows and outflows of resources that are attributable to the acquisition, construction or improvement of those assets.

Restricted: Result when constraints placed on the use of the net position are either externally imposed by creditors, grantors, contributors, or imposed by law through constitutional provisions or enabling legislation.

Unrestricted: Represents the resources derived primarily from services rendered to patients and other operating revenues and not meeting the previously listed criteria. These resources are used for transactions related to the general healthcare and academic operations of the Corporation and may be used at the discretion of the Board of Directors to meet current expenses for any purpose.

Condensed Statements of Net Position are as follows:

| | | | | | | | | 2024-2 | 2023 |
|---|-------|-----------|-----|-----------|----|-----------|----|-----------|----------|
| | 101 | 2024 | J.L | 2023 | | 2022 | | \$ Change | % Change |
| Assets | ~ ~ (| | | | | | | | |
| Current assets, excluding assets whose use is limited | \$ \$ | 203,094 | \$ | 189,816 | \$ | 210,427 | \$ | 13,278 | 7.0 |
| Assets whose use is limited | | 191,601 | | 170,621 | | 157,516 | | 20,980 | 12.3 |
| Capital assets, net | | 282,632 | | 313,039 | | 359,386 | | (30,407) | (9.7) |
| Net pension asset | | - | | - | | 77,538 | | - | - |
| Other assets | | 9,978 | | 8,906 | | 7,780 | | 1,072 | 12.0 |
| Total assets | | 687,305 | | 682,382 | | 812,647 | | 4,923 | 0.7 |
| Deferred outflows of resources | | 151,740 | | 159,464 | | 178,411 | | (7,724) | (4.8) |
| | | . , . | | , - | | -, | | | <u> </u> |
| Total assets and deferred | | | | | | | | | |
| outflows of resources | \$ | 839,045 | \$ | 841,846 | \$ | 991,058 | \$ | (2,801) | (0.3) |
| Liabilities | | | | | | | | | |
| Current liabilities | \$ | 339,603 | \$ | 302,347 | \$ | 303,848 | \$ | 37,256 | 12.3 |
| Noncurrent liabilities | φ | 637,616 | φ | 730,926 | φ | 560,724 | φ | (93,310) | (12.8) |
| Total liabilities | | 977,219 | | 1,033,273 | | 864,572 | | | |
| Total habilities | | 977,219 | | 1,033,273 | | 004,372 | | (56,054) | (5.4) |
| Deferred inflows of resources | | 142,978 | | 84,740 | | 396,441 | | 58,238 | 68.7 |
| Net Position | | | | | | | | | |
| Net investment in capital assets | | 46,303 | | 58,654 | | 85,013 | | (12,351) | (21.1) |
| Restricted | | 46,938 | | 29,012 | | 12,314 | | 17,926 | 61.8 |
| Unrestricted | | (374,393) | | (363,833) | | (367,282) | | (10,560) | (2.9) |
| Total net position | | (281,152) | | (276,167) | | (269,955) | | (4,985) | (1.8) |
| Total liabilities, deferred inflows | | | | | | | | | |
| of resources and net position | \$ | 839,045 | \$ | 841,846 | \$ | 991,058 | \$ | (2,801) | (0.3) |

Management's Discussion and Analysis December 31, 2024 (Dollars in Thousands)

Statements of Net Position (Continued)

Comparison of December 31, 2024 to December 31, 2023

Overall, total assets and deferred outflows of resources decreased \$2,801 from 2023 to 2024.

The following variances in total assets are noteworthy:

Total current assets, excluding the current portion of assets whose use is limited, increased by \$13,278 due to the following:

- Cash, cash equivalents and investments increased by \$13,813 due to the receipt of certain disproportionate share (DSH/IGT) payments, increased collections on billed accounts receivable, increased retroactive insurance payer settlements, accumulation of unrestricted investment income, a retrospective reimbursement settlement related to the 340b drug pricing program and the receipt of \$17.3 million of FEMA program reimbursement payments. These inflows were partially offset by management's payment of the New York State Pension Plan contribution as required and ongoing operating vendor and employee payments.
- Patient accounts receivable, net, decreased by \$8,681 due to increased collections efforts through increased staffing levels and successful insurance payer claim settlements achieved during the year. Also decreasing the balance are certain reserves recorded on professional billing accounts receivable as a result of a significant delay in billing due to the February 2024 Change Healthcare cyber attack.
- Other receivables decreased by \$27,715 which is due to a \$28,473 decrease in Medicaid DSH and UPL program receivables as a result of timing of payments, an increase of \$393 in due from third party payors and a \$365 increase in other receivables.

The following variances in non-current assets and deferred outflows of resources are noteworthy:

- Assets whose use is limited, including current portion, increased by a net of \$20,980, which is due to an increase in assets designated for capital and technology projects of \$16,724, gains on investments of \$8,584 offset by a decrease in reserve account funding for actuarial liabilities and other limited use assets of \$4,238.
- Capital assets, net, decreased by \$30,407 due to the shortfall in capital asset investments during 2024 as compared to the ongoing depreciation expense on all capital assets, which is a continued result of reduced cash flow availability. Investments in capital assets are summarized in a following section.
- Deferred outflows of resources decreased \$7,724 due to combined increases in differences between expected and actual actuarial experience offset by decreases in changes in assumptions related to the pension and other post-employment benefits deferred outflows of resources.

Overall, total liabilities and deferred inflows increased \$2,184 and net position decreased \$4,985 from 2023 to 2024.

The following variances in total liabilities are noteworthy:

- Accounts payable and accrued salaries and benefits increased by \$9,550 due to timing of payments to vendors and employees at year-end.
- Accrued other liabilities increased by \$15,538 largely as a result of increases in payor advances of \$13,604 related to the Change Healthcare cyber-attacks and Medicaid DSH and UPL repayment liability of \$9,743 offset by decreases in amounts due to Erie County of \$8,761.

Management's Discussion and Analysis December 31, 2024 (Dollars in Thousands)

Statements of Net Position (Continued)

- Unearned revenue increased by \$5,355 due to investment income accumulation on unearned revenue coupled with an increase in grants restricted for certain purposes.
- The line of credit liability remained unchanged due to borrowings that remain outstanding at December 31, 2024.
- Deferred inflows of resources increased \$58,238 largely as a result of increases in differences between projected and actual investment earnings on pension plan investments.
- The long-term portion of self-insured obligations decreased by \$7,281 due to decreases in actuarial estimates for self-insured retentions for malpractice and workers' compensation claims and payments made on those claims. The current portion of these self-insured obligations decreased by \$410.
- Net pension liability, including current portion, decreased \$43,612 due to changes in actuarial assumptions used to value the plan as of December 31, 2024.
- The liability for Other Post-Employment Benefits (OPEB) decreased by \$15,315 primarily as a result of the favorable impact of a change in actuarial assumptions related to favorable healthcare trend rates and an increase in the discount rate used to measure the obligation.
- Net position decreased by \$4,985 due to unfavorable financial performance related to inflationary
 pressures on operating expenses continuing to outpace increases in patient volume and payor
 reimbursement rates.

Comparison of December 31, 2023 to December 31, 2022

Overall, total assets and deferred outflows of resources decreased \$149,212 from 2022 to 2023. The following variances in total assets are noteworthy:

Total current assets, excluding the current portion of assets whose use is limited, decreased by \$20,611 due to the following:

- Cash, cash equivalents and investments decreased by \$20,029 due to losses from operations and the timing of the annual DSH and Upper Payment Limit (UPL) cash receipts offset by earnings on investments.
- Patient accounts receivable, net, increased by \$18,820 as a result of current year decreases in collections due to an increase in unbilled accounts as a result of staffing shortages and increased patient volumes.
- Other receivables decreased by \$21,822 which is due to a \$21,856 decrease in Medicaid DSH and UPL program receivables, a decrease of \$286 in due from third party payors and a \$320 increase in other receivables.

The following variances in non-current assets are noteworthy:

- Assets whose use is limited, including current portion, increased by a net of \$13,105, which is due to a required deposit of collateral of \$11,015 related to a new line of credit agreement, unrealized gains on investments of \$3,786 and an increase in reserve account funding for actuarial liabilities and other limited use assets of \$2,311, offset by a decrease in assets designated for long-term investment of \$4,007.
- Capital assets, net, decreased by \$46,347 due to the shortfall in capital asset investments during 2023 as compared to the ongoing depreciation expense on all capital assets, which is a continued result of reduced cash flow availability driven by operating losses. Investments in capital assets are summarized in a following section.

Management's Discussion and Analysis December 31, 2024 (Dollars in Thousands)

Statements of Net Position (Continued)

• Net pension asset decreased \$77,538 and was eliminated due to changes in actuarial assumptions, which increased the liability thus creating a net pension liability, which is further discussed in the section below.

Overall, total liabilities and deferred inflows decreased \$143,000 and net position decreased \$6,212 from 2022.

The following variances in total liabilities are noteworthy:

- Accounts payable and accrued salaries and benefits decreased by \$17,339 due to timing of payments to vendors and employees at year-end.
- Accrued other liabilities increased by \$1,908 largely as a result of increases in amounts due to Erie County and third-party payors.
- Unearned revenue decreased by \$22,517 due to a decrease of \$27,000 related to the New York State grant received in late December 2022 for the calendar year 2023, thus recognized during 2023. Other unearned revenue increased \$4,483.
- The line of credit liability remained unchanged due to borrowings that remain outstanding at December 31, 2023.
- The long-term portion of self-insured obligations increased by \$3,238 due to changes in actuarial estimates for self-insured retentions for malpractice and workers' compensation claims greater than payments made on those claims. The current portion of these self-insured obligations decreased by \$148.
- Net pension liability, including current portion, was established at \$198,936 due to changes in actuarial assumptions used to value the plan as of December 31, 2023. As noted above, at December 31, 2022, the Corporation had recorded a net pension asset of \$77,538.
- The liability for Other Post-Employment Benefits (OPEB) increased by \$22,516 primarily as a result of the unfavorable impact of a change in actuarial assumptions related to unfavorable healthcare trend rates and a decrease in the discount rate used to measure the obligation.
- Net position decreased by \$6,212 due to unfavorable financial performance related to inflationary pressures on operating expenses continuing to outpace increases in patient volume and payor reimbursement rates.

Management's Discussion and Analysis December 31, 2024 (Dollars in Thousands)

Statements of Revenues, Expenses and Changes in Net Position

Condensed Statements of Revenues, Expenses and Changes in Net Position are as follows:

| | | | | | | | | 2024-2023 | | | | |
|--|----|-----------|----|-----------|----|-----------|----|------------|----------|--|--|--|
| | | 2024 | | 2023 | | 2022 | 9 | Change | % Change | | | |
| Net patient service revenue | \$ | 656,228 | \$ | 603,720 | \$ | 566,389 | \$ | 52,508 | 8.7 | | | |
| Disproportionate share (DSH) revenue | | 164,953 | | 107,105 | | 68,295 | | 57,848 | 54.0 | | | |
| Other operating revenue | | 72,133 | | 46,639 | | 26,095 | | 25,494 | 54.7 | | | |
| Total operating revenues | | 893,314 | | 757,464 | | 660,779 | | 135,850 | 17.9 | | | |
| Operating expenses: | | | | | | | | | | | | |
| Payroll and employee benefits | | 463,302 | | 440,770 | | 410,664 | | 22,532 | 5.1 | | | |
| Professional fees | | 112,289 | | 110,577 | | 109,113 | | 1,712 | 1.5 | | | |
| Purchased services | | 72,027 | | 81,712 | | 78,037 | | (9,685) | (11.9) | | | |
| Supplies | | 153,120 | | 132,197 | | 117,877 | | 20,923 | 15.8 | | | |
| Other operating expenses | | 26,769 | | 30,529 | | 29,185 | | (3,760) | (12.3) | | | |
| Depreciation and amortization | | 47,115 | Dr | 49,812 |)0 | 49,872 | | (2,697) | (5.4) | | | |
| Total operating expenses | 5 | 874,622 | 1 | 845,597 | 7 | 794,748 | | 29,025 | 3.4 | | | |
| Operating income (loss) before pension | A | J. | M | 1 | | | | | | | | |
| and other post employment expense (benefit), | | | | | | | | | | | | |
| amortization components | | 18,692 | | (88,133) | | (133,969) | | 106,825 | 121.2 | | | |
| DEL SE | | Ju C | | 930 | | 300 | | (a. (a.a.) | () | | | |
| Pension expense (benefit), amortization component | | 30,347 | | 39,752 | | (32,537) | | (9,405) | (23.7) | | | |
| OPEB expense (benefit), amortization component | E | 6,072 | - | (20,424) | | (29,861) | | 26,496 | (129.7) | | | |
| Operating loss | | (17,727) | | (107,461) | | (71,571) | | 89,734 | 83.5 | | | |
| Non-operating revenues (expenses): Investment gain (loss) Grant revenue and capital contribution | | | | | | | | | | | | |
| Investment gain (loss) | | 7,411 | | 6,283 | | (13,966) | | 1,128 | 18.0 | | | |
| Grant revenue and capital contribution | | 17,352 | | 107,230 | | 63,151 | | (89,878) | (83.8) | | | |
| Interest expense | | (12,021) | | (12,264) | | (12,028) | | 243 | 2.0 | | | |
| Total change in net position | | (4,985) | | (6,212) | | (34,414) | | 1,227 | 19.8 | | | |
| Net position—beginning of year | | (276,167) | | (269,955) | | (235,541) | | (6,212) | (2.3) | | | |
| Net position—end of year | \$ | (281,152) | \$ | (276,167) | \$ | (269,955) | \$ | (4,985) | (1.8) | | | |

Comparison of December 31, 2024 to December 31, 2023

Overall, total operating revenues increased by \$135,850 or 17.9% in 2024 with changes attributable to the following:

- Net patient service revenue increased \$52,508, or 8.7%, in 2024 as a result of a combination of overall increased patient volumes, an increase in contracted reimbursement rates and revenue cycle improvements. Provisions for bad debts increased by \$8,067 due to reserves recorded related to the Change Healthcare cyber attack as further described in Note 4.
- DSH revenue increased by \$57,848, or 54.0%, in 2024 as a result of a decrease in the nursing home upper payment limit of \$607 due to a slight decrease in the pool size in the State Plan Amendment and a \$58,455 increase in federal DSH due to an increase in uncompensated care as a result of volume growth, and continued cost inflation exceeding increases in reimbursements from the Medicaid program.
- Other operating revenue increased \$25,494, or 54.7% primarily due to growth in specialty pharmacy operations of \$20,620, an increase in third-party quality incentives of \$2,553 and an increase in grant revenue of \$1,826.

Management's Discussion and Analysis December 31, 2024 (Dollars in Thousands)

Statements of Revenues, Expenses and Changes in Net Position (Continued)

Total operating expenses including pension expense/benefit and other post-employment benefit expenses increased \$46,116 or 5.3% in 2024. Expense changes are attributable to the following:

- Payroll and employee benefit expenses have increased by \$22,532 or 5.1% as a result of contracted rate and step increases as well as necessary additional pay incentives offered to fill open shifts to meet New York State minimum staffing standards for both the hospital and the skilled nursing facility. Salaries and employee benefit expense as a percent of net patient service revenue decreased by 2.4%, from 73.0% in 2023 to 70.6% in 2024.
- Purchased services have decreased \$9,685 as a result of a nonrecurring expense during 2023 of \$11,239 to write-off an abandoned IT capital related project. The remaining variance is due to an increase in contract labor of \$2,058 due to staffing shortages.
- Pension expense decreased by \$1,074 as a result of changes in actuarial assumptions used to value the plan including investment returns and other demographic assumptions offset by an increase in our proportionate share of that expense.
- Supplies expense increased by \$20,923 or 15.8% as a result of increased surgical volume, significant growth in volume within the specialty pharmacy operations, pharmaceutical cost increases related to drug shortages and continued cost inflation on medical supplies.
- OPEB benefit decreased \$7,117 or 36.8% as a result of unfavorable differences between projected and actual experience of net claims cost and benefit payments made under the plan.

Comparison of December 31, 2023 to December 31, 2022

Overall, total operating revenues increased by \$96,685 or 14.6% in 2023 with changes attributable to the following:

- Net patient service revenue increased \$37,331, or 6.6%, in 2023 as a result of a combination of
 overall increased patient volumes, an increase in contracted reimbursement rates, improvements in
 bad debt write-offs and improvements in ECMCC's ability to discharge patients into the community.
- DSH revenue increased by \$38,810, or 56.8%, in 2023 as a result of an increase in the nursing home upper payment limit of \$5,885 due to a significant increase in the pool size in the State Plan Amendment and a \$32,925 increase in federal DSH due to an increase in uncompensated care net of anticipated formula changes in the Medicaid DSH cap calculation enacted through legislation but not yet implemented which will exclude costs from services provided to Medicaid-eligible beneficiaries who are dually eligible for Medicare or any other coverage.
- Other operating revenue increased \$20,544, or 78.7% due to an increase in specialty pharmacy operations of \$20,777.

Total operating expenses including pension expense/benefit and other post-employment benefit expenses increased \$132,575 or 18.1% in 2023. Expense changes are attributable to the following:

- Payroll and employee benefit expenses have increased by \$30,106 or 7.3% as a result of increases in salaries due to new collective bargaining agreements' market rate adjustments and additional pay incentives offered to fill open shifts to meet New York State minimum staffing standards for both the hospital and the skilled nursing facility. Salaries and employee benefit expense as a percent of net patient service revenue increased by 0.5%, from 72.5% in 2022 to 73.0% in 2023.
- Pension expense increased by \$65,834 as a result of changes in actuarial assumptions used to value the plan including investment returns, discount rates and other demographic assumptions.

Management's Discussion and Analysis December 31, 2024 (Dollars in Thousands)

Statements of Revenues, Expenses and Changes in Net Position (Continued)

- Supplies expense increased by \$14,320 or 12.1% as a result of increased surgical volume, increased volume within the specialty pharmacy operations and pharmaceutical cost increases related to drug shortages.
- OPEB benefit decreased \$11,976 or 38.2% as a result of unfavorable differences between projected and actual experience of net claims cost and benefit payment made to current employees.

Capital Assets, Net

At December 31, 2024, the Corporation had capital assets, including lease and subscription-based information technology arrangement assets (SBITAs), net of accumulated depreciation of \$282,632 compared to \$313,039 at December 31, 2023, representing a decrease of \$30,407 or 9.7%.

During 2024, the Corporation invested \$16,805 in various capital assets (\$6,375), leases (\$2,887) and SBITAs (\$7,543). Noteworthy investments in capital assets include infusion pumps and related software (\$2,222) and purchases of other medical and non-medical equipment, furniture and fixtures, and information systems infrastructure investments. Noteworthy additions to capital leases include mobile x-ray system (\$794) and other various leased medical and non-medical equipment. Noteworthy additions to SBITAs includes a new payroll software system (\$3,261) and other medical and non-medical and non-medical equipment. Noteworthy additions to SBITAs includes a new payroll software system (\$3,261) and other medical and non-medical software. GASB Statement No. 87, *Leases*, establishes the foundational principle that leases are financing of the right-to-use an underlying asset for a period of time. The Corporation recorded lease assets, net of accumulated depreciation, in the amount of \$22,797 and \$26,371 in 2024 and 2023, respectively. GASB Statement No. 96, *Subscription-Based Information Technology Arrangements*, extends the right-of-use accounting concepts introduced in GASB Statement No. 87, *Leases*, to SBITAs. The Corporation recorded SBITA assets in the amount of \$22,322 in 2024 and \$25,761 in 2023.

Forward-Looking Factors

Management has prepared the following forward-looking factors to assist the reader in understanding the financial, economic and market factors impacting the Corporation:

Collective Bargaining Agreements

The Corporation operates under three collective bargaining agreements that cover substantially all employees. Corporation employees of the Civil Service Employee Association (CSEA) are covered by a contract negotiated in concert with Erie County, New York, which contains a sub-bargaining unit representing only Corporation employees. The agreement began January 1, 2023 and runs through December 31, 2027. Registered Nurses (RNs) are covered under an agreement with the New York State Nurses Association (NYSNA). This agreement began January 1, 2023 that runs through December 31, 2027. The Corporation's agreement with the American Federation of State, County and Municipal Employees (AFSCME), a contract negotiated in concert with the County of Erie, New York, and ratified with AFSCME employees in 2022 runs through December 31, 2026.

Transactions with the County of Erie

The Corporation is a component unit of the County of Erie, New York. The County has ongoing contractual and legal obligations to the Corporation and the Corporation has ongoing contractual and legal obligations to the County.

Management's Discussion and Analysis December 31, 2024 (Dollars in Thousands)

Medicare and Medicaid Reimbursement

The future state of both reimbursement levels and reimbursement methods related to the Medicare and Medicaid programs remains uncertain. Unimplemented formulaic changes as well as budget proposals related to both of these programs for the upcoming year and beyond may significantly alter reimbursements or methodologies, thus changing the environment in which we conduct business as the Corporation relies heavily on these programs for reimbursement for services. The impact of these state and federal rule changes and budget proposals are unknown at this time but could materially impact the Corporation.

Contacting the Corporation's Financial Management

This financial report is designed to provide our community and creditors with a general overview of Erie County Medical Center Corporation's finances and to demonstrate the Corporation's accountability for the resources it receives. If you have any questions about this report or need additional financial information. contact the Chief Financial Officer, Erie County Medical Center Corporation, 462 Grider Street, Buffalo, New York 14215.

inor in a the final in the fina

Statements of Net Position December 31, 2024 and 2023 (Dollars in Thousands)

| | 2024 | 2023 |
|--|----------------------|-----------|
| Assets and Deferred Outflows of Resources | | |
| Current assets: | | |
| Cash and cash equivalents | \$ 34,586 \$ | 20,773 |
| Investments | 42,825 | 10,646 |
| Assets whose use is limited | 84,714 | 113,986 |
| Patient accounts receivable, net | 93,708 | 102,389 |
| Other receivables | 12,893 | 40,608 |
| Supplies, prepaids and other | 19,082 | 15,400 |
| Total current assets | 287,808 | 303,802 |
| | 201,000 | 303,002 |
| ssets whose use is limited | 106,887 | 56,635 |
| apital assets, net | 282,632 | 313,039 |
| ther assets, net | 9,978 | 8,906 |
| | 399,497 | 378,580 |
| Tatel seasts | | 602.202 |
| Total assets | 687,305 | 682,382 |
| Deferred outflows of resources: | | |
| Pension | 121,188 | 123,115 |
| Other post employment benefits | 21,151 | 25,670 |
| Other | 9,401 | 10,679 |
| Total deferred outflows of resources | 151,740 | 159,464 |
| | e. | , |
| Total assets and deferred outflows of resources | <u>\$ 839,045 \$</u> | 841,846 |
| internation of Provide | | |
| iabilities, Deferred Inflows of Resources and Net Position urrent liabilities: Current portion of long-term debt Line of credit Current portion of lease and SBITA liability Accounts payable Accrued salaries, wages and employee benefits Net pension liability Other post employment benefits Accrued other liabilities Unearned revenue | | |
| urrent liabilities: | 0.1 | |
| Current portion of long-term debt | \$ 12,755 \$ | 12,128 |
| Line of credit | 10,000 | 10,000 |
| Current portion of lease and SBITA liability | 15,147 | 16,409 |
| Accounts payable | 64,579 | 59,927 |
| Accrued salaries, wages and employee benefits | 44,501 | 39,603 |
| Net pension liability | 41,138 | 34,131 |
| Other post employment benefits | 12,767 | 12,326 |
| Accrued other liabilities | 57,559 | 42,021 |
| Unearned revenue | 81,157 | 75,802 |
| Total current liabilities | 339,603 | 302,347 |
| | 170 070 | 100 515 |
| ong-term debt, net | 179,372 | 190,515 |
| ong-term lease and SBITA liability, net | 27,805 | 34,682 |
| let pension liability, net of current portion | 114,186 | 164,805 |
| elf-insured obligations | 44,840 | 52,121 |
| ther post employment benefits, net of current portion | 265,829 | 281,585 |
| ther | 5,584 | 7,218 |
| Total liabilities | 977,219 | 1,033,273 |
| eferred inflows of resources: | | |
| eterred inflows of resources: Pension | 95,637 | 23,737 |
| Other post employment benefits | 45,778 | 59,337 |
| Leases | 45,776 | 1,666 |
| Total deferred inflows of resources | 142,978 | 84,740 |
| | | |
| et Position: | 46.000 | E0.054 |
| et investment in capital assets | 46,303 | 58,654 |
| estricted: | | 00 - 1- |
| Expendable | 46,938 | 29,012 |
| nrestricted | (374,393) | (363,833 |
| Total net position | (281,152) | (276,167) |
| Total liabilities, deferred inflows of resources and net position | \$ 839,045 \$ | 841,846 |
| | 000,010 V | 0.1,040 |

Statements of Revenues, Expenses and Changes in Net Position Years Ended December 31, 2024 and 2023 (Dollars in Thousands)

| | 2024 | 2023 |
|---|--------------|--------------|
| Operating revenues: | | |
| Net patient service revenue, net of provision for | \$ 656,228 | \$ 603,720 |
| bad debts of \$12,663 and \$4,596 for 2024 and 2023, respectively | | |
| Disproportionate share revenue (DSH) | 164,953 | 107,105 |
| Other operating revenue | 72,133 | 46,639 |
| Total operating revenues | 893,314 | 757,464 |
| Operating expenses: | | |
| Payroll and employee benefits | 463,302 | 440,770 |
| Professional fees | 112,289 | 110,577 |
| Purchased services | 72,027 | 81,712 |
| Supplies | 153,120 | 132,197 |
| Other operating expenses | 26,769 | 30,529 |
| Depreciation and amortization | 47,115 | 49,812 |
| Total operating expenses | 874,622 | 845,597 |
| Operating income (loss) before pension benefit and other | | |
| post employment benefits amortization components | 18,692 | (88,133) |
| Pension expense, amortization component | 30,347 | 39,752 |
| OPEB expense (benefit), amortization component | 6,072 | (20,424) |
| OPEB expense (benefit), amortization component Operating loss | (17,727) | (107,461) |
| Nonoperating revenues (expenses): | | |
| Investment gain | 7,411 | 6,283 |
| Grant revenue | 17,333 | 107,230 |
| Interest expense | (12,021) | (12,264) |
| Total nonoperating revenues | 12,723 | 101,249 |
| Loss before capital contributions | (5,004) | (6,212) |
| Capital contributions | 19 | - |
| Total change in net position | (4,985) | (6,212) |
| Net position—beginning of year | (276,167) | (269,955) |
| Net position—end of year | \$ (281,152) | \$ (276,167) |

Statements of Cash Flows Years Ended December 31, 2024 and 2023 (Dollars in Thousands)

| | | 2024 | 2023 |
|---|----|-----------|---------------|
| Cash flows from operating activities: | | | |
| Receipts from patients and third-party payors | \$ | 691,467 | \$ 608,472 |
| Payments to employees for salaries and benefits | | (422,231) | (415,584) |
| Payments to vendors for supplies and other | | (345,921) | (354,111) |
| Other receipts | | 171,416 | 119,572 |
| Net cash provided by (used in) operating activities | | 94,731 | (41,651) |
| Cash flows from capital and related financing activities: | | | |
| Purchases of capital assets | | (12,551) | (12,554) |
| Payments on long-term debt | | (12,255) | (11,714) |
| Interest paid on long-term debt | | (9,797) | (10,264) |
| Payments on leases and SBITAs | | (15,676) | (15,253) |
| Interest paid on leases and SBITAs | | (2,224) | (2,000) |
| Net cash used in capital and related financing activities | 1 | (52,503) | (51,785) |
| Cash flows from noncapital financing activities: | 3 | | |
| Grant funding | | 17,333 | 80,229 |
| Net cash provided by noncapital financing activities | | 17,333 | 80,229 |
| | | · | · |
| Cash flows from investing activities: | | | |
| Purchases of assets whose use is limited, net | | (20,980) | (13,105) |
| Investment gain | | 7,411 | 6,283 |
| Purchases of investments, net | | (32,179) | (3,393) |
| Net cash used in investing activities | | (45,748) | (10,215) |
| Net change in cash and cash equivalents | | 13,813 | (23,422) |
| Cash and cash equivalents: | | | |
| Beginning | | 20,773 | 44,195 |
| Ending | \$ | 34,586 | \$ 20,773 |

Noncash capital and related financing activities:

Included in accounts payable at December 31, 2024 and 2023, was \$624 and \$1,357, respectively, of invoices related to capital asset acquisitions.

(Continued)

Statements of Cash Flows (Continued) Years Ended December 31, 2024 and 2023 (Dollars in Thousands)

| | 2024 | 2023 |
|---|-------------------|-----------|
| Reconciliation of operating loss to net cash | | |
| provided by (used in) operating activities: | | |
| Operating loss | \$ (17,727) \$ | (107,461) |
| Adjustments to reconcile operating loss to net cash | | |
| used in operating activities: | | |
| Depreciation and amortization | 47,115 | 49,812 |
| Provision for bad debts | 12,663 | 4,596 |
| Changes in assets, deferred outflows, liabilities and deferred inflows: | | |
| Patient accounts receivable | (3,982) | (23,416) |
| Other receivables | 27,715 | 21,822 |
| Supplies, prepaids and other | (4,754) | (3,546) |
| Deferred outflows of resources | 7,724 | 18,947 |
| Accounts payable | 9,313 | (4,634) |
| Accrued liabilities | 20,436 | 5,468 |
| Unearned revenue | 5,355 | 4,484 |
| Estimated third-party payor settlements | (1,157) | 1,750 |
| Self-insured obligations | (7,281) | 3,238 |
| Net pension liability | (43,612) | 276,474 |
| OPEB CI CONTO | (15,315) | 22,516 |
| Deferred inflows of resources | 58,238 | (311,701) |
| Net cash provided by (used in) operating activities | \$ 94,731 \$ | (41,651) |

Statements of Net Position—Discretely Presented Component Units December 31, 2024 and 2023 (Dollars in Thousands)

| | | | | 2 | 2024 | | 2023 | | | | | | | | | |
|------------------------------------|------|--------------|--------|------------------|----------------|-----------------|-----------|----------|--------|-------------|--------|-----------------|--------------|-------------|-----------|--------|
| | | | | The | R | esearch for | | | | | | The | Research for | | | |
| | | ЕСМС | Grider | | er Health in A | | Aggregate | | CMC | | Grider | ł | Health in | | Aggregate | |
| | Foun | dation, Inc. | | Initiative, Inc. | Erie | County, Inc. * | | Total | Founda | ation, Inc. | lr | nitiative, Inc. | Erie | County, Inc | | Total |
| Assets | | | | | | | | | | | | | | | | |
| Current assets: | | | | | | | | | | | | | | | | |
| Cash and cash equivalents | \$ | 2,239 | \$ | 270 | \$ | - | \$ | 2,509 | \$ | 2,365 | \$ | 270 | \$ | - | \$ | 2,635 |
| Investments | | - | | - | | - | | O' | | - | | - | | - | | - |
| Other receivables | | 1,235 | | - | | - | | 1,235 | | 938 | | - | | - | | 938 |
| Supplies, prepaids and other | | 13 | | - | | DEN | 5- | 13 | | 259 | | - | | - | | 259 |
| Total current assets | | 3,487 | | 270 | | BA P - | DUI | 3,757 | | 3,562 | | 270 | | - | | 3,832 |
| Other receivables | | | | | | | | | | 887 | | | | | | 887 |
| | | - 4,005 | | 9,898 | | ISSIC- | | - | | | | - | | - | | |
| Endowment and other investments | | , | | 9,090 | | Chie Chi | | 6013,903 | | 3,129 | | 9,962 | | - | | 13,091 |
| Equipment and vehicles, net | | - | | P | DIS | - 40 | <u>dr</u> | - | | - | | - | | - | | - |
| | | 4,005 | | 9,898 | 1 4 6 | CH L | 00 | 13,903 | | 4,016 | | 9,962 | | - | | 13,978 |
| Total assets | \$ | 7,492 | \$ | 10,168 | \$ | RIGH | \$ | 17,660 | \$ | 7,578 | \$ | 10,232 | \$ | | \$ | 17,810 |
| Liabilities and Net Position | | | | | | | | | | | | | | | | |
| Current liabilities: | | | | | | | | | | | | | | | | |
| Accounts payable | \$ | 257 | \$ | - | \$ | - | \$ | 257 | \$ | 11 | \$ | - | \$ | - | \$ | 11 |
| Funds held in custody for others | • | 897 | • | - | • | - | • | 897 | + | 596 | • | - | Ŧ | - | • | 596 |
| Total current liabilities | | 1,154 | | - | | - | | 1,154 | | 607 | | - | | - | | 607 |
| Long-term liabilities: | | | | | | | | | | | | | | | | |
| Related party | | - | | - | | - | | - | | 969 | | - | | - | | 969 |
| Unearned revenue | 1 | 309 | | - | | - | | 309 | | 335 | | - | | - | | 335 |
| Total liabilities | | 1,463 | | - | | - | | 1,463 | | 1,911 | | - | | - | | 1,911 |
| Net Position | | | | | | | | | | | | | | | | |
| Restricted: | | | | | | | | | | | | | | | | |
| Nonexpendable | | 50 | | 10,000 | | - | | 10,050 | | 50 | | 10,000 | | - | | 10,050 |
| Expendable | | 3,078 | | 168 | | - | | 3,246 | | 2,634 | | 232 | | - | | 2,866 |
| Unrestricted | | 2,901 | | - | | - | | 2,901 | | 2,983 | | | | - | | 2,983 |
| Total net position | | 6,029 | | 10,168 | | - | | 16,197 | | 5,667 | | 10,232 | | - | | 15,899 |
| Total liabilities and net position | \$ | 7,492 | \$ | 10,168 | \$ | | \$ | 17,660 | \$ | 7,578 | \$ | 10,232 | \$ | - | \$ | 17,810 |

* - Activity related to the Reseach for Health in Erie County, Inc. is included within the ECMC Foundation, Inc. financial statements since the entity was merged into the ECMC Foundation, Inc. in 2023.

Statements of Revenues, Expenses and Changes in Net Position—Discretely Presented Component Units Years Ended December 31, 2024 and 2023

(Dollars in Thousands)

| | | | | 20 | 024 | | | | 2023 | | | | | | | | | | |
|--|-------|------------------|--------|---------------|-------------|----------|-------|------------------------------|------|---------------|-------|-------------|--------------|----------------|----|----------|--|--|--|
| | | The Research for | | | | | | | | | The | | Research for | | | | | | |
| | E | СМС | Grider | | Health in | | Α | Aggregate | | ECMC | | Grider | | Health in | A | ggregate | | | |
| | Found | lation, Inc. | Ini | tiative, Inc. | Erie County | , Inc. * | | Total | Fou | ndation, Inc. | Initi | ative, Inc. | Erie | e County, Inc. | | Total | | | |
| Operating revenues: | | | | | | | | | | | | | | | | | | | |
| Grants, contributions and special events | \$ | 3,754 | \$ | - | \$ | - | \$ | 3,754 | \$ | 4,732 | \$ | - | \$ | - | \$ | 4,732 | | | |
| Total operating revenues | | 3,754 | | - | | - | | 3,754 | 112 | 4,732 | | - | | - | | 4,732 | | | |
| Operating expenses: | | | | | | | | | | | | | | | | | | | |
| Program services and grants | | 697 | | 500 | | | | 1,197 | | 970 | | - | | 1,107 | | 2,077 | | | |
| Fundraising | | 1,815 | | - | | off V | | 1,815 | | 1,640 | | - | | - | | 1,640 | | | |
| Other operating expenses | | 941 | | Mr. | MIN RSI | <u> </u> | Q | <u> </u> | | 641 | | - | | - | | 641 | | | |
| Total operating expenses | | 3,453 | | 500 | AGGUIE (| Cl Agen | - AC | 9 ⁰⁰ 3,953 | | 3,251 | | - | | 1,107 | | 4,358 | | | |
| Operating income (loss) | | 301 | 0 | (500) | | spro | glore | (199) | | 1,481 | | - | | (1,107) | | 374 | | | |
| Nonoperating revenue: | | | | | | | | | | | | | | | | | | | |
| Investment income (loss) | | 61 | | 436 | | - | | 497 | | 127 | | 385 | | 13 | | 525 | | | |
| | | 10. | | Mac | | | | | | | | | | | | | | | |
| Change in net position | | 362 | | (64) | | - | | 298 | | 1,608 | | 385 | | (1,094) | | 899 | | | |
| Net position—beginning of year | | 5,667 | | 10,232 | | - | | 15,899 | | 4,059 | | 9,847 | | 1,094 | | 15,000 | | | |
| Net position—end of year | \$ | 6,029 | \$ | 10,168 | \$ | - | \$ | 16,197 | \$ | 5,667 | \$ | 10,232 | \$ | - | \$ | 15,899 | | | |

* - Activity related to the Reseach for Health in Erie County, Inc. is included within the ECMC Foundation, Inc. financial statements since the entity was merged into the ECMC Foundation, Inc. in 2023.

Notes to the Financial Statements Year Ended December 31, 2024 (Dollars in Thousands)

Note 1. Organization

The Corporation: Erie County Medical Center Corporation (referred to as the Corporation or ECMCC) is a public benefit corporation created by the Erie County Medical Center Corporation Act, Chapter 143 of the Laws of New York State, 2003 (Title 6 of Article 10-C of the Public Authorities Law) (the Act) as amended in 2016. The Corporation was created under the Act to secure a form of governance which permits the Corporation to have the legal, financial, and managerial flexibility to operate its health care facilities for the benefit of the residents of New York State (the State), the County of Erie (the County), and Western New York, including persons in need who lack the ability to pay.

The Corporation's "Health Care Facilities" consist of the Medical Center, a 573-bed acute tertiary care facility providing inpatient, emergency, outpatient, primary care and specialty clinic services (Medical Center), a 390-bed residential health care facility (Terrace View) both located on Grider Street in the City of Buffalo and three chemical dependency and alcohol rehabilitation clinics located throughout the County. The Medical Center serves as the region's only Level 1 Adult Trauma Center, burn center, comprehensive traumatic brain injury and spinal cord injury rehabilitative center, Comprehensive Psychiatric Emergency Program provider for acute psychiatric emergencies, Regional Center of Excellence for Transplantation and Kidney Care.

The Corporation has the power under the Act to acquire, operate, and manage its facilities and to issue bonds and notes to finance the costs of providing such facilities. The Act specifically provides that the Corporation's existence shall continue until terminated by law; provided, however, that no such termination shall take effect so long as the Corporation shall have bonds or other obligations outstanding unless adequate provision has been made for the payment or satisfaction thereof. The Corporation's primary purpose is the operation of the Medical Center and Terrace View, and its powers, duties and functions are as set forth in the Act, as amended, and other applicable laws.

The Corporation qualifies as a governmental entity and, accordingly, is exempt from federal income tax pursuant to Section 115 of the Internal Revenue Code of 1986.

In accordance with Governmental Accounting Standards Board (GASB) Statement No. 14, *The Financial Reporting Entity*, as amended, the Corporation's financial statements are included, as a discretely presented component unit, in the County's Annual Comprehensive Financial Report (ACFR). A copy of the ACFR can be obtained from the Erie County Comptroller's Office, 95 Franklin Street, Room 1100, Buffalo, New York 14202. The Corporation is subject to New York civil service law.

Governance: The Corporation is governed by its Board of Directors (the Board) consisting of fifteen (15) voting directors, eight (8) of whom are appointed by the Governor of the State of New York and seven (7) of whom are appointed by the Erie County Executive with the advice and consent of the Erie County Legislature. There are four non-voting representatives, as well. The directors and non-voting members serve staggered terms and continue to hold office until their successors are appointed. Directors have experience in the fields of health care services, quality and patient safety, human resources, strategic growth, law, and financial management and reflect a broad representation of the community served by the Corporation. Regular meetings of the Board are scheduled eleven (11) times per year. Board leaders are appointed by the Board.

Notes to the Financial Statements Year Ended December 31, 2024 (Dollars in Thousands)

Note 1. Organization (Continued)

Great Lakes Heath System: The Corporation is a member of Great Lakes Health System of Western New York (Great Lakes). Great Lakes is a not-for-profit, community-based corporation comprised of unified partners whose objective is to provide the highest quality of healthcare to the residents of Western New York. Great Lakes is comprised of the Corporation, Kaleida Health (KH), The Center for Hospice and Palliative Care and the State University of New York at Buffalo (the University).

Great Lakes Health Integrated Network: The Corporation, together with KH has formed Great Lakes Health Integrated Network (GLIN) with each maintaining a 50% ownership interest. As of December 31, 2024 and 2023, capital contributions due to GLIN totaled \$393 and \$326, respectively. Contributions are used to pay for care coordination services, information systems infrastructure and routine operating expenses to support community population health management.

Medical School Collaboration: The Corporation serves as a primary teaching hospital for the Jacobs School of Medicine and Biomedical Sciences of the State University of New York at Buffalo (the Medical School). An agreement governs the relationship between the Corporation and the Medical School. The Corporation serves as an integral part of the education and research mission of the Medical School by providing the clinical settings for the Medical School's public mission to educate and train physicians, nurses and other healthcare professionals, conduct clinical research programs and deliver healthcare services to patients. There are currently 187 full-time equivalent medical residents assigned to the Corporation in various Academic College of Graduate Medical Education accredited residency programs.

Component Units: Accounting principles generally accepted in the United States of America (U.S. GAAP) require the inclusion within the Corporation's financial statements of certain organizations as component units. The component units discussed below are included because the nature and significance of their relationship to the Corporation are such that exclusion would cause the reporting entity's financial statements to be misleading or incomplete under criteria set forth by the GASB.

The component unit information in the accompanying basic financial statements includes the financial data of the Corporation's three discretely presented component units. The three discretely presented component units are discussed in more detail below:

ECMC Foundation, Inc.: The ECMC Foundation, Inc. (the Foundation) is a not-for-profit organization exempt from federal income taxes under Section 501(c)(3) of the Internal Revenue Code (IRC). The Foundation was formed for the purpose of supporting Corporation programs. The financial statements of the Foundation have been prepared on an accrual basis. The annual financial report can be obtained by writing to: Executive Director, ECMC Foundation, Inc., 462 Grider Street, Buffalo, NY 14215.

The Grider Initiative, Inc.: The Grider Initiative, Inc. (the Physician Endowment) is a not-for-profit organization exempt from federal income taxes under Section 501(c)(3) of the IRC. The Physician Endowment was funded in 2010, for the purpose of recruiting physicians who shall practice on the Grider Street campus of the Corporation. The entity was funded with an initial transfer of \$10,000 from the Corporation. Earnings from the investment of the initial transfer may be used only for physician recruitment and retention and necessary expenses of the entity. The financial statements of The Grider Initiative, Inc. have been prepared on an accrual basis. The annual financial report can be obtained by writing to: Chair, The Grider Initiative, Inc. 462 Grider Street, Buffalo, NY 14215.

Notes to the Financial Statements Year Ended December 31, 2024 (Dollars in Thousands)

Note 1. Organization (Continued)

Research for Health in Erie County, Inc.: Research for Health in Erie County, Inc. (RHEC) was a not-for-profit organization dedicated to supporting research activities relating to the causes, nature, and treatment of diseases, disorders, and defects of particular importance to the public health in areas served by the Corporation. During 2023, RHEC was dissolved and the remaining net assets were contributed to the ECMC Foundation in order for ECMC Foundation to carry out the original RHEC mission.

In addition, the financial statements of the Corporation include the operations of the following component units, which are blended with the accounts of the Corporation:

PPC Strategic Services LLC (PPC): The Corporation is the sole owner of this enterprise, which was established to enable the Corporation to enter into various other business relationships.

Grider Support Services, LLC: The Corporation is the sole owner of this enterprise, which was formed to act as an MSO for physician practice services, which includes providing employees, management and administrative services.

Grider Community Gardens, LLC: This entity is wholly owned and controlled by the Corporation and was formed for the purpose of purchasing and holding properties in proximity to the Corporation's Grider Street Campus.

1827 *Fillmore, LLC:* This entity is controlled by the Corporation and was formed for the purchase and development of property immediately adjacent to the Corporation's Grider Street campus.

Note 2. Summary of Significant Accounting Policies

Basis of accounting: The Corporation uses the accrual basis of accounting. Revenue is recognized in the period it is earned and expenses are recognized in the period incurred. Under this basis of accounting, all assets, deferred outflows of resources, liabilities and deferred inflows of resources associated with the operation of the Corporation are included in the statements of net position.

For financial accounting and reporting purposes, the Corporation follows all pronouncements of the GASB. All references to relevant authoritative literature issued by the GASB with which the Corporation must comply are hereinafter referred to generally as U.S. GAAP. The discretely presented component units, as previously described, report under Financial Accounting Standards Board (FASB) standards. As such, certain revenue recognition criteria and presentation features are different from GASB revenue recognition criteria and presentation features.

Use of estimates: The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. The reserve for uncollectible accounts, contractual allowances, estimated third-party payor settlements, workers compensation reserves, malpractice reserves, net pension obligations, other post-employment benefit obligations, self-insured obligations, as well as, Disproportionate Share (DSH) revenue and certain other accounts, require the use of estimates. Actual results could differ from those estimates.

Notes to the Financial Statements Year Ended December 31, 2024 (Dollars in Thousands)

Note 2. Summary of Significant Accounting Policies (Continued)

Included in net patient service revenue are adjustments to prior year estimated third-party payor settlements, and their related estimated receivables and payables that were originally recorded in the period the related services were rendered, as well as adjustments to the net realization rate for collections on patient accounts receivable. These adjustments are made in the normal course of operations and amounts reported are consistent with the approach in prior years. The adjustments to prior year estimates and other third-party reimbursement or recoveries that relate to prior years also impact DSH revenues as discussed in Note 5. The combined effect of changes related to prior years' estimates resulted in an increase of \$3,508 and \$5,472 in total operating revenues for the years ended December 31, 2024 and 2023, respectively.

Cash and cash equivalents: The Corporation's cash and cash equivalents include cash on hand and cash in checking and money market accounts as well as investments with a maturity of three months or less when purchased. Cash and cash equivalents designated for long-term purposes or received with donor-imposed restrictions limiting their use to long-term purposes are not considered cash and cash equivalents for purposes of the statements of cash flows. Monies deposited in Federal Deposit Insurance Corporation (FDIC) insured commercial banks are collateralized with specifically designated securities held by a pledging financial institution, as required by State regulations.

Patient accounts receivable: Patient accounts receivable are reported net of both an estimated allowance for contractual adjustments and an estimated allowance for uncollectible accounts. The contractual adjustments represent the difference between established billing rates and estimated reimbursement from Medicare, Medicaid and other third-party payor programs. Current operations are charged with an estimated provision for bad debts estimated based on the age of the account, prior experience and any other circumstances which affect collectability. The Corporation's policy does not require collateral or other security for patient accounts receivable and the Corporation routinely accepts assignment of, or is otherwise entitled to receive, patient benefits payable under health insurance programs, plans or policies. The allowance for estimated doubtful accounts at December 31, 2024 and 2023 was approximately \$72,469 and \$64,577, respectively.

Investments and assets whose use is limited: The Corporation generally records its investments at fair value. Such assets are comprised of cash and cash equivalents, including money market funds, fixed income securities, commercial paper and equity funds. Assets classified as investments are unrestricted. Assets classified as limited as to use are restricted under Board designation or terms of agreements with third parties and include debt service funds, funds for self-insured workers' compensation costs and medical malpractice costs, collateral for insured workers' compensation programs, patient and resident monies, funding for future retiree health costs, and funds limited as to use for the acquisition of property, plant, equipment and information technology.

Investment securities are exposed to various risks, such as interest rate, market and credit risk. Due to the level of risk associated with certain investment securities and the level of uncertainty related to changes in the fair value of investment securities, it is at least possible that changes in risks in the near term could materially affect the net position of ECMCC.

Notes to the Financial Statements Year Ended December 31, 2024 (Dollars in Thousands)

Note 2. Summary of Significant Accounting Policies (Continued)

Other receivables: The composition of other receivables, as of December 31 is as follows:

| | 2024 | | 2023 | |
|--|--------------|-----|--------|--|
| DSH and Upper Payment Limit (UPL) (Note 5) | \$ - | \$ | 28.473 | |
| Due from affiliated organizations and joint ventures | 867 | · | 1,233 | |
| Due from third-party payors | 7,374 | | 6,980 | |
| Other | 4,652 | | 3,922 | |
| | \$ 12,893 | \$ | 40,608 | |
| | | . 4 | | |

Capital assets: Capital assets are stated at cost. Depreciation is computed under the straight-line method over the estimated useful life of the asset. Estimated useful lives of assets have been established as follows:

| | Years |
|---|------------------------|
| Land and land improvements Buildings and improvements Fixed equipment | 5-25 10-40 10-20 |
| Major movable equipment | 3-20 |

When assets are retired, or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts, and any resulting gain or loss is reflected for the period. Maintenance and repairs are charged to expense as incurred with significant renewals and betterments being capitalized.

Capital assets that are donated (without restriction) are recorded at their fair value as a direct increase to the component of net investment in capital assets.

Deferred outflows of resources: Deferred outflows of resources represent a consumption of net position that applies to a future period(s) and therefore will not be recognized as an outflow of resources (expense) until that time. Deferred outflows of resources consist primarily of unrecognized items not yet charged to pension expense and retiree health expense related to the net pension liability and post-employment benefit obligations, and items related to the 2017 financing transaction as described below, amongst other deferred resources.

The 2017 financing transaction included the payment of points, in the amount of \$17,040 to Erie County associated with the differential in interest rate on the 2017 financing using the credit rating of Erie County and the rate that the Corporation was projected to pay independent of a relationship with Erie County. The points are being amortized on the interest method over the term of the 2017 financing. The unamortized amount of points at December 31, 2024 and 2023, is \$7,650 and \$8,712, respectively. The 2017 financing transaction also included the advance refunding of the 2011 financing, the proceeds of which were used to finance the construction of the Terrace View Nursing Home on the Corporation's campus. The deposit required to the advance refunding escrow was greater than the balance outstanding on the 2011 financing in the amount of \$2,038 and is being amortized on the interest method over the life of the advance refunding component of the transaction. The unamortized portion of this advance refunding at December 31, 2024 and 2023 is \$485 and \$652, respectively.

Notes to the Financial Statements Year Ended December 31, 2024 (Dollars in Thousands)

Note 2. Summary of Significant Accounting Policies (Continued)

Other assets: Ownership interests in various business enterprises amongst other assets are included in the other assets caption in the statements of net position.

Collaborative Care Ventures, LLC (Collaborative Care) was formed in 2014 by ECMCC and KH. Collaborative Care was created as a vehicle for ECMCC and KH to participate in various investments in the future consistent with their missions. At December 31, 2024 and 2023, the Corporation's share of the net assets of Collaborative Care amounted to \$1,351 and \$1,022, respectively.

Great Lakes Health Integrated Network (GLIN) was formed in 2018 by ECMCC and KH. GLIN was formed to support, manage and negotiate value-based contracts and/or risk-based contracts with thirdparty payors for the purpose of managing population health and anticipated payment reform. The Corporation's share of contributed capital supports organizational development and ongoing operations. The Corporation's share of GLIN's profit or loss is recognized as non-operating revenue. At December 31, 2024 and 2023, the Corporation's share of the net assets of GLIN amounted to \$6,283 and \$4,324, respectively.

Leases: The Corporation is a lessee for noncancellable leases of real estate and equipment. The Corporation recognizes a lease liability and an intangible right-to-use lease asset in the financial statements for leases. At the commencement of a lease, the Corporation measures the lease liability at the interest rate charged on the lease, if available, or otherwise discounted using the Corporation's incremental borrowing rate. The lease assets are amortized over the shorter of the lease term or the underlying asset useful life.

The Corporation is also a lessor for noncancellable leases of real estate. The Corporation recognizes a lease receivable and deferred inflow of resources in the financial statements for these leases. At the commencement of the lease, the Corporation measures the lease receivable at the interest rate charged on the lease, if available, or otherwise discounted using the Corporation's incremental borrowing rate.

Subscription Based Information Technology Arrangements (SBITAs): The Corporation recognizes an intangible subscription asset and corresponding subscription liability for its SBITAs. The subscription asset is measured as the subscription liability plus direct costs incurred in implementing the subscription asset. The subscription asset is amortized on a straight-line basis over the shorter of the subscription term or the useful life of the underlying subscription asset. At the subscription commencement, the subscription liability is measured at the present value of payments expected to be made during the subscription term and utilizes the interest rate charged in the SBITA, if available, or otherwise discounted using the Corporation's incremental borrowing rate to calculate the present value of the payments.

Unearned revenue: Unearned revenue represents funds received by the Corporation under certain grant programs that have not yet been earned.

Notes to the Financial Statements Year Ended December 31, 2024 (Dollars in Thousands)

Note 2. Summary of Significant Accounting Policies (Continued)

Compensated absences: The Corporation has accrued liabilities for certain compensated absences earned by its employees, to include vacation, sick, and compensatory time. The Corporation's employees are permitted to accumulate unused vacation and sick leave time up to certain maximum limits. The Corporation accrues the estimated obligation related to vacation pay based on pay rates currently in effect. Sick leave credits, if accumulated above certain prescribed levels, may be the basis of a supplemental payment to employees upon retirement. The Corporation accrues an estimated liability for these estimated terminal payments. These amounts have been included in the statements of net position within the caption accrued salaries, wages and employee benefits. Compensated absences activity for the years ended December 31, is as follows:

| | 2024 | R | 2023 |
|---|-------------|----|----------|
| | | | |
| Accrued compensated absences, beginning of year | \$ 2017,496 | \$ | 15,295 |
| Compensated absences earned | 24,733 | | 24,771 |
| Compensated absences paid out | (24,099) | | (22,570) |
| Accrued compensated absences, end of year | \$ 18,130 | \$ | 17,496 |
| | A A | | |

Deferred inflows of resources: Deferred inflows of resources represent an acquisition of net position that applies to a future period(s) and therefore will not be recognized as an inflow of resources (revenue) until that time. Deferred inflows of resources consist primarily of the unamortized portion of certain items related to the Corporation's pension, other post-employment benefits and the value of leases receivable plus any payments received at or before the commencement of the lease term that relates to future periods.

Net position: Net position is classified into three categories according to external donor restrictions or availability of assets for satisfaction of the Corporation's obligations. The Corporation's net position is described as follows:

Net investment in capital assets: This represents the Corporation's total investment in capital assets, net of accumulated depreciation, and reduced by outstanding debt and deferred inflows and outflows of resources that are attributable to the acquisition, construction or improvement of those assets. To the extent debt has been incurred but not yet expended for capital assets, such amounts are not included as a component of net investment in capital assets.

Restricted: The restricted expendable component of net position consists of constraints placed on net position through external constraints imposed by creditors (such as through debt covenants), grantors, contributors, or laws or regulations of other governments or constraints imposed by law through constitutional provisions or enabling legislation. The restricted nonexpendable component of net position is permanently unavailable for use. The earnings on the nonexpendable net position are classified as restricted expendable.

Unrestricted: This component of net position consists of net position that does not meet the definition of other components of net position described above. These resources are used for transactions relating to the general health care operations of the Corporation and may be used at the discretion of the Board of Directors to meet current expenses for any purpose.

Notes to the Financial Statements Year Ended December 31, 2024 (Dollars in Thousands)

Note 2. Summary of Significant Accounting Policies (Continued)

Net patient service revenue: Net patient service revenue is reported as services are rendered at estimated net realizable amounts, including estimated retroactive revenue adjustments under reimbursement agreements with third-party payors. Estimated settlements under third-party reimbursement agreements are accrued in the period the related services are rendered and adjusted in future periods as final settlements are determined. An estimated provision for bad debts is included in net patient service revenue.

Charity care: The Corporation provides care to patients who meet certain criteria under its charity care policy, without charge or at amounts less than established rates. Because the Corporation does not pursue collection of amounts determined to qualify as charity care, they are not reported as net patient service revenue in the accompanying statements of revenues, expenses and changes in net position. The estimated costs of caring for charity care patients were \$3,944 and \$4,459 for the years ended December 31, 2024 and 2023, respectively. Additionally, the Corporation provided approximately \$4,245 and \$2,397 in discounts to self-pay patients for the years ended December 31, 2024 and 2023, respectively.

Contributions: ECMC Foundation reports gifts or promises to give as restricted contributions when they are received with donor stipulations that limit the use of the donated assets. When the intent of the donor is that the assets are to remain in perpetuity and the Foundation does not have the right to invade the original principal, the assets are reported as restricted net position. When a donor restriction expires, restricted-expendable net positions are released to unrestricted net position. The Foundation conducted a capital campaign to raise funds to support the construction of a new Level 1 Adult Trauma Center, Emergency Department and other capital needs in support of the mission of the Corporation. Pledges receivable associated with this campaign are recorded net of a reserve for uncollectible pledges and are discounted to present value using a 4.38% discount rate over the collection period of the pledges.

Classification of revenues: The Corporation has classified its revenues as either operating or nonoperating revenues according to the following criteria:

Operating revenues: Operating revenues include activities that have the characteristics of exchange transactions, such as payments for providing services and payments for goods and services received, for health care services provided to patients, net of contractual adjustments and provisions for bad debts.

Nonoperating revenues: Nonoperating revenues include activities that have the characteristics of nonexchange transactions, such as gifts and contributions, NYSDOH Distressed Hospital grant funding, Federal Emergency Management Agency (FEMA) funding, income from investments and contributions.

Income taxes: The Corporation is a Public Benefit Corporation of the State of New York and is exempt from federal income taxes under Section 115 of the Internal Revenue Code. Accordingly, no provision for income taxes has been made in the accompanying financial statements.

Contributed services: Certain immaterial amounts related to contributed rents have been reflected in the Foundation's financial statements as contribution revenue. The Foundation generally pays for services requiring specific expertise. However, many individuals volunteer their time and perform a variety of tasks that assist the Foundation in meeting its goals and objectives. Such services are not recognized in the Foundation financial statements.

Notes to the Financial Statements Year Ended December 31, 2024 (Dollars in Thousands)

Note 2. Summary of Significant Accounting Policies (Continued)

No amounts have been reflected in the Physician Endowment financial statements for contributed services, as the value of contributed services meeting the requirements for recognition in the financial statements was not material.

Recent and pending accounting pronouncements: Effective January 1, 2023, the Corporation adopted GASB issued Statement No. 99, *Omnibus 2022*. The objectives of this Statement are to enhance comparability in accounting and financial reporting and to improve the consistency of authoritative literature by addressing: (1) practice issues that have been identified during implementation and application of certain GASB Statements, and (2) accounting and financial reporting for financial guarantees. There was no significant impact on the Corporation's financial statements as a result of the adoption of this standard.

Effective January 1, 2023, the Corporation adopted GASB issued Statement No. 100, Accounting Changes and Error Corrections-An Amendment of GASB No. 62. This Statement defines accounting changes as changes in accounting principles, changes in accounting estimates, and changes to or within the financial reporting entity and describes the transactions or other events that constitute those changes. As part of those descriptions, for: (1) certain changes in accounting principles, and (2) certain changes in accounting estimates that result from a change in measurement methodology, a new principle or methodology should be justified on the basis that it is preferable to the principle or methodology used before the change. That preferability should be based on the qualitative characteristics of financial reporting-understandability, reliability, relevance, timeliness, consistency, and comparability. This Statement also addresses corrections of errors in previously issued financial statements. There was no significant impact on the Corporation's financial statements as a result of the adoption of this standard.

Effective January 1, 2023, the Corporation adopted GASB issued Statement No. 101, *Compensated Absences*. The objective of this Statement is to better meet the information needs of financial statement users by updating the recognition and measurement guidance for compensated absences. That objective is achieved by aligning the recognition and measurement guidance under a unified model and by amending certain previously required disclosures. There was no significant impact on the Corporation's financial statements as a result of the adoption of this standard.

In December 2023, GASB issued Statement No. 102, *Certain Risk Disclosures*. The objective of this Statement is to provide users of government financial statements with essential information about risks related to a government's vulnerabilities due to certain concentrations or constraints. This Statement defines a *concentration* as a lack of diversity related to an aspect of a significant inflow of resources or outflow of resources. A *constraint* is a limitation imposed on a government by an external party or by formal action of the government's highest level of decision-making authority. Concentrations and constraints may limit a government's ability to acquire resources or control spending. This Statement requires a government to assess whether a concentration or constraint makes the primary government reporting unit or other reporting units that report a liability for revenue debt vulnerable to the risk of a substantial impact. Additionally, this Statement requires a government to assess whether a concentration that could cause the substantial impact to have occurred, have begun to occur, or are more likely than not to begin to occur within 12 months of the date the financial statements are issued. The requirements of this Statement are effective for fiscal years beginning after June 15, 2024, and all reporting periods thereafter. Earlier application is encouraged. The Corporation has not yet determined the impact this statement will have on the financial statements.

Notes to the Financial Statements Year Ended December 31, 2024 (Dollars in Thousands)

Note 2. Summary of Significant Accounting Policies (Continued)

In April 2024, GASB issued Statement No. 103, Financial Reporting Model Improvements. The objective of this Statement is to improve key components of the financial reporting model to enhance its effectiveness in providing information that is essential for decision making and assessing a government's accountability. This Statement also addresses certain application issues. This Statement continues the requirement that the basic financial statements be preceded by management's discussion and analysis (MD&A), which is presented as required supplementary information (RSI). MD&A provides an objective and easily readable analysis of the government's financial activities based on currently known facts, decisions, or conditions and presents comparisons between the current year and the prior year. This Statement requires that the information presented in MD&A be limited to the related topics discussed in five sections: (1) Overview of the Financial Statements, (2) Financial Summary, (3) Detailed Analyses, (4) Significant Capital Asset and Long-Term Financing Activity, and (5) Currently Known Facts, Decisions, or Conditions. Furthermore, this Statement stresses that the detailed analyses should explain why balances and results of operations changed rather than simply presenting the amounts or percentages by which they changed. This Statement describes unusual or infrequent items as transactions and other events that are either unusual in nature or infrequent in occurrence. Furthermore, governments are required to display the inflows and outflows related to each unusual or infrequent item separately as the last presented flow(s) of resources prior to the net change in resource flows in the government-wide, governmental fund, and proprietary fund statements of resource flows. Finally, This Statement requires governments to present budgetary comparison information using a single method of communication-RSI. Governments also are required to present (1) variances between original and final budget amounts and (2) variances between final budget and actual amounts. An explanation of significant variances is required to be presented in notes to RSI. The requirements of this Statement are effective for fiscal years beginning after June 15, 2025. The Corporation has not yet determined the impact this statement will have on the financial statements.

In September 2024, GASB issued Statement No. 104, *Disclosure of Certain Capital Assets*. This Statement requires certain types of capital assets to be disclosed separately in the capital assets note disclosures required by Statement 34. Lease assets recognized in accordance with Statement No. 87, *Leases*, and intangible right-to-use assets recognized in accordance with Statement No. 94, *Public-Private and Public-Public Partnerships and Availability Payment Arrangements*, should be disclosed separately by major class of underlying asset in the capital as-sets note disclosures. Subscription assets recognized in accordance with Statement No. 96, *Subscription-Based Information Technology Arrangements*, also should be separately disclosed. In addition, this Statement requires intangible assets other than those three types to be disclosed separately by major class. This Statement also requires additional disclosures for capital assets held for sale. The requirements of this Statement are effective for fiscal years beginning after June 15, 2025. The Corporation has not yet determined the impact this statement will have on the financial statements.

Reclassifications: Certain prior-year amounts have been reclassified to conform to the current-year presentation. Such reclassifications had no effect on previously reported operating loss/income or changes in net position.

Subsequent events: The Corporation has evaluated subsequent events for potential recognition and/or disclosure through [DATE], the date the financial statements were issued.

Notes to the Financial Statements Year Ended December 31, 2024 (Dollars in Thousands)

Note 3. Federal Emergency Management Agency (FEMA)

Under the CARES Act, financial relief was provided through FEMA's Disaster Relief Fund. During the years ended December 31, 2024 and 2023, the Corporation recognized grant revenue received from FEMA to cover eligible COVID-19 related expenses in the amount of \$17,333 and \$3,829, respectively. The Corporation is still awaiting additional funds from FEMA for pending reimbursement submissions related to remaining eligible expenses under this program.

Note 4. Net Patient Service Revenue and Patient Accounts Receivable

The Corporation has agreements with third-party payors that provide for payment to the Corporation at amounts different from its established rates. A summary of the payment arrangements for hospital services with major third-party payors is as follows:

Medicare: Inpatient acute care services rendered to Medicare program beneficiaries are paid at prospectively determined rates per discharge and per patient day depending on the service. Acute care rates vary according to a patient classification system that is based on clinical, diagnostic, and other factors. Certain inpatient and outpatient services, as well as defined organ acquisition, capital and medical education costs related to Medicare beneficiaries are paid based on regulatory proscribed formulae. The Corporation is reimbursed for such items at a tentative rate with final settlement determined after submission of annual cost reports by the Corporation and audits thereof by the Medicare fiscal intermediary. The Corporation's classification of patients under the Medicare program and the appropriateness of their admission are subject to an independent review by a peer review organization under contract with the Corporation. Most outpatient reimbursements are based on an Ambulatory Payment Classification weighting by acuity system, although some outpatient cost reimbursement still exists.

Medicaid: Inpatient services rendered to Medicaid program beneficiaries are reimbursed at prospectively determined rates in accordance with Part 86 of the New York Codes, Rules and Regulations and New York State Law which are promulgated by the New York State Department of Health (DOH). Outpatient services are similarly paid at either prospective rates or fee schedule amounts.

Under the New York Health Care Reform Act, the Corporation also enters into payment agreements with certain commercial insurance carriers, health maintenance organizations, and preferred provider organizations. The basis for payment to the Corporation under these agreements includes prospectively determined rates, discounts from charges, and prospectively determined per diem rates. Medicaid, Workers' Compensation and No-fault continue to have reimbursement rates determined based on New York's Prospective Reimbursement Methodology.

Terrace View provides services to residents under agreements with third-party payors (Medicaid, Medicare and HMO's) under provisions of their respective cost reimbursement formulas or contractually negotiated rates. If amounts received are less than established billing rates, the difference is accounted for as a reduction of revenue. Final determination of the reimbursement rates are subject to review by appropriate third-party payors. Provisions are made in the financial statements for anticipated adjustments that may result from such reviews. The difference between the estimated amounts accrued and final settlements are reported in operations in the year of settlement.

Notes to the Financial Statements Year Ended December 31, 2024 (Dollars in Thousands)

Note 4. Net Patient Service Revenue and Patient Accounts Receivable (Continued)

Net patient service revenue, as reported on the statements of revenues, expenses and changes in net position, is comprised of the following for the years ended December 31:

| | 2024 | 2023 |
|--------------------------|--------------|--------------|
| Gross charges | \$ 1,852,746 | \$ 1,673,523 |
| Less: | | |
| Discounts and allowances | 1,183,855 | 1,065,207 |
| Provision for bad debts | 12,663 | 4,596 |
| | \$ 656,228 | \$ 603,720 |
| | | 2 |

Net patient service revenue by payor for the years ended December 31 is as follows:

| | 2024 | | 2023 | |
|---|------------|-----------|---------|--------|
| | Amount | % | Amount | % |
| | RIFUE GOUL | ale - | | |
| Medicare* | \$ 250,023 | 38.1% \$ | 247,282 | 41.0% |
| Medicaid* | 208,681 | 31.8% | 164,815 | 27.3% |
| Commercial and other third-party payors | 166,026 | 25.3% | 164,704 | 27.3% |
| No-fault | 26,249 | 4.0% | 20,452 | 3.4% |
| Self-pay | 5,249 | 0.8% | 6,467 | 1.0% |
| | \$ 656,228 | 100.0% \$ | 603,720 | 100.0% |
| | 10 | | | |

*Medicare and Medicaid include Managed Care plans.

Laws and regulations governing Medicare, Medicaid, and other third-party payor programs are extremely complex and subject to interpretation. As a result, there is at least a reasonable possibility that recorded estimates could change by a material amount in future periods. The Corporation believes that it is in compliance with all applicable laws and regulations and is not aware of any pending or threatened investigations involving allegations of potential wrongdoing. Compliance with such laws and regulations can be subject to future government review and interpretation as well as significant regulatory action including fines, penalties, and exclusion from the Medicare and Medicaid programs.

Patient accounts receivable consist of the following at December 31:

| | 2024 | 2023 |
|-----------------------------------|-------------------|-------------------|
| Gross accounts receivable | \$ 307,107 | \$ 295,805 |
| Less: Discounts and allowances | 140.020 | 100 000 |
| Allowance for bad debts | 140,930 72,469 | 128,839 64,577 |
| | \$ 93,708 | \$ 102,389 |

Notes to the Financial Statements Year Ended December 31, 2024 (Dollars in Thousands)

Note 4. Net Patient Service Revenue and Patient Accounts Receivable (Continued)

In early 2024, Change Healthcare, a third-party billing company, fell victim to a cyber attack impacting their ability to access their billing software. The Corporation contracts with Change Healthcare for billing services related to certain professional billing services. As a result of the attack, billing through Change Healthcare was unable to proceed for an extended period of time. As such, the Corporation has considered the delay in the billing when establishing reserves on the related gross charges impacted by this attack.

The Corporation has received advances from third party payors including Change Healthcare for claims that have not been adjudicated due to the cyber attack. As of December 31, 2024, the Corporation has recorded a liability of \$13,604 related to those advances within the accrued other liabilities caption of the statements of net position.

Concentration of credit risk: The Corporation grants credit without collateral to its patients, most of whom are insured under third-party payor arrangements. The mix of net receivables from patients and third-party payors at December 31, is as follows:

| MALAN FOR U TE | 2024 | 2023 |
|---|--------|--------|
| Medicare* | 33.6% | 33.2% |
| Commercial and other third party payors | 32.6% | 32.7% |
| Medicaid* | 26.0% | 27.8% |
| No-fault | 7.4% | 5.5% |
| Self-pay | 0.4% | 0.8% |
| Total | 100.0% | 100.0% |
| ROM AND AND A | | |

*Medicare and Medicaid include Managed Care plans.

Note 5. Disproportionate Share (DSH) Revenue

The Medicaid DSH program is designed to provide funds to certain hospitals to help offset the cost of uncompensated care provided to the uninsured. Each state has a specified Federal DSH allotment. In addition, New York State law authorizes the New York State Department of Health (DOH) to make supplemental DSH medical assistance payments to public hospitals located in Erie County, Nassau County, and Westchester County. For long term care facilities, DSH revenue is recognized in accordance with Upper Payment Limit (UPL) regulations promulgated by the Centers for Medicare and Medicaid Services (CMS).

In 2024 and 2023, DSH funding recorded by the Corporation totaled \$164,953 and \$107,105, respectively. The DSH funding process is complex and includes both tentative and final settlements for various state fiscal years which are subject to the availability of state and federal funding among other factors. As a result, DSH revenue is estimated and final settlements may vary significantly from the initial estimates.

For hospital services, DSH revenue of \$149,675 and \$91,220 was recognized in 2024 and 2023, respectively. In addition, during 2024 and 2023, the Corporation recognized \$15,278 and \$15,885, respectively, of UPL revenue for Terrace View. UPL revenue has been recognized based off New York State fiscal year 2024-2025, as determined by the DOH, using cost report year 2022 data.

Notes to the Financial Statements Year Ended December 31, 2024 (Dollars in Thousands)

Note 5. Disproportionate Share (DSH) Revenue (Continued)

CMS has indicated that cost reports dating back to the 2022 reporting year and the methodology employed to calculate DSH revenue are subject to audit for those years. At this time, the impact of the CMS audit activity on the Corporation's DSH revenue is not certain. Management has taken what it believes to be reasonable and appropriate steps to assure compliance with the CMS methodology.

Note 6. Cash and Cash Equivalents, Investments and Assets Whose Use is Limited

Cash and cash equivalents and investments: The Corporation's investments are made in accordance with State regulations and its own investment policy. The investment policy is regularly reviewed by an investment committee of the Board which evaluates the performance of investment managers and monitors compliance with the investment policy.

The Corporation's investments are generally reported at fair value, as discussed in Note 2. The carrying amounts of cash and cash equivalents, investments and assets whose use is limited are included in the Corporation's statements of net position as follows:

| | 3 | 2024 | | 2023 |
|---|----|--|----|--|
| Cash and cash equivalents Investments Assets whose use is limited—current Assets whose use is limited—noncurrent | \$ | 34,586 42,825 84,714 106,887 269,012 | \$ | 20,773 10,646 113,986 56,635 202,040 |
| Designated: O Self-insured obligations | \$ | 53,666 | \$ | 57,904 |
| Capital | Ψ | 59,930 | Ψ | 36,265 |
| Other | | 44,327 | | 42,407 |
| | | 157,923 | | 136,576 |
| Restricted: | | | | |
| Debt service | | 24,560 | | 23,872 |
| Self-insured obligations | | 9,118 | | 10,173 |
| | | 33,678 | | 34,045 |
| Total assets whose use is limited Less portion required for current liabilities | | 191,601 (84,714) | | 170,621 (113,986) |
| | \$ | 106,887 | \$ | 56,635 |

The Corporation's cash and cash equivalents, as well as investments, are exposed to various risks, including credit, custodial credit, interest rate and market risks, as discussed in more detail below:

Deposits

All monies are deposited with banks or trust companies designated by the Corporation's investment committee of the Board of Directors. Funds not needed for immediate expenditure may be deposited in interest or non-interest-bearing accounts or invested in various marketable securities and bonds.

Notes to the Financial Statements Year Ended December 31, 2024 (Dollars in Thousands)

Note 6. Cash and Cash Equivalents, Investments and Assets Whose Use is Limited (Continued)

Custodial credit risk: Custodial credit risk is the risk that, in the event of bank failure, the Corporation's deposits might not be recovered. FDIC insurance through December 31, 2023, for funds held in interest bearing accounts is \$250 per depositor per category of legal ownership. New York law requires that deposits in excess of FDIC insured amounts are collateralized. The Corporation's bank deposits at December 31, 2024 and 2023, totaled \$37,133 and \$27,068, of which \$1,030 in both years were insured. Amounts over FDIC insured limits were fully collateralized with securities held by the pledging financial institution.

Investments

The Corporation's investment policy authorizes the Corporation to invest in accordance with New York State Finance Law Section 8(14), Section 201 and Public Authorities Law Article 9 Section 2800 to 2985, as well as the relevant provisions of the ECMCC Act. Compliance with the policy is monitored by the Corporation's investment committee and reported on regularly throughout the year by the Corporation's investment advisor.

Credit risk: Credit risk is the risk that the issuer or other counterparty to an investment will not fulfill its obligation, causing the Corporation to experience a loss of principal. The Corporation's investment policy limits investments in equity and fixed income securities with ratings only in the highest category. ECMCC's investments in government bonds carry the explicit guarantee of the U.S. government. The corporate bonds, short-term fixed income and government bonds are all rated AA+ or better by the Standards & Poor's rating agency.

Interest rate risk: Interest rate risk is the risk that changes in interest rates will adversely affect the fair value of an investment. The Corporation's cash equivalent securities are limited to maturities of no greater than eighteen months; short-term fixed income securities are limited to maturities of no greater than five years; and long-term fixed income securities are limited to maturities to no more than ten years. Substantially all of the Corporation's investments and assets whose use is limited have stated maturities of less than one year.

Custodial credit risk: For an investment, custodial credit risk is the risk that, in the event of the failure of the counterparty, the Corporation will not be able to recover the value of its investments or collateral securities that are in the possession of an outside party. The Corporation's investment policy does not address custodial credit risk.

Concentration of credit risk: Concentration of credit risk is the risk of loss attributable to the magnitude of investments in any single issuer. The Corporation's investment policy indicates the combined holdings of securities from one issuer shall not constitute more than 5.0% of the fund except for issues guaranteed directly or indirectly by the U.S. Government. The Corporation had no holdings in Federal National Mortgage Association (Fannie Mae) or Federal Home Loan Mortgage Corporation (Freddie Mac) issues at December 31, 2024 and 2023.

Notes to the Financial Statements Year Ended December 31, 2024 (Dollars in Thousands)

Note 6. Cash and Cash Equivalents, Investments and Assets Whose Use is Limited (Continued)

Fair value of financial instruments: Fair value is defined in the accounting standards as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Management utilizes valuation techniques that maximize the use of observable inputs (Levels 1 and 2) and minimize the use of unobservable inputs (Level 3) within the fair value hierarchy established by GASB. Assets carried at fair value are required to be classified and disclosed in one of the following three categories:

- **Level 1:** Valuations based on quoted prices in active markets for identical assets that the Corporation has the ability to access.
- Level 2: Valuations based on quoted prices in active markets for similar assets, quoted prices in markets that are not active or for which all significant inputs are observable, directly or indirectly. The Corporation has no Level 2 assets.
- Level 3: Valuations based on inputs that are unobservable and significant to the overall fair value measurement. These are generally company generated inputs and are not market-based inputs. The Corporation has no Level 3 assets.

| | | | | AUC2 | 024 | | |
|----------------------------------|----------|---------|----|---------|-----|---------|---------------|
| | <u> </u> | Level 1 | m | Level 2 | | Level 3 | Total |
| | | R | 36 | | | | |
| Cash and cash equivalents | \$ | 34,586 | \$ | - | \$ | - | \$ 34,586 |
| | 40 | | | | | | |
| Investments and assets whose use | | | | | | | |
| is limited: | | | | | | | |
| Cash and cash equivalents | | 163,669 | | - | | - | 163,669 |
| Marketable equity securities: | | | | | | | |
| Small/Mid cap equities | | 3,941 | | - | | - | 3,941 |
| Growth equities | | 1,596 | | - | | - | 1,596 |
| Core equities | | 11,683 | | - | | - | 11,683 |
| International equities | | 9,170 | | - | | - | 9,170 |
| U.S. fixed income | | 44,367 | | - | | - | 44,367 |
| Total investments and assets | | | | | | | |
| whose use is limited | | 234,426 | | - | | - | 234,426 |
| Total | \$ | 269,012 | \$ | - | \$ | - | \$ 269,012 |

Notes to the Financial Statements Year Ended December 31, 2024 (Dollars in Thousands)

Note 6. Cash and Cash Equivalents, Investments and Assets Whose Use is Limited (Continued)

| | 2023 | | | | | | | |
|--|------|---------|------|-------------|----|--------|----|---------|
| | | Level 1 | | Level 2 Lev | | evel 3 | | Total |
| Cash and cash equivalents | \$ | 20,773 | \$ | - | \$ | - | \$ | 20,773 |
| Investments and assets whose use | | | | | | | | |
| is limited: Cash and cash equivalents | | 115,448 | | | | | | 115,448 |
| Marketable equity securities: | | 115,440 | | - | | - | | 115,440 |
| Small/Mid cap equities | | 4,423 | | - | | Marc | | 4,423 |
| Growth equities | | 1,447 | | - 77 | | 000 | | 1,447 |
| Core equities | | 9,921 | | - | | - | | 9,921 |
| International equities | | 10,190 | | - nrapo | | - | | 10,190 |
| U.S. fixed income | . [| 39,838 | P | Olo n | | - | | 39,838 |
| Total investments and assets | Ana | AL AL | 2/11 | ale | | | | |
| whose use is limited | Mnn | 181,267 | a | 195- | 6 | - | | 181,267 |
| Total | \$ | 202,040 | \$ | AND | \$ | - | \$ | 202,040 |
| | Die | n 410 | | Olon | | | | |

Note 7. Capital Assets, Net

Capital asset activity for the years ended December 31, is as follows:

| | 2024 | | | | | | |
|--|-------|------------|-------|------------|------------|----------|---------------|
| | E | Beginning | | | Disposals/ | | Ending |
| | | Balance | | Additions | T | ransfers | Balance |
| Capital assets—being depreciated: | | | | | | | |
| Land and land improvements | \$ | 41,197 | \$ | 24 | \$ | - | \$ 41,221 |
| Buildings and improvements | | 547,974 | | 1,478 | | - | 549,452 |
| Fixed/major moveable equipment | | 156,454 | | 8,775 | | (183) | 165,046 |
| Total capital assets—being | | | | | | | |
| depreciated | | 745,625 | | 10,277 | | (183) | 755,719 |
| | | | | | | | |
| Less accumulated depreciation | | (493,144) | | (30,264) | | 183 | (523,225) |
| Total capital assets—being | | | | | | | |
| depreciated, net | | 252,481 | | (19,987) | | - | 232,494 |
| | | | | | | | |
| Capital assets—not being depreciated: | | | | | | | |
| Construction in progress | | 8,426 | | 1,541 | | (4,948) | 5,019 |
| Capital assets, net, excluding | | | | | | | |
| lease and SBITA assets | \$ | 260,907 | \$ | (18,446) | \$ | (4,948) | \$ 237,513 |
| | | | | | | | |
| Lease and SBITA assets, net (Note 8) | | | | | | | \$ 45,119 |
| | | | | | | | |
| Total capital assets, net, as reported | in st | atements o | of ne | t position | | | \$ 282,632 |

Notes to the Financial Statements Year Ended December 31, 2024 (Dollars in Thousands)

Note 7. Capital Assets, Net (Continued)

| | | | | 20 |)23 | | |
|--|------|-------------|-------|------------|-----|------------|---------------|
| | E | Beginning | | | Γ | Disposals/ | Ending |
| | | Balance | | Additions | - | Transfers | Balance |
| Capital assets—being depreciated: | | | | | | | |
| Land and land improvements | \$ | 41,166 | \$ | 31 | \$ | - | \$ 41,197 |
| Buildings and improvements | | 545,092 | | 2,882 | | - | 547,974 |
| Fixed/major moveable equipment | | 151,523 | | 5,096 | | (165) | 156,454 |
| Total capital assets—being | | | | | | | |
| depreciated | | 737,781 | | 8,009 | | (165) | 745,625 |
| | | | | | | | |
| Less accumulated depreciation | | (461,308) | | (32,001) | | 165 | (493,144) |
| Total capital assets—being | | | aB | (F) | 20 | 3 | |
| depreciated, net | | 276,473 | | (23,992) | | - | 252,481 |
| | | | | | | | |
| Capital assets—not being depreciated: | | | | | | | |
| Construction in progress | Nor | 21,643 | ,- | 3,165 | Д | (16,382) | 8,426 |
| Capital assets, net, excluding | 0 | alle all | he | ALL CO | 07 | | |
| lease and SBITA assets | \$ | 298,116 | \$ | (20,827) | \$ | (16,382) | \$ 260,907 |
| | | aft he | all | 00 | | | |
| Lease and SBITA assets, net (Note 8) | | | | | | | \$ 52,132 |
| | | | | | | | |
| Total capital assets, net, as reported | in s | tatements o | of ne | t position | | | \$ 313,039 |
| | | | | | | | |

Construction in progress at December 31, 2024 and 2023, includes costs associated with various mechanical, electrical and information-technology security projects. The costs associated with an abandoned ambulatory electronic medical records system project of \$11,239 were written off during the year ended December 31, 2023 and recorded within purchased services expenses within the statements of revenues, expenses and changes in net position.

Depreciation expense amounted to \$30,264 and \$32,001 for the years ended December 31, 2024 and 2023, respectively.

Note 8. Leases and Subscription-Based Information Technology Arrangements

The Corporation is a lessee for various noncancellable leases of real estate and equipment. The expected lease payments are discounted using the interest rate charged on the lease, if available, and are otherwise discounted using the Corporation's incremental borrowing rate. The right-to-use assets are amortized over the shorter of the lease term or the underlying asset useful life.

The Corporation recognizes an intangible subscription asset and corresponding subscription liability for its subscription-based information technology agreements with others. These arrangements have terms requiring monthly, quarterly or annual payments. The expected payments are discounted using the interest rate charged on the arrangement, if available, or are otherwise discounted using the Corporation's incremental borrowing rate.

Notes to the Financial Statements Year Ended December 31, 2024 (Dollars in Thousands)

Note 8. Leases and Subscription-Based Information Technology Arrangements (Continued)

Lease and SBITA assets are reported within capital assets and lease and SBITA liabilities are reported separately in the statements of net position.

Right-to-use assets by major class and the related accumulated amortization for the years ended December 31 is summarized as follows:

| | | | | | 2024 | | | | |
|-----------|-----------|--|--|---|--|--|--|--|--|
| | Beginning | | | | | | | | Ending |
| | Balance | | Additions | Rem | easurements | F | Retirements | | Balance |
| | | | | | | | | | |
| \$ | 11,927 | \$ | 272 | \$ | - | \$ | - T | \$ | 12,199 |
| | 40,059 | | 1,948 | | 667 | | 134 | | 42,540 |
| _ | 51,986 | | 2,220 | | 667 | | 134 | | 54,739 |
| | | | | | | | | | |
| | 2,690 | | 1.063 | | 03- | | - | | 3,753 |
| | 22,925 | | 5,398 | | P - | | 134 | | 28,189 |
| | 25,615 | 20 | 6,461 | Use | <u></u> | | 134 | | 31,942 |
| | 26,371 | | (4,241) | . 6 | 667 | | - | | 22,797 |
| In | Magn | 26 | 310 | 1.0.1 | 9 | | | | |
| | 43,822 | | 6,209 | | 1,335 | | 1,186 | | 50,180 |
| | 18,061 | | 10,319 | | CC- | | 522 | | 27,858 |
| 1 | 25,761 | 36 | (4,110) | 210 | 1,335 | | 664 | | 22,322 |
| 7.C | - The | Re | 011 | 90 | | | | | |
| \$ | 52,132 | \$ | (8,351) | \$ | 2,002 | \$ | 664 | \$ | 45,119 |
| an | 011 | - 1 | Mon | | | | | | |
| 500 | TOP | S? | | | 2023 | | | | |
| - | Beginning | | | | | | | | Ending |
| R | Balance | | Additions | Rem | neasurements | F | Retirements | | Balance |
| <u>10</u> | | | | | | | | | |
| \$ | 13,969 | \$ | 718 | \$ | - | \$ | 2,760 | \$ | 11,927 |
| | 34,696 | | 3,950 | | 1,413 | | - | | 40,059 |
| _ | 48,665 | | 4,668 | | 1,413 | | 2,760 | | 51,986 |
| | | | | | | | | | |
| | 2,603 | | 1,156 | | - | | 1,069 | | 2,690 |
| | 16,008 | | 6,917 | | - | | - | | 22,925 |
| | 18,611 | | 8,073 | | - | | 1,069 | | 25,615 |
| _ | 30,054 | | (3,405) | | 1,413 | | 1,691 | | 26,371 |
| | 39,473 | | 4,349 | | - | | | | 43,822 |
| | | | | | | | | | 10,022 |
| | , | | 9 804 | | - | | - | | 18 061 |
| | 8,257 | | 9,804 | | - | | - | | 18,061 25,761 |
| | , | | 9,804 (5,455) | | - | | - | | 18,061 25,761 |
| | | Balance \$ 11,927 40,059 51,986 2,690 22,925 25,615 26,371 43,822 18,061 25,761 \$ 52,132 Beginning Balance \$ 13,969 34,696 48,665 2,603 16,008 18,611 | Balance \$ 11,927 \$ 40,059 51,986 2,690 22,925 25,615 26,6371 43,822 18,061 25,761 \$ 52,132 \$ Beginning Balance \$ 13,969 \$ 34,696 48,665 2,603 16,008 18,611 | Balance Additions \$ 11,927 \$ 272 40,059 1,948 51,986 2,220 2,690 1,063 22,925 5,398 25,615 6,461 26,371 (4,241) 43,822 6,209 18,061 10,319 25,761 (4,110) \$ 52,132 (8,351) Beginning Balance Additions \$ 13,969 \$ 13,969 718 34,696 3,950 48,665 4,668 2,603 1,156 16,008 6,917 18,611 8,073 | Balance Additions Rem \$ 11,927 \$ 272 \$ 40,059 1,948 51,986 2,220 2,690 1,063 22,925 5,398 25,615 6,461 26,371 (4,241) 43,822 6,209 18,061 10,319 25,761 (4,110) \$ 52,132 (8,351) Beginning Balance Additions Rem \$ 13,969 718 34,696 3,950 48,665 4,668 2,603 1,156 16,008 6,917 18,611 8,073 | $\begin{array}{c c c c c c c c c c c c c c c c c c c $ | $\begin{array}{c c c c c c c c c c c c c c c c c c c $ | $\begin{array}{c c c c c c c c c c c c c c c c c c c $ | $\begin{array}{c c c c c c c c c c c c c c c c c c c $ |

Notes to the Financial Statements Year Ended December 31, 2024 (Dollars in Thousands)

Note 8. Leases and Subscription-Based Information Technology Arrangements (Continued)

As of December 31, 2024, the principal and interest requirements to maturity for the lease liability are as follows:

| | Principal | Interest | [| Total |
|---------------------------|------------|----------|-------|--------|
| Years ending December 31: | | | | |
| 2025 | \$ 7,029 | \$ 80 |)1 \$ | 7,830 |
| 2026 | 4,799 | 52 | 25 | 5,324 |
| 2027 | 2,951 | 33 | 6 | 3,287 |
| 2028 | 1,673 | 21 | 5 | 1,888 |
| 2029 | 876 | 16 | 1 | 1,037 |
| 2030-2034 | 3,411 | 42 | 28 | 3,839 |
| 2035-2039 | 884 | 285 Z | 23 | 907 |
| | \$ 21,623 | \$ 2,48 | 39 \$ | 24,112 |
| | BY P BUILT | | | |

As of December 31, 2024, the principal and interest requirements to maturity for the SBITA liability are as follows:

| | | Principal | 9.3 | nterest | Total |
|-----------|---------------------------|-----------|-----|---------|--------------|
| Years end | ling December 31: | 0010 | | | |
| 2025 | all all the the Cos Bells | 8,118 | \$ | 1,159 | \$ 9,277 |
| 2026 | | 7,245 | | 615 | 7,860 |
| 2027 | | 4,280 | | 250 | 4,530 |
| 2028 | | 1,422 | | 76 | 1,498 |
| 2029 | 16. Nale | 264 | | 4 | 268 |
| | | \$ 21,329 | \$ | 2,104 | \$ 23,433 |

Lessor: The Corporation leases real estate to external parties. In accordance with GASB Statement No. 87, *Leases*, the Corporation records lease receivables and deferred inflows of resources based on the present value of expected receipts over the term of the respective leases. The Corporation recognized lease receivables (reported within other assets in the statements of net position) of \$822 and \$753 at December 31, 2024 and 2023, respectively, deferred inflows of resources of \$1,563 and \$1,666 at December 31, 2024 and 2023, respectively, and lease revenue of \$833 and \$632 during the years ended December 31, 2024 and 2023, respectively.

Notes to the Financial Statements Year Ended December 31, 2024 (Dollars in Thousands)

Note 9. Accrued Other Liabilities

The composition of accrued other liabilities as of December 31 is as follows:

| | | 2024 | 2023 |
|--|----|--------|--------------|
| Due to Erie County | \$ | 4,006 | \$ 12,767 |
| DSH and Upper Payment Limit (UPL) (Note 5) | | 9,743 | - |
| Payor advances | | 13,604 | - |
| Medical malpractice claims | | 2,133 | 1,792 |
| Estimated third-party payor settlements | | 5,643 | 4,486 |
| Asset retirement obligations | | 2,356 | 2,167 |
| Workers compensation claims | | 6,665 | 7,416 |
| Other | e | 13,409 | 13,393 |
| Total | \$ | 57,559 | \$ 42,021 |

GASB Statement No. 83, *Certain Asset Retirement Obligations*, establishes criteria for determining the timing and pattern of recognition of a liability and a corresponding deferred outflow of resources for asset retirement obligations (AROs). An ARO is a legally enforceable liability associated with the retirement of a tangible capital asset. In accordance with this Statement, the Corporation completes an analysis of assets meeting the criteria of an ARO for specific types of medical equipment such as medical imaging equipment (e.g., MRIs, CT scanners, and PET scanners), X-Rays, and ultrasounds as well as computers containing information protected by HIPAA laws, and certain types of laboratory equipment. In addition, the Corporation evaluates the requirements for disposal of underground fuel and lab acid tanks. The Corporation totaled \$2,356 and \$2,167 at December 31, 2024 and 2023, respectively. The assets have a remaining useful life ranging from 0 to 30 years. This obligation is discounted using a rate of 4.0% and an inflation factor of 3.0% at December 31, 2024 and 2023.

Note 10. Indebtedness

Long-term debt consisted of the following at December 31:

| | | | 2024 | | |
|--------------------------------|------------|-----------|-------------|------------|------------|
| | Beginning | | Payments/ | Ending | Due Within |
| | Balance | Additions | Forgiveness | Balance | One Year |
| Erie County—Guaranteed Senior | | | | | |
| Revenue Bonds, Series 2004 | \$ 56,970 | \$- | \$ (4,390) | \$ 52,580 | \$ 4,635 |
| Erie County—2017 loan payable | 87,374 | - | (2,849) | 84,525 | 2,920 |
| Erie County—2017 loan payable | 49,076 | - | (4,271) | 44,805 | 4,386 |
| Erie County—2017 capitalized | | | | | |
| interest assumption obligation | 7,274 | - | (238) | 7,036 | 243 |
| Finance obligations | 1,949 | 1,739 | (507) | 3,181 | 571 |
| Total debt | \$ 202,643 | \$ 1,739 | \$ (12,255) | \$ 192,127 | \$ 12,755 |

Notes to the Financial Statements Year Ended December 31, 2024 (Dollars in Thousands)

Note 10. Indebtedness (Continued)

| | | | 2023 | | |
|--------------------------------|------------|-----------|-------------|------------|------------|
| | Beginning | | Payments/ | Ending | Due Within |
| | Balance | Additions | Forgiveness | Balance | One Year |
| Erie County—Guaranteed Senior | | | | | |
| Revenue Bonds, Series 2004 | \$ 61,135 | \$- | \$ (4,165) | \$ 56,970 | \$ 4,390 |
| Erie County—2017 loan payable | 90,154 | - | (2,780) | 87,374 | 2,849 |
| Erie County—2017 loan payable | 53,235 | - | (4,159) | 49,076 | 4,271 |
| Erie County—2017 capitalized | | | | | |
| interest assumption obligation | 7,505 | - | (231) | 7,274 | 237 |
| Finance obligations | 2,328 | - | (379) | 1,949 | 381 |
| Total debt | \$ 214,357 | \$ - | \$ (11,714) | \$ 202,643 | \$ 12,128 |
| | | | all ast | 300 | |

Future annual principal payments applicable to long-term debt for the years subsequent to December 31, 2024 are as follows:

| Years ending December 31: | |
|---------------------------|---------------|
| 2025 | \$ 12,755 |
| | 13,215 |
| | 13,697 |
| 2028 | 14,198 |
| 2029 | 14,395 |
| 2030-2034 | 73,331 |
| 2035-2039 | 50,536 |
| Total | \$ 192,127 |

The Series 2004 Bonds are secured by a pledge of the gross receipts of the Corporation and amounts on deposit in certain debt service reserve funds. Interest rates on the bonds range from 5.5% to 5.7%, with principal payments ranging from \$4,165 to \$7,220 due annually on November 1 with interest payments due semi-annually on May 1 and November 1.

Pursuant to a Guaranty Agreement, the County has unconditionally guaranteed to the Corporation, the punctual payment of the principal, interest, and redemption premium, if any, on the Series 2004 Bonds, as the same shall become due and payable, and has pledged the faith and credit of the County for the performance of such guaranty. A municipal bond insurance policy has been purchased by the Corporation to guarantee all debt service payments in case of default by the Corporation and the County.

Notes to the Financial Statements Year Ended December 31, 2024 (Dollars in Thousands)

Note 10. Indebtedness (Continued)

In 2017, the Corporation entered into a loan agreement and a capitalized interest liability assumption agreement with the County of Erie, with the assistance of the Erie County Fiscal Stability Authority. The proceeds of the loan were used to finance the construction of a new Level 1 Adult Trauma Center and Emergency Department, fund various other capital projects on the Corporation's campus as well as refinance a 2011 loan. The loan has an interest rate of 3.377% with monthly principal and interest payments ranging from \$474 to \$930 during the term of the loan. In addition to the loan, the Corporation assumed the liability related to funds borrowed to pay capitalized interest during construction on the various projects noted above. The capitalized interest liability assumption has an interest rate of 3.377% with monthly principal and interest payments ranging from \$40 to \$77 during the term of the loan. The new money portion of the loan and the capitalized interest assumption agreement is fully amortized and matures in 2039. The refinancing component of the loan has an interest rate of 2.649% with monthly principal and interest payments ranging from \$300 to \$460 during the term of the loan and is fully amortized and maturing in 2034.

During 2018, the Corporation entered into a finance obligation agreement in the amount of \$2,044, the proceeds of which were used to purchase various equipment. The agreement requires principal and interest payments (cost of capital is estimated at 5.5%) of \$29 and matures September 2025.

During 2018, the Corporation entered into a second finance obligation agreement in the amount of \$409, the proceeds of which were used to purchase various suite improvements. The agreement required principal and interest payments (cost of capital is estimated at 3.8%) of \$4 and was paid in full during 2023.

During 2019, the Corporation entered into a finance obligation agreement in the amount of \$1,805, the proceeds of which were used to finance various cafeteria improvements. The agreement requires principal and interest payments (cost of capital ranges from 0% to 9.0%) of \$17 and matures March 2029.

During 2020, the Corporation entered into a finance obligation agreement in the amount of \$2,555, the proceeds of which were used to purchase various equipment. The agreement requires principal and interest payments (cost of capital is estimated at 5.5%) of \$39 and matures July 2026.

During 2021, the Corporation entered into a finance obligation agreement in the amount of \$1,552, the proceeds of which were used to finance a new food service line. The agreement requires principal and interest payments (cost of capital is 4.0%) of \$19 and matures in December 2028.

During 2021, the Corporation signed an agreement for an unsecured revolving line of credit with an original maturity date of November 2022 and was amended and extended to May 2025. The Corporation has available \$10,000 with interest payable at a variable rate of daily Secured Overnight Financing Rate (SOFR) plus 183 basis points. There was \$10,000 of outstanding borrowings against the line at both December 31, 2024 and 2023. Management is currently negotiating an extension for the maturity date of this agreement.

During 2024, the Corporation entered into a finance obligation agreement in the amount of \$1,739, the proceeds of which were used to finance a new food service equipment. The agreement requires principal payments of \$16 and matures in June 2033.

Notes to the Financial Statements Year Ended December 31, 2024 (Dollars in Thousands)

Note 11. Pension Plan

Retirement plan: The Corporation participates in the New York State and Local Retirement System (NYSLRS or the System), which is a cost-sharing, multiple-employer public employees' retirement system. There are more than 520,000 pensioners and beneficiaries in the System with over 1.2 million participants.

For purposes of measuring the net pension liability, deferred outflows of resources and deferred inflows of resources related to pensions, and pension expense/benefit, information about the fiduciary net position of the NYSLRS and additions to/deductions from NYSLRS' fiduciary net position have been determined on the same basis as they are reported by NYSLRS. For this purpose, benefit payments (including refunds of employee contributions) are recognized when due and payable in accordance with the benefit terms. The net pension liability is measured as the portion of the present value of projected benefit payments to be provided through the pension plan to current active and inactive employees that is attributed to those employees' past periods of service (total pension liability), less the amount of the pension plan's fiduciary net position. The net pension liability should be measured as of a date (measurement date) no earlier than the end of the employer's prior fiscal year, consistently applied from period to period.

Obligations of employers and employees to contribute and benefits to employees are governed by the New York State Retirement and Social Security Law (RSSL). As set forth in the RSSL, the Comptroller of the State of New York (the Comptroller) serves as sole trustee and administrative head of the System. The Comptroller shall adopt and may amend rules and regulations for the administration and transaction of the business of the System and for custody and control of its funds. The System issues a publicly available financial report that includes financial statements and required supplementary information. That report may be obtained by writing to the New York State and Local Retirement System, 110 State Street, Albany, NY 12244.

NYSLRS provides three main types of retirement benefits: service retirements, ordinary disability retirements (non-job-related disabilities), and accident disability retirements (job-related disabilities) to members who are in different Tiers. The members' Tier is determined by the date of membership. Subject to certain conditions, members generally become fully vested as to benefits upon the completion of five years of service depending on their Tier. Employees may be required to contribute a percentage of their salary to the pension plan based on their Tier, determined by their date of membership in the plan. Annual pension benefits can be calculated as a percentage of final average salary times number of years of service and changes with the number of years of membership within the plan.

At December 31, 2024 and 2023, the Corporation reported a liability of \$155,324 and \$198,936, respectively, for its proportionate share of the NYSLRS net pension liability. The total pension liability used to calculate the net pension liability is determined by an actuarial valuation as of April 1st each year and rolled forward to March 31st. The Corporation's proportion for the net pension liability for each fiscal year was based on the Corporation's indexed present value of future compensation to NYSLRS of all participating employers for 2024 and 2023, which was 1.0549% and 0.9277%, respectively.

Notes to the Financial Statements Year Ended December 31, 2024 (Dollars in Thousands)

Note 11. Pension Plan (Continued)

(a) Actuarial Assumptions

The total pension liability for the March 31, 2024 measurement date was determined using an actuarial valuation as of April 1, 2023, with update procedures used to roll-forward the total pension liability to March 31, 2024. The actuarial valuations used the following actuarial assumptions:

Inflation Salary increases Investment rate of return Cost of living adjustments Mortality improvement 2.9% 4.4%, including inflation 5.9%, net of pension plan investment expense 1.5% Society of Actuaries Scale MP-2021

The total pension asset for the March 31, 2023, measurement date was determined using an actuarial valuation as of April 1, 2022, with update procedures used to roll-forward the total pension liability to March 31, 2023. The actuarial valuations used the following actuarial assumptions:

Inflation Salary increases Investment rate of return Cost of living adjustments Mortality improvement

2.9% 4.4%, including inflation 5.9%, net of pension plan investment expense 1.5% Society of Actuaries Scale MP-2021

Notes to the Financial Statements Year Ended December 31, 2024 (Dollars in Thousands)

Note 11. Pension Plan (Continued)

(b) Expected Rate of Return on Investments

The long-term expected rate of return on pension plan investments was determined using a buildingblock method in which best-estimate ranges of expected future real rates of return (expected return, net of investment expenses and inflation) are developed for each major asset class. These ranges are combined to produce the long-term expected rate of return by weighting the expected future real rates of return by the target asset allocation percentage and by adding expected inflation. The target allocation and best estimates of arithmetic real rates of return for each major asset class are summarized in the following tables at December 31:

| | 20 | 24 |
|--|------------|----------------|
| | Target | Long-Term |
| | Asset | Expected Real |
| Asset class | Allocation | Rate of Return |
| SI DU and P | | |
| Domestic equity | 32.0% | 4.0% |
| International equity | 15.0% | 6.7% |
| Private equity | 10.0% | 7.3% |
| Real estate | 9.0% | 4.6% |
| Fixed income | 23.0% | 1.5% |
| Credit | 4.0% | 5.4% |
| Real assets | 3.0% | 5.8% |
| Opportunistic/absolute return strategy | 3.0% | 5.3% |
| Cash | 1.0% | 0.3% |
| | 100.0% | |

| | 20 | 23 |
|--|------------|----------------|
| | Target | Long-Term |
| | Asset | Expected Real |
| Asset class | Allocation | Rate of Return |
| | | |
| Domestic equity | 32.0% | 4.3% |
| International equity | 15.0% | 6.9% |
| Private equity | 10.0% | 7.5% |
| Real estate | 9.0% | 4.6% |
| Fixed income | 23.0% | 1.5% |
| Credit | 4.0% | 5.4% |
| Real assets | 3.0% | 5.8% |
| Opportunistic/absolute return strategy | 3.0% | 5.4% |
| Cash | 1.0% | 0.0% |
| | 100.0% | |

Notes to the Financial Statements Year Ended December 31, 2024 (Dollars in Thousands)

Note 11. Pension Plan (Continued)

(c) Discount Rate

The discount rate used to measure the total pension liability as of December 31, 2024 and 2023 was 5.9%. The projection of cash flows used to determine the discount rate assumes that contributions from plan members will be made at the current contribution rates and that contributions from employers will be made at statutorily required rates, actuarially determined. Based on those assumptions, the NYSLRS fiduciary net position was projected to be available to make all projected future benefit payments of current plan members. Therefore, the long-term expected rate of return on NYSLRS investments was applied to all periods of projected benefit payments to determine the total pension liability.

Sensitivity of the Net Pension Liability (Asset) to the Discount Rate



The following presents the Corporation's proportionate share of the net pension liability calculated using the discount rate of 5.9% at December 31, 2024 and 2023, as well as what the Corporation's proportionate share of the net pension liability would be if it were calculated using a discount rate that is one percentage point lower or one percentage point higher than the current rate:

| | Igs. | - Ballie |)- | 2024 | | | |
|--|------|--------------------|-------------|---------------------|--------|----------------------|--|
| | 1% | Decrease | 1% Increase | | | | |
| | 40 | (4.9%) (5.9%) | | | (6.9%) | | |
| Corporation's proportionate share of the | | | | | | | |
| net pension liability (asset) | \$ | 488,356 | \$ | 155,324 | \$ | (122,826) | |
| | | | | | | | |
| | | | | 0000 | | | |
| | | | | 2023 | | | |
| | 1% | Decrease | Dis | 2023 scount Rate | 19 | % Increase | |
| | 1% | Decrease (4.9%) | Dis | | 19 | % Increase (6.9%) | |
| Corporation's proportionate share of the | 1% | | Dis | scount Rate | 19 | | |

Notes to the Financial Statements Year Ended December 31, 2024 (Dollars in Thousands)

Note 11. Pension Plan (Continued)

(d) Deferred Outflows and Inflows of Resources

At December 31, 2024 and 2023, the Corporation reported deferred outflows of resources and deferred inflows of resources related to pensions from the following sources:

| | | 2024 | | 2023 |
|---|----|---------|----|---------|
| Deferred outflows of resources: | | | | |
| Differences between expected and actual actuarial experience | \$ | 50,030 | \$ | 21,188 |
| Changes in assumptions | | 58,725 | | 96,616 |
| Changes in proportion and differences between Corporation | | | | |
| contributions and proportionate share of contributions | | 12,433 | S | 5,311 |
| Total | \$ | 121,188 | \$ | 123,115 |
| | 09 | | | |
| Deferred inflows of resources: | | | | |
| Difference between expected and actual experience | \$ | 4,235 | \$ | 5,587 |
| Change in assumptions | | - | | 1,068 |
| Net difference between projected and actual investment earnings | ad | | | |
| on pension plan investments | | 75,875 | | 1,168 |
| Changes in proportion and differences between Corporation | | | | |
| contributions and proportionate share of contributions | | 15,527 | | 15,914 |
| Total CULPS DE Tres | \$ | 95,637 | \$ | 23,737 |
| | | | | |

The change in employer proportionate share is the difference between the employer proportionate share of net pension liability in the prior year compared to the current year. Changes in these amounts are amortized over a five-year closed period, reflecting the average remaining service life of plan members.

The net deferred outflows and inflows of resources of resources related to pensions will be recognized in pension expense as follows:

Years ending December 31:

| 2025 | \$ | (30,652) |
|------|----|----------|
| 2026 | Ψ | 27,472 |
| 2020 | | 44,470 |
| 2028 | | (15,739) |
| | \$ | 25,551 |

Annual Pension Expense

The Corporation's annual pension expense for calendar years ended 2024 and 2023, which includes contributions toward the actuarially determined asset or liability and the amortization of deferred outflows and inflows of resources, was approximately \$64,435 and \$65,509, respectively.

Notes to the Financial Statements Year Ended December 31, 2024 (Dollars in Thousands)

Note 12. Other Post-Employment Benefits (OPEB)

Plan description: The Corporation provides OPEB that include basic medical and hospitalization plan coverage to eligible retirees. Eligible retirees may only be covered under the indemnified plan of the Corporation. To qualify, a retiree must meet various eligibility requirements as agreed to in collective bargaining agreements. The Corporation pays varying amounts based on specific union agreements.

Funding the plan: Currently, there is no New York State statute that expressly authorizes local governments to create a trust for OPEB purposes. Additionally, New York State's General Municipal Law does not allow for a reserve fund to accumulate funds for OPEB obligations. The Corporation's Board of Directors and management believe it is prudent to reserve funds for the Plan and have therefore internally designated \$24,831 in 2024 and 2023, for purposes of funding future post-employment benefits. These internally designated funds are included within assets whose use is limited in the statements of net position. In addition to the funding for future post-employment benefits, the Corporation continues to finance current benefits on a pay-as-you-go basis.

Annual OPEB cost and net OPEB obligation: The Corporation's total OPEB liability measured at December 31, 2024 and 2023, of \$278,596 and \$293,911, respectively, was determined by an actuarial valuation as of January 1, 2024 and 2023, respectively. The measurement date of the obligation is December 31, 2024 and 2023.

(a) Actuarial Assumptions

The total OPEB liability in the December 31, 2024, actuarial valuation was determined using the following actuarial assumptions, applied to all periods included in the measurement, unless otherwise specified:

| Inflation |
|--------------------------------|
| Salary increases |
| Pre-Medicare Plans |
| Medicare Plans |
| Pre-Medicare Prescription Plan |
| Medicare Prescription Plan |
| Mortality |

2.5% 3.3% per annum 7.8% for 2024, 4.0% ultimate trend rate in 2075 5.0% for 2024, 4.0% ultimate trend rate in 2075 8.5% for 2024, 4.0% ultimate trend rate in 2075 4.0% for 2024, 4.0% ultimate trend rate in 2075 Society of Actuaries Scale MP-2021

The total OPEB liability in the December 31, 2023 actuarial valuation was determined using the following actuarial assumptions, applied to all periods included in the measurement, unless otherwise specified:

Inflation Salary increases Pre-Medicare Plans Medicare Plans Pre-Medicare Prescription Plan Medicare Prescription Plan Mortality 2.5% 3.3% per annum 7.8% for 2023, 4.0% ultimate trend rate in 2075 4.6% for 2023, 4.0% ultimate trend rate in 2075 7.8% for 2023, 4.0% ultimate trend rate in 2075 7.0% for 2023, 4.0% ultimate trend rate in 2075 Society of Actuaries Scale MP-2021

Notes to the Financial Statements Year Ended December 31, 2024 (Dollars in Thousands)

Note 12. Other Post-Employment Benefits (OPEB) (Continued)

(b) Changes in the OPEB Liability

| | | 2024 | 2023 |
|--|----|------------|----------|
| Changes in the OPEB obligation: | | | |
| Projected OPEB obligation at the beginning of year | \$ | 293,911 \$ | 271,395 |
| Service cost | | 3,153 | 2,620 |
| Interest cost | | 9,983 | 9,722 |
| Change of benefit terms | | 6,176 | - |
| Difference between expected and actual experience | | 14,200 | 232 |
| Change in assumptions | | (36,699) | 26,546 |
| Actual benefit payments | 5 | (12,128) | (16,604) |
| Projected OPEB obligation at the end of year | \$ | 278,596 \$ | 293,911 |
| | | | |

(c) Discount Rate

The discount rate used to measure the total OPEB liability was 4.1% and 3.3%, based on the Bond Buyer 20-year Bond GO index rate as of December 31, 2024 and 2023, respectively.

Sensitivity of the OPEB Liability to the Discount Rate

The following presents the Corporation's total OPEB liability calculated using the discount rate of 4.1%, as well as what the Corporation's total OPEB liability would be if it were calculated using a discount rate that is one percentage point lower (3.1%) or one percentage point higher (5.1%) than the current rate.

| | 2024 | | | | | | | |
|--|------------------------------|---------|---------------------------|---------|----|---------|--|------------|
| | 1% Decrease Discount Rate 1% | | 1% Decrease Discount Rate | | | | | 6 Increase |
| | | (3.1%) | (5.1%) | | | | | |
| The Corporation's total OPEB liability | \$ | 316,533 | \$ | 278,596 | \$ | 247,364 | | |

The discount rate used to measure the total OPEB liability as of December 31, 2023, was 3.3%, based on the Bond Buyer 20-year Bond GO index rate.

The following presents the Corporation's total OPEB liability calculated using the discount rate of 3.3%, as well as what the Corporation's total OPEB liability would be if it were calculated using a discount rate that is one percentage point lower (2.3%) or one percentage point higher (4.3%) than the current rate.

| | | | | 2023 | | |
|--|----|----------|-----|------------|----|------------|
| | 1% | Decrease | Dis | count Rate | 19 | 6 Increase |
| | | (2.3%) | | (3.3%) | | (4.3%) |
| The Corporation's total OPEB liability | \$ | 337,382 | \$ | 293,911 | \$ | 258,462 |

Notes to the Financial Statements Year Ended December 31, 2024 (Dollars in Thousands)

Note 12. Other Post-Employment Benefits (OPEB) (Continued)

Sensitivity of the OPEB Liability to the Healthcare Cost Trend Rates

The following presents the Corporation's total OPEB liability calculated using healthcare cost trend rates that are one percentage point lower or one percentage point higher than the current healthcare cost trend rates.

| | 2024 |
|--|--|
| | Healthcare |
| | 1% Decrease Cost Trend Rates 1% Increase |
| The Corporation's total OPEB liability | \$ 244,305 \$ 278,596 \$ 320,448 |
| | 2023 |
| | Healthcare |
| | 1% Decrease Cost Trend Rates 1% Increase |
| | CIOIN SE |
| The Corporation's total OPEB liability | \$ 255,222 \$ 293,911 \$ 341,658 |
| | |

⁽d) Deferred Outflows and Inflows of Resources

The following are components of deferred outflows and inflows at December 31, 2024 and 2023:

| Lifterences between expected and actual actuarial experience Changes in assumptions Total2024Differences between expected and actual actuarial experience S 21,151 \$ (45,778)\$ 9,881 \$ (7,662) 11,270 (38,116) \$ 21,151 \$ (45,778)Differences between expected and actual actuarial experience Changes in assumptions Total\$ 0,000 \$ (0,000) 11,270 (0,000)Differences between expected and actual actuarial experience Changes in assumptions Total\$ 0,000 \$ (0,000) 11,270 (0,000)Differences between expected and actual actuarial experience Changes in assumptions Total\$ 0,000 \$ (0,000) 11,270 (0,000)Differences between expected and actual actuarial experience Changes in assumptions Total\$ 0,000 \$ (0,000) 1,000 \$ (0,000)Differences between expected and actual actuarial experience Changes in assumptions Total\$ 0,000 \$ (0,000) 2,000 \$ (0,000) | | 20 | 024 | |
|--|--------|----------|-----|----------|
| Differences between expected and actual actuarial experience Changes in assumptions Total9,881 (7,662) (38,116) \$ 21,151 \$ (45,778)Differences between expected and actual actuarial experience Changes in assumptions2023 Deferred OutflowsDifferences between expected and actual actuarial experience Changes in assumptions\$ 544 (27,754) (31,583) | D | eferred | | Deferred |
| Changes in assumptions11,270(38,116)Total\$ 21,151 \$ (45,778)2023DeferredDeferredOutflowsInflowsDifferences between expected and actual actuarial experience\$ 544 \$ (27,754)Changes in assumptions | | Dutflows | | Inflows |
| Total \$ 21,151 \$ (45,778) 2023 2023 Deferred Deferred Outflows Inflows Differences between expected and actual actuarial experience \$ 544 \$ (27,754) Changes in assumptions 25,126 (31,583) | \$ | | \$ | () |
| Deferred OutflowsDeferred InflowsDifferences between expected and actual actuarial experience\$ 544 \$ (27,754) 25,126 (31,583) | \$ | , | \$ | |
| OutflowsInflowsDifferences between expected and actual actuarial experience\$ 544 \$ (27,754)Changes in assumptions25,126 (31,583) | | 20 | 023 | |
| Differences between expected and actual actuarial experience\$ 544\$ (27,754)Changes in assumptions25,126(31,583) | D | eferred | | Deferred |
| Changes in assumptions 25,126 (31,583) | 0 | Dutflows | | Inflows |
| | \$ | - | \$ | , , |
| | \$ | | \$ | · · · / |

Notes to the Financial Statements Year Ended December 31, 2024 (Dollars in Thousands)

Note 12. Other Post-Employment Benefits (OPEB) (Continued)

The net deferred outflows and inflows of resources at December 31, 2024, will be recognized as follows:

| Years ending December 31: | |
|---------------------------|----------------|
| 2025 | \$ (20,051) |
| 2026 | (2,845) |
| 2027 | (1,731) |
| | \$ (24,627) |
| | |

(e) Annual OPEB Benefit

The Corporation's annual OPEB benefit for the years ended December 31, 2024 and 2023, was \$12,226 and \$19,343, respectively.

Note 13. New York State Department of Health (NYSDOH) Grant Programs

The NYSDOH offers the Vital Access Provider Assurance Program (VAPAP) program. Funding under this program is made to public or safety net hospitals and health systems that meet certain criteria or that have been designated as critical access or sole community hospitals and is awarded to enable these facilities to maintain operations and provision of vital services while they implement longer-term solutions to achieve sustainable health care service delivery.

During the year ended December 31, 2023, the Corporation received grant payments under this program in the amount of \$76,838 and recognized \$103,838 as grant revenue in the statement of revenues, expenses and changes in net position as non-operating revenue. During the year ended December 31, 2024, as a result of improved financial performance, the Corporation did not receive any additional funding under this program.

Note 14. Transactions With the County of Erie

On December 30, 2009, the Corporation and the County entered into a Settlement Agreement. The Settlement Agreement resulted in the Corporation and the County entering into a number of transactions to resolve litigation and prepare for implementing the Corporation's master facility plan.

In October 2012, the Corporation and the County signed an amendment to the 2009 Settlement Agreement (the Amendment). The terms of the Amendment provide for the County to be reimbursed from the Corporation for certain workers' compensation claims incurred by Corporation employees that were paid by the County. The Amendment also provides for the County to reimburse the Corporation, over time, for post-retirement health expenses that the Corporation incurred for Corporation employees with service time at the County.

In 2017, the Corporation entered into a loan agreement and a capitalized interest liability assumption agreement with the County of Erie. A component of the loan agreement included the payment of points by the Corporation to the County of Erie in the amount of \$17,040 as further described in Note 2 and 10.

Notes to the Financial Statements Year Ended December 31, 2024 (Dollars in Thousands)

Note 14. Transactions With the County of Erie (Continued)

Other transactions: Amounts that are included in operating revenues and expenses in the statements of revenues, expenses and changes in net position, which represent related-party transactions that occurred between the Corporation and the County during the years ended December 31, 2024 and 2023, are as follows:

The Corporation earned revenue totaling \$3,969 and \$3,902 for the years ended December 31, 2024 and 2023, respectively, from the County. Revenue earned relates to services provided to School 84, mental health services and various other charges related to County departments located within the Corporation's physical plant.

The net amount due to the County of approximately \$3,737 and \$12,661 at December 31, 2024 and 2023, respectively, is non-interest bearing and reflect the Corporation's net amount owed to the County as a result of various transactions and services between parties.

Note 15. Self-Insured Obligations

The Corporation is self-insured for all medical malpractice claims for occurrences on or after January 1, 2004. Additionally, the Corporation began purchasing excess stop-loss insurance on a claims made basis for medical malpractice effective November 2008. The current policy provides \$35,000 of coverage in excess of a self-insured retention (SIR) of \$4,000 of individual claims or \$12,000 in aggregate claims effective November 19, 2018. Effective 11/19/2022, there is an additional \$1,000 buffer of individual claims or aggregate claims. Immediately prior to November 19, 2018, the policy provided \$35,000 of coverage in excess of a SIR \$3,000 of individual claims or \$10,000 in aggregate claims.

Effective April 1, 2016, the Corporation became self-insured for workers' compensation claims through a combination of self-insurance and a high-deductible plan for certain periods as follows: The Corporation maintains a stop-loss insurance policy for the claims in excess of \$750. As required by the NYS Workers' Compensation Board, ECMCC maintains a security deposit on its self-insured workers' compensation obligations. The value of the security deposit was \$30,689 as of December 31, 2024 and 2023. The deposit is maintained through a surety bond. The surety requires a collateral deposit to maintain the bond. The value of the collateral held by the surety was \$5,806 and \$5,512 as of December 31, 2024 and 2023, respectively. Effective January 1, 2012, the Corporation insured a portion of its workers' compensation exposure through an occurrence basis high-deductible plan. The Corporation remains responsible for the first \$750 of an individual claim payment after December 31, 2024 and 2023, \$3,312 and \$4,662, respectively, has been escrowed to service workers' compensation claims and included as part of assets whose use is limited. The Corporation remains self-insured for workers' compensation claims and included as part of assets whose use is limited. The Corporation remains self-insured for workers' compensation claims prior to January 1, 2012. The County has assumed a portion of liabilities for all occurrences originating prior to 2004.

Losses from asserted and unasserted medical malpractice and workers' compensation claims are accrued based on actuarial estimates that incorporate the Corporation's past experience, the nature of each claim or incident, relevant trend factors, and estimated recoveries, if any, on unsettled claims.

Notes to the Financial Statements Year Ended December 31, 2024 (Dollars in Thousands)

Note 15. Self-Insured Obligations (Continued)

The Corporation has accrued \$30,978 and \$33,407 at December 31, 2024 and 2023, respectively, for medical malpractice related exposures. Such amounts have been discounted at 2.0% for 2024 and 2023 and the accrued liabilities are included within the accrued other liabilities and self-insured obligations caption of the accompanying statements of net position. Charges to expense for medical malpractice costs are included within the other operating expenses caption of the accompanying statements of revenues, expenses and changes in net position.

The Corporation has accrued \$22,660 and \$27,922 at December 31, 2024 and 2023, respectively, for workers' compensation related exposures. Such amounts have been discounted at 1.75% for 2024 and 2023, and the liabilities are included within the accrued other liabilities and self-insured obligations captions of the accompanying statements of net position. Charges to expense for workers' compensation costs approximated \$1,167 and \$7,376 in 2024 and 2023, respectively, and are included within the payroll, employee benefits and contract labor caption of the accompanying statements of revenues, expenses and changes in net position.

Eligible retirees are provided basic medical and hospitalization coverage by the Corporation as more fully described in Note 12.

| | 5- | and I | | A TO TO | 0170 | 2024 | | | |
|-----------------------|-------|-----------|--------|-------------|------|----------|--------------|----|-----------|
| | Tan | Sur all | a le p | ctuarial | | | | | |
| | 3/4 E | Beginning | E | stimate of | | Claims | Ending | Du | ie Within |
| | | Balance | Clair | ns Incurred | | Paid | Balance | 0 | ne Year |
| | | MOL | 5 | | | | | | |
| Medical malpractice | \$ | 33,407 | \$ | 2,675 | \$ | (5,104) | \$ 30,978 | \$ | 2,133 |
| Workers' compensation | | 27,922 | | 382 | | (5,644) | 22,660 | | 6,665 |
| | \$ | 61,329 | \$ | 3,057 | \$ | (10,748) | \$ 53,638 | \$ | 8,798 |
| | | | | | | | | | |
| | | | | | | 2023 | | | |
| | | | А | ctuarial | | | | | |
| | E | Beginning | Es | stimate of | | Claims | Ending | Du | ie Within |
| | | Balance | Clair | ns Incurred | | Paid | Balance | 0 | ne Year |
| | | | | | | | | | |
| Medical malpractice | \$ | 30,975 | \$ | 4,750 | \$ | (2,318) | \$ 33,407 | \$ | 1,792 |
| Workers' compensation | | 27,264 | | 6,145 | | (5,487) | 27,922 | | 7,416 |
| | \$ | 58,239 | \$ | 10,895 | \$ | (7,805) | \$ 61,329 | \$ | 9,208 |

The composition of self-insured obligations as of December 31, is as follows:

Medical malpractice and workers' compensation amounts due within one year are management's estimates based on historical claims.

Notes to the Financial Statements Year Ended December 31, 2024 (Dollars in Thousands)

Note 16. Commitments and Contingencies

The health care industry is subject to numerous laws and regulations of federal, state and local governments. Compliance with these laws and regulations is subject to future government review and interpretation as well as regulatory actions unknown or unasserted at the time. Government activity, in recent years, has increased with respect to investigations and allegations concerning possible violations by health care providers of fraud and abuse statutes and regulations, which could result in the imposition of significant fines and penalties, as well as significant repayments for patient services previously billed. While no regulatory allegations have been made against the Corporation, compliance with such laws and regulations can be subject to future government review and interpretations, as well as regulatory actions unknown or unasserted at this time. Management and its counsel are not aware of any such actions that will have a material adverse effect on the Corporation's financial statements.

In October 2024, the Corporation committed to begin implementing a new electronic health record system along with a new enterprise resource planning software system in the first quarter of 2025. Both projects are expected to be completed by the end of 2026.

The healthcare industry is subject to changing political, regulatory, economic and other influences that may affect our business. Regulatory uncertainty has increased as a result of recent decisions issued by the U.S. Supreme Court that affect review of federal agency actions, and the outcome of the 2024 federal elections. Federal agencies oversee, regulate and otherwise affect many aspects of our business, including through Medicare and Medicaid payment and coverage policies, policies affecting the size of the uninsured population, administration of state Medicaid programs and enforcement and interpretation of fraud and abuse laws. The recent Supreme Court decisions may also result in inconsistent judicial interpretations and delays in and other impacts to agency rulemaking and legislative processes. The changes in executive and legislative leadership at the federal level increases regulatory uncertainty and the potential for significant policy changes. Management is actively monitoring the evolving potential changes, and at this time, the impact to the Corporation is unknown.

Loss contingency liabilities are recorded in accordance with U.S. GAAP, which requires recognition of a loss when it is deemed probable that an asset has been impaired or a liability has been incurred, and the amount of the loss can be reasonably estimated. As of December 31, 2024 and 2023, the Corporation has recorded no loss contingencies except as disclosed in Note 15.

The Corporation formed 1827 Fillmore, LLC (1827) for the purpose of acquiring and developing land immediately adjacent to its Grider Street campus. A condition of the acquisition was that 1827 demolish a building on the site with known asbestos abatement requirements. This condition was met in 2018. The Corporation has undertaken a community planning process to determine the future use(s) of the site. The site requires the environmental remediation expenditures; however, the amount of such expenditures is dependent on the ultimate use of the site and requirements from regulators. Through December 31, 2024, approximately \$4,600 has been spent on remediating and improving the land.

Required Supplementary Information

Required Supplementary Information Schedule of Corporation's Contributions NYSLRS Pension Plan December 31, 2024 (Dollars in Thousands)

| | 2024 | | 2023 | 2022 | 2021 | | 2020 | | 2019 | 2018 | 2017 | 2016 | 2015 |
|--|---------------|----|-----------------------------|---------------|---------------|----------|-----------------|----|---------|---------------|---------------|---------------|---------------|
| Contractually required contribution | \$ 34,131 | \$ | 25,153 | \$ 31,946 | \$ 30,167 | \$ | 27,343 | \$ | 26,447 | \$ 25,803 | \$ 25,235 | \$ 26,722 | \$ 29,771 |
| Contributions in relation to the contractually required contribution | 34,131 | | 25,153 | 31,946 | 30,167 | | 27,343 | | 26,447 | 25,803 | 25,235 | 26,722 | 29,771 |
| Contribution deficiency | \$ - | \$ | - | \$ - | \$ 2 | \$ | 0 | \$ | - | \$ - | \$ - | \$ - | \$ - |
| | | | | | AFT | | 28 ⁵ | | | | | | |
| ECMCC covered-employee payroll | \$ 295,295 | \$ | 245,606 | \$ 244,519 | \$ 235,767 | \$ | 216,871 | \$ | 204,007 | \$ 193,386 | \$ 183,540 | \$ 166,691 | \$ 175,409 |
| Contributions as a percentage of covered-employee payroll | 11.6% | B. | 10.2% RELL 800 800 | | 12.8% | CC CC | 12.6% |) | 13.0% | 13.3% | 13.7% | 16.0% | 17.0% |

Required Supplementary Information

Schedule of Corporation's Proportionate Share of Net Pension Liability (Asset)

NYSLRS Pension Plan

December 31, 2024

(Dollars in Thousands)

| | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|-----------------------|--------------------------|---------------------------|----------------|-----------------------|-------------------|----------------------|---------------------|-----------------------|
| ECMCC proportion of the net pension (asset) liability ECMCC proportionate share of the net pension (asset) liability | 1.0549% \$ 155.324 | 0.9277% \$ 198,936 \$ | 0.9485% \$ (77,538) \$ | 0.9187% 915 | 0.8504% \$ 225.197 | 0.8079% 57.240 | 0.7646% \$ 24.677 | 0.7614% \$71.544 | 0.7228% \$ 116.006 |
| ECMCC covered-employee payroll | 295,295 | 245,606 | 273,555 | 249,490 | \$ 223,197 246,772 | 235,284 | \$ 24,677 216,044 | 183,540 | 166,691 |
| ECMCC proportionate share of the net pension liability as a percentage of its covered-employee payroll | 52.6% | 81.0% | -28.3% | 0.4% | 91.3% | 24.3% | 11.4% | 39.0% | 69.6% |
| Plan fiduciary net position as a percentage of the total pension liability | 93.9% | 90.8% | 103.7% | 100.0% | 86.4% | 96.3% | 98.2% | 94.7% | 90.7% |

Note: GASB requires 10 years of information to be presented in this table. However, until a full 10-year trend is compiled,

the Corporation will present information for those year for which information is available.

Change in Benefit Terms

The New York State Legislature lowered the vesting requirement for Tier 5 and Tier 6 from 10 years to five years (Chapter 56 0f the Laws of 2022), prior to the April 1, 2022 actuarial valuation.

Changes of Assumptions

2023: The mortality improvement assumption was updated to the Society of Actuaries' Scale MP-2021, inflation was updated to 2.9%, cost-of-living updated to 1.5%, for the April 1, 2022 actuarial valuation.

2022: The mortality improvement assumption was updated to the Society of Actuaries' Scale MP-2020, inflation was updated to 2.7%, cost-of-living updated to 1.4%, and the interest rate assumption was reduced to 5.9% for the April 1, 2021 actuarial valuation.

Required Supplementary Information Schedule of Corporation's Changes in Total OPEB Liability and Related Ratios December 31, 2024 and 2023 (Dollars in Thousands)

| | | 2024 | 2023 |
|--|----|----------|---------------|
| Total OPEB liability: | | | |
| Service cost | \$ | 3,153 | \$ 2,620 |
| Interest cost | | 9,983 | 9,722 |
| Change of Benefit Terms | | 6,176 | - |
| Differences between expected and actual experience | | 14,200 | 232 |
| Changes of assumptions | | (36,699) | 26,546 |
| Benefit payments | | (12,128) | (16,604) |
| Net change in total OPEB liability | | (15,315) | 22,516 |
| Total OPEB liability—beginning | SE | 293,911 | 271,395 |
| Total OPEB liability—ending | \$ | 278,596 | \$ 293,911 |
| Covered employee payroll | \$ | 85,437 | \$ 87,249 |
| Total OPEB liability as a percentage of covered employee payroll | | 326.08% | 336.86% |
| Discount rate | | 4.1% | 3.3% |
| Change in Benefit Terms | | | |

There were no significant changes in benefits during 2024 and 2023.

Changes of Assumptions

2024: The discount rate was increased from 3.3% to 4.1% as well as an update to the medical and prescription trend rates.

2023: The discount rate was decreased from 3.7% to 3.3%, while salary increases were adjusted from 3.7% to 3.3% as well as an update to the medical and prescription trend rates.

Erie County Medical Center Corporation

(A Component Unit of the County of Erie)

Uniform Guidance Audit Requirements December 31, 2024

For Review and Discussion Putposes Only Not to be Reproduced

Schedule of Expenditures of Federal Awards For the Year Ended December 31, 2024

| Federal Grantor/Pass-Through Grantor/Program or Cluster Title | Federal Assistance Listing Number | Pass-Through Entity Identifying Number | Provided to Subrecipients | Total Federal Expenditures |
|---|--------------------------------------|---|------------------------------|-------------------------------|
| Grantol/Program of Cluster Title | | Entry Identifying Number | Subrecipients | Experioritures |
| J.S. Department of Health and Human Services Health Resources and | | | | |
| Services Administration Direct Programs: | | | | |
| Training in General, Pediatric, and Public Health Dentistry | 93.059 | N/A | - | 964,198 |
| | 00.000 | | | 001,100 |
| Ryan White HIV/AIDS Dental Reimbursement and Community | | | | |
| Based Dental Partnership Grants | 93.924 | N/A | - | 168,89 |
| | | | | , |
| Oral Diseases and Disorders Research | 93.121 | N/A | - | 348,028 |
| Substance Abuse and Mental Health Services Projects of | | | | |
| Regional and National Significance | 93.243 | N/A | | 497,41 |
| | | | | |
| otal U.S. Department of Health and Human Services Health | | | | |
| Resources and Services Administration Direct Programs | | | - | 1,978,52 |
| .S. Department of Health and Human Services pass-through program from: | | | | |
| Health Research Inc. | | | | |
| National Bioterrorism Hospital Preparedness Program | 93.889 | NU90TP000515 | - | 42,50 |
| | | | | |
| otal U.S. Department of Health and Human Services Pass-Through Programs | | | -1 | 42,50 |
| S. Department of Justice Pass-Through Program From: | | | | |
| New York State Office of Victim Crime Services | | | | |
| Crime Victim Assistance | 16.575 | OVS01-C11259GG-1080200 | - | 240,78 |
| New York State Division Criminal Justice Services | | | | |
| Crime Victim Assistance | 16.575 | OVS01-C11259GG-1080200 | - | 97,39 |
| Office of Victim Services | | | | |
| Crime Victim Assistance | 16.575 | OVS01-T11152GG-1080200 | - | 153,95 |
| Office of Victim Services | | | | |
| Crime Victim Assistance | 16.575 | OVS01-T11152GG-1080200 | - | 50,09 |
| Total: 16.575 | | | - | 542,22 |
| | | | | |
| New York State Office of Victim Crime Services | 2 - A BILL | | | 0.40.00 |
| Crime Victim Assistance/Discretionary Grants | 16.582 | 15POVC-22-GK-01799-NONF | - | 246,66 |
| New York State Division Criminal Justice Services | | | | |
| Violence Against Women Formula Grants | 16.588 | C00256GG-1090000 | | 45.61 |
| Violence Against Women i official Granits | 10.300 | 0023088-1030000 | - | 45,01 |
| Office of Justice Programs | | | | |
| Services for Trafficking Victims | 16.320 | 15POVC-24-GG-01824-HT | _ | 7,58 |
| Sources for Hamoking Vicinity | 0.020 | 151 010-24-00-01024-111 | | 1,00 |
| otal U.S. Department of Justice Pass-Through Program | | | - | 842,09 |
| | | | | 2.2,00 |
| S. Department of Homeland Security (Federal Emergency Management Agency) | | | | |
| COVID-19: Disaster Grants - Public Assistance (Presidentially Declared Disasters) | 97.036 | N/A | _ | 17,333,18 |
| COMPTO. Disaster Granto - Fublic Assistance (Freshentially Decidied Disasters) | 97.000 | 19/2 | | 17,000,10 |
| Total Expenditures of Federal Awards | | | \$ - | \$ 20,196,31 |
| Total Expenditules of Federal Awards | | | Ψ - | ψ 20,130,3 |

See notes to the schedule of expenditures of federal awards.

Notes to Schedule of Expenditures of Federal Awards Year Ended December 31, 2024

Note 1. Basis of Presentation

The accompanying schedule of expenditures of federal awards (the Schedule) includes the federal award activity of the Erie County Medical Center Corporation (the Corporation) under programs of the federal government for the year ended December 31, 2024. The information on this Schedule is presented in accordance with the requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance).

For purposes of the Schedule, federal awards include all federal assistance entered into directly between the Corporation and the federal government and sub-awards from nonfederal organizations made under federally sponsored agreements. The Schedule does not include payments received under Medicare and Medicaid reimbursement programs. Because the Schedule presents only a selected portion of the activities of the Corporation, it is not intended to, and does not, present the financial position, changes in net position and cash flows of the Corporation.

Note 2. Summary of Significant Accounting Policies

Expenditures reported on the Schedule are reported on the accrual basis of accounting. Such expenditures are recognized following cost principles contained in the Uniform Guidance, wherein certain types of expenditures are not allowable or are limited as to reimbursement. The Corporation has elected to not exercise its option to use the 10% de minimis indirect cost rate as allowed under the Uniform Guidance.

Note 3. Other Federal Awards

There were no federal awards expended for noncash assistance, insurance, or any loans, loan guarantees, or interest subsidies outstanding at December 31, 2024.

Note 4. Subrecipients

The Corporation did not provide federal awards to any subrecipients during the year ended December 31, 2024.

Report on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance With *Government Auditing Standards*

Independent Auditor's Report

Board of Directors Erie County Medical Center Corporation

We have audited, in accordance with the auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States (*Government Auditing Standards*), the financial statements of the business-type activities and the aggregate discretely presented component units of Erie Medical Center Corporation (the Corporation), as of and for the year ended December 31, 2024, and the related notes to the financial statements, which collectively comprise the Corporation's basic financial statements, and have issued our report thereon dated [DATE].

The financial statements of ECMC Foundation, Inc., the Grider Initiative, Inc. and Research for Health in Erie County, Inc. were not audited in accordance with *Government Auditing Standards*, and accordingly, this report does not include reporting on internal controls over financial reporting or instances of reportable noncompliance associated with ECMC Foundation, Inc., the Grider Initiative, Inc. and Research for Health in Erie County, Inc.

Report on Internal Control Over Financial Reporting

In planning and performing our audit of the financial statements, we considered the Corporation's internal control over financial reporting (internal control) as a basis for designing audit procedures that are appropriate in the circumstances for the purpose of expressing our opinions on the financial statements, but not for the purpose of expressing an opinion on the effectiveness of the Corporation's internal control. Accordingly, we do not express an opinion on the effectiveness of the Corporation's internal control.

A *deficiency in internal control* exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A *material weakness* is a deficiency, or a combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected and corrected, on a timely basis. A *significant deficiency* is a deficiency, or a combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected and corrected, on a timely basis. A *significant deficiency* is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.


Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses or significant deficiencies may exist that were not identified.

Report on Compliance and Other Matters

As part of obtaining reasonable assurance about whether the Corporation's financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements, noncompliance with which could have a direct and material effect on the basic financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

Purpose of This Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the Corporation's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the Corporation's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.



Report on Compliance For Each Major Federal Program; Report on Internal Control Over Compliance; and Report on Schedule of Expenditures of Federal Awards Required by the Uniform Guidance

Independent Auditor's Report

Board of Directors Erie County Medical Center Corporation

Report on Compliance for Each Major Federal Program

Opinion on Each Major Federal Program



We have audited Erie County Medical Center Corporation's (the Corporation) compliance with the types of compliance requirements identified as subject to audit in the OMB *Compliance Supplement* that could have a direct and material effect on each of the Corporation's major federal programs for the year ended December 31, 2024. The Corporation's major federal programs are identified in the summary of auditor's results section of the accompanying schedule of findings and questioned costs.

In our opinion, the Corporation complied, in all material respects, with the compliance requirements referred to above that could have a direct and material effect on each of its major federal programs for the year ended December 31, 2024.

Basis for Opinion on Each Major Federal Program

We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America (GAAS); the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States (*Government Auditing Standards*); and the audit requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Our responsibilities under those standards and the Uniform Guidance are further described in the Auditor's Responsibilities for the Audit of Compliance section of our report.

We are required to be independent of the Corporation and to meet our other ethical responsibilities, in accordance with relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on compliance for each major federal program. Our audit does not provide a legal determination of the Corporation's compliance with the compliance requirements referred to above.

Responsibilities of Management for Compliance

Management is responsible for compliance with the requirements referred to above and for the design, implementation and maintenance of effective internal control over compliance with the requirements of laws, statutes, regulations, rules and provisions of contracts or grant agreements applicable to the Corporation's federal programs.

Auditor's Responsibility for the Audit of Compliance

Our objectives are to obtain reasonable assurance about whether material noncompliance with the compliance requirements referred to above occurred, whether due to fraud or error, and express an opinion on the Corporation's compliance based on our audit. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS, *Government Auditing Standards*, and the Uniform Guidance will always detect material noncompliance when it exists. The risk of not detecting material noncompliance resulting from fraud is higher than for that resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations or the override of internal control. Noncompliance with the compliance requirements referred to above is considered material, if there is a substantial likelihood that, individually or in the aggregate, it would influence the judgment made by a reasonable user of the report on compliance about the Corporation's compliance with the requirements of each major federal program as a whole.

In performing an audit in accordance with GAAS, *Government Auditing Standards*, and the Uniform Guidance, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material noncompliance, whether due to fraud or error, and design
 and perform audit procedures responsive to those risks. Such procedures include examining, on a
 test basis, evidence regarding the Corporation's compliance with the compliance requirements
 referred to above and performing such other procedures as we considered necessary in the
 circumstances.
- Obtain an understanding of the Corporation's internal control over compliance relevant to the audit in
 order to design audit procedures that are appropriate in the circumstances and to test and report on
 internal control over compliance in accordance with the Uniform Guidance, but not for the purpose of
 expressing an opinion on the effectiveness of the Corporation's internal control over compliance.
 Accordingly, no such opinion is expressed.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and any significant deficiencies and material weaknesses in internal control over compliance that we identified during the audit.

Report on Internal Control Over Compliance

A deficiency in internal control over compliance exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. A *material weakness in internal control over compliance* is a deficiency, or a combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. A *significant deficiency in internal control over compliance* is a deficiency, or a combination of deficience, yet and corrected of the timely basis. A *significant deficiency in internal control over compliance* is a deficiency, or a combination of deficience, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the Auditor's Responsibilities for the Audit of Compliance section above and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies in internal control over compliance. Given these limitations, during our audit we did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses, as defined above. However, material weaknesses or significant deficiencies in internal control over compliance that we consider to be material weaknesses, as defined above. However, material weaknesses or significant deficiencies in internal control over compliance that we consider to be material weaknesses.

Our audit was not designed for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, no such opinion is expressed.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.

Report on Schedule of Expenditures of Federal Awards Required by the Uniform Guidance

We have audited the financial statements of the business-type activities and the aggregate discretely presented component unit of the Corporation as of and for the year ended December 31, 2024, and the related notes to the financial statements, which collectively comprise the Corporation's basic financial statements. We issued our report thereon dated [DATE], which contained unmodified opinions on those financial statements. Our audit was performed for the purpose of forming opinions on the financial statements that collectively comprise the basic financial statements. The accompanying schedule of expenditures of federal awards is presented for purposes of additional analysis as required by the Uniform Guidance and is not a required part of the basic financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the basic financial statements. The information has been subjected to the auditing procedures applied in the audit of the basic financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the basic financial statements or to the basic financial statements expendit unancial statemen erection erection for work to be reproduced to themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the schedule of expenditures of federal awards is fairly stated in all material respects in relation to the basic financial statements as a whole.

Cleveland, Ohio [DATE]

Erie County Medical Center Corporation (A Component Unit of the County of Erie)

Schedule of Findings and Questioned Costs Year Ended December 31, 2024

Section I—Summary of Auditor's Results

Financial Statements

| Type of auditor's report issued on whether the financial statements audited were prepared in accordance with GAAP: | | Unmodifi | ed | |
|--|---|------------|-----------------|---------------------|
| Internal control over financial reporting: Material weakness(es) identified? | | ves | Х | no |
| Significant deficiency(ies) identified? | | yes | X | none reported |
| Noncompliance material to financial statements noted? | DRAFT | yes | X | no |
| Federal Awards | | | | |
| Internal control over major programs: Material weakness(es) identified? Significant deficiency(ies) identified? | Change Change | yes yes | X X | no none reported |
| Type of auditor's report issued on compliance for major programs: | | Unmodifi | ed | |
| Any audit findings disclosed that are required to be report in accordance with 2 CFR Section 200.516(a)? | ed | yes | X | no |
| Identification of major federal programs: | | | | |
| Federal Assistance Listing Number(s) | Name of Fe | deral Pro | gram or Cluste | <u>r</u> |
| 97.036 | | | Grants - Public | Assistance |
| 93.243 | (Presidentially Declared Disasters) Substance Abuse and Mental Health Services Projects of Regional and National Significance | | | |
| Dollar threshold used to distinguish between Type A and Type B programs: | | | \$ 750,000 | |
| Auditee qualified as a low risk auditee? | X | yes | | no |
| (Continu | ied) | | | |

Erie County Medical Center Corporation (A Component Unit of the County of Erie)

Schedule of Findings and Questioned Costs (Continued) Year Ended December 31, 2024

Section II—Financial Statement Findings

No findings were noted.

Section III—Findings and Questioned Costs for Federal Awards

No findings were noted.

Erie County Medical Center Corporation (A Component Unit of the County of Erie)

Summary Schedule of Prior Year Findings and Questioned Costs Year Ended December 31, 2024

Section I—Financial Statement Findings

No findings were noted in the prior (2023) audit.

Section II—Findings and Questioned Costs for Federal Awards

No findings were noted in the prior (2023) audit.

Resolution Approving the Corporation's Annual Report

Approved March 25, 2025

WHEREAS, Erie County Medical Center Corporation (the "Corporation") is a public benefit corporation obligated under sections 2800 and 3642 of New York Public Authorities Law to prepare, approve and distribute an Annual Report of its operations; and

WHEREAS, the Corporation has prepared a draft of the 2024 Annual Report and distributed this draft to members of the Corporation's Board of Directors for consideration before the meeting called to consider approval;

Now, THEREFORE, the Board of directors resolves as follows:

1. The 2024 Annual Report prepared by the Corporation is approved in substantially the form and content as presented to the Board of Directors.

2. The Corporation is directed to file and distribute the 2024 Annual Report in the manner prescribed by New York Public Authorities Law.

3. This resolution shall take effect immediately.

Sharon L. Hanson Corporation Secretary

2024 ANNUAL REPORT OF

ERIE COUNTY MEDICAL CENTER CORPORATION

(AS REQUIRED BY N.Y. PUBLIC AUTHORITIES LAW)



Respectfully Submitted by the Corporation March 31, 2025

TABLE OF CONTENTS

| Message from the Leadership of ECMC Corporation | Pages 3-7 |
|---|-------------|
| Certification | Page 8 |
| Mission Statement | Page 9 |
| Accomplishments | Page 10-15 |
| Performance Goals | Pages 16-19 |
| Capital Projects | Page 20 |
| Real Property & Property Acquisitions | Page 20 |
| Code of Conduct | Page 21 |
| Internal Control Structure and Procedures | Page 21 |
| Pending Litigation | Page 21 |
| Corporation and Board Structure | Pages 22-32 |
| Subsidiary Information | Pages 33-34 |

APPENDIX A

NOT FINAL

Financial Reports

Four-Year Financial Plan

Outstanding Bonds and Notes

APPENDIX B

Compensation Schedule

APPENDIX C

Corporation Expenditures in Excess of \$100,000

APPENDIX D

Enabling Legislation

Charter or By-Laws

MESSAGE FROM THE LEADERSHIP OF ECMC CORPORATION

Throughout 2024, ECMC experienced continued growth in our healthcare services, building on our post-pandemic successes in restoring overall hospital operations and patient volumes. Like other safety net hospitals across the country and locally, it has been challenging, but the focus on our patients by our entire ECMC Family has supported our ability to continue to make progress and provide our community with the high-quality care they expect and deserve.

In almost every measurable category, increases demonstrated a sustainable positive trend in patient volumes that is certainly beneficial to serving our community and improving our financial challenges. Positive operational growth was reflected in our inpatient and outpatient services, Emergency Department visits, and surgeries.

We often speak about ECMC's unique culture and the dedication and resilience of our caregivers. They are the cornerstone of our institution. Their accomplishments and nationally recognized clinical excellence supports and strengthens our recruitment efforts. ECMC has had tremendous success recruiting nurses in the past year, eliminating almost all agency nurses. In 2024, we brought on 769 new hires that includes 165 new RNs, 48 LPNs and 114 CNAs. We hear routinely that many of our new employees are attracted to ECMC based on their knowledge of our inclusive, diverse and talented workforce and supportive culture. And we continue to elevate our surrounding community with our top hiring from our own 14215 zip code. Also, 136 new physicians were onboarded during the year and resulted in the expansion of services on our health campus.

Among our many clinical accomplishments, accreditations and national recognition in 2024, ECMC's Medical Intensive Care Units (MICU) were recognized by the American Association of Critical-Care Nurses (AACN) with a gold-level Beacon Award for Excellence. With this accomplishment, ECMC is 1 of only 2 Level 1 Trauma Centers in New York State with more than 1 Gold Beacon Unit, 1 of 7 hospitals in the state with more than one Gold Beacon unit, and one of two hospitals in Western New York with more than one Gold Beacon unit. The Beacon Award for Excellence — a significant milestone on the path to exceptional patient care and healthy work environments — recognizes caregivers who successfully improve patient outcomes and align practices with AACN's six Healthy Work Environment Standards. The AACN's Gold Beacon Award for Excellence is further evidence of ECMC's national best-in-class patient care that we have become known for throughout our community.

Expanding our state-of-the-art surgical capabilities, a fifth surgical robot, the ION robotic navigational bronchoscopy platform was added this past year to ECMC's surgical services. It is designed to reach smaller lung nodules in the periphery of the lung to diagnose lung cancer earlier and increase the survival rate.

In another indication of national affirmation of ECMC's clinical excellence, we earned status in 2024 as an American College of Surgeons (ACS) Surgical Quality Partner due to ECMC's participation in multiple ACS quality programs. According to the ACS, "Hospital systems that implement ACS Quality Programs help hospitals prioritize a proactive quality and safety culture, reduce unnecessary hospital stays, and save money." We were proud to be recognized by such a prestigious national organization for our commitment to quality services, patient safety, and sound management of our institution.

In Orthopedics, ECMC was honored by US News and Annual Report in their annual High Performance Hospitals report as a High Performing Institution for Hip Replacement. According to their report, "Over 6,000 hospitals were evaluated and eligible hospitals received one of three ratings -- high performing (593 hospitals), average (1,376 hospitals) or below average (488 hospitals) with the balance either not offering the service or performing too few of the procedures to be rated. Hospitals that earned a high performing rating were significantly better than the national average."

The American College of Emergency Physicians (ACEP) informed ECMC that our Emergency Department in 2024 achieved the bronze standard — Level 3 Geriatric Emergency Department Accreditation (GEDA) accreditation. The voluntary GEDA program, which includes three levels similar to trauma center designations, provides specific criteria and goals for emergency clinicians and administrators to target. This accreditation from ACEP reinforces the high-quality care and clinical excellence that ECMC is known for, particularly in our Emergency Department. It further highlights our caregivers' commitment to ensuring that all patients, notably older adults, receive the very best healthcare services they need.

ECMC's clinical services continued to receive national recognition for their excellence and innovation. Lucia Gioeli MA, VP of Ambulatory Services & Population Health and Amanda Farrell BSN,RN,CMSRN,AMB-BC, Population Health Clinical Data Analyst presented the "Perceived Control of Chronic Condition" this past June within the Innovation in Healthcare track at America's Essential Hospital's national annual meeting VITAL2024.

Dr. Anthony Martinez, ECMC's Medical Director of Hepatology was honored in July with the Coalition for Global Hepatitis Elimination's 2024 Hepatitis Elimination Champion award. Dr. Martinez was one of eight Champions selected worldwide from seven countries, reinforcing the scope and level of excellence of ECMC's clinicians. The Coalition for Global Hepatitis Elimination, a program of The Task Force for Global Health, is a nonprofit bringing together global partners to achieve worldwide elimination of viral hepatitis.

And in further recognition of ECMC's innovative high-quality healthcare services, the national publication Healthcare IT News published a high-profile feature story on our Ambulatory Services very successful Remote Patient Monitoring program, which was developed in collaboration with Independent Health.

Demonstrating ECMC's clinical leadership in our region, our Rehabilitation Medicine and Acute Care Services held its seventh annual Rehab Symposium, titled "A Multidisciplinary Approach to the Acute Care Patient." For this well-attended conference, many of the region's most experienced clinicians were invited to speak on a variety of topics pertaining to rehabilitation on acute and critical care services. Area therapists, rehab professionals, and therapy students from the community were invited to learn about some of the specialty services that are available at ECMC.

We celebrated the opening of ECMC's new satellite Trauma Recovery Center, that is affiliated with the institution's BRAVE (Buffalo Rising Against Violence) initiative, which is our hospitalbased violence intervention trauma recovery effort that serves individuals who have experienced acute victimization and violence. In October 2023, ECMC's BRAVE program achieved designation/certification as Western New York's only Trauma Recovery Center (TRC). It is only the second NYS Office of Victims Services(OVS)-funded program in the state to attain that distinction from the National Alliance of Trauma Recovery Centers (NATRC); the other TRC in the state is located in Brooklyn. There are only 52 TRCs in the United States. It's a successful model that treats victims of violence holistically and proactively through comprehensive case management and assertive outreach.

We were pleased and gratified that Terrace View Long-Term Care Facility was again recognized on Newsweek's Best Nursing Homes 2025 list. This prestigious award, which Terrace View has received in five consecutive years, is presented by Newsweek and Statista Inc., the world-leading statistics portal and industry ranking provider. Of the 600 skilled nursing facilities that operate in New York State, 69 received this recognition for 2025. This prestigious, national third-party assessment reinforces the high-quality care that distinguishes Terrace View and underscores the professionalism and commitment of our Terrace View caregivers.

And this past year we were proud to celebrate the 10th Anniversary of the opening of our Center for Occupational & Environmental Medicine (COEM). The COEM was designed as a regional health facility for Western New York workforce members with work-related health needs and to prevent work-related illnesses and injuries through increased awareness and health education, early diagnosis and treatment. The COEM was created at ECMC in close collaboration with Western New York's labor unions to help workers exposed to occupational and environmental conditions and injuries in the workplace. Beginning in 2014 with just 15 patients, the COEM has grown tremendously, now having served over 36,000 patients over the past decade. This growth reflects our commitment to the health and wellness of our community and the benefit of having such a center available to workers from throughout our region.

ECMC was again recognized by the Lown Institute among the best nationally and in New York State, receiving 'A' grades on the 2024-2025 Lown Institute Hospitals Index across five metrics, including: health equity, community benefit, inclusivity, value of care, and avoiding overuse. The Lown Hospitals Index is the only national ranking to provide a holistic evaluation of hospital performance across health equity, value, and outcomes.

Essential to our continuing ability to maintain high-quality healthcare services is our ability to access funding from a variety of sources that strengthen ECMC. In 2024, with the strong support of our Congressional delegation, we received \$14,624,938 from the U.S. Department of Homeland Security's Federal Emergency Management Agency (FEMA) to cover costs associated with emergency protective measures and increased staffing taken for ECMC's COVID response dating back to the start of the pandemic in Spring 2020. This funding was provided at a 100% federal cost share. Contract labor costs were very expensive during the COVID-19 pandemic and necessary to ensure we could support our ECMC caregivers as they worked to save the lives of the most vulnerable patients in our community.

Further, ECMC received \$13.6M from FEMA to upgrade and modernize our emergency generators. Again, thanks to the support of our Congressional delegation, this grant will enable ECMC to acquire and install six new state-of-the-art emergency generators that will protect ECMC for many years to come.

ECMC also was awarded \$8,279,008 through New York State's Vital Access Provider Program (VAP). The VAP program was implemented to fund operational costs for turnaround initiatives to help financially distressed New York State healthcare entities seeking to: Improve facility financial viability; meet community service needs; improve the quality of care; and increase

health equity for populations at risk. With this funding, ECMC expanded our Comprehensive Transition of Care program to further understand the needs of underserved patients at the highest risk of readmission, avoidable admission, and extended length of stay. By deploying interdisciplinary clinical care across the continuum, improved access to primary care, and community support ECMC will be equipped to better address social determinants of health and reduce readmissions, avoidable admissions, and length of hospital stays. The funding spans over a period of three years.

We were also pleased to learn that our Employee Health and Hepatology teams were both awarded \$250,000 each (\$500,000 total) in grant funding from Erie County and the Erie County Department of Health to aid in the community's response to the opioid crisis. Employee Health is using the funds to create employee assistance programs for both ECMC and the community, and the Hepatology team is working on a community-wide approach with a focus of addressing the needs of criminal justice-involved persons and the needs of pregnant or parenting women and their families.

As an institution, ECMC has been very intentional and successful in procuring goods and services from NYS-certified MWBEs. Over the past few years, we have been heralded by the Governor for our quantifiable success, twice receiving the state's MWBE Champions Award. Since 2020, ECMC has utilized over \$42 million in MWBE services on a variety of projects throughout our institution. And in the state's 2023-2024 fiscal year, ECMC was responsible for \$4.35 million to NYS Certified MWBEs, representing a 48% utilization, well exceeding the NYS goal of 30%.

The dynamic culture of ECMC is best represented in the success of our ECMC Foundation Annual Giving Campaign. Because of our ECMC Family's generosity in 2024, we achieved the highest level of support from staff throughout our institution. By exceeding 50% participation in charitable giving, we realized the highest percentage ever (52.26%) for contributions to the Annual Giving Campaign. With \$483,204 in total support in 2024, the Foundation reinvests those proceeds back into the care our staff deliver through a variety of programs that support professional development for staff, equipment and technology to enhance our high-quality healthcare services and other initiatives to ensure they have all of the support and resources they need to provide lifesaving care to our patients.

This past July marked the second year of ECMC's Healthcare Explorers program, which is an immersive Summer Healthcare Internship for high school students from throughout our region that provides them with hands-on learning opportunities, while exploring multiple healthcare specialties & disciplines. For this past summer's five two-day sessions, applications from area high school students increased 71% over last year, which resulted in 150 student participants from 45 schools. The success of the program caught the attention of HANYS, which filmed one of the sessions and shared highlights, including interviews with participants and program organizers, with their 500 not-for-profit and public hospitals, nursing homes, and other healthcare member organizations statewide as part of their Member Spotlight series.

We also continue to recognize and support our nurses, and this year the ECMC Foundation Nursing Education and Professional Development Fund supported 48 nursing scholarships and 35 nursing certifications. Since 2017 through 2024, 464 nursing scholarships and 299 nursing certifications have been granted. And to help prepare for future nurses here at ECMC, from 2020 through 2024, we have hosted 6,853 nursing students, RNs and LPNs, all of whom completed a clinical experience in our institution. We know that many of the students ultimately choose to pursue their nursing careers at ECMC based on their experience training here.

After several years devoted to restoring ECMC's finances, operations and patient volumes, we are beginning to witness the overall improvements we have dedicated ourselves to achieving. Thanks to the guidance and support of our Board of Directors, ECMC maintains its strong position in our region as a healthcare institution that provides nationally recognized and honored high-quality healthcare services to the residents of Western New York – no matter their condition or circumstance.

Sincerely,

Thomas J. Quatroche Jr., PhD President & CEO Committee

agoing Jusi

Eugenio Russi Chair, Board of Directors

Jennifer Pugh, MD, MBA, FACEP President, Medical Executive

CERTIFICATION

MISSION

To provide every patient the highest quality of care delivered with compassion.

VISION

ECMC WILL BE A LEADER IN AND RECOGNIZED FOR:

- High quality family centered care resulting in exceptional patient experiences.
- Superior clinical outcomes.
- The hospital of choice for physicians, nurses, and staff.
- Strong collaboration with community partners to improve access to healthcare and the quality of life and vitality of the region.
- Academic affiliations that provide the best education for physicians, dentists, nurses, and other clinical staff.

CORE VALUES

COMMUNITY

and a healthy environment.

COLLABORATION

COMPASSION

STEWARDSHIP

volunteers, and families.

ACCESS

All patients get equal care regardless of their ability to pay or source of payment. We address the healthcare needs of each patient that we can appropriately serve, without bias or pre-judgment.

EXCELLENCE

Excellence is a standard that will never be lowered; there is an expectation of excellence in all areas.

DIVERSITY

We recognize the importance and value of diversity and the enrichment that diversity can bring to ECMCC.

FULFILLING POTENTIAL

We respect the value and potential of each individual as offering a significant contribution to the good of the whole organization. Personal growth and development is important for organizational success.

DIGNITY

Each individual, no matter his or her limitations, background or situation, has intrinsic dignity and unique capabilities.

PRIVACY

GreatLakes

We honor each person's right to privacy and confidentiality.

and for the benefit of our patients and community.

Equity and fairness are guidelines for all decision-making.

In accomplishing our mission we remain mindful of the public's

trust and are always responsive to the immediate surrounding

Collaboration with other organizations is beneficial within the

All involved with ECMCC's service delivery demonstrate caring,

We can only be successful in carrying out our mission through

provided to us are used effectively, in the way they were intended,

solid financial performance and by assuring that resources

compassion, and understanding for patients, employees,

context of our mission and is fundamental to achieving our goals.

community and our natural environment. This commitment

represents both our organization and us as individuals. A successful future for ECMCC depends on a vibrant community

We demand personal and institutional integrity.



The difference between healthcare and true care™

Accomplishments ECMC - 2024

- ECMC's **Employee Health and Hepatology teams** were both awarded \$250,000 each (\$500,000 total) in grant funding from Erie County and the Erie County Department of Health to aid in the community's response to the opioid crisis. Employee Health will use the funds to create employee assistance programs for both ECMC and the community, and the Hepatology team will work on a community-wide approach with a focus of addressing the needs of criminal justice-involved persons and the needs of pregnant or parenting women and their families.
- Lucia Rossi's (MA VP of Ambulatory Services & Population Health) and Amanda • Farrell's (BSN,RN,CMSRN,AMB-BC, Population Health Clinical Data Analyst) submission, Addressing Perceived Control of Chronic Condition was accepted to be presented on Wednesday, June 19, 2024, within the Innovation in Healthcare track at America's Essential Hospital's annual meeting VITAL2024 in San Diego. Chronic conditions are a leading cause of global mortality. Many patients lack self-management skills due to low perceived behavioral control, leading to poor health outcomes. Perceived behavioral control reflects a patient's view of how easy or difficult it is to execute a behavior, like a lifestyle modification. ECMC incorporated a patient empowerment intervention into chronic condition management programs. This intervention aims to measure perceived behavioral control, and address perceived difficulty related to self-management through intensive case management. Data revealed that the intervention has had positive impact on perceived behavioral control. These findings are promising indicators of the program's effectiveness in promoting compliance and improving health perceptions among patients.
- In addition, Amanda Farrell also submitted another abstract, **Optimizing Diabetes Management: A Comprehensive Care Model**, which was accepted for America's Essential Hospital's **VITAL2024** poster session that will be held during the conference's opening reception, showcasing Amanda's work to the participants including the association's leadership and board of directors. According to AEH, abstracts like Amanda's highlight their members' outstanding, innovative work to deliver efficient and effective care to those in greatest need.
- ECMC awarded a **NYSDOH Vital Access Program and Safety Net Provider grant** of \$8,279,008. The VAP program was implemented to fund operational costs for turnaround initiatives to help financially distressed New York State healthcare entities seeking to: Improve facility financial viability; meet community service needs; improve the quality of care; and increase health equity for populations at risk. With this funding, ECMC will expand its Comprehensive Transition of Care program to further understand the needs of underserved patients at the highest risk of readmission, avoidable admission, and extended length of stay. By deploying interdisciplinary clinical care across the continuum, improved access to primary care, and community support ECMC will be equipped to better address SDOH and reduce readmissions, avoidable admissions, and length of hospital stays. The funding spans over a period of three years.

- U.S. Senate Majority Leader Charles E. Schumer and U.S. Senator Kirsten Gillibrand announced ECMC received \$14,624,938 from the U.S. Department of Homeland Security's **Federal Emergency Management Agency** (FEMA) to cover costs associated with emergency protective measures and increased staffing taken for their COVID responses dating back to the start of the pandemic in Spring 2020. This funding is provided at a 100% federal cost share.
- Global Healthcare Exchange (GHX) announced that ECMC is among the inaugural class of its "Supply Chains of Distinction Award for 2023," which recognized 75 top performing hospitals and health systems in North America. The Supply Chains of Distinction Award honors GHX Exchange-connected provider organizations that excelled in driving best-in-class supply chain operations. The award is based upon a set of "perfect order" metrics for a calendar year, rated as a percentage of PO lines sent across the GHX Exchange that are touchless and completely automated, from purchase through payment. The line must satisfy all requirements to be rated as "perfect."
- ECMC received \$13.6M from **FEMA** to upgrade and modernize its emergency generators. Applied for the grant in June of 2022. Thanks to the support of our Congressional delegation, this grant will enable ECMC to acquire and install six new state-of-the-art emergency generators that will protect ECMC for many years to come.
- On Saturday, March 9th, ECMC and the ECMC Foundation held its **seventh annual Rehab Symposium**, titled "A Multidisciplinary Approach to the Acute Care Patient." For this conference, many of the region's most experienced clinicians were invited to speak on a variety of topics pertaining to rehabilitation on acute and critical care services. Area therapists, rehab professionals, and therapy students from the community were invited to learn about some of the specialty services that are available at ECMC.
- ECMC's Material Management team were honored by the **Buffalo Purchasing Initiative** for achieving Highest Outreach and Engagement for local MBE vendors. Their successful effort resulted in ECMC generating \$924k in direct spending with local businesses owned by an MBE.
- In March, ECMC was awarded \$8,279,008 through New York State's Vital Access Provider Program (VAP). The VAP program was implemented to fund operational costs for turnaround initiatives to help financially distressed New York State healthcare entities seeking to: Improve facility financial viability; meet community service needs; improve the quality of care; and increase health equity for populations at risk. With this funding, ECMC expanded our Comprehensive Transition of Care program to further understand the needs of underserved patients at the highest risk of readmission, avoidable admission, and extended length of stay. By deploying interdisciplinary clinical care across the continuum, improved access to primary care, and community support ECMC will be equipped to better address SDOH and reduce readmissions, avoidable admissions, and length of hospital stays. The funding spans over a period of three years.

- At the American Academy of Oral Medicine Annual Conference in Orlando, FL (4/17-4/20/24), ECMC's Drs. Elizabeth Kapral and Jennifer Frustino presented at the event's Meet the Expert Sessions. Dr. Kapral spoke on 'Special Patient Care' and Dr. Frustino spoke on 'Oral and Oropharyngeal Cancer: Screening and Prevention'. In addition, Drs. Brooke Kolber and Nicole Piscatelli were granted fellowship into the Academy based on passing the fellowship examination in 2023.
- ECMC was one of 462 national healthcare institutions to earn an "LGBTQ+ Healthcare Equality High Performer" designation from the Human Rights Campaign; 1,065 healthcare facilities nationwide were evaluated for their dedication and commitment to LGBTQ+ inclusion.
- Dr. Anthony Martinez, ECMC's Medical Director of Hepatology who was honored with the Coalition for Global Hepatitis Elimination's 2024 Hepatitis Elimination Champion award. Dr. Martinez was one of eight Champions selected worldwide from seven countries. His clinic at ECMC, "La Bodega," has been recognized nationally and globally as a novel co-localized model for managing viral hepatitis and addiction disorders. Since 2013, the clinic has treated thousands of individuals for hepatitis C (HCV) and substance use disorder. It has been recognized twice with the New York State World AIDS Day Commissioner's Special Recognition Award. The Coalition for Global Hepatitis Elimination, a program of The Task Force for Global Health, is a nonprofit bringing together global partners to achieve worldwide elimination of viral hepatitis.
- Terrace View received an overall 4-star rating from a recent survey conducted by **The Centers for Medicare and Medicaid Services (CMS)**. The overall rating is based on a nursing home's performance on 3 sources: health inspections, staffing, and quality of resident care measures. The health inspection rating incorporates data reported through June 30, 2024. The time periods for each of the quality measures that contribute to the Quality Measure (QM) rating are detailed in the CMS report. The staffing rating is based on payroll-based journal (PBJ) staffing data reported through the first calendar quarter of 2024.
- ECMC awarded \$157,002 from the **Ryan White Part F program**. These funds are reimbursement for dental care provided to HIV positive patients.
- ECMC received funding from NYS OMH to move forward with the **adolescent Help Center project**. Total dollar amount is \$250,000. ECMC submitted its funding request through OMH's RFP entitled "Mental Health Outpatient Treatment & Rehabilitative Services (MHOTRS) OMH107."
- Terrace View Long-Term Care received its **formal recertification from the NYS Department of Health** following a multi-day survey in August.

- In Orthopedics, ECMC was honored by **US News and Annual Report** in their annual High Performance Hospitals report as a High Performing Institution for Hip Replacement. According to their report, "Over 6,000 hospitals were evaluated and eligible hospitals received one of three ratings -- high performing (593 hospitals), average (1,376 hospitals) or below average (488 hospitals) with the balance either not offering the service or performing too few of the procedures to be rated. Hospitals that earned a high performing rating were significantly better than the national average."
- Celebrated the opening of ECMC's new satellite **Trauma Recovery Center**, that is affiliated with the institution's BRAVE (Buffalo Rising Against Violence) initiative, which is our hospital-based violence intervention trauma recovery effort that serves individuals who have experienced acute victimization and violence. In October 2023, ECMC's BRAVE program achieved designation/certification as Western New York's only Trauma Recovery Center (TRC). It is only the second NYS Office of Victims Services(OVS)-funded program in the state to attain that distinction from the National Alliance of Trauma Recovery Centers (NATRC); the other TRC in the state is located in Brooklyn. There are only 52 TRCs in the United States. It's a successful model that treats victims of violence holistically and proactively through comprehensive case management and assertive outreach.
- ECMC again recognized by the Lown Institute among the best nationally and in New York State, receiving 'A' grades on the **2024-2025 Lown Institute Hospitals Index** across five metrics, including: health equity, community benefit, inclusivity, value of care, and avoiding overuse. The Lown Hospitals Index is the only national ranking to provide a holistic evaluation of hospital performance across health equity, value, and outcomes. Top grades on the Index represent independent, data-backed recognition of success in these areas. The Lown Hospitals Index for Social Responsibility is the only ranking to include metrics of health equity and value of care alongside patient outcomes, creating a holistic view of hospitals as total community partners.
- Through this award, \$525,550 over three years from DOJ Office for Victims of Crime • (OVC) FY24 Services for Victims of Human Trafficking grant, Buffalo Rising Against Violence at Erie County Medical Center Trauma Recovery Center (BRAVE TRC) will expand comprehensive services to support the needs of human trafficking survivors and increase community capacity to screen, identify, and appropriately refer survivors for services. BRAVE TRC will utilize project funds to hire personnel dedicated to project activities, expand and strengthen victim services for all forms of human trafficking, develop and expand trauma-informed screening protocols across hospital systems in order to identify trafficking victims more effectively. The project will also increase community collaboration and capacity regarding identification, services, and referral pathways for trafficking survivors, with data-driven decisions guiding outreach, training, and collaboration activities. BRAVE TRC will identify victims of all types of human trafficking and ensure that a comprehensive array of services is readily available to meet the individualized needs of survivors, including foreign nationals and U.S. citizens, male survivors, and those exploited by labor trafficking.
- Terrace View Long-Term Care Facility recognized on **Newsweek's Best Nursing Homes** 2024 list. This prestigious award is presented by Newsweek and Statista Inc., the world-leading statistics portal and industry ranking provider. Only four percent of nursing

homes nationwide received this distinction. Of the 600 skilled nursing facilities statewide that operate, 69 received this recognition. It is a distinct honor to be ranked amongst the best nursing homes within both the state and the nation. This is the fifth consecutive year Terrace View has received this recognition.

- Trustees of the **B. Thomas Golisano Foundation**, at their quarterly meeting in October, approved a grant of \$70,000 to support ECMC's Special Needs Dentistry Program overseen by Dr. Elizabeth Kapral DDS, MS. The grant will support the purchase of specialized dental equipment that will be used to provide comprehensive care in the dental operating room and specialty outpatient clinic, which specializes in caring for people with intellectual and developmental disabilities. This ECMC service is the largest program providing critical dental health services to patients with IDD in Western New York.
- ECMC's Medical Intensive Care Units (MICU) North and South were each recognized by the American Association of Critical-Care Nurses (AACN) with a **gold-level Beacon Award for Excellence**. With this accomplishment, ECMC is 1 of 2 Level 1 Trauma Centers in New York State with more than 1 Gold Beacon Unit, 1 of 7 hospitals in the state with more than one Gold Beacon unit, and one of two hospitals in Western New York with more than one Gold Beacon unit. The Beacon Award for Excellence a significant milestone on the path to exceptional patient care and healthy work environments recognizes caregivers who successfully improve patient outcomes and align practices with AACN's six Healthy Work Environment Standards. The gold-level Beacon Award for Excellence earned by ECMC's MICU North and South nurses signifies effective and systematic approaches to policies, procedures, and processes.
- In another indication of national affirmation of ECMC's clinical excellence, we earned status in 2024 as an American College of Surgeons (ACS) Surgical Quality Partner due to ECMC's participation in multiple ACS quality programs. According to the ACS, "Hospital systems that implement ACS Quality Programs help hospitals prioritize a proactive quality and safety culture, reduce unnecessary hospital stays, and save money." We were proud to be recognized by such a prestigious national organization for our commitment to quality services, patient safety, and sound management of our institution.
- The American College of Emergency Physicians (ACEP) informed ECMC that our Emergency Department in 2024 achieved the bronze standard — Level 3 Geriatric
 Emergency Department Accreditation (GEDA) accreditation. The voluntary GEDA program, which includes three levels similar to trauma center designations, provides specific criteria and goals for emergency clinicians and administrators to target. This accreditation from ACEP reinforces the high-quality care and clinical excellence that ECMC is known for, particularly in our Emergency Department. It further highlights our caregivers' commitment to ensuring that all patients, notably older adults, receive the very best healthcare services they need.
- Expanding our state-of-the-art surgical capabilities, a fifth surgical robot was added this past year to our surgical services. The **ION robotic navigational bronchoscopy platform** was delivered to ECMC on September 9th. It is designed to reach smaller lung nodules in the periphery of the lung to diagnose lung cancer earlier and increase the survival rate. ECMC's Thoracic Surgeon, Dr. Thamer Qaqish successfully first utilized

the ION robot on September 25th, expanding our cutting-edge surgical technology for the benefit of our patients. The robotic platform is designed to reach smaller lung nodules in the periphery of the lung to diagnose lung cancer earlier and increase patients' survival rate. In addition, in 2024 we completed a 12-week Operation Room lighting modernization project, which now provides significantly enhanced and improved lighting for our dedicated surgical teams.

• This past July marked the second year of ECMC's **Healthcare Explorers program**, which is an immersive Summer Healthcare Internship for high school students from throughout our region that provides them with hands-on learning opportunities, while exploring multiple healthcare specialties & disciplines. For this summer's five two-day sessions, applications from area high school students increased 71% over last year, which resulted in 150 student participants from 45 schools. The success of the program caught the attention of HANYS, which filmed one of the sessions and shared highlights, including interviews with participants and program organizers, with their 500 not-for-profit and public hospitals, nursing homes, and other healthcare member organizations statewide as part of their Member Spotlight series.

2024 PERFORMANCE GOALS/OUTCOMES

ECMC Strategic Plan Priorities and Goals

1. Exceptional Quality and Experience – Raise the standard of clinical care to improve quality, patient safety, research and patient experience in the acute care and ambulatory environments.

2. Cultural Identity – Preserve ECMC's strong cultural identity while further instilling a sense of urgency and genuine stewardship to achieve our organizational objectives.

3. Campus Transformation – Address our deferred maintenance issues, expand capacity, and integrate the development of Kensington Heights and the surrounding community.

4. Performance Improvement – Generate the margin necessary to meet our budgetary goals by lowering ECMC's overall cost position, enhancing revenue cycle performance, and targeted growth.

5. Population Health Capabilities – Take greater responsibility for managing the overall health of our patient populations through a shift from fee-for-service to risk-based arrangements.

6. Community Needs – Through partnerships and targeted investments, be a leading corporate citizen by addressing socioeconomic challenges that impact our communities.
 7. Great Lakes Health Collaboration – Further increase interconnectivity between

ECMC, Kaleida and our partners through clinical and operational collaborations.

8. Strengthen Relationship with Academic Partners – Partner with the University at Buffalo and other local professional training programs to enhance our impact across the tripartite academic mission.

Progress Against Strategic Plan Priorities and Goals

1. Exceptional Quality and Experience

- All major accreditations, regulatory licensure and certifications have been maintained. Preparation for several accreditations in 2025, including hospital Joint Commission Survey.
- Medical Intensive Care Units earned American Association of Critical Care Nurses gold-level Beacon Award for Excellence.
- Maintained ANCC Pathway to Excellence designation.
- ECMC selected as a site for multiple oncology related clinical trials sponsored by various companies including Lipella Pharmaceuticals, Inc., MeiraGTx, MTGroup, and Merck.
- Presented ECMC's Ambulatory Services & Population Health's Addressing Perceived Control of Chronic Condition study within the Innovation in Healthcare track at America's Essential Hospital's annual meeting VITAL2024. The study incorporated patient empowerment intervention into chronic condition management programs. This intervention aimed to measure perceived behavioral control, and address perceived difficulty related to self-management through intensive case management. Data revealed that the intervention had positive impact on patients perceived behavioral control.
- Participated in the American Diabetes Association State of Diabetes in November 2024.
- Updated ECMC's Quality and Patient Safety Program to provide a safe environment for patients and staff free from recognizable safety issues and medical errors, while managing activities toward reducing risk of harm and injury.

2. Cultural Identity

- ECMC was one of 462 national healthcare institutions to earn an "LGBTQ+ Healthcare Equality High Performer" designation from the Human Rights Campaign; 1,065 healthcare facilities nationwide were evaluated for their dedication and commitment to LGBTQ+ inclusion.
- ECMC's Office of Diversity, Equity and Inclusion oversees six Employee Resource Groups, which facilitate a cultural awareness initiative to promote inclusion and belonging across our organization.

3. Campus Transformation

- Completion of OR lighting modernization program.
- Kensington Heights and Grider Street development initiatives.

4. Performance Improvement

- Strategic Plan updated with focus on: patient throughput, quality, post-acute care, capacity and efficiency processes, and further development of key service lines (e.g., Behavioral Health, Primary Care & Orthopedics).
- Continued expansion of Accelerating Excellence programs and projects.
- Oral Oncology & Maxillofacial Prosthetics acquired Artec Space Spider 3D Scanner and SprintRay Pro 95 S Printer, which is leading to more comfortable visits for patients, greater speed and accuracy in our laboratory work, and greater patient satisfaction.
- Daily bed huddles 7 days per week.
- Expanded state-of-the-art surgical capabilities with a fifth surgical robot added this past year to surgical services (along with existing DaVinci, Rosa and Mako systems). The ION robotic navigational bronchoscopy platform is designed to reach smaller lung nodules in the periphery of the lung to diagnose lung cancer earlier and increase the survival rate.
- ECMC Center for Cardiovascular Care in collaboration with the ECMC Radiology Department added a new diagnostic service of Coronary CTA's.
- Expanded Intensive Outpatient Program and Help Center operations.
- Developed new patient tracking system called TeleProcedure.
- Added 769 new hires that includes 165 new RNs and 48 LPNs and 114 CNAs.
- Recruited 136 new physicians to the ECMC Medical Staff, including new surgeons in surgeons in Ortho, Neuro, GI, Urology.
- IT improvements included: enhancements to Adult Medical Emergency and Patient Safety Check app, which includes EVS scrub tracker and room cleaning tracker, along with fall risk indicator and audible alerts for safety checks; community-based lab results and clinical integration in Altera; Altera change capture implemented in multiple clinics; Internet bandwith upgraded from 1Gbps to 3Gbps; Asimily device management implemented, Biomed collaboration, improves awareness of risks and software updates.

5. Population Health Capabilities

- Conducted multiple cancer screening and prevention events in vulnerable communities throughout the city with a variety of partners.
- ECMC's Population Health's *Optimizing Diabetes Management: A Comprehensive Care Model* abstract was accepted for America's Essential Hospital's VITAL2024 poster session, showcasing their work to the participants including the association's leadership and board of directors. According to AEH, abstracts like ECMC's highlight their members' outstanding, innovative work to deliver efficient and effective care to those in greatest need.
- Participated in 50 outreach events across vulnerable neighborhoods, where essential health
 education was provided and conducted blood pressure screenings. These efforts reflect our
 ongoing commitment to supporting community well-being and addressing health disparities in
 underserved areas. Our engagement has not only contributed to increased awareness of chronic
 health conditions but also fostered trust and collaboration with local populations.
- Provision of clinical mental health services with expertise and training in the treatment of acute trauma and polyvictimization for underserved crime survivors including vulnerable populations such as persons of color, the homeless, LGBTQ people, chronically mentally ill, non-English speaking and those living in poverty.
- New federal grant funds to provide basic needs to under resourced survivors of violence with focus for services within Buffalo's zip codes with the combined highest social deprivation index scores and the highest rates of gun violence through the past 15 years of available data. Primary zip codes of focus will be 14215 and 14211, with a secondary focus on six other zip codes within the city (14204, 14207, 14208, 14212, 14213, and 14214).

6. Community Needs

- Exceeded MWBE goal for 2024, reaching 48% utilization.
- ECMC honored in 2024 by Buffalo Purchasing Initiative (BPI) for highest increase in eligible spend from previous year among region's 14 participating organizations in the BPI.
- Recognized by the Lown Institute, for outstanding social responsibility, receiving an "A" grade on the 2024-25 across five metrics, including: health equity, community benefit, inclusivity, value of care, and avoiding overuse.
- Maintained partnership with the Buffalo City Mission focused on its Recuperative Care Unit.
- Opened new satellite Trauma Recovery Center, that is affiliated with the institution's Buffalo Rising Against Violence (BRAVE) initiative, which is ECMC's hospital-based violence intervention trauma recovery effort that serves individuals who have experienced acute victimization and violence. There are only three such Centers in New York State and 52 in the country.
- Received over \$2.8 million dollars in state funding for ECMC's SNUG program, which, along with ECMC's BRAVE program, provides services to victims of penetrating trauma to decrease recidivism and improve service linkage post discharge.
- Received \$456,239.58 in continued funding for ECMC's BRAVE program to provide 24/7 hospital response to victims of domestic violence, elder abuse and human trafficking.
- Received new federal grant to screen and provide victim services to survivors of human trafficking.

7. Great Lakes Health Collaboration

- Continued partnership and investment in Great Lakes Integrated Network
- Continued successful collaborative value-analysis program.

8. Strengthen Relationship with Academic Partners

- Between 2020-2024, approximately 6,900 Nursing students have rotated through ECMC as part of their clinicals.
- Strengthened Neurological surgery with UB Neurosurgery. Dr. Hanna Algattas performing skulled-based neurosurgery for tumors, which is only procedure of this kind currently in WNY.
- New elective for fourth year medical students: "Trauma Surgery and Trauma Informed Care" in conjunction with UB Department of Surgery with focus on trauma surgery and community-based research on health disparities.
- Recruited 70 new physicians, 59 Allied Health Professionals, including surgeons, neurologists, gastroenterologists and urologists.
- Credentialing and privileging transformation entered into a collaborative agreement with Kaleida Health and UAHS to transform credentialing to a fully electronic format with dates aligned throughout. Return on investment includes increased efficiencies and provider satisfaction.

2025 HIGH PRIORITY INITIATIVES

- New quality structure and Performance Improvement Program to support continuing journey to a High Reliability Organization.
- Electronic Health Record Transformation entered not a collaborative agreement with Kaleida Health and UBMD to transform healthcare access for patients, improve access to data, and improve overall health system performance through Epic Community Connect.
- Grow research initiatives and clinical trial opportunities for clinical investigators with grants and sponsors.
- Maintain a survey ready environment, focused on Joint Commission Hospital, Laboratory and Substance Use Treatment Survey in 2025.

CAPITAL PROJECTS IN PROCESS IN 2024

| Mammography Suite | Began August 2024 |
|--------------------------------|---------------------|
| Generator Replacements | Began January 2024 |
| Fire Damper Duct Access Panels | Began November 2024 |

REAL PROPERTY ACQUISTIONS

| Address of Location Purchased | Name of Seller | Purchase Price |
|----------------------------------|----------------|----------------|
| NONE | | |

CODE OF ETHICS

See Appendix D. Article XI; Sections 1-8

INTERNAL CONTROL STRUCTURE AND PROCEDURES

Assessment of Effectiveness of Internal Controls New York State Public Authority Reporting System (PARIS) Erie County Medical Center Corporation

At and For the Year Ended December 31, 2024

The evaluation of the system of internal control is an ongoing process conducted throughout the year by myself in the capacity as the Chief Financial Officer of Erie County Medical Center Corporation. In this ongoing process there is engagement and oversight by the Audit Committee of the Board of Directors with support, advice and assistance provided by the Chief Executive Officer, the Chief Operating Officer, the General Counsel and a robust internal audit function.

The conclusions of the ongoing assessment were that no control deficiencies, significant deficiencies or material weaknesses, collectively as defined in generally accepted auditing standards, in internal controls were identified, however, performance improvement opportunities to enhance internal control were identified and implemented.

Based on my ongoing assessment, the work of the internal audit function and the work of the independent audit firm for ECMC there is an effective system of internal control to safeguard assets and to assure that transactions are properly authorized.

Respectfully submitted,

Jonathan T. Swiatkowski, CPA Chief Financial Officer

PENDING LITIGATION

The corporation is involved in several matters related to medical malpractice, workers' compensation, and business disputes as discussed in Note 15 in the enclosed audited financial statements beginning on page 49. There are no other material matters pending litigation at this time.

CORPORATION AND BOARD STRUCTURE

ECMC Corporation's Board of Directors is comprised of 15 voting Directors, drawn from institutions and occupations across Western New York. Of these directors, eight are appointed by the Governor of New York – via the recommendations of the County Executive (3), County Legislature (3), the Temporary President of the NYS Senate (1) and the Speaker of the NYS Assembly (1) – and seven are appointed by the County Executive with the advice and consent of the Erie County legislature. In addition, the Board has four non-voting members: (1) appointed by Erie County Executive; (1) appointed by Erie County Legislature Majority; (1) appointed by Erie County Legislature Minority; (1) ECMCC President and CEO via Public Authorities Law.

ECMC CORPORATION BOARD OF DIRECTORS

OFFICERS Eugenio Russi Chair

Sharon L. Hanson Secretary

Darby Fishkin, CPA Treasurer

Thomas J. Quatroche Jr., PhD President & CEO

BOARD MEMBERS

Ronald P. Bennett, Esq.

Reverend Mark E. Blue

Jonathan A. Dandes

Michael H. Hoffert

Christian Johnson

James L. Lawicki, II

Christopher J. O'Brien, Esq.

The Honorable John O'Donnell, J.S.C.

Reverend Kinzer M. Pointer

Michael A. Seaman

Philip Stegemann, MD

Benjamin Swanekamp

BOARD OF DIRECTORS REGULAR AND ANNUAL MEETINGS

Tuesday, January 23, 2024 (Annual and Regular Meeting)

| Present: | Reverend Mark Blue*, Ronald Bennett*, Ronald A Chapin*, Jonathan Dandes, Darby Fishkin, Sharon Hanson, Michael Hoffert*, James Lawicki*, Christopher O'Brien, Hon. John O'Donnell, Reverend Kinzer Pointer, Thomas J. Quatroche, Eugenio Russi, Michael Seaman, Philip Stegemann, Benjamin Swanekamp |
|------------------|---|
| Excused: | Christian Johnson, Jennifer Persico |
| Also Present: | Donna Brown, Samuel Cloud, MD, Peter Cutler, Andrew Davis, Cassandra Davis, Joseph Giglia, Susan Gonzalez, Donna Jones, Pamela Lee, Charlene Ludlow, Jennifer Pugh, MD, Jonathan Swiatkowski |

Tuesday, February 27, 2024

| Present: | Ronald Bennett*, Reverend Mark Blue, Ronald A Chapin*, Jonathan Dandes, Sharon Hanson, Michael Hoffert*, Christian Johnson*, Christopher O'Brien*, Hon. John O'Donnell, Reverend Kinzer Pointer, Thomas J. Quatroche, Eugenio Russi, Michael Seaman, Philip Stegeman, Benjamin Swanekamp |
|----------|---|
| Excused: | Darby Fishkin, James Lawicki, Jennifer Persico |
| Also | |
| Present: | Donna Brown*, Peter Cutler, Andrew Davis, Cassandra Davis, Joseph Giglia, Susan |
| | Gonzalez*, Donna Jones, Pamela Lee, Charlene Ludlow, Jennifer Pugh, MD, Jonathan |
| | Swiatkowski |

Tuesday, March 28, 2024

| Present: | Ronald Bennett*, Reverend Mark Blue, Ronald A Chapin*, Jonathan Dandes, Sharon Hanson, Michael Hoffert*, Christian Johnson*, Christopher O'Brien*, Hon. John O'Donnell, Reverend Kinzer Pointer, Thomas J. Quatroche, Eugenio Russi, Michael Seaman, Philip Stegeman, Benjamin Swanekamp |
|------------------|---|
| Excused: | Darby Fishkin, James Lawicki*, Jennifer Persico |
| Also Present: | Donna Brown*, Peter Cutler, Andrew Davis, Cassandra Davis, Joseph Giglia, Susan Gonzalez*, Donna Jones, Pamela Lee, Charlene Ludlow, Jennifer Pugh, MD, Jonathan Swiatkowski |

Tuesday, April 23, 2024

| Present: | Ronald Bennett*, Reverend Mark Blue*, Ronald A Chapin*, Darby Fishkin, Sharon Hanson, Michael Hoffert*, Christian Johnson*, James Lawicki*, Christopher O'Brien, Hon. John O'Donnell, Reverend Kinzer Pointer, Thomas J. Quatroche, Eugenio Russi, Michael Seaman, Benjamin Swanekamp |
|------------------|--|
| Excused: | Jonathan Dandes, Michael Hoffert, Christian Johnson, Jennifer Persico, Philip Stegeman |
| Also Present: | Donna Brown, Peter Cutler, Andrew Davis, Cassandra Davis*, Joseph Giglia, Susan Gonzalez, Donna Jones, Pamela Lee*, Charlene Ludlow, Jennifer Pugh, MD, Jonathan Swiatkowski* |

Tuesday, May 28, 2024

| Present: | Ronald Bennett*, Reverend Mark Blue, Ronald A Chapin*, Jonathan Dandes, Darby Fishkin*, Sharon Hanson, Christopher O'Brien*, Hon. John O'Donnell, Reverend Kinzer Pointer, Thomas J. Quatroche, Michael Seaman, Benjamin Swanekamp |
|----------|--|
| Excused: | Michael Hoffert, Christian Johnson, James Lawicki, Jennifer Persico, Eugenio Russi; Philip Stegeman |
| Also | |
| Present: | Donna Brown, Peter Cutler, Andrew Davis, Cassandra Davis, Joseph Giglia, Susan Gonzalez, Donna Jones, Pamela Lee, Charlene Ludlow, Jennifer Pugh, MD, Jonathan Swiatkowski |

Tuesday, June 25, 2024

| Present: | Ronald Bennett*, Reverend Mark Blue*, Jonathan Dandes*, Darby Fishkin*, Sharon Hanson, Michael Hoffert*, James Lawicki*, Hon. John O'Donnell, Reverend Kinzer Pointer, Thomas J. Quatroche, Eugenio Russi, Michael Seaman, Benjamin Swanekamp |
|----------|---|
| Excused: | Ronald Chapin, Christian Johnson, Christopher O'Brien, Jennifer Persico, Philip Stegeman |
| Also | |
| Present: | Donna Brown, Peter Cutler, Andrew Davis, Cassandra Davis, Joseph Giglia, Susan |
| | Gonzalez, Donna Jones, Pamela Lee, Charlene Ludlow, Jennifer Pugh, MD, Jonathan |
| | Swiatkowski |

Tuesday, July 23, 2024

Present: Ronald Bennett*, Reverend Mark Blue, Darby Fishkin*, Chistopher O'Brien*, Hon. John O'Donnell, Reverend Kinzer Pointer, Thomas J. Quatroche, Eugenio Russi, Michael Seaman, Dr. Philip Stegemann, Benjamin Swanekamp

Tuesday, July 23, 2024 (continued)

Excused: Jonathan Dandes, Sharon Hanson, Michael Hoffert, Christian Johnson, James Lawicki, Jennifer Persico

Also Present: Donna Brown, Peter Cutler, Andrew Davis, Cassandra Davis, Joseph Giglia, Susan Gonzalez, Donna Jones, Pamela Lee, Charlene Ludlow, Jennifer Pugh, MD, Jonathan Swiatkowski

Tuesday, September 24, 2024

| Present: | Ronald Bennett*, Reverend Mark Blue*, Jonathan Dandes, Darby Fishkin, Sharon Hanson, Michael Hoffert*, James Lawicki*, Hon. John O'Donnell*, Reverend Kinzer Pointer, Thomas J. Quatroche, Eugenio Russi, Michael Seaman, Dr. Philip Stegemann, Benjamin Swanekamp* |
|------------------|--|
| Excused: | Christian Johnson, Christopher O'Brien, Jennifer Persico |
| Also Present: | Samuel Cloud*, MD, Peter Cutler, Andrew Davis*, Cassandra Davis, Joseph Giglia*, Susan Gonzalez, Pamela Lee, Charlene Ludlow, Phyllis Murawski, Jennifer Pugh, MD, Jonathan Swiatkowski |

Tuesday, October 22, 2024

| Present: | Ronald Bennett*, Reverend Mark Blue*, Jonathan Dandes, Sharon Hanson, Michael Hoffert*, James Lawicki*, Christopher O'Brien*, Reverend Kinzer Pointer, Thomas J. Quatroche, Eugenio Russi, Michael Seaman, Dr. Philip Stegemann, Benjamin Swanekamp* |
|------------------|---|
| Excused: | Darby Fishkin, Christian Johnson, Hon. John O'Donnell*, Jennifer Persico |
| Also Present: | Samuel Cloud, MD, Peter Cutler, Andrew Davis, Cassandra Davis, Joseph Giglia, Pamela Lee, Charlene Ludlow, Phyllis Murawski, Jennifer Pugh, MD, Anastasia Roeder, Jonathan Swiatkowski |

Tuesday, December 3, 2024

Present: Ronald Bennett*, Reverend Mark Blue*, Darby Fishkin, Sharon Hanson, Michael Hoffert*, James Lawicki*, Hon. John O'Donnell, Reverend Kinzer Pointer, Thomas J. Quatroche, Eugenio Russi, Michael Seaman, Dr. Philip Stegemann, Benjamin Swanekamp*

Tuesday, December 3, 2024 (continued)

Excused: Jonathan Dandes, Christian Johnson, Christopher O'Brien, Jennifer Persico

Also

Present: Samuel Cloud, MD, Peter Cutler, Andrew Davis, Cassandra Davis, Joseph Giglia, Pamela Lee, Charlene Ludlow, Phyllis Murawski, Jennifer Pugh, MD, Anastasia Roeder, Jonathan Swiatkowski

ECMC BOARD OF DIRECTORS STANDING COMMITTEE APPOINTMENTS

| STANDING COMMITTEE | # OF MEMBERS | BOARD MEMBERSHIP | STAFF |
|--|-----------------|--|---|
| EXECUTIVE Quarterly or Call of Chair | 4 | Eugenio Russi - Chair Jonathan Dandes Darby Fishkin Sharon L. Hanson Thomas Quatroche, ex officio Joseph Giglia, ex officio | Andrew L. Davis Jonathan Swiatkowski Samuel D Cloud, MD Jeffra Wilson (Asst.) x4823 |
| QUALITY IMPROVEMENT/ PATIENT SAFETY Meets Monthly | 3 | <u>MICHAEL HOFFERT - Chair</u> Kinzer Pointer Judge John O'Donnell Benjamin Swanekamp Christian Johnson | Andrew Davis Thomas Quatroche Donna Jones Samuel D. Cloud, MD Charlene Ludlow Pam Lee Jackie Wilson (Asst.) x5888 |
| FINANCE Meets Monthly | 5 | <u>MICHAEL A. SEAMAN - Chair</u> Mark Blue Darby Fishkin Benjamin Swanekamp Phil Stegemann | Andrew Davis Jonathan Swiatkowski Thomas Quatroche Lynn Sacha (Asst.) x6331 |
| AUDIT & COMPLIANCE Quarterly or Call of Chair | 4 | DARBY FISHKIN - Chair James Lawicki Christopher O'Brien Reverend Kinzer Pointer Joseph Giglia, ex-officio | Andrew Davis Jonathan Swiatkowski Thomas Quatroche Lindy Nesbitt Nadine Mund Lynn Sacha (Asst.) x6331 |
| EXECUTIVE COMPENSATION Call of Chair | 4 | JONATHAN DANDES - Chair Sharon Hanson Christopher O'Brien | Thomas Quatroche Joseph Giglia |

ECMC BOARD OF DIRECTORS STANDING COMMITTEE APPOINTMENTS

| 2 | 0 | 24 | |
|---|---|----|--|
| | | | |

| STANDING COMMITTEE | # OF MEMBERS | BOARD MEMBERSHIP | STAFF |
|--|-----------------|---|---|
| GOVERNANCE Call of Chair | 4 | <u>SHARON HANSON - Chair</u> Judge John O'Donnell Jon Dandes Darby Fishkin Thomas Quatroche, Jr., ex officio Joseph Giglia, ex officio | Lindy Nesbitt Lori Hoffman (Asst.) x5684 |
| HUMAN RESOURCES Quarterly or Call of Chair | 3 | <u>MICHAEL SEAMAN - Chair</u> Michael Hoffert Kinzer Pointer | Andy Davis Michelle Kroupa(Asst.)x5273 |
| INVESTMENT Semi-Annually or Call of Chair | 3 | <u>EUGENIO RUSSI - Chair</u> Sharon L. Hanson Judge John O'Donnell | Jonathan Swiatkowski Thomas Quatroche Michael Seaman Lynn Sacha (Asst.) x6331 |
| BUILDINGS & GROUNDS Quarterly or Call of Chair | 3 | <u>RONALD BENNETT - Chair</u> Michael Hoffert Mark Blue | Andrew Davis Thomas Quatroche Pam Lee Michelle Kroupa(Asst.)x5273 |
| WBE/MBE SUBCOMMITTEE Quarterly or Call of Chair | 3 | <u>REVEREND MARK BLUE - Chair</u> Rev. Kinzer Pointer Christian Johnson | Diane Artieri Sarina Rohloff Nicholas Long Joseph Giglia Andrew Davis Lindy Nesbitt Patty Chase (Asst.) x7595 |
| POST-ACUTE QI Quarterly or Call of Chair | 3 | <u>Michael Seaman - Chair</u> Rev. Kinzer Pointer Christopher O'Brien | Andrew Davis Stephen Woodruff Monica Hunjan (Asst.) x7279 |

ECMC BOARD OF DIRECTORS STANDING COMMITTEE APPOINTMENTS

2024

| STANDING COMMITTEE | # OF MEMBERS | BOARD MEMBERSHIP | STAFF |
|-----------------------|-----------------|------------------------------------|----------------------------|
| CONTRACTS | 3 | <u>CHRISTOPHER O'BRIEN - Chair</u> | Joseph Giglia |
| Quarterly or call of | | Ronald Bennett | Lindy Nesbitt |
| Chair | | Jennifer Persico | Lori Hoffman (Asst.) x6584 |

Erie County Medical Center Corporation Confidential Evaluation of Board Performance

| | | Somewhat | Somewhat | |
|--|-------|----------|----------|----------|
| Criteria | Agree | Agree | Disagree | Disagree |
| Board members have a shared understanding | | | | |
| of the mission and purpose of ECMCC. | | | | |
| The policies, practices and decisions of the | | | | |
| Board are always consistent with this mission. | | | | |
| Board members comprehend their role and | | | | |
| fiduciary responsibilities and hold themselves | | | | |
| and each other to these principles. | | | | |
| The Board has adopted policies, by-laws, and | | | | |
| practices for the effective governance, | | | | |
| management and operations of ECMCC and | | | | |
| reviews these annually. | | | | |
| The Board sets clear and measurable | | | | |
| performance goals for ECMCC that | | | | |
| contribute to accomplishing its mission. | | | | |
| The decisions made by Board members are | | | | |
| arrived at through independent judgment and | | | | |
| deliberation, free of political influence or self- | | | | |
| interest. | | | | |
| Individual Board members communicate | | | | |
| effectively with executive staff so as to be well | | | | |
| informed on the status of all important issues. | - | | | |
| Board members are knowledgeable about | | | | |
| ECMCC's programs, financial statements, | | | | |
| reporting requirements, and other transactions. | | | | |
| The Board meets to review and approve all | | | | |
| documents and reports prior to public release and is confident that the information being | | | | |
| presented is accurate and complete. | | | | |
| The Board knows the statutory obligations of | | | | |
| ECMCC and if ECMCC is in compliance with | | | | |
| state law. | | | | |
| Board and committee meetings facilitate open, | | | | |
| deliberate and thorough discussion, and the | | | | |
| active participation of members. | | | | |
| Board members have sufficient opportunity to | | | | |
| research, discuss, question and prepare before | | | | |
| decisions are made and votes taken. | | | | |
| Individual Board members feel empowered to | | | | 1 |
| delay votes, defer agenda items, or table | | | | |
| actions if they feel additional information or | | | | |
| discussion is required. | | | | |
| The Board exercises appropriate oversight of | 1 | | | |
| the CEO and other executive staff, including | | | | |
| setting performance expectations and | | | | |
| reviewing performance annually. | | | | |
| The Board has identified the areas of most risk | | | | |
| to ECMCC and works with management to | | | | |
| implement risk mitigation strategies before | | | | |
| problems occur. | | | | |
| Board members demonstrate leadership and | 1 | | | |
| vision and work respectfully with each other. | | | | |

ECMC CORPORATION EXECUTIVE ADMINISTRATION

Thomas J. Quatroche Jr., PhD President and Chief Executive Officer

Andrew L. Davis, MBA Chief Operating Officer

Samuel D. Cloud, MD *Chief Medical Officer*

Jonathan T. Swiatkowski, CPA Chief Financial Officer

Charlene Ludlow, MHA, RN, CIC Senior Vice President of Nursing

Cassandra Davis Senior Vice President of Operations

Pamela Lee, MBA, MS, RN Senior Vice President of Operations

Joseph T. Giglia, II, Esq. General Counsel

Donna M. Brown Associate Hospital Administrator

Peter K. Cutler Vice President of Communications and External Affairs

Phyllis Murawski Chief Quality Officer

John Cumbo Interim Chief Information Officer

Anastasia Roeder Interim Executive Director, ECMC Foundation

ECMC CORPORATION MEDICAL-DENTAL STAFF OFFICERS

Jennifer Pugh, MD, MBA, FACEP *President*

Michael Cummings, MD Immediate Past President

Michael A. Manka Jr., MD President-Elect

Ashvin Tadakamalla, MD Treasurer

James Lukan, MD, FACS Secretary

PRIMARY CORPORATION

Erie County Medical Center Corporation

ECMC Corporation was established as a New York State Public Benefit Corporation and since 2004 has included an advanced academic medical center with 573 inpatient beds, on- and off-campus health centers, more than 30 outpatient specialty care services and Terrace View, a 390-bed long-term care facility. ECMC is Western New York's only Level 1 Adult Trauma Center, as well as a regional center for burn care, behavioral health services, transplantation, medical oncology and head & neck cancer care, rehabilitation and a major teaching facility for the University at Buffalo. Most ECMC physicians, dentists and pharmacists are dedicated faculty members of the university and/or members of a private practice plan. More Western New York residents are choosing ECMC for exceptional patient care and patient experiences – the difference between healthcare and true care™.

ECMC Corporation Employees: 4,119

ACTIVE SUBSIDIARY INFORMATION

PPC Strategic Services, LLC

ECMC Corporation is the sole owner of this enterprise, which was established to enable the Corporation to enter into various other business relationships, and to provide management services to them, as needed. The accounts of PPC Strategic Services LLC are consolidated into the accounts of the Corporation as of, and for the years ended, December 31, 2024 and 2023, respectively.

The sole member of this entity is Erie County Medical Center Corporation. Employees: None

PPC Strategic Services LLC (formerly named ECMCC Strategic Services, LLC) owns Greater Buffalo Niagara SC Venture, LLC, a presently inactive entity. The ownership interest is accounted for utilizing the equity method of accounting.

The sole member of this entity is Erie County Medical Center Corporation. Employees: None

Grider Community Gardens, LLC

This entity is wholly owned and controlled by the Corporation. The Corporation's net investment as of December 31, 2024 and 2023 is approximately \$935 thousand and \$1 million, respectively, and is reflected in other non-current assets of the parent company's financial statements.

The sole member of this entity is Erie County Medical Center Corporation. Employees: None

Grider Support Services, LLC

This entity was formed to act as a Management Services Organization ("MSO") for physician services for ECMC Hospital. The accounts of Grider Support Services, LLC are consolidated into the accounts of the Corporation as of, and for the years ended, December 31, 2024 and 2023, respectively.

The sole member of this entity is Erie County Medical Center Corporation. Employees: 181

1827 Fillmore, LLC

This entity was formed in order to purchase real estate adjacent to the current health campus for the purpose of future development. Its activities to date consist of remediating and improving land adjacent to the ECMC campus and is consolidated into ECMC Corporation.

Net position as of December 31, 2024 and 2023 is (\$210) and \$144 thousand, respectively.

The sole member of this entity is Erie County Medical Center Corporation. Employees: None

Erie County Medical Center Corporation

(A Component Unit of the County of Erie)

Financial Report December 31, 2024

PRELIMINARY DRAFT poses Only PRELIMINARY DRAFT poses Only PRELIMINARY DRAFT poses Only PRELIMINARY DRAFT Post to be purposed subject to performed Not to be produced Not to be produced

Contents

| Independent auditor's report | 1-3 |
|---|-------|
| Management's discussion and analysis Basic financial statements | 4-15 |
| Statements of net position | 16 |
| Statements of revenues, expenses and changes in net position | 17 |
| Statements of cash flows | 18-19 |
| Statements of net position—discretely presented component units | 20 |
| Statements of revenues, expenses and changes in net position—discretely presented component units | 21 |
| Notes to the financial statements | 22-56 |
| Required supplementary information | |
| Schedule of corporation's contributions NYSLRS pension plan | 57 |
| Schedule of corporation's proportionate share of net pension liability NYSLRS pension plan | 58 |
| Schedule of corporation's changes in total OPEB liability and related ratios | 59 |
| Uniform guidance audit requirements | |
| Schedule of expenditures of federal awards | 60 |
| Notes to schedule of expenditures of federal awards | 61 |
| Report on internal control over financial reporting and on compliance and other matters based on an audit of financial statements performed in accordance with <i>Government Auditing Standards</i> | 62-63 |
| Report on compliance for each major federal program; report on internal control over compliance; and report on schedule of expenditures of federal awards required by the Uniform Guidance | 64-66 |
| Schedule of findings and questioned costs | 67-68 |
| Summary schedule of prior year findings and questioned costs | 69 |

Independent Auditor's Report

Board of Directors Erie County Medical Center Corporation

Report on the Audit of the Financial Statements

Opinions

We have audited the financial statements of the business-type activities and the aggregate discretely presented component units of Erie County Medical Center Corporation (the Corporation), a component unit of the County of Erie, as of and for the years ended December 31, 2024 and 2023, and the related notes to the financial statements, which collectively comprise the Corporation's basic financial statements as listed in the table of contents.

In our opinion, the accompanying financial statements referred to above present fairly, in all material respects, the respective financial position of the business-type activities and the aggregate discretely presented component units of Erie County Medical Center Corporation, as of December 31, 2024 and 2023, and the respective changes in financial position, and, where applicable, cash flows thereof for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinions

We conducted our audits in accordance with auditing standards generally accepted in the United States of America (GAAS) and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States (*Government Auditing Standards*). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of the Corporation and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinions. The financial statements of ECMC Foundation, Inc., the Grider Initiative, Inc., and Research for Health in Erie County, Inc. were not audited in accordance with *Government Auditing Standards*.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Corporation's ability to continue as a going concern for twelve months beyond the financial statement date, including any currently known information that may raise substantial doubt shortly thereafter.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinions. Reasonable assurance is a high level of assurance but is not absolute assurance and, therefore, is not a guarantee that an audit conducted in accordance with GAAS and *Government Auditing Standards* will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with GAAS and Government Auditing Standards, we

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to
 fraud or error, and design and perform audit procedures responsive to those risks. Such procedures
 include examining, on a test basis, evidence regarding the amounts and disclosures in the financial
 statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Corporation's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that
 raise substantial doubt about the Corporation's ability to continue as a going concern for a reasonable
 period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

Required Supplementary Information

Accounting principles generally accepted in the United States of America require that management's discussion and analysis as well as the required supplementary information for certain pension and other postemployment benefits (OPEB) related data, as listed in the table of contents, be presented to supplement the basic financial statements. Such information is the responsibility of management and, although not a part of the basic financial statements, is required by the Governmental Accounting Standards Board (GASB) who considers it to be an essential part of financial reporting for placing the basic financial statements in an appropriate operational, economic or historical context. We have applied certain limited procedures to the required supplementary information in accordance with auditing standards generally accepted in the United States of America, which consisted of inquiries of management about the methods of preparing the information and comparing the information for consistency with management's responses to our inquiries, the basic financial statements, and other knowledge we obtained during our audits of the basic financial statements. We do not express an opinion or provide any assurance.

Other Reporting Required by Government Auditing Standards

In accordance with *Government Auditing Standards*, we have also issued our report dated [DATE] on our consideration of the Corporation's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements and other matters. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the Corporation's internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the Corporation's internal control over financial reporting and compliance.

Cleveland, Ohio [DATE]

For Review and be Reproduced Not to be Reproduced

Management's Discussion and Analysis December 31, 2024 (Dollars in Thousands)

Management's Discussion and Analysis

Erie County Medical Center Corporation (the Corporation or ECMCC) is a state public benefit corporation dedicated to providing every patient the highest quality of care delivered with compassion. The Corporation fully embraces its position as a safety net provider for the eight-county region of Western New York State (encompassing over 1.5 million residents), supporting persons in need who lack the ability to pay.

To assist the reader in understanding the operations of the Corporation, this annual report has been organized into three parts that should be read together:

- Management's discussion and analysis
- Financial statements and notes to the financial statements and
- Supplemental schedules

The purpose of the discussion and analysis is to provide the reader with objective data to evaluate the financial position and the activities of the Corporation for the year ended December 31, 2024. This narrative and the financial statements and footnotes are the responsibility of the Corporation's management.

The financial statements (the statements of net position, the statements of revenues, expenses and changes in net position and the statements of cash flows) present financial information in a form similar to that used by other government hospitals and have been prepared in accordance with accounting principles generally accepted in the United States of America.

The accompanying financial statements of the Corporation include financial data of the Corporation's discretely presented component units: (i) ECMC Foundation, Inc., and (ii) The Grider Initiative, Inc. however, Management's Discussion and Analysis focuses on the Corporation.

Introduction

During 2024, the Corporation improved in both quality outcome metrics and operational growth while facing another year of financial challenges. During this period, despite these challenges, ECMCC continued to provide high quality, compassionate care to the tens of thousands of Western New Yorkers who depend on it, serve as the region's community hospital and trauma center, and help patients from the most influential to the most vulnerable. ECMCC's dedicated caregivers, support staff, executive leadership, as well as an involved and supportive Board of Directors, continue to advance the mission of the Corporation and its service to the greater Western New York area. The Corporation continues to be a provider of choice in our community as a result of its continual focus on high quality healthcare services, the patient experience and physician engagement.

Management's Discussion and Analysis December 31, 2024 (Dollars in Thousands)

Operations Analysis

The Corporation continued its recovery across inpatient and outpatient care, serving not only Western New York residents but also many individuals from beyond the region, bringing patient volume closer to pre-pandemic levels. The following outlines the patient volume encounters (not expressed in thousands):

| | | | | | | % Growth |
|-------------|---------|---------|---------|---------|---------|-----------|
| | 2020 | 2021 | 2022 | 2023 | 2024 | 2023-2024 |
| | | | | | | |
| Inpatients | 19,110 | 18,903 | 17,412 | 17,643 | 18,105 | 2.6% |
| Surgeries | 12,481 | 13,803 | 12,478 | 13,321 | 13,672 | 2.6% |
| Emergency | 65,261 | 68,384 | 59,064 | 63,715 | 63,917 | 0.3% |
| Outpatients | 299,297 | 280,611 | 274,402 | 297,168 | 299,098 | 0.6% |
| Dialysis | 27,973 | 26,116 | 24,961 | 25,159 | 25,771 | 2.4% |
| Transplants | 134 | 146 | 148 | 151 | 143 | -5.3% |

During 2024, the healthcare industry both nationally and locally faced several challenges, including rising costs and workforce shortages. Despite these obstacles, the Corporation successfully increased patient volumes through a dedicated focus on improving patient throughput. ECMCC's inpatient volumes ended the year 2.6% higher in patient discharges and 6.2% higher in inpatient surgeries, while the average length of stay improved by 3.7%. Outpatient surgeries saw a slight increase of 0.4% compared to the previous year, and emergency department visits rose by 0.3%, contributing to a 0.6% overall growth in total outpatient visits. As the Regional Center of Excellence for Transplantation and Kidney Care, the Corporation completed 143 transplant surgeries (kidney and pancreas) in 2024, following a record year in 2023.

The COVID-19 pandemic officially ended on May 11, 2023. While the public emergency concluded, the Corporation continues to await reimbursement for certain incremental eligible expenses incurred during the pandemic from the Federal Emergency Management Agency (FEMA), which provided financial relief through its Disaster Relief Fund. As of December 31, 2024, the Corporation has received \$23.9 million from FEMA to cover eligible COVID-19-related expenses.

Rising costs due to inflation and workforce shortages continue to affect both the healthcare industry and the Corporation. To sustain mission-critical services, ECMCC continues to work closely with the New York State Department of Health's various grant and operational assistance programs to address cash flow funding gaps. ECMCC has implemented a series of operational improvements aimed at mitigating cost escalations and increasing payor reimbursement. These efforts have led to financial improvements, and when coupled with certain supplemental funding receipts from FEMA, the Corporation did not require supplemental funding from the New York State Department of Health in 2024 after having received \$76.3 million of supplemental funding during 2023.

Management's Discussion and Analysis December 31, 2024 (Dollars in Thousands)

Operations Analysis (Continued)

The continued volume and visit trends reflect the trust that the Western New York community has placed in ECMCC. Notable achievements in 2024 include:

- **Global Healthcare Exchange** (GHX) announced that ECMCC is among the inaugural class of its "Supply Chains of Distinction Award for 2024," which recognized 75 top performing hospitals and health systems in North America. The Supply Chains of Distinction Award honors GHX Exchangeconnected provider organizations that excelled in driving best-in-class supply chain operations.
- ECMCC was honored by the **Buffalo Purchasing Initiative** for achieving Highest Outreach and Engagement for local Minority Business Enterprise vendors.
- ECMC is one of 462 national healthcare institutions to earn an "LGBTQ+ Healthcare Equality High Performer" designation from the Human Rights Campaign; 1,065 healthcare facilities nationwide were evaluated for their dedication and commitment to LGBTQ+ inclusion.
- Dr. Anthony Martinez, ECMC's Medical Director of Hepatology who was honored with the Coalition for Global Hepatitis Elimination's 2024 Hepatitis Elimination Champion award. Dr. Martinez was one of eight Champions selected worldwide from seven countries. His clinic at ECMC, "La Bodega," has been recognized nationally and globally as a novel co-localized model for managing viral hepatitis and addiction disorders.
- In Orthopedics, ECMCC was honored by **US News and Annual Report** in their annual High Performance Hospitals report as a High Performing Institution for Hip Replacement.
- ECMCC again recognized by the Lown Institute among the best nationally and in New York State, receiving 'A' grades on the 2024-2025 Lown Institute Hospitals Index across five metrics, including: health equity, community benefit, inclusivity, value of care, and avoiding overuse.
- Terrace View Long-Term Care Facility recognized on **Newsweek's Best Nursing Homes** 2024 list. Only four percent of nursing homes nationwide received this distinction. This is the fifth consecutive year Terrace View has received this recognition.
- Terrace View Long-Term Care Facility received an overall 4-star rating from a recent survey conducted by The Centers for Medicare and Medicaid Services (CMS).
- Terrace View Long-Term Care Facility received its **formal recertification from the NYS Department of Health** following a multi-day survey in August.
- ECMCC's Medical Intensive Care Units (MICU) North and South were each recognized by the American Association of Critical-Care Nurses (AACN) with a gold-level Beacon Award for Excellence.
- In another indication of national affirmation of ECMCC's clinical excellence, we earned status in 2024 as an **American College of Surgeons (ACS) Surgical Quality Partner** due to ECMC's participation in multiple ACS quality programs.
- The American College of Emergency Physicians (ACEP) informed ECMCC that our Emergency Department in 2024 achieved the bronze standard — Level 3 Geriatric Emergency Department Accreditation (GEDA) accreditation.
- ECMCC celebrated the opening of our new satellite **Trauma Recovery Center**, that is affiliated with the institution's BRAVE (Buffalo Rising Against Violence) initiative, which is our hospital-based violence intervention trauma recovery effort that serves individuals who have experienced acute victimization and violence.

Management's Discussion and Analysis December 31, 2024 (Dollars in Thousands)

Operations Analysis (Continued)

Financial Metric Analysis

The Corporation's total net position decreased in 2024 primarily due to significant non-cash expenses related to the actuarial liability adjustments for the New York State Pension Plan and Post-Retirement Health Benefit obligations. Additional drivers of performance are discussed in further detail below.

Comparative financial ratios for the Corporation to the 2023 (most recent publicly available audited data) averages of other comparable New York State (NYS) Public Benefit Corporation (PBC) hospitals are presented in the following table. The financial statements used for the calculation of the following ratios, where appropriate, have been reclassified to conform to the presentation used in the development of the benchmarks, consistent with generally accepted accounting principles (U.S. GAAP) for entities not subject to the Governmental Accounting Standards Board (GASB) standards.

| | | ECMCC | S | NYS PBC Average |
|--------------------------------|------------|--------|--------|--------------------|
| | 2024 | 2023 | 2022 | 2023 |
| | MALAN - RO | M | | |
| Operating margin | -2.0% | -14.2% | -10.8% | -14.3% |
| Operating cash flow margin | 4.6% | -6.0% | 4.6% | -8.2% |
| Debt service coverage | 1.70 | 2.7 | 1.5 | -0.5 |
| Unrestricted days cash on hand | 32.8 | 14.1 | 29.2 | 25.6 |
| Days cash on hand | 114.0 | 90.5 | 118.7 | 56.6 |
| Days in accounts receivable | 52.3 | 66.0 | 53.9 | 40.9 |
| Average age of plant | 17.3 | 15.4 | 13.0 | 19.1 |

The operational performance ratios for 2024 generally represent improvements from the Corporation's 2023 performance ratios and favorable comparisons to the NYS Healthcare Public Benefit Corporations' ratios. Notably, the operating margin for 2024 improved to -2.0%, compared to -14.2% in 2023, reflecting a positive shift but remaining negative. This improvement is largely driven by operational growth, despite the continued unfavorable impact of amortization components of the pension and postemployment benefit liabilities. Although these changes have no cash flows associated with them, the changes to the liabilities associated with them are included within the operating margin. Excluding the impact of the amortization components of pension and postemployment benefits, the operating margin for 2024 and 2023 stands at 2.1% and -11.6%, respectively. This shift indicates favorable operational performance and growth during 2024. Grants received from the New York State Department of Health (NYSDOH) and FEMA have been recognized as non-operating revenue and are excluded from the operating margin ratio calculations as required under GASB accounting standards. Unrestricted days cash on hand increased 18.7 days (132.6%) due to receipt of FEMA grant awards, accumulation of unrestricted investment income and an increase in annual Disproportionate Share Hospital (DSH) Revenue, a portion of which is subject to future reconciliation and repayment. Days in accounts receivable decreased by 13.7 days (20.1%) due to the improved collection efforts, improved staffing levels, and successful payment settlements with various insurance plans. Average age of plant increased by 1.9 years (12.3%) as a result of reduced capital investment aimed at managing cash flow needs to maintain essential community services amid operating challenges.

Management's Discussion and Analysis December 31, 2024 (Dollars in Thousands)

Summary Financial Statements with Analysis

Management is providing the following summary financial statements and variance analysis for certain financial statement lines where it believes the readers understanding of the financial statements is enhanced.

Statements of Net Position

Net position is categorized as follows:

Net investment in capital assets: Consists of capital assets, net of accumulated depreciation and reduced by outstanding debt and deferred inflows and outflows of resources that are attributable to the acquisition, construction or improvement of those assets.

Restricted: Result when constraints placed on the use of the net position are either externally imposed by creditors, grantors, contributors, or imposed by law through constitutional provisions or enabling legislation.

Unrestricted: Represents the resources derived primarily from services rendered to patients and other operating revenues and not meeting the previously listed criteria. These resources are used for transactions related to the general healthcare and academic operations of the Corporation and may be used at the discretion of the Board of Directors to meet current expenses for any purpose.

Condensed Statements of Net Position are as follows:

| HEW BINC | | | | | 2024-2023 | | | | |
|---|--------|-----------|----|-----------|-----------|-----------|----|-----------|----------|
| | VIDN | 2024 | J | 2023 | | 2022 | | \$ Change | % Change |
| Assets | 20 | - 101a | | | | | | | |
| Current assets, excluding assets whose use is limited | 5 \$ (| 203,094 | \$ | 189,816 | \$ | 210,427 | \$ | 13,278 | 7.0 |
| Assets whose use is limited | | 191,601 | | 170,621 | | 157,516 | | 20,980 | 12.3 |
| Capital assets, net | | 282,632 | | 313,039 | | 359,386 | | (30,407) | (9.7) |
| Net pension asset | | - | | - | | 77,538 | | - | - |
| Other assets | | 9,978 | | 8,906 | | 7,780 | | 1,072 | 12.0 |
| Total assets | | 687,305 | | 682,382 | | 812,647 | | 4,923 | 0.7 |
| Deferred outflows of resources | | 151,740 | | 159,464 | | 178,411 | | (7,724) | (4.8) |
| | | | | | | | | | |
| Total assets and deferred outflows of resources | \$ | 839,045 | \$ | 841,846 | \$ | 991,058 | \$ | (2,801) | (0.3) |
| | φ | 039,043 | φ | 041,040 | φ | 991,000 | φ | (2,001) | (0.3) |
| Liabilities | | | | | | | | | |
| Current liabilities | \$ | 339,603 | \$ | 302,347 | \$ | 303,848 | \$ | 37,256 | 12.3 |
| Noncurrent liabilities | | 637,616 | | 730,926 | | 560,724 | | (93,310) | (12.8) |
| Total liabilities | | 977,219 | | 1,033,273 | | 864,572 | | (56,054) | (5.4) |
| Deferred inflows of resources | | 142,978 | | 84,740 | | 396,441 | | 58,238 | 68.7 |
| Net Position | | | | | | | | | |
| Net investment in capital assets | | 46,303 | | 58,654 | | 85,013 | | (12,351) | (21.1) |
| Restricted | | 46,938 | | 29,012 | | 12,314 | | 17,926 | 61.8 |
| Unrestricted | | (374,393) | | (363,833) | | (367,282) | | (10,560) | (2.9) |
| Total net position | | (281,152) | | (276,167) | | (269,955) | | (4,985) | (1.8) |
| Total liabilities, deferred inflows | | | | | | | | | |
| of resources and net position | \$ | 839,045 | \$ | 841,846 | \$ | 991,058 | \$ | (2,801) | (0.3) |

Management's Discussion and Analysis December 31, 2024 (Dollars in Thousands)

Statements of Net Position (Continued)

Comparison of December 31, 2024 to December 31, 2023

Overall, total assets and deferred outflows of resources decreased \$2,801 from 2023 to 2024.

The following variances in total assets are noteworthy:

Total current assets, excluding the current portion of assets whose use is limited, increased by \$13,278 due to the following:

- Cash, cash equivalents and investments increased by \$13,813 due to the receipt of certain disproportionate share (DSH/IGT) payments, increased collections on billed accounts receivable, increased retroactive insurance payer settlements, accumulation of unrestricted investment income, a retrospective reimbursement settlement related to the 340b drug pricing program and the receipt of \$17.3 million of FEMA program reimbursement payments. These inflows were partially offset by management's payment of the New York State Pension Plan contribution as required and ongoing operating vendor and employee payments.
- Patient accounts receivable, net, decreased by \$8,681 due to increased collections efforts through increased staffing levels and successful insurance payer claim settlements achieved during the year. Also decreasing the balance are certain reserves recorded on professional billing accounts receivable as a result of a significant delay in billing due to the February 2024 Change Healthcare cyber attack.
- Other receivables decreased by \$27,715 which is due to a \$28,473 decrease in Medicaid DSH and UPL program receivables as a result of timing of payments, an increase of \$393 in due from third party payors and a \$365 increase in other receivables.

The following variances in non-current assets and deferred outflows of resources are noteworthy:

- Assets whose use is limited, including current portion, increased by a net of \$20,980, which is due to an increase in assets designated for capital and technology projects of \$16,724, gains on investments of \$8,584 offset by a decrease in reserve account funding for actuarial liabilities and other limited use assets of \$4,238.
- Capital assets, net, decreased by \$30,407 due to the shortfall in capital asset investments during 2024 as compared to the ongoing depreciation expense on all capital assets, which is a continued result of reduced cash flow availability. Investments in capital assets are summarized in a following section.
- Deferred outflows of resources decreased \$7,724 due to combined increases in differences between expected and actual actuarial experience offset by decreases in changes in assumptions related to the pension and other post-employment benefits deferred outflows of resources.

Overall, total liabilities and deferred inflows increased \$2,184 and net position decreased \$4,985 from 2023 to 2024.

The following variances in total liabilities are noteworthy:

- Accounts payable and accrued salaries and benefits increased by \$9,550 due to timing of payments to vendors and employees at year-end.
- Accrued other liabilities increased by \$15,538 largely as a result of increases in payor advances of \$13,604 related to the Change Healthcare cyber-attacks and Medicaid DSH and UPL repayment liability of \$9,743 offset by decreases in amounts due to Erie County of \$8,761.

Management's Discussion and Analysis December 31, 2024 (Dollars in Thousands)

Statements of Net Position (Continued)

- Unearned revenue increased by \$5,355 due to investment income accumulation on unearned revenue coupled with an increase in grants restricted for certain purposes.
- The line of credit liability remained unchanged due to borrowings that remain outstanding at December 31, 2024.
- Deferred inflows of resources increased \$58,238 largely as a result of increases in differences between projected and actual investment earnings on pension plan investments.
- The long-term portion of self-insured obligations decreased by \$7,281 due to decreases in actuarial estimates for self-insured retentions for malpractice and workers' compensation claims and payments made on those claims. The current portion of these self-insured obligations decreased by \$410.
- Net pension liability, including current portion, decreased \$43,612 due to changes in actuarial assumptions used to value the plan as of December 31, 2024.
- The liability for Other Post-Employment Benefits (OPEB) decreased by \$15,315 primarily as a result of the favorable impact of a change in actuarial assumptions related to favorable healthcare trend rates and an increase in the discount rate used to measure the obligation.
- Net position decreased by \$4,985 due to unfavorable financial performance related to inflationary
 pressures on operating expenses continuing to outpace increases in patient volume and payor
 reimbursement rates.

Comparison of December 31, 2023 to December 31, 2022

Overall, total assets and deferred outflows of resources decreased \$149,212 from 2022 to 2023. The following variances in total assets are noteworthy:

Total current assets, excluding the current portion of assets whose use is limited, decreased by \$20,611 due to the following:

- Cash, cash equivalents and investments decreased by \$20,029 due to losses from operations and the timing of the annual DSH and Upper Payment Limit (UPL) cash receipts offset by earnings on investments.
- Patient accounts receivable, net, increased by \$18,820 as a result of current year decreases in collections due to an increase in unbilled accounts as a result of staffing shortages and increased patient volumes.
- Other receivables decreased by \$21,822 which is due to a \$21,856 decrease in Medicaid DSH and UPL program receivables, a decrease of \$286 in due from third party payors and a \$320 increase in other receivables.

The following variances in non-current assets are noteworthy:

- Assets whose use is limited, including current portion, increased by a net of \$13,105, which is due to a required deposit of collateral of \$11,015 related to a new line of credit agreement, unrealized gains on investments of \$3,786 and an increase in reserve account funding for actuarial liabilities and other limited use assets of \$2,311, offset by a decrease in assets designated for long-term investment of \$4,007.
- Capital assets, net, decreased by \$46,347 due to the shortfall in capital asset investments during 2023 as compared to the ongoing depreciation expense on all capital assets, which is a continued result of reduced cash flow availability driven by operating losses. Investments in capital assets are summarized in a following section.

Management's Discussion and Analysis December 31, 2024 (Dollars in Thousands)

Statements of Net Position (Continued)

• Net pension asset decreased \$77,538 and was eliminated due to changes in actuarial assumptions, which increased the liability thus creating a net pension liability, which is further discussed in the section below.

Overall, total liabilities and deferred inflows decreased \$143,000 and net position decreased \$6,212 from 2022.

The following variances in total liabilities are noteworthy:

- Accounts payable and accrued salaries and benefits decreased by \$17,339 due to timing of payments to vendors and employees at year-end.
- Accrued other liabilities increased by \$1,908 largely as a result of increases in amounts due to Erie County and third-party payors.
- Unearned revenue decreased by \$22,517 due to a decrease of \$27,000 related to the New York State grant received in late December 2022 for the calendar year 2023, thus recognized during 2023. Other unearned revenue increased \$4,483.
- The line of credit liability remained unchanged due to borrowings that remain outstanding at December 31, 2023.
- The long-term portion of self-insured obligations increased by \$3,238 due to changes in actuarial estimates for self-insured retentions for malpractice and workers' compensation claims greater than payments made on those claims. The current portion of these self-insured obligations decreased by \$148.
- Net pension liability, including current portion, was established at \$198,936 due to changes in actuarial assumptions used to value the plan as of December 31, 2023. As noted above, at December 31, 2022, the Corporation had recorded a net pension asset of \$77,538.
- The liability for Other Post-Employment Benefits (OPEB) increased by \$22,516 primarily as a result of the unfavorable impact of a change in actuarial assumptions related to unfavorable healthcare trend rates and a decrease in the discount rate used to measure the obligation.
- Net position decreased by \$6,212 due to unfavorable financial performance related to inflationary pressures on operating expenses continuing to outpace increases in patient volume and payor reimbursement rates.

Management's Discussion and Analysis December 31, 2024 (Dollars in Thousands)

Statements of Revenues, Expenses and Changes in Net Position

Condensed Statements of Revenues, Expenses and Changes in Net Position are as follows:

| | | | | | | | 2024-2023 | | | |
|--|----|-----------|----|-----------|----|-----------|-----------|------------|----------|--|
| | | 2024 | | 2023 | | 2022 | 9 | Change | % Change | |
| Net patient service revenue | \$ | 656,228 | \$ | 603,720 | \$ | 566,389 | \$ | 52,508 | 8.7 | |
| Disproportionate share (DSH) revenue | | 164,953 | | 107,105 | | 68,295 | | 57,848 | 54.0 | |
| Other operating revenue | | 72,133 | | 46,639 | | 26,095 | | 25,494 | 54.7 | |
| Total operating revenues | | 893,314 | | 757,464 | | 660,779 | | 135,850 | 17.9 | |
| Operating expenses: | | | | | | | | | | |
| Payroll and employee benefits | | 463,302 | | 440,770 | | 410,664 | | 22,532 | 5.1 | |
| Professional fees | | 112,289 | | 110,577 | | 109,113 | | 1,712 | 1.5 | |
| Purchased services | | 72,027 | | 81,712 | | 78,037 | | (9,685) | (11.9) | |
| Supplies | | 153,120 | | 132,197 | | 117,877 | | 20,923 | 15.8 | |
| Other operating expenses | | 26,769 | | 30,529 | | 29,185 | | (3,760) | (12.3) | |
| Depreciation and amortization | | 47,115 | Dr | 49,812 |)0 | 49,872 | | (2,697) | (5.4) | |
| Total operating expenses | 5 | 874,622 | 1 | 845,597 | 7 | 794,748 | | 29,025 | 3.4 | |
| Operating income (loss) before pension | A | J. | M | 1 | | | | | | |
| and other post employment expense (benefit), | | | | | | | | | | |
| amortization components | | 18,692 | | (88,133) | | (133,969) | | 106,825 | 121.2 | |
| DEL SE | | Ju C | | 930 | | 300 | | (a. (a.a.) | () | |
| Pension expense (benefit), amortization component | | 30,347 | | 39,752 | | (32,537) | | (9,405) | (23.7) | |
| OPEB expense (benefit), amortization component | E | 6,072 | - | (20,424) | | (29,861) | | 26,496 | (129.7) | |
| Operating loss | | (17,727) | | (107,461) | | (71,571) | | 89,734 | 83.5 | |
| Non-operating revenues (expenses): Investment gain (loss) Grant revenue and capital contribution | | | | | | | | | | |
| Investment gain (loss) | | 7,411 | | 6,283 | | (13,966) | | 1,128 | 18.0 | |
| Grant revenue and capital contribution | | 17,352 | | 107,230 | | 63,151 | | (89,878) | (83.8) | |
| Interest expense | | (12,021) | | (12,264) | | (12,028) | | 243 | 2.0 | |
| Total change in net position | | (4,985) | | (6,212) | | (34,414) | | 1,227 | 19.8 | |
| Net position—beginning of year | | (276,167) | | (269,955) | | (235,541) | | (6,212) | (2.3) | |
| Net position—end of year | \$ | (281,152) | \$ | (276,167) | \$ | (269,955) | \$ | (4,985) | (1.8) | |

Comparison of December 31, 2024 to December 31, 2023

Overall, total operating revenues increased by \$135,850 or 17.9% in 2024 with changes attributable to the following:

- Net patient service revenue increased \$52,508, or 8.7%, in 2024 as a result of a combination of overall increased patient volumes, an increase in contracted reimbursement rates and revenue cycle improvements. Provisions for bad debts increased by \$8,067 due to reserves recorded related to the Change Healthcare cyber attack as further described in Note 4.
- DSH revenue increased by \$57,848, or 54.0%, in 2024 as a result of a decrease in the nursing home upper payment limit of \$607 due to a slight decrease in the pool size in the State Plan Amendment and a \$58,455 increase in federal DSH due to an increase in uncompensated care as a result of volume growth, and continued cost inflation exceeding increases in reimbursements from the Medicaid program.
- Other operating revenue increased \$25,494, or 54.7% primarily due to growth in specialty pharmacy operations of \$20,620, an increase in third-party quality incentives of \$2,553 and an increase in grant revenue of \$1,826.

Management's Discussion and Analysis December 31, 2024 (Dollars in Thousands)

Statements of Revenues, Expenses and Changes in Net Position (Continued)

Total operating expenses including pension expense/benefit and other post-employment benefit expenses increased \$46,116 or 5.3% in 2024. Expense changes are attributable to the following:

- Payroll and employee benefit expenses have increased by \$22,532 or 5.1% as a result of contracted rate and step increases as well as necessary additional pay incentives offered to fill open shifts to meet New York State minimum staffing standards for both the hospital and the skilled nursing facility. Salaries and employee benefit expense as a percent of net patient service revenue decreased by 2.4%, from 73.0% in 2023 to 70.6% in 2024.
- Purchased services have decreased \$9,685 as a result of a nonrecurring expense during 2023 of \$11,239 to write-off an abandoned IT capital related project. The remaining variance is due to an increase in contract labor of \$2,058 due to staffing shortages.
- Pension expense decreased by \$1,074 as a result of changes in actuarial assumptions used to value the plan including investment returns and other demographic assumptions offset by an increase in our proportionate share of that expense.
- Supplies expense increased by \$20,923 or 15.8% as a result of increased surgical volume, significant growth in volume within the specialty pharmacy operations, pharmaceutical cost increases related to drug shortages and continued cost inflation on medical supplies.
- OPEB benefit decreased \$7,117 or 36.8% as a result of unfavorable differences between projected and actual experience of net claims cost and benefit payments made under the plan.

Comparison of December 31, 2023 to December 31, 2022

Overall, total operating revenues increased by \$96,685 or 14.6% in 2023 with changes attributable to the following:

- Net patient service revenue increased \$37,331, or 6.6%, in 2023 as a result of a combination of
 overall increased patient volumes, an increase in contracted reimbursement rates, improvements in
 bad debt write-offs and improvements in ECMCC's ability to discharge patients into the community.
- DSH revenue increased by \$38,810, or 56.8%, in 2023 as a result of an increase in the nursing home upper payment limit of \$5,885 due to a significant increase in the pool size in the State Plan Amendment and a \$32,925 increase in federal DSH due to an increase in uncompensated care net of anticipated formula changes in the Medicaid DSH cap calculation enacted through legislation but not yet implemented which will exclude costs from services provided to Medicaid-eligible beneficiaries who are dually eligible for Medicare or any other coverage.
- Other operating revenue increased \$20,544, or 78.7% due to an increase in specialty pharmacy operations of \$20,777.

Total operating expenses including pension expense/benefit and other post-employment benefit expenses increased \$132,575 or 18.1% in 2023. Expense changes are attributable to the following:

- Payroll and employee benefit expenses have increased by \$30,106 or 7.3% as a result of increases in salaries due to new collective bargaining agreements' market rate adjustments and additional pay incentives offered to fill open shifts to meet New York State minimum staffing standards for both the hospital and the skilled nursing facility. Salaries and employee benefit expense as a percent of net patient service revenue increased by 0.5%, from 72.5% in 2022 to 73.0% in 2023.
- Pension expense increased by \$65,834 as a result of changes in actuarial assumptions used to value the plan including investment returns, discount rates and other demographic assumptions.

Management's Discussion and Analysis December 31, 2024 (Dollars in Thousands)

Statements of Revenues, Expenses and Changes in Net Position (Continued)

- Supplies expense increased by \$14,320 or 12.1% as a result of increased surgical volume, increased volume within the specialty pharmacy operations and pharmaceutical cost increases related to drug shortages.
- OPEB benefit decreased \$11,976 or 38.2% as a result of unfavorable differences between projected and actual experience of net claims cost and benefit payment made to current employees.

Capital Assets, Net

At December 31, 2024, the Corporation had capital assets, including lease and subscription-based information technology arrangement assets (SBITAs), net of accumulated depreciation of \$282,632 compared to \$313,039 at December 31, 2023, representing a decrease of \$30,407 or 9.7%.

During 2024, the Corporation invested \$16,805 in various capital assets (\$6,375), leases (\$2,887) and SBITAs (\$7,543). Noteworthy investments in capital assets include infusion pumps and related software (\$2,222) and purchases of other medical and non-medical equipment, furniture and fixtures, and information systems infrastructure investments. Noteworthy additions to capital leases include mobile x-ray system (\$794) and other various leased medical and non-medical equipment. Noteworthy additions to SBITAs includes a new payroll software system (\$3,261) and other medical and non-medical and non-medical equipment. Noteworthy additions to SBITAs includes a new payroll software system (\$3,261) and other medical and non-medical software. GASB Statement No. 87, *Leases*, establishes the foundational principle that leases are financing of the right-to-use an underlying asset for a period of time. The Corporation recorded lease assets, net of accumulated depreciation, in the amount of \$22,797 and \$26,371 in 2024 and 2023, respectively. GASB Statement No. 96, *Subscription-Based Information Technology Arrangements*, extends the right-of-use accounting concepts introduced in GASB Statement No. 87, *Leases*, to SBITAs. The Corporation recorded SBITA assets in the amount of \$22,322 in 2024 and \$25,761 in 2023.

Forward-Looking Factors

Management has prepared the following forward-looking factors to assist the reader in understanding the financial, economic and market factors impacting the Corporation:

Collective Bargaining Agreements

The Corporation operates under three collective bargaining agreements that cover substantially all employees. Corporation employees of the Civil Service Employee Association (CSEA) are covered by a contract negotiated in concert with Erie County, New York, which contains a sub-bargaining unit representing only Corporation employees. The agreement began January 1, 2023 and runs through December 31, 2027. Registered Nurses (RNs) are covered under an agreement with the New York State Nurses Association (NYSNA). This agreement began January 1, 2023 that runs through December 31, 2027. The Corporation's agreement with the American Federation of State, County and Municipal Employees (AFSCME), a contract negotiated in concert with the County of Erie, New York, and ratified with AFSCME employees in 2022 runs through December 31, 2026.

Transactions with the County of Erie

The Corporation is a component unit of the County of Erie, New York. The County has ongoing contractual and legal obligations to the Corporation and the Corporation has ongoing contractual and legal obligations to the County.

Management's Discussion and Analysis December 31, 2024 (Dollars in Thousands)

Medicare and Medicaid Reimbursement

The future state of both reimbursement levels and reimbursement methods related to the Medicare and Medicaid programs remains uncertain. Unimplemented formulaic changes as well as budget proposals related to both of these programs for the upcoming year and beyond may significantly alter reimbursements or methodologies, thus changing the environment in which we conduct business as the Corporation relies heavily on these programs for reimbursement for services. The impact of these state and federal rule changes and budget proposals are unknown at this time but could materially impact the Corporation.

Contacting the Corporation's Financial Management

This financial report is designed to provide our community and creditors with a general overview of Erie County Medical Center Corporation's finances and to demonstrate the Corporation's accountability for the resources it receives. If you have any questions about this report or need additional financial information. contact the Chief Financial Officer, Erie County Medical Center Corporation, 462 Grider Street, Buffalo, New York 14215.

inor in at the C is report or need incal Center Corporate AREAD SOLUTION OF A SOLUTION

Statements of Net Position December 31, 2024 and 2023 (Dollars in Thousands)

| | 2024 | | | 2023 |
|---|-----------|------------------|----|-----------------|
| Assets and Deferred Outflows of Resources | | | | |
| Current assets: | | | | |
| Cash and cash equivalents | \$ | 34,586 | \$ | 20,773 |
| Investments | | 42,825 | | 10,646 |
| Assets whose use is limited | | 84,714 | | 113,986 |
| Patient accounts receivable, net | | 93,708 | | 102,389 |
| Other receivables | | 12,893 | | 40,608 |
| Supplies, prepaids and other | | 19,082 | | 15,400 |
| Total current assets | | 287,808 | | 303,802 |
| Assets whose use is limited | | 106,887 | | 56,635 |
| Capital assets, net | | 282,632 | | 313,039 |
| other assets, net | | 9,978 | | 8,906 |
| | | 399,497 | | 378,580 |
| Total assets | | 687,305 | | 682,382 |
| ET. | GU |) | | |
| Deferred outflows of resources: Pension | | 121,188 | | 123,115 |
| Other post employment benefits | | 21,151 | | 25,670 |
| Other | | 9,401 | | 10,679 |
| Total deferred outflows of resources | - | 151,740 | | 159,464 |
| | 2 | 151,740 | | 159,404 |
| Total assets and deferred outflows of resources | <u>\$</u> | 839,045 | \$ | 841,846 |
| Liabilities, Deferred Inflows of Resources and Net Position | | | | |
| Liabilities, Deferred Inflows of Resources and Net Position Current liabilities: Current portion of long-term debt Line of credit Current portion of lease and SBITA liability Accounds payable Accrued salaries, wages and employee benefits Net pension liability Other post employment benefits Accrued other liabilities Unearned revenue | | | | |
| Current portion of long-term debt | \$ | 12,755 | \$ | 12,128 |
| Line of credit | ÷ | 10,000 | Ψ | 10,000 |
| Current portion of lease and SBITA liability | | 15,147 | | 16,409 |
| Accounts payable | | 64,579 | | 59,927 |
| Accrued salaries, wages and employee benefits | | 44,501 | | 39.603 |
| Active salaries, wages and employee perients | | | | 1 |
| Net pension liability | | 41,138 | | 34,131 |
| Other post employment benefits | | 12,767 | | 12,326 |
| Accrued other liabilities | | 57,559 | | 42,021 |
| Unearned revenue | | 81,157 | | 75,802 |
| Total current liabilities | | 339,603 | | 302,347 |
| .ong-term debt, net | | 179,372 | | 190,515 |
| .ong-term lease and SBITA liability, net | | 27,805 | | 34,682 |
| let pension liability, net of current portion | | 114,186 | | 164,805 |
| elf-insured obligations | | 44,840 | | 52,121 |
| ther post employment benefits, net of current portion | | 265,829 | | 281,585 |
| ther | | 5,584 | | 7,218 |
| Total liabilities | | 977,219 | | 1,033,273 |
| Deferred inflows of resources: | | | | |
| Pension | | 95,637 | | 23,737 |
| Other post employment benefits | | 45,778 | | 59,337 |
| | | | | |
| Leases Total deferred inflows of resources | | 1,563 142,978 | | 1,666 84,740 |
| let Position: | | | | |
| vet Position: Vet investment in capital assets | | 46,303 | | 58,654 |
| Restricted: | | | | |
| Expendable | | 46,938 | | 29,012 |
| Inrestricted | | (374,393) | | (363,833) |
| Total net position | | (281,152) | | (276,167) |
| | | | | |
| Total liabilities, deferred inflows of resources and net position | \$ | 839,045 | \$ | 841,846 |

See notes to the financial statements.

Statements of Revenues, Expenses and Changes in Net Position Years Ended December 31, 2024 and 2023 (Dollars in Thousands)

| | 2024 | 2023 |
|---|-----------------|-----------------|
| Operating revenues: | | |
| Net patient service revenue, net of provision for | \$ 656,228 | \$ 603,720 |
| bad debts of \$12,663 and \$4,596 for 2024 and 2023, respectively | | |
| Disproportionate share revenue (DSH) | 164,953 | 107,105 |
| Other operating revenue | 72,133 | 46,639 |
| Total operating revenues | 893,314 | 757,464 |
| Operating expenses: | | |
| Payroll and employee benefits | 463,302 | 440,770 |
| Professional fees | 112,289 | 110,577 |
| Purchased services | 72,027 | 81,712 |
| Supplies | 153,120 | 132,197 |
| Other operating expenses | 26,769 | 30,529 |
| Depreciation and amortization | 47,115 | 49,812 |
| Total operating expenses | 874,622 | 845,597 |
| Operating income (loss) before pension benefit and other | | |
| post employment benefits amortization components | 18,692 | (88,133) |
| Pension expense, amortization component | 30,347 | 39,752 |
| OPEB expense (benefit), amortization component Operating loss Nonoperating revenues (expenses): | 6,072 | (20,424) |
| Operating loss | (17,727) | (107,461) |
| operating loss | (17,727) | (107,401) |
| Nonoperating revenues (expenses): | | |
| Investment gain | 7,411 | 6,283 |
| Grant revenue | 17,333 | 107,230 |
| Interest expense | (12,021) | (12,264) |
| Total nonoperating revenues | 12,723 | 101,249 |
| Loss before capital contributions | (5,004) | (6,212) |
| Capital contributions | 19 | |
| Total change in net position | (4,985) | (6,212) |
| Net position—beginning of year | (276,167) | (269,955) |
| Net position—end of year | \$ (281,152) | \$ (276,167) |

See notes to the financial statements.

Statements of Cash Flows Years Ended December 31, 2024 and 2023 (Dollars in Thousands)

| | | 2024 | 2023 |
|---|----|-----------|---------------|
| Cash flows from operating activities: | | | |
| Receipts from patients and third-party payors | \$ | 691,467 | \$ 608,472 |
| Payments to employees for salaries and benefits | | (422,231) | (415,584) |
| Payments to vendors for supplies and other | | (345,921) | (354,111) |
| Other receipts | | 171,416 | 119,572 |
| Net cash provided by (used in) operating activities | | 94,731 | (41,651) |
| Cash flows from capital and related financing activities: | | | |
| Purchases of capital assets | | (12,551) | (12,554) |
| Payments on long-term debt | | (12,255) | (11,714) |
| Interest paid on long-term debt | | (9,797) | (10,264) |
| Payments on leases and SBITAs | | (15,676) | (15,253) |
| Interest paid on leases and SBITAs | | (2,224) | (2,000) |
| Net cash used in capital and related financing activities | 1 | (52,503) | (51,785) |
| Cash flows from noncapital financing activities: | 3 | | |
| Grant funding | | 17,333 | 80,229 |
| Net cash provided by noncapital financing activities | | 17,333 | 80,229 |
| | | · | · |
| Cash flows from investing activities: | | | |
| Purchases of assets whose use is limited, net | | (20,980) | (13,105) |
| Investment gain | | 7,411 | 6,283 |
| Purchases of investments, net | | (32,179) | (3,393) |
| Net cash used in investing activities | | (45,748) | (10,215) |
| Net change in cash and cash equivalents | | 13,813 | (23,422) |
| Cash and cash equivalents: | | | |
| Beginning | | 20,773 | 44,195 |
| Ending | \$ | 34,586 | \$ 20,773 |

Noncash capital and related financing activities:

Included in accounts payable at December 31, 2024 and 2023, was \$624 and \$1,357, respectively, of invoices related to capital asset acquisitions.

(Continued)

Statements of Cash Flows (Continued) Years Ended December 31, 2024 and 2023 (Dollars in Thousands)

| | 2024 | 2023 |
|---|-------------------|-----------|
| Reconciliation of operating loss to net cash | | |
| provided by (used in) operating activities: | | |
| Operating loss | \$ (17,727) \$ | (107,461) |
| Adjustments to reconcile operating loss to net cash | | |
| used in operating activities: | | |
| Depreciation and amortization | 47,115 | 49,812 |
| Provision for bad debts | 12,663 | 4,596 |
| Changes in assets, deferred outflows, liabilities and deferred inflows: | | |
| Patient accounts receivable | (3,982) | (23,416) |
| Other receivables | 27,715 | 21,822 |
| Supplies, prepaids and other | (4,754) | (3,546) |
| Deferred outflows of resources | 7,724 | 18,947 |
| Accounts payable | 9,313 | (4,634) |
| Accrued liabilities | 20,436 | 5,468 |
| Unearned revenue | 5,355 | 4,484 |
| Estimated third-party payor settlements | (1,157) | 1,750 |
| Self-insured obligations | (7,281) | 3,238 |
| Net pension liability | (43,612) | 276,474 |
| OPEB | (15,315) | 22,516 |
| Deferred inflows of resources | 58,238 | (311,701) |
| Net cash provided by (used in) operating activities | \$ 94,731 \$ | (41,651) |

See notes to the financial statements.

Statements of Net Position—Discretely Presented Component Units December 31, 2024 and 2023

(Dollars in Thousands)

| | | 2 | 2024 | 2023 | | | | | | | | |
|------------------------------------|------------------|------------------|---------------------|-----------|------------------|------------------|-------------------|-----------|--|--|--|--|
| | | The | Research for | | | The | Research for | | | | | |
| | ECMC | Grider | Health in | Aggregate | ECMC | Grider | Health in | Aggregate | | | | |
| | Foundation, Inc. | Initiative, Inc. | Erie County, Inc. * | Total | Foundation, Inc. | Initiative, Inc. | Erie County, Inc. | Total | | | | |
| Assets | | | | | | | | | | | | |
| Current assets: | | | | | | | | | | | | |
| Cash and cash equivalents | \$ 2,239 | \$ 270 | \$- | \$ 2,509 | 2,365 | \$ 270 | \$- | \$ 2,635 | | | | |
| Investments | - | - | | ~0 | 1000 - | - | - | - | | | | |
| Other receivables | 1,235 | - | | (1,235 | 938 | - | - | 938 | | | | |
| Supplies, prepaids and other | 13 | - | ALL STREET | 0 13 | 259 | - | - | 259 | | | | |
| Total current assets | 3,487 | 270 | | 3,757 | 3,562 | 270 | - | 3,832 | | | | |
| | | | | | 007 | | | 007 | | | | |
| Other receivables | - | | MILL RESIDE | ing 2m | 887 | - | - | 887 | | | | |
| Endowment and other investments | 4,005 | 9,3.\8 | Chi Chi | 013,903 | 3,129 | 9,962 | - | 13,091 | | | | |
| Equipment and vehicles, net | - | phi- | 012 - 00 | - AUIO | - | - | - | - | | | | |
| | 4,005 | 9,898 | his the second | 13,903 | 4,016 | 9,962 | - | 13,978 | | | | |
| Total assets | \$ 7,492 | \$ 10,16% | uplot Ret | \$ 17,660 | \$ 7,578 | \$ 10,232 | \$ - | \$ 17,810 | | | | |
| Liabilities and Net Position | | | | | | | | | | | | |
| Current liabilities: | | | | | | | | | | | | |
| Accounts payable | \$ 257 | \$ - | \$ - | \$ 257 | \$ 11 | s - | s - | \$ 11 | | | | |
| Funds held in custody for others | ¢ 207 897 | ÷ - | Ψ - - | 897 | 596 | φ - - | ÷ - | 596 | | | | |
| Total current liabilities | 1,154 | - | | 1,154 | 607 | | - | 607 | | | | |
| Total current nabilities | 1,134 | - | | 1,134 | 007 | | | 007 | | | | |
| Long-term liabilities: | | | | | | | | | | | | |
| Related party | - | - | - | - | 969 | - | - | 969 | | | | |
| Unearned revenue | 309 | - | - | 309 | 335 | - | - | 335 | | | | |
| Total liabilities | 1,463 | | - | 1,463 | 1,911 | - | - | 1,911 | | | | |
| Not Beelfer | | | | | | | | | | | | |
| Net Position | | | | | | | | | | | | |
| Restricted: | | | | | 50 | | | | | | | |
| Nonexpendable | 50 | 10,000 | - | 10,050 | 50 | 10,000 | - | 10,050 | | | | |
| Expendable | 3,078 | 168 | - | 3,246 | 2,634 | 232 | - | 2,866 | | | | |
| Unrestricted | 2,901 | - | - | 2,901 | 2,983 | - | - | 2,983 | | | | |
| Total net position | 6,029 | 10,168 | - | 16,197 | 5,667 | 10,232 | - | 15,899 | | | | |
| Total liabilities and net position | \$ 7,492 | \$ 10.168 | | | | | | \$ 17,810 | | | | |

* - Activity related to the Research for Health in Erie County, Inc. is included within the ECMC Foundation, Inc. financial statements since the entity was merged into the ECMC Foundation, Inc. in 2023.

See notes to the financial statements.

20

Statements of Revenues, Expenses and Changes in Net Position—Discretely Presented Component Units Years Ended December 31, 2024 and 2023 (Dollars in Thousands)

| | | 2024 | | | | | | | 2023 | | | | | | | |
|--|------|--|-----|--------|----------------------|----------|-------------|-------------------|------|-------|----|--------|----|------------|----|----------|
| | | | | The | Research | for | | | | | | The | Re | search for | | |
| | | ECMC | | Grider | Health in | | A | Aggregate | | ECMC | | Grider | | Health in | | ggregate |
| | Foun | Foundation, Inc. Initiative, Inc. Erie County, Inc. * Total Four | | Foun | dation, Inc. | Initi | ative, Inc. | Erie County, Inc. | | Total | | | | | | |
| Operating revenues: | | | | | | | | | | | | | | | | |
| Grants, contributions and special events | \$ | 3,754 | \$ | - | \$ | - | \$ | 3,754 | \$ | 4,732 | \$ | - | \$ | - | \$ | 4,732 |
| Total operating revenues | | 3,754 | | - | | - | 1 | 3,754 | 10.8 | 4,732 | | - | | - | | 4,732 |
| | | | | | | 25 | 51 | - 65 | | | | | | | | |
| Operating expenses: | | | | | | | | | | | | | | | | |
| Program services and grants | | 697 | | 500 | A ba | -0 | | 1,197 | | 970 | | - | | 1,107 | | 2,077 |
| Fundraising | | 1,815 | | - | all Alla | Sile V | | / 1,815 | | 1,640 | | - | | - | | 1,640 |
| Other operating expenses | | 941 | | Mr. | and and | <u> </u> | | <u> </u> | | 641 | | - | | - | | 641 |
| Total operating expenses | | 3,453 | | 500 | self a | -Hou | | <u> </u> | | 3,251 | | - | | 1,107 | | 4,358 |
| | | | | Pro A | J ¹⁹ , 40 | | 9m. | 9 | | | | | | | | |
| Operating income (loss) | | 301 | | (500) | 1000 | afor | | (199) | | 1,481 | | - | | (1,107) | | 374 |
| | | | | | | | | | | | | | | | | |
| Nonoperating revenue: | | | | | | | | | | | | | | | | |
| Investment income (loss) | | 61 | 200 | 436 | 6 la | - | | 497 | | 127 | | 385 | | 13 | | 525 |
| | | 10. | | 1.0- | | | | | | | | | | | | |
| Change in net position | | 362 | | (64) | | - | | 298 | | 1,608 | | 385 | | (1,094) | | 899 |
| Net position—beginning of year | | 5,667 | | 10,232 | | | | 15,899 | | 4,059 | | 9,847 | | 1,094 | | 15,000 |
| | | | | | | | | | | | | | | | | |
| Net position—end of year | \$ | 6,029 | \$ | 10,168 | \$ | - | \$ | 16,197 | \$ | 5,667 | \$ | 10,232 | \$ | - | \$ | 15,899 |

* - Activity related to the Reseach for Health in Erie County, Inc. is included within the ECMC Foundation, Inc. financial statements since the entity was merged into the ECMC Foundation, Inc. in 2023.

See notes to the financial statements.

21

Notes to the Financial Statements Year Ended December 31, 2024 (Dollars in Thousands)

Note 1. Organization

The Corporation: Erie County Medical Center Corporation (referred to as the Corporation or ECMCC) is a public benefit corporation created by the Erie County Medical Center Corporation Act, Chapter 143 of the Laws of New York State, 2003 (Title 6 of Article 10-C of the Public Authorities Law) (the Act) as amended in 2016. The Corporation was created under the Act to secure a form of governance which permits the Corporation to have the legal, financial, and managerial flexibility to operate its health care facilities for the benefit of the residents of New York State (the State), the County of Erie (the County), and Western New York, including persons in need who lack the ability to pay.

The Corporation's "Health Care Facilities" consist of the Medical Center, a 573-bed acute tertiary care facility providing inpatient, emergency, outpatient, primary care and specialty clinic services (Medical Center), a 390-bed residential health care facility (Terrace View) both located on Grider Street in the City of Buffalo and three chemical dependency and alcohol rehabilitation clinics located throughout the County. The Medical Center serves as the region's only Level 1 Adult Trauma Center, burn center, comprehensive traumatic brain injury and spinal cord injury rehabilitative center, Comprehensive Psychiatric Emergency Program provider for acute psychiatric emergencies, Regional Center of Excellence for Transplantation and Kidney Care.

The Corporation has the power under the Act to acquire, operate, and manage its facilities and to issue bonds and notes to finance the costs of providing such facilities. The Act specifically provides that the Corporation's existence shall continue until terminated by law; provided, however, that no such termination shall take effect so long as the Corporation shall have bonds or other obligations outstanding unless adequate provision has been made for the payment or satisfaction thereof. The Corporation's primary purpose is the operation of the Medical Center and Terrace View, and its powers, duties and functions are as set forth in the Act, as amended, and other applicable laws.

The Corporation qualifies as a governmental entity and, accordingly, is exempt from federal income tax pursuant to Section 115 of the Internal Revenue Code of 1986.

In accordance with Governmental Accounting Standards Board (GASB) Statement No. 14, *The Financial Reporting Entity*, as amended, the Corporation's financial statements are included, as a discretely presented component unit, in the County's Annual Comprehensive Financial Report (ACFR). A copy of the ACFR can be obtained from the Erie County Comptroller's Office, 95 Franklin Street, Room 1100, Buffalo, New York 14202. The Corporation is subject to New York civil service law.

Governance: The Corporation is governed by its Board of Directors (the Board) consisting of fifteen (15) voting directors, eight (8) of whom are appointed by the Governor of the State of New York and seven (7) of whom are appointed by the Erie County Executive with the advice and consent of the Erie County Legislature. There are four non-voting representatives, as well. The directors and non-voting members serve staggered terms and continue to hold office until their successors are appointed. Directors have experience in the fields of health care services, quality and patient safety, human resources, strategic growth, law, and financial management and reflect a broad representation of the community served by the Corporation. Regular meetings of the Board are scheduled eleven (11) times per year. Board leaders are appointed by the Board.

Notes to the Financial Statements Year Ended December 31, 2024 (Dollars in Thousands)

Note 1. Organization (Continued)

Great Lakes Heath System: The Corporation is a member of Great Lakes Health System of Western New York (Great Lakes). Great Lakes is a not-for-profit, community-based corporation comprised of unified partners whose objective is to provide the highest quality of healthcare to the residents of Western New York. Great Lakes is comprised of the Corporation, Kaleida Health (KH), The Center for Hospice and Palliative Care and the State University of New York at Buffalo (the University).

Great Lakes Health Integrated Network: The Corporation, together with KH has formed Great Lakes Health Integrated Network (GLIN) with each maintaining a 50% ownership interest. As of December 31, 2024 and 2023, capital contributions due to GLIN totaled \$393 and \$326, respectively. Contributions are used to pay for care coordination services, information systems infrastructure and routine operating expenses to support community population health management.

Medical School Collaboration: The Corporation serves as a primary teaching hospital for the Jacobs School of Medicine and Biomedical Sciences of the State University of New York at Buffalo (the Medical School). An agreement governs the relationship between the Corporation and the Medical School. The Corporation serves as an integral part of the education and research mission of the Medical School by providing the clinical settings for the Medical School's public mission to educate and train physicians, nurses and other healthcare professionals, conduct clinical research programs and deliver healthcare services to patients. There are currently 187 full-time equivalent medical residents assigned to the Corporation in various Academic College of Graduate Medical Education accredited residency programs.

Component Units: Accounting principles generally accepted in the United States of America (U.S. GAAP) require the inclusion within the Corporation's financial statements of certain organizations as component units. The component units discussed below are included because the nature and significance of their relationship to the Corporation are such that exclusion would cause the reporting entity's financial statements to be misleading or incomplete under criteria set forth by the GASB.

The component unit information in the accompanying basic financial statements includes the financial data of the Corporation's three discretely presented component units. The three discretely presented component units are discussed in more detail below:

ECMC Foundation, Inc.: The ECMC Foundation, Inc. (the Foundation) is a not-for-profit organization exempt from federal income taxes under Section 501(c)(3) of the Internal Revenue Code (IRC). The Foundation was formed for the purpose of supporting Corporation programs. The financial statements of the Foundation have been prepared on an accrual basis. The annual financial report can be obtained by writing to: Executive Director, ECMC Foundation, Inc., 462 Grider Street, Buffalo, NY 14215.

The Grider Initiative, Inc.: The Grider Initiative, Inc. (the Physician Endowment) is a not-for-profit organization exempt from federal income taxes under Section 501(c)(3) of the IRC. The Physician Endowment was funded in 2010, for the purpose of recruiting physicians who shall practice on the Grider Street campus of the Corporation. The entity was funded with an initial transfer of \$10,000 from the Corporation. Earnings from the investment of the initial transfer may be used only for physician recruitment and retention and necessary expenses of the entity. The financial statements of The Grider Initiative, Inc. have been prepared on an accrual basis. The annual financial report can be obtained by writing to: Chair, The Grider Initiative, Inc. 462 Grider Street, Buffalo, NY 14215.

23

Notes to the Financial Statements Year Ended December 31, 2024 (Dollars in Thousands)

Note 1. Organization (Continued)

Research for Health in Erie County, Inc.: Research for Health in Erie County, Inc. (RHEC) was a not-for-profit organization dedicated to supporting research activities relating to the causes, nature, and treatment of diseases, disorders, and defects of particular importance to the public health in areas served by the Corporation. During 2023, RHEC was dissolved and the remaining net assets were contributed to the ECMC Foundation in order for ECMC Foundation to carry out the original RHEC mission.

In addition, the financial statements of the Corporation include the operations of the following component units, which are blended with the accounts of the Corporation:

PPC Strategic Services LLC (PPC): The Corporation is the sole owner of this enterprise, which was established to enable the Corporation to enter into various other business relationships.

Grider Support Services, LLC: The Corporation is the sole owner of this enterprise, which was formed to act as an MSO for physician practice services, which includes providing employees, management and administrative services.

Grider Community Gardens, LLC: This entity is wholly owned and controlled by the Corporation and was formed for the purpose of purchasing and holding properties in proximity to the Corporation's Grider Street Campus.

1827 *Fillmore, LLC:* This entity is controlled by the Corporation and was formed for the purchase and development of property immediately adjacent to the Corporation's Grider Street campus.

Note 2. Summary of Significant Accounting Policies

Basis of accounting: The Corporation uses the accrual basis of accounting. Revenue is recognized in the period it is earned and expenses are recognized in the period incurred. Under this basis of accounting, all assets, deferred outflows of resources, liabilities and deferred inflows of resources associated with the operation of the Corporation are included in the statements of net position.

For financial accounting and reporting purposes, the Corporation follows all pronouncements of the GASB. All references to relevant authoritative literature issued by the GASB with which the Corporation must comply are hereinafter referred to generally as U.S. GAAP. The discretely presented component units, as previously described, report under Financial Accounting Standards Board (FASB) standards. As such, certain revenue recognition criteria and presentation features are different from GASB revenue recognition criteria and presentation features.

Use of estimates: The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. The reserve for uncollectible accounts, contractual allowances, estimated third-party payor settlements, workers compensation reserves, malpractice reserves, net pension obligations, other post-employment benefit obligations, self-insured obligations, as well as, Disproportionate Share (DSH) revenue and certain other accounts, require the use of estimates. Actual results could differ from those estimates.

Notes to the Financial Statements Year Ended December 31, 2024 (Dollars in Thousands)

Note 2. Summary of Significant Accounting Policies (Continued)

Included in net patient service revenue are adjustments to prior year estimated third-party payor settlements, and their related estimated receivables and payables that were originally recorded in the period the related services were rendered, as well as adjustments to the net realization rate for collections on patient accounts receivable. These adjustments are made in the normal course of operations and amounts reported are consistent with the approach in prior years. The adjustments to prior year estimates and other third-party reimbursement or recoveries that relate to prior years also impact DSH revenues as discussed in Note 5. The combined effect of changes related to prior years' estimates resulted in an increase of \$3,508 and \$5,472 in total operating revenues for the years ended December 31, 2024 and 2023, respectively.

Cash and cash equivalents: The Corporation's cash and cash equivalents include cash on hand and cash in checking and money market accounts as well as investments with a maturity of three months or less when purchased. Cash and cash equivalents designated for long-term purposes or received with donor-imposed restrictions limiting their use to long-term purposes are not considered cash and cash equivalents for purposes of the statements of cash flows. Monies deposited in Federal Deposit Insurance Corporation (FDIC) insured commercial banks are collateralized with specifically designated securities held by a pledging financial institution, as required by State regulations.

Patient accounts receivable: Patient accounts receivable are reported net of both an estimated allowance for contractual adjustments and an estimated allowance for uncollectible accounts. The contractual adjustments represent the difference between established billing rates and estimated reimbursement from Medicare, Medicaid and other third-party payor programs. Current operations are charged with an estimated provision for bad debts estimated based on the age of the account, prior experience and any other circumstances which affect collectability. The Corporation's policy does not require collateral or other security for patient accounts receivable and the Corporation routinely accepts assignment of, or is otherwise entitled to receive, patient benefits payable under health insurance programs, plans or policies. The allowance for estimated doubtful accounts at December 31, 2024 and 2023 was approximately \$72,469 and \$64,577, respectively.

Investments and assets whose use is limited: The Corporation generally records its investments at fair value. Such assets are comprised of cash and cash equivalents, including money market funds, fixed income securities, commercial paper and equity funds. Assets classified as investments are unrestricted. Assets classified as limited as to use are restricted under Board designation or terms of agreements with third parties and include debt service funds, funds for self-insured workers' compensation costs and medical malpractice costs, collateral for insured workers' compensation programs, patient and resident monies, funding for future retiree health costs, and funds limited as to use for the acquisition of property, plant, equipment and information technology.

Investment securities are exposed to various risks, such as interest rate, market and credit risk. Due to the level of risk associated with certain investment securities and the level of uncertainty related to changes in the fair value of investment securities, it is at least possible that changes in risks in the near term could materially affect the net position of ECMCC.

Notes to the Financial Statements Year Ended December 31, 2024 (Dollars in Thousands)

Note 2. Summary of Significant Accounting Policies (Continued)

Other receivables: The composition of other receivables, as of December 31 is as follows:

| | | 2024 | | 2023 |
|--|----|--------|-----|--------|
| DSH and Upper Payment Limit (UPL) (Note 5) | \$ | - | \$ | 28.473 |
| Due from affiliated organizations and joint ventures | · | 867 | | 1,233 |
| Due from third-party payors | | 7,374 | | 6,980 |
| Other | | 4,652 | | 3,922 |
| | \$ | 12,893 | \$ | 40,608 |
| | | | . 1 | |

Capital assets: Capital assets are stated at cost. Depreciation is computed under the straight-line method over the estimated useful life of the asset. Estimated useful lives of assets have been established as follows:

| | Years |
|---|------------------------|
| Land and land improvements Buildings and improvements Fixed equipment | 5-25 10-40 10-20 |
| Major movable equipment | 3-20 |

When assets are retired, or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts, and any resulting gain or loss is reflected for the period. Maintenance and repairs are charged to expense as incurred with significant renewals and betterments being capitalized.

Capital assets that are donated (without restriction) are recorded at their fair value as a direct increase to the component of net investment in capital assets.

Deferred outflows of resources: Deferred outflows of resources represent a consumption of net position that applies to a future period(s) and therefore will not be recognized as an outflow of resources (expense) until that time. Deferred outflows of resources consist primarily of unrecognized items not yet charged to pension expense and retiree health expense related to the net pension liability and post-employment benefit obligations, and items related to the 2017 financing transaction as described below, amongst other deferred resources.

The 2017 financing transaction included the payment of points, in the amount of \$17,040 to Erie County associated with the differential in interest rate on the 2017 financing using the credit rating of Erie County and the rate that the Corporation was projected to pay independent of a relationship with Erie County. The points are being amortized on the interest method over the term of the 2017 financing. The unamortized amount of points at December 31, 2024 and 2023, is \$7,650 and \$8,712, respectively. The 2017 financing transaction also included the advance refunding of the 2011 financing, the proceeds of which were used to finance the construction of the Terrace View Nursing Home on the Corporation's campus. The deposit required to the advance refunding escrow was greater than the balance outstanding on the 2011 financing in the amount of \$2,038 and is being amortized on the interest method over the life of the advance refunding component of the transaction. The unamortized portion of this advance refunding at December 31, 2024 and 2023 is \$485 and \$652, respectively.

Notes to the Financial Statements Year Ended December 31, 2024 (Dollars in Thousands)

Note 2. Summary of Significant Accounting Policies (Continued)

Other assets: Ownership interests in various business enterprises amongst other assets are included in the other assets caption in the statements of net position.

Collaborative Care Ventures, LLC (Collaborative Care) was formed in 2014 by ECMCC and KH. Collaborative Care was created as a vehicle for ECMCC and KH to participate in various investments in the future consistent with their missions. At December 31, 2024 and 2023, the Corporation's share of the net assets of Collaborative Care amounted to \$1,351 and \$1,022, respectively.

Great Lakes Health Integrated Network (GLIN) was formed in 2018 by ECMCC and KH. GLIN was formed to support, manage and negotiate value-based contracts and/or risk-based contracts with thirdparty payors for the purpose of managing population health and anticipated payment reform. The Corporation's share of contributed capital supports organizational development and ongoing operations. The Corporation's share of GLIN's profit or loss is recognized as non-operating revenue. At December 31, 2024 and 2023, the Corporation's share of the net assets of GLIN amounted to \$6,283 and \$4,324, respectively.

Leases: The Corporation is a lessee for noncancellable leases of real estate and equipment. The Corporation recognizes a lease liability and an intangible right-to-use lease asset in the financial statements for leases. At the commencement of a lease, the Corporation measures the lease liability at the interest rate charged on the lease, if available, or otherwise discounted using the Corporation's incremental borrowing rate. The lease assets are amortized over the shorter of the lease term or the underlying asset useful life.

The Corporation is also a lessor for noncancellable leases of real estate. The Corporation recognizes a lease receivable and deferred inflow of resources in the financial statements for these leases. At the commencement of the lease, the Corporation measures the lease receivable at the interest rate charged on the lease, if available, or otherwise discounted using the Corporation's incremental borrowing rate.

Subscription Based Information Technology Arrangements (SBITAs): The Corporation recognizes an intangible subscription asset and corresponding subscription liability for its SBITAs. The subscription asset is measured as the subscription liability plus direct costs incurred in implementing the subscription asset. The subscription asset is amortized on a straight-line basis over the shorter of the subscription term or the useful life of the underlying subscription asset. At the subscription commencement, the subscription liability is measured at the present value of payments expected to be made during the subscription term and utilizes the interest rate charged in the SBITA, if available, or otherwise discounted using the Corporation's incremental borrowing rate to calculate the present value of the payments.

Unearned revenue: Unearned revenue represents funds received by the Corporation under certain grant programs that have not yet been earned.

Notes to the Financial Statements Year Ended December 31, 2024 (Dollars in Thousands)

Note 2. Summary of Significant Accounting Policies (Continued)

Compensated absences: The Corporation has accrued liabilities for certain compensated absences earned by its employees, to include vacation, sick, and compensatory time. The Corporation's employees are permitted to accumulate unused vacation and sick leave time up to certain maximum limits. The Corporation accrues the estimated obligation related to vacation pay based on pay rates currently in effect. Sick leave credits, if accumulated above certain prescribed levels, may be the basis of a supplemental payment to employees upon retirement. The Corporation accrues an estimated liability for these estimated terminal payments. These amounts have been included in the statements of net position within the caption accrued salaries, wages and employee benefits. Compensated absences activity for the years ended December 31, is as follows:

| | 2024 | R | 2023 |
|---|-----------|----|----------|
| | | | |
| Accrued compensated absences, beginning of year | \$17,496 | \$ | 15,295 |
| Compensated absences earned | 24,733 | | 24,771 |
| Compensated absences paid out | (24,099) | | (22,570) |
| Accrued compensated absences, end of year | \$ 18,130 | \$ | 17,496 |
| | A | | |

Deferred inflows of resources: Deferred inflows of resources represent an acquisition of net position that applies to a future period(s) and therefore will not be recognized as an inflow of resources (revenue) until that time. Deferred inflows of resources consist primarily of the unamortized portion of certain items related to the Corporation's pension, other post-employment benefits and the value of leases receivable plus any payments received at or before the commencement of the lease term that relates to future periods.

Net position: Net position is classified into three categories according to external donor restrictions or availability of assets for satisfaction of the Corporation's obligations. The Corporation's net position is described as follows:

Net investment in capital assets: This represents the Corporation's total investment in capital assets, net of accumulated depreciation, and reduced by outstanding debt and deferred inflows and outflows of resources that are attributable to the acquisition, construction or improvement of those assets. To the extent debt has been incurred but not yet expended for capital assets, such amounts are not included as a component of net investment in capital assets.

Restricted: The restricted expendable component of net position consists of constraints placed on net position through external constraints imposed by creditors (such as through debt covenants), grantors, contributors, or laws or regulations of other governments or constraints imposed by law through constitutional provisions or enabling legislation. The restricted nonexpendable component of net position is permanently unavailable for use. The earnings on the nonexpendable net position are classified as restricted expendable.

Unrestricted: This component of net position consists of net position that does not meet the definition of other components of net position described above. These resources are used for transactions relating to the general health care operations of the Corporation and may be used at the discretion of the Board of Directors to meet current expenses for any purpose.

Notes to the Financial Statements Year Ended December 31, 2024 (Dollars in Thousands)

Note 2. Summary of Significant Accounting Policies (Continued)

Net patient service revenue: Net patient service revenue is reported as services are rendered at estimated net realizable amounts, including estimated retroactive revenue adjustments under reimbursement agreements with third-party payors. Estimated settlements under third-party reimbursement agreements are accrued in the period the related services are rendered and adjusted in future periods as final settlements are determined. An estimated provision for bad debts is included in net patient service revenue.

Charity care: The Corporation provides care to patients who meet certain criteria under its charity care policy, without charge or at amounts less than established rates. Because the Corporation does not pursue collection of amounts determined to qualify as charity care, they are not reported as net patient service revenue in the accompanying statements of revenues, expenses and changes in net position. The estimated costs of caring for charity care patients were \$3,944 and \$4,459 for the years ended December 31, 2024 and 2023, respectively. Additionally, the Corporation provided approximately \$4,245 and \$2,397 in discounts to self-pay patients for the years ended December 31, 2024 and 2023, respectively.

Contributions: ECMC Foundation reports gifts or promises to give as restricted contributions when they are received with donor stipulations that limit the use of the donated assets. When the intent of the donor is that the assets are to remain in perpetuity and the Foundation does not have the right to invade the original principal, the assets are reported as restricted net position. When a donor restriction expires, restricted-expendable net positions are released to unrestricted net position. The Foundation conducted a capital campaign to raise funds to support the construction of a new Level 1 Adult Trauma Center, Emergency Department and other capital needs in support of the mission of the Corporation. Pledges receivable associated with this campaign are recorded net of a reserve for uncollectible pledges and are discounted to present value using a 4.38% discount rate over the collection period of the pledges.

Classification of revenues: The Corporation has classified its revenues as either operating or nonoperating revenues according to the following criteria:

Operating revenues: Operating revenues include activities that have the characteristics of exchange transactions, such as payments for providing services and payments for goods and services received, for health care services provided to patients, net of contractual adjustments and provisions for bad debts.

Nonoperating revenues: Nonoperating revenues include activities that have the characteristics of nonexchange transactions, such as gifts and contributions, NYSDOH Distressed Hospital grant funding, Federal Emergency Management Agency (FEMA) funding, income from investments and contributions.

Income taxes: The Corporation is a Public Benefit Corporation of the State of New York and is exempt from federal income taxes under Section 115 of the Internal Revenue Code. Accordingly, no provision for income taxes has been made in the accompanying financial statements.

Contributed services: Certain immaterial amounts related to contributed rents have been reflected in the Foundation's financial statements as contribution revenue. The Foundation generally pays for services requiring specific expertise. However, many individuals volunteer their time and perform a variety of tasks that assist the Foundation in meeting its goals and objectives. Such services are not recognized in the Foundation financial statements.

Notes to the Financial Statements Year Ended December 31, 2024 (Dollars in Thousands)

Note 2. Summary of Significant Accounting Policies (Continued)

No amounts have been reflected in the Physician Endowment financial statements for contributed services, as the value of contributed services meeting the requirements for recognition in the financial statements was not material.

Recent and pending accounting pronouncements: Effective January 1, 2023, the Corporation adopted GASB issued Statement No. 99, *Omnibus 2022*. The objectives of this Statement are to enhance comparability in accounting and financial reporting and to improve the consistency of authoritative literature by addressing: (1) practice issues that have been identified during implementation and application of certain GASB Statements, and (2) accounting and financial reporting for financial guarantees. There was no significant impact on the Corporation's financial statements as a result of the adoption of this standard.

Effective January 1, 2023, the Corporation adopted GASB issued Statement No. 100, Accounting Changes and Error Corrections-An Amendment of GASB No. 62. This Statement defines accounting changes as changes in accounting principles, changes in accounting estimates, and changes to or within the financial reporting entity and describes the transactions or other events that constitute those changes. As part of those descriptions, for: (1) certain changes in accounting principles, and (2) certain changes in accounting estimates that result from a change in measurement methodology, a new principle or methodology should be justified on the basis that it is preferable to the principle or methodology used before the change. That preferability should be based on the qualitative characteristics of financial reporting-understandability, reliability, relevance, timeliness, consistency, and comparability. This Statement also addresses corrections of errors in previously issued financial statements. There was no significant impact on the Corporation's financial statements as a result of the adoption of this standard.

Effective January 1, 2023, the Corporation adopted GASB issued Statement No. 101, *Compensated Absences*. The objective of this Statement is to better meet the information needs of financial statement users by updating the recognition and measurement guidance for compensated absences. That objective is achieved by aligning the recognition and measurement guidance under a unified model and by amending certain previously required disclosures. There was no significant impact on the Corporation's financial statements as a result of the adoption of this standard.

In December 2023, GASB issued Statement No. 102, *Certain Risk Disclosures*. The objective of this Statement is to provide users of government financial statements with essential information about risks related to a government's vulnerabilities due to certain concentrations or constraints. This Statement defines a *concentration* as a lack of diversity related to an aspect of a significant inflow of resources or outflow of resources. A *constraint* is a limitation imposed on a government by an external party or by formal action of the government's highest level of decision-making authority. Concentrations and constraints may limit a government's ability to acquire resources or control spending. This Statement requires a government to assess whether a concentration or constraint makes the primary government reporting unit or other reporting units that report a liability for revenue debt vulnerable to the risk of a substantial impact. Additionally, this Statement requires a government to assess whether a concentration that could cause the substantial impact to have occurred, have begun to occur, or are more likely than not to begin to occur within 12 months of the date the financial statements are issued. The requirements of this Statement are effective for fiscal years beginning after June 15, 2024, and all reporting periods thereafter. Earlier application is encouraged. The Corporation has not yet determined the impact this statement will have on the financial statements.

Notes to the Financial Statements Year Ended December 31, 2024 (Dollars in Thousands)

Note 2. Summary of Significant Accounting Policies (Continued)

In April 2024, GASB issued Statement No. 103, Financial Reporting Model Improvements. The objective of this Statement is to improve key components of the financial reporting model to enhance its effectiveness in providing information that is essential for decision making and assessing a government's accountability. This Statement also addresses certain application issues. This Statement continues the requirement that the basic financial statements be preceded by management's discussion and analysis (MD&A), which is presented as required supplementary information (RSI). MD&A provides an objective and easily readable analysis of the government's financial activities based on currently known facts, decisions, or conditions and presents comparisons between the current year and the prior year. This Statement requires that the information presented in MD&A be limited to the related topics discussed in five sections: (1) Overview of the Financial Statements, (2) Financial Summary, (3) Detailed Analyses, (4) Significant Capital Asset and Long-Term Financing Activity, and (5) Currently Known Facts, Decisions, or Conditions. Furthermore, this Statement stresses that the detailed analyses should explain why balances and results of operations changed rather than simply presenting the amounts or percentages by which they changed. This Statement describes unusual or infrequent items as transactions and other events that are either unusual in nature or infrequent in occurrence. Furthermore, governments are required to display the inflows and outflows related to each unusual or infrequent item separately as the last presented flow(s) of resources prior to the net change in resource flows in the government-wide, governmental fund, and proprietary fund statements of resource flows. Finally, This Statement requires governments to present budgetary comparison information using a single method of communication-RSI. Governments also are required to present (1) variances between original and final budget amounts and (2) variances between final budget and actual amounts. An explanation of significant variances is required to be presented in notes to RSI. The requirements of this Statement are effective for fiscal years beginning after June 15, 2025. The Corporation has not yet determined the impact this statement will have on the financial statements.

In September 2024, GASB issued Statement No. 104, *Disclosure of Certain Capital Assets*. This Statement requires certain types of capital assets to be disclosed separately in the capital assets note disclosures required by Statement 34. Lease assets recognized in accordance with Statement No. 87, *Leases*, and intangible right-to-use assets recognized in accordance with Statement No. 94, *Public-Private and Public-Public Partnerships and Availability Payment Arrangements*, should be disclosed separately by major class of underlying asset in the capital as-sets note disclosures. Subscription assets recognized in accordance with Statement No. 96, *Subscription-Based Information Technology Arrangements*, also should be separately disclosed. In addition, this Statement requires intangible assets other than those three types to be disclosed separately by major class. This Statement also requires additional disclosures for capital assets held for sale. The requirements of this Statement are effective for fiscal years beginning after June 15, 2025. The Corporation has not yet determined the impact this statement will have on the financial statements.

Reclassifications: Certain prior-year amounts have been reclassified to conform to the current-year presentation. Such reclassifications had no effect on previously reported operating loss/income or changes in net position.

Subsequent events: The Corporation has evaluated subsequent events for potential recognition and/or disclosure through [DATE], the date the financial statements were issued.

Notes to the Financial Statements Year Ended December 31, 2024 (Dollars in Thousands)

Note 3. Federal Emergency Management Agency (FEMA)

Under the CARES Act, financial relief was provided through FEMA's Disaster Relief Fund. During the years ended December 31, 2024 and 2023, the Corporation recognized grant revenue received from FEMA to cover eligible COVID-19 related expenses in the amount of \$17,333 and \$3,829, respectively. The Corporation is still awaiting additional funds from FEMA for pending reimbursement submissions related to remaining eligible expenses under this program.

Note 4. Net Patient Service Revenue and Patient Accounts Receivable

The Corporation has agreements with third-party payors that provide for payment to the Corporation at amounts different from its established rates. A summary of the payment arrangements for hospital services with major third-party payors is as follows:

Medicare: Inpatient acute care services rendered to Medicare program beneficiaries are paid at prospectively determined rates per discharge and per patient day depending on the service. Acute care rates vary according to a patient classification system that is based on clinical, diagnostic, and other factors. Certain inpatient and outpatient services, as well as defined organ acquisition, capital and medical education costs related to Medicare beneficiaries are paid based on regulatory proscribed formulae. The Corporation is reimbursed for such items at a tentative rate with final settlement determined after submission of annual cost reports by the Corporation and audits thereof by the Medicare fiscal intermediary. The Corporation's classification of patients under the Medicare program and the appropriateness of their admission are subject to an independent review by a peer review organization under contract with the Corporation. Most outpatient reimbursements are based on an Ambulatory Payment Classification weighting by acuity system, although some outpatient cost reimbursement still exists.

Medicaid: Inpatient services rendered to Medicaid program beneficiaries are reimbursed at prospectively determined rates in accordance with Part 86 of the New York Codes, Rules and Regulations and New York State Law which are promulgated by the New York State Department of Health (DOH). Outpatient services are similarly paid at either prospective rates or fee schedule amounts.

Under the New York Health Care Reform Act, the Corporation also enters into payment agreements with certain commercial insurance carriers, health maintenance organizations, and preferred provider organizations. The basis for payment to the Corporation under these agreements includes prospectively determined rates, discounts from charges, and prospectively determined per diem rates. Medicaid, Workers' Compensation and No-fault continue to have reimbursement rates determined based on New York's Prospective Reimbursement Methodology.

Terrace View provides services to residents under agreements with third-party payors (Medicaid, Medicare and HMO's) under provisions of their respective cost reimbursement formulas or contractually negotiated rates. If amounts received are less than established billing rates, the difference is accounted for as a reduction of revenue. Final determination of the reimbursement rates are subject to review by appropriate third-party payors. Provisions are made in the financial statements for anticipated adjustments that may result from such reviews. The difference between the estimated amounts accrued and final settlements are reported in operations in the year of settlement.

Notes to the Financial Statements Year Ended December 31, 2024 (Dollars in Thousands)

Note 4. Net Patient Service Revenue and Patient Accounts Receivable (Continued)

Net patient service revenue, as reported on the statements of revenues, expenses and changes in net position, is comprised of the following for the years ended December 31:

| | 2024 | 2023 |
|--------------------------|--------------|--------------|
| Gross charges | \$ 1,852,746 | \$ 1,673,523 |
| Less: | | |
| Discounts and allowances | 1,183,855 | 1,065,207 |
| Provision for bad debts | 12,663 | 4,596 |
| | \$ 656,228 | \$ 603,720 |
| | | 2 |

Net patient service revenue by payor for the years ended December 31 is as follows:

| | 2024 | | 2023 | |
|---|------------|-----------|---------|--------|
| | Amount | % | Amount | % |
| | RIFUE GOUL | ale - | | |
| Medicare* | \$ 250,023 | 38.1% \$ | 247,282 | 41.0% |
| Medicaid* | 208,681 | 31.8% | 164,815 | 27.3% |
| Commercial and other third-party payors | 166,026 | 25.3% | 164,704 | 27.3% |
| No-fault | 26,249 | 4.0% | 20,452 | 3.4% |
| Self-pay | 5,249 | 0.8% | 6,467 | 1.0% |
| | \$ 656,228 | 100.0% \$ | 603,720 | 100.0% |
| | 10 | | | |

*Medicare and Medicaid include Managed Care plans.

Laws and regulations governing Medicare, Medicaid, and other third-party payor programs are extremely complex and subject to interpretation. As a result, there is at least a reasonable possibility that recorded estimates could change by a material amount in future periods. The Corporation believes that it is in compliance with all applicable laws and regulations and is not aware of any pending or threatened investigations involving allegations of potential wrongdoing. Compliance with such laws and regulations can be subject to future government review and interpretation as well as significant regulatory action including fines, penalties, and exclusion from the Medicare and Medicaid programs.

Patient accounts receivable consist of the following at December 31:

| | 2024 | 2023 |
|-----------------------------------|-------------------|-------------------|
| Gross accounts receivable | \$ 307,107 | \$ 295,805 |
| Less: Discounts and allowances | 140.020 | 100 020 |
| Allowance for bad debts | 140,930 72,469 | 128,839 64,577 |
| | \$ 93,708 | \$ 102,389 |

Notes to the Financial Statements Year Ended December 31, 2024 (Dollars in Thousands)

Note 4. Net Patient Service Revenue and Patient Accounts Receivable (Continued)

In early 2024, Change Healthcare, a third-party billing company, fell victim to a cyber attack impacting their ability to access their billing software. The Corporation contracts with Change Healthcare for billing services related to certain professional billing services. As a result of the attack, billing through Change Healthcare was unable to proceed for an extended period of time. As such, the Corporation has considered the delay in the billing when establishing reserves on the related gross charges impacted by this attack.

The Corporation has received advances from third party payors including Change Healthcare for claims that have not been adjudicated due to the cyber attack. As of December 31, 2024, the Corporation has recorded a liability of \$13,604 related to those advances within the accrued other liabilities caption of the statements of net position.

Concentration of credit risk: The Corporation grants credit without collateral to its patients, most of whom are insured under third-party payor arrangements. The mix of net receivables from patients and third-party payors at December 31, is as follows:

| MALAN FOR U TE | 2024 | 2023 |
|---|--------|--------|
| Medicare* | 33.6% | 33.2% |
| Commercial and other third party payors | 32.6% | 32.7% |
| Medicaid* | 26.0% | 27.8% |
| No-fault | 7.4% | 5.5% |
| Self-pay | 0.4% | 0.8% |
| Total | 100.0% | 100.0% |
| ROM AND AND A | | |

*Medicare and Medicaid include Managed Care plans.

Note 5. Disproportionate Share (DSH) Revenue

The Medicaid DSH program is designed to provide funds to certain hospitals to help offset the cost of uncompensated care provided to the uninsured. Each state has a specified Federal DSH allotment. In addition, New York State law authorizes the New York State Department of Health (DOH) to make supplemental DSH medical assistance payments to public hospitals located in Erie County, Nassau County, and Westchester County. For long term care facilities, DSH revenue is recognized in accordance with Upper Payment Limit (UPL) regulations promulgated by the Centers for Medicare and Medicaid Services (CMS).

In 2024 and 2023, DSH funding recorded by the Corporation totaled \$164,953 and \$107,105, respectively. The DSH funding process is complex and includes both tentative and final settlements for various state fiscal years which are subject to the availability of state and federal funding among other factors. As a result, DSH revenue is estimated and final settlements may vary significantly from the initial estimates.

For hospital services, DSH revenue of \$149,675 and \$91,220 was recognized in 2024 and 2023, respectively. In addition, during 2024 and 2023, the Corporation recognized \$15,278 and \$15,885, respectively, of UPL revenue for Terrace View. UPL revenue has been recognized based off New York State fiscal year 2024-2025, as determined by the DOH, using cost report year 2022 data.

Notes to the Financial Statements Year Ended December 31, 2024 (Dollars in Thousands)

Note 5. Disproportionate Share (DSH) Revenue (Continued)

CMS has indicated that cost reports dating back to the 2022 reporting year and the methodology employed to calculate DSH revenue are subject to audit for those years. At this time, the impact of the CMS audit activity on the Corporation's DSH revenue is not certain. Management has taken what it believes to be reasonable and appropriate steps to assure compliance with the CMS methodology.

Note 6. Cash and Cash Equivalents, Investments and Assets Whose Use is Limited

Cash and cash equivalents and investments: The Corporation's investments are made in accordance with State regulations and its own investment policy. The investment policy is regularly reviewed by an investment committee of the Board which evaluates the performance of investment managers and monitors compliance with the investment policy.

The Corporation's investments are generally reported at fair value, as discussed in Note 2. The carrying amounts of cash and cash equivalents, investments and assets whose use is limited are included in the Corporation's statements of net position as follows:

| | 3 | 2024 | | 2023 |
|---|----|--|----|--|
| Cash and cash equivalents Investments Assets whose use is limited—current Assets whose use is limited—noncurrent | \$ | 34,586 42,825 84,714 106,887 269,012 | \$ | 20,773 10,646 113,986 56,635 202,040 |
| Designated: O Self-insured obligations | \$ | 53,666 | \$ | 57,904 |
| Capital | Ψ | 59,930 | Ψ | 36,265 |
| Other | | 44,327 | | 42,407 |
| | | 157,923 | | 136,576 |
| Restricted: | | | | |
| Debt service | | 24,560 | | 23,872 |
| Self-insured obligations | | 9,118 | | 10,173 |
| | | 33,678 | | 34,045 |
| Total assets whose use is limited Less portion required for current liabilities | | 191,601 (84,714) | | 170,621 (113,986) |
| | \$ | 106,887 | \$ | 56,635 |

The Corporation's cash and cash equivalents, as well as investments, are exposed to various risks, including credit, custodial credit, interest rate and market risks, as discussed in more detail below:

Deposits

All monies are deposited with banks or trust companies designated by the Corporation's investment committee of the Board of Directors. Funds not needed for immediate expenditure may be deposited in interest or non-interest-bearing accounts or invested in various marketable securities and bonds.

Notes to the Financial Statements Year Ended December 31, 2024 (Dollars in Thousands)

Note 6. Cash and Cash Equivalents, Investments and Assets Whose Use is Limited (Continued)

Custodial credit risk: Custodial credit risk is the risk that, in the event of bank failure, the Corporation's deposits might not be recovered. FDIC insurance through December 31, 2023, for funds held in interest bearing accounts is \$250 per depositor per category of legal ownership. New York law requires that deposits in excess of FDIC insured amounts are collateralized. The Corporation's bank deposits at December 31, 2024 and 2023, totaled \$37,133 and \$27,068, of which \$1,030 in both years were insured. Amounts over FDIC insured limits were fully collateralized with securities held by the pledging financial institution.

Investments

The Corporation's investment policy authorizes the Corporation to invest in accordance with New York State Finance Law Section 8(14), Section 201 and Public Authorities Law Article 9 Section 2800 to 2985, as well as the relevant provisions of the ECMCC Act. Compliance with the policy is monitored by the Corporation's investment committee and reported on regularly throughout the year by the Corporation's investment advisor.

Credit risk: Credit risk is the risk that the issuer or other counterparty to an investment will not fulfill its obligation, causing the Corporation to experience a loss of principal. The Corporation's investment policy limits investments in equity and fixed income securities with ratings only in the highest category. ECMCC's investments in government bonds carry the explicit guarantee of the U.S. government. The corporate bonds, short-term fixed income and government bonds are all rated AA+ or better by the Standards & Poor's rating agency.

Interest rate risk: Interest rate risk is the risk that changes in interest rates will adversely affect the fair value of an investment. The Corporation's cash equivalent securities are limited to maturities of no greater than eighteen months; short-term fixed income securities are limited to maturities of no greater than five years; and long-term fixed income securities are limited to maturities to no more than ten years. Substantially all of the Corporation's investments and assets whose use is limited have stated maturities of less than one year.

Custodial credit risk: For an investment, custodial credit risk is the risk that, in the event of the failure of the counterparty, the Corporation will not be able to recover the value of its investments or collateral securities that are in the possession of an outside party. The Corporation's investment policy does not address custodial credit risk.

Concentration of credit risk: Concentration of credit risk is the risk of loss attributable to the magnitude of investments in any single issuer. The Corporation's investment policy indicates the combined holdings of securities from one issuer shall not constitute more than 5.0% of the fund except for issues guaranteed directly or indirectly by the U.S. Government. The Corporation had no holdings in Federal National Mortgage Association (Fannie Mae) or Federal Home Loan Mortgage Corporation (Freddie Mac) issues at December 31, 2024 and 2023.

Notes to the Financial Statements Year Ended December 31, 2024 (Dollars in Thousands)

Note 6. Cash and Cash Equivalents, Investments and Assets Whose Use is Limited (Continued)

Fair value of financial instruments: Fair value is defined in the accounting standards as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Management utilizes valuation techniques that maximize the use of observable inputs (Levels 1 and 2) and minimize the use of unobservable inputs (Level 3) within the fair value hierarchy established by GASB. Assets carried at fair value are required to be classified and disclosed in one of the following three categories:

- **Level 1:** Valuations based on quoted prices in active markets for identical assets that the Corporation has the ability to access.
- Level 2: Valuations based on quoted prices in active markets for similar assets, quoted prices in markets that are not active or for which all significant inputs are observable, directly or indirectly. The Corporation has no Level 2 assets.
- Level 3: Valuations based on inputs that are unobservable and significant to the overall fair value measurement. These are generally company generated inputs and are not market-based inputs. The Corporation has no Level 3 assets.

| | | | duc | 2024 | | |
|----------------------------------|-----------|------|---------|------|---------|---------------|
| | Level 1 | Tar | Level 2 | | Level 3 | Total |
| | | REL | | | | |
| Cash and cash equivalents | \$ 34,58 | 6 \$ | - | \$ | - | \$ 34,586 |
| | 40 · | | | | | |
| Investments and assets whose use | | | | | | |
| is limited: | | | | | | |
| Cash and cash equivalents | 163,66 | 9 | - | | - | 163,669 |
| Marketable equity securities: | | | | | | |
| Small/Mid cap equities | 3,94 | 1 | - | | - | 3,941 |
| Growth equities | 1,59 | 6 | - | | - | 1,596 |
| Core equities | 11,68 | 3 | - | | - | 11,683 |
| International equities | 9,17 | 0 | - | | - | 9,170 |
| U.S. fixed income | 44,36 | 7 | - | | - | 44,367 |
| Total investments and assets | | | | | | |
| whose use is limited | 234,42 | 6 | - | | - | 234,426 |
| Total | \$ 269,01 | 2 \$ | - | \$ | - | \$ 269,012 |

Notes to the Financial Statements Year Ended December 31, 2024 (Dollars in Thousands)

Note 6. Cash and Cash Equivalents, Investments and Assets Whose Use is Limited (Continued)

| | 2023 | | | | | | | |
|--|------|---------|------|---------|---------------|------|----|---------|
| | | Level 1 | Le | evel 2 | vel 2 Level 3 | | | Total |
| Cash and cash equivalents | \$ | 20,773 | \$ | - | \$ | - | \$ | 20,773 |
| Investments and assets whose use | | | | | | | | |
| is limited: Cash and cash equivalents | | 115,448 | | | | | | 115,448 |
| Marketable equity securities: | | 115,440 | | - | | - | | 115,440 |
| Small/Mid cap equities | | 4,423 | | - | | Marc | | 4,423 |
| Growth equities | | 1,447 | | - 77 | | 000 | | 1,447 |
| Core equities | | 9,921 | | - | | - | | 9,921 |
| International equities | | 10,190 | | - nrapo | | - | | 10,190 |
| U.S. fixed income | . [| 39,838 | P | Olo n | | - | | 39,838 |
| Total investments and assets | Ana | AL AL | 2/11 | ale | | | | |
| whose use is limited | Mnn | 181,267 | a | 195- | 6 | - | | 181,267 |
| Total | \$ | 202,040 | \$ | AND | \$ | - | \$ | 202,040 |
| | Die | n 410 | | Olon | | | | |

Note 7. Capital Assets, Net 🔗

Capital asset activity for the years ended December 31, is as follows:

| ear his | yo | | | 20 |)24 | | | |
|---|------|--|-------------|---|-----|-------------------------|----|-----------|
| 410 m Mar | E | Beginning | | | Di | sposals/ | | Ending |
| | | Balance | | Additions | Т | ransfers | | Balance |
| Capital assets—being depreciated: | | | | | | | | |
| Land and land improvements | \$ | 41,197 | \$ | 24 | \$ | - | \$ | 41,221 |
| Buildings and improvements | | 547,974 | | 1,478 | | - | | 549,452 |
| Fixed/major moveable equipment | | 156,454 | | 8,775 | | (183) | | 165,046 |
| Total capital assets—being | | | | | | | | |
| depreciated | | 745,625 | | 10,277 | | (183) | | 755,719 |
| | | | | | | | | |
| Less accumulated depreciation | | (493,144) | | (30,264) | | 183 | | (523,225) |
| | | | | | | | | |
| depreciated, net | | 252,481 | | (19,987) | | - | | 232,494 |
| | | | | | | | | |
| | | 0.400 | | | | (1.0.10) | | 1 - |
| | | 8,426 | | 1,541 | | (4,948) | | 5,019 |
| | • | ~~~~ | • | (10,110) | • | (| • | |
| lease and SBITA assets | \$ | 260,907 | \$ | (18,446) | \$ | (4,948) | \$ | 237,513 |
| | | | | | | | • | 45 440 |
| Lease and SBITA assets, net (Note 8) | | | | | | | \$ | 45,119 |
| Total capital assets, net, as reported i | in s | tatements o | f ne | t position | | | \$ | 282,632 |
| Total capital assets—being depreciated, net Capital assets—not being depreciated: Construction in progress Capital assets, net, excluding lease and SBITA assets Lease and SBITA assets, net (Note 8) Total capital assets, net, as reported i | \$ | 252,481 8,426 260,907 tatements c | \$ of ne | (19,987) <u>1,541</u> <u>(18,446)</u> t position | \$ | - (4,948) (4,948) | \$ | - |

Notes to the Financial Statements Year Ended December 31, 2024 (Dollars in Thousands)

Note 7. Capital Assets, Net (Continued)

| | 2023 | | | | | | | | |
|--|------|-------------|-------|------------|----|------------|----|-----------|--|
| | E | Beginning | | | Γ | Disposals/ | | Ending | |
| | | Balance | | Additions | - | Transfers | | Balance | |
| Capital assets—being depreciated: | | | | | | | | | |
| Land and land improvements | \$ | 41,166 | \$ | 31 | \$ | - | \$ | 41,197 | |
| Buildings and improvements | | 545,092 | | 2,882 | | - | | 547,974 | |
| Fixed/major moveable equipment | | 151,523 | | 5,096 | | (165) | | 156,454 | |
| Total capital assets—being | | | | | | | | | |
| depreciated | | 737,781 | | 8,009 | | (165) | | 745,625 | |
| | | | | | | | | | |
| Less accumulated depreciation | | (461,308) | | (32,001) | | 165 | | (493,144) | |
| Total capital assets—being | | | aB | (F) | 20 | 3 | | | |
| depreciated, net | | 276,473 | | (23,992) | | - | | 252,481 | |
| | | | | | | | | | |
| Capital assets—not being depreciated: | | | | | | | | | |
| Construction in progress | Nor | 21,643 | ,- | 3,165 | Д | (16,382) | | 8,426 | |
| Capital assets, net, excluding | 0 | alle all | he | ALL CO | 07 | | | | |
| lease and SBITA assets | \$ | 298,116 | \$ | (20,827) | \$ | (16,382) | \$ | 260,907 | |
| | | aft he | all | 00 | | | | | |
| Lease and SBITA assets, net (Note 8) | | | | | | | \$ | 52,132 | |
| | | | | | | | | | |
| Total capital assets, net, as reported | in s | tatements o | of ne | t position | | | \$ | 313,039 | |
| | | | | | | | | | |

Construction in progress at December 31, 2024 and 2023, includes costs associated with various mechanical, electrical and information-technology security projects. The costs associated with an abandoned ambulatory electronic medical records system project of \$11,239 were written off during the year ended December 31, 2023 and recorded within purchased services expenses within the statements of revenues, expenses and changes in net position.

Depreciation expense amounted to \$30,264 and \$32,001 for the years ended December 31, 2024 and 2023, respectively.

Note 8. Leases and Subscription-Based Information Technology Arrangements

The Corporation is a lessee for various noncancellable leases of real estate and equipment. The expected lease payments are discounted using the interest rate charged on the lease, if available, and are otherwise discounted using the Corporation's incremental borrowing rate. The right-to-use assets are amortized over the shorter of the lease term or the underlying asset useful life.

The Corporation recognizes an intangible subscription asset and corresponding subscription liability for its subscription-based information technology agreements with others. These arrangements have terms requiring monthly, quarterly or annual payments. The expected payments are discounted using the interest rate charged on the arrangement, if available, or are otherwise discounted using the Corporation's incremental borrowing rate.

Notes to the Financial Statements Year Ended December 31, 2024 (Dollars in Thousands)

Note 8. Leases and Subscription-Based Information Technology Arrangements (Continued)

Lease and SBITA assets are reported within capital assets and lease and SBITA liabilities are reported separately in the statements of net position.

Right-to-use assets by major class and the related accumulated amortization for the years ended December 31 is summarized as follows:

| | | | | | 2024 | | | | |
|-----------|-----------|--|---|---|--|--|--|--|--|
| | Beginning | | | | | | | | Ending |
| | Balance | | Additions | Rem | easurements | F | Retirements | | Balance |
| | | | | | | | | | |
| \$ | 11,927 | \$ | 272 | \$ | - | \$ | - T | \$ | 12,199 |
| | 40,059 | | 1,948 | | 667 | | 134 | | 42,540 |
| _ | 51,986 | | 2,220 | | 667 | | 134 | | 54,739 |
| | | | | | | | | | |
| | 2,690 | | 1.063 | | 03- | | - | | 3,753 |
| | 22,925 | | 5,398 | | P - | | 134 | | 28,189 |
| | 25,615 | 20 | 6,461 | Use | <u></u> | | 134 | | 31,942 |
| | 26,371 | | (4,241) | . 6 | 667 | | - | | 22,797 |
| In | Magn | 26 | 310 | 1.0.1 | 9 | | | | |
| | 43,822 | | 6,209 | | 1,335 | | 1,186 | | 50,180 |
| | 18,061 | | 10,319 | | CC- | | 522 | | 27,858 |
| 1 | 25,761 | 36 | (4,110) | 210 | 1,335 | | 664 | | 22,322 |
| 7.C | - The | Re | 011 | 90 | | | | | |
| \$ | 52,132 | \$ | (8,351) | \$ | 2,002 | \$ | 664 | \$ | 45,119 |
| an | 011 | - 1 | Mon | | | | | | |
| 500 | TOP | S? | | | 2023 | | | | |
| - | Beginning | | | | | | | | Ending |
| R | Balance | | Additions | Rem | neasurements | F | Retirements | | Balance |
| <u>10</u> | | | | | | | | | |
| \$ | 13,969 | \$ | 718 | \$ | - | \$ | 2,760 | \$ | 11,927 |
| | 34,696 | | 3,950 | | 1,413 | | - | | 40,059 |
| | 48,665 | | 4,668 | | 1,413 | | 2,760 | | 51,986 |
| | | | | | | | | | |
| | 2,603 | | 1,156 | | - | | 1,069 | | 2,690 |
| | 16,008 | | 6,917 | | - | | - | | 22,925 |
| | 18,611 | | 8,073 | | - | | 1,069 | | 25,615 |
| _ | 30,054 | | (3,405) | | 1,413 | | 1,691 | | 26,371 |
| | 39,473 | | 4,349 | | - | | | | 43,822 |
| | | | | | | | | | 10,022 |
| | , | | 9 804 | | - | | - | | 18 061 |
| | 8,257 | | 9,804 | | - | | - | | 18,061 25,761 |
| | , | | 9,804 (5,455) | | - | | - | | 18,061 25,761 |
| | | Balance \$ 11,927 40,059 51,986 2,690 22,925 25,615 26,371 43,822 18,061 25,761 \$ 52,132 Beginning Balance \$ 13,969 34,696 48,665 2,603 16,008 18,611 | Balance \$ 11,927 \$ 40,059 51,986 2,690 22,925 25,615 26,371 43,822 18,061 25,761 \$ 52,132 \$ Beginning Balance \$ 13,969 \$ 34,696 48,665 2,603 16,008 18,611 | Balance Additions \$ 11,927 \$ 272 40,059 1,948 51,986 2,220 2,690 1,063 22,925 5,398 25,615 6,461 26,371 (4,241) 43,822 6,209 18,061 10,319 25,761 (4,110) \$ 52,132 (8,351) Beginning Balance Additions \$ 13,969 \$ 13,969 718 34,696 3,950 48,665 4,668 2,603 1,156 16,008 6,917 18,611 8,073 | Balance Additions Rem \$ 11,927 \$ 272 \$ 40,059 1,948 51,986 2,220 2,690 1,063 22,925 5,398 25,615 6,461 26,371 (4,241) 43,822 6,209 18,061 10,319 25,761 (4,110) \$ 52,132 (8,351) Beginning Balance Additions Rem \$ 13,969 718 34,696 3,950 48,665 4,668 2,603 1,156 16,008 6,917 18,611 8,073 | $\begin{array}{c c c c c c c c c c c c c c c c c c c $ | $\begin{array}{c c c c c c c c c c c c c c c c c c c $ | $\begin{array}{c c c c c c c c c c c c c c c c c c c $ | $\begin{array}{c c c c c c c c c c c c c c c c c c c $ |

Notes to the Financial Statements Year Ended December 31, 2024 (Dollars in Thousands)

Note 8. Leases and Subscription-Based Information Technology Arrangements (Continued)

As of December 31, 2024, the principal and interest requirements to maturity for the lease liability are as follows:

| | Principal | Interest | [| Total |
|---------------------------|------------|----------|-------|--------|
| Years ending December 31: | | | | |
| 2025 | \$ 7,029 | \$ 80 |)1 \$ | 7,830 |
| 2026 | 4,799 | 52 | 25 | 5,324 |
| 2027 | 2,951 | 33 | 6 | 3,287 |
| 2028 | 1,673 | 21 | 5 | 1,888 |
| 2029 | 876 | 16 | 1 | 1,037 |
| 2030-2034 | 3,411 | 42 | 28 | 3,839 |
| 2035-2039 | 884 | 285 Z | 23 | 907 |
| | \$ 21,623 | \$ 2,48 | 39 \$ | 24,112 |
| | BY P BUILT | | | |

As of December 31, 2024, the principal and interest requirements to maturity for the SBITA liability are as follows:

| | | Principal | 2 | nterest | Total |
|-----------|-------------------|-------------------|----|---------|--------------|
| Years end | ling December 31: | 10 ¹⁰¹ | | | |
| 2025 | | \$ 8,118 | \$ | 1,159 | \$ 9,277 |
| 2026 | | 7,245 | | 615 | 7,860 |
| 2027 | | 4,280 | | 250 | 4,530 |
| 2028 | | 1,422 | | 76 | 1,498 |
| 2029 | Alo. Kale | 264 | | 4 | 268 |
| | | \$ 21,329 | \$ | 2,104 | \$ 23,433 |

Lessor: The Corporation leases real estate to external parties. In accordance with GASB Statement No. 87, *Leases*, the Corporation records lease receivables and deferred inflows of resources based on the present value of expected receipts over the term of the respective leases. The Corporation recognized lease receivables (reported within other assets in the statements of net position) of \$822 and \$753 at December 31, 2024 and 2023, respectively, deferred inflows of resources of \$1,563 and \$1,666 at December 31, 2024 and 2023, respectively, and lease revenue of \$833 and \$632 during the years ended December 31, 2024 and 2023, respectively.

Notes to the Financial Statements Year Ended December 31, 2024 (Dollars in Thousands)

Note 9. Accrued Other Liabilities

The composition of accrued other liabilities as of December 31 is as follows:

| | | 2024 | 2023 |
|--|-----------|--------|--------------|
| Due to Erie County | \$ | 4,006 | \$ 12,767 |
| DSH and Upper Payment Limit (UPL) (Note 5) | | 9,743 | - |
| Payor advances | | 13,604 | - |
| Medical malpractice claims | | 2,133 | 1,792 |
| Estimated third-party payor settlements | | 5,643 | 4,486 |
| Asset retirement obligations | | 2,356 | 2,167 |
| Workers compensation claims | | 6,665 | 7,416 |
| Other | e | 13,409 | 13,393 |
| Total | \$ | 57,559 | \$ 42,021 |

GASB Statement No. 83, *Certain Asset Retirement Obligations*, establishes criteria for determining the timing and pattern of recognition of a liability and a corresponding deferred outflow of resources for asset retirement obligations (AROs). An ARO is a legally enforceable liability associated with the retirement of a tangible capital asset. In accordance with this Statement, the Corporation completes an analysis of assets meeting the criteria of an ARO for specific types of medical equipment such as medical imaging equipment (e.g., MRIs, CT scanners, and PET scanners), X-Rays, and ultrasounds as well as computers containing information protected by HIPAA laws, and certain types of laboratory equipment. In addition, the Corporation evaluates the requirements for disposal of underground fuel and lab acid tanks. The Corporation totaled \$2,356 and \$2,167 at December 31, 2024 and 2023, respectively. The assets have a remaining useful life ranging from 0 to 30 years. This obligation is discounted using a rate of 4.0% and an inflation factor of 3.0% at December 31, 2024 and 2023.

Note 10. Indebtedness

Long-term debt consisted of the following at December 31:

| | | | 2024 | | |
|--------------------------------|------------|-----------|------------------------------|------------|------------|
| | Beginning | | Payments/ | Ending | Due Within |
| | Balance | Additions | dditions Forgiveness Balance | | One Year |
| Erie County—Guaranteed Senior | | | | | |
| Revenue Bonds, Series 2004 | \$ 56,970 | \$- | \$ (4,390) | \$ 52,580 | \$ 4,635 |
| Erie County—2017 loan payable | 87,374 | - | (2,849) | 84,525 | 2,920 |
| Erie County—2017 loan payable | 49,076 | - | (4,271) | 44,805 | 4,386 |
| Erie County—2017 capitalized | | | | | |
| interest assumption obligation | 7,274 | - | (238) | 7,036 | 243 |
| Finance obligations | 1,949 | 1,739 | (507) | 3,181 | 571 |
| Total debt | \$ 202,643 | \$ 1,739 | \$ (12,255) | \$ 192,127 | \$ 12,755 |

Notes to the Financial Statements Year Ended December 31, 2024 (Dollars in Thousands)

Note 10. Indebtedness (Continued)

| | | | 2023 | | |
|--------------------------------|--------------------|-----------|-------------|------------|------------|
| | Beginning Payments | | Payments/ | Ending | Due Within |
| | Balance | Additions | Forgiveness | Balance | One Year |
| Erie County—Guaranteed Senior | | | | | |
| Revenue Bonds, Series 2004 | \$ 61,135 | \$- | \$ (4,165) | \$ 56,970 | \$ 4,390 |
| Erie County—2017 loan payable | 90,154 | - | (2,780) | 87,374 | 2,849 |
| Erie County—2017 loan payable | 53,235 | - | (4,159) | 49,076 | 4,271 |
| Erie County—2017 capitalized | | | | | |
| interest assumption obligation | 7,505 | - | (231) | 7,274 | 237 |
| Finance obligations | 2,328 | - | (379) | 1,949 | 381 |
| Total debt | \$ 214,357 | \$ - | \$ (11,714) | \$ 202,643 | \$ 12,128 |
| | | | all ast | 300 | |

Future annual principal payments applicable to long-term debt for the years subsequent to December 31, 2024 are as follows:

| Years ending December 31: | |
|---------------------------|---------------|
| 2025 | \$ 12,755 |
| | 13,215 |
| | 13,697 |
| 2028 | 14,198 |
| 2029 | 14,395 |
| 2030-2034 | 73,331 |
| 2035-2039 | 50,536 |
| Total | \$ 192,127 |

The Series 2004 Bonds are secured by a pledge of the gross receipts of the Corporation and amounts on deposit in certain debt service reserve funds. Interest rates on the bonds range from 5.5% to 5.7%, with principal payments ranging from \$4,165 to \$7,220 due annually on November 1 with interest payments due semi-annually on May 1 and November 1.

Pursuant to a Guaranty Agreement, the County has unconditionally guaranteed to the Corporation, the punctual payment of the principal, interest, and redemption premium, if any, on the Series 2004 Bonds, as the same shall become due and payable, and has pledged the faith and credit of the County for the performance of such guaranty. A municipal bond insurance policy has been purchased by the Corporation to guarantee all debt service payments in case of default by the Corporation and the County.

Notes to the Financial Statements Year Ended December 31, 2024 (Dollars in Thousands)

Note 10. Indebtedness (Continued)

In 2017, the Corporation entered into a loan agreement and a capitalized interest liability assumption agreement with the County of Erie, with the assistance of the Erie County Fiscal Stability Authority. The proceeds of the loan were used to finance the construction of a new Level 1 Adult Trauma Center and Emergency Department, fund various other capital projects on the Corporation's campus as well as refinance a 2011 loan. The loan has an interest rate of 3.377% with monthly principal and interest payments ranging from \$474 to \$930 during the term of the loan. In addition to the loan, the Corporation assumed the liability related to funds borrowed to pay capitalized interest during construction on the various projects noted above. The capitalized interest liability assumption has an interest rate of 3.377% with monthly principal and interest payments ranging from \$40 to \$77 during the term of the loan. The new money portion of the loan and the capitalized interest assumption agreement is fully amortized and matures in 2039. The refinancing component of the loan has an interest rate of 2.649% with monthly principal and interest payments ranging from \$300 to \$460 during the term of the loan and is fully amortized and maturing in 2034.

During 2018, the Corporation entered into a finance obligation agreement in the amount of \$2,044, the proceeds of which were used to purchase various equipment. The agreement requires principal and interest payments (cost of capital is estimated at 5.5%) of \$29 and matures September 2025.

During 2018, the Corporation entered into a second finance obligation agreement in the amount of \$409, the proceeds of which were used to purchase various suite improvements. The agreement required principal and interest payments (cost of capital is estimated at 3.8%) of \$4 and was paid in full during 2023.

During 2019, the Corporation entered into a finance obligation agreement in the amount of \$1,805, the proceeds of which were used to finance various cafeteria improvements. The agreement requires principal and interest payments (cost of capital ranges from 0% to 9.0%) of \$17 and matures March 2029.

During 2020, the Corporation entered into a finance obligation agreement in the amount of \$2,555, the proceeds of which were used to purchase various equipment. The agreement requires principal and interest payments (cost of capital is estimated at 5.5%) of \$39 and matures July 2026.

During 2021, the Corporation entered into a finance obligation agreement in the amount of \$1,552, the proceeds of which were used to finance a new food service line. The agreement requires principal and interest payments (cost of capital is 4.0%) of \$19 and matures in December 2028.

During 2021, the Corporation signed an agreement for an unsecured revolving line of credit with an original maturity date of November 2022 and was amended and extended to May 2025. The Corporation has available \$10,000 with interest payable at a variable rate of daily Secured Overnight Financing Rate (SOFR) plus 183 basis points. There was \$10,000 of outstanding borrowings against the line at both December 31, 2024 and 2023. Management is currently negotiating an extension for the maturity date of this agreement.

During 2024, the Corporation entered into a finance obligation agreement in the amount of \$1,739, the proceeds of which were used to finance a new food service equipment. The agreement requires principal payments of \$16 and matures in June 2033.

Notes to the Financial Statements Year Ended December 31, 2024 (Dollars in Thousands)

Note 11. Pension Plan

Retirement plan: The Corporation participates in the New York State and Local Retirement System (NYSLRS or the System), which is a cost-sharing, multiple-employer public employees' retirement system. There are more than 520,000 pensioners and beneficiaries in the System with over 1.2 million participants.

For purposes of measuring the net pension liability, deferred outflows of resources and deferred inflows of resources related to pensions, and pension expense/benefit, information about the fiduciary net position of the NYSLRS and additions to/deductions from NYSLRS' fiduciary net position have been determined on the same basis as they are reported by NYSLRS. For this purpose, benefit payments (including refunds of employee contributions) are recognized when due and payable in accordance with the benefit terms. The net pension liability is measured as the portion of the present value of projected benefit payments to be provided through the pension plan to current active and inactive employees that is attributed to those employees' past periods of service (total pension liability), less the amount of the pension plan's fiduciary net position. The net pension liability should be measured as of a date (measurement date) no earlier than the end of the employer's prior fiscal year, consistently applied from period to period.

Obligations of employers and employees to contribute and benefits to employees are governed by the New York State Retirement and Social Security Law (RSSL). As set forth in the RSSL, the Comptroller of the State of New York (the Comptroller) serves as sole trustee and administrative head of the System. The Comptroller shall adopt and may amend rules and regulations for the administration and transaction of the business of the System and for custody and control of its funds. The System issues a publicly available financial report that includes financial statements and required supplementary information. That report may be obtained by writing to the New York State and Local Retirement System, 110 State Street, Albany, NY 12244.

NYSLRS provides three main types of retirement benefits: service retirements, ordinary disability retirements (non-job-related disabilities), and accident disability retirements (job-related disabilities) to members who are in different Tiers. The members' Tier is determined by the date of membership. Subject to certain conditions, members generally become fully vested as to benefits upon the completion of five years of service depending on their Tier. Employees may be required to contribute a percentage of their salary to the pension plan based on their Tier, determined by their date of membership in the plan. Annual pension benefits can be calculated as a percentage of final average salary times number of years of service and changes with the number of years of membership within the plan.

At December 31, 2024 and 2023, the Corporation reported a liability of \$155,324 and \$198,936, respectively, for its proportionate share of the NYSLRS net pension liability. The total pension liability used to calculate the net pension liability is determined by an actuarial valuation as of April 1st each year and rolled forward to March 31st. The Corporation's proportion for the net pension liability for each fiscal year was based on the Corporation's indexed present value of future compensation to NYSLRS of all participating employers for 2024 and 2023, which was 1.0549% and 0.9277%, respectively.

Notes to the Financial Statements Year Ended December 31, 2024 (Dollars in Thousands)

Note 11. Pension Plan (Continued)

(a) Actuarial Assumptions

The total pension liability for the March 31, 2024 measurement date was determined using an actuarial valuation as of April 1, 2023, with update procedures used to roll-forward the total pension liability to March 31, 2024. The actuarial valuations used the following actuarial assumptions:

Inflation Salary increases Investment rate of return Cost of living adjustments Mortality improvement 2.9% 4.4%, including inflation 5.9%, net of pension plan investment expense 1.5% Society of Actuaries Scale MP-2021

The total pension asset for the March 31, 2023, measurement date was determined using an actuarial valuation as of April 1, 2022, with update procedures used to roll-forward the total pension liability to March 31, 2023. The actuarial valuations used the following actuarial assumptions:

Inflation Salary increases Investment rate of return Cost of living adjustments Mortality improvement

2.9% 4.4%, including inflation 5.9%, net of pension plan investment expense 1.5% Society of Actuaries Scale MP-2021

Notes to the Financial Statements Year Ended December 31, 2024 (Dollars in Thousands)

Note 11. Pension Plan (Continued)

(b) Expected Rate of Return on Investments

The long-term expected rate of return on pension plan investments was determined using a buildingblock method in which best-estimate ranges of expected future real rates of return (expected return, net of investment expenses and inflation) are developed for each major asset class. These ranges are combined to produce the long-term expected rate of return by weighting the expected future real rates of return by the target asset allocation percentage and by adding expected inflation. The target allocation and best estimates of arithmetic real rates of return for each major asset class are summarized in the following tables at December 31:

| | 20 | 24 |
|--|------------|----------------|
| | Target | Long-Term |
| | Asset | Expected Real |
| Asset class | Allocation | Rate of Return |
| SI DU and P | | |
| Domestic equity | 32.0% | 4.0% |
| International equity | 15.0% | 6.7% |
| Private equity | 10.0% | 7.3% |
| Real estate | 9.0% | 4.6% |
| Fixed income | 23.0% | 1.5% |
| Credit | 4.0% | 5.4% |
| Real assets | 3.0% | 5.8% |
| Opportunistic/absolute return strategy | 3.0% | 5.3% |
| Cash | 1.0% | 0.3% |
| | 100.0% | |

| | 20 | 23 |
|--|------------|----------------|
| | Target | Long-Term |
| | Asset | Expected Real |
| Asset class | Allocation | Rate of Return |
| | | |
| Domestic equity | 32.0% | 4.3% |
| International equity | 15.0% | 6.9% |
| Private equity | 10.0% | 7.5% |
| Real estate | 9.0% | 4.6% |
| Fixed income | 23.0% | 1.5% |
| Credit | 4.0% | 5.4% |
| Real assets | 3.0% | 5.8% |
| Opportunistic/absolute return strategy | 3.0% | 5.4% |
| Cash | 1.0% | 0.0% |
| | 100.0% | |

Notes to the Financial Statements Year Ended December 31, 2024 (Dollars in Thousands)

Note 11. Pension Plan (Continued)

(c) Discount Rate

The discount rate used to measure the total pension liability as of December 31, 2024 and 2023 was 5.9%. The projection of cash flows used to determine the discount rate assumes that contributions from plan members will be made at the current contribution rates and that contributions from employers will be made at statutorily required rates, actuarially determined. Based on those assumptions, the NYSLRS fiduciary net position was projected to be available to make all projected future benefit payments of current plan members. Therefore, the long-term expected rate of return on NYSLRS investments was applied to all periods of projected benefit payments to determine the total pension liability.

Sensitivity of the Net Pension Liability (Asset) to the Discount Rate



The following presents the Corporation's proportionate share of the net pension liability calculated using the discount rate of 5.9% at December 31, 2024 and 2023, as well as what the Corporation's proportionate share of the net pension liability would be if it were calculated using a discount rate that is one percentage point lower or one percentage point higher than the current rate:

| | Igs. | - Ballie |)- | 2024 | | | |
|--|------|---------------------------|-----|---------------------|--------|----------------------|--|
| | 1% | 1% Decrease Discount Rate | | | | 1% Increase | |
| | 40 | (4.9%) (5.9%) | | | (6.9%) | | |
| Corporation's proportionate share of the | | | | | | | |
| net pension liability (asset) | \$ | 488,356 | \$ | 155,324 | \$ | (122,826) | |
| | | | | | | | |
| | | | | 0000 | | | |
| | | | | 2023 | | | |
| | 1% | Decrease | Dis | 2023 scount Rate | 19 | % Increase | |
| | 1% | Decrease (4.9%) | Dis | | 19 | % Increase (6.9%) | |
| Corporation's proportionate share of the | 1% | | Dis | scount Rate | 19 | | |

Notes to the Financial Statements Year Ended December 31, 2024 (Dollars in Thousands)

Note 11. Pension Plan (Continued)

(d) Deferred Outflows and Inflows of Resources

At December 31, 2024 and 2023, the Corporation reported deferred outflows of resources and deferred inflows of resources related to pensions from the following sources:

| | | 2024 | | 2023 |
|---|----|---------|----|---------|
| Deferred outflows of resources: | | | | |
| Differences between expected and actual actuarial experience | \$ | 50,030 | \$ | 21,188 |
| Changes in assumptions | | 58,725 | | 96,616 |
| Changes in proportion and differences between Corporation | | | | |
| contributions and proportionate share of contributions | | 12,433 | S | 5,311 |
| Total | \$ | 121,188 | \$ | 123,115 |
| | 09 | | | |
| Deferred inflows of resources: | | | | |
| Difference between expected and actual experience | \$ | 4,235 | \$ | 5,587 |
| Change in assumptions | | - | | 1,068 |
| Net difference between projected and actual investment earnings | ad | | | |
| on pension plan investments | | 75,875 | | 1,168 |
| Changes in proportion and differences between Corporation | | | | |
| contributions and proportionate share of contributions | | 15,527 | | 15,914 |
| Total CULPS DE Tres | \$ | 95,637 | \$ | 23,737 |
| | | | | |

The change in employer proportionate share is the difference between the employer proportionate share of net pension liability in the prior year compared to the current year. Changes in these amounts are amortized over a five-year closed period, reflecting the average remaining service life of plan members.

The net deferred outflows and inflows of resources of resources related to pensions will be recognized in pension expense as follows:

Years ending December 31:

| 2025 | \$ (30,652) |
|------|----------------|
| 2026 | 27,472 |
| 2027 | 44,470 |
| 2028 | (15,739) |
| | \$ 25,551 |

Annual Pension Expense

The Corporation's annual pension expense for calendar years ended 2024 and 2023, which includes contributions toward the actuarially determined asset or liability and the amortization of deferred outflows and inflows of resources, was approximately \$64,435 and \$65,509, respectively.

Notes to the Financial Statements Year Ended December 31, 2024 (Dollars in Thousands)

Note 12. Other Post-Employment Benefits (OPEB)

Plan description: The Corporation provides OPEB that include basic medical and hospitalization plan coverage to eligible retirees. Eligible retirees may only be covered under the indemnified plan of the Corporation. To qualify, a retiree must meet various eligibility requirements as agreed to in collective bargaining agreements. The Corporation pays varying amounts based on specific union agreements.

Funding the plan: Currently, there is no New York State statute that expressly authorizes local governments to create a trust for OPEB purposes. Additionally, New York State's General Municipal Law does not allow for a reserve fund to accumulate funds for OPEB obligations. The Corporation's Board of Directors and management believe it is prudent to reserve funds for the Plan and have therefore internally designated \$24,831 in 2024 and 2023, for purposes of funding future post-employment benefits. These internally designated funds are included within assets whose use is limited in the statements of net position. In addition to the funding for future post-employment benefits, the Corporation continues to finance current benefits on a pay-as-you-go basis.

Annual OPEB cost and net OPEB obligation: The Corporation's total OPEB liability measured at December 31, 2024 and 2023, of \$278,596 and \$293,911, respectively, was determined by an actuarial valuation as of January 1, 2024 and 2023, respectively. The measurement date of the obligation is December 31, 2024 and 2023.

(a) Actuarial Assumptions

The total OPEB liability in the December 31, 2024, actuarial valuation was determined using the following actuarial assumptions, applied to all periods included in the measurement, unless otherwise specified:

| Inflation |
|--------------------------------|
| Salary increases |
| Pre-Medicare Plans |
| Medicare Plans |
| Pre-Medicare Prescription Plan |
| Medicare Prescription Plan |
| Mortality |

2.5% 3.3% per annum 7.8% for 2024, 4.0% ultimate trend rate in 2075 5.0% for 2024, 4.0% ultimate trend rate in 2075 8.5% for 2024, 4.0% ultimate trend rate in 2075 4.0% for 2024, 4.0% ultimate trend rate in 2075 Society of Actuaries Scale MP-2021

The total OPEB liability in the December 31, 2023 actuarial valuation was determined using the following actuarial assumptions, applied to all periods included in the measurement, unless otherwise specified:

Inflation Salary increases Pre-Medicare Plans Medicare Plans Pre-Medicare Prescription Plan Medicare Prescription Plan Mortality 2.5% 3.3% per annum 7.8% for 2023, 4.0% ultimate trend rate in 2075 4.6% for 2023, 4.0% ultimate trend rate in 2075 7.8% for 2023, 4.0% ultimate trend rate in 2075 7.0% for 2023, 4.0% ultimate trend rate in 2075 Society of Actuaries Scale MP-2021

Notes to the Financial Statements Year Ended December 31, 2024 (Dollars in Thousands)

Note 12. Other Post-Employment Benefits (OPEB) (Continued)

(b) Changes in the OPEB Liability

| | | 2024 | 2023 |
|--|----|------------|----------|
| Changes in the OPEB obligation: | | | |
| Projected OPEB obligation at the beginning of year | \$ | 293,911 \$ | 271,395 |
| Service cost | | 3,153 | 2,620 |
| Interest cost | | 9,983 | 9,722 |
| Change of benefit terms | | 6,176 | - |
| Difference between expected and actual experience | | 14,200 | 232 |
| Change in assumptions | | (36,699) | 26,546 |
| Actual benefit payments | 5 | (12,128) | (16,604) |
| Projected OPEB obligation at the end of year | \$ | 278,596 \$ | 293,911 |
| | | | |

(c) Discount Rate

The discount rate used to measure the total OPEB liability was 4.1% and 3.3%, based on the Bond Buyer 20-year Bond GO index rate as of December 31, 2024 and 2023, respectively.

Sensitivity of the OPEB Liability to the Discount Rate

The following presents the Corporation's total OPEB liability calculated using the discount rate of 4.1%, as well as what the Corporation's total OPEB liability would be if it were calculated using a discount rate that is one percentage point lower (3.1%) or one percentage point higher (5.1%) than the current rate.

| | 2024 | | | | | |
|--|---------------------------|---------|--------|-------------|--------|---------|
| | 1% Decrease Discount Rate | | | 1% Increase | | |
| | | (3.1%) | (4.1%) | | (5.1%) | |
| The Corporation's total OPEB liability | \$ | 316,533 | \$ | 278,596 | \$ | 247,364 |

The discount rate used to measure the total OPEB liability as of December 31, 2023, was 3.3%, based on the Bond Buyer 20-year Bond GO index rate.

The following presents the Corporation's total OPEB liability calculated using the discount rate of 3.3%, as well as what the Corporation's total OPEB liability would be if it were calculated using a discount rate that is one percentage point lower (2.3%) or one percentage point higher (4.3%) than the current rate.

| | | | | 2023 | | |
|--|----|----------|-----|------------|----|------------|
| | 1% | Decrease | Dis | count Rate | 19 | 6 Increase |
| | | (2.3%) | | (3.3%) | | (4.3%) |
| The Corporation's total OPEB liability | \$ | 337,382 | \$ | 293,911 | \$ | 258,462 |

Notes to the Financial Statements Year Ended December 31, 2024 (Dollars in Thousands)

Note 12. Other Post-Employment Benefits (OPEB) (Continued)

Sensitivity of the OPEB Liability to the Healthcare Cost Trend Rates

The following presents the Corporation's total OPEB liability calculated using healthcare cost trend rates that are one percentage point lower or one percentage point higher than the current healthcare cost trend rates.

| | 2024 |
|--|--|
| | Healthcare |
| | 1% Decrease Cost Trend Rates 1% Increase |
| The Corporation's total OPEB liability | \$ 244,305 \$ 278,596 \$ 320,448 |
| | 2023 |
| | Healthcare |
| | 1% Decrease Cost Trend Rates 1% Increase |
| | CIOIN SE |
| The Corporation's total OPEB liability | \$ 255,222 \$ 293,911 \$ 341,658 |
| | |

⁽d) Deferred Outflows and Inflows of Resources

The following are components of deferred outflows and inflows at December 31, 2024 and 2023:

| | | 2 | 024 | |
|--|----|----------|-----|----------|
| | C |)eferred | | Deferred |
| | | Dutflows | | Inflows |
| Differences between expected and actual actuarial experience | \$ | 9,881 | \$ | (7,662) |
| Changes in assumptions | | 11,270 | | (38,116) |
| Total | \$ | 21,151 | \$ | (45,778) |
| | | 2 | 023 | |
| | D | eferred | | Deferred |
| | 0 | Dutflows | | Inflows |
| | | | | |
| Differences between expected and actual actuarial experience | \$ | 544 | \$ | (27,754) |
| Changes in assumptions | | 25,126 | | (31,583) |
| Total | \$ | 25,670 | \$ | (59,337) |

Notes to the Financial Statements Year Ended December 31, 2024 (Dollars in Thousands)

Note 12. Other Post-Employment Benefits (OPEB) (Continued)

The net deferred outflows and inflows of resources at December 31, 2024, will be recognized as follows:

| Years ending December 31: | |
|---------------------------|----------------|
| 2025 | \$ (20,051) |
| 2026 | (2,845) |
| 2027 | (1,731) |
| | \$ (24,627) |
| | |

(e) Annual OPEB Benefit

The Corporation's annual OPEB benefit for the years ended December 31, 2024 and 2023, was \$12,226 and \$19,343, respectively.

Note 13. New York State Department of Health (NYSDOH) Grant Programs

The NYSDOH offers the Vital Access Provider Assurance Program (VAPAP) program. Funding under this program is made to public or safety net hospitals and health systems that meet certain criteria or that have been designated as critical access or sole community hospitals and is awarded to enable these facilities to maintain operations and provision of vital services while they implement longer-term solutions to achieve sustainable health care service delivery.

During the year ended December 31, 2023, the Corporation received grant payments under this program in the amount of \$76,838 and recognized \$103,838 as grant revenue in the statement of revenues, expenses and changes in net position as non-operating revenue. During the year ended December 31, 2024, as a result of improved financial performance, the Corporation did not receive any additional funding under this program.

Note 14. Transactions With the County of Erie

On December 30, 2009, the Corporation and the County entered into a Settlement Agreement. The Settlement Agreement resulted in the Corporation and the County entering into a number of transactions to resolve litigation and prepare for implementing the Corporation's master facility plan.

In October 2012, the Corporation and the County signed an amendment to the 2009 Settlement Agreement (the Amendment). The terms of the Amendment provide for the County to be reimbursed from the Corporation for certain workers' compensation claims incurred by Corporation employees that were paid by the County. The Amendment also provides for the County to reimburse the Corporation, over time, for post-retirement health expenses that the Corporation incurred for Corporation employees with service time at the County.

In 2017, the Corporation entered into a loan agreement and a capitalized interest liability assumption agreement with the County of Erie. A component of the loan agreement included the payment of points by the Corporation to the County of Erie in the amount of \$17,040 as further described in Note 2 and 10.

Notes to the Financial Statements Year Ended December 31, 2024 (Dollars in Thousands)

Note 14. Transactions With the County of Erie (Continued)

Other transactions: Amounts that are included in operating revenues and expenses in the statements of revenues, expenses and changes in net position, which represent related-party transactions that occurred between the Corporation and the County during the years ended December 31, 2024 and 2023, are as follows:

The Corporation earned revenue totaling \$3,969 and \$3,902 for the years ended December 31, 2024 and 2023, respectively, from the County. Revenue earned relates to services provided to School 84, mental health services and various other charges related to County departments located within the Corporation's physical plant.

The net amount due to the County of approximately \$3,737 and \$12,661 at December 31, 2024 and 2023, respectively, is non-interest bearing and reflect the Corporation's net amount owed to the County as a result of various transactions and services between parties.

Note 15. Self-Insured Obligations

The Corporation is self-insured for all medical malpractice claims for occurrences on or after January 1, 2004. Additionally, the Corporation began purchasing excess stop-loss insurance on a claims made basis for medical malpractice effective November 2008. The current policy provides \$35,000 of coverage in excess of a self-insured retention (SIR) of \$4,000 of individual claims or \$12,000 in aggregate claims effective November 19, 2018. Effective 11/19/2022, there is an additional \$1,000 buffer of individual claims or aggregate claims. Immediately prior to November 19, 2018, the policy provided \$35,000 of coverage in excess of a SIR \$3,000 of individual claims or \$10,000 in aggregate claims.

Effective April 1, 2016, the Corporation became self-insured for workers' compensation claims through a combination of self-insurance and a high-deductible plan for certain periods as follows: The Corporation maintains a stop-loss insurance policy for the claims in excess of \$750. As required by the NYS Workers' Compensation Board, ECMCC maintains a security deposit on its self-insured workers' compensation obligations. The value of the security deposit was \$30,689 as of December 31, 2024 and 2023. The deposit is maintained through a surety bond. The surety requires a collateral deposit to maintain the bond. The value of the collateral held by the surety was \$5,806 and \$5,512 as of December 31, 2024 and 2023, respectively. Effective January 1, 2012, the Corporation insured a portion of its workers' compensation exposure through an occurrence basis high-deductible plan. The Corporation remains responsible for the first \$750 of an individual claim payment after December 31, 2024 and 2023, \$3,312 and \$4,662, respectively, has been escrowed to service workers' compensation claims and included as part of assets whose use is limited. The Corporation remains self-insured for workers' compensation claims and included as part of assets whose use is limited. The Corporation remains self-insured for workers' compensation claims prior to January 1, 2012. The County has assumed a portion of liabilities for all occurrences originating prior to 2004.

Losses from asserted and unasserted medical malpractice and workers' compensation claims are accrued based on actuarial estimates that incorporate the Corporation's past experience, the nature of each claim or incident, relevant trend factors, and estimated recoveries, if any, on unsettled claims.

Notes to the Financial Statements Year Ended December 31, 2024 (Dollars in Thousands)

Note 15. Self-Insured Obligations (Continued)

The Corporation has accrued \$30,978 and \$33,407 at December 31, 2024 and 2023, respectively, for medical malpractice related exposures. Such amounts have been discounted at 2.0% for 2024 and 2023 and the accrued liabilities are included within the accrued other liabilities and self-insured obligations caption of the accompanying statements of net position. Charges to expense for medical malpractice costs are included within the other operating expenses caption of the accompanying statements of revenues, expenses and changes in net position.

The Corporation has accrued \$22,660 and \$27,922 at December 31, 2024 and 2023, respectively, for workers' compensation related exposures. Such amounts have been discounted at 1.75% for 2024 and 2023, and the liabilities are included within the accrued other liabilities and self-insured obligations captions of the accompanying statements of net position. Charges to expense for workers' compensation costs approximated \$1,167 and \$7,376 in 2024 and 2023, respectively, and are included within the payroll, employee benefits and contract labor caption of the accompanying statements of revenues, expenses and changes in net position.

Eligible retirees are provided basic medical and hospitalization coverage by the Corporation as more fully described in Note 12.

| | 12 - | and L | | A TO RE | 1710 | 2024 | | | |
|-----------------------|------|-----------|-------|-------------|-----------------------|----------|--------------|---------|-----------|
| | Tan | Sur all | ACIA | ctuarial | | | | | |
| | BAR | Beginning | Es Es | stimate of | | Claims | Ending | Du | e Within |
| | | Balance | Clair | ns Incurred | | Paid | Balance | 0 | ne Year |
| | | MOL | 5 | | | | | | |
| Medical malpractice | \$ | 33,407 | \$ | 2,675 | \$ | (5,104) | \$ 30,978 | \$ | 2,133 |
| Workers' compensation | | 27,922 | | 382 | | (5,644) | 22,660 | | 6,665 |
| | \$ | 61,329 | \$ | 3,057 | \$ | (10,748) | \$ 53,638 | \$ | 8,798 |
| | | | | | | | | | |
| | | | | | | 2023 | | | |
| | | | A | ctuarial | | | | | |
| | E | Beginning | Es | stimate of | | Claims | Ending | Du | ie Within |
| | | Balance | Clair | ns Incurred | Incurred Paid Balance | | 0 | ne Year | |
| | | | | | | | | | |
| Medical malpractice | \$ | 30,975 | \$ | 4,750 | \$ | (2,318) | \$ 33,407 | \$ | 1,792 |
| Workers' compensation | | 27,264 | | 6,145 | | (5,487) | 27,922 | | 7,416 |
| | \$ | 58,239 | \$ | 10,895 | \$ | (7,805) | \$ 61,329 | \$ | 9,208 |

The composition of self-insured obligations as of December 31, is as follows:

Medical malpractice and workers' compensation amounts due within one year are management's estimates based on historical claims.

Notes to the Financial Statements Year Ended December 31, 2024 (Dollars in Thousands)

Note 16. Commitments and Contingencies

The health care industry is subject to numerous laws and regulations of federal, state and local governments. Compliance with these laws and regulations is subject to future government review and interpretation as well as regulatory actions unknown or unasserted at the time. Government activity, in recent years, has increased with respect to investigations and allegations concerning possible violations by health care providers of fraud and abuse statutes and regulations, which could result in the imposition of significant fines and penalties, as well as significant repayments for patient services previously billed. While no regulatory allegations have been made against the Corporation, compliance with such laws and regulations can be subject to future government review and interpretations, as well as regulatory actions unknown or unasserted at this time. Management and its counsel are not aware of any such actions that will have a material adverse effect on the Corporation's financial statements.

In October 2024, the Corporation committed to begin implementing a new electronic health record system along with a new enterprise resource planning software system in the first quarter of 2025. Both projects are expected to be completed by the end of 2026.

The healthcare industry is subject to changing political, regulatory, economic and other influences that may affect our business. Regulatory uncertainty has increased as a result of recent decisions issued by the U.S. Supreme Court that affect review of federal agency actions, and the outcome of the 2024 federal elections. Federal agencies oversee, regulate and otherwise affect many aspects of our business, including through Medicare and Medicaid payment and coverage policies, policies affecting the size of the uninsured population, administration of state Medicaid programs and enforcement and interpretation of fraud and abuse laws. The recent Supreme Court decisions may also result in inconsistent judicial interpretations and delays in and other impacts to agency rulemaking and legislative processes. The changes in executive and legislative leadership at the federal level increases regulatory uncertainty and the potential for significant policy changes. Management is actively monitoring the evolving potential changes, and at this time, the impact to the Corporation is unknown.

Loss contingency liabilities are recorded in accordance with U.S. GAAP, which requires recognition of a loss when it is deemed probable that an asset has been impaired or a liability has been incurred, and the amount of the loss can be reasonably estimated. As of December 31, 2024 and 2023, the Corporation has recorded no loss contingencies except as disclosed in Note 15.

The Corporation formed 1827 Fillmore, LLC (1827) for the purpose of acquiring and developing land immediately adjacent to its Grider Street campus. A condition of the acquisition was that 1827 demolish a building on the site with known asbestos abatement requirements. This condition was met in 2018. The Corporation has undertaken a community planning process to determine the future use(s) of the site. The site requires the environmental remediation expenditures; however, the amount of such expenditures is dependent on the ultimate use of the site and requirements from regulators. Through December 31, 2024, approximately \$4,600 has been spent on remediating and improving the land.

Required Supplementary Information

Required Supplementary Information Schedule of Corporation's Contributions NYSLRS Pension Plan December 31, 2024 (Dollars in Thousands)

| | | 2024 | | 2023 | 2022 | | 2021 | | 2020 | | 2019 | | 2018 | | 2017 | 2016 | 2015 |
|--|----|---------|--------|---------|---------------|----|---------|----------------------|-----------------|----|----------|----|---------|----|---------|---------------|---------------|
| Contractually required contribution | \$ | 34,131 | \$ | 25,153 | \$ 31,946 | \$ | 30,167 | \$ | 27,343 | \$ | 26,447 | \$ | 25,803 | \$ | 25,235 | \$ 26,722 | \$ 29,771 |
| Contributions in relation to the contractually required contribution | | 34,131 | | 25,153 | 31,946 | | 30,167 | | 27,343 | 00 | 1 26,447 | | 25,803 | | 25,235 | 26,722 | 29,771 |
| Contribution deficiency | \$ | - | \$ | - | \$ - | \$ | 2 | \$ | 0 | 1 | <u> </u> | \$ | - | \$ | - | \$ - | \$ - |
| | _ | | | | | ~ | AP V | | 28 ⁹ | | | | | | | | |
| ECMCC covered-employee payroll | \$ | 295,295 | \$ | 245,606 | \$ 244,519 | 03 | 235,767 | 0 | 216,871 | \$ | 204,007 | \$ | 193,386 | \$ | 183,540 | \$ 166,691 | \$ 175,409 |
| Contributions as a percentage of covered-employee payroll | | 11.6% | , P | 10.2% | 13.1% | | 12.8% |) (C ⁶ | 12.6% | Ď | 13.0% | I | 13.3% | 5 | 13.7% | 16.0% | 17.0% |

57

Required Supplementary Information Schedule of Corporation's Proportionate Share of Net Pension Liability (Asset) NYSLRS Pension Plan December 31, 2024 (Dollars in Thousands)

| | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|----------------------------------|----------------------------------|-----------------------------------|------------------------------|----------------------------------|---------------------------------|---------------------------------|---------------------------------|----------------------------------|
| ECMCC proportion of the net pension (asset) liability ECMCC proportionate share of the net pension (asset) liability ECMCC covered-employee payroll | 1.0549% \$ 155,324 295,295 | 0.9277% \$ 198,936 245.606 | 0.9485% \$ (77,538) 273.555 | 0.9187% \$ 915 249.490 | 0.8504% \$ 225,197 246.772 | 0.8079% \$ 57,240 235,284 | 0.7646% \$ 24,677 216.044 | 0.7614% \$ 71,544 183.540 | 0.7228% \$ 116,006 166.691 |
| ECMCC proportionate share of the net pension liability as a percentage of its covered-employee payroll | 52.6% | 81.0% | -28.3% | 0.4% | 91.3% | 24.3% | 11.4% | 39.0% | 69.6% |
| Plan fiduciary net position as a percentage of the total pension liability | 93.9% | 90.8% | 103.7% | 100.0% | 86.4% | 96.3% | 98.2% | 94.7% | 90.7% |
| | | | | | | | | | |

Note: GASB requires 10 years of information to be presented in this table. However, until a full 10-year trend is compiled,

the Corporation will present information for those year for which information is available.

Change in Benefit Terms

The New York State Legislature lowered the vesting requirement for Tier 5 and Tier 6 from 10 years to five years (Chapter 56 0f the Laws of 2022), prior to the April 1, 2022 actuarial valuation.

Changes of Assumptions

2023: The mortality improvement assumption was updated to the Society of Actuaries' Scale MP-2021, inflation was updated to 2.9%, cost-of-living updated to 1.5%, for the April 1, 2022 actuarial valuation.

2022: The mortality improvement assumption was updated to the Society of Actuaries' Scale MP-2020, inflation was updated to 2.7%, cost-of-living updated to 1.4%, and the interest rate assumption was reduced to 5.9% for the April 1, 2021 actuarial valuation.

58

Required Supplementary Information Schedule of Corporation's Changes in Total OPEB Liability and Related Ratios December 31, 2024 and 2023 (Dollars in Thousands)

| | | 2024 | 2023 |
|--|----|----------|---------------|
| Total OPEB liability: | | | |
| Service cost | \$ | 3,153 | \$ 2,620 |
| Interest cost | | 9,983 | 9,722 |
| Change of Benefit Terms | | 6,176 | - |
| Differences between expected and actual experience | | 14,200 | 232 |
| Changes of assumptions | | (36,699) | 26,546 |
| Benefit payments | | (12,128) | (16,604) |
| Net change in total OPEB liability | | (15,315) | 22,516 |
| Total OPEB liability—beginning | SE | 293,911 | 271,395 |
| Total OPEB liability—ending | \$ | 278,596 | \$ 293,911 |
| Covered employee payroll | \$ | 85,437 | \$ 87,249 |
| Total OPEB liability as a percentage of covered employee payroll | | 326.08% | 336.86% |
| Discount rate | | 4.1% | 3.3% |
| Change in Benefit Terms | | | |

There were no significant changes in benefits during 2024 and 2023.

Changes of Assumptions

2024: The discount rate was increased from 3.3% to 4.1% as well as an update to the medical and prescription trend rates.

2023: The discount rate was decreased from 3.7% to 3.3%, while salary increases were adjusted from 3.7% to 3.3% as well as an update to the medical and prescription trend rates.

Erie County Medical Center Corporation

(A Component Unit of the County of Erie)

Uniform Guidance Audit Requirements December 31, 2024

For Review and Discussion Putposes Only Not to be Reproduced

Schedule of Expenditures of Federal Awards For the Year Ended December 31, 2024

| Federal Grantor/Pass-Through Grantor/Program or Cluster Title | Federal Assistance Listing Number | Pass-Through Entity Identifying Number | Provided to Subrecipients | Total Federal Expenditures |
|---|--------------------------------------|---|------------------------------|-------------------------------|
| Grantol/Program of Cluster Title | | Entry Identifying Number | Subrecipients | Experioritures |
| J.S. Department of Health and Human Services Health Resources and | | | | |
| Services Administration Direct Programs: | | | | |
| Training in General, Pediatric, and Public Health Dentistry | 93.059 | N/A | - | 964,198 |
| | 00.000 | | | 001,100 |
| Ryan White HIV/AIDS Dental Reimbursement and Community | | | | |
| Based Dental Partnership Grants | 93.924 | N/A | - | 168,89 |
| | | | | , |
| Oral Diseases and Disorders Research | 93.121 | N/A | - | 348,028 |
| Substance Abuse and Mental Health Services Projects of | | | | |
| Regional and National Significance | 93.243 | N/A | | 497,41 |
| | | | | |
| otal U.S. Department of Health and Human Services Health | | | | |
| Resources and Services Administration Direct Programs | | | - | 1,978,52 |
| .S. Department of Health and Human Services pass-through program from: | | | | |
| Health Research Inc. | | | | |
| National Bioterrorism Hospital Preparedness Program | 93.889 | NU90TP000515 | - | 42,50 |
| | | | | |
| otal U.S. Department of Health and Human Services Pass-Through Programs | | | -1 | 42,50 |
| S. Department of Justice Pass-Through Program From: | | | | |
| New York State Office of Victim Crime Services | | | | |
| Crime Victim Assistance | 16.575 | OVS01-C11259GG-1080200 | - | 240,78 |
| New York State Division Criminal Justice Services | | | | |
| Crime Victim Assistance | 16.575 | OVS01-C11259GG-1080200 | - | 97,39 |
| Office of Victim Services | | | | |
| Crime Victim Assistance | 16.575 | OVS01-T11152GG-1080200 | - | 153,95 |
| Office of Victim Services | | | | |
| Crime Victim Assistance | 16.575 | OVS01-T11152GG-1080200 | - | 50,09 |
| Total: 16.575 | | | - | 542,22 |
| | | | | |
| New York State Office of Victim Crime Services | 3 - A BILL | | | 0.40.00 |
| Crime Victim Assistance/Discretionary Grants | 16.582 | 15POVC-22-GK-01799-NONF | - | 246,66 |
| New York State Division Criminal Justice Services | | | | |
| Violence Against Women Formula Grants | 16.588 | C00256GG-1090000 | | 45.61 |
| Violence Against Women i official Granits | 10.300 | 0023088-1030000 | - | 45,01 |
| Office of Justice Programs | | | | |
| Services for Trafficking Victims | 16.320 | 15POVC-24-GG-01824-HT | _ | 7,58 |
| Sources for Hamoking Vicinity | 0.020 | 151 010-24-00-01024-111 | | 1,00 |
| otal U.S. Department of Justice Pass-Through Program | | | - | 842,09 |
| | | | | 2.2,00 |
| S. Department of Homeland Security (Federal Emergency Management Agency) | | | | |
| COVID-19: Disaster Grants - Public Assistance (Presidentially Declared Disasters) | 97.036 | N/A | _ | 17,333,18 |
| COMPTO. Disaster Granto - Fublic Assistance (Freshentially Decidied Disasters) | 97.000 | 19/2 | | 17,000,10 |
| Total Expenditures of Federal Awards | | | \$ - | \$ 20,196,31 |
| Total Expenditules of Federal Awards | | | Ψ - | ψ 20,130,3 |

See notes to the schedule of expenditures of federal awards.

Notes to Schedule of Expenditures of Federal Awards Year Ended December 31, 2024

Note 1. Basis of Presentation

The accompanying schedule of expenditures of federal awards (the Schedule) includes the federal award activity of the Erie County Medical Center Corporation (the Corporation) under programs of the federal government for the year ended December 31, 2024. The information on this Schedule is presented in accordance with the requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance).

For purposes of the Schedule, federal awards include all federal assistance entered into directly between the Corporation and the federal government and sub-awards from nonfederal organizations made under federally sponsored agreements. The Schedule does not include payments received under Medicare and Medicaid reimbursement programs. Because the Schedule presents only a selected portion of the activities of the Corporation, it is not intended to, and does not, present the financial position, changes in net position and cash flows of the Corporation.

Note 2. Summary of Significant Accounting Policies

Expenditures reported on the Schedule are reported on the accrual basis of accounting. Such expenditures are recognized following cost principles contained in the Uniform Guidance, wherein certain types of expenditures are not allowable or are limited as to reimbursement. The Corporation has elected to not exercise its option to use the 10% de minimis indirect cost rate as allowed under the Uniform Guidance.

Note 3. Other Federal Awards

There were no federal awards expended for noncash assistance, insurance, or any loans, loan guarantees, or interest subsidies outstanding at December 31, 2024.

Note 4. Subrecipients

The Corporation did not provide federal awards to any subrecipients during the year ended December 31, 2024.

Report on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance With *Government Auditing Standards*

Independent Auditor's Report

Board of Directors Erie County Medical Center Corporation

We have audited, in accordance with the auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States (*Government Auditing Standards*), the financial statements of the business-type activities and the aggregate discretely presented component units of Erie Medical Center Corporation (the Corporation), as of and for the year ended December 31, 2024, and the related notes to the financial statements, which collectively comprise the Corporation's basic financial statements, and have issued our report thereon dated [DATE].

The financial statements of ECMC Foundation, Inc., the Grider Initiative, Inc. and Research for Health in Erie County, Inc. were not audited in accordance with *Government Auditing Standards*, and accordingly, this report does not include reporting on internal controls over financial reporting or instances of reportable noncompliance associated with ECMC Foundation, Inc., the Grider Initiative, Inc. and Research for Health in Erie County, Inc.

Report on Internal Control Over Financial Reporting

In planning and performing our audit of the financial statements, we considered the Corporation's internal control over financial reporting (internal control) as a basis for designing audit procedures that are appropriate in the circumstances for the purpose of expressing our opinions on the financial statements, but not for the purpose of expressing an opinion on the effectiveness of the Corporation's internal control. Accordingly, we do not express an opinion on the effectiveness of the Corporation's internal control.

A *deficiency in internal control* exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A *material weakness* is a deficiency, or a combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected and corrected, on a timely basis. A *significant deficiency* is a deficiency, or a combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected and corrected, on a timely basis. A *significant deficiency* is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.


Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses or significant deficiencies may exist that were not identified.

Report on Compliance and Other Matters

As part of obtaining reasonable assurance about whether the Corporation's financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements, noncompliance with which could have a direct and material effect on the basic financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

Purpose of This Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the Corporation's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the Corporation's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.



Report on Compliance For Each Major Federal Program; Report on Internal Control Over Compliance; and Report on Schedule of Expenditures of Federal Awards Required by the Uniform Guidance

Independent Auditor's Report

Board of Directors Erie County Medical Center Corporation

Report on Compliance for Each Major Federal Program

Opinion on Each Major Federal Program



We have audited Erie County Medical Center Corporation's (the Corporation) compliance with the types of compliance requirements identified as subject to audit in the OMB *Compliance Supplement* that could have a direct and material effect on each of the Corporation's major federal programs for the year ended December 31, 2024. The Corporation's major federal programs are identified in the summary of auditor's results section of the accompanying schedule of findings and questioned costs.

In our opinion, the Corporation complied, in all material respects, with the compliance requirements referred to above that could have a direct and material effect on each of its major federal programs for the year ended December 31, 2024.

Basis for Opinion on Each Major Federal Program

We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America (GAAS); the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States (*Government Auditing Standards*); and the audit requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Our responsibilities under those standards and the Uniform Guidance are further described in the Auditor's Responsibilities for the Audit of Compliance section of our report.

We are required to be independent of the Corporation and to meet our other ethical responsibilities, in accordance with relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on compliance for each major federal program. Our audit does not provide a legal determination of the Corporation's compliance with the compliance requirements referred to above.

Responsibilities of Management for Compliance

Management is responsible for compliance with the requirements referred to above and for the design, implementation and maintenance of effective internal control over compliance with the requirements of laws, statutes, regulations, rules and provisions of contracts or grant agreements applicable to the Corporation's federal programs.

Auditor's Responsibility for the Audit of Compliance

Our objectives are to obtain reasonable assurance about whether material noncompliance with the compliance requirements referred to above occurred, whether due to fraud or error, and express an opinion on the Corporation's compliance based on our audit. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS, *Government Auditing Standards*, and the Uniform Guidance will always detect material noncompliance when it exists. The risk of not detecting material noncompliance resulting from fraud is higher than for that resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations or the override of internal control. Noncompliance with the compliance requirements referred to above is considered material, if there is a substantial likelihood that, individually or in the aggregate, it would influence the judgment made by a reasonable user of the report on compliance about the Corporation's compliance with the requirements of each major federal program as a whole.

In performing an audit in accordance with GAAS, *Government Auditing Standards*, and the Uniform Guidance, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material noncompliance, whether due to fraud or error, and design
 and perform audit procedures responsive to those risks. Such procedures include examining, on a
 test basis, evidence regarding the Corporation's compliance with the compliance requirements
 referred to above and performing such other procedures as we considered necessary in the
 circumstances.
- Obtain an understanding of the Corporation's internal control over compliance relevant to the audit in
 order to design audit procedures that are appropriate in the circumstances and to test and report on
 internal control over compliance in accordance with the Uniform Guidance, but not for the purpose of
 expressing an opinion on the effectiveness of the Corporation's internal control over compliance.
 Accordingly, no such opinion is expressed.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and any significant deficiencies and material weaknesses in internal control over compliance that we identified during the audit.

Report on Internal Control Over Compliance

A deficiency in internal control over compliance exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. A material weakness in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. A significant deficiency in internal control over compliance is a deficiency, or a combination of deficiency, or a combination of deficiency, or a timely basis. A significant deficiency in internal control over compliance is a deficiency, or a combination of deficiency, or a combination of deficiency in a timely basis. A significant deficiency in internal control over compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. A significant deficiency in internal control over compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the Auditor's Responsibilities for the Audit of Compliance section above and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies in internal control over compliance. Given these limitations, during our audit we did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses, as defined above. However, material weaknesses or significant deficiencies in internal control over compliance that we consider to be material weaknesses, as defined above. However, material weaknesses or significant deficiencies in internal control over compliance that we consider to be material weaknesses.

Our audit was not designed for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, no such opinion is expressed.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.

Report on Schedule of Expenditures of Federal Awards Required by the Uniform Guidance

We have audited the financial statements of the business-type activities and the aggregate discretely presented component unit of the Corporation as of and for the year ended December 31, 2024, and the related notes to the financial statements, which collectively comprise the Corporation's basic financial statements. We issued our report thereon dated [DATE], which contained unmodified opinions on those financial statements. Our audit was performed for the purpose of forming opinions on the financial statements that collectively comprise the basic financial statements. The accompanying schedule of expenditures of federal awards is presented for purposes of additional analysis as required by the Uniform Guidance and is not a required part of the basic financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the basic financial statements. The information has been subjected to the auditing procedures applied in the audit of the basic financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the basic financial statements or to the basic financial statements end biscussion of the subject to be Reproduced to be repr themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the schedule of expenditures of federal awards is fairly stated in all material respects in relation to the basic financial statements as a whole.

Cleveland, Ohio [DATE]

Erie County Medical Center Corporation (A Component Unit of the County of Erie)

Schedule of Findings and Questioned Costs Year Ended December 31, 2024

Section I—Summary of Auditor's Results

Financial Statements

| Type of auditor's report issued on whether the financial statements audited were prepared in accordance with GAAP: | | Unmodif | ied | _ |
|--|------------|------------|--|---------------------|
| Internal control over financial reporting: | | ¥00 | v | - |
| Material weakness(es) identified? Significant deficiency(ies) identified? | | yes yes | X | no none reported |
| Noncompliance material to financial statements noted? | ORAFT | yes | <u> </u> | no |
| Federal Awards | | | | |
| Internal control over major programs: Material weakness(es) identified? Significant deficiency(ies) identified? | Change | yes yes | X X | no none reported |
| Type of auditor's report issued on compliance for major programs: | FGIA. | Unmodif | ied | - |
| Any audit findings disclosed that are required to be reporte in accordance with 2 CFR Section 200.516(a)? | ed | yes | X | no |
| Identification of major federal programs: | | | | |
| Federal Assistance Listing Number(s) | Name of Fe | ederal Pro | ogram or Cluste | <u>er</u> |
| 97.036 | | | Grants - Public | Assistance |
| 93.243 | Substance | Abuse an | red Disasters) Id Mental Healtl and National S | |
| Dollar threshold used to distinguish between Type A and Type B programs: | | | \$ 750,000 | - |
| Auditee qualified as a low risk auditee? | X | yes | | no |
| (Continue | ed) | | | |

Erie County Medical Center Corporation (A Component Unit of the County of Erie)

Schedule of Findings and Questioned Costs (Continued) Year Ended December 31, 2024

Section II—Financial Statement Findings

No findings were noted.

Section III—Findings and Questioned Costs for Federal Awards

No findings were noted.

Erie County Medical Center Corporation (A Component Unit of the County of Erie)

Summary Schedule of Prior Year Findings and Questioned Costs Year Ended December 31, 2024

Section I—Financial Statement Findings

No findings were noted in the prior (2023) audit.

Section II—Findings and Questioned Costs for Federal Awards

No findings were noted in the prior (2023) audit.

The difference between healthcare and true care™ 🗾 🥁 🏭 🛄

Erie County Medical Center Corporation



Operating and Capital Budgets For the year ending 2025 The difference between healthcare and true care[™] **E C M C** ecmc.edu

Table of Contents

| | Page |
|--------------------------------------|-------|
| Management Discussion and Analysis | 3-8 |
| Regulatory Reporting Requirements | 9 |
| Budget Process | 10 |
| Performance Comparison | 11 |
| Key Financial Ratios | 12 |
| Financial Statements | 13-15 |
| Operating Performance Reconciliation | 16 |
| Principal Budget Assumptions | 17-24 |
| Performance Improvement Initiatives | 25 |
| Emerging Issues and Risk Areas | 26 |
| Capital Budget Summary | 27 |
| 2026 - 2028 Financial Projections | 28-31 |

The difference between healthcare and true care™ 🗾 🧲 🎇 🎧

Management Discussion and Analysis

September 30, 2024

The year ending December 2024 has been a year of positive movement along our stepped recovery path. The 2025 Budget maintains that path while also continuing to further the ECMCC Strategic Plan which focuses on both short and long-term growth, expanding access to care in our surrounding community and investing in the workforce to meet certain staffing requirements resulting in continuous financial and operational improvement despite the ongoing industry and market challenges. ECMCC's long-term goals will continue to be measured through the achievement of the ECMCC mission: improving clinical quality, service excellence, and the continued provision of health services to the communities ECMCC serves with compassion. In the short-term a renewed focus has been placed on retention of staff through investments in our people and steady growth through improved patient access.

The difference between healthcare and true care™ 📕 🧲 🎇 😭 ecmc.edu

Management Discussion and Analysis

The industry generally is also seeing financial and operational recovery, while also experiencing many of the similar financial and operational challenges both locally and nationally. ECMCC has recognized that growth, improved efficiency, and reimbursement enhancements along with future external support are needed to properly provide for a pathway to sustainability. Despite the significant operating and admission challenges seen in the local community care settings ECMCC's 2025 goal is to improve operating results before accounting for actuarial expense increases through efficiency and revenue improvements, as well as programmatic growth without impacting the critical services we provide while simultaneously maintaining our exceptional quality outcomes. The proposed 2025 operating budget reflects an operating loss of \$35 million before grant support. The proposed budget has been developed with the following goals in mind:

Budget Goals

- Maintain the highest quality of care provided
- Maintain critical services provided to the community
- Continue a stepped approach to recovery while managing community admission challenges
- Maintain routine capital and equipment upgrades
- Maximize retention of staff, improve staffing efficiency and meet NYS minimum standards
- Prepare the budget to accomplish the goals without significant job actions

The difference between healthcare and true care 🕷 🧾 🦉 🏭 🥵

Management Discussion and Analysis

Budgetary assumptions are a key component of the process that was followed in developing the Budget. The following summarizes Management's perspective in the development of these assumptions

Activity Levels

The Budget has been prepared using the actual volume seen during 2024 as a baseline. Further consideration was given to the changes internally related to recent trends in volume and activity, an improvement in the ability to discharge patients and ultimately reduced length of stay, the shift of inpatient cases into the outpatient setting as a result of changing regulations and payer payment policies, growth of various service lines, new physician recruitment, as well as other factors. Management believes that the levels of activity contained within the Budget are achievable. The difference between healthcare and true care[™] 🗾 🥥 🏭 🚰



Management Discussion and Analysis

Revenue and Reimbursement

Projected reimbursement from government payers is based on current and proposed regulations where Management has evaluated as probable. Reimbursement from commercial payers is based on current contracts or at rates that Management has evaluated as probable for contracts currently being negotiated. Increases in net revenue associated with revenue cycle improvement initiatives related to contract underpayments and payer denial management have also been incorporated at levels that Management believes are attainable.

Other operating revenue has been budgeted based on historical experience while taking into account the impact of anticipated growth and improved efficiency in the operation of ECMCC's Specialty Pharmacy services provided to our patients.

Disproportionate share and upper payment limit payments have been budgeted based on the most current information available to Management.

The difference between healthcare and true care[™] 📕 🧲 🏭 🚅

Management Discussion and Analysis

Operating Expenses

Projected operating expenses are budgeted based on the volume of anticipated activity, along with adjustments for salary rate increases consistent with current collective bargaining agreements, estimated benefit costs as adjusted for actuarially projected gains or losses, supply and other expense inflation rates as well as impacts of performance improvement initiatives. Management believes that the overall growth in expenses of approximately 8.3% contained in the budget are reasonable given the significant increases in actuarially driven benefit costs, volume related supply costs and specialty pharmacy drug costs.

Non-Operating Revenue

Non-Operating Revenues have been budgeted consistent with the recent historical trends related to investment income. The reduction is the result of an anticipated decrease in available investments in 2025 and an assumption that interest rates will decline from 2024 levels. Although ECMCC expects to continue to work closely with NYS on future funding needs for 2025 as a participant in the Vital Access Provider Assurance grant program, Management has elected not to include any additional Federal or New York State operational support for planning purposes in the 2025 operating budget.

The difference between healthcare and true care™ 🗾 🧲 🏭 🎧



Management Discussion and Analysis

Cash Flows

2025 cash flow will remain a key focus of Management given the challenges. Cash flows have been budgeted based on the results of operations, investments in routine and nonroutine capital assets, principal payments on long-term debt, continued investments in our clinically integrated network and the funding of employee benefit plans. In an effort to avoid reducing critical services through significant program and personnel cuts the budget reflects losses which may result in a need for future operational and capital cash flow support from governmental agency partners including New York State.

Range of Outcomes and Contingency Plans

Management has considered the sensitivity of each material assumption within the Budget. Management believes that the Budget is reasonably positioned within the range of potential outcomes and recognizes its responsibility for achieving these results. Given the uncertainty of certain material assumptions related to uncertain inflationary pressures, community post-acute capacity, staffing and retention challenges, emergent capital or technology needs, future governmental reimbursement and benefit cost fluctuations, Management acknowledges that it may have to adjust operationally during 2025.




Regulatory Budget Reporting Requirements

- All requirements have been met
 - NYCRR, Part 203, Chapter V, Title 2
 - This package communicates each of the 18 requirements
- New York State Office Of The State Comptroller
- Authority Budget Office
- PARIS submission and certification



Budget Process

- Executive Leadership Team (ELT) adopt budget schedule and goals
- Using 2024 year-to-date performance and known or anticipated budget variances, a baseline budget and financial projections were prepared
- Department managers worked with ELT to develop departmental targets and performance improvement initiatives
- ELT budget recommendation reviewed and approved by Finance Committee of ECMCC Board
- Budget recommendation reviewed and approved by ECMCC Board



The difference between healthcare and true care[™] **E C M C** ecmc.edu

Key Financial Ratios

| | | | Projected | Budget | |
|---|-------------|-------------|------------------|---------------|--|
| | <u>2022</u> | <u>2023</u> | <u>2024</u> | 2025 | |
| Operating Margin % | -10.8% | -14.2% | -3.7% | -3.8% | |
| NYS PBC Average % | -16.1% | -14.3% | | | |
| Operating EBITDA % | 4.6% | -6.0% | 3.3% | 2.4% | |
| NYS PBC Average % | -10.0% | -8.2% | | | |
| FTE's | 3,473 | 3,684 | 3,738 | 3,802 | |
| Days Operating Cash On Hand | 29 | 14 | 32 | 15 | |
| NYS PBC Average | 49 | 26 | | | |
| Debt Service Coverage | 1.5 | 2.2 | 1.8 | 0.2 | |
| NYS PBC Average | (0.5) | (0.5) | | | |
| Salaries, Wages & Benefits % of Revenue | 61.5% | 76.2% | 68.5% | 69.9% | |
| Supply Expense % of Revenue | 20.8% | 21.9% | 22.0% | 22.7% | |
| Benefit % of Salaries and Wages | 12.9% | 35.7% | 29.3% | 34.7% | |
| Days In Accounts Receivable, net | 53.9 | 66.0 | 59.0 | 55.0 | |
| | | | | | |



Statements of Revenues and Expenses

(Thousands)

| | 2023 Audited 2024 Projection | | 2025 Budget | Increase (De | <u>crease)</u> |
|---|------------------------------|----------|-------------|--------------|------------------|
| Net Patient Revenue | 603,720 | 670,943 | 719,848 | 48,905 | 7.3% |
| Disproportionate Share / IGT and UPL Payments | 107,105 | 123,299 | 130,932 | 7,633 | 6.2% |
| Other Operating Revenues | 46,639 | 60,968 | 74,547 | 13,579 | 22.3% |
| Total Operating Revenues | 757,464 | 855,210 | 925,327 | 70,117 | 8.2% |
| Operating Expenses | | | | | |
| Salaries and Wages | 339,019 | 355,319 | 373,418 | 18,099 | 5.1% |
| Employee Benefits | 121,079 | 104,182 | 129,688 | 25,506 | 24.5% |
| Physician & Resident Fees | 110,577 | 115,517 | 123,394 | 7,877 | 6.8% |
| Purchased Services | 81,712 | 74,209 | 81,281 | 7,072 | 9.5% |
| Supplies | 132,197 | 147,840 | 163,047 | 15,207 | 10.3% |
| Other Expenses | 30,529 | 29,913 | 32,381 | 2,468 | 8.3% |
| Depreciation | 49,812 | 48,209 | 45,603 | (2,606) | -5.4% |
| Interest | 12,264 | 11,438 | 11,513 | 75 | 0.7% |
| Total Operating Expenses | 877,189 | 886,627 | 960,325 | 73,698 | <u>8.3</u> % |
| Operating Income | (119,725) | (31,417) | (34,998) | (3,581) | -11.4% |
| Grant revenue | 107,230 | 25,480 | - | (25,480) | - <u>100.0</u> % |
| Income/(Loss) from Operations with grants | (12,495) | (5,937) | (34,998) | (29,061) | -489.5% |
| Non Operating Revenues | 6,283 | 5,836 | 3,734 | (2,102) | - <u>36.0</u> % |
| Excess of Revenues Over Expenses | (6,212) | (101) | (31,264) | (31,163) -3 | 80956.6% |
| | | | | | |

The difference between healthcare and true care[™] **E C M C** ecmc.edu



Statements of Net Position

| Assets 2023 Audited 2024 Projection 2025 Budget Increase (Decrease) Current Assets Cash \$ 20,773 \$ 33,170 \$ 28,998 \$ (4,172) -12.6% Patient Accounts Receivable, Net 102,389 108,086 108,460 374 0.3% Other Current Assets 66,654 82,458 83,952 1,494 1.8% Total Current Assets 189,816 2223,714 221,410 (2,304) -1.0% Assets Whose Use Is Limited 170,619 164,108 166,180 2,072 1.3% Property and Equipment, Net 313,038 272,828 235,226 (37,602) -1.5% Total Assets | (Thousands) | | | | | | | | | |
|---|---|--------------|-----------------|-------------|------------------------------|--|--|--|--|--|
| Current Assets Cash \$ 20,773 \$ 33,170 \$ 28,998 \$ (4,172) -12.6% Patient Accounts Receivable, Net 102,389 108,086 108,460 374 0.3% Other Current Assets 66,654 82,458 83,952 1,494 1.8% Total Current Assets 189,816 223,714 221,410 (2,304) -1.0% Assets Whose Use Is Limited 170,619 164,108 166,180 2,072 1.3% Property and Equipment, Net 313,038 272,828 235,226 (37,602) -1.3% Other Assets 168,370 168,189 160,550 (7,639) -4.5% Iabilities and Net Assets 841,843 828,839 783,366 (45,473) -5.5% Current Liabilities 209,563 307,145 310,144 2.999 1.0% Accounts Payable, Third-Party & Accrued 227,1026 269,680 284,656 14,976 5.6% Total Current Liabilities 309,563 307,145 </td <td></td> <td>2023 Audited</td> <td>2024 Projection</td> <td>2025 Budget</td> <td>Increase (Decrease)</td> | | 2023 Audited | 2024 Projection | 2025 Budget | Increase (Decrease) | | | | | |
| Cash \$ 20,773 \$ 33,170 \$ 28,998 \$ (4,172) -12.6% Patient Accounts Receivable, Net 102,389 108,086 108,460 374 0.3% Other Current Assets 66,654 82,458 83,952 1,494 1.8% Total Current Assets 189,816 223,714 221,410 (2,304) -1.0% Assets Whose Use Is Limited 170,619 164,108 166,180 2,072 1.3% Property and Equipment, Net 313,038 272,828 235,226 (37,602) -1.3% Other Assets 168,370 168,189 160,550 (7,639) -4.5% Current Liabilities 841,843 828,839 783,366 (45,473) -5.5% Liabilities and Net Assets 271,026 269,680 284,656 14,976 5.6% Current Portion of Long Term Debt 38,537 37,465 25,488 (11,977) -32.0% Accounts Payable, Third-Party & Accrued 271,026 269,680 284,656 14,976 5.6% Total Current Liabilities 309,563 307,145 310,144 2,999 1.0% <td>Assets</td> <td></td> <td></td> <td></td> <td></td> | Assets | | | | | | | | | |
| Patient Accounts Receivable, Net 102,389 108,086 108,460 374 0.3% Other Current Assets 66,654 82,458 83,952 1,494 1.8% Total Current Assets 189,816 223,714 221,410 (2,304) -1.0% Assets Whose Use Is Limited 170,619 164,108 166,180 2,072 1.3% Property and Equipment, Net 313,038 272,828 235,226 (37,602) -13.8% Other Assets 168,370 168,189 160,550 (7,639) -4.5% Total Assets 841,843 828,839 783,366 (45,473) -5.5% Liabilities and Net Assets Current Portion of Long Term Debt 38,537 37,465 25,488 (11,977) -32.0% Accounts Payable, Third-Party & Accrued 271,026 269,680 284,656 14,976 5.6% Total Current Liabilities 309,563 307,145 310,144 2,999 1.0% Long Term Debt 225,197 217,508 206,020 (11,488) -5.3% < | Current Assets | | | | | | | | | |
| Other Current Assets 66,654 82,458 83,952 1,494 1.8% Total Current Assets 189,816 223,714 221,410 (2,304) -1.0% Assets Whose Use Is Limited 170,619 164,108 166,180 2,072 1.3% Property and Equipment, Net 313,038 272,828 235,226 (37,602) -13.8% Other Assets 168,370 168,189 160,550 (7,639) -4.5% Total Assets 841,843 828,839 783,366 (45,473) -5.5% Liabilities and Net Assets Current Liabilities | | | | | | | | | | |
| Total Current Assets 189,816 223,714 221,410 (2,304) -1.0% Assets Whose Use Is Limited 170,619 164,108 166,180 2,072 1.3% Property and Equipment, Net 313,038 272,828 235,226 (37,602) -13.8% Other Assets 168,370 168,189 160,550 (7,639) -4.5% Total Assets 841,843 828,839 783,366 (45,473) -5.5% Liabilities and Net Assets Current Portion of Long Term Debt 38,537 37,465 25,488 (11,977) -32.0% Accounts Payable, Third-Party & Accrued 271,026 269,680 284,656 14,976 5.6% Total Current Liabilities 309,563 307,145 310,144 2,999 1.0% Long Term Debt 225,197 217,508 206,020 (11,488) 5.3% Deferred Inflows 84,739 84,976 85,976 1,000 1.2% Other Post Employment Benefits 281,585 262,097 269,960 7,863 3.0% | | | | í l | | | | | | |
| Assets Whose Use Is Limited 170,619 164,108 166,180 2,072 1.3% Property and Equipment, Net 313,038 272,828 235,226 (37,602) -13.8% Other Assets 168,370 168,189 160,550 (7,639) -4.5% Total Assets 841,843 828,839 783,366 (45,473) -5.5% Liabilities and Net Assets Current Portion of Long Term Debt 38,537 37,465 25,488 (11,977) -32.0% Accounts Payable, Third-Party & Accrued 271,026 269,680 284,656 14,976 5.6% Total Current Liabilities 309,563 307,145 310,144 2,999 1.0% Long Term Debt 225,197 217,508 206,020 (11,488) -5.3% Deferred Inflows 84,739 84,976 85,976 1,000 1.2% Other Post Employment Benefits 281,585 262,097 269,960 7,863 3.0% Self Insurance Liabilities 1,118,010 1,105,107 1,090,898 (14,209) -1.3% Net Position (276,167) (276,268) (307,532) <td>Other Current Assets</td> <td>66,654</td> <td>82,458</td> <td>83,952</td> <td><u>1,494</u> <u>1.8</u>%</td> | Other Current Assets | 66,654 | 82,458 | 83,952 | <u>1,494</u> <u>1.8</u> % | | | | | |
| Property and Equipment, Net 313,038 272,828 235,226 (37,602) -13.8% Other Assets 168,370 168,189 160,550 (7,639) -4.5% Total Assets 841,843 828,839 783,366 (45,473) -5.5% Liabilities and Net Assets Current Liabilities - - - - Current Portion of Long Term Debt 38,537 37,465 25,488 (11,977) -32.0% Accounts Payable, Third-Party & Accrued 271,026 269,680 284,656 14,976 5.6% Total Current Liabilities 309,563 307,145 310,144 2,999 1.0% Long Term Debt 225,197 217,508 206,020 (11,488) -5.3% Deferred Inflows 84,739 84,976 85,976 1,000 1.2% Other Post Employment Benefits 281,585 262,097 269,960 7,863 3.0% Self Insurance Liabilities 1,118,010 1,105,107 1,090,898 (14,209) -1.3% Net Position (276,167) (276,268) (307,532) (31,264) -11.3% | Total Current Assets | 189,816 | 223,714 | 221,410 | (2,304) - <u>1.0</u> % | | | | | |
| Other Assets 168,370 168,189 160,550 (7,639) -4.5% Total Assets 841,843 828,839 783,366 (45,473) -5.5% Liabilities and Net Assets Current Liabilities 38,537 37,465 25,488 (11,977) -32.0% Current Portion of Long Term Debt 38,537 37,465 25,488 (11,977) -32.0% Accounts Payable, Third-Party & Accrued 271,026 269,680 284,656 14,976 5.6% Total Current Liabilities 309,563 307,145 310,144 2.999 1.00% Long Term Debt 225,197 217,508 206,020 (11,488) -5.3% Deferred Inflows 84,739 84,976 85,976 1,000 1.2% Other Post Employment Benefits 216,926 233,381 218,798 (14,583) -6.2% Self Insurance Liabilities 1,118,010 1,105,107 1,090,898 (14,209) -1.3% Net Position (276,167) (276,268) (307,532) (31,264) -11.3% | Assets Whose Use Is Limited | 170,619 | 164,108 | 166,180 | 2,072 1.3% | | | | | |
| Total Assets 841,843 828,839 783,366 (45,473) -5.5% Liabilities and Net Assets - < | Property and Equipment, Net | 313,038 | 272,828 | 235,226 | (37,602) -13.8% | | | | | |
| Liabilities and Net Assets Current Liabilities Current Portion of Long Term Debt 38,537 37,465 25,488 (11,977) -32.0% Accounts Payable, Third-Party & Accrued 271,026 269,680 284,656 14,976 5.6% Total Current Liabilities 309,563 307,145 310,144 2,999 1.0% Long Term Debt 225,197 217,508 206,020 (11,488) -5.3% Deferred Inflows 84,739 84,976 85,976 1,000 1.2% Other Post Employment Benefits 281,585 262,097 269,960 7,863 3.0% Self Insurance Liabilities 1,118,010 1,105,107 1,090,898 (14,209) -1.3% Net Position (276,167) (276,268) (307,532) (31,264) -11.3% | Other Assets | 168,370 | 168,189 | 160,550 | (7,639) - <u>4.5</u> % | | | | | |
| Current Liabilities Current Portion of Long Term Debt 38,537 37,465 25,488 (11,977) -32.0% Accounts Payable, Third-Party & Accrued 271,026 269,680 284,656 14,976 5.6% Total Current Liabilities 309,563 307,145 310,144 2,999 1.0% Long Term Debt 225,197 217,508 206,020 (11,488) -5.3% Deferred Inflows 84,739 84,976 85,976 1,000 1.2% Other Post Employment Benefits 281,585 262,097 269,960 7,863 3.0% Self Insurance Liabilities 1,118,010 1,105,107 1,090,898 (14,209) -1.3% Net Position (276,167) (276,268) (307,532) (31,264) -11.3% | Total Assets | 841,843 | 828,839 | 783,366 | <u>(45,473)</u> <u>-5.5%</u> | | | | | |
| Current Portion of Long Term Debt 38,537 37,465 25,488 (11,977) -32.0% Accounts Payable, Third-Party & Accrued 271,026 269,680 284,656 14,976 5.6% Total Current Liabilities 309,563 307,145 310,144 2,999 1.0% Long Term Debt 225,197 217,508 206,020 (11,488) -5.3% Deferred Inflows 84,739 84,976 85,976 1,000 1.2% Other Post Employment Benefits 281,585 262,097 269,960 7,863 3.0% Self Insurance Liabilities 1,118,010 1,105,107 1,090,898 (14,209) -1.3% Net Position (276,167) (276,268) (307,532) (31,264) -11.3% | Liabilities and Net Assets | | | | | | | | | |
| Accounts Payable, Third-Party & Accrued 271,026 269,680 284,656 14,976 5.6% Total Current Liabilities 309,563 307,145 310,144 2,999 1.0% Long Term Debt 225,197 217,508 206,020 (11,488) -5.3% Deferred Inflows 84,739 84,976 85,976 1,000 1.2% Other Post Employment Benefits 281,585 262,097 269,960 7,863 3.0% Self Insurance Liabilities 216,926 233,381 218,798 (14,583) -6.2% Total Liabilities 1,118,010 1,105,107 1,090,898 (14,209) -1.3% Net Position (276,167) (276,268) (307,532) (31,264) -11.3% | Current Liabilities | | | | | | | | | |
| Total Current Liabilities309,563307,145310,1442,9991.0%Long Term Debt225,197217,508206,020(11,488)-5.3%Deferred Inflows84,73984,97685,9761,0001.2%Other Post Employment Benefits281,585262,097269,9607,8633.0%Self Insurance Liabilities216,926233,381218,798(14,583)-6.2%Total Liabilities1,118,0101,105,1071,090,898(14,209)-1.3%Net Position(276,167)(276,268)(307,532)(31,264)-11.3% | Current Portion of Long Term Debt | 38,537 | 37,465 | 25,488 | (11,977) -32.0% | | | | | |
| Long Term Debt 225,197 217,508 206,020 (11,488) -5.3% Deferred Inflows 84,739 84,976 85,976 1,000 1.2% Other Post Employment Benefits 281,585 262,097 269,960 7,863 3.0% Self Insurance Liabilities 216,926 233,381 218,798 (14,583) -6.2% Total Liabilities 1,118,010 1,105,107 1,090,898 (14,209) -1.3% Net Position (276,167) (276,268) (307,532) (31,264) -11.3% | Accounts Payable, Third-Party & Accrued | 271,026 | 269,680 | 284,656 | 14,976 5.6% | | | | | |
| Deferred Inflows 84,739 84,976 85,976 1,000 1.2% Other Post Employment Benefits 281,585 262,097 269,960 7,863 3.0% Self Insurance Liabilities 216,926 233,381 218,798 (14,583) -6.2% Total Liabilities 1,118,010 1,105,107 1,090,898 (14,209) -1.3% Net Position (276,167) (276,268) (307,532) (31,264) -11.3% | Total Current Liabilities | 309,563 | 307,145 | 310,144 | 2,999 1.0% | | | | | |
| Deferred Inflows 84,739 84,976 85,976 1,000 1.2% Other Post Employment Benefits 281,585 262,097 269,960 7,863 3.0% Self Insurance Liabilities 216,926 233,381 218,798 (14,583) -6.2% Total Liabilities 1,118,010 1,105,107 1,090,898 (14,209) -1.3% Net Position (276,167) (276,268) (307,532) (31,264) -11.3% | Long Term Debt | 225,197 | 217,508 | 206,020 | (11,488) -5.3% | | | | | |
| Self Insurance Liabilities 216,926 233,381 218,798 (14,583) -6.2% Total Liabilities 1,118,010 1,105,107 1,090,898 (14,209) -1.3% Net Position (276,167) (276,268) (307,532) (31,264) -11.3% | - | 84,739 | 84,976 | 85,976 | 1,000 1.2% | | | | | |
| Total Liabilities 1,118,010 1,105,107 1,090,898 (14,209) -1.3% Net Position (276,167) (276,268) (307,532) (31,264) -11.3% | Other Post Employment Benefits | 281,585 | 262,097 | 269,960 | 7,863 3.0% | | | | | |
| Net Position (276,167) (276,268) (307,532) (31,264) -11.3% | Self Insurance Liabilities | 216,926 | 233,381 | 218,798 | (14,583) -6.2% | | | | | |
| | Total Liabilities | 1,118,010 | 1,105,107 | 1,090,898 | (14,209) - <u>1.3</u> % | | | | | |
| Total Liabilities and Net Assets \$ 841.843 \$ 828.839 \$ 783.366 \$ (45.473) -5.5% | Net Position | (276,167) | (276,268) | (307,532) | (31,264) - <u>11.3</u> % | | | | | |
| | Total Liabilities and Net Assets | \$ 841,843 | \$ 828,839 | \$ 783,366 | <u>\$ (45,473) -5.5</u> % | | | | | |



The difference between healthcare and true care[™] **E E M E Statements of Cash Flow**

(Thousands)

| | Audited | Projected | Budget |
|--|------------|-----------|-------------|
| | 2023 | 2024 | 2025 |
| Cash Flows From Operating Activities | | | |
| Excess of Revenues Over Expenses | \$ (6,212) | \$ (101) | \$ (31,264) |
| Depreciation & Amortization | 49,812 | 48,209 | 45,603 |
| Provision for Bad Debt | 4,596 | 15,014 | 15,427 |
| (Increase) Decrease in Non-operating revenues | (101,248) | (19,879) | 7,779 |
| (Increase) Decrease in Patient Accounts Receivable, Net | (23,416) | (20,711) | (15,801) |
| (Increase) Decrease in Current and Other Assets | 37,223 | (15,622) | 6,144 |
| Increase (Decrease) in Accounts Payable, Third-Party & Accrued | 268,289 | (1,345) | 14,976 |
| Increase (Decrease) in Deferred In-Flows | (289,185) | 236 | 1,000 |
| Increase (Decrease) in Self Insurance Liabilities | 3,238 | (3,032) | (6,720) |
| Net Cash Provided By (Used In) Operating Activities | (56,903) | 2,769 | 37,144 |
| | | | |
| Cash Flows From Investing Activities | | | |
| Other Investing Activities, Net | (10,215) | 12,347 | 1,662 |
| Net Cash Provided By (Used In) Investing Activities | (10,215) | 12,347 | 1,662 |
| | | | |
| Cash Flows From Financing Activities | | | |
| Additions to Property and Equipment | (12,554) | (8,000) | (8,000) |
| Non-operating grants | 80,229 | 25,480 | - |
| Changes in Long-Term Debt | (23,979) | (20,199) | (34,978) |
| Net Cash Provided By (Used In) Financing Activities | 43,696 | (2,719) | (42,978) |
| | | | |
| Net Increase (Decrease) in Cash and Investments | (23,422) | 12,397 | (4,172) |
| | 1.1.1.1 | 3 | |
| Cash, Beginning | 44,195 | 20,773 | 33,170 |
| | ¢ 20.772 | ¢ 22.470 | ¢ 20.000 |
| Cash, Ending | \$ 20,773 | \$ 33,170 | \$ 28,998 |
| | | | |

The difference between healthcare and true care™ 🗾 🧲 🎆 😭 ecmc.edu

Operating Performance Reconciliation (Thousands)

| | | | Increase / |
|---|--------------------|---------------|-------------|
| | <u>2024 Budget</u> | 2025 Budget | (Decrease) |
| | | | |
| 2024 Budgeted Loss from Operations | | | \$ (35,005) |
| | | | |
| Operating Revenues | | | |
| Net Patient Service Revenue | \$ 645,857 | \$ 719,848 | 73,991 |
| Disproportionate Share, IGT and UPL Revenue | 123,280 | 130,932 | 7,652 |
| Other Operating Revenue | 49,890 | 74,547 | 24,657 |
| Total Operating Revenues | 819,027 | 925,327 | 106,300 |
| | | | |
| Operating Expenses | | | |
| Salaries and Benefits | 446,981 | 503,106 | 56,125 |
| Physician Fees and Professional Services | 199,443 | 204,675 | 5,232 |
| Supplies | 130,625 | 163,047 | 32,422 |
| Other Expenses | 30,136 | 32,381 | 2,245 |
| Depreciation and Amortization | 37,100 | 45,603 | 8,503 |
| Interest | 9,747 | <u>11,513</u> | 1,766 |
| Total Operating Expenses | 854,032 | 960,325 | 106,293 |
| | | | |
| 2025 Budgeted Loss from Operations | \$ (35,005) | \$ (34,998) | \$ (34,998) |
| A STATE OF A | | | |
| | | | |

The difference between healthcare and true care[™] 📕 🧲 🎆 🚅 ecmc.edu

Principal Budget Assumptions

- Volume
- Patient Revenue and Reimbursement
- IGT / UPL Payments
- Other Revenues
- Staffing Costs / Non-Clinical Vacancy Management
- Other Expenses
- Cash Flows

The difference between healthcare and true care™ 🗾 💭 🎆 💴



Volume Summary 2023 2024 2025 Increase (Decrease) Actual Projection Budget <u> 24 - 25</u> <u>%</u> Discharges 282 2.1% Acute 12,579 13,174 13,456 Other 0.3% 5,066 5,234 5,250 16 Total 17,645 298 18,408 18,706 1.6% Average Length of Stay Acute 8.1 7.8 7.5 (0.3)-3.6% Other 11.9 11.0 11.2 0.2 2.0% 8.5 (0.2) -<u>2.4</u>% Total 9.5 8.7 **Observation Cases** 2,884 0.0% 3,303 3,303 (0) **Outpatient Visits** 297,224 300,768 307,976 7,208 2.4% Clinics 4,885 154,566 158,929 163,814 3.1% **Behavioral Health** 36,547 35,564 37,868 2,304 6.5% **Chemical Dependency** 20,592 18,709 19,398 689 3.7% Dialysis 25,109 25,368 25,621 253 1.0% Other 60,410 62,197 61,275 -1.5% (922) Surgical Cases Inpatient 5,407 5,523 666 12.1% 6,189 5.6% Outpatient 7,914 449 8,062 8,511 Total 13,321 13,585 14,700 1,115 8.2% Case Mix Index - Acute 1.81 1.91 1.88 (0.03) -1.7% **Emergency Visits** 54,435 55,013 56,444 1,431 2.6% **CPEP** Visits 9,508 9,810 10,157 347 3.5% Terrace View ADC 364.8 369.0 380.0 11.0 3.0%

The difference between healthcare and true care™ 📕 🧲 🏭 🚅

Revenue

- Net average revenue rate increase of 7% (includes all payers)
 - Larger increase is driven by add-ons for Medicare Wage Index
- Acute IP Discharges of 2.1% increase from 2024 levels
 - Growth in inpatient cases related to improved community skilled nursing facility access, average length of stay reductions, and growth from increased admissions from an increase in emergency department visits and expanded operating room hours increasing surgical procedures
- Outpatient visits increase of 2.4% increase from 2024 levels
 - Increases in specialty clinic visits
- Terrace View average daily census increase of 3% to 380 residents
 - Staffing levels have increased and units reopened to allow for increased census
- IGT Year over year growth based upon estimated net changes in allowable costs net of increases in associated Medicaid revenue
- Revenue cycle process improvements of \$5M included within contract underpayments, denials, bad debt expense reductions and improved coding and documentation

The difference between healthcare and true care™ 🖪 🧲 🎆 🚅 ecmc.edu

DSH/IGT and UPL Revenue (Accrual Basis Revenue)

| | Budget <u>2024</u> | Projected <u>2024</u> | Budget <u>2025</u> |
|-------|-----------------------|--------------------------|-----------------------|
| DSH | \$ 100,351 | \$ 109,804 | \$ 117,437 |
| UPL | 16,000 | 13,495 | 13,495 |
| Total | \$ 116,351 | \$ 123,299 | \$ 130,932 |

The difference between healthcare and true care™ 🗾 🧲 👫 🚰

Expenses

- Salaries
 - Increase in overall FTE's to 3,802 (3,760 @ 8/31/24)
 - NYS minimum staffing reg's, expanded and/or new services (OR hours, mammography), NYS VAP grant funded infrastructure
 - Reduced premium costs (OT and shift bonuses)
 - Contracted salary increases total an average of 3.5%
 - Non-Union wage increases total 3%
 - Implementation of other contracted enhancements (step changes, other shift pay changes)

Benefits

- Increased health insurance costs, workers compensation, unemployment related costs
- \$7M increase in pension expense due to higher FTEs, salaries, actuarial assumptions and ECMCC's increased share of the cost
- \$11M increase in post-retiree health benefit cost as a result of actuarial assumption impact estimates



Expenses (cont'd)

- Physician & Residents
 - Significant physician service contracted fee increases for various service lines
 - University faculty (GME) and resident salary inflation
- Contractual Fees/Purchased Services
 - Continued use of temporary agency nursing personnel with an anticipated reduction from current levels, while maintaining desired staffing
 - Increase in software expense due to inflation along with new tools for improving clinical efficiencies along with related maintenance and support costs
 - Increased costs for specialty pharmacy program operations due to increased volume

The difference between healthcare and true care™ 📕 🧲 🌉 🚅

Expenses (cont'd)

Supplies

- Increase in volume from projected 2024 volume levels including an 8.2% increase in total surgeries
- Inflationary increases in all supply categories, most significant in pharmacy costs partially offset by savings initiatives (physician preference, pricing, joint contracting)
- Increase in specialty pharmacy drug costs due to program expansion
- Supply chain direct cost savings initiatives of \$2.25 million

Depreciation and Interest

- Decreased overall depreciation and interest costs
 - Expense based upon remaining depreciation on existing assets plus new capital anticipated.
 - Reduced non-project capital expenditures during 2020 2024.



Cash Flow Assumptions

- Net change in cash of (\$4.2) million without any 2025 NYS operating grants
 - Days operating cash on hand decreased to 15 days from projected 2024 (excludes designated funds)
- Days in accounts receivable improving to 55 days
- Days in accounts payable holding at 60 days
- Routine capital budget spend consistent with 2023 and 2024 at \$8.0 million
- Line of credit balance paid when expires
- Pension payment increase of \$7 million

The difference between healthcare and true care'' 📕 🥥 🌉 🎇

Performance Improvement Initiatives

- Length of stay improvements
- Revenue cycle improvement initiatives
- Non-clinical vacancy management / premium time reduction
- Value analysis program reducing supply costs
- Reduction in certain purchased services
- Inpatient and outpatient growth strategies
- Continued infrastructure investment in population health strategies
- Insurance plan relationships, increased rates through contracting, MCR wage index, improved governance

The difference between healthcare and true care[™] 📕 🧲 🏭 ecmc.edu

Emerging Issues and Risk Areas

- Timing of future DSH/IGT payments
- Operating performance improvements
 - Market driven length of stay challenges (Post-acute staffing)
 - Recruitment and retention risks
 - FTE vacancy management risks
- Continued inflationary pressures on non-salary operating costs and pharmaceutical shortages
- Federal and NYS operational support uncertainty
- Federal and NYS reimbursement uncertainty
- Inpatient and outpatient volume sensitivity
 - Ambulatory surgery market
- Benefit expense and contribution changes
 - Pension and OPEB
- Technology limitations EHR



2025 Capital Budget Summary

Given stepped recovery, ECMCC must limit routine capital spending funding from internal operations and remain consistent with 2024

• \$8 Million routine capital spend (\$8M in 2024)

\$8M from internal operating funds



3 Year Financial Projections

- Reimbursement rate increases adjusted to historical net rate increases, excluding one-time increases
- IGT/UPL at current projections
- Salary expense consistent with current collective bargaining agreements
- Benefits % of salary expense steady throughout projection period
- Supply and other expense inflation consistent with 2024 and 2025
- Reflects potential cash flow need for additional operational Federal and/or New York State support in addition to management potential future operational improvements



Statements of Revenues and Expenses – Projected (Thousands)

| | Audited 2023 | Projected 2024 | Budget 2025 | 2026 | Projected 2027 | 2028 |
|--|-----------------|--|--|-------------|--|-------------------|
| Operating Revenues | | | | | | |
| Net Patient Service Revenue | \$ 603,720 | \$ 670,943 | \$ 719,848 | \$ 755,354 | \$ 791,457 | \$ 827,978 |
| Disproportionate Share, IGT and UPL Revenue | 107,105 | 123,299 | 130,932 | 130,932 | 130,932 | 130,932 |
| Other Operating Revenue | 46,639 | 60,968 | 74,547 | 75,293 | 76,046 | 76,806 |
| Total Operating Revenues | 757,464 | 855,210 | 925,327 | 961,579 | 998,435 | 1,035,716 |
| Operating Expenses | | | | | | |
| Salaries and Benefits | 460,098 | 459,501 | 503,106 | 548,198 | 574,327 | 601,668 |
| Physician Fees and Professional Services | 192,289 | 189,726 | 204,675 | 208,768 | 212,944 | 217,202 |
| Supplies | 132,197 | 147,840 | 163,047 | 171,376 | 177,799 | 184,332 |
| Other Expenses | 30,529 | 29,913 | 32,381 | 34,020 | 35,742 | 37,552 |
| Depreciation and Amortization | 49,812 | 48,209 | 45,603 | 43,140 | 40,808 | 38,602 |
| Interest | 12,264 | 11,438 | 11,513 | 11,589 | 11,665 | 11,741 |
| Total Operating Expenses | 877,189 | 886,627 | 960,325 | 1,017,091 | 1,053,285 | 1,091,097 |
| | (119,725) | (31,417) | (34,998) | (55,512) | (54,850) | (55,381) |
| Operational Support & Improvements | - | | | 38,012 | 44,850 | 50,381 |
| Income/(Loss) from Operations | (119,725) | (31,417) | (34,998) | (17,500) | (10,000) | (5,000) |
| Grant revenue | 107,230 | 25,480 | - | | - 18 | |
| Income/(Loss) from Operations with Grants | (12,495) | (5,937) | (34,998) | (17,500) | (10,000) | (5,000) |
| Non Operating Revenues & Capital Contributions | 6,283 | 5,836 | 3,734 | 3,734 | 3,734 | 3,734 |
| Excess of Revenues Over Expenses | \$ (6,212) | \$ (101) | \$ (31,264) | \$ (13,766) | \$ (6,266) | \$ (1,266) |
| | | and the second s | CALLER AND | - | and the second s | A DECK PROVIDENCE |



Statements of Financial Position – Projected

(Thousands)

| | Audited 2023 | | Projected 2024 | | Budget 2025 | | 2026 | | Projected 2027 | | 2028 | |
|---|-----------------|-----------|-------------------|-----------|----------------|-----------|------|-----------|-------------------|-----------|------|-----------|
| ASSETS | - | | | | | | | | | | | |
| Current Assets | | | | | | | | | | | | |
| Cash | \$ | 20,773 | \$ | 33,170 | \$ | 28,998 | \$ | 33,237 | \$ | 33,050 | \$ | 39,394 |
| Patient Accounts Receivable | | 102,389 | | 108,086 | | 108,460 | | 113,795 | | 119,240 | | 124,741 |
| Other Current Assets | | 66,654 | | 82,458 | | 83,952 | | 85,021 | _ | 86,602 | | 87,578 |
| Total Current Assets | | 189,816 | | 223,714 | | 221,410 | _ | 232,053 | | 238,892 | | 251,713 |
| Assets Whose Use Is Limited | | 170,619 | | 164,108 | | 166,180 | | 167,317 | | 168,486 | | 170,691 |
| Property and Equipment | | 313,038 | | 272,828 | | 235,226 | | 202,086 | | 186,277 | | 172,675 |
| Other Assets | | 168,370 | | 168,189 | | 160,550 | | 159,261 | | 158,053 | | 156,925 |
| Total Assets | \$ | 841,843 | \$ | 828,839 | \$ | 783,366 | \$ | 760,717 | \$ | 751,708 | \$ | 752,004 |
| LIABILITIES AND NET ASSETS | | | | | | | | | | | | |
| Current Liabilities | | | | | | | | | | | | |
| Current Portion of Long Term Debt | \$ | 38,537 | \$ | 37,465 | \$ | 25,488 | \$ | 22,509 | \$ | 18,902 | \$ | 15,686 |
| Accounts Payable, Third-Party & Accrued | | 271,026 | | 269,680 | | 284,656 | | 287,101 | | 286,258 | | 285,818 |
| Total Current Liabilities | | 309,563 | | 307,145 | | 310,144 | | 309,610 | | 305,160 | | 301,504 |
| | | | | | | | | | | | | |
| Long Term Debt | | 225,197 | | 217,508 | | 206,020 | | 193,511 | | 184,609 | | 178,923 |
| Deferred Inflows | | 84,739 | | 84,976 | | 85,976 | | 86,976 | | 87,976 | | 88,976 |
| Other Post Employment Benefits | | 281,585 | | 262,097 | | 269,960 | | 278,059 | | 286,401 | | 294,993 |
| Self Insurance Reserves | | 216,926 | | 233,381 | | 218,798 | | 213,859 | _ | 215,126 | | 216,438 |
| Total Liabilities | | 1,118,010 | | 1,105,107 | | 1,090,898 | _ | 1,082,015 | | 1,079,272 | ant | 1,080,834 |
| Net Position | | (276,167) | _ | (276,268) | Contra | (307,532) | | (321,298) | | (327,564) | T | (328,830) |
| Total Liabilities and Net Assets | \$ | 841,843 | \$ | 828,839 | \$ | 783,366 | \$ | 760,717 | \$ | 751,708 | \$ | 752,004 |

The difference between healthcare and true care[™] **E S M S** ecmc.edu



Statements of Cash Flow - Projected

(Thousands)

| | Audited | Projected | Budget | | Projected | |
|---|------------|-----------|-------------|-------------|------------|------------|
| | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
| Cash Flows From Operating Activities | | | | | | |
| Excess of Revenues Over Expenses | \$ (6,212) | \$ (101) | \$ (31,264) | \$ (13,766) | \$ (6,266) | \$ (1,266) |
| Depreciation & Amortization | 49,812 | 48,209 | 45,603 | 43,140 | 40,808 | 38,602 |
| Provision for bad debt | 4,596 | 15,014 | 15,427 | 15,747 | 15,784 | 15,821 |
| (Increase) Decrease in Non-operating revenues | (101,248) | (19,879) | 7,779 | 7,855 | 7,931 | 8,008 |
| (Increase) Decrease in Patient Accounts Receivable, Net | (23,416) | (20,711) | (15,801) | (21,082) | (21,229) | (21,322) |
| (Increase) Decrease in Current and Other Assets | 37,223 | (15,622) | 6,144 | 221 | (373) | 151 |
| Increase (Decrease) in Accounts Payable, Third-Pary & Accrued | 268,289 | (1,345) | 14,976 | 2,444 | (842) | (440) |
| Increase (Decrease) in Deferred In Flows | (289,185) | 236 | 1,000 | 1,000 | 1,000 | 1,000 |
| Increase (Decrease) in Self Insurance Liabilities | 3,238 | (3,032) | (6,720) | 3,160 | 9,609 | 9,904 |
| Net Cash Provided By (Used In) Operating Activities | (56,903) | 2,769 | 37,144 | 38,719 | 46,422 | 50,458 |
| Cash Flows From Investing Activities | | | | | | |
| Other Investing Activities, Net | (10,215) | 12,347 | 1,662 | 2,597 | 2,565 | 1,529 |
| Net Cash Provided By (Used In) Investing Activities | (10,215) | 12,347 | 1,662 | 2,597 | 2,565 | 1,529 |
| Cash Flows From Financing Activities | | | | | | |
| Additions to Property and Equipment | (12,554) | (8,000) | (8,000) | (10,000) | (25,000) | (25,000) |
| Non-operating grants | 80,229 | 25,480 | - | - | - | |
| Changes in Long Term Debt | (23,979) | (20,199) | (34,978) | (27,077) | (24,174) | (20,643) |
| Net Cash Provided By (Used In) Financing Activities | 43,696 | (2,719) | (42,978) | (37,077) | (49,174) | (45,643) |
| Net Increase (Decrease) in Cash and Investments | (23,422) | 12,397 | (4,172) | 4,239 | (187) | 6,344 |
| Cash, Beginning | 44,195 | 20,773 | 33,170 | 28,998 | 33,237 | 33,050 |
| Cash, Ending | \$ 20,773 | \$ 33,170 | \$ 28,998 | \$ 33,237 | \$ 33,050 | \$ 39,394 |

Appendix A

Outstanding Bonds and Notes

Erie County Guaranteed Senior Revenue Bonds, Series 2004

No bonds were issued, called, or re-financed during 2024. \$4,390,000 of bonds matured or were redeemed in 2024. \$52,580,000 of 2004 bonds remain outstanding on December 31, 2024.

Erie County Loan Payable-2017 (Refinance)

During 2017, the Corporation refinanced its 2011 Loan with a \$74,366,859 loan from the County of Erie. \$4,271,358 in principal payments were made in 2024.

\$44,805,489 of debt is outstanding on December 31, 2024.

Erie County Loan Payable-2017 (New Money)

During 2017, the Corporation entered into a \$99,492,034 loan with the County of Erie. \$2,848,667 in principal payments were made in 2024. \$84,525,603 of debt is outstanding on December 31, 2024.

Erie County Capitalized Interest Assumption Obligation-2017

During 2017, the Corporation entered into an \$8,281,141 capitalized interest assumption obligation with the County of Erie. \$237,106 in principal payments were made in 2024. \$7,035,423 of debt is outstanding on December 31, 2024.

Line of Credit

During 2021, the Corporation signed an agreement for an unsecured revolving line of credit. \$0 in principal payments were made in 2024.

\$10,000,000 of outstanding borrowings against the line of credit on December 31, 2024.

Metz Culinary Management Food Service Improvements Loan

During 2019, the Corporation entered into a \$1,805,430 loan with Metz Culinary Management. \$180,543 in principal payments were made in 2024.

\$767,307 of debt is outstanding on December 31, 2024.

During 2021, the Corporation entered into a \$1,552,000 loan with Metz Culinary Management.

\$200,258 in principal payments were made in 2024.

\$801,032 of debt is outstanding on December 31, 2024.

During 2024, the Corporation entered into a \$1,738,997 loan with Metz Culinary Management.

\$126,472 in principal payments were made in 2024.

\$1,612,524 of debt is outstanding on December 31, 2024.

| Name | Job Title | 2024 Gross Earnings | Annual Salary |
|---------------------------|--|---------------------|---------------|
| Abafita, Aziza | General Duty Nurse | 122,773 | 109,725 |
| Addison, Jessica M O | Charge Nurse | 195,298 | 118,866 |
| Adgate, Jamie | Nursing Team Leader LTC | 115,258 | 101,795 |
| Aiad, Jean V | Dentist ECMC | 120,894 | 120,894 |
| Albanese, Pamela J | Identity & Access Accounts Control Coordinator | 104,182 | 104,036 |
| Albert, Alison M. S. | Director of Admissions Medical Rehabilit | 137,261 | 128,835 |
| Aldrich, Alana | Pharmacist | 149,464 | 149,464 |
| Almadrahi, Abdelkadr Q | General Duty Nurse | 110,724 | 103,424 |
| Almeter, Katherine A | Charge Nurse | 131,371 | 112,025 |
| Alwan, Nadare | Nurse Practitioner Rehabilitation Services | 94,003 | 135,434 |
| Alyasiri, Sarah | General Duty Nurse | 116,172 | 116,172 |
| Ambrose, Keith | Director of Capital Projects | 117,098 | 117,229 |
| Amendola, Amy M | General Duty Nurse | 117,383 | 109,725 |
| Anders, Mark J | Medical Specialist | 182,331 | 264,000 |
| Anderson, Jennifer A | Charge Nurse | 145,664 | 118,866 |
| Andrews, Kristin M | Assistant Head Nurse | 130,990 | 118,867 |
| Aquilina, Marina G | General Duty Nurse | 123,264 | 100,418 |
| Armstrong, Dawn G | RN Med Surg Data Review | 100,773 | 102,526 |
| Artieri, Diane | Vice President of Materials Management | 190,449 | 185,658 |
| Atkinson, Maria | Senior Financial Analyst | 100,674 | 100,786 |
| Augostini, Anna M | Pharmacist | 153,903 | 143,437 |
| Austin, Cheryl A | Director of Imaging Services | 144,269 | 145,396 |
| Aziz, George Mina | Pharmacist | 5,395 | 140,270 |
| Baetzhold-Fabiniak, Karen | Physician Assistant | 117,246 | 150,012 |
| Bagley, Emily C | Nursing Team Leader | 179,902 | 107,253 |
| Bailen, Matthew W | Assistant Vice President of Nursing Education | 147,378 | 148,000 |
| Bailey, Steven E | Nursing Supervisor LTC | 117,974 | 117,974 |
| Baker, Aimee L | General Duty Nurse | 107,972 | 109,725 |
| Baker, Shawn D | General Duty Nurse | 160,330 | 109,724 |
| Balk, Andrew K | Healthcare Information Security Analyst II | 114,668 | 106,340 |
| Ballard, Katrina L | Nurse Case Manager - Behavioral Health | 142,247 | 132,707 |
| Bandoh, Anthony K | HCInfoSecurityMgr | 133,286 | 125,804 |
| Barnett, Lee R | General Duty Nurse | 164,352 | 103,423 |
| Barr-Buday, Tamara L | Clinical Documentation Specialist | 134,674 | 108,771 |
| Barry, Jennifer L | PROGRAM DIRECTOR-BEHAVIORAL HEALTH | 111,629 | 108,150 |
| Basher, William R | Nursing Team Leader Dialysis Services | 125,110 | 124,344 |
| Bass, Cynthia R | Director of Diversity and Inclusion | 142,689 | 137,917 |
| Bass, Edmond G | Nursing Informatics Manager | 143,092 | 143,411 |
| Bastian, Michele L | General Duty Nurse | 120,687 | 109,724 |
| Batson, John B | General Duty Nurse | 105,081 | 103,424 |
| Bauer, Christine H | Charge Nurse | 25,191 | 101,290 |
| Beauchamp, Emily | Assistant Director of Population Health | 91,599 | 114,572 |
| Beaver, Michael J | Pharmacist | 141,631 | 140,270 |
| Becker, Cynthia A | General Duty Nurse | 108,544 | 106,530 |
| Becker, Melissa A | Unit Manager Operating Room | 161,204 | 138,058 |
| Becker, Paula K | Pharmacist | 152,729 | 152,893 |
| Beiter, Sean P | Director of Labor & Employee Relations | 153,659 | 153,832 |
| Bell, Shentelle D | Director of Nursing Services Ambulatory | 137,565 | 132,613 |
| Bellagamba, Sharon A | General Duty Nurse | 105,096 | 100,417 |
| Bellido-Clark, Dana C | Unit Manager MedicalSurgical | 96,653 | 136,386 |
| Bennett, Murnita A | General Duty Nurse | 109,110 | 109,725 |

| Benning, Natasha E | Clinical Documentation Specialist | 138,027 | 108,771 |
|--|--|---------|---------|
| Benson, Amanda R | General Duty Nurse | 131,987 | 108,771 |
| Bentley, Katherine L | General Duty Nurse | 120,899 | 103,424 |
| Bermingham, Morgan | Pharmacist | 143,345 | 140,270 |
| Bernier, Deborah A | Operations Manager LTC | 126,559 | 140,270 |
| Beshures, Shreen M | Clinical Pharmacy Specialist | 112,012 | 112,002 |
| Bethea, Marquita E | Director of Admissions LTC | 143,709 | 112,012 |
| Bianco, Carolyn A | General Duty Nurse | | |
| Bieber, Jolene | General Duty Nurse | 103,227 | 103,424 |
| | Supervisor of Rehabilitation Medicine | 114,555 | 100,418 |
| Bieber, Stephanie E Bielicki, Kim M | General Duty Nurse | 107,275 | 108,563 |
| | · · · · · · · · · · · · · · · · · · · | 122,975 | 109,725 |
| Bielmann, Beth A | Nursing Team Leader Ambulatory Services | 117,134 | 128,076 |
| Biersbach, Bret | Anesthesiologist | 547,846 | 484,500 |
| Birmingham, Marissa A | General Duty Nurse | 77,967 | 100,417 |
| Bittner, Michelle C | Charge Nurse | 123,157 | 118,866 |
| Blackchief, Tawny L | General Duty Nurse | 113,263 | 100,418 |
| Blair, Lawrence V | Behavioral Health Clinical Manager | 145,647 | 130,543 |
| Blair, Lindsey N | General Duty Nurse | 121,710 | 109,725 |
| Blair, Sean M | Nurse Case Manager | 148,828 | 136,675 |
| Blaszak, Linette R | Clinical Resource Nurse Emerg Services | 152,434 | 118,866 |
| Blecha, Kortney L | Charge Nurse | 235,142 | 118,866 |
| Bobeck, Mabel C V | Charge Nurse | 111,473 | 105,595 |
| Bogardus, Elizabeth P | Nursing Supervisor LTC | 128,977 | 117,889 |
| Boice, Allison R | Nurse Case Manager | 134,398 | 136,674 |
| Bolden, Taywanda T | Behavioral Health Clinical Manager | 144,757 | 130,543 |
| Bonito, Nicole K | Anesthetist | 186,658 | 244,283 |
| Borton, Angela R | Pharmacist | 144,257 | 143,437 |
| Boyer, Maria A | General Duty Nurse | 164,331 | 103,423 |
| Boyer, Nikita A | General Duty Nurse LTC | 136,357 | 100,417 |
| Brady, Holly D | Manager of Revenue Capture and Integrity | 83,922 | 104,036 |
| Brennan, Melinda M | Unit Manager MedicalSurgical | 137,437 | 134,031 |
| Brennan, Stephanie | Pharmacist | 150,768 | 146,583 |
| Brian, Stephanie R | Pharmacist | 142,409 | 140,270 |
| Brindisi, Joseph V | Nurse Practitioner ECMC | 146,338 | 148,000 |
| Brinker, Debra L | Charge Nurse | 143,146 | 118,865 |
| Brinkworth, Jennifer L | Charge Nurse | 171,270 | 118,866 |
| Brittain, Leah | Nursing Team Leader | 108,834 | 110,498 |
| Broeneman, Kourtney A | Nurse Case Manager | 141,705 | 140,774 |
| Brooks, Latoya A | Unit Manager MedicalSurgical | 146,758 | 146,447 |
| Brown, Alesha J | Charge Nurse | 152,802 | 105,595 |
| Brown, Dana A | Anesthetist | 310,597 | 244,284 |
| Brown, Donna M | Associate Hospital Administrator | 144,473 | 141,903 |
| Brown, Huba | General Duty Nurse | 123,515 | 123,515 |
| Brown, Jillian S W | Vice President of Behavioral Health Services | 179,714 | 168,810 |
| Brown, Lisa K | Admissions Coordinator LTC | 111,000 | 102,526 |
| Brundin, Douglas A | Anesthetist | 258,158 | 244,283 |
| Brunner, Stephanie A | Transplant Coordinator | 168,294 | 125,073 |
| Bryant, Monica M | Nursing Team Leader | 47,865 | 109,174 |
| Buckley, Peter P | Nursing Team Leader LTC | 120,981 | 113,813 |
| Bufalino, Rosalia | General Duty Nurse | 127,016 | 109,725 |
| Bulger, Bethany J | General Duty Nurse | 87,337 | 103,423 |
| Bulinski, Alexis M | Charge Nurse | 143,945 | 103,423 |
| Burgio, Susan M | Clinical Lab Quality Coord | 145,507 | 120,598 |
| Burke, Brandy R | Charge Nurse | 117,388 | 112,024 |

| Burke, Caitlyn E | Nursing Inservice Instructor ECMC | 105,201 | 107,253 |
|--------------------------------------|---|---------|--------------------|
| Burke, Mark S | Attending Physician | 784,785 | 759,143 |
| Burnett, Wayne T | Senior Physical Therapist | 109,060 | 106,184 |
| Burridge, Suzanne L | Pharmacist | 128,089 | |
| Burt, Mary M | | 128,089 | 128,089 128,076 |
| Calicutt, Steven | Nursing Team Leader Chief Healthcare Information Security Of | 219,145 | 219,391 |
| Calire, Gina F | Clinical Documentation Specialist | 139,079 | 112,024 |
| Canallatos, Paul | Dentist ECMC | | |
| | | 266,198 | 315,000 |
| Cantie, Shawn M Capaccio, Rose M | Anesthesiologist Chief Histotechnologist | 553,201 | 514,080 |
| Capozzi, Nicole K | General Duty Nurse | 114,069 | 100,441 |
| | · · | 131,203 | 109,725 |
| Carl, Karen A Carnevale, Marinela | Nursing Team Leader | 132,071 | 128,076 |
| | Emergency Department Patient Flow Team Lead | 148,041 | 124,344 |
| Carpenter, Cheryl A | Director of Medical Dental Staff Svcs | 126,128 | 126,269 |
| Carroll, Jennifer L | Behavioral Health Clinical Manager | 140,853 | 136,219 |
| Casali, Colleen M | General Duty Nurse | 130,589 | 109,724 |
| Castonguay, Andrea | Physician Assistant | 124,616 | 125,000 |
| Cavo, Paul G | Clinical Systems Analyst | 128,252 | 108,662 |
| Cecula, Jessica A | Emergency Department Patient Flow Team Lead | 118,578 | 113,813 |
| Celej, Daniel E | General Duty Nurse | 110,312 | 100,417 |
| Chaudhuri, Biswendu | Senior Clinical Laboratory Technologist | 103,262 | 101,260 |
| Cheng, Yi Shun Felix | Attending Physician | 319,933 | 357,999 |
| Chestnut, Essence N | General Duty Nurse | 104,825 | 104,825 |
| Chikaraishi, Juli | Director of Outpatient Opers & Oncolog | 128,209 | 123,594 |
| Chilbert, Kevin | Clinical Pharmacy Specialist | 157,683 | 155,736 |
| Chiro, Zachary | Charge Nurse | 117,914 | 105,595 |
| Chrzanowski, Kristy L | General Duty Nurse | 94,727 | 103,423 |
| Ciancone, Gabriella | Infection Prevention Practioner | 129,051 | 128,075 |
| Cicchinelli, Salvadore | Project Manager HIT | 109,550 | 105,607 |
| Cieri, Margaret M | Nursing Care Coordinator | 226,786 | 152,121 |
| Cirillo, Joseph B | Director of Public Relations Communic. | 151,110 | 143,068 |
| Ciurczak, Tiffany A | Emergency Department Patient Flow Team Lead | 149,109 | 128,076 |
| Clark, Cynthia L | Nurse Case Manager | 148,488 | 140,774 |
| Cleckley, Shonda S | General Duty Nurse | 219,610 | 109,724 |
| Cloud, Samuel | Medical Director ECMC | 565,866 | 566,501 |
| Codd, Margaret A | Charge Nurse | 139,877 | 115,405 |
| Colebeck, Amanda C | Dentist ECMC | 318,648 | 322,514 |
| Colling, Laurali E | General Duty Nurse | 118,187 | 100,418 |
| Comstock, Scott | Charge Nurse | 162,024 | 118,866 |
| Coniglio, Julia G | Anesthetist | 261,666 | 244,284 |
| Conley, Meghan E | Charge Nurse | 122,726 | 112,024 |
| Connors, Marchelle P | Charge Nurse Ambulatory Care | 117,517 | 118,866 |
| Contino, Alyse M | Charge Nurse | 83,305 | 108,771 |
| Costanzo, Debra L | Nursing Staffing Office Specialist | 128,973 | 128,973 |
| Cox-Wu, Chaundra Mie | Pharmacist | 82,763 | 140,270 |
| Cozzemera, John D | Nursing Team Leader Ambulatory Services | 114,757 | 124,345 |
| Cretacci, Nicole A | Unit Manager MedicalSurgical | 148,856 | 146,446 |
| Cross, Kelly C | General Duty Nurse | 124,646 | 100,418 |
| Culligan, Tanya L | Clinical Documentation Specialist | 156,881 | 118,867 |
| Cumbo, John Nicholas | Vice President of Information Technology | 253,119 | 244,007 |
| Cureton, Keari M | General Duty Nurse | 133,164 | 133,164 |
| Currin, Shawntres M | Unit Manager MedicalSurgical | 143,618 | 138,058 |
| Curtin, Daniel P | Manager of Financial Reporting | 104,550 | 100,786 |
| Cutler, Peter K | Vice President of Communications & External Affairs | 289,734 | 275,834 |

| Cutting, Karen E | Healthcare Business Sys Analyst | 110.010 | 100 240 |
|--------------------------------------|---|--------------------|--------------------|
| Czerwinski-Brown, Lynn M | General Duty Nurse | 110,016 107,036 | 106,340 107,036 |
| Dalton, Wendy C | Nursing Team Leader LTC | 127,931 | 107,030 |
| D'Angelo, Dino M | Charge Nurse | 127,523 | 117,234 |
| Daniels, Judy A | OfficeManagerPEDSPD | 107,923 | 113,403 |
| Daniels, Steven | Sr. Human Resources Info System Admin | 132,062 | 107,923 |
| Daniels, Victoria R | General Duty Nurse | 105,141 | 127,309 |
| | Charge Nurse | | |
| Dantzler, Tamika Davis, Andrew L | Chief Operating Officer ECMC | 140,109 | 108,772 |
| | | 702,788 | 677,490 |
| Davis, Cassandra A Davis, Karen A | Senior Vice President of Operations-Outpatient Clinic | 317,247 | 302,357 |
| | Charge Nurse | 101,819 | 110,699 |
| Dean, Rachel M | Charge Nurse Assistant Head Nurse | 114,796 | 108,771 |
| DeFilippo, Jenna B | | 151,804 | 115,405 |
| Degnan, Kimberly A | General Duty Nurse | 121,491 | 100,418 |
| Deguire, Janelle C | Assistant Nurse Case Manager | 109,561 | 112,024 |
| DelGuidice, Natalie | Clinical Pharmacy Specialist | 160,230 | 159,201 |
| DelPrince, Becky S | Vice President of Systems and Integrated Care | 204,971 | 199,722 |
| DelVecchio, Regina A | Staff Counsel ECMC | 207,180 | 199,722 |
| Denga, Sherri | General Duty Nurse | 113,386 | 100,418 |
| DeNisco, Lona J | General Duty Nurse | 109,027 | 109,027 |
| DePlato, Anthony J | Anesthesiologist | 602,659 | 564,408 |
| D'Errico, Heather L | Senior Speech Pathologist | 117,714 | 101,317 |
| DeSantis-Evans, Leigh Ann | General Duty Nurse | 114,258 | 109,724 |
| Dettman, Brittany | Nursing Supervisor LTC | 125,579 | 114,439 |
| DeYoung, Candice M | Nursing Team Leader | 118,542 | 128,076 |
| Diaw, Vanessa R | General Duty Nurse | 145,644 | 106,530 |
| Diaz, Alec | Anesthetist | 119,221 | 226,410 |
| Diez, Tyler | Senior Director Outpatient Operations | 131,698 | 126,690 |
| Diina, David J | Nurse Practitioner Transplant | 274,866 | 166,561 |
| Dillabough, Andrew D | Point of Care Clinical Laboratory Coord | 117,121 | 116,132 |
| Dimitroff, Breanna Katelyn | Nurse Recruiter | 100,557 | 109,395 |
| DiOrio, Leigh-Anne Brittany | Nurse Practitioner Transplant | 174,806 | 132,357 |
| Dishunts, Olga | Clinical Informatics Educator | 130,911 | 106,340 |
| Dobson, Judy L | Vice President Medical Surgical Nursing Services | 151,966 | 193,799 |
| Dolansky, Evan P | Pharmacist | 157,386 | 152,892 |
| Dombrowski, Jennifer B | Senior Occupational Therapist | 107,194 | 104,697 |
| Donaldson, Jessie | Physician Assistant | 28,000 | 145,600 |
| Donegan, Shawn M | Charge Nurse | 101,991 | 108,771 |
| Donovan, Kevin J | General Duty Nurse | 104,179 | 106,530 |
| Dove, Theresa M | General Duty Nurse | 104,291 | 109,724 |
| Dowdell, Anne B | General Duty Nurse | 88,507 | 105,250 |
| Draper, Cristina M | General Duty Nurse | 122,552 | 109,724 |
| Draves, Bailee | Clinical Resource Nurse | 109,205 | 102,526 |
| Drysdale, Michelle G | InService Education Coordinator | 181,124 | 132,707 |
| Duell, Susan S | Minimum Data Set Director | 137,379 | 128,835 |
| Duffin, Joy R | Transplant Coordinator | 208,036 | 140,774 |
| Duman, Eileen A | Administrative Director of Laboratory Se | 164,676 | 161,257 |
| Dunn, Bethany | Physician Assistant | 105,303 | 135,000 |
| Dunn, Natalie M | General Duty Nurse | 109,070 | 103,424 |
| Durant, Jason M | Systems Administrator | 141,150 | 114,572 |
| Dvinova, Larisa M | Charge Nurse LTC | 157,070 | 114,572 |
| Dwyer, Lisa Y | General Duty Nurse | 117,682 | 118,807 |
| | | 117,002 | |
| Dyson, Alicia M | General Duty Nurse | 22,531 | 109,720 |

| Eck, Brooke | Director of Respiratory Therapy Services | 126,308 | 124,493 |
|----------------------------|---|--------------------|--------------------|
| Eckert, Patricia L | Senior Ultrasonographer | 136,040 | 102,258 |
| Egan, Carol L | Nursing Team Leader LTC | 137,723 | 128,076 |
| Eleey, Lynnette J | Charge Nurse | 125,991 | 118,866 |
| Erhardt, Laurie E | Minimum Data Set Specialist | 121,738 | 120,760 |
| Erhardt, Robert M | Chief Hospital Public Safety Officer | 168,283 | 127,481 |
| Ervolina, Daryl M | Senior Pharmacist ECMC | 179,462 | 169,659 |
| Estes, Ashley | Nursing Care Coordinator | 91,964 | 131,219 |
| Ettipio, Marie L | General Duty Nurse | 126,255 | 106,530 |
| Eustace, Amy B | General Duty Nurse | 130,417 | 100,530 |
| Evans, Michele L | Nursing Team Leader LTC | 141,226 | 128,076 |
| Everette, Rayonia | Licensed Practical Nurse LTC | 125,401 | 125,401 |
| Everette, Shawndre | Licensed Practical Nurse LTC | 124,785 | 124,785 |
| Exposito Vazquez, Manuel O | Certified Nursing Assistant | 198,029 | 198,029 |
| Falck, Eldora E | General Duty Nurse | 142,150 | 100,417 |
| Falco, Mark H | Attending Physician | 538,840 | 509,231 |
| Fanning, Rozalyn N | Nursing Team Leader | 137,015 | 120,759 |
| Farkas, Tina L | General Duty Nurse | 115,837 | 120,739 |
| Farr, Kelsey M | General Duty Nurse | 119,059 | 100,418 |
| Farrell, Amanda L | Clinical Nurse Specialist-Population Health | 136,663 | 157,015 |
| Farrell, Michael Edward | Attending Physician | 318,942 | 400,000 |
| Fenner, Nicholas J | Pharmacist | 151,016 | 143,437 |
| Ferguson, Richard E | Director of Neurology | 378,638 | 378,638 |
| Fetzer, Melanie C | General Duty Nurse | 107,782 | 106,530 |
| Fezer, Stephen J | Anesthetist | 252,996 | 244,283 |
| Fiden, Donna | General Duty Nurse | 124,210 | 109,724 |
| Firestone, Lisa A | Nurse Case Manager - Ambulatory Services | 130,026 | 132,706 |
| Flaherty, Amy A | Staff Counsel - Risk Management | | |
| Fleming, Laura A | Privacy Officer | 168,621 | 168,810 |
| Fletcher, Lynn J | Nursing Care Coordinator | 115,797 149,993 | 112,323 139,230 |
| Flett, Deborah A | Nursing Team Leader LTC | 132,964 | 139,230 |
| Flett, Kayleigh | Nursing Team Leader | 88,687 | 128,078 |
| Flynn, William J | Director of Surgery | 318,984 | 318,984 |
| Foster, Antoinette R | Charge Nurse | 150,445 | 102,525 |
| Fowler, Julia R | Nursing Care Coordinator | 165,378 | 102,525 |
| Fox, Heather M | Nurse Case Manager - Ambulatory Services | 141,632 | |
| Frey, Jordan | Attending Physician | 689,178 | 140,775 650,000 |
| Frustino, Jennifer L | Dentist ECMC | 269,082 | 273,368 |
| Furan, Amanda M | General Duty Nurse | 98,546 | 100,417 |
| Furlani, Lisa A | Anesthetist | 106,024 | 106,024 |
| Furnari, Graziella | Clinical Pharmacy Specialist | 155,602 | 155,735 |
| Gallagher, Heather A | Senior Director Of Compensation Benefits HRIS | 151,506 | 148,951 |
| Galley, Sarah T | Charge Nurse | 119,591 | 148,931 |
| Gallineau, Anne-Marie | Nursing Care Coordinator | | 152,121 |
| Galuski, Tabatha A | - | 167,193 124,154 | |
| , | General Duty Nurse | | 124,154 |
| Gambino, Lorraine M | General Duty Nurse | 108,219 | 103,424 |
| Gan, Dalong Gant Bamona | Anesthetist Director of Nursing Services LTC | 245,633 | 226,410 |
| Gant, Ramona | | 136,346 | 157,074 |
| Gardy-Batson, Marcell K | Assistant Director of Nursing LTC | 139,566 | 140,000 |
| Garfoot, John B | Anesthesiologist | 417,776 | 422,999 |
| Garvey, Benjamin J | RN Renal/Hemo Data Reviewer | 105,975 | 108,771 |
| George, Kristin A | Charge Nurse Ambulatory Care | 107,576 | 108,771 |
| Gerretsen, Carly A | Nurse Practitioner ECMC | 110,560 | 143,684 |
| Gian, Kathleen M | General Duty Nurse | 171,248 | 109,724 |

| Gibson, Breona | Licensed Practical Nurse LTC | 110,882 | 110,882 |
|---|---|--------------------|---------|
| Giglia, Joseph T | General Counsel | 545,289 | 545,901 |
| Gill, Elise R | Physician Assistant | 129,716 | 125,000 |
| Gillon-Harper, Alicia R | Nursing Supervisor LTC | 4,618 | 114,439 |
| Ginter, Jennifer | General Duty Nurse | 120,866 | 114,433 |
| Gloss, Margaret E | Technical Dir Echocardiography | 85,168 | 106,340 |
| Golombek, Kelly L | General Duty Nurse | 109,237 | 100,340 |
| Golubski, Adam D | Charge Nurse | 106,815 | 105,595 |
| Gomez, Melissa | Director of Clin. Coding Record Qual Mg | 100,813 | 103,393 |
| Gompah, Santosha M | Unit Manager MedicalSurgical | 170,992 | 107,331 |
| Gonzalez, Susan M | Executive Director ECMC Lifeline Foundation | 236,421 | 206,931 |
| Gorczynski, Thomas S | Director of Information Technology | 165,612 | 159,650 |
| Gorski, Amanda L | General Duty Nurse | 111,544 | 111,544 |
| Gozdalski, Nicole M | Charge Nurse | | 111,344 |
| Grabski, Meghan L | Charge Nurse | 141,932 259,732 | 118,800 |
| Grantham, Ayanna L | Assistant Director of Nursing LTC | 139,566 | 140,000 |
| Green, Kimberly R | Nursing Team Leader | 103,946 | 140,000 |
| Greenaway, Wanda R | Nurse Practitioner Surgical Services | 174,444 | |
| | Director of CPEP | | 157,014 |
| Greene Clark, Maria E | | 30,047 | 128,749 |
| Gregorio, Tara A | Unit Manager MedicalSurgical Anesthetist | 147,960 | 142,183 |
| Grolemund, Stephanie A | | 263,877 | 244,284 |
| Grzebinski, Jane F | Pharmacist | 163,545 | 156,120 |
| Grzybowski, Helen T | InService Education Coordinator | 145,801 | 135,035 |
| Guerinot, Chris C | Director of Community Based Strategies and Practice | 90,734 | 147,443 |
| Guerinot, Ryan | Director of Development & Marketing ECMC | 40,385 | 105,001 |
| Gulczewski, Michelle L | General Duty Nurse | 111,398 | 109,725 |
| Habonimana, Colette | Charge Nurse | 147,937 | 118,866 |
| Haefner, Lori J | Charge Nurse | 132,484 | 118,866 |
| Haefner, Paula | Project Manager HIT | 111,223 | 111,348 |
| Haines, Tracey M | Charge Nurse | 153,569 | 112,025 |
| Halladay, Nicholas B | Charge Nurse | 125,510 | 112,024 |
| Halloran, Ashley Hamilton, Catherine M | Vice President of Pharmacy Operations Director of Patient Financial Services | 201,344 | 201,570 |
| | | 131,862 | 132,010 |
| Hamilton, Holly R | Pharmacist | 7,567 | 139,258 |
| Handley, Sarah E | Pharmacist | 143,914 | 143,437 |
| Hanlon, Barbara L | Nursing Team Leader | 136,309 | 128,076 |
| Hanna, Jennifer D | Charge Nurse | 140,591 | 112,024 |
| Harhara, Ameen | Nursing Care Coordinator | 144,941 | 123,693 |
| Harris, Rachel | Nurse Practitioner Plastic Recon Surger | 145,316 | 148,000 |
| Hartman, Nancy L | RN Trauma Registrar | 130,012 | 128,076 |
| Hartman, Sandra A | Nursing Supervisor LTC | 51,450 | 135,036 |
| Hartmann, Erica L | Dentist ECMC | 185,243 | 209,999 |
| Haseley, Nicole M | Nurse Practitioner Transplant | 239,886 | 161,710 |
| Hathaway, Amy E | Senior Occupational Therapist | 103,643 | 103,230 |
| Hatten, Khadija A | Nursing Care Coordinator | 106,138 | 139,230 |
| Hauss, Lisa Marie | Nurse Case Manager | 138,581 | 140,774 |
| Havers, Amy M | Charge Nurse | 129,792 | 112,025 |
| Hayden, Katelyn A | Nursing Team Leader LTC | 88,728 | 104,146 |
| Hayes, Ellyn I | General Duty Nurse | 132,711 | 132,711 |
| Hayes, Renee M | Charge Nurse | 226,354 | 112,024 |
| Healy, Jaclyn | Pharmacist | 146,348 | 140,271 |
| Henry, Bridgett L | General Duty Nurse | 103,471 | 100,418 |
| Herdman, Jennifer L | General Duty Nurse | 123,186 | 109,724 |
| Herr, Alexandra C | Staff Counsel ECMC | 127,166 | 127,309 |

| Hess, Corian | Pharmacist | 47,541 | 140,270 |
|--|---|--------------------|---------|
| Hidalgo, Francisco | Code Compliance Manager | 131,805 | 130,114 |
| Hierl, Michele R | Charge Nurse | 136,950 | 112,024 |
| Highway, Lisa K | Director of Recruitment and Retention | 132,062 | 127,309 |
| Hinckley, Debbra R | General Duty Nurse | 121,978 | 109,724 |
| Hinderliter, Vanessa S | Vice President of Finance ECMC | 207,270 | 201,570 |
| Hines, Holly L | Nurse Case Manager | 140,748 | 140,774 |
| Hodan, Patricia A | Infection Prevention Practioner | 128,943 | 140,774 |
| Hodgson, Matthew W | Nurse Practitioner Plastic Recon Surger | 161,122 | 161,709 |
| Hoeglmeier, Leandra M | General Duty Nurse | 106,735 | 101,705 |
| Hoerner, Audrey A | Senior Nurse Practitioner - Burn Unit | 189,825 | 186,476 |
| Holcomb, Steven | General Duty Nurse | 103,433 | 100,417 |
| Honkomp, Cheryl L | Assistant Head Nurse | 128,820 | 118,867 |
| Hoppe, Erin C | Behavioral Health Supervisor | 120,320 | 110,168 |
| Horesh, Fayelyn J | Anesthetist | 180,902 | 180,902 |
| Horne, Shawndre L | Senior Clinical Laboratory Technologist | 116,465 | 103,173 |
| Horton, Melissa E | General Duty Nurse | 112,447 | 103,173 |
| Hovak, Melissa M | Nurse Practitioner Transplant | 257,974 | 166,560 |
| Hudson, Jeremiah B | General Duty Nurse | 118,657 | 100,300 |
| Hughes, Christopher J | Attending Physician | 297,554 | 456,001 |
| Hulme, Christine M | General Duty Nurse | | - |
| | Clinical Patient Care Liaison | 105,528 150,125 | 106,530 |
| Hunley, Kizzie Hunt, Benjamin J | | | 147,690 |
| | Nursing Inservice Instructor Psych | 126,513 | 124,344 |
| Hunter, Renee M | Charge Nurse | 140,329 | 108,771 |
| Hunter, Thameena Z | Director of System Health and Safety | 141,307 | 140,998 |
| Hutchings, Michelle A | Nurse Case Manager | 136,878 | 140,774 |
| Hyman, Daniel J Iheke, Patience O | Assistant VP of Operations General Duty Nurse | 129,875 | 130,000 |
| · · · · · · · · · · · · · · · · · · · | · · · · · · · · · · · · · · · · · · · | 106,870 | 100,417 |
| Isch, Pamela Jack, Dennis M | Assistant Director Ambulatory Services | 114,630 | 114,572 |
| Jack, Jennifer A | Nurse Practitioner Transplant | 236,687 | 139,510 |
| Jack, Jennier A Jackson, Seanessa R | Charge Nurse | 148,890 | 115,405 |
| Jacob, Avneet | Nurse Case Manager Nursing Team Leader | 143,704 | 140,774 |
| | Licensed Practical Nurse LTC | 126,788 | 113,813 |
| James, Ivory M | | 106,163 | 106,163 |
| Jamison, Shannon M | Charge Nurse | 140,453 | 118,865 |
| Janczyk, Daryl M | Nursing Inservice Instructor Psych | 112,225 | 112,225 |
| Janetzke, David L | Charge Nurse | 127,473 | 108,772 |
| Jaworski, Crystal L Jellinick, Lori L | Charge Nurse | 126,470 | 102,525 |
| | Director of Rehabilation Services | 134,597 | 143,068 |
| Jenney, Kevin C | Supervisor of Rehabilitation Medicine | 31,800 | 113,799 |
| Jensen, Erik J | Anesthesiologist | 588,907 | 527,153 |
| Jerzewski, Stephanie R | Clinical Systems Analyst | 123,920 | 104,036 |
| Jimerson, Mary L | Unit Manager Ambulatory Care | 139,552 | 134,031 |
| Jocoy, Angela A | Rehab Services Quality Coordinator-ECMCC | 109,644 | 106,184 |
| Johnson, Desiree A | Charge Nurse | 132,977 | 105,595 |
| Johnson, Marie A | Vice President of Rehab Services | 174,286 | 174,481 |
| Johnson, Maureen B | Charge Nurse | 167,577 | 118,866 |
| Jones, Donna | Chief Quality of Care Officer and Operations Administ | 284,012 | 275,834 |
| Jones, Veronica L | Charge Nurse | 149,478 | 118,865 |
| Jonmaire, Kenneth F | Senior Director Outpatient Operations | 144,647 | 135,970 |
| Jordan, Laondrea L | General Duty Nurse | 132,046 | 100,418 |
| Julyan, Erika A | Senior Occupational Therapist | 111,451 | 104,697 |
| Juncewicz, Edmund | Anesthesiologist | 528,862 | 484,500 |
| Kabayiza, Thamar U | General Duty Nurse | 124,859 | 109,724 |

| Kaid, Rafiq | Charge Nurse | 128,624 | 108,771 |
|----------------------------|---|---------|---------|
| Kalinka, Lisa M | Nurse Practitioner Transplant | 256,292 | 157,015 |
| Kaminska, Stephanie | Physician Assistant | 125,492 | 125,000 |
| Kane, Justin C | General Duty Nurse | 140,257 | 109,724 |
| Kantorski, Ryan A | General Duty Nurse PT and PD | 110,197 | 110,197 |
| Kapral, Elizabeth B | Dentist ECMC | 215,733 | 219,419 |
| Karl, Joseph G | General Duty Nurse | 8,557 | 104,000 |
| Karl, Stephanie A | Nurse Case Manager | 129,340 | 132,707 |
| Katilus, Alan J | General Duty Nurse | 144,905 | 106,530 |
| Kaurich, Justine | Vice President of Operations | 212,125 | 212,363 |
| Kawka, April L | General Duty Nurse | 116,360 | 106,530 |
| Kayler, Liise K | Attending Physician | 208,813 | 208,813 |
| Kazmierczak, Jessica | Anesthetist | 105,885 | 226,410 |
| Keenan-Uschold, Lisa A | Chief Clinical Psychologist | 153,966 | 149,735 |
| Keeney, Alicia C | Nursing Inservice Instructor Ambulatory Services | 120,376 | 128,076 |
| Kellner, Jean M | General Duty Nurse | 105,700 | 106,530 |
| Kelly-Planter, Jan-Marie D | General Duty Nurse | 121,827 | 109,724 |
| Kemp, Amanda M | Charge Nurse | 164,061 | 108,772 |
| Kemp, Michelle L | Nurse Case Manager | 128,570 | 128,835 |
| Kempston, Shauna L | General Duty Nurse | 112,836 | 112,836 |
| Kent, Joanne | Charge Nurse | 130,456 | 108,771 |
| Kiel, Christina A | General Duty Nurse | 69,931 | 100,417 |
| Kimble, Karen A | Behavioral Health Clinical Manager | 131,083 | 130,543 |
| Kimori, Everesto M | Nursing Care Coordinator | 193,511 | 193,511 |
| Kinkade, Phillip D | General Duty Nurse | 128,440 | 109,724 |
| Kinney, Elizabeth C | Charge Nurse | 141,604 | 118,866 |
| Kitson, Rebecca A | General Duty Nurse | 109,035 | 109,725 |
| Kleinhans, Shannon | Quality Care Coordinator | 128,240 | 125,072 |
| Knihinicki, Crystal J | General Duty Nurse | 120,044 | 103,424 |
| Koch, Elizabeth | Anesthesiologist | 521,581 | 477,542 |
| Kocz, Remek | Anesthesiologist | 500,786 | 488,058 |
| Kolb, Beth A | Charge Nurse | 160,907 | 105,595 |
| Kolber, Brooke | Dentist ECMC | 112,538 | 112,538 |
| Kolbert, Cynthia | Charge Nurse | 129,928 | 118,866 |
| Konikoff, Karen S | Vice President Critical Care & Emergency Services | 123,090 | 183,856 |
| Kordasiewicz, Lynn M | Nurse Practitioner Wound Care | 173,155 | 166,561 |
| Korff, Kathryn C | Dentist ECMC | 275,932 | 315,999 |
| Kostek, Heather M | Nursing Team Leader | 97,530 | 120,758 |
| Koszuta, Ceilia A | Nurse Case Manager | 143,152 | 140,775 |
| Kotoroka-Yiadom, Martin | Charge Nurse | 130,576 | 105,595 |
| Kovanic-Spiro, Paula | Assistant Director Social Work Servs | 108,119 | 104,036 |
| Kowarko, Joanne M | General Duty Nurse | 118,378 | 100,418 |
| Krakowiak, Daryl A | Assistant Director of Social Work BH | 114,294 | 113,316 |
| Krawczyk, Heather L | Charge Nurse | 117,436 | 108,771 |
| Kruse, Kelley M | General Duty Nurse | 104,965 | 106,530 |
| Kurek, Alecia L | Unit Manager MedicalSurgical | 157,881 | 146,447 |
| Kuropatwinski, David J | Nursing Team Leader | 121,196 | 124,345 |
| Kurzdorfer, Scott G | Minimum Data Set Specialist | 100,971 | 110,497 |
| Kuzdzal, Chelsie A | Assistant Program Director of Behavioral Health | 68,345 | 104,036 |
| Kwiatkowski, Andrew J | Director of Project Management HIT | 175,308 | 165,526 |
| La Porta, Kathleen A | Senior Clinical Laboratory Technologist | 106,636 | 107,118 |
| Labelle, Jamie L | Unit Manager Hemodialysis | 145,544 | 146,447 |
| Labelle, Marc P | Vice President Surgical Services | 182,466 | 182,671 |
| Lampka, Sydney N | Charge Nurse | 107,371 | 102,525 |

| Lancaster, Maria A | General Duty Nurse | 79,476 | 100,418 |
|---|---|---------|---------|
| Lang, Julie T | Project Manager HIT | 111,223 | 111,348 |
| Laraiso, Joelle L | General Duty Nurse | 110,395 | 106,530 |
| Larkin, Rachel L | Nursing Team Leader | 69,191 | 124,344 |
| Larson, Amanda M | General Duty Nurse | 101,951 | 101,951 |
| Lauer, Sandra L | Director of Continuum Care | 150,074 | 139,584 |
| Lavarnway, Nicole M | Infection & Wound Care Preventionist LTC | 146,168 | 140,775 |
| Lawandus, Sarah E | Patient Safety Clinical Investigation Coordinator | 116,250 | 132,706 |
| Lawley, Melinda M | Unit Manager Critical Care | 150,303 | 146,447 |
| Leas, Adam C | General Duty Nurse | 118,946 | 106,530 |
| Leas, Christie L | General Duty Nurse | 114,495 | 100,418 |
| Lee, Pamela R | Senior VP of Operations ECMC | 333,785 | 331,058 |
| Leeds, Margaret M | General Duty Nurse | 121,259 | 121,259 |
| Leitten, Deborah A | General Duty Nurse | 125,895 | 109,724 |
| Lenhard, Eric | Pharmacist | 153,256 | 146,583 |
| Leonard, Jamie L | Charge Nurse | 131,542 | 108,771 |
| Lewandowski, Emily E | Pharmacist | 127,017 | 140,272 |
| Lewis, Gary D | Licensed Practical Nurse LTC | 101,280 | 101,280 |
| Lewis, Jennifer R | Charge Nurse | 158,707 | 101,280 |
| Lezynski, Sharon A | General Duty Nurse | 143,328 | 109,724 |
| Lilic, Dijana | Charge Nurse | 203,532 | 118,865 |
| Lillard, Jamie L | Charge Nurse | 125,856 | 102,525 |
| Linneborn, Tracey M | Assistant Director Social Work Servs | 108,246 | 102,323 |
| Lipiarz, Jennifer L | Charge Nurse | 128,903 | 100,340 |
| Liptak, Jacqueline Rae | Pharmacist | 128,508 | |
| LoFaso, John | Anesthesiologist | 215,077 | 140,270 |
| | Clinical Documentation Specialist | | 440,001 |
| Logel, Cassandra J Lorden, Bernard N | · · · · · · · · · · · · · · · · · · · | 122,091 | 108,771 |
| | Network Analyst | 143,439 | 110,994 |
| Loree, Thom R | Attending Physician | 992,690 | 991,129 |
| Loughran, Vicki A Lowitzer, Heidi | General Duty Nurse | 112,241 | 109,725 |
| | Charge Nurse | 124,685 | 108,771 |
| Lowmaster, Stephen K Lucas, Paul J | General Duty Nurse | 100,603 | 103,423 |
| | General Duty Nurse | 126,130 | 109,724 |
| Ludlow, Charlene J | Senior VP of Nursing | 370,898 | 371,314 |
| Lydo, Kaitlin M | RN Trauma Registrar | 122,636 | 117,233 |
| Macaluso, Ann M | Pharmacist | 40,915 | 140,270 |
| Mack, Markita N | Unit Manager Critical Care | 141,800 | 142,183 |
| MacNeil, Sarah L | General Duty Nurse | 167,599 | 106,530 |
| MacTurk, Nancy A | General Duty Nurse | 119,672 | 109,725 |
| Madison, Mark E | General Duty Nurse | 111,646 | 109,725 |
| Madoo, Kevin M | Director of Plant Operations | 129,914 | 130,060 |
| Madore, Donat | General Duty Nurse | 125,136 | 109,725 |
| Maggio, Sarah L | ASSISTANT VP of BH Nrsing & Edu | 174,367 | 153,832 |
| Maloney, Jennifer L | Unit Manager MedicalSurgical | 147,117 | 146,447 |
| Manning, Jeremy J | Charge Nurse | 132,645 | 112,024 |
| Marczak, Juliet M | Nurse Practitioner ECMC | 158,227 | 161,709 |
| Markiewicz, Anthony A | Vice President Clinical Business Intelligence and Infor | 207,300 | 196,368 |
| Marks, Jack E | General Duty Nurse | 114,312 | 109,725 |
| Marshall, Michelle L | PROGRAM DIRECTOR-BEHAVIORAL HEALTH | 127,061 | 123,599 |
| Marso, Lisa K | Anesthetist | 266,951 | 244,284 |
| Martin, Donna M | General Duty Nurse | 110,215 | 109,725 |
| Martina, Kristin L | Nursing Team Leader | 163,797 | 117,233 |
| Martinez, Kristen M | Director of Rehabilation Services LTC | 109,782 | 106,621 |
| Masters, Raymond J | Anesthetist | 246,789 | 244,283 |

| Matteliano, Andrea Marie | Physician Assistant | 90,385 | 125,000 |
|---|---|---------|--------------------|
| Mattina, Adrianne A | General Duty Nurse | 123,644 | 123,000 |
| Matyjasik, Robin L | Clinical Resource Nurse Emerg Services | 134,029 | 103,724 |
| Maul, Sara E | Charge Nurse | 115,083 | 112,024 |
| Maxson, Karen L | General Duty Nurse | 116,190 | 109,724 |
| Mayer, John | Director of System Health and Safety | 42,714 | 124,116 |
| Mazur, Christopher | Senior Pharmacist ECMC | 177,082 | 159,201 |
| McAndrews, Lisa M | Charge Nurse | 123,476 | 118,867 |
| McCartan, Daniel P | Emergency Preparedness Manager | 109,836 | 109,959 |
| McCarthy, Kevin M | Senior Clinical Laboratory Technologist | 115,553 | 105,555 |
| McCloud, Arletha S | Charge Nurse | 133,445 | 118,866 |
| McCray, Timiah D | General Duty Nurse LTC | 143,303 | 143,303 |
| McCullor, Sandra J | Charge Nurse | 130,734 | 118,866 |
| Mcdougall, Sarah N | Pharmacist | 143,369 | 143,437 |
| McDuffie, Ann M | Nursing Team Leader Orthopedics | 143,309 | 143,437 |
| McGuigan, Jessica L | Unit Manager MedicalSurgical | 143,323 | 146,447 |
| McKeever, Ashley L | Anesthetist | 262,555 | 244,284 |
| McLaughlin, Gloria E | General Duty Nurse | 121,085 | 109,724 |
| McLean, Terrence R | Dentist ECMC | 472,594 | 473,502 |
| McNair, Antionette L | Nursing Care Coordinator | 114,931 | 114,931 |
| McRae, Jennifer | Nursing Team Leader LTC | 124,270 | 114,931 |
| Mehmedovic, Andrea J | Chief Clinical Laboratory Technologist | 159,054 | 115,812 |
| Mendola, Kathryn K | Director of Campaigns & Major Gifts | 112,253 | 110,132 |
| Menter, Danielle A | Charge Nurse | 173,731 | 108,212 |
| Merineau, Rock | Project Manager HIT | 22,902 | 113,403 |
| Metz, Martha R | Clinical Nurse Specialist Crit Care ER | 132,733 | - |
| Metzler, Ashley M | Unit Manager Post Anesthesia Care | 153,858 | 139,511 146,447 |
| Meyers, Tracy M | RN Trauma Registrar | 131,003 | 140,447 |
| Miano, Joanne C | Nurse Case Manager | 139,012 | 128,070 |
| Miller, Crystal M | General Duty Nurse | 173,222 | 173,222 |
| Miller, Kelly L | Emergency Department Patient Flow Team Lead | 175,222 | 173,222 |
| Miller, Loretta J | Safe Patient Handling Coordinator | 123,798 | 113,799 |
| Miller, Melissa K | Assistant Head Nurse | 111,544 | 115,404 |
| Minhas, Parveen K | Senior Nurse Practitioner-Transplant | 272,210 | 113,404 |
| Mitchell, Alexandria N | Unit Manager MedicalSurgical | 148,705 | 146,447 |
| Mitchell, Shawn D | General Duty Nurse | 225,453 | 109,725 |
| Mogavero, Joseph N | Healthcare Business System Manager | 142,171 | 140,135 |
| Moll, Scott Edward | Nursing Supervisor LTC | 29,575 | 116,477 |
| Monaghan, Anna E | General Duty Nurse | 106,117 | 100,418 |
| Mondoux, Jessica | Vice President Transplantation & Renal Care | 150,707 | 175,999 |
| Monkelbaan, Ashley Nicole | Nursing Team Leader LTC | 103,538 | 104,146 |
| Monnier, Thomas J | Director of Biomedical Services | 103,558 | 111,394 |
| Monnin, Katherine E | General Duty Nurse | 90,853 | 100,417 |
| Montague, Victoria J | Charge Nurse | 152,656 | 100,417 |
| Montague, Victoria J Moody, Jacqueline | Charge Nurse | 130,575 | 102,525 |
| Mooney, Michelle H | Nurse Case Manager | 141,406 | 140,775 |
| Moore-Haley, Maureen M | General Duty Nurse | 127,936 | 140,775 |
| Morello, Joseph | General Duty Nurse | 95,721 | 109,725 |
| Morrissey, Colin P | Anesthetist | 247,465 | 244,284 |
| Morrissey, Com P Moses, Beth A | Trauma Injury Prevention & Education Coo | 132,409 | 128,076 |
| Moses, Thomas M | Charge Nurse | 116,978 | 128,076 |
| Mosleh, Kaid A | General Duty Nurse | 163,489 | 102,525 |
| Mosley, Steven | Healthcare Information Security Analyst II | 103,489 | 103,489 |
| Mukandamutsa, Berthilde | Certified Nursing Assistant | 116,491 | |
| Widkandamutsa, Dertinide | Certificu Mursing Assistant | 110,491 | 116,491 |

| Mulderig, Christian E | General Duty Nurse | 111,976 | 100,418 |
|------------------------|---|---------|---------|
| Mullen, Meghan J | Trauma Program Manager | 163,756 | 166,559 |
| Mulvenna, Tina M | Admissions Coordinator LTC | 105,960 | 108,771 |
| Mund, Nadine M | Director of Corporate Compliance | 138,646 | 138,646 |
| Murawski, Phyllis A | Quality Officer | 235,232 | 274,999 |
| Murphy, Evelyn M | General Duty Nurse | 108,807 | 109,725 |
| Nagai, Michael Y | Attending Physician | 608,758 | 599,409 |
| Najmulski, Kellie | Nursing Team Leader | 152,694 | 110,497 |
| Nance, Michele D | Assistant Nurse Case Manager | 127,041 | 118,866 |
| Napierala, Randal J | Pharmacist | 144,047 | 143,437 |
| Nasca, Maureen S | Dentist ECMC | 464,839 | 464,839 |
| Nawojski, Kari A | Charge Nurse | 239,572 | 115,405 |
| Nawojski, Michelle | Minimum Data Set Specialist | 109,472 | 110,497 |
| Neff, Melissa A | Unit Manager Cardiac Cath Lab | 243,699 | 146,447 |
| Nesbitt, David L | Asst VP of Compliance and Senior Counsel | 222,539 | 222,789 |
| Nicotra, James P | Senior Director Outpatient Operations | 80,350 | 128,882 |
| Nieswiadomy, Kayla M | Nurse Practitioner Transplant | 198,962 | 152,422 |
| Nisbet, Kaela A | General Duty Nurse | 116,576 | 103,424 |
| Noller, Dawn M | General Duty Nurse | 106,746 | 106,530 |
| Nowak, Kevin | Anesthesiologist | 523,038 | 457,777 |
| Nowak, Kristine M | Behavioral Health Clinical Manager | 136,286 | 130,543 |
| Nowak, Lisa M | Nursing Team Leader LTC | 160,587 | 117,234 |
| Nowotarski, Donna M | Clinical Laboratory Technologist | 111,123 | 100,441 |
| Nye, Maria L | Charge Nurse | 143,144 | 118,865 |
| Obstarczyk, Valerie M | Clinical Documentation Specialist | 113,568 | 108,772 |
| Occhino, Erin L | Clinical Pharmacy Specialist | 158,032 | 155,736 |
| O'Connor, Ashley J | Charge Nurse | 89,341 | 108,771 |
| O'Connor, Brendan J | Clinical Resource Nurse Emerg Services | 116,397 | 112,025 |
| O'Neil, Vanessa | Assistant Director of Nursing LTC | 131,922 | 140,000 |
| Ordon, Cheryl A | Nurse Case Manager | 140,407 | 140,774 |
| Orloff, Patrick J | Director of Internal Audit | 83,133 | 132,400 |
| Orta, Adrian J | Clinical Systems Analyst | 118,200 | 106,340 |
| Ott, Michael C | Clinical Coord Pharmacy Services | 171,873 | 162,661 |
| Pagano, Christina M | Physician Assistant | 141,047 | 135,970 |
| Paladino, Matthew J | Anesthesiologist | 535,756 | 487,094 |
| Palermo, Loretta L | Emergency Department Patient Flow Team Lead | 155,164 | 128,077 |
| Paluchowski, Jeffrey M | Respiratory Care Practitioner LTC | 123,489 | 123,489 |
| Panesar, Mandip | Chief Medical Information Officer | 474,057 | 470,457 |
| Paolini, Cherise M | General Duty Nurse | 107,219 | 109,725 |
| Park-Brooks, Jessica S | General Duty Nurse | 114,737 | 109,725 |
| Parker, Adam | Assistant Director of Pharmacy | 153,041 | 153,213 |
| Parks, Mary A | Charge Nurse | 130,947 | 115,405 |
| Patterson, Caralyn R | Nursing Team Leader LTC | 83,582 | 112,455 |
| Patterson, Malanie | General Duty Nurse LTC | 120,193 | 120,193 |
| Patterson, Sandra J | Nursing Team Leader Ambulatory Services | 36,719 | 122,853 |
| Pawar, Ravinder K | General Duty Nurse | 111,271 | 109,725 |
| Payne, Angela M | Nursing Care Coordinator Emergency Dept | 166,706 | 131,219 |
| Peals, Letrice | Charge Nurse | 27,310 | 110,699 |
| Pellicane, Stephen R | General Duty Nurse | 167,934 | 109,724 |
| Pelton, Lisa A | General Duty Nurse | 106,830 | 106,529 |
| Perkins, Melissa S | Unit Manager MedicalSurgical | 147,070 | 146,446 |
| Perry, Melissa B | Clinical Resource Nurse | 117,637 | 108,772 |
| Pesta, Joslyn D | Pharmacist | 142,249 | 140,271 |
| Petit, Kristy L | Charge Nurse LTC | 153,270 | 153,270 |

| Petri, Jeanenne | General Duty Nurse | 123,615 | 123,615 |
|---------------------------------------|---|-----------|-----------|
| Petronsky, William M | Senior Rad Techonologist Imaging Specialist | 106,454 | 104,764 |
| Petry, Christina J | Nursing Team Leader Ostomy Wound Care | 134,235 | 128,076 |
| Phillips, Kristen F | Anesthetist | 234,227 | 226,410 |
| Phillips, Rachael | General Duty Nurse | 41,393 | 100,418 |
| Picciano, Cathleen M | Lead Clinical Documentation Specialist | 18,260 | 122,852 |
| Picciano, Thomas | Manager - Care Management | 139,764 | 140,000 |
| Piedmonte, Gina M | General Duty Nurse | 117,162 | 109,724 |
| Pierce, Erin B | General Duty Nurse | 29,022 | 109,723 |
| Pietrzyk, Mathew R | Clinical Teacher | 9,033 | 137,565 |
| Piscatelli, Nicole | Dentist ECMC | 180,499 | 180,499 |
| Pittman, Courtney S | Director of Patient Access Services | 126,128 | 126,269 |
| Pitz, Anita A | Charge Nurse | 146,784 | 118,866 |
| Plotnicki, Ursula | General Duty Nurse | 118,180 | 100,417 |
| Plueckhahn, Jennifer | Minimum Data Set Specialist | 116,751 | 117,234 |
| Pollock, Michael P | Info Technology Operations Manager | 140,753 | 137,267 |
| Poodry, Abby J | Charge Nurse | 136,575 | 118,866 |
| Popat, Saurin R | Attending Physician | 477,588 | 477,588 |
| Porter, Bradley S | Nursing Team Leader LTC | 36,926 | 105,992 |
| Porter, Tricia M | General Duty Nurse | 171,726 | 109,725 |
| Powers, Lauren Ashley | Pharmacist | 21,590 | 140,270 |
| Powers, Paul J | Information Systems Analyst | 125,640 | 108,662 |
| Powers, Shawntey M | Nursing Team Leader | 125,209 | 124,344 |
| Pressley, Charles G | Staff Counsel ECMC | 136,661 | 136,815 |
| Principe, Tamara L | Charge Nurse | 120,559 | 105,595 |
| Przybylak, Thomas L | Information Technology Systems Architect | 35,000 | 130,000 |
| Pulka, Ashley L | Pharmacist | 143,277 | 143,437 |
| Quatroche, Thomas | Chief Executive Officer ECMC | 1,524,460 | 1,536,636 |
| Queener, Fontella | General Duty Nurse | 119,234 | 109,725 |
| Quintin, Krystal | General Duty Nurse LTC | 107,445 | 105,725 |
| Radovic, Vladan | Attending Physician | 414,827 | 388,068 |
| Ransom, Autumn | General Duty Nurse | 108,345 | 108,345 |
| Rassman, Jeffrey | Physician Assistant | 133,018 | 133,167 |
| Rathgeber, Pandora P | General Duty Nurse | 119,325 | 109,724 |
| Ratinskaya, Olga M | General Duty Nurse | 141,353 | 100,418 |
| Reamsnyder, Cynthia A | General Duty Nurse | 78,123 | 100,413 |
| Reed, Karen S | Anesthesiologist | 569,509 | 527,153 |
| Reeners, Eric S | Director of Finance ECMC | 146,812 | 144,201 |
| Regelin, Lucas | Pharmacist | 117,385 | 140,270 |
| Reigle, Corey L | Charge Nurse | 133,412 | 118,865 |
| Reilly, Mary B | Vice President Critical Care & Emergency Services | 170,711 | 175,999 |
| Reinhardt, Julie A | General Duty Nurse | 109,210 | 109,725 |
| Remillard, Sara | Anesthetist | 186,000 | 244,284 |
| Renda, Amanda L | General Duty Nurse | 115,900 | 103,423 |
| Resetarits, Christopher M | Chief Anesthetist | 288,077 | 288,400 |
| Reynolds, Katrina R | General Duty Nurse | 30,158 | 102,582 |
| Reynolds, Tracy N | General Duty Nurse | 122,724 | 102,582 |
| Richardson, Eden M | Charge Nurse LTC | 111,690 | |
| Ricks, Tiffany L | Charge Nurse | | 112,024 |
| · · · · · · · · · · · · · · · · · · · | | 197,077 | 105,595 |
| Riley, Peggy-Sue L | Charge Nurse Anesthetist | 142,928 | 118,866 |
| Ring, Alan J Bitor, Dobro A | Assistant Director of Social Work BH | 246,984 | 226,410 |
| Riter, Debra A Rizzo, Ann M | | 110,718 | 113,316 |
| | General Duty Nurse | 114,561 | 109,725 |
| Rizzo, Heather R | Anesthetist | 192,209 | 192,209 |

| Rizzo, John A | Unit Manager MedicalSurgical | 137,011 | 138,058 |
|---------------------------|---|--------------------|---------|
| Robb, Noel R | Charge Nurse | 137,011 | 138,058 |
| Roberts, Sara M | Lead Clinical Documentation Specialist | | |
| Robertson, Heather | Charge Nurse | 160,318 135,984 | 120,759 |
| , | | , | 115,405 |
| Robertson, Reilly V | General Duty Nurse | 160,088 | 103,424 |
| Roblee, Chelsey L | Nursing Team Leader | 132,491 | 124,345 |
| Rodriguez, Erin T | Charge Nurse | 119,120 | 115,405 |
| Roeder, Anastasia M | Director of Development & Marketing ECMC | 141,215 | 118,412 |
| Rogan, Ilona E | EchoCardiography Technician | 131,042 | 100,168 |
| Rogers, Angeline P | Nurse Case Manager | 141,774 | 140,774 |
| Rohatgi, Nidhika | Pharmacist | 33,293 | 140,270 |
| Rohl, Kathleen M | Assistant Head Nurse | 126,292 | 118,867 |
| Rohloff, Sarina M | Director of Procurement Compliance | 107,782 | 107,903 |
| Rohrbacher, Bernhard J | Medical Specialist | 129,541 | 129,541 |
| Roman, Julie A | Clinical Documentation Specialist | 158,743 | 115,404 |
| Roof, Angela E | Nurse Case Manager | 122,932 | 125,073 |
| Roof, Donald P | Director of Materials Management | 119,922 | 118,235 |
| Roopchand, John-Paul | Network Analyst | 106,220 | 104,036 |
| Root, Sarah E | Infection & Wound Care Preventionist LTC | 128,545 | 140,774 |
| Ross, Nicole A | Pharmacist | 148,950 | 140,271 |
| Rossi, Lucia J | Vice President of Ambulatory Svs & Population Healt | 176,082 | 169,744 |
| Rossitto, Rachael A | Chief of Service Dentistry | 354,093 | 409,999 |
| Ross-McComb, Holly G | Clinical Nurse Specialist Behavioral Hea | 152,963 | 152,422 |
| Rubin, Kari L | Nurse Case Manager | 139,074 | 140,774 |
| Rudyk, Jenine M | Unit Manager Critical Care | 143,892 | 142,183 |
| Rudyk, Stanley | General Duty Nurse | 100,039 | 100,417 |
| Ruh, Christine A | Assistant Director of Pharmacy | 167,434 | 167,622 |
| Rust, Shawna M | Charge Nurse | 139,756 | 118,866 |
| Rutkowski, Tammy M | General Duty Nurse | 109,329 | 109,725 |
| Rutty, Amy J | General Duty Nurse | 114,089 | 109,725 |
| Ryan, Taylor M | Charge Nurse | 151,140 | 105,595 |
| Saia, Sarah Jane | Nursing Inservice Instructor Psych | 115,077 | 110,498 |
| Sammarco-Delmont, Renee S | Unit Manager MedicalSurgical | 167,809 | 146,446 |
| Sands, Robert P | Anesthesiologist | 358,612 | 516,815 |
| Sanger, Tami L | Senior Clinical Laboratory Technologist | 120,997 | 101,260 |
| Santillo, Alexis L | Physician Assistant | 130,733 | 125,000 |
| Santo, Angela M | Charge Nurse | 137,521 | 108,771 |
| Sarkisian, Kevin G | Sr Healthcare Info Reporting Specialist | 123,689 | 106,340 |
| Sauer, Jillian M | Unit Manager MedicalSurgical | 136,846 | 138,058 |
| Sayles, Saryna M | General Duty Nurse | 116,259 | 100,418 |
| Scanlon, Lora A | General Duty Nurse | 105,425 | 100,418 |
| Scherer, Paul C | Healthcare Business Sys Analyst | 120,807 | 115,635 |
| Schihl, Cassandra L | Charge Nurse | 153,304 | 105,595 |
| Schoelerman, Ronald M | Assistant VP of BH & Community | 159,993 | 153,829 |
| Schubbe, Jayson | Healthcare Data Warehouse Architect | 129,233 | 124,582 |
| Schubbe, Michele A | Healthcare Business Sys Analyst | 134,692 | 110,995 |
| Schultz, Kathryn M | General Duty Nurse | 112,705 | 100,419 |
| Schultz, Rachael M | Anesthetist | 158,674 | 158,674 |
| Schummer, Abby J | General Duty Nurse | 122,221 | 106,529 |
| Schunke, Katrina M | Pharmacist | 88,315 | 156,120 |
| Schurr, Karen D | Clinical Asst to VP Surg & Card. Services | 147,639 | 144,201 |
| Schwanekamp, Karen A | Anesthetist | 270,955 | 244,284 |
| Schwartz, Danielle M | General Duty Nurse | 142,352 | 142,352 |
| Johnwartz, Damene IVI | Scheral Duty Nulse | 142,332 | 142,332 |

| Scrocco, Mary Carol | Nurse Practitioner Cardiovascular Lab | 132,216 | 159,769 |
|-------------------------|---|---------|---------|
| Scruggs, Tammie R | General Duty Nurse | 72,093 | 105,251 |
| Seay, Michelle D | Clinical Patient Care Liaison | 155,718 | 152,121 |
| Sell, Gregory S | Nursing Inservice Instructor Crit Care | 107,922 | 113,813 |
| Semrau, Jeffrey M | Senior Pharmacist ECMC | 182,220 | 155,736 |
| Senchoway, Laura M | Anesthetist | 237,074 | 226,410 |
| Serafin, Laura J | General Duty Nurse | 151,798 | 151,798 |
| | | | |
| Seweryniak, Sara M | General Duty Nurse | 108,669 | 100,418 |
| Shanahan, Robert M | Network Analyst | 137,439 | 110,994 |
| Shanley, Kayla M | General Duty Nurse Clinical Resource Nurse | 104,567 | 103,423 |
| Shaw, Patrick T | | 121,583 | 115,404 |
| Sheppard, Judith E | Nursing Supervisor LTC | 159,898 | 140,774 |
| Shine, Quivonna J | Nursing Supervisor LTC | 3,818 | 114,439 |
| Silfies, Robert F | Charge Nurse | 134,121 | 102,526 |
| Simon, Alexander P | Clinical Application Systems Manager | 128,631 | 120,531 |
| Simone, Jessica N | General Duty Nurse | 112,135 | 100,418 |
| Sitgreaves, Theressa A | Charge Nurse | 116,659 | 112,024 |
| Smith, Andrew N | Nurse Case Manager | 148,872 | 140,774 |
| Smith, Jennifer L | General Duty Nurse | 111,916 | 109,725 |
| Smith, Laura J | General Duty Nurse | 109,399 | 100,418 |
| Smith, Taneca V | Nurse Case Manager | 133,122 | 128,836 |
| Smolen, Ashley J | General Duty Nurse | 112,731 | 106,530 |
| Snyder, Brigette | Charge Nurse | 133,446 | 105,595 |
| So, Timmy Jk | Assistant Director of Social Work BH | 113,009 | 110,995 |
| Sojda, Hollie M | EchoCardiography Technician | 122,777 | 100,168 |
| Sole, Jennifer A | Nursing Team Leader | 137,561 | 128,076 |
| Sorce, Lynn M | Charge Nurse | 118,862 | 118,867 |
| Soto-Gott, Sheree A | General Duty Nurse LTC | 166,234 | 166,234 |
| Sousis, Julie M | Assistant Director Ambulatory Services | 122,629 | 119,733 |
| Spencer, Jessica L | General Duty Nurse | 111,138 | 100,418 |
| Sperry, Howard E | Clinical Director Medicine | 342,637 | 328,637 |
| Stadler, Nicholas P | General Duty Nurse | 131,598 | 100,418 |
| Stanford, Benjamin A | Unit Manager MedicalSurgical | 146,759 | 142,183 |
| Staniorski, Paula F | General Duty Nurse | 57,600 | 105,250 |
| Stark, Angela M | General Duty Nurse | 118,151 | 100,418 |
| Steffen, Tracy H | Nurse Case Manager | 139,572 | 140,774 |
| Stegemann, Philip M | Chief of Orthopedic Surgery | 76,574 | 117,148 |
| Sterner, Jared T | Nursing Team Leader | 139,165 | 120,759 |
| Steward, Kevin R | Nursing Care Coordinator | 166,511 | 152,121 |
| Stobnicki, Cortney B | Anesthetist | 261,068 | 244,284 |
| Stoll, Jami S | Charge Nurse | 91,914 | 102,525 |
| Stroud, Kerry A | Nursing Care Coordinator | 166,142 | 152,121 |
| Sturtz, Janice M | Nursing Team Leader Ostomy Wound Care | 122,041 | 124,344 |
| Suchy, Thomas C | Attending Physician | 502,116 | 498,623 |
| Sullivan, Michele M | General Duty Nurse | 136,644 | 109,724 |
| Surowiec, Stephanie A | General Duty Nurse | 105,079 | 100,418 |
| Sutkowski, Jordan L | Charge Nurse | 113,714 | 100,410 |
| Sutton, Danielle R | Charge Nurse | 132,407 | 118,866 |
| Swain, Anthony R | Charge Nurse | 125,974 | 118,866 |
| Swain, Maureen A | Charge Nurse | 59,961 | 118,800 |
| Sweetland, Jennifer M | Nursing Informatics Manager | 151,187 | 152,121 |
| Sweitzer, Sarah M | General Duty Nurse PT and PD | 159,883 | 152,121 |
| Swiatkowski, Jonathan T | Chief Financial Officer ECMC | 591,586 | 592,249 |
| | | | |
| Swiderski, Leah | General Duty Nurse | 124,164 | 124,164 |

| Syracuse, Wendy A | General Duty Nurse | 119,753 | 103,424 |
|-----------------------------|--|---------|---------|
| Tadak, Monica J | Director of Revenue Capture and Integrit | 119,733 | 103,424 |
| Tadt, Stephanie R | Nurse Case Manager | 138,244 | 140,774 |
| Tague, Dana E | Nurse Practitioner Rehabilitation Services | 180,896 | 166,561 |
| Tait, Christopher A | Nurse Case Manager | 141,807 | 140,774 |
| Taylor, Austin J | General Duty Nurse PT and PD | 101,945 | 101,945 |
| Thanki, Pamela S | Senior Financial Analyst | 117,242 | 113,022 |
| Thimot, Veronica A | General Duty Nurse | 116,154 | 100,418 |
| Thomas, Dylan | Pharmacist | 114,477 | 140,270 |
| Thomas, Katheleen | Infection Prevention Practioner | 146,837 | 128,077 |
| Thomas, Lakeisha A | Charge Nurse | 126,761 | 102,525 |
| Thomas, Michael | General Duty Nurse | 113,366 | 100,418 |
| Thomas, Sherry D | General Duty Nurse | 47,822 | 102,186 |
| Thompson, Denise B | Nursing Care Coordinator | 162,683 | 147,690 |
| Thoms, Amy C | Clinical Documentation Specialist | 149,340 | 118,867 |
| Thorpe, Lisa F | Director of Rehabilation Services | 151,644 | 143,067 |
| Tiwana, Harwinder K | General Duty Nurse | 44,207 | 105,248 |
| Tkalich, Ostap | General Duty Nurse | 101,730 | 101,730 |
| Toal, Emily R | Charge Nurse | 133,633 | 115,405 |
| Tornabene, Jillian | Nurse Practitioner Orthopedic Services | 152,183 | 148,000 |
| Tornambe, Lynne L | Pharmacist | 153,885 | 149,734 |
| Torres, Carmen | Nurse Practitioner ECMC | 189,481 | 166,560 |
| Toscano, Shannon M | Charge Nurse | 106,594 | 105,595 |
| Toy, Amy M | Charge Nurse | 134,794 | 118,865 |
| Troise, Emily A | Nursing Inservice Instructor Crit Care | 123,026 | 120,759 |
| Turner, Charlaina J | General Duty Nurse PT and PD | 120,852 | 120,852 |
| Turner, Jacqueline E | General Duty Nurse | 120,356 | 109,725 |
| Turner, Marcy L | General Duty Nurse | 137,271 | 103,424 |
| Twichell, Jerome D | Senior Director Outpatient Operations | 141,047 | 135,970 |
| Urban, Paul | Assistant Info Tech Sys Architect | 131,862 | 132,010 |
| Vacanti, Angela | Manager Infection Control | 156,968 | 152,121 |
| Vacanti, Charles M | Nursing Team Leader | 145,172 | 128,076 |
| Vacanti, Jason M | General Duty Nurse | 259,177 | 103,423 |
| Vaccaro, Jessica R | Charge Nurse | 126,703 | 108,771 |
| VanSteenburg, Monica Dawyot | Anesthetist | 222,405 | 226,410 |
| Vazquez, Alexandra M | Charge Nurse | 143,347 | 112,024 |
| Vazquez, Dionna C | Utilization Review Nurse | 174,119 | 103,424 |
| Villacorta, Maria C | Charge Nurse | 156,123 | 118,866 |
| Volk, Karleigh Mary | Dentist ECMC | 47,789 | 140,001 |
| Vullo, Lori A | General Duty Nurse | 106,382 | 106,530 |
| Walden, Jenna M | Nurse Practitioner Transplant | 130,499 | 148,000 |
| Wallace, Lauren M | Nursing Team Leader LTC | 117,043 | 110,497 |
| Walsh, Evelyn P | Attending Physician | 297,715 | 279,999 |
| Walter, Robert H | Chief Clinical Laboratory Technologist | 142,443 | 122,899 |
| Walters, Amy M | General Duty Nurse | 125,425 | 109,724 |
| Walters, Kimberly J | General Duty Nurse | 170,862 | 109,724 |
| Wang, Nana | Pharmacist | 128,947 | 140,270 |
| Warmus, Renelle M | Nurse Case Manager | 135,918 | 136,675 |
| Warren, Daniel R | Manager of Financial Reporting | 110,446 | 102,999 |
| Warren, Susan I | General Duty Nurse | 121,372 | 106,530 |
| Weaver, Stephanie C | Clinical Teacher Dedicated Education Unit Instructor | 134,300 | 132,706 |
| Weber, Joseph P | Network Analyst | 137,839 | 110,994 |
| Weigand, Sara J | General Duty Nurse | 104,237 | 104,237 |
| Weise, Thomas H | Nursing Supervisor LTC | 127,230 | 121,428 |

| Weiss, Katherine A | Pharmacist | 183,835 | 156,121 |
|-------------------------|--|---------|---------|
| Weiss, Nicole | Pharmacist | 146,013 | 140,270 |
| Weld, Tiffani Marie | Charge Nurse | 156,991 | 105,595 |
| Welka, Andrew J | Anesthesiologist | 509,545 | 466,151 |
| West, Ashley M | Nurse Case Manager | 140,653 | 140,774 |
| West, Lindsey A | Unit Manager MedicalSurgical | 135,036 | 134,031 |
| Wheeler, Jennifer L | General Duty Nurse | 97,885 | 100,417 |
| Whelan, Stephen D | Nursing Inservice Instructor Psych | 117,392 | 110,498 |
| Whipkey, Colleen M | Charge Nurse | 116,546 | 118,867 |
| White, Katie L | General Duty Nurse | 105,898 | 103,423 |
| Wickett, Rachel C | General Duty Nurse | 161,294 | 100,418 |
| Wiggins, Shaniqua P | General Duty Nurse | 107,689 | 107,689 |
| Wik, Michelle L | Charge Nurse | 145,038 | 108,772 |
| Wilde, Michelle A | Charge Nurse | 141,677 | 118,865 |
| Williams, Kameo S | General Duty Nurse LTC | 131,917 | 131,917 |
| Williams, Sara K | General Duty Nurse | 114,175 | 103,424 |
| Williams, Sonia | Assistant Director Ambulatory Services | 130,566 | 127,481 |
| Williams, Stephanie A | General Duty Nurse | 174,836 | 103,424 |
| Williamson, Katrina L | General Duty Nurse | 108,706 | 109,725 |
| Wilson, Brittany M | Nursing Inservice Instructor ECMC | 103,542 | 101,795 |
| Wilson, Karyn M | Assistant Director Ambulatory Services | 115,043 | 114,571 |
| Wilson, Nicolette M | Vice President Revenue Cycle | 189,193 | 189,405 |
| Wilson, Tiffany A | Charge Nurse | 133,259 | 112,024 |
| Wing, Kathryn M | General Duty Nurse | 109,169 | 109,725 |
| Wise, Sean P | Charge Nurse | 112,577 | 105,595 |
| Wittenbrink, Timothy B | Nursing Team Leader | 122,050 | 117,234 |
| Wittmann, Paula A | Charge Nurse | 133,025 | 118,866 |
| Wojtowicz, Jean M | General Duty Nurse | 110,429 | 109,725 |
| Wolf, Jo Ann S | Vice President Medical Surgical Nursing Services | 160,480 | 175,999 |
| Wood, Jamie L | General Duty Nurse | 124,574 | 109,724 |
| Wood, Rebecca A | Charge Nurse | 117,548 | 108,771 |
| Woodruff, Stephen R | Administrator LTC | 174,851 | 175,048 |
| Woods, Kara A | Physician Assistant | 139,287 | 135,970 |
| Wright, Kiayra-Elexus T | General Duty Nurse | 102,188 | 102,188 |
| Wright, Shaunda M | Unit Manager Behavioral Health | 157,338 | 142,182 |
| Yak, Joseph Y | Chief Clinical Laboratory Technologist | 134,832 | 116,132 |
| Yates, Robert A | Anesthetist | 246,973 | 226,410 |
| Yerdon, Kerri L | General Duty Nurse | 133,035 | 100,418 |
| York-Renaud, Jamie L | Nursing Inservice Instructor OR | 135,810 | 128,076 |
| Yotter, Emily A | Charge Nurse | 5,102 | 104,338 |
| Young, Amanda N | Junior Staff Counsel ECMC | 102,884 | 102,999 |
| Young, Grace K | General Duty Nurse PT and PD | 102,896 | 102,896 |
| Zajac, Jamie E | Emergency Department Patient Flow Team Lead | 153,724 | 128,077 |
| Zak, Katherine J | General Duty Nurse | 135,985 | 109,724 |
| Zanghi, Marie R | Nurse Case Manager | 126,053 | 140,774 |
| Zayac, Jason A | Anesthesiologist | 410,569 | 447,000 |
| Zdon, Glen W | Unit Manager Hemodialysis | 135,998 | 138,058 |
| Zielinski, Danielle M | General Duty Nurse | 105,316 | 100,418 |
| Zimmer, Michelle L | Charge Nurse | 152,811 | 118,866 |
| Zinzola, Amie M | General Duty Nurse | 146,853 | 103,424 |
| Zolnowski, Kimberly | Charge Nurse | 138,570 | 112,024 |
| Zynda, Elizabeth A | Nurse Practitioner Transplant | 226,703 | 161,710 |

| | 2024 \$100 | K Procureme | ent Report EC | мсс | |
|---|------------------------------|--------------|-------------------------|-------------------------|---|
| Vendor Name | Payments | Reporting | Contract | Contract | Purpose |
| | | Year | Start | End | |
| MCKESSON DRUG CO | \$61,172,776 | 2024 | 2/1/2021 | 8/31/2028 | Commodities/Supplies |
| | \$18,947,148 | 2024 | 4/6/2019 12/1/2012 | 8/31/2027 | Other Professional Services |
| CARDINAL VALUE LINK UNIVERSITY MEDICAL RESIDENT SERVICES, P.C. | \$13,591,797 \$12,565,379 | 2024 2024 | 1/4/2012 | 6/30/2027 1/3/2029 | Commodities/Supplies Other Professional Services |
| UBMD PSYCHIATRY | \$12,485,599 | 2024 | 8/1/2019 | 12/31/2025 | Other Professional Services |
| GENERAL PHYSICIAN, P.C. | \$12,482,990 | 2024 | 12/1/2023 | 11/30/2028 | Other Professional Services |
| ERIE COUNTY COMPTROLLER'S OFFICE | \$12,341,865 | 2024 | 1/22/2010 | Evergreen | Other |
| APOGEE MEDICAL MANAGEMENT | \$11,387,674 | 2024 | 9/1/2015 | 6/30/2029 | Other Professional Services |
| GRIDER SUPPORT SERVICES, LLC | \$ 9,659,355 | 2024 | 3/1/2012 | Evergreen | Other |
| UPSTATE NEW YORK TRANSPLANT | \$ 9,322,135 | 2024 | 8/2/2016 | Evergreen | Commodities/Supplies |
| ACADEMIC MEDICAL SERVICES, INC. | \$ 8,999,718 | 2024 | 3/8/2018 | 3/7/2025 | Other Professional Services |
| THE RESEARCH FOUNDATION | \$ 8,980,450 | 2024 | 12/2/2011 | 12/31/2050 | Other Professional Services |
| UNIV. @ BFLO SURGEONS, INC. | \$ 8,972,300 | 2024 | 7/1/2022 | 6/30/2025 | Other Professional Services |
| GREAT LAKES MEDICAL IMAGING, LLC | \$ 8,835,959 | 2024 | 9/1/2015 | 8/31/2027 | Other Professional Services |
| BUFFALO INTERNIST AND ASSOCIATES | \$ 5,962,784 | 2024 | 6/13/2017 | 12/31/2025 | Other Professional Services |
| ZIMMER BIOMET | \$ 5,955,282 | 2024 | 12/29/2022 | 6/30/2026 | Commodities/Supplies |
| TRELLIS RX, LLC | \$ 5,422,986 | 2024 | 5/1/2021 | 4/30/2026 | Other Professional Services |
| UNIVERSITY EMERGENCY MEDICAL | \$ 4,395,812 | 2024 | 8/1/2017 | 7/31/2027 | Other Professional Services |
| | \$ 3,573,396 | 2024 | 9/18/2019 | 10/24/2026 | Commodities/Supplies |
| STRYKER ORTHOPAEDICS | \$ 3,476,272 | 2024 | 9/20/2022 | 3/31/2027 | Commodities/Supplies |
| GLOBUS MEDICAL INC SMITH & NEPHEW US | \$ 3,470,159 | 2024 2024 | 4/30/2015 9/11/2020 | 9/30/2026 12/31/2025 | Commodities/Supplies Commodities/Supplies |
| CARDINAL HEALTH MED PROD & | \$ 3,469,558 \$ 3,092,580 | 2024 | 12/1/2012 | 6/30/2027 | Commodities/Supplies |
| UB FAMILY MEDICINE INC. | \$ 3,065,807 | 2024 | 6/1/2020 | 5/31/2027 | Other Professional Services |
| UNIV. ORTHOPAEDIC SERVICES | \$ 2,588,987 | 2024 | 12/31/2021 | 12/31/2025 | Other Professional Services |
| KALEIDA HEALTH | \$ 2,547,828 | 2024 | 11/24/2014 | Evergreen | Other |
| ROCHE DIAGNOSTIC CORP | \$ 2,537,390 | 2024 | 5/1/2002 | 5/21/2025 | Commodities/Supplies |
| ARTHREX | \$ 2,317,348 | 2024 | 10/1/2018 | 2/12/2025 | Commodities/Supplies |
| SUPPLEMENTAL HEALTH CARE | \$ 2,275,733 | 2024 | 12/8/2016 | 10/27/2025 | Staffing Services |
| BAXTER HEALTHCARE CORP | \$ 2,238,206 | 2024 | 9/11/2024 | 9/30/2027 | Commodities/Supplies |
| UB NEUROSURGERY, INC. | \$ 2,231,057 | 2024 | 9/30/2019 | 9/29/2027 | Other Professional Services |
| ABBOTT LABORATORIES, INC. | \$ 2,090,398 | 2024 | 3/1/2022 | 2/28/2025 | Commodities/Supplies |
| CARDINAL HEALTH | \$ 1,896,090 | 2024 | 5/1/2020 | 8/30/2027 | Commodities/Supplies |
| AMERGIS HEALTHCARE STAFFING | \$ 1,872,179 | 2024 | 8/23/2023 | 8/22/2026 | Staffing Services |
| KSL DIAGNOSTICS, INC | \$ 1,867,104 | 2024 | 1/7/2019 | 9/30/2025 | Other Professional Services |
| CORE BTS INC | \$ 1,804,583 | 2024 | 12/20/2023 | 11/30/2025 | Technology - Software |
| LAB CORP OF AMERICA | \$ 1,728,468 | 2024 | 10/1/2018 | 9/30/2026 | Other Professional Services |
| | \$ 1,696,671 | 2024 | 5/2/2019 | 5/1/2025 | Other Professional Services |
| MEDICAL SOLUTIONS, LLC DELL MARKETING LP | \$ 1,656,543 \$ 1,648,686 | 2024 2024 | 12/4/2018 11/30/2015 | 12/3/2025 11/29/2025 | Staffing Services Technology - Hardware |
| | | | | | |
| TORNIER INC | \$ 1,531,404 | 2024 | 9/20/2022 | 3/31/2027 | Commodities/Supplies |
| INTUITIVE SURGICAL INC | \$ 1,493,042 | 2024 | 12/31/2021 | 12/30/2026 | Commodities/Supplies |
| THE MARTIN GROUP LLC | \$ 1,381,138 | 2024 | 6/9/2014 | 12/31/2025 | Other Professional Services |
| UB PATHOLOGISTS INC. | \$ 1,333,295 | 2024 | 2/14/2022 | 2/13/2026 | Other Professional Services |
| BOSTON SCIENTIFIC CORPORATION | \$ 1,295,200 | 2024 | 4/28/2016 | 4/27/2026 7/13/2025 | Commodities/Supplies Technology - Software |
| MEDICAL INFORMATION TECHNOLOGIES IN PHARMERICA | \$ 1,111,397 \$ 1,044,534 | 2024 2024 | 7/14/2011 12/1/2022 | 6/30/2025 | Commodities/Supplies |
| JOHNSON & JOHNSON HLTH CARE SYS INC | \$ 1,044,534 \$ 1,033,824 | 2024 | 9/18/2019 | 10/24/2026 | Commodities/Supplies |
| MEDTRONIC INC NEUROLOGICAL DIV | \$ 1,016,520 | 2024 | 8/30/2020 | 9/11/2026 | Commodities/Supplies |
| PARTS SOURCE | \$ 1,013,258 | 2024 | 9/1/2023 | 8/31/2026 | Commodities/Supplies |
| SUICIDE PREVENTION & | \$ 993,587 | 2024 | 10/1/2018 | 9/30/2026 | Other Professional Services |
| CREEKRIDGE CAPITAL, LLC | \$ 983,693 | 2024 | 2/24/2009 | 1/24/2025 | Financial Services |
| DEPUY ACE MEDICAL COMPANY | \$ 968,818 | 2024 | 9/18/2019 | 10/24/2026 | Commodities/Supplies |
| AMERISOURCE BERGEN DRUG CORP | \$ 965,610 | 2024 | 2/5/2021 | 2/4/2028 | Commodities/Supplies |
| UNIVERSITY DENTAL RESIDENT SERVICES, P.C. | \$ 958,769 | 2024 | 1/4/2019 | 1/3/2029 | Other Professional Services |
| NATIONAL GRID | \$ 920,699 | 2024 | 1/22/2010 | Evergreen | Other |
| CHUDY PAPER COMPANY, INC. | \$ 883,744 | 2024 | 11/1/2023 | 10/31/2026 | Commodities/Supplies |
| KALEIDA HEALTH | \$ 849,149 | 2024 | 1/17/2012 | Evergreen | Other |
| JOHNSON CONTROLS FIRE PROTECTION LP | \$ 832,317 | 2024 | 8/27/2019 | 8/26/2034 | Design and Construction/Maintenance |
| CITY OF BUFFALO | \$ 828,203 | 2024 | 1/22/2010 | Evergreen | Other |
| CARAHSOFT TECHNOLOGY CORPORATION | \$ 816,485 | 2024 | 1/12/2018 | 6/4/2025 | Technology - Software |

| STERICYCLE INC | \$ 814,785 | 2024 | 6/1/2022 | 5/31/2027 | Other Professional Services |
|---|--------------------------|--------------|------------------------|-------------------------|---|
| WILLIAM BELLES PC | \$ 811,682 | 2024 | 12/1/2022 | 11/30/2025 | Other Professional Services |
| HEWLETT-PACKARD COMPANY | \$ 765,399 | 2024 | 6/30/2013 | 12/19/2028 | Technology - Hardware |
| W L GORE & ASSOC INC | \$ 759,745 | 2024 | 10/29/2020 | 7/31/2026 | Commodities/Supplies |
| STRYKER INSTRUMENTS | \$ 755,042 | 2024 | 5/10/2019 | 6/30/2025 | Commodities/Supplies |
| STERIS CORPORATION | \$ 743,761 | 2024 | 2/1/2021 | 1/31/2027 | Commodities/Supplies |
| MANUFACTURERS & TRADERS TRUST | \$ 741,484 | 2024 | 11/12/2021 | 5/11/2025 | Financial Services |
| MEDLINE INDUSTRIES INC | \$ 728,554 | 2024 | 1/1/2022 | 12/31/2026 | Commodities/Supplies |
| MERIDIAN IT INC. | \$ 728,309 | 2024 | 1/1/2024 | 12/31/2028 | Technology - Software |
| SIEMENS MEDICAL SOLUTIONS | \$ 723,326 | 2024 | 10/21/2021 | 10/20/2026 | Other Professional Services |
| PHILIPS MEDICAL SYSTEMS | \$ 717,020 | 2024 | 10/1/2022 | 9/30/2025 | Commodities/Supplies |
| PHILIPS MEDICAL SYSTEMS NA CO | \$ 716,269 | 2024 | 6/1/2021 | 5/31/2027 | Commodities/Supplies |
| INTEGRA LIFESCIENCES CORP | \$ 695,430 | 2024 | 12/1/2020 | 11/30/2026 | Commodities/Supplies |
| UB FOUNDATION ACTIVITES | \$ 685,897 | 2024 | 1/4/2019 | 1/3/2029 | Other Professional Services |
| 3M HEALTH INFORMATION | \$ 674,846 | 2024 | 10/1/2018 | Evergreen | Technology - Software |
| MEDTRONIC SPINAL AND BIOLOGICS | \$ 663,249 | 2024 | 5/2/2012 | 9/30/2026 | Commodities/Supplies |
| STRYKER CRANIOMAXILLOFACIAL | \$ 658,957 | 2024 | 11/1/2019 | 10/31/2025 | Commodities/Supplies |
| EXPERIAN HEALTH, INC. | \$ 652,062 | 2024 | 12/21/2021 | 2/4/2027 | Technology - Software |
| BIOCARE SD | \$ 644,554 | 2024 | 1/1/2015 | 6/30/2028 | Commodities/Supplies |
| AMERICAN RED CROSS BLOOD SVCS | \$ 625,571 | 2024 | 7/19/2021 | 7/19/2025 | Commodities/Supplies |
| BUFFALO TRANSPORTATION INC. | \$ 605,899 | 2024 | 5/24/2021 | 5/23/2025 | Other Professional Services |
| DELL FINANCIAL SERVICES LLC | \$ 605,505 | 2024 | 11/30/2022 | 11/29/2025 | Financial Services |
| BECTON, DICKINSON AND COMPANY | \$ 585,279 | 2024 | 12/1/2023 | 11/30/2026 | Commodities/Supplies |
| ABBOTT LABORATORIES DIAGNOSTIC DIV | \$ 545,049 | 2024 | 4/15/2021 | 10/31/2025 | Commodities/Supplies |
| WNY UROLOGY ASSOCIATES LLC | \$ 528,458 | 2024 | 10/1/2018 | 9/30/2025 | Other Professional Services |
| HEALOGICS WOUND CARE & | \$ 517,273 | 2024 | 1/18/2019 | 9/2/2029 | Other Professional Services |
| FRESENIUS USA MARKETING, INC. | \$ 514,490 | 2024 | 8/1/2020 | 7/31/2028 | Commodities/Supplies |
| XENTEGRA-GOV, LLC | \$ 501,740 | 2024 | 11/23/2022 | 6/26/2027 | Technology - Software |
| TREACE MEDICAL CONCEPTS, INC | \$ 500,867 | 2024 | 10/23/2020 | 10/31/2025 | Commodities/Supplies |
| HILL-ROM CO INC | \$ 496,133 | 2024 | 3/1/2022 | 2/28/2025 | Commodities/Supplies |
| MAGAVERN, MAGAVERN & GRIMM LLP | \$ 494,283 | 2024 | 7/1/2022 | 7/1/2027 | Legal Services |
| ALLSCRIPTS-MISYS LLC | \$ 482,992 | 2024 | 5/4/2010 | Evergreen | Technology - Software |
| LAUNCHTECH, LLC | \$ 478,590 | 2024 | 12/20/2023 | Evergreen | Technology - Hardware |
| J&J DETAILS & MAINTENANCE LLC | \$ 478,584 | 2024 | 12/11/2023 | 12/11/2024 | Other Professional Services |
| INTIVITY, INC. | \$ 476,760 | 2024 | 8/1/2020 | 5/31/2029 | Commodities/Supplies |
| BRITE | \$ 468,298 | 2024 | 12/23/2022 | 1/31/2026 | Technology - Software |
| CS BUSINESS SYSTEMS INC. | \$ 464,453 | 2024 | 3/14/2024 | Evergreen | Technology - Software |
| HEALTH SYSTEM SERVICE | \$ 461,427 | 2024 | 6/1/2016 | 5/31/2025 | Commodities/Supplies |
| ALTERA DIGITAL HEALTH, INC. | \$ 452,430 | 2024 | 2/7/2022 | Evergreen | Technology - Software |
| FERGUSON ELECTRIC SVC | \$ 448,009 | 2024 | 10/1/2020 | 9/30/2025 | Design and Construction/Maintenance |
| FUJIFILM HEALTHCARE AMERICAS | \$ 442,204 | 2024 | 3/1/2024 | 2/28/2029 | Technology - Software |
| STANSBERRY AND KNIGHT | \$ 436,420 | 2024 | 3/28/2018 | 12/31/2025 | Other Professional Services |
| CDW GOVERNMENT INC | \$ 429,509 | 2024 | 11/1/2020 | 10/31/2026 | Commodities/Supplies |
| KCI | \$ 427,046 | 2024 | 6/1/2022 | 5/31/2025 | Commodities/Supplies |
| NUANCE | \$ 425,318 | 2024 | 6/30/2014 | 6/30/2025 | Technology - Software |
| B BRAUN MEDICAL INC. | \$ 424,035 | 2024 | 7/1/2023 | 7/1/2026 | Commodities/Supplies |
| HEALTH CATALYST, INC. | \$ 422,525 | 2024 | 8/6/2018 | 8/5/2026 | Technology - Software |
| UNIVERSITY GYNECOLOGISTS | \$ 422,496 | 2024 | 10/1/2016 | 9/30/2025 | Other Professional Services |
| KEYSTONE PERFUSION SERVICES, PC | \$ 421,958 | 2024 | 1/1/2020 | 4/1/2025 | Other Professional Services |
| KERECIS | \$ 418,616 | 2024 | 4/1/2024 | 3/31/2027 | Commodities/Supplies |
| PARAGON 28, INC. | \$ 417,172 | 2024 | 9/21/2020 | 8/31/2027 | Commodities/Supplies |
| RICOTTA, MATTREY, CALLOCCHIA, | \$ 409,477 | 2024 | 4/1/2021 | 4/1/2026 | Legal Services |
| AXOGEN CORP | \$ 387,698 | 2024 | 8/4/2021 | 3/31/2027 | Commodities/Supplies |
| UB ORAL AND MAXILLOFACIAL | \$ 371,118 | 2024 | 6/17/2020 | 6/15/2027 | Other Professional Services |
| UKG KRONOS SYSTEMS, LLC | \$ 370,679 | 2024 | 12/30/2022 | 12/31/2027 | Technology - Software |
| OLYMPUS AMERICA INC | \$ 367,295 | 2024 | 11/18/2022 | 11/17/2025 | Commodities/Supplies |
| FFF ENTERPRISES INC | \$ 365,668 | 2024 | 4/24/2020 | 3/31/2025 | Commodities/Supplies |
| SUMMIT HEALTH CARE | \$ 359,650 | 2024 | 9/2/2014 | 11/30/2025 | Other Professional Services |
| MIZUHO AMER INC | \$ 359,308 | 2024 | 2/1/2023 | 1/31/2027 | Commodities/Supplies |
| INSPIRE MEDICAL SYSTEMS, INC. | \$ 354,075 | 2024 | 4/2/2018 | 4/1/2025 | Commodities/Supplies |
| CHANGE HEALTHCARE | \$ 353,016 | 2024 | 6/1/2008 | 8/31/2025 | Staffing Services |
| UNIV. OPHTHALMOLOGY SERVICE, INC. | \$ 351,207 | 2024 | 4/1/2013 | 2/28/2029 | Other Professional Services |
| PATTERSON DENTAL INC | \$ 349,201 | 2024 | 4/1/2023 | 3/31/2026 | Commodities/Supplies |
| | 4 | | - 14 - 1- | | |
| FAVORITE HEALTHCARE STAFFING INC DCB ELEVATOR CO INC | \$ 342,404 \$ 339,596 | 2024 2024 | 7/22/2021 7/20/2023 | 12/31/2025 7/19/2028 | Staffing Services Design and Construction/Maintenance |

| UP TO DATE | \$ 338,393 | 2024 | 9/1/2023 | 8/31/2028 | Technology - Software |
|---|--------------------------|--------------|------------------------|------------------------|---|
| MORRISON LIVING | \$ 333,130 | 2024 | 1/1/2013 | 12/31/2023 | Other Professional Services |
| BROOK, INC | \$ 329,335 | 2024 | 7/1/2022 | 6/30/2025 | Technology - Software |
| EVERGREEN MEDICAL SERVICES, INC | \$ 324,822 | 2024 | 11/28/2021 | 11/30/2026 | Design and Construction/Maintenance |
| AMER EXPRESS CPC | \$ 320,813 | 2024 | 9/30/2021 | 9/29/2026 | Other |
| RUPP PFALZGRAF LLC | \$ 314,023 | 2024 | 11/1/2019 | 5/3/2027 | Legal Services |
| CENTRAL RADIOPHARMACEUTICAL SVC | \$ 311,403 | 2024 | 4/12/2024 | 10/1/2026 | Commodities/Supplies |
| WRIGHT MEDICAL TECHNOLOGY INC | \$ 306,761 | 2024 | 5/19/2021 | 12/31/2025 | Commodities/Supplies |
| MERGE HEALTHCARE | \$ 304,986 | 2024 | 6/29/2017 | Evergreen | Technology - Software |
| SYSMEX | \$ 303,247 | 2024 | 8/1/2022 | 7/31/2025 | Commodities/Supplies |
| US POSTAL SERVICE | \$ 300,000 | 2024 | 6/4/2001 | Evergreen | Commodities/Supplies |
| GRAYLINE NIAGARA FALLS/BUFFALO | \$ 295,510 | 2024 | 12/4/2017 | 11/15/2024 | Other Professional Services |
| BIOFIRE DIAGNOSTICS LLC | \$ 293,830 | 2024 | 1/1/2021 | 1/31/2029 | Commodities/Supplies |
| AMN LEADERSHIP SOLUTIONS, INC | \$ 292,302 | 2024 | 4/9/2018 | 4/9/2026 | Other Professional Services |
| SYNTHES MAXILLOFACIAL | \$ 290,689 | 2024 | 9/18/2020 | 11/12/2027 | Commodities/Supplies |
| ABBVIE INC | \$ 290,459 | 2024 | 10/31/2022 | 10/31/2027 | Commodities/Supplies |
| MENTAL HEALTH ADVOCATES | \$ 288,246 | 2024 | 5/9/2019 | 5/9/2025 | Other Professional Services |
| ROACH, BROWN, | \$ 284,921 | 2024 | 4/13/2021 | 4/14/2026 | Legal Services |
| TRI-DELTA RESOURCES CORP | \$ 278,520 | 2024 | 5/1/2022 | 4/30/2025 | Technology - Software |
| VOCERA COMMUNICATIONS INC | \$ 277,590 | 2024 | 12/13/2019 | 9/30/2024 | Technology - Hardware |
| WELLSKY CORPORATION | \$ 268,252 | 2024 | 3/26/2019 | 3/26/2026 | Technology - Software |
| HEALTHSTREAM | \$ 265,236 | 2024 | 7/31/2024 | 7/30/2029 | Technology - Software |
| KIDENEY ARCHITECTS PC | \$ 261,093 | 2024 | 5/31/2018 | 5/30/2025 | Design and Construction/Maintenance |
| SIRTEX MEDICAL, INC. | \$ 260,855 | 2024 | 7/13/2023 | Evergreen | Commodities/Supplies |
| OPTUM360 LLC | \$ 257,304 | 2024 | 5/22/2017 | 5/21/2027 | Technology - Software |
| VERIZON WIRELESS | \$ 254,634 | 2024 | 5/30/2008 | 2/25/2030 | Other |
| TELEFLEX LLC | \$ 252,006 | 2024 | 7/1/2022 | 6/30/2026 | Commodities/Supplies |
| COOK INC | \$ 250,384 | 2024 | 7/1/2022 | 6/30/2025 | Commodities/Supplies |
| AQUA SCIENCES INC | \$ 241,308 | 2024 | 10/17/2001 | Evergreen | Other Professional Services |
| FREED MAXICK CPAs PC | \$ 238,721 | 2024 | 1/1/2022 | 12/31/2025 | Consulting Services |
| DRFIRST.COM INC | \$ 237,920 | 2024 | 9/1/2011 | 9/15/2025 | Technology - Software |
| ISECURE, LLC | \$ 237,632 | 2024 | 7/24/2022 | 7/23/2025 | Technology - Software |
| PENUMBRA, INC. | \$ 236,842 | 2024 | 11/1/2021 | 10/31/2027 | Commodities/Supplies |
| BUFFALO CITY MISSION | \$ 235,550 \$ 231.850 | 2024 2024 | 8/3/2015 | 10/31/2025 | Other |
| CARESTREAM HEALTH INC ARTERIOCYTE MEDICAL SYSTEMS | - / | 2024 | 11/12/2020 7/1/2021 | 12/25/2027 | Technology - Software Commodities/Supplies |
| VOYCE, INC. | \$ 231,490 \$ 229,156 | 2024 | 8/1/2021 | 6/30/2027 7/31/2025 | Other Professional Services |
| FISHER HEALTHCARE | \$ 228,779 | 2024 | 1/1/2019 | 4/30/2028 | Commodities/Supplies |
| LAWLEY AGENCY, LLC | \$ 227,344 | 2024 | 5/1/2021 | 4/30/2028 | Other Professional Services |
| INTELLIGENT MEDICAL OBJECTS, INC. | \$ 224,675 | 2024 | 8/1/2013 | 11/19/2025 | Technology - Software |
| DRAEGER MEDICAL | \$ 222,853 | 2024 | 7/1/2023 | 6/30/2026 | Commodities/Supplies |
| ORTHOFIX, INC. | \$ 215,859 | 2024 | 11/1/2023 | 10/31/2026 | Commodities/Supplies |
| OFFICE DEPOT | \$ 213,633 | 2024 | 8/1/2023 | 7/31/2026 | Commodities/Supplies |
| KARL STORZ ENDOSCOPY-AMERICA | \$ 213,041 | 2024 | 1/1/2024 | 12/31/2026 | Commodities/Supplies |
| INT'L INSTITUTE OF BFLO | \$ 212,580 | 2024 | 1/1/2018 | 2/28/2026 | Other Professional Services |
| NXSTAGE MEDICAL INC | \$ 212,233 | 2024 | 6/8/2021 | 6/7/2025 | Commodities/Supplies |
| AIRGAS EAST | \$ 211,689 | 2024 | 11/1/2020 | 5/31/2026 | Commodities/Supplies |
| BAYER CORPORATION | \$ 209,520 | 2024 | 1/1/2024 | 12/31/2026 | Commodities/Supplies |
| DE LAGE LANDEN FINANCIAL | \$ 208,818 | 2024 | 2/15/2024 | 2/14/2027 | Financial Services |
| CROWN CASTLE FIBER, LLC. | \$ 207,149 | 2024 | 3/2/2010 | 4/27/2026 | Telecommunication Equipment or Services |
| CANON MEDICAL SYSTEMS USA, INC. | \$ 203,875 | 2024 | 2/10/2021 | 2/9/2026 | Other Professional Services |
| SYNOVIS MICRO COMPANIES ALLIANCE | \$ 203,150 | 2024 | 1/31/2012 | Evergreen | Commodities/Supplies |
| SAMIE, MOHAMMAD REZA | \$ 201,710 | 2024 | 6/1/2016 | 5/31/2025 | Other Professional Services |
| PRESS GANEY ASSOCIATES INC | \$ 200,069 | 2024 | 7/1/2014 | 7/31/2025 | Other Professional Services |
| RSM MCGLADREY INC | \$ 199,100 | 2024 | 12/3/2018 | Evergreen | Consulting Services |
| WNY TRANSPORTATION SERVICES, | \$ 194,231 | 2024 | 10/1/2020 | 9/30/2025 | Other Professional Services |
| TRISALUS LIFE SCIENCES | \$ 193,750 | 2024 | 9/19/2023 | 9/19/2025 | Commodities/Supplies |
| THE CHARTIS GROUP, LLC | \$ 190,837 | 2024 | 6/10/2019 | 9/30/2025 | Consulting Services |
| NALCO CO | \$ 190,463 | 2024 | 4/27/2018 | 4/26/2028 | Commodities/Supplies |
| UNITED NETWORK FOR ORGAN SHARING | \$ 187,010 | 2024 | 3/31/2017 | Evergreen | Other Professional Services |
| SIEMENS INDUSTRY INC | \$ 186,835 | 2024 | 5/20/2022 | 2/28/2025 | Other Professional Services |
| WNY INDEPENDENT LIVING | \$ 183,948 | 2024 | 9/1/2020 | 8/31/2026 | Other Professional Services |
| GREAT LAKES BUILDING SYSTEMS | \$ 183,411 | 2024 | 8/27/2019 | 8/26/2034 | Design and Construction/Maintenance |
| XEROX CORPORATION | \$ 177,033 | 2024 | 8/1/2019 | 7/31/2025 | Other |
| BUFFALO PAPER AND TWINE CO | \$ 175,122 | 2024 | 11/1/2023 | 10/31/2026 | Commodities/Supplies |

| MAKO SURGICAL CORPORATION | \$ 175,000 | 2024 | 9/21/2022 | 9/20/2027 | Commodities/Supplies |
|--|--------------------------|--------------|------------|--------------------------|--|
| ZOLL MEDICAL CORPORATION | \$ 172,174 | 2024 | 9/1/2022 | 8/31/2025 | Commodities/Supplies |
| STRYKER ENDOSCOPY | \$ 169,407 | 2024 | 1/1/2024 | 12/31/2026 | Commodities/Supplies |
| QIAGEN | \$ 167,843 | 2024 | 3/15/2021 | Evergreen | Commodities/Supplies |
| MID-CITY OFFICE FURNITURE | \$ 167,704 | 2024 | 12/5/2023 | 12/1/2028 | Commodities/Supplies |
| FLEXICARE, INC | \$ 167,400 | 2024 | 5/1/2023 | 8/31/2026 | Commodities/Supplies |
| ADVANCED STERILIZATION | \$ 159,554 | 2024 | 3/1/2021 | 2/28/2027 | Commodities/Supplies |
| ALLOSOURCE | \$ 158,569 | 2024 | 7/1/2021 | 6/30/2027 | Commodities/Supplies |
| VANTIVE US HEALTHCARE LLC | \$ 158,176 | 2024 | 2/2/2024 | Evergreen | Commodities/Supplies |
| DENTSPLY IH, INC. | \$ 157,550 | 2024 | 6/2/2014 | Evergreen | Commodities/Supplies |
| GE HEALTHCARE FIN SERVICES | \$ 155,964 | 2024 | 12/15/2023 | 12/15/2026 | Commodities/Supplies |
| TELETRACKING | \$ 151,276 | 2024 | 3/1/2016 | 10/5/2028 | Technology - Software |
| RISKONNECT, INC. | \$ 149,373 | 2024 | 6/17/2022 | 6/16/2025 | Technology - Software |
| GP ROCHESTER dba PAUL DAVIS | \$ 149,040 | 2024 | 11/20/2023 | 11/20/2026 | Design and Construction/Maintenance |
| PENTAX MEDICAL | \$ 148,731 | 2024 | 4/1/2018 | 1/31/2026 | Commodities/Supplies |
| BAXTER BIOSCIENCE | \$ 147,963 | 2024 | 7/1/2022 | 6/30/2025 | Commodities/Supplies |
| LINDE GAS & EQUIPMENT INC. | \$ 147,832 | 2024 | 11/1/2020 | 5/31/2026 | Commodities/Supplies |
| CROTHALL HEALTHCARE | \$ 146,320 | 2024 | 3/1/2019 | 12/31/2023 | Other Professional Services |
| PALO ALTO NETWORKS | \$ 146,104 | 2024 | 2/14/2014 | 2/13/2023 | Technology - Software |
| PMA COMPANIES | \$ 144,446 | 2024 | 10/1/2021 | 9/30/2026 | Other Professional Services |
| TRUSTED MANAGED SERVICES | \$ 144,446 | 2024 | 7/1/2021 | 6/30/2028 | Other Professional Services |
| | | 2024 | 7/31/2024 | | Other Professional Services |
| PRE-EMPLOY.COM INC GENERAL PHYSICIAN SUB II, PLLC | -, | 2024 | | Evergreen | Other Professional Services Other Professional Services |
| | . , | | 1/1/2018 | Evergreen | |
| | \$ 143,150 \$ 142,996 | 2024 | 10/12/2023 | 10/11/2025 12/31/2025 | Commodities/Supplies Other Professional Services |
| UNIVERSITY NEUROLOGY, INC. | | 2024 | 6/14/2016 | | |
| INTELLIPRINT SOLUTIONS, INC | \$ 139,571 | 2024 | 8/1/2022 | 7/31/2025 | Commodities/Supplies |
| ORLICK, ARTHUR | \$ 138,703 | 2024 | 1/1/2018 | 12/31/2025 | Other Professional Services |
| TERUMO MEDICAL CORPORATION | \$ 138,157 | 2024 | 11/12/2018 | 9/30/2025 | Commodities/Supplies |
| CONSORTIUM INFORMATION SERVICES INC | \$ 136,639 | 2024 | 7/2/2001 | Evergreen | Technology - Software |
| LARRY'S DENTAL LAB, INC. | \$ 132,964 | 2024 | 12/31/2022 | 12/31/2025 | Commodities/Supplies |
| INNOVICE, LLC | \$ 132,603 | 2024 | 9/14/2023 | 9/13/2025 | Commodities/Supplies |
| BARD PERIPHERAL VASCULAR INC | \$ 132,329 | 2024 | 2/1/2023 | 1/31/2026 | Commodities/Supplies |
| MCG HEALTH LLC | \$ 131,352 | 2024 | 8/1/2022 | 7/31/2025 | Technology - Software |
| LIFENET | \$ 128,385 | 2024 | 7/1/2021 | 6/30/2027 | Commodities/Supplies |
| B.E. SMITH LLC | \$ 128,101 | 2024 | 4/9/2018 | 4/9/2026 | Staffing Services |
| GE HEALTHCARE | \$ 126,883 | 2024 | 1/1/2024 | 12/31/2026 | Other Professional Services |
| FREE UP MD, LLC | \$ 126,622 | 2024 | 1/12/2023 | 1/11/2025 | Other Professional Services |
| KLS MARTIN L P | \$ 125,544 | 2024 | 11/1/2019 | 10/31/2025 | Commodities/Supplies |
| CARINGTON HOME SAFETY, INC | \$ 125,487 | 2024 | | 3/30/2026 | |
| SPOK, INC. | \$ 123,565 | 2024 | 2/5/2022 | 2/5/2027 | Technology - Software |
| UNITED UNIFORM CO INC | \$ 123,118 | 2024 | 4/29/2022 | 4/28/2027 | Commodities/Supplies |
| PROVATION SOFTWARE, INC | \$ 121,436 | 2024 | 7/29/2024 | 7/28/2027 | Technology - Software |
| CREST/GOOD MFG CO INC | \$ 119,601 | 2024 | 1/4/2012 | Evergreen | Commodities/Supplies |
| ECOLAB/MICROTEK MEDICAL | \$ 117,644 | 2024 | 3/1/2020 | 2/28/2025 | Commodities/Supplies |
| WESCO DISTRIBUTION INC. | \$ 117,293 | 2024 | 1/10/2024 | 1/10/2029 | Commodities/Supplies |
| HYLAND SOFTWARE, INC. | \$ 116,462 | 2024 | 9/30/2015 | Evergreen | Technology - Software |
| HENRY SCHEIN PRACTICE SOLUTIONS | \$ 116,238 | 2024 | 1/1/2022 | 12/31/2025 | Commodities/Supplies |
| ORTHO CLINICAL DIAGNOSTICS | \$ 115,963 | 2024 | 2/1/2022 | 1/31/2025 | Commodities/Supplies |
| MANATT PHELPS & PHILLIPS LLP | \$ 115,100 | 2024 | 3/20/2024 | 12/31/2025 | Consulting Services |
| CALYXO INC | \$ 114,706 | 2024 | 5/16/2024 | 5/15/2026 | Commodities/Supplies |
| VERTOS MEDICAL, INC | \$ 113,700 | 2024 | 5/1/2021 | 4/30/2025 | Commodities/Supplies |
| SIEMENS MEDICAL | \$ 113,598 | 2024 | 12/15/2022 | 12/15/2027 | Commodities/Supplies |
| ANGIO DYNAMICS INC | \$ 113,166 | 2024 | 12/1/2023 | 11/30/2026 | Commodities/Supplies |
| BUFFALO CPR & | \$ 111,904 | 2024 | 8/16/2017 | Evergreen | Other Professional Services |
| EAST COAST ORTHOTIC | \$ 111,835 | 2024 | 6/20/2016 | 6/19/2025 | Commodities/Supplies |
| MICROSOFT CORPORATION | \$ 111,421 | 2024 | 1/26/2022 | 1/25/2027 | Technology - Software |
| CARA MEDICAL | \$ 111,022 | 2024 | 3/15/2012 | Evergreen | Commodities/Supplies |
| BUFFALO CANVAS | \$ 110,875 | 2024 | 11/1/2020 | 10/31/2025 | Commodities/Supplies |
| RELIEVANT MEDSYSTEMS, INC | \$ 110,205 | 2024 | 5/1/2023 | 4/30/2025 | Commodities/Supplies |
| HYBRIDGE SOLUTIONS, INC. | \$ 108,957 | 2024 | 5/31/2023 | 6/2/2027 | Other Professional Services |
| DONICO CRECIALIZER OVETENACING | 1 A | 2024 | 8/27/2019 | 8/26/2034 | Commodities/Supplies |
| RONCO SPECIALIZED SYSTEMS INC | \$ 108,250 | 2024 | | | |
| ALPHATEC SPINE INC | \$ 108,250 \$ 106,651 | 2024 | 4/1/2018 | 7/31/2025 | Commodities/Supplies |
| | | 2024 2024 | | 7/31/2025 6/14/2025 | Commodities/Supplies Technology - Software |
| ALPHATEC SPINE INC | \$ 106,651 | 2024 | 4/1/2018 | | |

| GLAXO SMITH KLINE | \$ 103,683 | 2024 | 7/1/2015 | 6/30/2025 | Commodities/Supplies |
|------------------------------|---------------|------|-----------|-----------|---|
| TRI-ANIM HEALTH SERVICES INC | \$ 102,753 | 2024 | 5/1/2023 | 8/31/2026 | Technology - Software |
| POWER-FLO TECHNOLOGIES INC | \$ 102,658 | 2024 | 7/1/2022 | 6/30/2025 | Commodities/Supplies |
| WINDSTREAM | \$ 101,655 | 2024 | 9/28/2021 | 9/15/2025 | Telecommunication Equipment or Services |
| CAREFUSION | \$ 101,510 | 2024 | 7/1/2021 | 6/30/2026 | Other Professional Services |
| ARC BUILDING PARTNERS, LLC | \$ 101,375 | 2024 | 2/18/2019 | 2/18/2029 | Design and Construction/Maintenance |
| ZAVATION MEDICAL PRODUCTS | \$ 100,074 | 2024 | 12/6/2021 | 12/5/2029 | Commodities/Supplies |

BY-LAWS

OF

ERIE COUNTY MEDICAL

CENTER CORPORATION

As Amended Through September 23, 2022

TABLE OF CONTENTS

| Preamble1 |
|---|
| Article I - Offices1 |
| Article II - Purpose of By-Laws1 |
| Article III - Corporate Purpose1 |
| Article IV - Erie County Medical Center Corporation Board of Directors1 |
| Section 1 – General Powers1 |
| Section 2 –Hiring Powers2 |
| Section 3 - Voting Directors2 |
| Section 4 - Nonvoting Representatives2 |
| Section 5 - Resignation2 |
| Section 6 - Removal2 |
| Section 7 – Vacancies2 |
| Section 8 - Monthly Meetings2 |
| Section 9 - Annual & Special Meetings3 |
| Section 10 - Open Meetings Law3 |
| Section 11 - Quorum |
| Section 12 – Telephone Meetings |
| Section 13 – Action by Written Consent |
| Section 14 – Minutes of Meetings |
| Section 15 - Compensation3 |
| Section 16 – Defense and Indemnification3 |
| Section 17 – Extension of Credit4 |

| Article V - Officers | ł |
|---|---|
| Section 1 - General4 | - |
| Section 2 - Election, Term of Office4 | - |
| Section 3 - Resignation4 | - |
| Section 4 - Removal4 | - |
| Section 5 - Vacancies | - |
| Section 6 – Chairperson of the Board4 | - |
| Section 7 – Vice-Chairperson(s) of the Board5 | , |
| Section 8 - Chief Executive Officer5 | , |
| Section 9 – President5 | |
| Section 10 – Secretary & Assistant Secretary5 | , |
| Section 11 - Treasurer6 |) |
| Section 12 – Immediate Past Chair6 | , |
| Article VI - Committees |) |
| Section 1 – General | 5 |
| Section 2 – Appointment of Committees6 |) |
| Section 3 – Structure of Committees | 5 |
| Section 4 – Resignation | 5 |
| Section 5 – Removal | 7 |
| Section 6 – Vacancies | , |
| Section 7 - Quorum | , |
| Section 8 - Voting | , |
| Section 9 - Minutes | , |
| Section 10 - The Executive Committee | 1 |

| Section 11 - The Quality Improvement Committee7 |
|---|
| Section 12 - The Finance Committee |
| Section 13 - The Audit & Compliance Committee |
| Section 14 – Buildings and Grounds Committee9 |
| Section 15 - The Human Resources Committee9 |
| Section 16 - The Executive Compensation/Evaluation Committee |
| Section 17 - Terrace View Quality Improvement Committee |
| Section 18 - The Governance Committee10 |
| Section 19 - The Investment Committee10 |
| Section 20 - The Contracts Committee |
| Article VII - Medical/Dental Staff11 |
| Section 1 – Organization11 |
| Section 2 - Medical Staff Governance Documents11 |
| Section 3 - Appointment of Medical Staff11 |
| Section 4 – Authority for Medical Staff Conduct |
| Section 5 - Duties of the Medical Staff12 |
| Section 6 – Quality of Patient Care12 |
| Section 7 - Rights at Meetings12 |
| Article VIII - Standards of Patient Care12 |
| Article IX - The School of Medicine - State University of New York at Buffalo13 |
| Article X - Subsidiary Corporations and Entities |

| Article XI - Code of Ethics and Conflicts of Interest | 13 |
|--|----|
| Section 1 – Responsibility of Members of the Board and Employees | 13 |
| Section 2 – Implementation of Code of Ethics | 14 |
| Section 3 - Compliance | 14 |
| Section 4 – Conflict of Interest Policy | 14 |
| Section 5 – Disclosure of Personal Interest and Abstention | 15 |
| Section 6 – Self-Dealing | 15 |
| Section 7 – Influence of Decision Makers | 15 |
| Section 8 – No Forfeit of Office of Employment | 15 |
| Article XII - Amendments | 15 |

By-Laws

OF

ERIE COUNTY MEDICAL CENTER CORPORATION

PREAMBLE

The State of New York has enacted legislation, codified at Article 10-C of the Public Authorities Law of the State of New York (the "Act"), creating the Erie County Medical Center Corporation ("ECMCC" or the "Corporation"). These by-laws are intended to supplement the requirements of the Act.

ARTICLE I

OFFICES

ECMCC may maintain offices at such places within or without Erie County, New York as the Board of Directors may, from time to time, determine.

ARTICLE II

PURPOSE OF BY-LAWS

Pursuant to the broad powers granted by the Act, the Board of Directors of ECMCC (the "Board") has adopted these By-Laws, to govern and manage its proceedings and affairs and for the advice and guidance of its members, and nothing contained in these By-Laws shall be deemed, nor are they intended in any manner or degree, to limit or restrict the power and right of the Board under existing law, to manage, control, operate and administer ECMCC and its personnel, patients and medical staff.

ARTICLE III CORPORATE PURPOSE

To continue as a general, municipal hospital and provide health care services and health facilities for the benefit of the residents of the State of New York and the County of Erie, including persons in need of health care services without the ability to pay, as required by law.

ARTICLE IV ERIE COUNTY MEDICAL CENTER CORPORATION BOARD OF DIRECTORS

Section 1. General Powers.

In addition to the powers and authorities expressly conferred by these By-laws, the Board may exercise all such general and special powers of the Corporation and do all such lawful acts and things as enumerated by the Act.

Section 2. <u>Hiring Powers.</u>

The Board shall hire, determine the compensation and benefits, and annually review the performance of the Chief Executive Officer ("CEO") and President of the Corporation. Appointments made to fill the roles of the Chief Operating Officer ("COO"), Chief Financial Officer ("CFO"), Chief Medical Officer ("CMO"), Administrator of Terrace View, Chief Nursing Officer ("CNO"), Chief Strategy Officer, and General Counsel of the Corporation shall be made by the CEO of the Corporation, who shall thereafter also be responsible for determining the compensation and benefits of the persons occupying these positions and for the annual review of the incumbents. The Board shall have the authority to discharge the CEO with or without cause; provided that the removal shall not prejudice the contract rights, if any, of such executive. The CEO shall have the authority to discharge the COO, CFO, CMO, Administrator of Terrace View, Chief Nursing Officer, Chief Strategy Officer, and General Counsel with or without cause, provided that the removal shall not prejudice the contract rights, if any, of such executive.

Section 3. Voting Directors.

The Corporation shall be governed by fifteen voting Directors. The membership, term of office, selection of the voting Directors and the powers and duties of the Board shall be in accordance with the Act and these By-laws.

Section 4. Nonvoting Representatives.

The Corporation shall have four nonvoting Representatives. The term of office, selection and powers and duties of the nonvoting Representatives shall be in accordance with the Act and these By-laws. For the purpose of these By-Laws, the term "member" or "Board member" shall refer to both voting Directors and non- voting Representatives.

Section 5. Resignation.

Any Director or Representative may resign at any time by giving written notice to the Chairperson of the Board. Such resignation shall take effect at the time specified therein and unless otherwise specified therein the acceptance of such resignation shall not be necessary to make it effective.

Section 6. Removal.

Members of the Board may be removed from office by the Board for inefficiency, neglect of duty, or misconduct of any kind, including but not limited to violation of the law, after the Board has given such member a copy of the charges against him or her and an opportunity to be heard in person or by counsel in his or her defense, upon not less than ten days' notice.

Section 7. Vacancies.

Vacancies occurring other than by expiration of term shall be filled for the unexpired terms in the manner provided for original appointment in accordance with the Act.

Section 8. Monthly Meetings.

The Board shall hold regular monthly meetings at the ECMCC offices or other convenient locations as designated by the Board at such time as the Board may designate. In the event that a previously scheduled regular monthly meeting may not be required for a particular month, the Board may cancel that meeting.

Section 9. <u>Annual & Special Meetings.</u>

A meeting of the Board shall be held annually at which time officers of the Corporation shall be elected. A special meeting may be called by the Chairperson or Vice Chairperson acting in the Chairperson's absence, or by any three (3) members of the Board at any time upon proper notice under the Public Officers Law. The only action that can be taken at a special meeting is the consideration of the subject or subjects designated in the notice for the special meeting.

Section 10. Open Meetings Law.

All meetings of the Board shall comply with the requirements of Article 7 of the Public Officers Law. In a regular, annual or special meeting, the Board may request an Executive Session pursuant to Article 7 of the Public Officers Law or applicable sections of the Act.

Section 11. Quorum.

The powers of the Corporation shall be vested in and shall be exercised by the Board at a duly called and held meeting, where a quorum of eight Directors is present. No action shall be taken by the Corporation except pursuant to the favorable vote of at least eight Directors present at the meeting at which such action is taken.

Section 12. <u>Telephone Meetings.</u>

The members of the Board or any committee thereof may participate in a meeting of such Board or committee by means of a conference telephone or similar communications equipment allowing all persons participating in the meeting to hear each other at the same time. Participation by such means shall constitute presence in person at a meeting.

Section 13. Action by Written Consent.

To the extent permitted by law, any action required or permitted to be taken by the Board or any committee thereof may be taken without a meeting if all members of the Board or the committee consent in writing to the adoption of a resolution authorizing the action. The resolution and the written consents thereto by the members of the Board or committee shall be filed with the minutes of the proceedings of the Board or committee.

Section 14. Minutes of Meetings.

The Board shall keep a written record of all business conducted, including resolutions, findings, conclusions and recommendations that shall be filed with the minutes of the proceedings of the Board or committee.

Section 15. Compensation.

Neither the voting Directors nor the nonvoting Representatives shall receive compensation for their services but shall be reimbursed for all their actual and necessary expenses incurred in connection with their duties under the Act and these By-laws.

Section 16. Defense and Indemnification.

The Corporation shall defend and indemnify the Directors of the Corporation and its officers for any and all lawful actions executed in the performance of their duties, to the full extent to which indemnification is permitted under the laws of the State of New York.

Section 17. Extension of Credit.

Pursuant to New York Public Authorities Law Section 2824(5), the Corporation shall not, directly, or indirectly, including through any subsidiary, extend or maintain credit, arrange for the extension of credit, or renew any extension of credit, in the form of a personal loan to or for any Director, officer, or employee (or equivalent thereof) of the Corporation.

ARTICLE V

OFFICERS

Section 1. General.

The officers of the Corporation shall be elected by the Board and shall be comprised of a Chairperson of the Board, a Vice Chairperson of the Board, a CEO, a Secretary, and a Treasurer. The Board may also appoint an Assistant Secretary and such other officers as the Board shall from time to time provide. All such officers shall exercise the duties as described in the Act, applicable law, by these By-Laws, and/or by Board resolution.

Section 2. Election, Term of Office.

The officers of the Corporation shall be elected by the Board at its annual meeting. Each officer elected shall hold office until his successor has been duly chosen and has qualified or until his or her earlier resignation or removal.

Section 3. Resignation.

Any officer may resign at any time by giving written notice thereof to the Board, provided that the resignation shall not prejudice the contract rights, if any, of the Corporation. Any such resignation shall take effect at the time specified therein and unless otherwise specified therein the acceptance of such resignation shall not be necessary to make it effective.

Section 4. Removal.

The Directors shall have the authority to discharge any officer with or without cause; provided that the removal without cause shall not prejudice the contract rights, if any, of the officer.

Section 5. Vacancies.

In the event of a vacancy occurring in the office of the Chairperson or Vice Chairperson, any member designated by the Board shall serve as Acting Chairperson for that meeting. In the event of a vacancy occurring in any other office, any member designated by the Board shall serve as an Acting officer for that meeting.

Section 6. Chairperson of the Board.

The Directors shall, by majority vote, select one of the fifteen Directors as the Chairperson of the Board. The Chairperson shall preside over all meetings of the Board, shall chair the Executive Committee of the Board, and shall have such other duties as the Directors may provide. Other than the Governance Committee, the Chairperson shall serve <u>ex officio</u> on all Board committees with full voting rights. The Chairperson shall serve for a two-year term of office. No member of the Board shall be permitted to serve more than two consecutive two-year terms as Chairperson of the Board.

Section 7. Vice-Chairperson(s) of the Board.

The Directors shall, by majority vote, select one or more of the fifteen Directors as the Vice-Chairperson of the Board. The Vice-Chairperson shall preside over all meetings where the Chairperson of the Board is absent and shall have such other duties as the Directors may provide. The Vice-Chairperson shall serve for a two-year term of office. At least one Vice-Chairperson shall be designated by a majority vote of the Board as "Vice-Chair, Chair-Elect" in the second year of that Vice- Chairperson's term of office. At the conclusion of the term of the Vice-Chair, Chair-Elect, the Board shall retain authority to appoint the Vice-Chair, Chair-Elect or any other member of the Board of Directors as Chairperson of the Board of Directors.

Section 8. Chief Executive Officer.

The Board shall hire, set the compensation of, execute direct oversight of, and annually review the performance of the CEO. The CEO shall carry out the policies of the Board, provide services to the Board; and shall be subject to the By-Laws, rules and regulations of the Board. He or she shall have all the general powers and duties of a Superintendent of a public general municipal hospital as set forth and enumerated in the General Municipal Law of the State of New York, Section 129, sub. 1 through 9 as amended and of a chief executive officer as set forth in Title 10, subpart 405.3 of the New York Codes, Rules and Regulations and the Act. The CEO shall provide leadership, direction, and administration in all aspects of the Corporation's activities and other corporate entities to ensure compliance with established objectives and the realization of quality, economical health care services, and other related lines of business. The CEO shall ensure the Corporation's compliance with all applicable laws and regulations. The CEO shall submit monthly and special reports to the Board and its committees regarding strategic, operational and financial performance, along with the current status of ECMCC services and facilities. The CEO shall be expected to provide feedback to the Board regarding those employees which report directly to the CEO. The CEO shall ensure that subordinate officers provide meaningful reports to the Board regarding the previous month's activities. The CEO shall coordinate with the Board, Medical Staff, and other Corporation personnel to respond to the community's needs for quality healthcare services and monitor the adequacy of the Corporation's medical activities.

Section 9. President.

The Board shall hire, set the compensation and annually review the performance of the President. The duties of the President shall be distinct from the duties of other officers of the Corporation and shall be enumerated in a job description reviewed by the Executive Committee of the Board.

Section 10. Secretary & Assistant Secretary.

The Board shall, by majority vote, select either Directors or Representatives to serve as the Secretary and Assistant Secretary, if applicable. The Secretary shall send notices for all meetings of the Board. The Secretary shall act as custodian for all records and reports and shall be responsible for keeping and reporting of adequate records of all meetings of the Board. The Secretary may delegate these duties to another officer or employee of the Corporation to act on his/her behalf. The Secretary will approve and sign the minutes of all meetings of the Board which shall be kept in an official record book. In the absence of the Secretary at any meeting, the Assistant Secretary, if applicable, or any member designated by the Chairperson shall act as the Secretary for that meeting.

Section 11. Treasurer.

The Board shall, by majority vote, select either a Director or a Representative to serve as the Treasurer. The Treasurer shall monitor the financial affairs of ECMCC as managed by the officers of the Corporation. The Treasurer will also have the power to establish bank accounts in the name of the Corporation. He or she shall do and perform all other duties incident to the office of Treasurer as may be prescribed by the Board from time to time.

Section 12. Immediate Past Chair.

The Immediate Past Chair of the Board shall remain available to the Board and the Chair for purposes of transitional continuity and may be appointed to serve as a member of any Standing or Special Committee of the Board, assuming his or her term of office as a Director has not expired.

ARTICLE VI COMMITTEES

General Rules

Section 1. General.

The Standing Committees of the Board shall be: the Executive Committee, the Quality Improvement Committee, the Finance Committee, the Audit and Compliance Committee, the Building and Grounds Committee, the Human Resources Committee, the Executive Compensation Committee, the Terrace View Quality Improvement Committee, the Governance Committee, the Investment Committee and the Contracts Committee. At the discretion of the Chairperson, and upon the advice of the Board, additional special committees may be appointed to address specific issues.

Section 2. Appointment of Committees.

The Chairperson of the Board shall appoint all members of standing and special committees. Appointments will be made at the first regular meeting following the annual election of officers, or at such other time deemed necessary by the Chairperson. The Chairperson of the Board shall appoint a Chairperson for each committee. Committee Chairpersons shall serve one-year terms of office but are not prohibited from serving consecutive one-year terms. The Chairperson may appoint individuals other than Board members to committees either standing or special, except the Executive Committee.

Section 3. Structure of Committees.

In addition to the individual Committee duties set forth below, each Committee shall be tasked annually with reviewing their applicable charter and recommending changes thereto, as well as setting forth goals for the Committee for the upcoming year. Such goals shall be determined in consultation with the Chairperson of the Board.

Section 4. Resignation.

A committee member may resign at any time by giving written notice to the Chairperson of the Board. Such resignation shall take effect at the time specified therein and unless otherwise specified therein the acceptance of such resignation shall not be necessary to make it effective.

Section 5. Removal.

Committee members may be removed from committee membership by the Board for inefficiency, neglect of duty, or misconduct of any kind, including but not limited to, violation of the law, after the board has given such member a copy of the charges against him or her and an opportunity to be heard in person or by counsel in his or her defense, upon not less than ten days' notice.

Section 6. Vacancies.

Vacancies occurring otherwise than by expiration of term of office shall be filled for the unexpired terms by appointment from the Chairperson of the Board.

Section 7. Quorum.

At a committee meeting, a quorum shall be one-half the number of members of the committee.

Section 8. Voting.

Only the members of the Board serving on a Standing or Special Committee, or an appointed non-member of the Board serving on a Standing or Special Committee, and the Chairperson of the Board serving <u>ex officio</u>, shall have a vote.

Section 9. Minutes.

Each committee meeting shall have an agenda, time convened and adjourned recorded, and shall submit minutes of its meeting to the Secretary of the Board in advance of the regular monthly meeting.

Standing Committees

Section 10. The Executive Committee.

The Executive Committee shall consist of four (4) Board members. The Corporation's General Counsel and Chief Executive Officer shall serve <u>ex officio</u> as members of the Executive Committee. Other members of the Board may be added when advisable. The Chairperson shall preside at all meetings of the Committee. The Executive Committee shall meet at least quarterly, or upon the call of the Chairperson.

Section 11. The Quality Improvement Committee.

The Quality Improvement Committee shall consist of three (3) members. The Chairperson of the Committee may, in his or her discretion, request the presence of other persons, as the issues before the Committee may dictate. The Committee shall meet at least quarterly, or upon the call of the Chairperson. The Committee shall be responsible for the following:

- a. Inform the Board of patient safety, performance improvement and quality assurance issues of relevance to ECMCC.
- b. Establishment, maintenance and operation of a coordinated quality assurance program integrating the review of activities of all hospital services in order to enhance the quality of patient care and to identify and prevent professional malpractice. The specific responsibilities of the Committee are further set forth in the quality assurance plan of the hospital.
- c. Other duties and responsibilities as may be assigned from time to time by the Board.

Section 12. The Finance Committee.

The Finance Committee shall consist of five (5) financially literate members of the Board. The Chairperson of the Committee may, in his or her discretion, request the presence of other persons, as the issues before the Committee may dictate. The Finance Committee shall meet at least quarterly, or upon the call of the Chairperson. The Committee shall be responsible for the following:

- a. Review relevant budgets of the Corporation and maintain ongoing oversight of the financial situation of the Corporation.
- b. Oversee, evaluate, and where appropriate, make recommendations with respect to financial operations of the Corporation.
- c. Other duties and responsibilities as may be assigned from time to time by the Board.

Section 13. The Audit & Compliance Committee.

The Audit & Compliance Committee shall consist of at least four (4) members. At least three (3) of the Committee's members shall be independent, as that term is defined by state law. The Corporation's General Counsel shall serve <u>ex officio</u> as a member of the Audit & Compliance Committee. The Chairperson of the Committee may, in his or her discretion, request the presence of other persons, as the issues before the committee may dictate. The Audit & Compliance Committee shall meet at least quarterly, or upon the call of the Chairperson. The Committee shall be responsible for the following:

- a. Oversight of any independent auditors engaged by ECMCC.
- b. Oversight of all ECMCC internal audit processes.
- c. Collaboration with the Quality Improvement Committee in the establishment and maintenance of a coordinated quality assurance program.
- d. Collaboration with the Compliance Officer on the establishment, maintenance and operation of a comprehensive compliance program, which shall comply with the Office of the Inspector General Compliance Program Guidance for Hospitals. Specifically, the Committee shall:
 - 1. Analyze the legal requirements and specific risk areas of the health care industry,
 - 2. Assess existing policies that address legal requirements and risk areas for possible incorporation into the ECMCC compliance program,
 - 3. Work with ECMCC departments to develop standards of conduct and policies and procedures to promote compliance with the ECMCC compliance program,
 - 4. Recommend and monitor the development of internal systems and controls to carry out ECMCC's standards, policies and procedures as part of its daily operations,
 - 5. Determine appropriate strategy to promote compliance with the ECMCC compliance program and detection of possible violations, including fraud reporting mechanisms,
 - 6. Develop a system to solicit, evaluate and respond to complaints and problems, and
 - 7. Promote ethics, integrity, and compliance with laws, policies, and procedures.
- e. Other duties and responsibilities as may be assigned from time to time by the Board.

Section 14. Buildings and Grounds Committee.

The Buildings and Grounds Committee shall consist of three (3) members. The Corporation's General Counsel shall serve <u>ex officio</u> as a member of the Buildings and Grounds Committee. The Chairperson of the Committee may, at his or her discretion, request the presence of other persons, as the issues before the Committee may dictate. The Buildings and Grounds Committee shall meet at least quarterly, or upon the call of the Chairperson. The Committee shall be responsible for the following:

- a. Evaluation and provision of recommendations with respect to proposed and ongoing construction and renovation projects and budgets.
- b. Other duties and responsibilities as may be assigned from time to time by the Board.

Section 15. The Human Resources Committee.

The Human Resources Committee shall consist of three (3) members. The Chairperson of the Committee may, in his or her discretion, request the presence of other persons, as the issues before the Committee may dictate. The Committee will meet at least quarterly or upon the call of the Chairperson. The Committee shall be responsible for the following:

- a. Establishment of a formal channel of communication among the Board, ECMCC management and the Labor Unions.
- b. Responsibility for assuring that appropriate guidelines are in place and monitored to ensure and maintain open communication.
- c. Discussion of issues that arise in the operation of the hospital as they affect all parties.
- d. Other duties and responsibilities as may be assigned from time to time by the Board.

Section 16. The Executive Compensation/Evaluation Committee.

The Executive Compensation/Evaluation Committee shall consist of no more than four (4) members of the Board. No person whose compensation is determined by the Executive Compensation/Evaluation Committee may serve as a member of the Committee. The Chairperson of the Committee may, in his or her discretion, request the presence of other persons, as the issues before the committee may dictate. The Executive Compensation/Evaluation Committee shall meet at least quarterly, or upon the call of the Chairperson. The Committee shall be responsible for the following:

- a. Evaluation, at least annually, of the CEO and President of the Corporation.
- b. Determination of the compensation, including benefits, of the above listed Corporation executives.
- c. Other duties and responsibilities as may be assigned from time to time by the Board.

Section 17. The Terrace View Quality Improvement Committee.

The Terrace View Quality Improvement Committee shall consist of at least three (3) members. The Committee shall meet at least quarterly, or upon the call of the Chairperson. The Committee shall be responsible for the following:

- a. Establishment and maintenance of a coordinated quality assurance program as specifically applicable to Terrace View.
- b. Other duties and responsibilities as may be assigned from time to time by the Board.

Section 18. <u>The Governance Committee.</u>

The Governance Committee shall consist of at least four (4) independent members, as that term is defined in New York Public Authorities Law §2825. The Chief Executive Officer and the General Counsel for the Corporation shall serve <u>ex officio</u> as members of the Committee, and the Chairperson of the Board may attend Committee meetings but will not be a member of the Committee and will not vote. The Committee Chairperson may, at his or her discretion, request the presence of other persons as issues before the Committee may dictate. The Governance Committee shall meet at least semi- annually, or upon the call of the Committee Chairperson. The Committee shall be responsible for the following:

- a. Provision of information to the Board regarding current best governance practices.
- b. Review of corporate governance trends.
- c. Recommend updates to the Corporation's governance principles.
- d. Provision of advice to the Governor and to the Erie County Executive in their appointment of potential Board members regarding the skills and experience required of Board members.
- e. Annually review and, as necessary, make recommendations to the Board regarding updating of the Corporation's Bylaws; annually review and, as necessary, make recommendations to the applicable Committees regarding updates to Committee charters.
- f. Other duties and responsibilities as may be assigned from time to time by the Board.

Section 19. The Investment Committee.

The Investment Committee shall consist of at least three (3) members. The Chair of the Finance Committee and the Chief Executive Officer shall serve <u>ex officio</u> as members of the Investment Committee and the Chief Financial Officer shall serve as staff to the Committee. The Committee Chairperson may, at his or her discretion, request the presence of other persons as issues before the Committee may dictate. The Investment Committee shall meet at least semi-annually, or upon the call of the Committee Chairperson. The Committee shall be responsible for the following:

- a. Recommendations regarding the designation of the Corporation's investment officer.
- b. Recommendations regarding investment policies and procedures consistent with applicable law and the needs of the Corporation.
- c. Implementation of appropriate internal controls for investments.
- d. Recommendations regarding the selection of the Corporation's investment advisors and investment managers.
- e. Review of independent audits of the investment program.
- f. Review of quarterly reports from the Corporation's investment advisors and investment managers.
- g. Reports to the Board on a quarterly basis.
- h. Monitoring the Corporation's system of internal controls and the performance of the Corporation's investment advisors and investment managers.
- i. Other duties and responsibilities as may be assigned from time to time by the Board.

Section 20. The Contracts Committee.

The Contracts Committee shall consist of at least three (3) members. The Contracts Committee shall review and make recommendations to the Board with respect to the approval of all contracts required to be approved by the Board pursuant to Corporation policy and applicable law, including Section 2879(3)(b)(ii) of the Public Authorities Law. The Contracts Committee shall meet at least quarterly or upon the call of the Committee Chairperson. The Committee shall be responsible for the following:

- a. Review of contracts of the Corporation requiring Board approval and make recommendations to the Board regarding such contracts.
- b.
- c. Annually review contracts requiring such review pursuant to Corporation policy and/or applicable law.
- d. Redacting sensitive information from contracts before presentation to the Board to ensure compliance with the Corporation's contractual and confidentiality requirements.
- e. Report to the Board on a quarterly basis regarding the foregoing subsections.
- f. Other duties and responsibilities as may be assigned from time to time by the Board.

ARTICLE VII MEDICAL/DENTAL STAFF

Section 1. Organization.

The Board shall cause to be created a medical staff organization to be known as the ECMC Medical Dental Staff ("Medical Staff") whose membership shall be comprised of certain categories of health care practitioners, as determined by the Board. Members of the Medical Staff may only practice within the scope of privileges granted by the Board.

Section 2. Medical Staff Governance Documents.

The Medical Staff shall develop, adopt and at least once every three years review the following Medical Staff Governance Documents: By-Laws; Rules & Regulations; Credentials Procedures Manual; and Collegial Intervention, Peer Review, Fair Hearing & Appellate Review Procedures. These Governance Documents shall establish controls that are designed to ensure the achievement and maintenance of the highest quality medical care and high standards of professional and ethical practice. The Board shall approve all such Medical Staff Governance Documents.

Section 3. Appointment of Medical Staff.

Appointments and reappointments to the Medical Staff shall be made by the Board. The Board shall be responsible for granting and defining the scope of the clinical privileges to be exercised by each member of the Medical Staff, including but not limited to providing approval of modifications, suspensions and termination of such privileges and Medical Staff membership in accordance with the Medical Staff Governance Documents and written ECMCC policies. In acting on matters of Medical Staff membership and scope of privileges, the Board shall consider the recommendations of the Medical Staff's Medical Executive Committee. The procedures for Medical Staff appointment are more specifically outlined in the Medical Staff's Credentials Procedure Manual. Section 4. Authority for Medical Staff Conduct.

Ultimate responsibility for the conduct of the Medical Staff remains with the Board. The Board shall enforce compliance with all medical staff Governance Documents by all members of the Medical Staff. No assignment, referral or delegation of authority by the Board to the Medical Director, COO, CEO, the Medical Staff or any other person shall preclude the Board from exercising the authority required to meet its responsibility for the conduct of the Corporation. The Board retains the right to rescind any such delegation.

Section 5. Duties of the Medical Staff.

The Board shall delegate to the Medical Staff the authority to monitor, evaluate and document professional performance of Medical Staff members in accordance with its Governance Documents. The Board shall hold the Medical Staff accountable, through the chiefs of service of the departments and the Medical Director, for making recommendations based on well-defined and written criteria related to the goals and standards of the Corporation concerning Medical Staff appointments, reappointments and clinical privileges.

Section 6. Quality of Patient Care.

The Medical Staff is accountable to the Board for the quality of care provided to patients.

Section 7. Rights at Meetings.

Members of the Medical Staff shall be entitled to be heard at all public meetings and committee meetings of the Board.

ARTICLE VIII Standards of Patient Care

The Board shall require that the following patient care practices are implemented, shall monitor ECMCC's compliance with these patient care practices, and shall take corrective action as necessary to attain compliance:

- a. Every patient of ECMCC, whether an in-patient, emergency patient, or out-patient, shall be provided care that meets generally accepted standards of professional practice.
- b. Every patient is under the care of a health care practitioner who is a member of the medical staff.
- c. Patients are admitted to ECMCC only on the recommendation of a member of the medical staff permitted by the State law and Medical Staff Governance Documents to admit patients to the hospital.
- d. A physician, a registered physician's assistant or a nurse practitioner, under the general supervision of a physician, is on duty at all times in the hospital.
- e. A physician shall be responsible for the care of each patient with respect to any medical or psychiatric problem that is present on admission or develops during hospitalization.
- f. In the event that human research is conducted within ECMCC, written policies and procedures shall be adopted and implemented pursuant to the provisions of Public Health Law Article 24-A for the protection of human subjects.
- g. ECMCC shall have available at all times personnel sufficient to meet patient care needs.

ARTICLE IX <u>The School of Medicine</u> <u>State University of New York at Buffalo</u>

The Board strongly supports the relationship between ECMCC and the School of Medicine and Biomedical Sciences of the State University of New York at Buffalo through an affiliation agreement. The Board shall take all appropriate action to retain and enhance the benefits arising from said relationship provided that the Board shall hold uppermost the discharge of its legal and fiduciary duties to ECMCC.

ARTICLE X SUBSIDIARY CORPORATIONS AND ENTITIES

Except as expressly limited by law, the Corporation may exercise and perform all or part of its purposes, powers, duties, functions or activities through one or more subsidiary corporations or companies owned or controlled wholly or in part by the Corporation, which shall be formed pursuant to the Business Corporation Law, the Limited Liability Company Law, or the Not-For-Profit Corporation Law. Any such subsidiary may be authorized to act as a general or limited partner in a partnership or as a member of a limited liability company and to enter into an arrangement calling for an initial and subsequent payment by such subsidiary in consideration of an interest in revenues or other contractual rights. The Board has the exclusive authority to create subsidiaries or other entities related to the Corporation.

ARTICLE XI CODE OF ETHICS AND CONFLICTS OF INTEREST

Section 1. Responsibility of Members of the Board and Employees.

This Code of Ethics shall apply to all officers and employees of the Corporation. These policies shall serve as a guide for official conduct and are intended to enhance the ethical and professional performance of the Corporation's directors and employees and to preserve public confidence in the Corporation's mission. It is accordingly the responsibility of each member of the Board and each employee to perform in accordance with the following:

- a. Each member of the Board and all employees of the Corporation shall perform their duties with transparency, without favor and refrain from engaging in outside matters of financial or personal interest, including other employment, that could impair independence of judgment, or prevent the proper exercise of one's official duties.
- b. Each member of the Board and all employees shall not directly or indirectly, make, advise, or assist any person to make any financial investment based upon information available through the director's or employee's official position that could create any conflict between their public duties and interests and their private interests.
- c. Each member of the Board and all employees shall not accept or receive any gift or gratuities where the circumstances would permit the inference that: (a) the gift is intended to influence the individual in the performance of official business or (b) the gift constitutes a tip, reward, or sign of appreciation for any official act by the

individual. This prohibition extends to any form of financial payments, services, loans, travel reimbursement, entertainment, hospitality, thing or promise from any entity doing business with or before the Corporation.

- d. Each member of the Board and all employees shall not use or attempt to use their official position with the Corporation to secure unwarranted privileges for themselves, members of their family or others, including employment with the Corporation or contracts for materials or services with the Corporation.
- e. Each member of the Board and all employees must conduct themselves at all times in a manner that avoids any appearance that they can be improperly or unduly influenced, that they could be affected by the position of or relationship with any other party, or that they are acting in violation of their public trust.
- f. Each member of the Board and all employees may not engage in any official transaction with an outside entity in which they have a direct or indirect financial interest that may reasonably conflict with the proper discharge of their official duties.
- g. Each member of the Board and all employees shall manage all matters within the scope of the Corporation's mission independent of any other affiliations or employment. Directors, including ex officio board members, and employees employed by more than one government entity shall strive to fulfill their professional responsibility to the Corporation without bias and shall support the Corporation's mission to the fullest.
- h. Each member of the Board and all employees shall not use Corporation property, including equipment, telephones, vehicles, computers, or other resources, or disclose information acquired in the course of their official duties in a manner inconsistent with State or local law or policy and the Corporation's mission and goals.
- i. Each member of the Board and all employees are prohibited from appearing or practicing before the Corporation for two (2) years following employment with the Corporation consistent with the provisions of Public Officers Law.

Section 2. Implementation of Code of Ethics.

This Code of Ethics shall be provided to all members of the Board and all employees upon commencement of employment or appointment and shall be reviewed annually by the Governance Committee.

Section 3. Compliance.

The members of the Board agree to comply with all applicable local and state regulations and laws regarding conflicts of interest.

Section 4. Conflict of Interest Policy.

The Board shall develop, implement, and update as needed a written policy governing conflict of interest by members of the Board. The policy shall be reviewed annually by the Governance Committee and included and incorporated into these By-Laws as <u>Appendix A</u>.

Section 5. Disclosure of Personal Interest and Abstention.

It is the responsibility of every Board member to disclose to the Chairperson of the Board any personal or business interest in any matter that comes before the Board for consideration. Each member of the Board shall abstain from voting on any matter in which he or she has a personal or business interest.

Section 6. Self-Dealing.

The Corporation shall not engage in any transaction with a person, firm, or other business entity in which one or more of the Board members has a financial interest in such person, firm or other business entity, unless such interest is disclosed in good faith to the Board, and the Board authorizes such transaction by a vote sufficient for such purpose, without counting the vote of the interested Board member.

Section 7. Influence of Decision Makers.

No member of the Board shall use his or her position to influence the judgment or any decision of any Corporation employee concerning the procurement of goods or services on behalf of the Corporation.

Section 8. No Forfeit of Office or Employment.

Except as provided by law, no officer, member, or employee of the state or of any public corporation shall forfeit his or her office or employment by reason of his or her acceptance of appointment as a director, nonvoting representative, officer, or employee of the Corporation, nor shall such service as such a director, nonvoting representative, officer or employee be deemed incompatible or in conflict with such office or employment; and provided further, however, that no public officer elected to his or her office pursuant to the laws of the state or any municipality thereof may serve as a member of the governing body of the Corporation during his or her term of office.

ARTICLE XII

AMENDMENTS

These By-Laws of the Board may be amended by the affirmative vote of a quorum of members at the annual meeting, special or regular meetings of the Board, provided that a full presentation of such proposed amendment(s) shall have been presented to the Board at least thirty (30) days prior to the meeting, unless waived by majority of the whole number of the members of the Board.

A Resolution of the Board of Directors of Erie County Medical Center Corporation Approving Changes to the Corporation By-Laws

Approved March 25, 2025

WHEREAS, in accordance with Article XII of the Erie County Medical Center Corporation (the "Corporation") By-Laws, the Corporation may amend the By-Laws by the affirmative vote of a quorum of members at an annual, regular, or special meeting of the Board of Directors (the "Board"), following presentation of such proposed amendment at least thirty (30) days prior; and

WHEREAS, Article VI, Section 18 of the By-Laws delegates responsibility to the Board's Governance Committee to annually review and, as necessary, make recommendations to the Board regarding updates to the By-Laws; and

WHEREAS, the Governance Committee reviewed the By-Laws and presented the attached recommended changes to the Board; and

WHEREAS, on February 25, 2025, the Board was presented with the proposed changes to the By-Laws;

WHEREAS, on March 25, 2025, a quorum of the Board met and voted to approve the recommended changes;

NOW, THEREFORE, the Board of Directors resolves as follows:

1. The Board of Directors of Erie County Medical Center Corporation approves and ratifies the proposed changes to the Corporation By-Laws in accordance with the recommendations of the Governance Committee.

2. The Corporation is authorized to take all necessary steps to implement this Resolution.

3. This Resolution shall take effect immediately.

Sharon L. Hanson Corporation Secretary

BY-LAWS

OF

ERIE COUNTY MEDICAL

CENTER CORPORATION

As Amended Through September 23, 2022

Page 403 of 423

TABLE OF CONTENTS

| Preamble1 |
|---|
| Article I - Offices1 |
| Article II - Purpose of By-Laws1 |
| Article III - Corporate Purpose1 |
| Article IV - Erie County Medical Center Corporation Board of Directors1 |
| Section 1 – General Powers1 |
| Section 2 –Hiring Powers2 |
| Section 3 - Voting Directors2 |
| Section 4 - Nonvoting Representatives2 |
| Section 5 - Resignation2 |
| Section 6 - Removal2 |
| Section 7 – Vacancies2 |
| Section 8 - Monthly Meetings2 |
| Section 9 - Annual & Special Meetings3 |
| Section 10 - Open Meetings Law3 |
| Section 11 - Quorum |
| Section 12 – Telephone Meetings |
| Section 13 – Action by Written Consent |
| Section 14 – Minutes of Meetings |
| Section 15 - Compensation |
| Section 16 – Defense and Indemnification |
| Section 17 – Extension of Credit4 |

| Article V - Officers | 4 |
|--|---|
| Section 1 - General | 4 |
| Section 2 - Election, Term of Office | 4 |
| Section 3 - Resignation | 4 |
| Section 4 - Removal | 4 |
| Section 5 - Vacancies | 4 |
| Section 6 – Chairperson of the Board | 4 |
| Section 7 – Vice-Chairperson(s) of the Board | 5 |
| Section 8 - Chief Executive Officer | 5 |
| Section 9 – President | 5 |
| Section 10 – Secretary & Assistant Secretary | 5 |
| Section 11 - Treasurer | 6 |
| Section 12 – Immediate Past Chair | 6 |
| Article VI - Committees | 6 |
| Section 1 – General | 6 |
| Section 2 – Appointment of Committees | 6 |
| Section 3 – Structure of Committees | 6 |
| Section 4 – Resignation | 6 |
| Section 5 – Removal | 7 |
| Section 6 – Vacancies | 7 |
| Section 7 - Quorum | 7 |
| Section 8 - Voting | 7 |
| Section 9 - Minutes | 7 |
| Section 10 - The Executive Committee | 7 |

| Section 11 - The Quality Improvement Committee | 7 |
|---|------|
| Section 12 - The Finance Committee | .8 |
| Section 13 - The Audit & Compliance Committee | .8 |
| Section 14 – Buildings and Grounds Committee | .9 |
| Section 15 - The Human Resources Committee | .9 |
| Section 16 - The Executive Compensation/Evaluation Committee | .9 |
| Section 17 - Terrace View Quality Improvement Committee | .9 |
| Section 18 - The Governance Committee | .10 |
| Section 19 - The Investment Committee | .10 |
| Section 20 - The Contracts Committee | .11 |
| Article VII - Medical/Dental Staff | .11 |
| Section 1 – Organization | . 11 |
| Section 2 - Medical Staff Governance Documents | .11 |
| Section 3 - Appointment of Medical Staff | .11 |
| Section 4 – Authority for Medical Staff Conduct | .12 |
| Section 5 - Duties of the Medical Staff | .12 |
| Section 6 – Quality of Patient Care | .12 |
| Section 7 - Rights at Meetings | .12 |
| Article VIII - Standards of Patient Care | .12 |
| Article IX - The School of Medicine - State University of New York at Buffalo | .13 |
| Article X - Subsidiary Corporations and Entities | .13 |

| Article XI - Code of Ethics and Conflicts of Interest | 13 |
|--|------|
| Section 1 – Responsibility of Members of the Board and Employees | 13 |
| Section 2 – Implementation of Code of Ethics | 14 |
| Section 3 - Compliance | 14 |
| Section 4 – Conflict of Interest Policy | 14 |
| Section 5 – Disclosure of Personal Interest and Abstention | 15 |
| Section 6 – Self-Dealing | 15 |
| Section 7 – Influence of Decision Makers | 15 |
| Section 8 – No Forfeit of Office of Employment | 15 |
| Article XII - Amendments | . 15 |

By-Laws

OF

ERIE COUNTY MEDICAL CENTER CORPORATION

PREAMBLE

The State of New York has enacted legislation, codified at Article 10-C of the Public Authorities Law of the State of New York (the "Act"), creating the Erie County Medical Center Corporation ("ECMCC" or the "Corporation"). These by-laws are intended to supplement the requirements of the Act.

ARTICLE I

OFFICES

ECMCC may maintain offices at such places within or without Erie County, New York as the Board of Directors may, from time to time, determine.

ARTICLE II

PURPOSE OF BY-LAWS

Pursuant to the broad powers granted by the Act, the Board of Directors of ECMCC (the "Board") has adopted these By-Laws, to govern and manage its proceedings and affairs and for the advice and guidance of its members, and nothing contained in these By-Laws shall be deemed, nor are they intended in any manner or degree, to limit or restrict the power and right of the Board under existing law, to manage, control, operate and administer ECMCC and its personnel, patients and medical staff.

ARTICLE III CORPORATE PURPOSE

To continue as a general, municipal hospital and provide health care services and health facilities for the benefit of the residents of the State of New York and the County of Erie, including persons in need of health care services without the ability to pay, as required by law.

ARTICLE IV ERIE COUNTY MEDICAL CENTER CORPORATION BOARD OF DIRECTORS

Section 1. General Powers.

In addition to the powers and authorities expressly conferred by these By-laws, the Board may exercise all such general and special powers of the Corporation and do all such lawful acts and things as enumerated by the Act.

Section 2. Hiring Powers.

The Board shall hire, determine the compensation and benefits, and annually review the performance of the Chief Executive Officer ("CEO") and President of the Corporation. Appointments made to fill all other executive the roles of the Chief Operating Officer ("COO"), Chief Financial Officer ("CFO"), Chief Medical Officer ("CMO"), Administrator of Terrace View, Chief Nursing Officer ("CNO"), Chief Strategy Officer, and General Counsel of within the Corporation shall be made by the CEO of the Corporation, who shall thereafter also be responsible for determining the compensation and benefits of the persons occupying these positions and for the annual review of the incumbents. The Board shall have the authority to discharge the CEO with or without cause; provided that the removal shall not prejudice the contract rights, if any, of such executive. The CEO shall have the authority to discharge the COO, CMO, Administrator of Terrace View, Chief Nursing Officer, Chief Strategy Officer, Chief Strategy Officer, and General Counsel all other executives with or without cause, provided that the removal shall not prejudice the contract rights, if any, of such executives with or without cause, provided that the removal shall not prejudice the contract rights, if any, of such executives with or without cause, provided that the removal shall not prejudice the contract rights, if any, of such executives with or without cause, provided that the removal shall not prejudice the contract rights, if any, of such executives with or without cause, provided that the removal shall not prejudice the contract rights, if any, of such executives with or without cause.

Section 3. Voting Directors.

The Corporation shall be governed by fifteen voting Directors. The membership, term of office, selection of the voting Directors and the powers and duties of the Board shall be in accordance with the Act and these By-laws.

Section 4. Nonvoting Representatives.

The Corporation shall have four nonvoting Representatives. The term of office, selection and powers and duties of the nonvoting Representatives shall be in accordance with the Act and these By-laws. For the purpose of these By-Laws, the term "member" or "Board member" shall refer to both voting Directors and non- voting Representatives.

Section 5. Resignation.

Any Director or Representative may resign at any time by giving written notice to the Chairperson of the Board. Such resignation shall take effect at the time specified therein and unless otherwise specified therein the acceptance of such resignation shall not be necessary to make it effective.

Section 6. Removal.

Members of the Board may be removed from office by the Board for inefficiency, neglect of duty, or misconduct of any kind, including but not limited to violation of the law, after the Board has given such member a copy of the charges against him or her and an opportunity to be heard in person or by counsel in his or her defense, upon not less than ten days' notice.

Section 7. Vacancies.

Vacancies occurring other than by expiration of term shall be filled for the unexpired terms in the manner provided for original appointment in accordance with the Act.

Section 8. Monthly Meetings.

The Board shall hold regular monthly meetings at the ECMCC offices or other convenient locations as designated by the Board at such time as the Board may designate. In the event that a previously scheduled regular monthly meeting may not be required for a particular month, the Board may cancel that meeting.

Section 9. <u>Annual & Special Meetings.</u>

A meeting of the Board shall be held annually at which time officers of the Corporation shall be elected. A special meeting may be called by the Chairperson or Vice Chairperson acting in the Chairperson's absence, or by any three (3) members of the Board at any time upon proper notice under the Public Officers Law. The only action that can be taken at a special meeting is the consideration of the subject or subjects designated in the notice for the special meeting.

Section 10. Open Meetings Law.

All meetings of the Board shall comply with the requirements of Article 7 of the Public Officers Law. In a regular, annual or special meeting, the Board may request an Executive Session pursuant to Article 7 of the Public Officers Law or applicable sections of the Act.

Section 11. Quorum.

The powers of the Corporation shall be vested in and shall be exercised by the Board at a duly called and held meeting, where a quorum of eight Directors is present. No action shall be taken by the Corporation except pursuant to the favorable vote of at least eight Directors present at the meeting at which such action is taken.

Section 12. <u>Telephone Meetings.</u>

The members of the Board or any committee thereof may participate in a meeting of such Board or committee by means of a conference telephone or similar communications equipment allowing all persons participating in the meeting to hear each other at the same time. Participation by such means shall constitute presence in person at a meeting.

Section 13. Action by Written Consent.

To the extent permitted by law, any action required or permitted to be taken by the Board or any committee thereof may be taken without a meeting if all members of the Board or the committee consent in writing to the adoption of a resolution authorizing the action. The resolution and the written consents thereto by the members of the Board or committee shall be filed with the minutes of the proceedings of the Board or committee.

Section 14. <u>Minutes of Meetings.</u>

The Board shall keep a written record of all business conducted, including resolutions, findings, conclusions and recommendations that shall be filed with the minutes of the proceedings of the Board or committee.

Section 15. Compensation.

Neither the voting Directors nor the nonvoting Representatives shall receive compensation for their services but shall be reimbursed for all their actual and necessary expenses incurred in connection with their duties under the Act and these By-laws.

Section 16. Defense and Indemnification.

The Corporation shall defend and indemnify the Directors of the Corporation and its officers for any and all lawful actions executed in the performance of their duties, to the full extent to which indemnification is permitted under the laws of the State of New York.

Section 17. Extension of Credit.

Pursuant to New York Public Authorities Law Section 2824(5), the Corporation shall not, directly, or indirectly, including through any subsidiary, extend or maintain credit, arrange for the extension of credit, or renew any extension of credit, in the form of a personal loan to or for any Director, officer, or employee (or equivalent thereof) of the Corporation.

ARTICLE V OFFICERS

Section 1. General.

The officers of the Corporation shall be elected by the Board and shall be comprised of a Chairperson of the Board, a Vice Chairperson of the Board, a CEO, a Secretary, and a Treasurer. The Board may also appoint an Assistant Secretary and such other officers as the Board shall from time to time provide. All such officers shall exercise the duties as described in the Act, applicable law, by these By-Laws, and/or by Board resolution.

Section 2. Election, Term of Office.

The officers of the Corporation shall be elected by the Board at its annual meeting. Each officer elected shall hold office until his successor has been duly chosen and has qualified or until his or her earlier resignation or removal.

Section 3. Resignation.

Any officer may resign at any time by giving written notice thereof to the Board, provided that the resignation shall not prejudice the contract rights, if any, of the Corporation. Any such resignation shall take effect at the time specified therein and unless otherwise specified therein the acceptance of such resignation shall not be necessary to make it effective.

Section 4. <u>Removal.</u>

The Directors shall have the authority to discharge any officer with or without cause; provided that the removal without cause shall not prejudice the contract rights, if any, of the officer.

Section 5. Vacancies.

In the event of a vacancy occurring in the office of the Chairperson or Vice Chairperson, any member designated by the Board shall serve as Acting Chairperson for that meeting. In the event of a vacancy occurring in any other office, any member designated by the Board shall serve as an Acting officer for that meeting.

Section 6. Chairperson of the Board.

The Directors shall, by majority vote, select one of the fifteen Directors as the Chairperson of the Board. The Chairperson shall preside over all meetings of the Board, shall chair the Executive Committee of the Board, and shall have such other duties as the Directors may provide. Other than the Governance Committee, the Chairperson shall serve <u>ex officio</u> on all Board committees with full voting rights, though his presence shall not be counted for establishment of a quorum on committees if he serves only by nature of being ex officio. The Chairperson shall serve for a two-year term of office. No member of the Board shall be permitted

to serve more than two consecutive two-year terms as Chairperson of the Board.

Section 7. Vice-Chairperson(s) of the Board.

The Directors shall, by majority vote, select one or more of the fifteen Directors as the Vice-Chairperson of the Board. The Vice-Chairperson shall preside over all meetings where the Chairperson of the Board is absent and shall have such other duties as the Directors may provide. The Vice-Chairperson shall serve for a two-year term of office. At least one Vice-Chairperson shall be designated by a majority vote of the Board as "Vice-Chair, Chair-Elect" in the second year of that Vice- Chairperson's term of office. At the conclusion of the term of the Vice-Chair, Chair-Elect, the Board shall retain authority to appoint the Vice-Chair, Chair-Elect or any other member of the Board of Directors as Chairperson of the Board of Directors.

Section 8. Chief Executive Officer.

The Board shall hire, set the compensation of, execute direct oversight of, and annually review the performance of the CEO. The CEO shall carry out the policies of the Board, provide services to the Board; and shall be subject to the By-Laws, rules and regulations of the Board. He or she shall have all the general powers and duties of a Superintendent of a public general municipal hospital as set forth and enumerated in the General Municipal Law of the State of New York, Section 129, sub. 1 through 9 as amended and of a chief executive officer as set forth in Title 10, subpart 405.3 of the New York Codes, Rules and Regulations and the Act. The CEO shall provide leadership, direction, and administration in all aspects of the Corporation's activities and other corporate entities to ensure compliance with established objectives and the realization of quality, economical health care services, and other related lines of business. The CEO shall ensure the Corporation's compliance with all applicable laws and regulations. The CEO shall submit monthly and special reports to the Board and its committees regarding strategic, operational and financial performance, along with the current status of ECMCC services and facilities. The CEO shall be expected to provide feedback to the Board regarding those employees which report directly to the CEO. The CEO shall determine when ensure that subordinate officers shall provide meaningful reports to the Board regarding the previous month'songoing activities. The CEO shall coordinate with the Board, Medical Staff, and other Corporation personnel to respond to the community's needs for quality healthcare services and monitor the adequacy of the Corporation's medical activities.

Section 9. President.

The Board shall hire, set the compensation and annually review the performance of the President. The duties of the President shall be distinct from the duties of other officers of the Corporation and shall be enumerated in a job description reviewed by the Executive Committee of the Board.

<u>Section 109.</u> <u>Secretary & Assistant Secretary.</u>

The Board shall, by majority vote, select either Directors or Representatives to serve as the Secretary and Assistant Secretary, if applicable. The Secretary shall send notices for all meetings of the Board. The Secretary shall act as custodian for all records and reports and shall be responsible for keeping and reporting of adequate records of all meetings of the Board. The Secretary may delegate these duties to another officer or employee of the Corporation to act on his/her behalf. The Secretary will approve and sign the minutes of all meetings of the Board which shall be kept in an official record book. In the absence of the Secretary at any meeting, the Assistant Secretary, if applicable, or any member designated by the Chairperson shall act as the Secretary for that meeting.

Section <u>110.</u> Treasurer.

The Board shall, by majority vote, select either a Director or a Representative to serve as the Treasurer. The Treasurer shall monitor the financial affairs of ECMCC as managed by the officers of the Corporation. The Treasurer will also have the power to establish bank accounts in the name of the Corporation. He or she shall do and perform all other duties incident to the office of Treasurer as may be prescribed by the Board from time to time.

Section 1211. Immediate Past Chair.

The Immediate Past Chair of the Board shall remain available to the Board and the Chair for purposes of transitional continuity and may be appointed to serve as a member of any Standing or Special Committee of the Board, assuming his or her term of office as a Director has not expired.

ARTICLE VI

<u>COMMITTEES</u>

General Rules

Section 1. General.

The Standing Committees of the Board shall be: the Executive Committee, the Quality Improvement Committee, the Finance Committee, the Audit and Compliance Committee, the Building and Grounds Committee, the Human Resources Committee, the Executive Compensation Committee, the Terrace View Quality Improvement Committee, the Governance Committee, the Investment Committee and the Contracts Committee. At the discretion of the Chairperson, and upon the advice of the Board, additional special committees may be appointed to address specific issues.

<u>Section 2.</u> <u>Appointment of Committees.</u>

The Chairperson of the Board shall appoint all members of standing and special committees. Appointments will be made at the first regular meeting following the annual election of officers, or at such other time deemed necessary by the Chairperson. The Chairperson of the Board shall appoint a Chairperson for each committee. Committee Chairpersons shall serve one-year terms of office but are not prohibited from serving consecutive one-year terms. The Chairperson may appoint individuals other than Board members to committees either standing or special, except the Executive Committee.

Section 3. Structure of Committees.

In addition to the individual Committee duties set forth below, each Committee shall be tasked annually with reviewing their applicable charter and recommending changes thereto, as well as setting forth goals for the Committee for the upcoming year. Such goals shall be determined in consultation with the Chairperson of the Board.

Section 4. Resignation.

A committee member may resign at any time by giving written notice to the Chairperson

of the Board. Such resignation shall take effect at the time specified therein and unless otherwise specified therein the acceptance of such resignation shall not be necessary to make it effective.

Section 5. Removal.

Committee members may be removed from committee membership by the Board for inefficiency, neglect of duty, or misconduct of any kind, including but not limited to, violation of the law, after the board has given such member a copy of the charges against him or her and an opportunity to be heard in person or by counsel in his or her defense, upon not less than ten days' notice.

Section 6. Vacancies.

Vacancies occurring otherwise than by expiration of term of office shall be filled for the unexpired terms by appointment from the Chairperson of the Board.

Section 7. Quorum.

At a committee meeting, a quorum shall be one-half the number of members of the committee.

Section 8. Voting.

Only the members of the Board serving on a Standing or Special Committee, or an appointed non-member of the Board serving on a Standing or Special Committee, and the Chairperson of the Board serving <u>ex officio</u>, shall have a vote.

Section 9. Minutes.

Each committee meeting shall have an agenda, time convened and adjourned recorded, and shall submit minutes of its meeting to the Secretary of the Board in advance of the regular monthly meeting.

Standing Committees

Section 10. The Executive Committee.

The Executive Committee shall consist of four (4) Board members. The Corporation's General Counsel and Chief Executive Officer shall serve <u>ex officio</u> as members of the Executive Committee. Other members of the Board may be added when advisable. The Chairperson shall preside at all meetings of the Committee. The Executive Committee shall meet at least quarterly, or upon the call of the Chairperson.

Section 11. The Quality Improvement Committee.

The Quality Improvement Committee shall consist of three (3) members. The Chairperson of the Committee may, in his or her discretion, request the presence of other persons, as the issues before the Committee may dictate. The Committee shall meet at least quarterly, or upon the call of the Chairperson. The Committee shall be responsible for the following:

- a. Inform the Board of patient safety, performance improvement and quality assurance issues of relevance to ECMCC.
- b. Establishment, maintenance and operation of a coordinated quality assurance program integrating the review of activities of all hospital services in order to enhance the quality of patient care and to identify and prevent professional malpractice. The

specific responsibilities of the Committee are further set forth in the quality assurance plan of the hospital.

<u>c.</u> Other duties and responsibilities as may be assigned from time to time by the Board.

Section 12. The Finance Committee.

The Finance Committee shall consist of five (5) financially literate members of the Board. The Chairperson of the Committee may, in his or her discretion, request the presence of other persons, as the issues before the Committee may dictate. The Finance Committee shall meet at least quarterly, or upon the call of the Chairperson. The Committee shall be responsible for the following:

- a. Review relevant budgets of the Corporation and maintain ongoing oversight of the financial situation of the Corporation.
- b. Oversee, evaluate, and where appropriate, make recommendations with respect to financial operations of the Corporation.
- c. Other duties and responsibilities as may be assigned from time to time by the Board.

Section 13. The Audit & Compliance Committee.

The Audit & Compliance Committee shall consist of at least four (4) members. At least three (3) of the Committee's members shall be independent, as that term is defined by state law. The Corporation's General Counsel shall serve <u>ex officio</u> as a member of the Audit & Compliance Committee. The Chairperson of the Committee may, in his or her discretion, request the presence of other persons, as the issues before the committee may dictate. The Audit & Compliance Committee shall meet at least quarterly, or upon the call of the Chairperson. The Committee shall be responsible for the following:

- a. Oversight of any independent auditors engaged by ECMCC.
- b. Oversight of all ECMCC internal audit processes.
- c. Collaboration with the Quality Improvement Committee in the establishment and maintenance of a coordinated quality assurance program.
- d. Collaboration with the Compliance Officer on the establishment, maintenance and operation of a comprehensive compliance program, which shall comply with the Office of the Inspector General Compliance Program Guidance for Hospitals. Specifically, the Committee shall:
 - 1. Analyze the legal requirements and specific risk areas of the health care industry,
 - 2. Assess existing policies that address legal requirements and risk areas for possible incorporation into the ECMCC compliance program,
 - 3. Work with ECMCC departments to develop standards of conduct and policies and procedures to promote compliance with the ECMCC compliance program,
 - 4. Recommend and monitor the development of internal systems and controls to carry out ECMCC's standards, policies and procedures as part of its daily operations,
 - 5. Determine appropriate strategy to promote compliance with the ECMCC compliance program and detection of possible violations, including fraud reporting mechanisms,
 - 6. Develop a system to solicit, evaluate and respond to complaints and problems, and

7. Promote ethics, integrity, and compliance with laws, policies, and procedures.e. Other duties and responsibilities as may be assigned from time to time by the Board.

Section 14. Buildings and Grounds Committee.

The Buildings and Grounds Committee shall consist of three (3) members. The Corporation's General Counsel shall serve <u>ex officio</u> as a member of the Buildings and Grounds Committee. The Chairperson of the Committee may, at his or her discretion, request the presence of other persons, as the issues before the Committee may dictate. The Buildings and Grounds Committee shall meet at least quarterly, or upon the call of the Chairperson. The Committee shall be responsible for the following:

- a. Evaluation and provision of recommendations with respect to proposed and ongoing construction and renovation projects and budgets.
- b. Other duties and responsibilities as may be assigned from time to time by the Board.

Section 15. The Human Resources Committee.

The Human Resources Committee shall consist of three (3) members. The Chairperson of the Committee may, in his or her discretion, request the presence of other persons, as the issues before the Committee may dictate. The Committee will meet at least quarterly or upon the call of the Chairperson. The Committee shall be responsible for the following:

- a. Establishment of a formal channel of communication among the Board, ECMCC management and the Labor Unions.
- b. Responsibility for assuring that appropriate guidelines are in place and monitored to ensure and maintain open communication.
- c. Discussion of issues that arise in the operation of the hospital as they affect all parties.
- d. Other duties and responsibilities as may be assigned from time to time by the Board.

Section 16. The Executive Compensation/Evaluation Committee.

The Executive Compensation/Evaluation Committee shall consist of no more than four (4) members of the Board. No person whose compensation is determined by the Executive Compensation/Evaluation Committee may serve as a member of the Committee. The Chairperson of the Committee may, in his or her discretion, request the presence of other persons, as the issues before the committee may dictate. The Executive Compensation/Evaluation Committee shall meet at least quarterly, or upon the call of the Chairperson. The Committee shall be responsible for the following:

- a. Evaluation, at least annually, of the CEO and President of the Corporation.
- b. Determination of the compensation, including benefits, of the above listed Corporation executives.
- c. Other duties and responsibilities as may be assigned from time to time by the Board.

Section 17. The Terrace View Quality Improvement Committee.

The Terrace View Quality Improvement Committee shall consist of at least three (3) members. The Committee shall meet at least quarterly, or upon the call of the Chairperson. The Committee shall be responsible for the following:

- a. Establishment and maintenance of a coordinated quality assurance program as specifically applicable to Terrace View.
- b. Other duties and responsibilities as may be assigned from time to time by the Board.

Section 18. The Governance Committee.

The Governance Committee shall consist of at least four (4) independent members, as that term is defined in New York Public Authorities Law §2825. The Chief Executive Officer and the General Counsel for the Corporation shall serve <u>ex officio</u> as members of the Committee, and the Chairperson of the Board may attend Committee meetings but will not be a member of the Committee and will not vote. The Committee Chairperson may, at his or her discretion, request the presence of other persons as issues before the Committee may dictate. The Governance Committee shall meet at least semi- annually, or upon the call of the Committee Chairperson. The Committee shall be responsible for the following:

- a. Provision of information to the Board regarding current best governance practices.
- b. Review of corporate governance trends.
- c. Recommend updates to the Corporation's governance principles.
- d. Provision of advice to the Governor and to the Erie County Executive in their appointment of potential Board members regarding the skills and experience required of Board members.
- e. Annually review and, as necessary, make recommendations to the Board regarding updating of the Corporation's Bylaws; annually review and, as necessary, make recommendations to the applicable Committees regarding updates to Committee charters.
- f. Other duties and responsibilities as may be assigned from time to time by the Board.

Section 19. The Investment Committee.

The Investment Committee shall consist of at least three (3) members. The Chair of the Finance Committee and the Chief Executive Officer shall serve <u>ex officio</u> as members of the Investment Committee and the Chief Financial Officer shall serve as staff to the Committee. The Committee Chairperson may, at his or her discretion, request the presence of other persons as issues before the Committee may dictate. The Investment Committee shall meet at least semi-annually, or upon the call of the Committee Chairperson. The Committee shall be responsible for the following:

- a. Recommendations regarding the designation of the Corporation's investment officer.
- b. Recommendations regarding investment policies and procedures consistent with applicable law and the needs of the Corporation.
- c. Implementation of appropriate internal controls for investments.
- d. Recommendations regarding the selection of the Corporation's investment advisors and investment managers.
- e. Review of independent audits of the investment program.
- f. Review of quarterly reports from the Corporation's investment advisors and investment managers.
- g. Reports to the Board on a quarterly basis.
- h. Monitoring the Corporation's system of internal controls and the performance of the

Corporation's investment advisors and investment managers.

i. Other duties and responsibilities as may be assigned from time to time by the Board.

Section 20. The Contracts Committee.

The Contracts Committee shall consist of at least three (3) members. The Contracts Committee shall review and make recommendations to the Board with respect to the approval of all contracts required to be approved by the Board pursuant to Corporation policy and applicable law, including Section 2879(3)(b)(ii) of the Public Authorities Law. The Contracts Committee shall meet at least quarterly or upon the call of the Committee Chairperson. The Committee shall be responsible for the following:

- a. Review of contracts of the Corporation requiring Board approval and make recommendations to the Board regarding such contracts.
- b. Annually review contracts requiring such review pursuant to Corporation policy and/or applicable law.
- c. Redacting sensitive information from contracts before presentation to the Board to ensure compliance with the Corporation's contractual and confidentiality requirements.
- d. Report to the Board on a quarterly basis regarding the foregoing subsections.
- e. Other duties and responsibilities as may be assigned from time to time by the Board.

ARTICLE VII

MEDICAL/DENTAL STAFF

Section 1. Organization.

The Board shall cause to be created a medical staff organization to be known as the ECMC Medical Dental Staff ("Medical Staff") whose membership shall be comprised of certain categories of health care practitioners, as determined by the Board. Members of the Medical Staff may only practice within the scope of privileges granted by the Board.

Section 2. Medical Staff Governance Documents.

The Medical Staff shall develop, adopt and at least once every three years review the following Medical Staff Governance Documents: By-Laws; Rules & Regulations; Credentials Procedures Manual; and Collegial Intervention, Peer Review, Fair Hearing & Appellate Review Procedures. These Governance Documents shall establish controls that are designed to ensure the achievement and maintenance of the highest quality medical care and high standards of professional and ethical practice. The Board shall approve all such Medical Staff Governance Documents.

Section 3. Appointment of Medical Staff.

Appointments and reappointments to the Medical Staff shall be made by the Board. The Board shall be responsible for granting and defining the scope of the clinical privileges to be exercised by each member of the Medical Staff, including but not limited to providing approval of modifications, suspensions and termination of such privileges and Medical Staff membership in accordance with the Medical Staff Governance Documents and written ECMCC policies. In acting on matters of Medical Staff membership and scope of privileges, the Board shall consider the recommendations of the Medical Staff's Medical Executive Committee. The procedures for Medical Staff appointment are more specifically outlined in the Medical Staff's Credentials Procedure Manual.

Section 4. Authority for Medical Staff Conduct.

Ultimate responsibility for the conduct of the Medical Staff remains with the Board. The Board shall enforce compliance with all medical staff Governance Documents by all members of the Medical Staff. No assignment, referral or delegation of authority by the Board to the Medical Director, COO, CEO, the Medical Staff or any other person shall preclude the Board from exercising the authority required to meet its responsibility for the conduct of the Corporation. The Board retains the right to rescind any such delegation.

Section 5. Duties of the Medical Staff.

The Board shall delegate to the Medical Staff the authority to monitor, evaluate and document professional performance of Medical Staff members in accordance with its Governance Documents. The Board shall hold the Medical Staff accountable, through the chiefs of service of the departments and the Medical Director, for making recommendations based on well-defined and written criteria related to the goals and standards of the Corporation concerning Medical Staff appointments, reappointments and clinical privileges.

Section 6. Quality of Patient Care.

The Medical Staff is accountable to the Board for the quality of care provided to patients.

Section 7. Rights at Meetings.

Members of the Medical Staff shall be entitled to be heard at all public meetings and committee meetings of the Board.

ARTICLE VIII Standards of Patient Care

The Board shall require that the following patient care practices are implemented, shall monitor ECMCC's compliance with these patient care practices, and shall take corrective action as necessary to attain compliance:

- a. Every patient of ECMCC, whether an in-patient, emergency patient, or out-patient, shall be provided care that meets generally accepted standards of professional practice.
- b. Every patient is under the care of a health care practitioner who is a member of the medical staff.
- c. Patients are admitted to ECMCC only on the recommendation of a member of the medical staff permitted by the State law and Medical Staff Governance Documents to admit patients to the hospital.
- d. A physician, a registered physician's assistant or a nurse practitioner, under the general supervision of a physician, is on duty at all times in the hospital.
- e. A physician shall be responsible for the care of each patient with respect to any medical or psychiatric problem that is present on admission or develops during hospitalization.
- f. In the event that human research is conducted within ECMCC, written policies and procedures shall be adopted and implemented pursuant to the provisions of Public

Health Law Article 24-A for the protection of human subjects.

g. ECMCC shall have available at all times personnel sufficient to meet patient care needs.

ARTICLE IX <u>THE SCHOOL OF MEDICINE</u> STATE UNIVERSITY OF NEW YORK AT BUFFALO

The Board strongly supports the relationship between ECMCC and the School of Medicine and Biomedical Sciences of the State University of New York at Buffalo through an affiliation agreement. The Board shall take all appropriate action to retain and enhance the benefits arising from said relationship provided that the Board shall hold uppermost the discharge of its legal and fiduciary duties to ECMCC.

ARTICLE X

SUBSIDIARY CORPORATIONS AND ENTITIES

Except as expressly limited by law, the Corporation may exercise and perform all or part of its purposes, powers, duties, functions or activities through one or more subsidiary corporations or companies owned or controlled wholly or in part by the Corporation, which shall be formed pursuant to the Business Corporation Law, the Limited Liability Company Law, or the Not-For-Profit Corporation Law. Any such subsidiary may be authorized to act as a general or limited partner in a partnership or as a member of a limited liability company and to enter into an arrangement calling for an initial and subsequent payment by such subsidiary in consideration of an interest in revenues or other contractual rights. The Board has the exclusive authority to create shall approve the creation of subsidiaries or other entities related to the Corporation.

ARTICLE XI CODE OF ETHICS AND CONFLICTS OF INTEREST

Section 1. Responsibility of Members of the Board and Employees.

This Code of Ethics shall apply to all officers and employees of the Corporation. These policies shall serve as a guide for official conduct and are intended to enhance the ethical and professional performance of the Corporation's directors and employees and to preserve public confidence in the Corporation's mission. It is accordingly the responsibility of each member of the Board and each employee to perform in accordance with the following:

- a. Each member of the Board and all employees of the Corporation shall perform their duties with transparency, without favor and refrain from engaging in outside matters of financial or personal interest, including other employment, that could impair independence of judgment, or prevent the proper exercise of one's official duties.
- b. Each member of the Board and all employees shall not directly or indirectly, make, advise, or assist any person to make any financial investment based upon information available through the director's or employee's official position that could create any conflict between their public duties and interests and their private interests.
- c. Each member of the Board and all employees shall not accept or receive any gift or gratuities where the circumstances would permit the inference that: (a) the gift is intended to influence the individual in the performance of official business or (b) the gift constitutes a tip, reward, or sign of appreciation for any official act by the

14

individual. This prohibition extends to any form of financial payments, services, loans, travel reimbursement, entertainment, hospitality, thing or promise from any entity doing business with or before the Corporation.

- d. Each member of the Board and all employees shall not use or attempt to use their official position with the Corporation to secure unwarranted privileges for themselves, members of their family or others, including employment with the Corporation or contracts for materials or services with the Corporation.
- e. Each member of the Board and all employees must conduct themselves at all times in a manner that avoids any appearance that they can be improperly or unduly influenced, that they could be affected by the position of or relationship with any other party, or that they are acting in violation of their public trust.
- f. Each member of the Board and all employees may not engage in any official transaction with an outside entity in which they have a direct or indirect financial interest that may reasonably conflict with the proper discharge of their official duties.
- g. Each member of the Board and all employees shall manage all matters within the scope of the Corporation's mission independent of any other affiliations or employment. Directors, including <u>ex officio</u> board members, and employees employed by more than one government entity shall strive to fulfill their professional responsibility to the Corporation without bias and shall support the Corporation's mission to the fullest.
- h. Each member of the Board and all employees shall not use Corporation property, including equipment, telephones, vehicles, computers, or other resources, or disclose information acquired in the course of their official duties in a manner inconsistent with State or local law or policy and the Corporation's mission and goals.
- i. Each member of the Board and all employees are prohibited from appearing or practicing before the Corporation for two (2) years following employment with the Corporation consistent with the provisions of Public Officers Law.

Section 2. Implementation of Code of Ethics.

This Code of Ethics shall be provided to all members of the Board and all employees upon commencement of employment or appointment and shall be reviewed annually by the Governance Committee.

Section 3. Compliance.

The members of the Board agree to comply with all applicable local and state regulations and laws regarding conflicts of interest.

Section 4. Conflict of Interest Policy.

The Board shall develop, implement, and update as needed a written policy governing conflict of interest by members of the Board. The policy shall be reviewed annually by the Governance Committee and included and incorporated into these By-Laws-as <u>Appendix A</u>.

Section 5. Disclosure of Personal Interest and Abstention.

It is the responsibility of every Board member to disclose to the Chairperson of the Board any personal or business interest in any matter that comes before the Board for consideration. Each member of the Board shall abstain from voting on any matter in which he or she has a personal or business interest.

Section 6. Self-Dealing.

The Corporation shall not engage in any transaction with a person, firm, or other business entity in which one or more of the Board members has a financial interest in such person, firm or other business entity, unless such interest is disclosed in good faith to the Board, and the Board authorizes such transaction by a vote sufficient for such purpose, without counting the vote of the interested Board member.

Section 7. Influence of Decision Makers.

No member of the Board shall use his or her position to influence the judgment or any decision of any Corporation employee concerning the procurement of goods or services on behalf of the Corporation.

Section 8. No Forfeit of Office or Employment.

Except as provided by law, no officer, member, or employee of the state or of any public corporation shall forfeit his or her office or employment by reason of his or her acceptance of appointment as a director, nonvoting representative, officer, or employee of the Corporation, nor shall such service as such a director, nonvoting representative, officer or employee be deemed incompatible or in conflict with such office or employment; and provided further, however, that no public officer elected to his or her office pursuant to the laws of the state or any municipality thereof may serve as a member of the governing body of the Corporation during his or her term of office.

ARTICLE XII

AMENDMENTS

These By-Laws of the Board may be amended by the affirmative vote of a quorum of members at the annual meeting, special or regular meetings of the Board, provided that a full presentation of such proposed amendment(s) shall have been presented to the Board at least thirty (30) days prior to the meeting, unless waived by majority of the whole number of the members of the Board.